(dp1
S'have,a,clinically'
p2
(F1
F0.00076452599388379206
I0
I1
I-1
tp3
sS'as,marplan,parnate'
p4
(F1
F0.00076452599388379206
I1
I0
I1
tp5
sS'were,significantly,higher'
p6
(F1
F0.00076452599388379206
I0
I1
I-1
tp7
sS'by,disc,diffusion'
p8
(F1
F0.00076452599388379206
I1
I0
I1
tp9
sS'by,cyp3a,and'
p10
(F1
F0.00076452599388379206
I1
I0
I1
tp11
sS'four,times,a'
p12
(F1
F0.0015290519877675841
I2
I0
I2
tp13
sS'myfortic,and,oral'
p14
(F1
F0.00076452599388379206
I0
I1
I-1
tp15
sS'and,package,labeling'
p16
(F1
F0.00076452599388379206
I0
I1
I-1
tp17
sS'tricyclic,antidepressants,and'
p18
(F1
F0.0022935779816513763
I3
I0
I3
tp19
sS'were,randomized,either'
p20
(F1
F0.00076452599388379206
I0
I1
I-1
tp21
sS'inhibitors,to,women'
p22
(F1
F0.00076452599388379206
I1
I0
I1
tp23
sS'trials,concomitantly,with'
p24
(F1
F0.00076452599388379206
I0
I1
I-1
tp25
sS'of,clinical,relevance'
p26
(F1
F0.00076452599388379206
I0
I1
I-1
tp27
sS'leading,to,increased'
p28
(F1
F0.0015290519877675841
I2
I0
I2
tp29
sS'may,also,interact'
p30
(F1
F0.0015290519877675841
I0
I2
I-2
tp31
sS'ea,signs,were'
p32
(F1
F0.00076452599388379206
I0
I1
I-1
tp33
sS'of,can,potentiate'
p34
(F1
F0.00076452599388379206
I1
I0
I1
tp35
sS'a,theoretical,basis'
p36
(F1
F0.00076452599388379206
I1
I0
I1
tp37
sS'determinations,of,these'
p38
(F1
F0.00076452599388379206
I1
I0
I1
tp39
sS'nsaids,can,reduce'
p40
(F1
F0.00076452599388379206
I1
I0
I1
tp41
sS'both,and,mpag'
p42
(F1
F0.00076452599388379206
I0
I1
I-1
tp43
sS'enhanced,cytotoxicity,in'
p44
(F1
F0.00076452599388379206
I1
I0
I1
tp45
sS'by,the,base-secreting'
p46
(F1
F0.00076452599388379206
I1
I0
I1
tp47
sS'hepg2,mcf7,and'
p48
(F1
F0.00076452599388379206
I0
I1
I-1
tp49
sS'attenuated,vaccines,should'
p50
(F1
F0.00076452599388379206
I1
I0
I1
tp51
sS'signaling,pathways,that'
p52
(F1
F0.00076452599388379206
I1
I0
I1
tp53
sS'b2,riboflavin,alcohol'
p54
(F1
F0.00076452599388379206
I1
I0
I1
tp55
sS'coeruleus,a5,a7'
p56
(F1
F0.00076452599388379206
I1
I0
I1
tp57
sS'the,two,with'
p58
(F1
F0.00076452599388379206
I0
I1
I-1
tp59
sS'interval,prolongation,and'
p60
(F1
F0.0015290519877675841
I2
I0
I2
tp61
sS'cyp3a4,i,and'
p62
(F1
F0.00076452599388379206
I1
I0
I1
tp63
sS'stronger,of,the'
p64
(F1
F0.00076452599388379206
I0
I1
I-1
tp65
sS'and,profound,sedation'
p66
(F1
F0.00076452599388379206
I1
I0
I1
tp67
sS'can,result,in'
p68
(F1
F0.00076452599388379206
I1
I0
I1
tp69
sS'two,drugs,with'
p70
(F1
F0.00076452599388379206
I0
I1
I-1
tp71
sS'verified,for,combination'
p72
(F1
F0.00076452599388379206
I0
I1
I-1
tp73
sS'is,not,recommended'
p74
(F1
F0.0015290519877675841
I2
I0
I2
tp75
sS'corresponded,to,the'
p76
(F1
F0.00076452599388379206
I0
I1
I-1
tp77
sS'exert,particular,caution'
p78
(F1
F0.00076452599388379206
I1
I0
I1
tp79
sS'live,organism,vaccines'
p80
(F1
F0.00076452599388379206
I1
I0
I1
tp81
sS'active,renal,tubular'
p82
(F1
F0.00076452599388379206
I0
I1
I-1
tp83
sS'studied,on,the'
p84
(F1
F0.00076452599388379206
I1
I0
I1
tp85
sS'lines,hela,hct116'
p86
(F1
F0.00076452599388379206
I0
I1
I-1
tp87
sS'for,changes,in'
p88
(F1
F0.00076452599388379206
I1
I0
I1
tp89
sS'effect,of,an'
p90
(F1
F0.00076452599388379206
I0
I1
I-1
tp91
sS'and,decrease,patient'
p92
(F1
F0.00076452599388379206
I1
I0
I1
tp93
sS'did,not,increase'
p94
(F0
F0
I1
I1
I0
tp95
sS'reported,to,enhance'
p96
(F1
F0.00076452599388379206
I1
I0
I1
tp97
sS'associated,with,a'
p98
(F0.33333333333333331
F0.00076452599388379206
I2
I1
I1
tp99
sS'not,inhibit,the'
p100
(F1
F0.0015290519877675841
I0
I2
I-2
tp101
sS'was,to,investigate'
p102
(F1
F0.00076452599388379206
I0
I1
I-1
tp103
sS'concentrations,and,serum'
p104
(F1
F0.00076452599388379206
I1
I0
I1
tp105
sS'rheumatoid,arthritis,patients'
p106
(F1
F0.0015290519877675841
I0
I2
I-2
tp107
sS'if,evista,is'
p108
(F1
F0.00076452599388379206
I1
I0
I1
tp109
sS'and,coumarin-type,anticoagulants'
p110
(F1
F0.00076452599388379206
I1
I0
I1
tp111
sS'treatment,for,myocardial'
p112
(F1
F0.00076452599388379206
I0
I1
I-1
tp113
sS'fold,by,but'
p114
(F1
F0.00076452599388379206
I1
I0
I1
tp115
sS'formal,study,were'
p116
(F1
F0.00076452599388379206
I0
I1
I-1
tp117
sS'concurrently,with,opioid'
p118
(F1
F0.00076452599388379206
I1
I0
I1
tp119
sS'level,increased,fold'
p120
(F1
F0.00076452599388379206
I1
I0
I1
tp121
sS'protein,binding,sites'
p122
(F0
F0
I1
I1
I0
tp123
sS'rat,liver,slices'
p124
(F1
F0.00076452599388379206
I0
I1
I-1
tp125
sS'to,fixed,combination'
p126
(F1
F0.00076452599388379206
I0
I1
I-1
tp127
sS'avoided,in,patients'
p128
(F1
F0.00076452599388379206
I0
I1
I-1
tp129
sS'day,a,single'
p130
(F1
F0.00076452599388379206
I0
I1
I-1
tp131
sS'intraocular,pressure,may'
p132
(F1
F0.00076452599388379206
I1
I0
I1
tp133
sS'activity,live,virus'
p134
(F1
F0.00076452599388379206
I1
I0
I1
tp135
sS'potential,interactions,of'
p136
(F1
F0.00076452599388379206
I0
I1
I-1
tp137
sS'were,observed,in'
p138
(F0
F0
I1
I1
I0
tp139
sS'is,a,theoretical'
p140
(F1
F0.00076452599388379206
I1
I0
I1
tp141
sS'reaction,reports,of'
p142
(F1
F0.00076452599388379206
I1
I0
I1
tp143
sS'glycosides,diuretic-induced,hypokalemia'
p144
(F1
F0.00076452599388379206
I1
I0
I1
tp145
sS'patients,taking,tobi'
p146
(F1
F0.00076452599388379206
I1
I0
I1
tp147
sS'or,toxicity,and'
p148
(F1
F0.00076452599388379206
I1
I0
I1
tp149
sS'indicating,a,role'
p150
(F1
F0.00076452599388379206
I0
I1
I-1
tp151
sS'interactions,concomitant,administration'
p152
(F1
F0.00076452599388379206
I1
I0
I1
tp153
sS'by,the,they'
p154
(F1
F0.00076452599388379206
I1
I0
I1
tp155
sS'administered,should,be'
p156
(F1
F0.00076452599388379206
I1
I0
I1
tp157
sS'from,small,studies'
p158
(F1
F0.00076452599388379206
I1
I0
I1
tp159
sS'during,which,low-dose'
p160
(F1
F0.00076452599388379206
I0
I1
I-1
tp161
sS'time,of,onset'
p162
(F1
F0.00076452599388379206
I1
I0
I1
tp163
sS'the,data,presently'
p164
(F1
F0.00076452599388379206
I0
I1
I-1
tp165
sS'of,and,could'
p166
(F1
F0.00076452599388379206
I1
I0
I1
tp167
sS'interaction,studies,have'
p168
(F0.33333333333333331
F0.00076452599388379206
I1
I2
I-1
tp169
sS'reverse,transcriptase,inhibitors'
p170
(F1
F0.00076452599388379206
I0
I1
I-1
tp171
sS'slices,do,not'
p172
(F1
F0.00076452599388379206
I0
I1
I-1
tp173
sS'does,not,always'
p174
(F1
F0.00076452599388379206
I0
I1
I-1
tp175
sS'other,alpha-adrenergic,blocking'
p176
(F1
F0.00076452599388379206
I0
I1
I-1
tp177
sS'of,aceon,tablets'
p178
(F0
F0
I1
I1
I0
tp179
sS'of,zemuron,rocuronium'
p180
(F1
F0.00076452599388379206
I0
I1
I-1
tp181
sS'the,sequential,administration'
p182
(F1
F0.00076452599388379206
I1
I0
I1
tp183
sS'contraction,that,may'
p184
(F1
F0.00076452599388379206
I0
I1
I-1
tp185
sS'spiriva,with,other'
p186
(F1
F0.00076452599388379206
I1
I0
I1
tp187
sS'mixture,of,three'
p188
(F1
F0.00076452599388379206
I0
I1
I-1
tp189
sS'of,breath,and'
p190
(F1
F0.00076452599388379206
I1
I0
I1
tp191
sS'normal,weight,subjects'
p192
(F1
F0.00076452599388379206
I0
I1
I-1
tp193
sS'classes,of,drugs'
p194
(F1
F0.00076452599388379206
I0
I1
I-1
tp195
sS'or,ordinarily,should'
p196
(F1
F0.00076452599388379206
I1
I0
I1
tp197
sS'on,clinical,circumstances'
p198
(F1
F0.00076452599388379206
I1
I0
I1
tp199
sS'muscular,rigidity,severe'
p200
(F1
F0.00076452599388379206
I1
I0
I1
tp201
sS'additive,with,those'
p202
(F1
F0.0015290519877675841
I2
I0
I2
tp203
sS'mechanism,of,action'
p204
(F1
F0.00076452599388379206
I1
I0
I1
tp205
sS'to,moderate,renal'
p206
(F1
F0.0015290519877675841
I2
I0
I2
tp207
sS'use,of,drugs'
p208
(F1
F0.0015290519877675841
I2
I0
I2
tp209
sS'tid,to,healthy'
p210
(F1
F0.00076452599388379206
I1
I0
I1
tp211
sS'adverse,events,in'
p212
(F1
F0.00076452599388379206
I0
I1
I-1
tp213
sS'faster,with,and'
p214
(F1
F0.00076452599388379206
I1
I0
I1
tp215
sS'magnesium-containing,when,administered'
p216
(F1
F0.00076452599388379206
I1
I0
I1
tp217
sS'a,stable,digitalis'
p218
(F1
F0.00076452599388379206
I0
I1
I-1
tp219
sS'study,were,shown'
p220
(F1
F0.00076452599388379206
I0
I1
I-1
tp221
sS'replacement,therapies,thiazide'
p222
(F1
F0.00076452599388379206
I0
I1
I-1
tp223
sS'chemotherapy,tumor,response'
p224
(F1
F0.00076452599388379206
I1
I0
I1
tp225
sS's-adenosylhomocysteine,adohcy,hydrolase'
p226
(F1
F0.00076452599388379206
I0
I1
I-1
tp227
sS'inhibition,of,src'
p228
(F1
F0.00076452599388379206
I1
I0
I1
tp229
sS'gp,iib,iiia'
p230
(F1
F0.00076452599388379206
I1
I0
I1
tp231
sS'that,the,combined'
p232
(F1
F0.00076452599388379206
I1
I0
I1
tp233
sS'eliminated,predominantly,by'
p234
(F1
F0.00076452599388379206
I1
I0
I1
tp235
sS'compounds,may,be'
p236
(F1
F0.00076452599388379206
I1
I0
I1
tp237
sS'see,clinical,pharmacology'
p238
(F1
F0.00076452599388379206
I1
I0
I1
tp239
sS'of,cyp2c19,a'
p240
(F1
F0.00076452599388379206
I1
I0
I1
tp241
sS'creatinine,clearance,from'
p242
(F1
F0.00076452599388379206
I1
I0
I1
tp243
sS'there,is,evidence'
p244
(F1
F0.0015290519877675841
I2
I0
I2
tp245
sS'intense,and,prolonged'
p246
(F1
F0.00076452599388379206
I1
I0
I1
tp247
sS'patients,receiving,both'
p248
(F1
F0.00076452599388379206
I1
I0
I1
tp249
sS'of,from,plasma'
p250
(F1
F0.00076452599388379206
I0
I1
I-1
tp251
sS'the,liver,thus'
p252
(F1
F0.00076452599388379206
I1
I0
I1
tp253
sS'to,adult,mice'
p254
(F1
F0.00076452599388379206
I0
I1
I-1
tp255
sS'and,catecholamines,levels'
p256
(F1
F0.00076452599388379206
I0
I1
I-1
tp257
sS'of,cytochrome,p450'
p258
(F0
F0
I2
I2
I0
tp259
sS'reduces,dopaminergic,and'
p260
(F1
F0.00076452599388379206
I0
I1
I-1
tp261
sS'efficacy,of,single'
p262
(F1
F0.00076452599388379206
I0
I1
I-1
tp263
sS'and,group,mg'
p264
(F1
F0.00076452599388379206
I0
I1
I-1
tp265
sS'by,a,mechanism'
p266
(F1
F0.00076452599388379206
I1
I0
I1
tp267
sS'established,there,have'
p268
(F1
F0.00076452599388379206
I1
I0
I1
tp269
sS'minimized,by,either'
p270
(F1
F0.00076452599388379206
I1
I0
I1
tp271
sS'of,hb-egf,cross-reacting'
p272
(F1
F0.00076452599388379206
I0
I1
I-1
tp273
sS'analgesic,activity,of'
p274
(F1
F0.00076452599388379206
I1
I0
I1
tp275
sS'produce,additive,cns'
p276
(F1
F0.00076452599388379206
I0
I1
I-1
tp277
sS'in,the,following'
p278
(F1
F0.00076452599388379206
I0
I1
I-1
tp279
sS'acetic,acid,writhing'
p280
(F1
F0.00076452599388379206
I1
I0
I1
tp281
sS'ml,similar,increases'
p282
(F1
F0.00076452599388379206
I1
I0
I1
tp283
sS'cautiously,in,the'
p284
(F1
F0.00076452599388379206
I1
I0
I1
tp285
sS'anticholinergic-like,effects,may'
p286
(F1
F0.00076452599388379206
I1
I0
I1
tp287
sS'concentrations,of,and'
p288
(F1
F0.00076452599388379206
I1
I0
I1
tp289
sS'prolonged,the,duration'
p290
(F1
F0.00076452599388379206
I1
I0
I1
tp291
sS'cyp3a,activities,are'
p292
(F1
F0.00076452599388379206
I0
I1
I-1
tp293
sS'synergism,of,these'
p294
(F1
F0.00076452599388379206
I1
I0
I1
tp295
sS'the,absence,of'
p296
(F0
F0
I1
I1
I0
tp297
sS'is,not,significantly'
p298
(F0
F0
I1
I1
I0
tp299
sS'of,altabax,is'
p300
(F1
F0.00076452599388379206
I0
I1
I-1
tp301
sS'with,prothrombin,time'
p302
(F1
F0.00076452599388379206
I1
I0
I1
tp303
sS'local,since,the'
p304
(F1
F0.00076452599388379206
I1
I0
I1
tp305
sS'recommended,dose,and'
p306
(F1
F0.00076452599388379206
I0
I1
I-1
tp307
sS'with,was,also'
p308
(F1
F0.00076452599388379206
I0
I1
I-1
tp309
sS'concentrations,are,increased'
p310
(F1
F0.00076452599388379206
I0
I1
I-1
tp311
sS'including,torsade,de'
p312
(F1
F0.00076452599388379206
I1
I0
I1
tp313
sS'dose,adjustment,of'
p314
(F1
F0.00076452599388379206
I1
I0
I1
tp315
sS'gsls,may,be'
p316
(F1
F0.00076452599388379206
I0
I1
I-1
tp317
sS'fludrocortisone,acetate,with'
p318
(F1
F0.00076452599388379206
I0
I1
I-1
tp319
sS'not,significantly,altered'
p320
(F1
F0.00076452599388379206
I1
I0
I1
tp321
sS'mg,of,ziagen'
p322
(F1
F0.00076452599388379206
I1
I0
I1
tp323
sS'with,an,increased'
p324
(F1
F0.00076452599388379206
I0
I1
I-1
tp325
sS'and,may,inhibit'
p326
(F1
F0.0015290519877675841
I2
I0
I2
tp327
sS'of,dtic,and'
p328
(F1
F0.00076452599388379206
I0
I1
I-1
tp329
sS'cmax,by,after'
p330
(F1
F0.00076452599388379206
I1
I0
I1
tp331
sS'of,xenical,and'
p332
(F1
F0.00076452599388379206
I0
I1
I-1
tp333
sS'enhanced,by,drugs'
p334
(F1
F0.00076452599388379206
I1
I0
I1
tp335
sS'may,enhance,or'
p336
(F1
F0.0015290519877675841
I2
I0
I2
tp337
sS'remeron,were,shown'
p338
(F1
F0.00076452599388379206
I1
I0
I1
tp339
sS'prolonged,by,concurrent'
p340
(F1
F0.00076452599388379206
I1
I0
I1
tp341
sS'expression,of,hb-egf'
p342
(F1
F0.00076452599388379206
I0
I1
I-1
tp343
sS'opioid,analgesics,may'
p344
(F1
F0.00076452599388379206
I1
I0
I1
tp345
sS'response,to,the'
p346
(F1
F0.00076452599388379206
I1
I0
I1
tp347
sS'alcohol,barbiturates,and'
p348
(F1
F0.00076452599388379206
I0
I1
I-1
tp349
sS'dasatinib-enhanced,cytotoxicity,in'
p350
(F1
F0.00076452599388379206
I1
I0
I1
tp351
sS'to,its,effects'
p352
(F1
F0.00076452599388379206
I1
I0
I1
tp353
sS'plasma,levels,returned'
p354
(F1
F0.00076452599388379206
I1
I0
I1
tp355
sS'caution,or,not'
p356
(F1
F0.0015290519877675841
I2
I0
I2
tp357
sS'efficiently,suppressed,by'
p358
(F1
F0.00076452599388379206
I1
I0
I1
tp359
sS'in,vitro,in'
p360
(F1
F0.0015290519877675841
I2
I0
I2
tp361
sS'contraindicated,pending,full'
p362
(F1
F0.00076452599388379206
I1
I0
I1
tp363
sS'events,including,torsade'
p364
(F1
F0.00076452599388379206
I1
I0
I1
tp365
sS'absorption,of,supplemental'
p366
(F1
F0.00076452599388379206
I0
I1
I-1
tp367
sS'either,or,both'
p368
(F1
F0.00076452599388379206
I0
I1
I-1
tp369
sS'qt,interval,prolongation'
p370
(F0.33333333333333331
F0.00076452599388379206
I2
I1
I1
tp371
sS'use,of,potassium-sparing'
p372
(F0
F0
I1
I1
I0
tp373
sS'virus,may,increase'
p374
(F1
F0.00076452599388379206
I1
I0
I1
tp375
sS'particular,focus,on'
p376
(F1
F0.00076452599388379206
I0
I1
I-1
tp377
sS'least,days,before'
p378
(F1
F0.00076452599388379206
I1
I0
I1
tp379
sS'in,either,of'
p380
(F1
F0.00076452599388379206
I0
I1
I-1
tp381
sS'since,the,action'
p382
(F1
F0.00076452599388379206
I1
I0
I1
tp383
sS'pressor,amines,is'
p384
(F1
F0.0015290519877675841
I2
I0
I2
tp385
sS'mg,kg,day'
p386
(F1
F0.0030581039755351682
I0
I4
I-4
tp387
sS'small,studies,indicate'
p388
(F1
F0.00076452599388379206
I1
I0
I1
tp389
sS'oral,contraceptives,stavudine'
p390
(F1
F0.00076452599388379206
I1
I0
I1
tp391
sS'may,develop,during'
p392
(F1
F0.00076452599388379206
I0
I1
I-1
tp393
sS'cell,lines,and'
p394
(F1
F0.0015290519877675841
I0
I2
I-2
tp395
sS'in,either,or'
p396
(F1
F0.00076452599388379206
I0
I1
I-1
tp397
sS'intensity,and,duration'
p398
(F1
F0.00076452599388379206
I1
I0
I1
tp399
sS'this,randomized,blinded'
p400
(F1
F0.00076452599388379206
I0
I1
I-1
tp401
sS'mg,maximum,mg'
p402
(F1
F0.00076452599388379206
I0
I1
I-1
tp403
sS'of,inhospital,administration'
p404
(F1
F0.00076452599388379206
I1
I0
I1
tp405
sS'efficacy,of,fixed'
p406
(F1
F0.00076452599388379206
I0
I1
I-1
tp407
sS'dopamine,transporter,and'
p408
(F1
F0.00076452599388379206
I1
I0
I1
tp409
sS'pharmacokinetics,of,taken'
p410
(F1
F0.00076452599388379206
I0
I1
I-1
tp411
sS'kg,was,similar'
p412
(F1
F0.00076452599388379206
I0
I1
I-1
tp413
sS'aceon,tablets,for'
p414
(F1
F0.00076452599388379206
I1
I0
I1
tp415
sS'combination,with,ultram'
p416
(F1
F0.00076452599388379206
I0
I1
I-1
tp417
sS'by,during,coadministration'
p418
(F1
F0.00076452599388379206
I1
I0
I1
tp419
sS'single,use,of'
p420
(F1
F0.00076452599388379206
I0
I1
I-1
tp421
sS'not,appreciably,metabolized'
p422
(F1
F0.00076452599388379206
I0
I1
I-1
tp423
sS'a,stable,regimen'
p424
(F1
F0.00076452599388379206
I0
I1
I-1
tp425
sS'under,the,curve'
p426
(F1
F0.00076452599388379206
I1
I0
I1
tp427
sS'other,diabetes,drug'
p428
(F1
F0.00076452599388379206
I1
I0
I1
tp429
sS'to,streptokinase,causes'
p430
(F1
F0.00076452599388379206
I1
I0
I1
tp431
sS'enzymes,may,change'
p432
(F1
F0.00076452599388379206
I0
I1
I-1
tp433
sS'dose,of,vesicare'
p434
(F1
F0.00076452599388379206
I1
I0
I1
tp435
sS'qrs,qtc,rr'
p436
(F1
F0.00076452599388379206
I0
I1
I-1
tp437
sS'only,known,component'
p438
(F1
F0.00076452599388379206
I1
I0
I1
tp439
sS'bind,bile,acids'
p440
(F0
F0
I1
I1
I0
tp441
sS'with,acute,coronary'
p442
(F1
F0.00076452599388379206
I1
I0
I1
tp443
sS'and,generally,should'
p444
(F1
F0.00076452599388379206
I1
I0
I1
tp445
sS'a,is,also'
p446
(F1
F0.00076452599388379206
I1
I0
I1
tp447
sS'data,from,a'
p448
(F1
F0.00076452599388379206
I1
I0
I1
tp449
sS'when,mykrox,tablets'
p450
(F1
F0.00076452599388379206
I1
I0
I1
tp451
sS'clinical,dose,of'
p452
(F1
F0.00076452599388379206
I0
I1
I-1
tp453
sS'who,experienced,a'
p454
(F1
F0.00076452599388379206
I1
I0
I1
tp455
sS'activity,is,significantly'
p456
(F1
F0.00076452599388379206
I0
I1
I-1
tp457
sS'with,reduced,the'
p458
(F1
F0.00076452599388379206
I1
I0
I1
tp459
sS'with,a,proof'
p460
(F1
F0.00076452599388379206
I1
I0
I1
tp461
sS'measurement,of,vma'
p462
(F1
F0.00076452599388379206
I0
I1
I-1
tp463
sS'metabolised,by,hepatic'
p464
(F1
F0.00076452599388379206
I1
I0
I1
tp465
sS'adjustment,is,needed'
p466
(F1
F0.00076452599388379206
I0
I1
I-1
tp467
sS'as,and,vitamin'
p468
(F1
F0.00076452599388379206
I1
I0
I1
tp469
sS'or,sedation,the'
p470
(F1
F0.00076452599388379206
I1
I0
I1
tp471
sS'after,starting,mexitil'
p472
(F1
F0.00076452599388379206
I1
I0
I1
tp473
sS'administered,medication,which'
p474
(F1
F0.00076452599388379206
I1
I0
I1
tp475
sS'but,to,a'
p476
(F1
F0.00076452599388379206
I1
I0
I1
tp477
sS'estrogen,antagonist,is'
p478
(F1
F0.00076452599388379206
I0
I1
I-1
tp479
sS'are,fluoroquinolone,used'
p480
(F1
F0.00076452599388379206
I0
I1
I-1
tp481
sS'to,sharply,increase'
p482
(F1
F0.00076452599388379206
I1
I0
I1
tp483
sS'plasma,concentrations,and'
p484
(F1
F0.00076452599388379206
I1
I0
I1
tp485
sS'drug-drug,interactions,with'
p486
(F1
F0.00076452599388379206
I1
I0
I1
tp487
sS'displace,from,its'
p488
(F1
F0.0015290519877675841
I0
I2
I-2
tp489
sS'followed,by,synergism'
p490
(F1
F0.00076452599388379206
I1
I0
I1
tp491
sS'dopamine,antagonists,since'
p492
(F1
F0.00076452599388379206
I1
I0
I1
tp493
sS'adrenergic,blockers,increase'
p494
(F1
F0.00076452599388379206
I1
I0
I1
tp495
sS'metabolism,and,that'
p496
(F1
F0.00076452599388379206
I1
I0
I1
tp497
sS'was,conducted,in'
p498
(F1
F0.00076452599388379206
I0
I1
I-1
tp499
sS'should,be,kept'
p500
(F0
F0
I1
I1
I0
tp501
sS'drugs,may,antagonize'
p502
(F1
F0.00076452599388379206
I1
I0
I1
tp503
sS'to,establish,potential'
p504
(F1
F0.00076452599388379206
I0
I1
I-1
tp505
sS'abc,lyase,greatly'
p506
(F1
F0.00076452599388379206
I0
I1
I-1
tp507
sS'will,be,additive'
p508
(F1
F0.00076452599388379206
I1
I0
I1
tp509
sS'of,uveitis,in'
p510
(F1
F0.00076452599388379206
I1
I0
I1
tp511
sS'achieve,appropriate,igf-i'
p512
(F1
F0.00076452599388379206
I1
I0
I1
tp513
sS'injected,with,inactivated'
p514
(F1
F0.00076452599388379206
I0
I1
I-1
tp515
sS'as,large,as'
p516
(F1
F0.00076452599388379206
I0
I1
I-1
tp517
sS'effect,on,appears'
p518
(F1
F0.00076452599388379206
I1
I0
I1
tp519
sS'interactions,occurred,when'
p520
(F1
F0.00076452599388379206
I0
I1
I-1
tp521
sS'especially,those,started'
p522
(F1
F0.00076452599388379206
I1
I0
I1
tp523
sS'confusion,disorientation,respiratory'
p524
(F1
F0.00076452599388379206
I1
I0
I1
tp525
sS'vitro,and,in'
p526
(F1
F0.0015290519877675841
I0
I2
I-2
tp527
sS'and,long,lasting'
p528
(F1
F0.00076452599388379206
I1
I0
I1
tp529
sS'bp,and,days'
p530
(F1
F0.00076452599388379206
I1
I0
I1
tp531
sS'or,sequential,administration'
p532
(F1
F0.00076452599388379206
I0
I1
I-1
tp533
sS'cns,depressant,tca'
p534
(F1
F0.00076452599388379206
I1
I0
I1
tp535
sS'while,dosing,with'
p536
(F1
F0.00076452599388379206
I1
I0
I1
tp537
sS'results,if,confirmed'
p538
(F1
F0.00076452599388379206
I0
I1
I-1
tp539
sS'or,other,complications'
p540
(F1
F0.00076452599388379206
I1
I0
I1
tp541
sS'unaltered,with,xenical'
p542
(F1
F0.00076452599388379206
I0
I1
I-1
tp543
sS'renal,function,as'
p544
(F1
F0.00076452599388379206
I1
I0
I1
tp545
sS'observed,before,the'
p546
(F1
F0.00076452599388379206
I1
I0
I1
tp547
sS'live,attenuated,vaccines'
p548
(F1
F0.00076452599388379206
I1
I0
I1
tp549
sS'increase,was,observed'
p550
(F1
F0.00076452599388379206
I1
I0
I1
tp551
sS'and,certain,interact'
p552
(F1
F0.00076452599388379206
I1
I0
I1
tp553
sS'cautiously,if,at'
p554
(F1
F0.00076452599388379206
I1
I0
I1
tp555
sS'way,crossover,study'
p556
(F1
F0.00076452599388379206
I0
I1
I-1
tp557
sS'administered,with,an'
p558
(F1
F0.00076452599388379206
I0
I1
I-1
tp559
sS'renal,function,has'
p560
(F1
F0.00076452599388379206
I1
I0
I1
tp561
sS'the,antihypertensive,effects'
p562
(F1
F0.00076452599388379206
I1
I0
I1
tp563
sS'concentrations,of,salicylic'
p564
(F1
F0.00076452599388379206
I1
I0
I1
tp565
sS'was,associated,with'
p566
(F0.33333333333333331
F0.00076452599388379206
I2
I1
I1
tp567
sS'a,database,of'
p568
(F1
F0.00076452599388379206
I0
I1
I-1
tp569
sS'characterization,of,potential'
p570
(F1
F0.00076452599388379206
I1
I0
I1
tp571
sS'of,an,hiv-positive'
p572
(F1
F0.00076452599388379206
I1
I0
I1
tp573
sS'therapeutic,effect,of'
p574
(F1
F0.00076452599388379206
I0
I1
I-1
tp575
sS'pharmacodynamics,fecal,fat'
p576
(F1
F0.00076452599388379206
I0
I1
I-1
tp577
sS'the,therapeutic,effect'
p578
(F1
F0.00076452599388379206
I0
I1
I-1
tp579
sS'xenical,inhibited,absorption'
p580
(F1
F0.00076452599388379206
I1
I0
I1
tp581
sS'hypoglycemia,may,be'
p582
(F1
F0.00076452599388379206
I1
I0
I1
tp583
sS'blockers,n,n'
p584
(F1
F0.00076452599388379206
I0
I1
I-1
tp585
sS'studies,were,conducted'
p586
(F1
F0.00076452599388379206
I0
I1
I-1
tp587
sS'mexitil,plasma,levels'
p588
(F1
F0.00076452599388379206
I1
I0
I1
tp589
sS'pt,and,international'
p590
(F1
F0.00076452599388379206
I1
I0
I1
tp591
sS'system,particularly,eg'
p592
(F1
F0.00076452599388379206
I1
I0
I1
tp593
sS'of,supplemental,analgesic'
p594
(F1
F0.00076452599388379206
I1
I0
I1
tp595
sS'which,limits,the'
p596
(F1
F0.00076452599388379206
I1
I0
I1
tp597
sS'enzyme,care,should'
p598
(F1
F0.00076452599388379206
I1
I0
I1
tp599
sS'when,the,dose'
p600
(F1
F0.00076452599388379206
I1
I0
I1
tp601
sS'mobic,is,not'
p602
(F1
F0.00076452599388379206
I0
I1
I-1
tp603
sS'cause,weakness,hyperreflexia'
p604
(F1
F0.00076452599388379206
I1
I0
I1
tp605
sS'rat,liver,has'
p606
(F1
F0.00076452599388379206
I1
I0
I1
tp607
sS'ethanol,decreases,the'
p608
(F1
F0.00076452599388379206
I1
I0
I1
tp609
sS'that,these,effects'
p610
(F1
F0.00076452599388379206
I1
I0
I1
tp611
sS'of,leukine,such'
p612
(F1
F0.00076452599388379206
I1
I0
I1
tp613
sS'to,toxicity,the'
p614
(F1
F0.00076452599388379206
I0
I1
I-1
tp615
sS'sites,will,elevate'
p616
(F1
F0.00076452599388379206
I0
I1
I-1
tp617
sS'a,p450,enzyme'
p618
(F1
F0.00076452599388379206
I0
I1
I-1
tp619
sS'may,be,necessary'
p620
(F1
F0.0022935779816513763
I3
I0
I3
tp621
sS'is,increased,with'
p622
(F1
F0.00076452599388379206
I1
I0
I1
tp623
sS'streptozocin,has,been'
p624
(F1
F0.00076452599388379206
I1
I0
I1
tp625
sS'initiates,or,discontinues'
p626
(F1
F0.00076452599388379206
I1
I0
I1
tp627
sS'effect,of,as'
p628
(F0
F0
I1
I1
I0
tp629
sS'that,myfortic,not'
p630
(F1
F0.00076452599388379206
I1
I0
I1
tp631
sS'any,of,these'
p632
(F1
F0.00076452599388379206
I0
I1
I-1
tp633
sS'be,administered,until'
p634
(F1
F0.00076452599388379206
I0
I1
I-1
tp635
sS'of,mpag,hydrolysis'
p636
(F1
F0.00076452599388379206
I0
I1
I-1
tp637
sS'or,other,centrally'
p638
(F1
F0.00076452599388379206
I0
I1
I-1
tp639
sS'absorption,of,fat-soluble'
p640
(F1
F0.00076452599388379206
I1
I0
I1
tp641
sS'of,or,of'
p642
(F1
F0.00076452599388379206
I0
I1
I-1
tp643
sS'with,ace,inhibitors'
p644
(F1
F0.00076452599388379206
I1
I0
I1
tp645
sS'p-450,drug-metabolizing,enzymes'
p646
(F1
F0.00076452599388379206
I0
I1
I-1
tp647
sS'use,of,mivacron'
p648
(F1
F0.0015290519877675841
I0
I2
I-2
tp649
sS'enhances,the,metabolism'
p650
(F1
F0.00076452599388379206
I1
I0
I1
tp651
sS'potentiated,by,inhibition'
p652
(F1
F0.00076452599388379206
I1
I0
I1
tp653
sS'probenecid,a,known'
p654
(F1
F0.00076452599388379206
I0
I1
I-1
tp655
sS'dopaminergic,and,noradrenergic'
p656
(F0
F0
I1
I1
I0
tp657
sS'macrolide,and,may'
p658
(F1
F0.00076452599388379206
I1
I0
I1
tp659
sS'concurrently,with,commonly'
p660
(F1
F0.00076452599388379206
I0
I1
I-1
tp661
sS'the,virus,may'
p662
(F1
F0.00076452599388379206
I1
I0
I1
tp663
sS'tubularly,secreted,could'
p664
(F1
F0.00076452599388379206
I1
I0
I1
tp665
sS'clinical,trials,the'
p666
(F1
F0.00076452599388379206
I0
I1
I-1
tp667
sS'addition,of,has'
p668
(F1
F0.00076452599388379206
I1
I0
I1
tp669
sS'used,during,anesthesia'
p670
(F1
F0.00076452599388379206
I0
I1
I-1
tp671
sS'women,and,other'
p672
(F1
F0.00076452599388379206
I1
I0
I1
tp673
sS'other,drugs,eliminated'
p674
(F1
F0.00076452599388379206
I1
I0
I1
tp675
sS'levels,of,are'
p676
(F1
F0.00076452599388379206
I1
I0
I1
tp677
sS'basic,media,and'
p678
(F1
F0.00076452599388379206
I1
I0
I1
tp679
sS'have,little,effect'
p680
(F1
F0.00076452599388379206
I1
I0
I1
tp681
sS'requirements,of,diprivan'
p682
(F1
F0.00076452599388379206
I1
I0
I1
tp683
sS'valproic,acid,to'
p684
(F1
F0.00076452599388379206
I1
I0
I1
tp685
sS'shrinkage,of,multiple'
p686
(F1
F0.00076452599388379206
I1
I0
I1
tp687
sS'include,divalproex,sodium'
p688
(F1
F0.00076452599388379206
I0
I1
I-1
tp689
sS'torsades,de,pointe'
p690
(F1
F0.00076452599388379206
I1
I0
I1
tp691
sS'ratio,of,gastrointestinal'
p692
(F1
F0.00076452599388379206
I1
I0
I1
tp693
sS'to,but,this'
p694
(F1
F0.00076452599388379206
I1
I0
I1
tp695
sS'be,avoided,and'
p696
(F1
F0.00076452599388379206
I1
I0
I1
tp697
sS'induced,apoptosis,of'
p698
(F1
F0.00076452599388379206
I1
I0
I1
tp699
sS'was,to,analyze'
p700
(F1
F0.00076452599388379206
I0
I1
I-1
tp701
sS'intramuscular,or,intravenous'
p702
(F1
F0.00076452599388379206
I1
I0
I1
tp703
sS'low,doses,of'
p704
(F1
F0.00076452599388379206
I0
I1
I-1
tp705
sS'trental,with,and'
p706
(F1
F0.00076452599388379206
I1
I0
I1
tp707
sS'clearance,of,chronic'
p708
(F1
F0.0015290519877675841
I2
I0
I2
tp709
sS'toxic,effects,of'
p710
(F1
F0.00076452599388379206
I1
I0
I1
tp711
sS'milligrams,of,nonheme'
p712
(F1
F0.00076452599388379206
I0
I1
I-1
tp713
sS'drugs,hcl,hcl'
p714
(F1
F0.00076452599388379206
I1
I0
I1
tp715
sS'with,other,macrolide'
p716
(F1
F0.00076452599388379206
I1
I0
I1
tp717
sS'subjects,administration,of'
p718
(F1
F0.00076452599388379206
I0
I1
I-1
tp719
sS'combination,n,or'
p720
(F1
F0.00076452599388379206
I0
I1
I-1
tp721
sS'thiazide,drugs,may'
p722
(F1
F0.00076452599388379206
I1
I0
I1
tp723
sS'a,controlled,pharmacokinetic'
p724
(F1
F0.00076452599388379206
I1
I0
I1
tp725
sS'phenytoin,can,increase'
p726
(F1
F0.00076452599388379206
I1
I0
I1
tp727
sS'and,arrested,cell'
p728
(F1
F0.00076452599388379206
I0
I1
I-1
tp729
sS'drugs,may,predispose'
p730
(F1
F0.00076452599388379206
I1
I0
I1
tp731
sS'affected,by,concurrent'
p732
(F1
F0.0015290519877675841
I0
I2
I-2
tp733
sS'patients,with,intramuscular'
p734
(F1
F0.00076452599388379206
I1
I0
I1
tp735
sS'is,unlikely,to'
p736
(F1
F0.0015290519877675841
I0
I2
I-2
tp737
sS'caution,should,be'
p738
(F0.66666666666666663
F0.0061162079510703364
I10
I2
I8
tp739
sS'who,were,conditioned'
p740
(F1
F0.00076452599388379206
I1
I0
I1
tp741
sS'half,because,amplifies'
p742
(F1
F0.00076452599388379206
I1
I0
I1
tp743
sS'vehicle-treated,animals,displayed'
p744
(F1
F0.00076452599388379206
I1
I0
I1
tp745
sS'digitalis,glycosides,serum'
p746
(F1
F0.00076452599388379206
I0
I1
I-1
tp747
sS'that,produce,dry'
p748
(F1
F0.00076452599388379206
I1
I0
I1
tp749
sS'transplant,patients,also'
p750
(F1
F0.00076452599388379206
I1
I0
I1
tp751
sS'cyp1a2,cyp2a6,cyp2c9'
p752
(F1
F0.00076452599388379206
I0
I1
I-1
tp753
sS'may,inhibit,its'
p754
(F1
F0.00076452599388379206
I1
I0
I1
tp755
sS'gsls,at,a'
p756
(F1
F0.00076452599388379206
I0
I1
I-1
tp757
sS'dose,of,myfortic'
p758
(F1
F0.00076452599388379206
I1
I0
I1
tp759
sS'depression,does,not'
p760
(F1
F0.00076452599388379206
I0
I1
I-1
tp761
sS'must,be,taken'
p762
(F1
F0.00076452599388379206
I1
I0
I1
tp763
sS'patients,concurrently,administered'
p764
(F1
F0.00076452599388379206
I1
I0
I1
tp765
sS'vaccination,and,decrease'
p766
(F1
F0.00076452599388379206
I1
I0
I1
tp767
sS'metabolized,eliminated,predominantly'
p768
(F1
F0.00076452599388379206
I1
I0
I1
tp769
sS'due,to,low'
p770
(F1
F0.00076452599388379206
I0
I1
I-1
tp771
sS'and,beta,adrenergic'
p772
(F1
F0.00076452599388379206
I1
I0
I1
tp773
sS'time,pt,and'
p774
(F1
F0.00076452599388379206
I1
I0
I1
tp775
sS'of,acetyl-l,carnitine'
p776
(F1
F0.00076452599388379206
I0
I1
I-1
tp777
sS'auc,of,and'
p778
(F1
F0.00076452599388379206
I1
I0
I1
tp779
sS'cylert,with,other'
p780
(F1
F0.00076452599388379206
I0
I1
I-1
tp781
sS'tablets,in,patients'
p782
(F1
F0.00076452599388379206
I1
I0
I1
tp783
sS'mg,bid,with'
p784
(F1
F0.00076452599388379206
I1
I0
I1
tp785
sS'unaffected,by,steady'
p786
(F1
F0.00076452599388379206
I0
I1
I-1
tp787
sS'total,clearance,in'
p788
(F1
F0.00076452599388379206
I1
I0
I1
tp789
sS's,wort,and'
p790
(F1
F0.00076452599388379206
I1
I0
I1
tp791
sS'extent,of,neuronal'
p792
(F1
F0.00076452599388379206
I1
I0
I1
tp793
sS'their,coexistence,may'
p794
(F1
F0.00076452599388379206
I0
I1
I-1
tp795
sS'adolescent,male,and'
p796
(F1
F0.00076452599388379206
I0
I1
I-1
tp797
sS'expected,to,be'
p798
(F1
F0.00076452599388379206
I1
I0
I1
tp799
sS'is,possible,that'
p800
(F1
F0.0015290519877675841
I2
I0
I2
tp801
sS'during,concomitant,therapy'
p802
(F1
F0.00076452599388379206
I1
I0
I1
tp803
sS'with,caution,in'
p804
(F1
F0.0038226299694189602
I5
I0
I5
tp805
sS'with,a,high'
p806
(F1
F0.00076452599388379206
I1
I0
I1
tp807
sS'a,limited,effect'
p808
(F1
F0.00076452599388379206
I0
I1
I-1
tp809
sS'the,signaling,pathways'
p810
(F1
F0.00076452599388379206
I1
I0
I1
tp811
sS'the,extent,of'
p812
(F0
F0
I1
I1
I0
tp813
sS'and,a,reduction'
p814
(F1
F0.00076452599388379206
I1
I0
I1
tp815
sS'affecting,hepatic,metabolism'
p816
(F1
F0.00076452599388379206
I0
I1
I-1
tp817
sS'isoflurane,and,administered'
p818
(F1
F0.00076452599388379206
I0
I1
I-1
tp819
sS'reduce,the,natriuretic'
p820
(F1
F0.00076452599388379206
I1
I0
I1
tp821
sS'effects,in,the'
p822
(F1
F0.00076452599388379206
I1
I0
I1
tp823
sS'drug,interaction,of'
p824
(F1
F0.00076452599388379206
I0
I1
I-1
tp825
sS'enhance,or,potentiate'
p826
(F1
F0.00076452599388379206
I1
I0
I1
tp827
sS'absorption,mainly,comes'
p828
(F1
F0.00076452599388379206
I1
I0
I1
tp829
sS'that,there,are'
p830
(F1
F0.00076452599388379206
I0
I1
I-1
tp831
sS'and,between,and'
p832
(F1
F0.00076452599388379206
I1
I0
I1
tp833
sS'plasma,concentration,of'
p834
(F1
F0.0022935779816513763
I3
I0
I3
tp835
sS'of,the,type'
p836
(F1
F0.00076452599388379206
I1
I0
I1
tp837
sS'clinically,important,pharmacokinetic'
p838
(F1
F0.0015290519877675841
I0
I2
I-2
tp839
sS'were,increased,by'
p840
(F1
F0.0015290519877675841
I2
I0
I2
tp841
sS'model,nitrogen,substituted'
p842
(F1
F0.00076452599388379206
I1
I0
I1
tp843
sS'and,female,rats'
p844
(F1
F0.00076452599388379206
I0
I1
I-1
tp845
sS'to,evaluate,the'
p846
(F1
F0.0022935779816513763
I0
I3
I-3
tp847
sS'have,been,rare'
p848
(F1
F0.00076452599388379206
I0
I1
I-1
tp849
sS'cisapride,astemizole,rifabutin'
p850
(F1
F0.00076452599388379206
I1
I0
I1
tp851
sS'the,liver,s'
p852
(F1
F0.00076452599388379206
I1
I0
I1
tp853
sS'specific,metabotropic,glutamate'
p854
(F1
F0.00076452599388379206
I0
I1
I-1
tp855
sS'may,have,an'
p856
(F1
F0.0015290519877675841
I2
I0
I2
tp857
sS'a,new,medication'
p858
(F1
F0.00076452599388379206
I1
I0
I1
tp859
sS'the,mean,auc'
p860
(F1
F0.00076452599388379206
I1
I0
I1
tp861
sS'receiving,treatment,with'
p862
(F1
F0.0015290519877675841
I2
I0
I2
tp863
sS'in,in-vivo,plasma'
p864
(F1
F0.00076452599388379206
I1
I0
I1
tp865
sS'system,and,are'
p866
(F1
F0.00076452599388379206
I1
I0
I1
tp867
sS'controlled,studies,documenting'
p868
(F1
F0.00076452599388379206
I0
I1
I-1
tp869
sS'effects,of,central'
p870
(F1
F0.00076452599388379206
I1
I0
I1
tp871
sS'of,the,virus'
p872
(F1
F0.00076452599388379206
I1
I0
I1
tp873
sS'medication,which,depresses'
p874
(F1
F0.00076452599388379206
I1
I0
I1
tp875
sS'absorption,of,various'
p876
(F1
F0.00076452599388379206
I1
I0
I1
tp877
sS'another,study,at'
p878
(F1
F0.00076452599388379206
I1
I0
I1
tp879
sS'of,vma,vanillylmandelic'
p880
(F1
F0.00076452599388379206
I0
I1
I-1
tp881
sS'cyp3a,isozymes,have'
p882
(F1
F0.00076452599388379206
I1
I0
I1
tp883
sS'be,closely,monitored'
p884
(F1
F0.0015290519877675841
I2
I0
I2
tp885
sS'not,have,a'
p886
(F1
F0.00076452599388379206
I0
I1
I-1
tp887
sS'the,molecular,basis'
p888
(F1
F0.00076452599388379206
I1
I0
I1
tp889
sS'parkinsonian,symptoms,whereas'
p890
(F1
F0.00076452599388379206
I1
I0
I1
tp891
sS'been,investigated,in'
p892
(F1
F0.00076452599388379206
I0
I1
I-1
tp893
sS'of,or,these'
p894
(F1
F0.00076452599388379206
I1
I0
I1
tp895
sS'activity,sympathomimetic,drugs'
p896
(F1
F0.00076452599388379206
I1
I0
I1
tp897
sS'following,the,coadministration'
p898
(F1
F0.00076452599388379206
I1
I0
I1
tp899
sS'patients,concurrently,receiving'
p900
(F1
F0.00076452599388379206
I0
I1
I-1
tp901
sS'disease,and,avian'
p902
(F1
F0.00076452599388379206
I0
I1
I-1
tp903
sS'clearance,and,hence'
p904
(F1
F0.00076452599388379206
I0
I1
I-1
tp905
sS'of,acute,myocardial'
p906
(F1
F0.00076452599388379206
I0
I1
I-1
tp907
sS'received,low-dose,in'
p908
(F1
F0.00076452599388379206
I0
I1
I-1
tp909
sS'streptokinase,causes,a'
p910
(F1
F0.00076452599388379206
I1
I0
I1
tp911
sS'fst,in,glass'
p912
(F1
F0.00076452599388379206
I0
I1
I-1
tp913
sS'secretion,of,in'
p914
(F1
F0.00076452599388379206
I1
I0
I1
tp915
sS'noticeably,effective,indicating'
p916
(F1
F0.00076452599388379206
I0
I1
I-1
tp917
sS'potent,inhalational,agents'
p918
(F1
F0.00076452599388379206
I0
I1
I-1
tp919
sS'may,increase,serum'
p920
(F1
F0.00076452599388379206
I0
I1
I-1
tp921
sS'inhibitor,of,cyp2c8'
p922
(F1
F0.00076452599388379206
I1
I0
I1
tp923
sS'or,inhibit,cyp450'
p924
(F1
F0.00076452599388379206
I0
I1
I-1
tp925
sS'are,increased,in'
p926
(F1
F0.00076452599388379206
I0
I1
I-1
tp927
sS'effect,of,symlin'
p928
(F1
F0.00076452599388379206
I0
I1
I-1
tp929
sS'mild,hepatotoxicity,has'
p930
(F1
F0.00076452599388379206
I1
I0
I1
tp931
sS'trilostane,may,interact'
p932
(F1
F0.00076452599388379206
I1
I0
I1
tp933
sS'torsades,de,pointes'
p934
(F0
F0
I1
I1
I0
tp935
sS'drugs,oral,hormone'
p936
(F1
F0.00076452599388379206
I0
I1
I-1
tp937
sS'of,other,drugs'
p938
(F0.5
F0.0015290519877675841
I1
I3
I-2
tp939
sS'significantly,reduces,methyl-4'
p940
(F1
F0.00076452599388379206
I1
I0
I1
tp941
sS'with,or,causing'
p942
(F1
F0.00076452599388379206
I1
I0
I1
tp943
sS'the,poor,cyp2d6'
p944
(F1
F0.00076452599388379206
I0
I1
I-1
tp945
sS'less,than,milligrams'
p946
(F1
F0.00076452599388379206
I0
I1
I-1
tp947
sS'or,other,drugs'
p948
(F0
F0
I1
I1
I0
tp949
sS'of,cell,surface'
p950
(F1
F0.00076452599388379206
I1
I0
I1
tp951
sS'ointment,on,the'
p952
(F1
F0.00076452599388379206
I1
I0
I1
tp953
sS'concurrently,receiving,certain'
p954
(F1
F0.00076452599388379206
I0
I1
I-1
tp955
sS'mexitil,has,been'
p956
(F0.33333333333333331
F0.00076452599388379206
I2
I1
I1
tp957
sS'effects,on,the'
p958
(F1
F0.00076452599388379206
I0
I1
I-1
tp959
sS'the,aim,of'
p960
(F1
F0.00076452599388379206
I0
I1
I-1
tp961
sS'oral,adjuvant,to'
p962
(F1
F0.00076452599388379206
I0
I1
I-1
tp963
sS'the,result,of'
p964
(F1
F0.0015290519877675841
I0
I2
I-2
tp965
sS'chemet,is,not'
p966
(F1
F0.00076452599388379206
I0
I1
I-1
tp967
sS'closely,monitor,patients'
p968
(F1
F0.0015290519877675841
I2
I0
I2
tp969
sS'there,is,in'
p970
(F1
F0.00076452599388379206
I1
I0
I1
tp971
sS'action,of,the'
p972
(F1
F0.00076452599388379206
I0
I1
I-1
tp973
sS'system,may,elicit'
p974
(F1
F0.00076452599388379206
I0
I1
I-1
tp975
sS'of,neonatal,treatment'
p976
(F1
F0.00076452599388379206
I0
I1
I-1
tp977
sS'caution,is,recommended'
p978
(F1
F0.0015290519877675841
I2
I0
I2
tp979
sS'ingestion,of,ml'
p980
(F1
F0.00076452599388379206
I0
I1
I-1
tp981
sS'monitoring,of,panobinostat-related'
p982
(F1
F0.00076452599388379206
I0
I1
I-1
tp983
sS'other,narcotic,analgesics'
p984
(F1
F0.00076452599388379206
I1
I0
I1
tp985
sS'the,sirna,knockdown'
p986
(F1
F0.00076452599388379206
I0
I1
I-1
tp987
sS'dosage,adjustment,is'
p988
(F1
F0.00076452599388379206
I0
I1
I-1
tp989
sS'was,also,conducted'
p990
(F1
F0.00076452599388379206
I0
I1
I-1
tp991
sS'was,observed,at'
p992
(F0
F0
I1
I1
I0
tp993
sS'of,to,human'
p994
(F1
F0.00076452599388379206
I0
I1
I-1
tp995
sS'show,that,there'
p996
(F1
F0.00076452599388379206
I0
I1
I-1
tp997
sS'not,only,enhanced'
p998
(F1
F0.00076452599388379206
I1
I0
I1
tp999
sS'adding,to,may'
p1000
(F1
F0.00076452599388379206
I1
I0
I1
tp1001
sS'experience,profiles,similar'
p1002
(F1
F0.00076452599388379206
I1
I0
I1
tp1003
sS'to,bleeding,associated'
p1004
(F1
F0.00076452599388379206
I1
I0
I1
tp1005
sS'using,in,combination'
p1006
(F1
F0.00076452599388379206
I0
I1
I-1
tp1007
sS'derivatives,or,inhibit'
p1008
(F1
F0.00076452599388379206
I1
I0
I1
tp1009
sS'terfenadine,and,certain'
p1010
(F1
F0.00076452599388379206
I1
I0
I1
tp1011
sS'preclinical,combination,of'
p1012
(F1
F0.00076452599388379206
I1
I0
I1
tp1013
sS'of,resulting,in'
p1014
(F1
F0.00076452599388379206
I1
I0
I1
tp1015
sS'care,in,patients'
p1016
(F1
F0.00076452599388379206
I1
I0
I1
tp1017
sS'trials,nsaids,have'
p1018
(F1
F0.00076452599388379206
I1
I0
I1
tp1019
sS'of,approximately,glasses'
p1020
(F1
F0.00076452599388379206
I0
I1
I-1
tp1021
sS'a4,inhibitors,resulting'
p1022
(F1
F0.00076452599388379206
I0
I1
I-1
tp1023
sS'reported,in,patients'
p1024
(F0.33333333333333331
F0.0015290519877675841
I4
I2
I2
tp1025
sS'curve,of,approximately'
p1026
(F1
F0.00076452599388379206
I0
I1
I-1
tp1027
sS'lower,clinical,and'
p1028
(F1
F0.00076452599388379206
I1
I0
I1
tp1029
sS'acetylsalicylic,acid,and'
p1030
(F1
F0.00076452599388379206
I1
I0
I1
tp1031
sS'reduced,absorption,of'
p1032
(F1
F0.00076452599388379206
I1
I0
I1
tp1033
sS'study,in,normal'
p1034
(F1
F0.00076452599388379206
I0
I1
I-1
tp1035
sS'mg,day,approximately'
p1036
(F1
F0.00076452599388379206
I0
I1
I-1
tp1037
sS'with,care,in'
p1038
(F1
F0.00076452599388379206
I1
I0
I1
tp1039
sS'interaction,studies,were'
p1040
(F1
F0.00076452599388379206
I0
I1
I-1
tp1041
sS'substrate,for,the'
p1042
(F1
F0.00076452599388379206
I0
I1
I-1
tp1043
sS'cylert,concomitantly,with'
p1044
(F1
F0.00076452599388379206
I1
I0
I1
tp1045
sS'and,auc,values'
p1046
(F0
F0
I1
I1
I0
tp1047
sS'twice,daily,mg'
p1048
(F1
F0.00076452599388379206
I0
I1
I-1
tp1049
sS'certain,herbal,supplements'
p1050
(F1
F0.00076452599388379206
I0
I1
I-1
tp1051
sS'doses,less,than'
p1052
(F1
F0.00076452599388379206
I0
I1
I-1
tp1053
sS'p,respectively,lower'
p1054
(F1
F0.00076452599388379206
I1
I0
I1
tp1055
sS'included,thyroid,hormones'
p1056
(F1
F0.00076452599388379206
I0
I1
I-1
tp1057
sS'than,of,control'
p1058
(F1
F0.00076452599388379206
I1
I0
I1
tp1059
sS'following,resulted,in'
p1060
(F1
F0.00076452599388379206
I1
I0
I1
tp1061
sS'was,delivered,by'
p1062
(F1
F0.00076452599388379206
I0
I1
I-1
tp1063
sS'to,metabolize,some'
p1064
(F1
F0.00076452599388379206
I1
I0
I1
tp1065
sS'combined,with,for'
p1066
(F1
F0.00076452599388379206
I1
I0
I1
tp1067
sS'of,cyp3a4,isozymes'
p1068
(F1
F0.0015290519877675841
I2
I0
I2
tp1069
sS'drugs,while,taking'
p1070
(F1
F0.00076452599388379206
I1
I0
I1
tp1071
sS'closely,monitored,if'
p1072
(F1
F0.00076452599388379206
I1
I0
I1
tp1073
sS'neulasta,should,have'
p1074
(F1
F0.00076452599388379206
I1
I0
I1
tp1075
sS'replication,of,the'
p1076
(F1
F0.00076452599388379206
I1
I0
I1
tp1077
sS'and,flomax,capsules'
p1078
(F0
F0
I1
I1
I0
tp1079
sS'tyrosine,hydroxylase,immunoreactivity'
p1080
(F1
F0.00076452599388379206
I1
I0
I1
tp1081
sS'which,blocks,the'
p1082
(F1
F0.00076452599388379206
I1
I0
I1
tp1083
sS'and,an,enhanced'
p1084
(F1
F0.00076452599388379206
I1
I0
I1
tp1085
sS'cholinesterase,inhibitors,a'
p1086
(F1
F0.00076452599388379206
I1
I0
I1
tp1087
sS'medications,like,or'
p1088
(F1
F0.00076452599388379206
I1
I0
I1
tp1089
sS'taking,tobi,concomitantly'
p1090
(F1
F0.00076452599388379206
I1
I0
I1
tp1091
sS'therapy,i,fludrocortisone'
p1092
(F1
F0.00076452599388379206
I0
I1
I-1
tp1093
sS'the,pharmacokinetic,disposition'
p1094
(F1
F0.00076452599388379206
I0
I1
I-1
tp1095
sS'mao,inhibitors,and'
p1096
(F0
F0
I1
I1
I0
tp1097
sS'of,as,chloride'
p1098
(F1
F0.00076452599388379206
I1
I0
I1
tp1099
sS'inhibitors,and,beta'
p1100
(F1
F0.00076452599388379206
I1
I0
I1
tp1101
sS'of,a,single'
p1102
(F0.7142857142857143
F0.0038226299694189602
I1
I6
I-5
tp1103
sS'receptor,antagonist,methyl-1'
p1104
(F0
F0
I1
I1
I0
tp1105
sS'course,of,therapy'
p1106
(F1
F0.00076452599388379206
I1
I0
I1
tp1107
sS'with,mg,than'
p1108
(F1
F0.00076452599388379206
I0
I1
I-1
tp1109
sS'cannot,take,if'
p1110
(F1
F0.00076452599388379206
I1
I0
I1
tp1111
sS'essential,hypertension,suggests'
p1112
(F1
F0.00076452599388379206
I1
I0
I1
tp1113
sS'on,the,methyl-4'
p1114
(F1
F0.00076452599388379206
I1
I0
I1
tp1115
sS'rate,or,extent'
p1116
(F1
F0.00076452599388379206
I0
I1
I-1
tp1117
sS'associated,with,overexpression'
p1118
(F1
F0.00076452599388379206
I1
I0
I1
tp1119
sS'containing,mg,of'
p1120
(F1
F0.00076452599388379206
I0
I1
I-1
tp1121
sS'status,was,unaltered'
p1122
(F1
F0.00076452599388379206
I0
I1
I-1
tp1123
sS'use,of,high-dose'
p1124
(F1
F0.00076452599388379206
I1
I0
I1
tp1125
sS'pharmacokinetic,study,concomitant'
p1126
(F0
F0
I1
I1
I0
tp1127
sS'and,or,in'
p1128
(F1
F0.00076452599388379206
I0
I1
I-1
tp1129
sS'level,subsequent,to'
p1130
(F1
F0.00076452599388379206
I1
I0
I1
tp1131
sS'combination,of,and'
p1132
(F1
F0.0030581039755351682
I4
I0
I4
tp1133
sS'resistant,to,many'
p1134
(F1
F0.00076452599388379206
I0
I1
I-1
tp1135
sS'of,and,p'
p1136
(F1
F0.00076452599388379206
I0
I1
I-1
tp1137
sS'and,motor,skills'
p1138
(F1
F0.00076452599388379206
I1
I0
I1
tp1139
sS'should,be,provided'
p1140
(F1
F0.00076452599388379206
I1
I0
I1
tp1141
sS'mg,day,to'
p1142
(F1
F0.00076452599388379206
I0
I1
I-1
tp1143
sS'diabetes,mellitus,being'
p1144
(F1
F0.00076452599388379206
I1
I0
I1
tp1145
sS'metabolite,profile,only'
p1146
(F1
F0.00076452599388379206
I0
I1
I-1
tp1147
sS'of,and,a'
p1148
(F1
F0.00076452599388379206
I1
I0
I1
tp1149
sS'in,vivo,biotransformation'
p1150
(F1
F0.00076452599388379206
I0
I1
I-1
tp1151
sS'system,drugs,that'
p1152
(F1
F0.00076452599388379206
I0
I1
I-1
tp1153
sS'than,mg,day'
p1154
(F1
F0.00076452599388379206
I1
I0
I1
tp1155
sS'been,used,concurrently'
p1156
(F1
F0.0015290519877675841
I0
I2
I-2
tp1157
sS'that,administering,with'
p1158
(F1
F0.00076452599388379206
I1
I0
I1
tp1159
sS'not,studied,with'
p1160
(F1
F0.00076452599388379206
I0
I1
I-1
tp1161
sS'statistically,significant,synergism'
p1162
(F1
F0.00076452599388379206
I1
I0
I1
tp1163
sS'that,impair,intestinal'
p1164
(F1
F0.00076452599388379206
I1
I0
I1
tp1165
sS'estradiol,and,auc'
p1166
(F1
F0.00076452599388379206
I0
I1
I-1
tp1167
sS'aceon,tablets,but'
p1168
(F1
F0.00076452599388379206
I1
I0
I1
tp1169
sS'by,the,cytochrome'
p1170
(F1
F0.0015290519877675841
I2
I0
I2
tp1171
sS'topical,use,of'
p1172
(F1
F0.00076452599388379206
I0
I1
I-1
tp1173
sS'caution,and,in'
p1174
(F1
F0.00076452599388379206
I1
I0
I1
tp1175
sS'is,a,therapeutic'
p1176
(F1
F0.00076452599388379206
I0
I1
I-1
tp1177
sS'to,chemotherapy,in'
p1178
(F1
F0.00076452599388379206
I1
I0
I1
tp1179
sS'concentration,of,metabolites'
p1180
(F1
F0.00076452599388379206
I1
I0
I1
tp1181
sS'alpha-adrenergic,receptors,or'
p1182
(F1
F0.00076452599388379206
I1
I0
I1
tp1183
sS'g,of,ethinyl'
p1184
(F1
F0.00076452599388379206
I0
I1
I-1
tp1185
sS'to,influence,locomotion'
p1186
(F1
F0.00076452599388379206
I1
I0
I1
tp1187
sS'and,selective,serotonin'
p1188
(F1
F0.00076452599388379206
I1
I0
I1
tp1189
sS'of,with,results'
p1190
(F1
F0.00076452599388379206
I1
I0
I1
tp1191
sS'and,did,not'
p1192
(F1
F0.0022935779816513763
I0
I3
I-3
tp1193
sS'inhibitors,are,given'
p1194
(F1
F0.00076452599388379206
I1
I0
I1
tp1195
sS'both,acetic,acid'
p1196
(F1
F0.00076452599388379206
I1
I0
I1
tp1197
sS'of,cyp,inhibitor'
p1198
(F1
F0.00076452599388379206
I0
I1
I-1
tp1199
sS'hplc,system,with'
p1200
(F1
F0.00076452599388379206
I0
I1
I-1
tp1201
sS'local,anesthetic,agents'
p1202
(F1
F0.00076452599388379206
I0
I1
I-1
tp1203
sS'not,exceed,a'
p1204
(F1
F0.00076452599388379206
I1
I0
I1
tp1205
sS'the,cns,depressant'
p1206
(F1
F0.0015290519877675841
I2
I0
I2
tp1207
sS'respond,to,drugs'
p1208
(F1
F0.00076452599388379206
I0
I1
I-1
tp1209
sS'use,of,fewer'
p1210
(F1
F0.00076452599388379206
I1
I0
I1
tp1211
sS'use,of,fixed'
p1212
(F1
F0.00076452599388379206
I1
I0
I1
tp1213
sS'cell,surface,of'
p1214
(F1
F0.00076452599388379206
I1
I0
I1
tp1215
sS'posicor,inhibits,some'
p1216
(F1
F0.00076452599388379206
I1
I0
I1
tp1217
sS'plasma,concentrations,of'
p1218
(F0.5
F0.0015290519877675841
I3
I1
I2
tp1219
sS'hydrochloride,and,cns'
p1220
(F1
F0.00076452599388379206
I1
I0
I1
tp1221
sS'reports,of,bleeding'
p1222
(F1
F0.00076452599388379206
I1
I0
I1
tp1223
sS'mellitus,being,treated'
p1224
(F1
F0.00076452599388379206
I1
I0
I1
tp1225
sS'not,have,clinically'
p1226
(F1
F0.00076452599388379206
I0
I1
I-1
tp1227
sS'parenteral,demonstrated,adverse'
p1228
(F1
F0.00076452599388379206
I1
I0
I1
tp1229
sS'administered,at,least'
p1230
(F1
F0.00076452599388379206
I1
I0
I1
tp1231
sS'aspirin,concomitant,administration'
p1232
(F1
F0.00076452599388379206
I1
I0
I1
tp1233
sS'absorption,of,the'
p1234
(F1
F0.00076452599388379206
I0
I1
I-1
tp1235
sS'ulceration,or,other'
p1236
(F1
F0.00076452599388379206
I1
I0
I1
tp1237
sS'and,paclitaxel-induced,apoptosis'
p1238
(F1
F0.00076452599388379206
I0
I1
I-1
tp1239
sS'drugs,antiarrhythmic,agents'
p1240
(F1
F0.00076452599388379206
I1
I0
I1
tp1241
sS'unaffected,in,either'
p1242
(F1
F0.00076452599388379206
I0
I1
I-1
tp1243
sS'methyl-4,phenyl-1,tetrahydropyridine'
p1244
(F0.33333333333333331
F0.0015290519877675841
I4
I2
I2
tp1245
sS'plasma,levels,be'
p1246
(F1
F0.00076452599388379206
I1
I0
I1
tp1247
sS'a,significant,effect'
p1248
(F0
F0
I1
I1
I0
tp1249
sS'activity,of,when'
p1250
(F1
F0.00076452599388379206
I1
I0
I1
tp1251
sS'marrow,depressants,can'
p1252
(F1
F0.00076452599388379206
I1
I0
I1
tp1253
sS'dosage,of,s-ketamine'
p1254
(F1
F0.00076452599388379206
I1
I0
I1
tp1255
sS'as,there,is'
p1256
(F1
F0.00076452599388379206
I1
I0
I1
tp1257
sS'not,recommended,pending'
p1258
(F1
F0.00076452599388379206
I1
I0
I1
tp1259
sS'of,cimetidine,mg'
p1260
(F1
F0.00076452599388379206
I1
I0
I1
tp1261
sS'of,serious,adverse'
p1262
(F1
F0.00076452599388379206
I0
I1
I-1
tp1263
sS'diminish,the,antihypertensive'
p1264
(F1
F0.00076452599388379206
I1
I0
I1
tp1265
sS'if,you,have'
p1266
(F1
F0.00076452599388379206
I1
I0
I1
tp1267
sS'of,clinical,drug-drug'
p1268
(F1
F0.00076452599388379206
I0
I1
I-1
tp1269
sS'patients,dosage,adjustments'
p1270
(F1
F0.00076452599388379206
I0
I1
I-1
tp1271
sS'blood,pressure,has'
p1272
(F1
F0.00076452599388379206
I1
I0
I1
tp1273
sS'probenecid,concurrent,use'
p1274
(F1
F0.00076452599388379206
I1
I0
I1
tp1275
sS'conjunction,with,mg'
p1276
(F1
F0.00076452599388379206
I1
I0
I1
tp1277
sS'or,because,the'
p1278
(F1
F0.00076452599388379206
I1
I0
I1
tp1279
sS'higher,concentrations,of'
p1280
(F1
F0.00076452599388379206
I0
I1
I-1
tp1281
sS'rate,compared,with'
p1282
(F1
F0.00076452599388379206
I1
I0
I1
tp1283
sS'of,compounds,known'
p1284
(F1
F0.00076452599388379206
I1
I0
I1
tp1285
sS'attributed,to,increased'
p1286
(F1
F0.00076452599388379206
I1
I0
I1
tp1287
sS'metabolized,by,this'
p1288
(F1
F0.00076452599388379206
I0
I1
I-1
tp1289
sS'in,the,half-life'
p1290
(F1
F0.00076452599388379206
I1
I0
I1
tp1291
sS'potential,for,drug'
p1292
(F1
F0.00076452599388379206
I1
I0
I1
tp1293
sS'and,formalin,test'
p1294
(F1
F0.00076452599388379206
I1
I0
I1
tp1295
sS'for,four,days'
p1296
(F1
F0.00076452599388379206
I1
I0
I1
tp1297
sS'dose,of,diflucan'
p1298
(F1
F0.00076452599388379206
I1
I0
I1
tp1299
sS'higher,serum,concentrations'
p1300
(F1
F0.00076452599388379206
I1
I0
I1
tp1301
sS'increase,salt,and'
p1302
(F1
F0.00076452599388379206
I0
I1
I-1
tp1303
sS'of,combined,with'
p1304
(F1
F0.0015290519877675841
I0
I2
I-2
tp1305
sS'the,day,of'
p1306
(F1
F0.0015290519877675841
I2
I0
I2
tp1307
sS'pharmacokinetics,of,were'
p1308
(F1
F0.0015290519877675841
I0
I2
I-2
tp1309
sS'agents,and,local'
p1310
(F1
F0.00076452599388379206
I0
I1
I-1
tp1311
sS'plasma,concentration,profile'
p1312
(F1
F0.0015290519877675841
I0
I2
I-2
tp1313
sS'or,peripheral,adrenergic'
p1314
(F1
F0.00076452599388379206
I0
I1
I-1
tp1315
sS'drug,interactions,should'
p1316
(F1
F0.00076452599388379206
I0
I1
I-1
tp1317
sS'inr,international,normalized'
p1318
(F1
F0.00076452599388379206
I0
I1
I-1
tp1319
sS'and,c9,or'
p1320
(F1
F0.00076452599388379206
I0
I1
I-1
tp1321
sS'since,marketing,therefore'
p1322
(F1
F0.00076452599388379206
I1
I0
I1
tp1323
sS'the,replication,of'
p1324
(F1
F0.00076452599388379206
I1
I0
I1
tp1325
sS'in,basic,media'
p1326
(F1
F0.00076452599388379206
I1
I0
I1
tp1327
sS'with,plus,inhibited'
p1328
(F1
F0.00076452599388379206
I1
I0
I1
tp1329
sS'be,exercised,when'
p1330
(F1
F0.0022935779816513763
I3
I0
I3
tp1331
sS'interact,with,increased'
p1332
(F0.33333333333333331
F0.00076452599388379206
I1
I2
I-1
tp1333
sS'data,and,with'
p1334
(F1
F0.00076452599388379206
I1
I0
I1
tp1335
sS'or,increase,the'
p1336
(F1
F0.0015290519877675841
I2
I0
I2
tp1337
sS'enzymes,cyp3a4,cyp2d6'
p1338
(F1
F0.00076452599388379206
I0
I1
I-1
tp1339
sS'can,be,used'
p1340
(F1
F0.00076452599388379206
I1
I0
I1
tp1341
sS'was,measured,in'
p1342
(F1
F0.00076452599388379206
I0
I1
I-1
tp1343
sS'in,those,receiving'
p1344
(F1
F0.00076452599388379206
I0
I1
I-1
tp1345
sS'with,other,containing'
p1346
(F1
F0.00076452599388379206
I1
I0
I1
tp1347
sS'ditropan,xl,was'
p1348
(F1
F0.00076452599388379206
I1
I0
I1
tp1349
sS'effects,may,increase'
p1350
(F1
F0.0015290519877675841
I2
I0
I2
tp1351
sS'reductase,inhibitors,no'
p1352
(F1
F0.00076452599388379206
I0
I1
I-1
tp1353
sS'the,average,anticoagulant'
p1354
(F1
F0.00076452599388379206
I0
I1
I-1
tp1355
sS'self,measured,bp'
p1356
(F1
F0.00076452599388379206
I1
I0
I1
tp1357
sS'that,were,initially'
p1358
(F1
F0.00076452599388379206
I1
I0
I1
tp1359
sS'the,oral,clearance'
p1360
(F0
F0
I1
I1
I0
tp1361
sS'there,were,decreases'
p1362
(F1
F0.00076452599388379206
I0
I1
I-1
tp1363
sS'oral,hypoglycemic,agents'
p1364
(F0.33333333333333331
F0.00076452599388379206
I2
I1
I1
tp1365
sS'with,cholinomimetics,and'
p1366
(F1
F0.00076452599388379206
I1
I0
I1
tp1367
sS'an,indication,that'
p1368
(F1
F0.00076452599388379206
I0
I1
I-1
tp1369
sS'is,not,possible'
p1370
(F1
F0.00076452599388379206
I0
I1
I-1
tp1371
sS'of,other,potentially'
p1372
(F1
F0.00076452599388379206
I0
I1
I-1
tp1373
sS'further,elucidate,the'
p1374
(F1
F0.00076452599388379206
I0
I1
I-1
tp1375
sS'not,altered,by'
p1376
(F1
F0.00076452599388379206
I0
I1
I-1
tp1377
sS'with,different,anti-cancer'
p1378
(F1
F0.00076452599388379206
I1
I0
I1
tp1379
sS'resulted,in,a'
p1380
(F1
F0.0022935779816513763
I3
I0
I3
tp1381
sS'to,urinary,alkalizing'
p1382
(F1
F0.00076452599388379206
I1
I0
I1
tp1383
sS'be,discontinued,well'
p1384
(F1
F0.00076452599388379206
I1
I0
I1
tp1385
sS'are,no,clinical'
p1386
(F1
F0.00076452599388379206
I0
I1
I-1
tp1387
sS'of,pth,by'
p1388
(F1
F0.00076452599388379206
I1
I0
I1
tp1389
sS'ethinyl,estradiol-,and'
p1390
(F1
F0.00076452599388379206
I1
I0
I1
tp1391
sS'for,mpa,were'
p1392
(F1
F0.00076452599388379206
I1
I0
I1
tp1393
sS'half-lives,for,a'
p1394
(F1
F0.00076452599388379206
I1
I0
I1
tp1395
sS'to,cerebral,ischemia'
p1396
(F1
F0.00076452599388379206
I0
I1
I-1
tp1397
sS'in,vitro,evidence'
p1398
(F1
F0.00076452599388379206
I1
I0
I1
tp1399
sS'precocene,i,metabolite'
p1400
(F1
F0.00076452599388379206
I0
I1
I-1
tp1401
sS'were,coadministered,to'
p1402
(F1
F0.00076452599388379206
I0
I1
I-1
tp1403
sS'of,the,positive'
p1404
(F1
F0.00076452599388379206
I0
I1
I-1
tp1405
sS'antidepressants,and,particularly'
p1406
(F1
F0.00076452599388379206
I1
I0
I1
tp1407
sS'of,gsls,was'
p1408
(F1
F0.00076452599388379206
I1
I0
I1
tp1409
sS'studies,patients,on'
p1410
(F1
F0.00076452599388379206
I1
I0
I1
tp1411
sS'dose,produced,a'
p1412
(F1
F0.00076452599388379206
I1
I0
I1
tp1413
sS'treated,with,for'
p1414
(F1
F0.00076452599388379206
I1
I0
I1
tp1415
sS'therapeutic,actions,and'
p1416
(F1
F0.00076452599388379206
I1
I0
I1
tp1417
sS'this,has,not'
p1418
(F1
F0.00076452599388379206
I1
I0
I1
tp1419
sS'may,be,additive'
p1420
(F1
F0.0015290519877675841
I2
I0
I2
tp1421
sS'expected,with,higher'
p1422
(F1
F0.00076452599388379206
I0
I1
I-1
tp1423
sS'effect,when,given'
p1424
(F1
F0.0015290519877675841
I2
I0
I2
tp1425
sS'data,presently,available'
p1426
(F1
F0.00076452599388379206
I0
I1
I-1
tp1427
sS's,ability,to'
p1428
(F1
F0.00076452599388379206
I1
I0
I1
tp1429
sS'with,the,use'
p1430
(F1
F0.00076452599388379206
I1
I0
I1
tp1431
sS'that,are,resistant'
p1432
(F1
F0.00076452599388379206
I0
I1
I-1
tp1433
sS'hypotensive,effects,of'
p1434
(F1
F0.00076452599388379206
I0
I1
I-1
tp1435
sS'at,doses,lower'
p1436
(F1
F0.00076452599388379206
I1
I0
I1
tp1437
sS'and,antiplatelets,after'
p1438
(F1
F0.00076452599388379206
I0
I1
I-1
tp1439
sS'mivacron,with,other'
p1440
(F1
F0.00076452599388379206
I0
I1
I-1
tp1441
sS'p27,kip1,decreased'
p1442
(F1
F0.00076452599388379206
I0
I1
I-1
tp1443
sS'relapsed,multiple,myeloma'
p1444
(F1
F0.00076452599388379206
I0
I1
I-1
tp1445
sS'r-warfarin,half-life,and'
p1446
(F1
F0.00076452599388379206
I1
I0
I1
tp1447
sS'profiles,of,and'
p1448
(F1
F0.00076452599388379206
I0
I1
I-1
tp1449
sS'unknown,slightly,shorter'
p1450
(F1
F0.00076452599388379206
I1
I0
I1
tp1451
sS'times,the,maximum'
p1452
(F1
F0.00076452599388379206
I0
I1
I-1
tp1453
sS'or,stimulantes,of'
p1454
(F1
F0.00076452599388379206
I1
I0
I1
tp1455
sS'lower,levels,bioavailability'
p1456
(F1
F0.00076452599388379206
I1
I0
I1
tp1457
sS'kg,saline,saline'
p1458
(F1
F0.00076452599388379206
I0
I1
I-1
tp1459
sS'with,inhibitors,or'
p1460
(F1
F0.00076452599388379206
I0
I1
I-1
tp1461
sS'evidence,of,reproductive'
p1462
(F1
F0.00076452599388379206
I0
I1
I-1
tp1463
sS'st,johns,wort'
p1464
(F1
F0.00076452599388379206
I1
I0
I1
tp1465
sS'k,nutritional,status'
p1466
(F1
F0.00076452599388379206
I0
I1
I-1
tp1467
sS'combined,with,against'
p1468
(F1
F0.0015290519877675841
I0
I2
I-2
tp1469
sS'seizure,activity,live'
p1470
(F1
F0.00076452599388379206
I1
I0
I1
tp1471
sS'with,or,without'
p1472
(F0
F0
I1
I1
I0
tp1473
sS'treated,with,monoamine'
p1474
(F1
F0.00076452599388379206
I1
I0
I1
tp1475
sS'fro,days,to'
p1476
(F1
F0.00076452599388379206
I0
I1
I-1
tp1477
sS'precautions,should,be'
p1478
(F1
F0.00076452599388379206
I1
I0
I1
tp1479
sS'eg,and,during'
p1480
(F1
F0.00076452599388379206
I0
I1
I-1
tp1481
sS'antagonists,drugs,that'
p1482
(F1
F0.00076452599388379206
I1
I0
I1
tp1483
sS'sympathomimetics,may,reduce'
p1484
(F1
F0.00076452599388379206
I1
I0
I1
tp1485
sS'of,administered,with'
p1486
(F1
F0.00076452599388379206
I0
I1
I-1
tp1487
sS'under,treatment,with'
p1488
(F1
F0.00076452599388379206
I0
I1
I-1
tp1489
sS'metolazone,as,well'
p1490
(F1
F0.00076452599388379206
I1
I0
I1
tp1491
sS'day,or,greater'
p1492
(F1
F0.00076452599388379206
I1
I0
I1
tp1493
sS'of,hypotensive,effects'
p1494
(F0
F0
I1
I1
I0
tp1495
sS'hydroxylase-positive,neurons,was'
p1496
(F1
F0.00076452599388379206
I1
I0
I1
tp1497
sS'female,subjects,the'
p1498
(F1
F0.00076452599388379206
I0
I1
I-1
tp1499
sS'be,administered,concurrently'
p1500
(F1
F0.00076452599388379206
I1
I0
I1
tp1501
sS'inhibitor,synergistically,inhibited'
p1502
(F1
F0.00076452599388379206
I1
I0
I1
tp1503
sS'increase,the,serum'
p1504
(F1
F0.00076452599388379206
I0
I1
I-1
tp1505
sS'experienced,a,possible'
p1506
(F1
F0.00076452599388379206
I1
I0
I1
tp1507
sS'or,inducers,of'
p1508
(F1
F0.00076452599388379206
I0
I1
I-1
tp1509
sS'an,hiv-positive,woman'
p1510
(F1
F0.0015290519877675841
I2
I0
I2
tp1511
sS'and,bananas,should'
p1512
(F1
F0.00076452599388379206
I1
I0
I1
tp1513
sS'supplemental,analgesic,agents'
p1514
(F1
F0.00076452599388379206
I1
I0
I1
tp1515
sS'pharmacokinetic,drug,interaction'
p1516
(F1
F0.00076452599388379206
I1
I0
I1
tp1517
sS'in,the,absorption'
p1518
(F1
F0.00076452599388379206
I1
I0
I1
tp1519
sS'the,study,was'
p1520
(F1
F0.00076452599388379206
I0
I1
I-1
tp1521
sS'be,increased,in'
p1522
(F1
F0.0015290519877675841
I2
I0
I2
tp1523
sS'increase,in,plasma'
p1524
(F1
F0.0030581039755351682
I4
I0
I4
tp1525
sS'cm3,confidence,interval'
p1526
(F1
F0.00076452599388379206
I1
I0
I1
tp1527
sS'yogurt,ripe,cheese'
p1528
(F1
F0.00076452599388379206
I1
I0
I1
tp1529
sS'methysergide,may,reverse'
p1530
(F1
F0.00076452599388379206
I1
I0
I1
tp1531
sS'prothrombin,time,may'
p1532
(F1
F0.00076452599388379206
I1
I0
I1
tp1533
sS'typical,of,the'
p1534
(F1
F0.00076452599388379206
I1
I0
I1
tp1535
sS'metabolism,lowering,serum'
p1536
(F1
F0.00076452599388379206
I1
I0
I1
tp1537
sS'the,phosphorylation,of'
p1538
(F1
F0.00076452599388379206
I1
I0
I1
tp1539
sS'by,the,cationic'
p1540
(F1
F0.00076452599388379206
I1
I0
I1
tp1541
sS'acetate,and,g'
p1542
(F1
F0.00076452599388379206
I0
I1
I-1
tp1543
sS'time,and,by'
p1544
(F1
F0.00076452599388379206
I1
I0
I1
tp1545
sS'after,discontinuing,mexitil'
p1546
(F1
F0.00076452599388379206
I1
I0
I1
tp1547
sS'patients,receiving,methadone-maintenance'
p1548
(F1
F0.00076452599388379206
I1
I0
I1
tp1549
sS'plate,test,in'
p1550
(F1
F0.00076452599388379206
I1
I0
I1
tp1551
sS'in,vitro,testing'
p1552
(F1
F0.00076452599388379206
I0
I1
I-1
tp1553
sS'subjects,receiving,xenical'
p1554
(F1
F0.0022935779816513763
I0
I3
I-3
tp1555
sS'for,patients,taking'
p1556
(F1
F0.00076452599388379206
I1
I0
I1
tp1557
sS'result,in,fatal'
p1558
(F1
F0.00076452599388379206
I1
I0
I1
tp1559
sS'has,stabilized,for'
p1560
(F1
F0.00076452599388379206
I1
I0
I1
tp1561
sS'chronic,stable,doses'
p1562
(F1
F0.00076452599388379206
I1
I0
I1
tp1563
sS'by,after,topical'
p1564
(F1
F0.00076452599388379206
I1
I0
I1
tp1565
sS'depressants,such,as'
p1566
(F1
F0.00076452599388379206
I1
I0
I1
tp1567
sS'pressor,response,of'
p1568
(F1
F0.0015290519877675841
I2
I0
I2
tp1569
sS'of,the,present'
p1570
(F1
F0.00076452599388379206
I0
I1
I-1
tp1571
sS'rats,using,locomotor'
p1572
(F1
F0.00076452599388379206
I0
I1
I-1
tp1573
sS'antidepressant-warfarin,interaction,and'
p1574
(F1
F0.00076452599388379206
I0
I1
I-1
tp1575
sS'and,melena,have'
p1576
(F1
F0.00076452599388379206
I1
I0
I1
tp1577
sS'oral,coumarin-type,anticoagulants'
p1578
(F1
F0.00076452599388379206
I1
I0
I1
tp1579
sS'and,other,nsaids'
p1580
(F1
F0.00076452599388379206
I1
I0
I1
tp1581
sS'with,phentermine,hydrochloride'
p1582
(F1
F0.00076452599388379206
I1
I0
I1
tp1583
sS'inhibition,studies,and'
p1584
(F1
F0.00076452599388379206
I0
I1
I-1
tp1585
sS'reported,in,association'
p1586
(F1
F0.00076452599388379206
I1
I0
I1
tp1587
sS'study,the,pharmacokinetics'
p1588
(F1
F0.00076452599388379206
I0
I1
I-1
tp1589
sS'of,onset,but'
p1590
(F1
F0.00076452599388379206
I1
I0
I1
tp1591
sS'as,or,are'
p1592
(F1
F0.0015290519877675841
I2
I0
I2
tp1593
sS'reduces,the,metabolism'
p1594
(F1
F0.00076452599388379206
I1
I0
I1
tp1595
sS'patients,may,require'
p1596
(F1
F0.00076452599388379206
I1
I0
I1
tp1597
sS'of,as,determined'
p1598
(F1
F0.00076452599388379206
I0
I1
I-1
tp1599
sS'and,may,interfere'
p1600
(F1
F0.00076452599388379206
I1
I0
I1
tp1601
sS'macrolide,eg,or'
p1602
(F1
F0.00076452599388379206
I1
I0
I1
tp1603
sS'no,dosage,adjustment'
p1604
(F0.33333333333333331
F0.00076452599388379206
I1
I2
I-1
tp1605
sS'antifungals,eg,or'
p1606
(F1
F0.00076452599388379206
I1
I0
I1
tp1607
sS'sedative,effect,of'
p1608
(F1
F0.00076452599388379206
I1
I0
I1
tp1609
sS'present,study,the'
p1610
(F1
F0.00076452599388379206
I0
I1
I-1
tp1611
sS'torsade,de,pointes'
p1612
(F1
F0.00076452599388379206
I1
I0
I1
tp1613
sS'hplc,and,dna'
p1614
(F1
F0.00076452599388379206
I0
I1
I-1
tp1615
sS'use,program,mexitil'
p1616
(F1
F0.00076452599388379206
I0
I1
I-1
tp1617
sS'salicylate,competes,with'
p1618
(F1
F0.00076452599388379206
I1
I0
I1
tp1619
sS'different,anti-cancer,drugs'
p1620
(F1
F0.00076452599388379206
I1
I0
I1
tp1621
sS'in,plasma,vitamin'
p1622
(F1
F0.00076452599388379206
I1
I0
I1
tp1623
sS'drugs,for,protein'
p1624
(F1
F0.00076452599388379206
I1
I0
I1
tp1625
sS'ergotamine-containing,or,ergot-type'
p1626
(F1
F0.00076452599388379206
I1
I0
I1
tp1627
sS'of,ergotamine-containing,or'
p1628
(F1
F0.00076452599388379206
I1
I0
I1
tp1629
sS'therapy,and,were'
p1630
(F1
F0.00076452599388379206
I0
I1
I-1
tp1631
sS'this,effect,in'
p1632
(F1
F0.00076452599388379206
I0
I1
I-1
tp1633
sS'zetia,is,administered'
p1634
(F1
F0.00076452599388379206
I0
I1
I-1
tp1635
sS'anticholinergics,antagonize,the'
p1636
(F1
F0.00076452599388379206
I1
I0
I1
tp1637
sS'levels,tended,to'
p1638
(F1
F0.00076452599388379206
I0
I1
I-1
tp1639
sS'pharmacokinetic,interaction,between'
p1640
(F1
F0.0015290519877675841
I0
I2
I-2
tp1641
sS'chickens,inoculated,with'
p1642
(F1
F0.00076452599388379206
I1
I0
I1
tp1643
sS'mg,was,given'
p1644
(F1
F0.0015290519877675841
I0
I2
I-2
tp1645
sS'hypotension,its,administration'
p1646
(F1
F0.00076452599388379206
I1
I0
I1
tp1647
sS'either,or,there'
p1648
(F1
F0.00076452599388379206
I0
I1
I-1
tp1649
sS'locus,coeruleus,a5'
p1650
(F1
F0.00076452599388379206
I1
I0
I1
tp1651
sS'of,the,mouth'
p1652
(F1
F0.00076452599388379206
I1
I0
I1
tp1653
sS'for,days,to'
p1654
(F1
F0.00076452599388379206
I0
I1
I-1
tp1655
sS'normalized,ratio,inr'
p1656
(F1
F0.00076452599388379206
I1
I0
I1
tp1657
sS'of,skelid,is'
p1658
(F1
F0.0015290519877675841
I2
I0
I2
tp1659
sS'compete,for,tubular'
p1660
(F1
F0.00076452599388379206
I0
I1
I-1
tp1661
sS'the,roles,of'
p1662
(F1
F0.00076452599388379206
I0
I1
I-1
tp1663
sS'non-specific,cyp,inhibitor'
p1664
(F1
F0.00076452599388379206
I0
I1
I-1
tp1665
sS'or,inhibition,of'
p1666
(F1
F0.00076452599388379206
I0
I1
I-1
tp1667
sS'be,carefully,monitored'
p1668
(F1
F0.0015290519877675841
I2
I0
I2
tp1669
sS'certain,primarily,an'
p1670
(F1
F0.00076452599388379206
I0
I1
I-1
tp1671
sS'by,remeron,were'
p1672
(F1
F0.00076452599388379206
I1
I0
I1
tp1673
sS'on,absorption,mainly'
p1674
(F1
F0.00076452599388379206
I1
I0
I1
tp1675
sS'infarction,the,use'
p1676
(F1
F0.00076452599388379206
I0
I1
I-1
tp1677
sS'of,was,decreased'
p1678
(F1
F0.0015290519877675841
I2
I0
I2
tp1679
sS'anticoagulants,metolazone,as'
p1680
(F1
F0.00076452599388379206
I1
I0
I1
tp1681
sS'daily,doses,of'
p1682
(F1
F0.0022935779816513763
I0
I3
I-3
tp1683
sS'levels,of,was'
p1684
(F1
F0.00076452599388379206
I1
I0
I1
tp1685
sS'increased,when,hyperthyroid'
p1686
(F1
F0.00076452599388379206
I0
I1
I-1
tp1687
sS'causing,too,great'
p1688
(F1
F0.00076452599388379206
I1
I0
I1
tp1689
sS'with,congenital,or'
p1690
(F1
F0.00076452599388379206
I0
I1
I-1
tp1691
sS'affect,the,exposure'
p1692
(F1
F0.00076452599388379206
I0
I1
I-1
tp1693
sS'treated,with,trental'
p1694
(F1
F0.00076452599388379206
I1
I0
I1
tp1695
sS'inhibitors,and,has'
p1696
(F1
F0.00076452599388379206
I0
I1
I-1
tp1697
sS'receiving,the,combination'
p1698
(F1
F0.0015290519877675841
I2
I0
I2
tp1699
sS'days,a,selective'
p1700
(F1
F0.00076452599388379206
I1
I0
I1
tp1701
sS'other,anti-pseudomonal,or'
p1702
(F1
F0.00076452599388379206
I1
I0
I1
tp1703
sS'coadministration,of,certain'
p1704
(F1
F0.00076452599388379206
I0
I1
I-1
tp1705
sS'be,coadministered,with'
p1706
(F1
F0.00076452599388379206
I1
I0
I1
tp1707
sS'protective,effect,of'
p1708
(F1
F0.00076452599388379206
I0
I1
I-1
tp1709
sS'mean,increase,of'
p1710
(F1
F0.00076452599388379206
I1
I0
I1
tp1711
sS'cyclosporine,the,total'
p1712
(F1
F0.00076452599388379206
I1
I0
I1
tp1713
sS'protective,effect,on'
p1714
(F1
F0.00076452599388379206
I1
I0
I1
tp1715
sS'alfa,pulmozyme,genentech'
p1716
(F1
F0.00076452599388379206
I1
I0
I1
tp1717
sS'mean,area,under'
p1718
(F1
F0.00076452599388379206
I1
I0
I1
tp1719
sS'use,of,diflucan'
p1720
(F1
F0.00076452599388379206
I1
I0
I1
tp1721
sS'and,has,been'
p1722
(F0.59999999999999998
F0.0022935779816513763
I4
I1
I3
tp1723
sS'reasonable,to,employ'
p1724
(F1
F0.0015290519877675841
I2
I0
I2
tp1725
sS'dose,of,predominantly'
p1726
(F1
F0.00076452599388379206
I0
I1
I-1
tp1727
sS'have,been,observed'
p1728
(F1
F0.00076452599388379206
I1
I0
I1
tp1729
sS'and,reduce,mpa'
p1730
(F1
F0.00076452599388379206
I0
I1
I-1
tp1731
sS'but,did,not'
p1732
(F0
F0
I1
I1
I0
tp1733
sS'spontaneous,reports,of'
p1734
(F1
F0.00076452599388379206
I1
I0
I1
tp1735
sS'injectable,emulsion,administration'
p1736
(F1
F0.00076452599388379206
I1
I0
I1
tp1737
sS'an,increased,incidence'
p1738
(F0.33333333333333331
F0.00076452599388379206
I1
I2
I-1
tp1739
sS'are,not,affected'
p1740
(F1
F0.0015290519877675841
I0
I2
I-2
tp1741
sS'and,mexitil,has'
p1742
(F1
F0.00076452599388379206
I1
I0
I1
tp1743
sS'taking,these,nsaids'
p1744
(F1
F0.00076452599388379206
I1
I0
I1
tp1745
sS'metabolism,of,oral'
p1746
(F1
F0.00076452599388379206
I1
I0
I1
tp1747
sS'the,rate,and'
p1748
(F0
F0
I1
I1
I0
tp1749
sS'ethynyl,pyridine-treated,monkeys'
p1750
(F1
F0.00076452599388379206
I1
I0
I1
tp1751
sS'oral,may,increase'
p1752
(F1
F0.00076452599388379206
I1
I0
I1
tp1753
sS'as,mivacron,include'
p1754
(F1
F0.00076452599388379206
I1
I0
I1
tp1755
sS'when,compared,with'
p1756
(F1
F0.00076452599388379206
I1
I0
I1
tp1757
sS'therefore,the,coadministration'
p1758
(F1
F0.00076452599388379206
I1
I0
I1
tp1759
sS'when,administering,concurrently'
p1760
(F1
F0.00076452599388379206
I1
I0
I1
tp1761
sS'cns-depressant,effect,of'
p1762
(F1
F0.00076452599388379206
I1
I0
I1
tp1763
sS'is,not,generally'
p1764
(F1
F0.00076452599388379206
I1
I0
I1
tp1765
sS'vitamin,a,and'
p1766
(F1
F0.00076452599388379206
I0
I1
I-1
tp1767
sS'co-injection,of,extracellular'
p1768
(F1
F0.00076452599388379206
I0
I1
I-1
tp1769
sS'in,c,max'
p1770
(F1
F0.00076452599388379206
I1
I0
I1
tp1771
sS'indications,that,could'
p1772
(F1
F0.00076452599388379206
I1
I0
I1
tp1773
sS'responses,of,chickens'
p1774
(F1
F0.00076452599388379206
I0
I1
I-1
tp1775
sS'and,was,studied'
p1776
(F1
F0.00076452599388379206
I0
I1
I-1
tp1777
sS'inhibition,by,of'
p1778
(F1
F0.00076452599388379206
I1
I0
I1
tp1779
sS'concentration,of,has'
p1780
(F1
F0.00076452599388379206
I1
I0
I1
tp1781
sS'dznep,and,abt-737'
p1782
(F1
F0.00076452599388379206
I1
I0
I1
tp1783
sS'of,drugs,such'
p1784
(F1
F0.00076452599388379206
I1
I0
I1
tp1785
sS'of,and,from'
p1786
(F1
F0.00076452599388379206
I1
I0
I1
tp1787
sS'be,monitored,when'
p1788
(F1
F0.00076452599388379206
I1
I0
I1
tp1789
sS'metabolism,of,metopirone'
p1790
(F1
F0.00076452599388379206
I1
I0
I1
tp1791
sS'treatment,with,and'
p1792
(F1
F0.00076452599388379206
I1
I0
I1
tp1793
sS'isoenzyme,cyp,d6'
p1794
(F1
F0.00076452599388379206
I1
I0
I1
tp1795
sS'to,ascertain,the'
p1796
(F1
F0.00076452599388379206
I0
I1
I-1
tp1797
sS'gsls,was,administered'
p1798
(F1
F0.00076452599388379206
I1
I0
I1
tp1799
sS'drugs,affecting,hepatic'
p1800
(F1
F0.00076452599388379206
I0
I1
I-1
tp1801
sS'receiving,and,generally'
p1802
(F1
F0.00076452599388379206
I1
I0
I1
tp1803
sS'transferase-mediated,dutp,nick-end'
p1804
(F1
F0.00076452599388379206
I0
I1
I-1
tp1805
sS'metabolized,by,cyp3a'
p1806
(F1
F0.00076452599388379206
I1
I0
I1
tp1807
sS'be,avoided,in'
p1808
(F1
F0.00076452599388379206
I0
I1
I-1
tp1809
sS'studies,the,recommended'
p1810
(F1
F0.00076452599388379206
I0
I1
I-1
tp1811
sS'and,n,poor'
p1812
(F1
F0.00076452599388379206
I0
I1
I-1
tp1813
sS'and,concurrent,use'
p1814
(F1
F0.00076452599388379206
I1
I0
I1
tp1815
sS'or,vehicle,were'
p1816
(F1
F0.00076452599388379206
I0
I1
I-1
tp1817
sS'absorption,of,nutrients'
p1818
(F1
F0.00076452599388379206
I1
I0
I1
tp1819
sS'recommended,pending,full'
p1820
(F1
F0.00076452599388379206
I1
I0
I1
tp1821
sS'by,of,cyp2c19'
p1822
(F1
F0.00076452599388379206
I1
I0
I1
tp1823
sS'of,has,no'
p1824
(F1
F0.0015290519877675841
I2
I0
I2
tp1825
sS'was,taking,infacol'
p1826
(F1
F0.00076452599388379206
I0
I1
I-1
tp1827
sS'lapatinib,enhances,herceptin-mediated'
p1828
(F1
F0.00076452599388379206
I1
I0
I1
tp1829
sS'or,decrease,in'
p1830
(F1
F0.00076452599388379206
I1
I0
I1
tp1831
sS'co-injection,of,heparinase'
p1832
(F1
F0.00076452599388379206
I1
I0
I1
tp1833
sS'inactivated,ai,vaccines'
p1834
(F1
F0.00076452599388379206
I1
I0
I1
tp1835
sS'based,on,studies'
p1836
(F1
F0.00076452599388379206
I0
I1
I-1
tp1837
sS'were,performed,in'
p1838
(F1
F0.00076452599388379206
I0
I1
I-1
tp1839
sS'with,was,conducted'
p1840
(F1
F0.00076452599388379206
I0
I1
I-1
tp1841
sS'increased,the,mean'
p1842
(F1
F0.00076452599388379206
I1
I0
I1
tp1843
sS'of,control,values'
p1844
(F1
F0.00076452599388379206
I1
I0
I1
tp1845
sS'ace,inhibitors,during'
p1846
(F1
F0.00076452599388379206
I1
I0
I1
tp1847
sS'and,concomitantly,as'
p1848
(F1
F0.00076452599388379206
I1
I0
I1
tp1849
sS'inhibitors,include,macrolide'
p1850
(F1
F0.00076452599388379206
I0
I1
I-1
tp1851
sS'than,did,cells'
p1852
(F1
F0.00076452599388379206
I1
I0
I1
tp1853
sS'effect,of,a'
p1854
(F1
F0.0022935779816513763
I0
I3
I-3
tp1855
sS'should,be,considered'
p1856
(F0.33333333333333331
F0.00076452599388379206
I2
I1
I1
tp1857
sS'in,subjects,receiving'
p1858
(F1
F0.00076452599388379206
I1
I0
I1
tp1859
sS'carbidopa,levodopa,carbidopa'
p1860
(F1
F0.00076452599388379206
I0
I1
I-1
tp1861
sS'fenofibrate,in,a'
p1862
(F1
F0.00076452599388379206
I1
I0
I1
tp1863
sS'p450,cyp,b6'
p1864
(F1
F0.00076452599388379206
I0
I1
I-1
tp1865
sS'anti-pseudomonal,or,parenteral'
p1866
(F1
F0.00076452599388379206
I1
I0
I1
tp1867
sS'is,clinically,warranted'
p1868
(F1
F0.00076452599388379206
I1
I0
I1
tp1869
sS'usp,because,they'
p1870
(F1
F0.00076452599388379206
I1
I0
I1
tp1871
sS'dosage,adjustments,for'
p1872
(F1
F0.00076452599388379206
I0
I1
I-1
tp1873
sS'limited,published,data'
p1874
(F1
F0.00076452599388379206
I1
I0
I1
tp1875
sS'or,female,rats'
p1876
(F1
F0.00076452599388379206
I0
I1
I-1
tp1877
sS'administering,zadaxin,therapy'
p1878
(F1
F0.00076452599388379206
I1
I0
I1
tp1879
sS'as,the,or'
p1880
(F1
F0.0015290519877675841
I2
I0
I2
tp1881
sS'carnitine,and,alpha'
p1882
(F1
F0.00076452599388379206
I0
I1
I-1
tp1883
sS'increases,of,fu'
p1884
(F1
F0.00076452599388379206
I1
I0
I1
tp1885
sS'is,ingested,with'
p1886
(F1
F0.00076452599388379206
I1
I0
I1
tp1887
sS'was,to,evaluate'
p1888
(F1
F0.0015290519877675841
I0
I2
I-2
tp1889
sS'two,with,respect'
p1890
(F1
F0.00076452599388379206
I0
I1
I-1
tp1891
sS'hypoglycemia,in,association'
p1892
(F1
F0.00076452599388379206
I1
I0
I1
tp1893
sS'occasions,with,implanon'
p1894
(F1
F0.00076452599388379206
I1
I0
I1
tp1895
sS'and,without,or'
p1896
(F1
F0.00076452599388379206
I1
I0
I1
tp1897
sS'subjects,mean,pre-dose'
p1898
(F1
F0.00076452599388379206
I1
I0
I1
tp1899
sS'to,patients,receiving'
p1900
(F0.33333333333333331
F0.00076452599388379206
I2
I1
I1
tp1901
sS'of,solid,tumors'
p1902
(F1
F0.00076452599388379206
I0
I1
I-1
tp1903
sS'study,conducted,in'
p1904
(F1
F0.00076452599388379206
I1
I0
I1
tp1905
sS'in,glass,jar'
p1906
(F1
F0.00076452599388379206
I0
I1
I-1
tp1907
sS'number,of,subjects'
p1908
(F1
F0.00076452599388379206
I1
I0
I1
tp1909
sS'other,nsaids,may'
p1910
(F1
F0.00076452599388379206
I1
I0
I1
tp1911
sS'of,an,oral'
p1912
(F1
F0.00076452599388379206
I0
I1
I-1
tp1913
sS'equivalent,to,g'
p1914
(F1
F0.00076452599388379206
I1
I0
I1
tp1915
sS'dutp,nick-end,labeling'
p1916
(F1
F0.00076452599388379206
I0
I1
I-1
tp1917
sS'to,have,little'
p1918
(F1
F0.00076452599388379206
I1
I0
I1
tp1919
sS'dose,of,mg'
p1920
(F0.33333333333333331
F0.00076452599388379206
I1
I2
I-1
tp1921
sS'approximately,doubled,auc0-'
p1922
(F1
F0.00076452599388379206
I1
I0
I1
tp1923
sS'concomitant,treatment,with'
p1924
(F1
F0.0015290519877675841
I2
I0
I2
tp1925
sS'studies,and,were'
p1926
(F1
F0.00076452599388379206
I0
I1
I-1
tp1927
sS'to,attenuate,some'
p1928
(F1
F0.00076452599388379206
I0
I1
I-1
tp1929
sS'of,much,study'
p1930
(F1
F0.00076452599388379206
I0
I1
I-1
tp1931
sS'cellular,cytotoxicity,by'
p1932
(F1
F0.00076452599388379206
I1
I0
I1
tp1933
sS'of,myfortic,was'
p1934
(F1
F0.00076452599388379206
I1
I0
I1
tp1935
sS'and,tolerability,of'
p1936
(F1
F0.00076452599388379206
I0
I1
I-1
tp1937
sS'vitro,but,not'
p1938
(F1
F0.00076452599388379206
I1
I0
I1
tp1939
sS'prothrombin,time,and'
p1940
(F0
F0
I1
I1
I0
tp1941
sS'with,hormonal,agents'
p1942
(F1
F0.00076452599388379206
I1
I0
I1
tp1943
sS'in,mice,while'
p1944
(F1
F0.00076452599388379206
I1
I0
I1
tp1945
sS'a,formal,study'
p1946
(F1
F0.00076452599388379206
I0
I1
I-1
tp1947
sS'mexitil,and,are'
p1948
(F1
F0.00076452599388379206
I1
I0
I1
tp1949
sS'in,the,bioavailability'
p1950
(F1
F0.00076452599388379206
I1
I0
I1
tp1951
sS'mofetil,given,that'
p1952
(F1
F0.00076452599388379206
I1
I0
I1
tp1953
sS'when,is,given'
p1954
(F1
F0.00076452599388379206
I1
I0
I1
tp1955
sS'tamoxifen,an,estrogen'
p1956
(F1
F0.00076452599388379206
I0
I1
I-1
tp1957
sS'in,the,concentrations'
p1958
(F1
F0.00076452599388379206
I0
I1
I-1
tp1959
sS'cell,layer,and'
p1960
(F1
F0.00076452599388379206
I0
I1
I-1
tp1961
sS'administration,should,be'
p1962
(F1
F0.00076452599388379206
I1
I0
I1
tp1963
sS'sulfoxone,may,increase'
p1964
(F1
F0.00076452599388379206
I1
I0
I1
tp1965
sS'nardil,in,the'
p1966
(F1
F0.00076452599388379206
I1
I0
I1
tp1967
sS'hepatic,metabolism,the'
p1968
(F1
F0.00076452599388379206
I0
I1
I-1
tp1969
sS'on,mycophenolate,mofetil'
p1970
(F1
F0.00076452599388379206
I0
I1
I-1
tp1971
sS'in,her2-positive,breast'
p1972
(F1
F0.0015290519877675841
I0
I2
I-2
tp1973
sS'not,cause,any'
p1974
(F1
F0.00076452599388379206
I0
I1
I-1
tp1975
sS'of,drugs,that'
p1976
(F1
F0.0022935779816513763
I3
I0
I3
tp1977
sS'skelid,by,up'
p1978
(F1
F0.00076452599388379206
I1
I0
I1
tp1979
sS'it,is,better'
p1980
(F1
F0.00076452599388379206
I1
I0
I1
tp1981
sS'such,as,slowly'
p1982
(F1
F0.00076452599388379206
I1
I0
I1
tp1983
sS'inhibitors,and,should'
p1984
(F1
F0.00076452599388379206
I1
I0
I1
tp1985
sS'reported,when,those'
p1986
(F1
F0.00076452599388379206
I1
I0
I1
tp1987
sS'and,not,be'
p1988
(F1
F0.00076452599388379206
I1
I0
I1
tp1989
sS'and,to,further'
p1990
(F1
F0.00076452599388379206
I0
I1
I-1
tp1991
sS'tumor,volume,per'
p1992
(F1
F0.00076452599388379206
I1
I0
I1
tp1993
sS'of,live,attenuated'
p1994
(F1
F0.00076452599388379206
I1
I0
I1
tp1995
sS'no,formal,interaction'
p1996
(F1
F0.00076452599388379206
I0
I1
I-1
tp1997
sS'in,an,increased'
p1998
(F1
F0.00076452599388379206
I1
I0
I1
tp1999
sS'or,its,carboxylated'
p2000
(F1
F0.00076452599388379206
I0
I1
I-1
tp2001
sS'in,patients,who'
p2002
(F1
F0.0022935779816513763
I3
I0
I3
tp2003
sS'concurrently,with,agents'
p2004
(F1
F0.00076452599388379206
I1
I0
I1
tp2005
sS'anesthetic,agents,has'
p2006
(F1
F0.00076452599388379206
I1
I0
I1
tp2007
sS'the,stomach,may'
p2008
(F1
F0.00076452599388379206
I1
I0
I1
tp2009
sS'either,to,fixed'
p2010
(F1
F0.00076452599388379206
I0
I1
I-1
tp2011
sS'secretion,and,thus'
p2012
(F1
F0.00076452599388379206
I1
I0
I1
tp2013
sS'drugs,oral,mg'
p2014
(F1
F0.00076452599388379206
I0
I1
I-1
tp2015
sS'not,prolong,the'
p2016
(F1
F0.00076452599388379206
I0
I1
I-1
tp2017
sS'can,increase,seizure'
p2018
(F1
F0.00076452599388379206
I1
I0
I1
tp2019
sS'elevate,the,level'
p2020
(F1
F0.00076452599388379206
I0
I1
I-1
tp2021
sS'soltab,diazepam,concomitant'
p2022
(F1
F0.00076452599388379206
I1
I0
I1
tp2023
sS'n,in,each'
p2024
(F1
F0.00076452599388379206
I0
I1
I-1
tp2025
sS'at,doses,less'
p2026
(F1
F0.00076452599388379206
I0
I1
I-1
tp2027
sS'patients,who,are'
p2028
(F0.59999999999999998
F0.0022935779816513763
I4
I1
I3
tp2029
sS'inhibits,the,renal'
p2030
(F1
F0.00076452599388379206
I1
I0
I1
tp2031
sS'given,to,increasing'
p2032
(F1
F0.00076452599388379206
I1
I0
I1
tp2033
sS'suggests,that,coadministration'
p2034
(F1
F0.00076452599388379206
I1
I0
I1
tp2035
sS'the,drug,metabolizing'
p2036
(F1
F0.00076452599388379206
I1
I0
I1
tp2037
sS'this,is,not'
p2038
(F1
F0.00076452599388379206
I0
I1
I-1
tp2039
sS'day,with,should'
p2040
(F1
F0.00076452599388379206
I1
I0
I1
tp2041
sS'rabbits,during,organogenesis'
p2042
(F1
F0.00076452599388379206
I0
I1
I-1
tp2043
sS'therapeutic,doses,of'
p2044
(F1
F0.00076452599388379206
I1
I0
I1
tp2045
sS'tacrolimus,there,have'
p2046
(F1
F0.00076452599388379206
I1
I0
I1
tp2047
sS'levels,and,a'
p2048
(F1
F0.00076452599388379206
I1
I0
I1
tp2049
sS'reduce,the,incidence'
p2050
(F1
F0.00076452599388379206
I0
I1
I-1
tp2051
sS'upon,initiation,of'
p2052
(F1
F0.00076452599388379206
I1
I0
I1
tp2053
sS'between,and,has'
p2054
(F1
F0.00076452599388379206
I1
I0
I1
tp2055
sS'blockers,oral,hypoglycemic'
p2056
(F1
F0.00076452599388379206
I0
I1
I-1
tp2057
sS'inhibitors,macrolide,antibiotics'
p2058
(F1
F0.00076452599388379206
I0
I1
I-1
tp2059
sS'increase,steady,state'
p2060
(F1
F0.00076452599388379206
I1
I0
I1
tp2061
sS'did,not,appear'
p2062
(F1
F0.00076452599388379206
I0
I1
I-1
tp2063
sS'auc,t,values'
p2064
(F1
F0.00076452599388379206
I1
I0
I1
tp2065
sS'occurs,with,ganglionic'
p2066
(F1
F0.00076452599388379206
I0
I1
I-1
tp2067
sS'dznep,could,synergistically'
p2068
(F1
F0.00076452599388379206
I1
I0
I1
tp2069
sS'administering,concurrently,with'
p2070
(F1
F0.00076452599388379206
I1
I0
I1
tp2071
sS'adjustment,of,the'
p2072
(F0
F0
I1
I1
I0
tp2073
sS'do,not,administer'
p2074
(F1
F0.00076452599388379206
I1
I0
I1
tp2075
sS'reduction,in,metabolism'
p2076
(F1
F0.00076452599388379206
I1
I0
I1
tp2077
sS'are,substrates,for'
p2078
(F1
F0.00076452599388379206
I0
I1
I-1
tp2079
sS'nonmatched,tacrolimus-treated,patients'
p2080
(F1
F0.00076452599388379206
I0
I1
I-1
tp2081
sS'to,the,apparent'
p2082
(F1
F0.00076452599388379206
I1
I0
I1
tp2083
sS'formal,study,n'
p2084
(F1
F0.00076452599388379206
I0
I1
I-1
tp2085
sS'and,were,shown'
p2086
(F1
F0.00076452599388379206
I1
I0
I1
tp2087
sS'lithium,increased,serum'
p2088
(F0
F0
I1
I1
I0
tp2089
sS'incremental,ldl-c,reduction'
p2090
(F1
F0.00076452599388379206
I1
I0
I1
tp2091
sS'mao,inhibitors,other'
p2092
(F1
F0.00076452599388379206
I1
I0
I1
tp2093
sS'by,approximately,have'
p2094
(F1
F0.00076452599388379206
I1
I0
I1
tp2095
sS'cyp2c9,and,cyp2c19'
p2096
(F1
F0.00076452599388379206
I0
I1
I-1
tp2097
sS'secreted,could,potentially'
p2098
(F1
F0.00076452599388379206
I1
I0
I1
tp2099
sS'since,is,partially'
p2100
(F1
F0.00076452599388379206
I1
I0
I1
tp2101
sS'information,available,from'
p2102
(F1
F0.00076452599388379206
I0
I1
I-1
tp2103
sS'will,elevate,the'
p2104
(F1
F0.00076452599388379206
I0
I1
I-1
tp2105
sS'and,represents,a'
p2106
(F1
F0.00076452599388379206
I1
I0
I1
tp2107
sS'mg,nonheme,as'
p2108
(F1
F0.00076452599388379206
I0
I1
I-1
tp2109
sS'we,found,antagonism'
p2110
(F1
F0.00076452599388379206
I1
I0
I1
tp2111
sS'may,compete,with'
p2112
(F1
F0.00076452599388379206
I1
I0
I1
tp2113
sS'has,shown,no'
p2114
(F1
F0.00076452599388379206
I1
I0
I1
tp2115
sS'of,heparinase,iii'
p2116
(F0.33333333333333331
F0.00076452599388379206
I1
I2
I-1
tp2117
sS'drugs,tricyclic,antidepressants'
p2118
(F1
F0.00076452599388379206
I1
I0
I1
tp2119
sS'addition,of,sodium'
p2120
(F1
F0.00076452599388379206
I0
I1
I-1
tp2121
sS'antidepressants,may,potentiate'
p2122
(F1
F0.00076452599388379206
I1
I0
I1
tp2123
sS'the,metabolism,and'
p2124
(F1
F0.00076452599388379206
I0
I1
I-1
tp2125
sS'since,bacteriostatic,drugs'
p2126
(F1
F0.00076452599388379206
I1
I0
I1
tp2127
sS'drugs,having,mixed'
p2128
(F1
F0.00076452599388379206
I0
I1
I-1
tp2129
sS'iib,iiia,inhibitors'
p2130
(F1
F0.00076452599388379206
I1
I0
I1
tp2131
sS'transduction,following,intravitreal'
p2132
(F1
F0.00076452599388379206
I0
I1
I-1
tp2133
sS'ssris,and,monoamine'
p2134
(F1
F0.00076452599388379206
I0
I1
I-1
tp2135
sS'presence,of,the'
p2136
(F1
F0.00076452599388379206
I0
I1
I-1
tp2137
sS'orthostatic,hypotension,its'
p2138
(F1
F0.00076452599388379206
I1
I0
I1
tp2139
sS'no,controlled,studies'
p2140
(F1
F0.00076452599388379206
I0
I1
I-1
tp2141
sS'the,area,under'
p2142
(F1
F0.00076452599388379206
I1
I0
I1
tp2143
sS'receiving,or,because'
p2144
(F1
F0.00076452599388379206
I1
I0
I1
tp2145
sS'with,hormonal,contraceptives'
p2146
(F1
F0.00076452599388379206
I0
I1
I-1
tp2147
sS'a,role,of'
p2148
(F1
F0.00076452599388379206
I0
I1
I-1
tp2149
sS'respiratory,depression,apnea'
p2150
(F1
F0.00076452599388379206
I1
I0
I1
tp2151
sS'cdk1,suggest,that'
p2152
(F1
F0.00076452599388379206
I1
I0
I1
tp2153
sS'bleeding,upon,initiation'
p2154
(F1
F0.00076452599388379206
I1
I0
I1
tp2155
sS'enhanced,but,also'
p2156
(F1
F0.00076452599388379206
I1
I0
I1
tp2157
sS'thiol,content,hplc'
p2158
(F1
F0.00076452599388379206
I0
I1
I-1
tp2159
sS'prior,use,appears'
p2160
(F1
F0.00076452599388379206
I1
I0
I1
tp2161
sS'increased,the,dose-dependent'
p2162
(F1
F0.00076452599388379206
I1
I0
I1
tp2163
sS'mpag,hydrolysis,may'
p2164
(F1
F0.00076452599388379206
I0
I1
I-1
tp2165
sS'activity,of,evaluated'
p2166
(F1
F0.00076452599388379206
I1
I0
I1
tp2167
sS'the,effect,of'
p2168
(F0.44444444444444442
F0.0061162079510703364
I5
I13
I-8
tp2169
sS'chronic,or,therapy'
p2170
(F1
F0.00076452599388379206
I1
I0
I1
tp2171
sS'cyp2c19,so,that'
p2172
(F1
F0.00076452599388379206
I0
I1
I-1
tp2173
sS'be,concluded,that'
p2174
(F1
F0.00076452599388379206
I1
I0
I1
tp2175
sS'antibiotics,and,protease'
p2176
(F1
F0.00076452599388379206
I0
I1
I-1
tp2177
sS'hypotensive,effects,can'
p2178
(F1
F0.00076452599388379206
I1
I0
I1
tp2179
sS'of,tobi,patients'
p2180
(F1
F0.00076452599388379206
I1
I0
I1
tp2181
sS'in,mice,and'
p2182
(F1
F0.00076452599388379206
I0
I1
I-1
tp2183
sS'inhibit,purine,metabolism'
p2184
(F1
F0.00076452599388379206
I1
I0
I1
tp2185
sS'can,cause,unusually'
p2186
(F1
F0.00076452599388379206
I1
I0
I1
tp2187
sS'of,azole,antimycotics'
p2188
(F1
F0.00076452599388379206
I1
I0
I1
tp2189
sS'administering,vumon,injection'
p2190
(F1
F0.00076452599388379206
I0
I1
I-1
tp2191
sS'of,mg,daily'
p2192
(F1
F0.00076452599388379206
I0
I1
I-1
tp2193
sS'demonstrated,that,coadministration'
p2194
(F1
F0.00076452599388379206
I1
I0
I1
tp2195
sS'marplan,parnate,or'
p2196
(F1
F0.00076452599388379206
I1
I0
I1
tp2197
sS'on,the,use'
p2198
(F0
F0
I1
I1
I0
tp2199
sS'anesthesia,or,sedation'
p2200
(F0
F0
I1
I1
I0
tp2201
sS'drug,interactions,it'
p2202
(F1
F0.00076452599388379206
I1
I0
I1
tp2203
sS'that,gh,treatment'
p2204
(F1
F0.00076452599388379206
I1
I0
I1
tp2205
sS'are,metabolized,by'
p2206
(F0
F0
I1
I1
I0
tp2207
sS's,wort,with'
p2208
(F1
F0.00076452599388379206
I1
I0
I1
tp2209
sS'to,investigate,the'
p2210
(F1
F0.00076452599388379206
I0
I1
I-1
tp2211
sS'to,further,elucidate'
p2212
(F1
F0.00076452599388379206
I0
I1
I-1
tp2213
sS'has,been,demonstrated'
p2214
(F1
F0.00076452599388379206
I1
I0
I1
tp2215
sS'should,avoid,taking'
p2216
(F1
F0.00076452599388379206
I1
I0
I1
tp2217
sS'the,difficulty,in'
p2218
(F1
F0.00076452599388379206
I0
I1
I-1
tp2219
sS'elicits,a,significant'
p2220
(F1
F0.00076452599388379206
I1
I0
I1
tp2221
sS'levodopa,does,not'
p2222
(F1
F0.00076452599388379206
I0
I1
I-1
tp2223
sS'subjects,coadministration,of'
p2224
(F1
F0.00076452599388379206
I0
I1
I-1
tp2225
sS'by,the,addition'
p2226
(F1
F0.00076452599388379206
I0
I1
I-1
tp2227
sS'reported,when,was'
p2228
(F1
F0.00076452599388379206
I0
I1
I-1
tp2229
sS'that,does,not'
p2230
(F1
F0.0022935779816513763
I0
I3
I-3
tp2231
sS'commonly,prescribed,medications'
p2232
(F1
F0.00076452599388379206
I0
I1
I-1
tp2233
sS'rate,of,gi'
p2234
(F1
F0.00076452599388379206
I1
I0
I1
tp2235
sS'of,using,in'
p2236
(F1
F0.00076452599388379206
I0
I1
I-1
tp2237
sS'plasma,cholinesterase,resistance'
p2238
(F1
F0.00076452599388379206
I1
I0
I1
tp2239
sS'of,with,other'
p2240
(F0.33333333333333331
F0.00076452599388379206
I2
I1
I1
tp2241
sS'to,the,hospital'
p2242
(F1
F0.00076452599388379206
I0
I1
I-1
tp2243
sS'observed,with,doses'
p2244
(F1
F0.00076452599388379206
I1
I0
I1
tp2245
sS'when,concomitantly,administered'
p2246
(F1
F0.00076452599388379206
I1
I0
I1
tp2247
sS'temperature,has,been'
p2248
(F1
F0.00076452599388379206
I1
I0
I1
tp2249
sS'but,an,effect'
p2250
(F1
F0.00076452599388379206
I1
I0
I1
tp2251
sS'spontaneous,adverse,reaction'
p2252
(F1
F0.00076452599388379206
I1
I0
I1
tp2253
sS'with,hypertensive,disease'
p2254
(F1
F0.00076452599388379206
I0
I1
I-1
tp2255
sS'cytochrome,p450,cp450'
p2256
(F1
F0.00076452599388379206
I1
I0
I1
tp2257
sS'in,mind,in'
p2258
(F1
F0.00076452599388379206
I1
I0
I1
tp2259
sS'cases,an,is'
p2260
(F1
F0.00076452599388379206
I1
I0
I1
tp2261
sS'and,conditioned,place'
p2262
(F1
F0.0015290519877675841
I0
I2
I-2
tp2263
sS'administering,tolectin,to'
p2264
(F1
F0.00076452599388379206
I1
I0
I1
tp2265
sS'monitoring,of,prothrombin'
p2266
(F1
F0.00076452599388379206
I1
I0
I1
tp2267
sS'this,drug,metabolizing'
p2268
(F1
F0.00076452599388379206
I0
I1
I-1
tp2269
sS'inhibitors,has,shown'
p2270
(F1
F0.00076452599388379206
I0
I1
I-1
tp2271
sS'of,increased,intraocular'
p2272
(F1
F0.00076452599388379206
I1
I0
I1
tp2273
sS'when,coadministered,with'
p2274
(F0
F0
I2
I2
I0
tp2275
sS'fever,severe,obstipation'
p2276
(F1
F0.00076452599388379206
I1
I0
I1
tp2277
sS'for,t-all,and'
p2278
(F1
F0.00076452599388379206
I0
I1
I-1
tp2279
sS'large,or,prolonged'
p2280
(F1
F0.00076452599388379206
I1
I0
I1
tp2281
sS'of,drugs,with'
p2282
(F1
F0.00076452599388379206
I1
I0
I1
tp2283
sS'and,were,ingested'
p2284
(F1
F0.00076452599388379206
I0
I1
I-1
tp2285
sS'or,by,drugs'
p2286
(F1
F0.00076452599388379206
I1
I0
I1
tp2287
sS'cardiac,arrhythmias,during'
p2288
(F1
F0.0015290519877675841
I2
I0
I2
tp2289
sS'green,fluorescent,protein'
p2290
(F1
F0.00076452599388379206
I0
I1
I-1
tp2291
sS'has,shown,that'
p2292
(F1
F0.00076452599388379206
I1
I0
I1
tp2293
sS'pyrimethamine,may,be'
p2294
(F1
F0.00076452599388379206
I0
I1
I-1
tp2295
sS'mycamine,and,mycophenolate'
p2296
(F1
F0.00076452599388379206
I0
I1
I-1
tp2297
sS'when,t,returned'
p2298
(F1
F0.00076452599388379206
I0
I1
I-1
tp2299
sS'cardiac,events,including'
p2300
(F1
F0.00076452599388379206
I1
I0
I1
tp2301
sS'protease,or,reverse'
p2302
(F1
F0.00076452599388379206
I0
I1
I-1
tp2303
sS'blood,levels,may'
p2304
(F1
F0.00076452599388379206
I1
I0
I1
tp2305
sS'secretion,by,the'
p2306
(F1
F0.00076452599388379206
I1
I0
I1
tp2307
sS'in,the,area'
p2308
(F1
F0.00076452599388379206
I1
I0
I1
tp2309
sS'important,drug-drug,interactions'
p2310
(F1
F0.00076452599388379206
I0
I1
I-1
tp2311
sS'structurally,related,to'
p2312
(F1
F0.00076452599388379206
I1
I0
I1
tp2313
sS'commonly,used,neuromuscular'
p2314
(F1
F0.00076452599388379206
I0
I1
I-1
tp2315
sS'is,no,evidence'
p2316
(F1
F0.00076452599388379206
I1
I0
I1
tp2317
sS'of,cytochromes,p450'
p2318
(F1
F0.00076452599388379206
I0
I1
I-1
tp2319
sS'administered,to,stable'
p2320
(F1
F0.00076452599388379206
I1
I0
I1
tp2321
sS'enhanced,serum,antibody'
p2322
(F1
F0.00076452599388379206
I1
I0
I1
tp2323
sS'are,concomitantly,administered'
p2324
(F1
F0.00076452599388379206
I1
I0
I1
tp2325
sS'anti-infective,medicines,and'
p2326
(F1
F0.00076452599388379206
I1
I0
I1
tp2327
sS'drugs,that,interfere'
p2328
(F1
F0.00076452599388379206
I0
I1
I-1
tp2329
sS'needed,higher,serum'
p2330
(F1
F0.00076452599388379206
I1
I0
I1
tp2331
sS'and,eg,chloral'
p2332
(F1
F0.00076452599388379206
I0
I1
I-1
tp2333
sS'no,effect,of'
p2334
(F1
F0.00076452599388379206
I0
I1
I-1
tp2335
sS'concurrent,use,decreases'
p2336
(F1
F0.00076452599388379206
I1
I0
I1
tp2337
sS'general,other,monoamine'
p2338
(F1
F0.00076452599388379206
I0
I1
I-1
tp2339
sS'strong,p450,a'
p2340
(F1
F0.00076452599388379206
I1
I0
I1
tp2341
sS'this,diminution,is'
p2342
(F1
F0.00076452599388379206
I1
I0
I1
tp2343
sS'rate,and,or'
p2344
(F1
F0.00076452599388379206
I1
I0
I1
tp2345
sS'than,with,mg'
p2346
(F1
F0.00076452599388379206
I0
I1
I-1
tp2347
sS'agents,or,cholinergic'
p2348
(F1
F0.00076452599388379206
I1
I0
I1
tp2349
sS'depressants,the,depressant'
p2350
(F1
F0.00076452599388379206
I1
I0
I1
tp2351
sS'of,proton,pump'
p2352
(F1
F0.00076452599388379206
I0
I1
I-1
tp2353
sS'or,ci,or'
p2354
(F1
F0.00076452599388379206
I1
I0
I1
tp2355
sS'the,case,of'
p2356
(F1
F0.00076452599388379206
I1
I0
I1
tp2357
sS'profile,of,after'
p2358
(F1
F0.00076452599388379206
I0
I1
I-1
tp2359
sS'may,increase,plasma'
p2360
(F1
F0.0015290519877675841
I2
I0
I2
tp2361
sS'muted,compared,with'
p2362
(F1
F0.00076452599388379206
I0
I1
I-1
tp2363
sS'a,significant,decrease'
p2364
(F1
F0.00076452599388379206
I1
I0
I1
tp2365
sS'documenting,the,use'
p2366
(F1
F0.00076452599388379206
I0
I1
I-1
tp2367
sS'any,of,subsequent'
p2368
(F1
F0.00076452599388379206
I0
I1
I-1
tp2369
sS'response,of,and'
p2370
(F1
F0.00076452599388379206
I0
I1
I-1
tp2371
sS'a,strong,cyp3a4'
p2372
(F1
F0.00076452599388379206
I1
I0
I1
tp2373
sS'increased,serum,and'
p2374
(F1
F0.00076452599388379206
I0
I1
I-1
tp2375
sS'resulting,in,a'
p2376
(F0.33333333333333331
F0.00076452599388379206
I2
I1
I1
tp2377
sS'depressed,to,approximately'
p2378
(F1
F0.00076452599388379206
I1
I0
I1
tp2379
sS'predictable,dose-related,myelotoxicity'
p2380
(F1
F0.00076452599388379206
I1
I0
I1
tp2381
sS'p27,kip1,sirna'
p2382
(F1
F0.00076452599388379206
I0
I1
I-1
tp2383
sS'and,phenothiazine-type,should'
p2384
(F1
F0.00076452599388379206
I0
I1
I-1
tp2385
sS'other,salicylate,drugs'
p2386
(F1
F0.00076452599388379206
I1
I0
I1
tp2387
sS'experience,as,with'
p2388
(F1
F0.00076452599388379206
I1
I0
I1
tp2389
sS'analyze,the,effects'
p2390
(F1
F0.00076452599388379206
I0
I1
I-1
tp2391
sS'ml,of,containing'
p2392
(F1
F0.00076452599388379206
I0
I1
I-1
tp2393
sS'acute,toxicity,of'
p2394
(F1
F0.00076452599388379206
I0
I1
I-1
tp2395
sS'hypertensive,crisis,has'
p2396
(F1
F0.00076452599388379206
I1
I0
I1
tp2397
sS'may,decrease,levels'
p2398
(F1
F0.00076452599388379206
I1
I0
I1
tp2399
sS'not,appear,as'
p2400
(F1
F0.00076452599388379206
I0
I1
I-1
tp2401
sS'mg,kg,administered'
p2402
(F1
F0.00076452599388379206
I0
I1
I-1
tp2403
sS'acid,against,the'
p2404
(F1
F0.00076452599388379206
I0
I1
I-1
tp2405
sS'decreased,following,the'
p2406
(F1
F0.00076452599388379206
I1
I0
I1
tp2407
sS'other,drugs,rivastigmine'
p2408
(F1
F0.00076452599388379206
I0
I1
I-1
tp2409
sS'with,depo-subq,provera'
p2410
(F1
F0.00076452599388379206
I1
I0
I1
tp2411
sS'ibuprofen,plasma,concentration'
p2412
(F1
F0.00076452599388379206
I1
I0
I1
tp2413
sS'cimetidine,mg,four'
p2414
(F1
F0.00076452599388379206
I1
I0
I1
tp2415
sS'concomitantly,administered,should'
p2416
(F1
F0.00076452599388379206
I1
I0
I1
tp2417
sS'comes,from,studies'
p2418
(F1
F0.00076452599388379206
I1
I0
I1
tp2419
sS'of,mivacron,before'
p2420
(F1
F0.00076452599388379206
I0
I1
I-1
tp2421
sS'impairment,of,motor'
p2422
(F1
F0.00076452599388379206
I1
I0
I1
tp2423
sS'pharmacokinetics,of,in'
p2424
(F1
F0.00076452599388379206
I0
I1
I-1
tp2425
sS'clinically,significant,pharmacokinetic'
p2426
(F1
F0.00076452599388379206
I0
I1
I-1
tp2427
sS'conjunction,with,oral'
p2428
(F1
F0.00076452599388379206
I1
I0
I1
tp2429
sS'or,intravenous,premedication'
p2430
(F1
F0.00076452599388379206
I1
I0
I1
tp2431
sS'the,toxicity,of'
p2432
(F1
F0.00076452599388379206
I1
I0
I1
tp2433
sS'measurements,of,dopamine'
p2434
(F1
F0.00076452599388379206
I1
I0
I1
tp2435
sS'less,likely,to'
p2436
(F1
F0.00076452599388379206
I0
I1
I-1
tp2437
sS'enhances,herceptin-mediated,antibody-dependent'
p2438
(F1
F0.00076452599388379206
I1
I0
I1
tp2439
sS'with,a,particular'
p2440
(F1
F0.00076452599388379206
I0
I1
I-1
tp2441
sS'valproic,acid,decreases'
p2442
(F1
F0.00076452599388379206
I1
I0
I1
tp2443
sS'on,plasma,concentrations'
p2444
(F1
F0.00076452599388379206
I1
I0
I1
tp2445
sS'reduction,due,to'
p2446
(F1
F0.00076452599388379206
I1
I0
I1
tp2447
sS'pharmacokinetic,studies,demonstrated'
p2448
(F1
F0.00076452599388379206
I0
I1
I-1
tp2449
sS'was,not,studied'
p2450
(F1
F0.00076452599388379206
I0
I1
I-1
tp2451
sS'rate,requirements,may'
p2452
(F1
F0.00076452599388379206
I1
I0
I1
tp2453
sS'interactions,should,be'
p2454
(F1
F0.00076452599388379206
I0
I1
I-1
tp2455
sS'be,necessary,eg'
p2456
(F1
F0.00076452599388379206
I1
I0
I1
tp2457
sS'aggrastat,has,been'
p2458
(F1
F0.00076452599388379206
I0
I1
I-1
tp2459
sS'avoided,except,where'
p2460
(F1
F0.00076452599388379206
I0
I1
I-1
tp2461
sS'of,by,the'
p2462
(F1
F0.00076452599388379206
I1
I0
I1
tp2463
sS'and,other,diabetes'
p2464
(F1
F0.00076452599388379206
I1
I0
I1
tp2465
sS'ginseng,stem-and,leaf'
p2466
(F1
F0.0015290519877675841
I0
I2
I-2
tp2467
sS'of,pain,without'
p2468
(F1
F0.00076452599388379206
I1
I0
I1
tp2469
sS'are,taking,a'
p2470
(F1
F0.00076452599388379206
I0
I1
I-1
tp2471
sS'toxicity,at,doses'
p2472
(F1
F0.00076452599388379206
I0
I1
I-1
tp2473
sS'such,as,amphotericin'
p2474
(F1
F0.00076452599388379206
I0
I1
I-1
tp2475
sS'shown,that,ritalin'
p2476
(F1
F0.00076452599388379206
I1
I0
I1
tp2477
sS'mexitil,theophylline,plasma'
p2478
(F1
F0.00076452599388379206
I1
I0
I1
tp2479
sS'decreased,absorption,of'
p2480
(F1
F0.00076452599388379206
I0
I1
I-1
tp2481
sS'study,with,was'
p2482
(F1
F0.0015290519877675841
I0
I2
I-2
tp2483
sS'an,inhibitor,of'
p2484
(F0.33333333333333331
F0.00076452599388379206
I2
I1
I1
tp2485
sS'is,administered,in'
p2486
(F1
F0.00076452599388379206
I1
I0
I1
tp2487
sS'of,s-ketamine,should'
p2488
(F1
F0.00076452599388379206
I1
I0
I1
tp2489
sS'that,diflucan,taken'
p2490
(F1
F0.00076452599388379206
I1
I0
I1
tp2491
sS'the,experiments,gsls'
p2492
(F1
F0.00076452599388379206
I0
I1
I-1
tp2493
sS'was,minutes,range'
p2494
(F1
F0.00076452599388379206
I0
I1
I-1
tp2495
sS'serum,concentrations,to'
p2496
(F1
F0.00076452599388379206
I1
I0
I1
tp2497
sS'increased,rate,of'
p2498
(F1
F0.00076452599388379206
I1
I0
I1
tp2499
sS'and,have,not'
p2500
(F1
F0.00076452599388379206
I0
I1
I-1
tp2501
sS'depressant,effects,of'
p2502
(F1
F0.0022935779816513763
I3
I0
I3
tp2503
sS'mg,dose,of'
p2504
(F1
F0.00076452599388379206
I1
I0
I1
tp2505
sS'of,zemuron,mg'
p2506
(F1
F0.00076452599388379206
I0
I1
I-1
tp2507
sS'may,result,in'
p2508
(F0.80000000000000004
F0.0061162079510703364
I9
I1
I8
tp2509
sS'with,other,nsaids'
p2510
(F1
F0.00076452599388379206
I1
I0
I1
tp2511
sS'tumor,response,to'
p2512
(F1
F0.00076452599388379206
I1
I0
I1
tp2513
sS'not,yet,been'
p2514
(F1
F0.00076452599388379206
I0
I1
I-1
tp2515
sS'three,stereoisomers,has'
p2516
(F1
F0.00076452599388379206
I0
I1
I-1
tp2517
sS'with,myfortic,the'
p2518
(F1
F0.00076452599388379206
I1
I0
I1
tp2519
sS'the,tpmt,enzyme'
p2520
(F1
F0.00076452599388379206
I1
I0
I1
tp2521
sS'coadministered,to,subjects'
p2522
(F1
F0.00076452599388379206
I1
I0
I1
tp2523
sS'not,in,other'
p2524
(F1
F0.00076452599388379206
I1
I0
I1
tp2525
sS'of,sanctura,with'
p2526
(F0
F0
I1
I1
I0
tp2527
sS'require,drug,therapy'
p2528
(F1
F0.00076452599388379206
I0
I1
I-1
tp2529
sS'when,administered,concurrently'
p2530
(F1
F0.00076452599388379206
I1
I0
I1
tp2531
sS'ecg,intervals,pr'
p2532
(F1
F0.00076452599388379206
I0
I1
I-1
tp2533
sS'a,shimadzu,hplc'
p2534
(F1
F0.00076452599388379206
I0
I1
I-1
tp2535
sS'strong,inhibitors,of'
p2536
(F1
F0.0015290519877675841
I2
I0
I2
tp2537
sS'potential,refer,to'
p2538
(F1
F0.00076452599388379206
I0
I1
I-1
tp2539
sS'to,severe,bone'
p2540
(F1
F0.00076452599388379206
I1
I0
I1
tp2541
sS'or,other,anticholinergic-like'
p2542
(F1
F0.00076452599388379206
I1
I0
I1
tp2543
sS'methyldopa,does,not'
p2544
(F1
F0.00076452599388379206
I0
I1
I-1
tp2545
sS'the,orthostatic,hypotension'
p2546
(F1
F0.00076452599388379206
I1
I0
I1
tp2547
sS'by,altering,concentrations'
p2548
(F1
F0.00076452599388379206
I1
I0
I1
tp2549
sS'the,half-life,of'
p2550
(F1
F0.00076452599388379206
I1
I0
I1
tp2551
sS'nsaids,have,produced'
p2552
(F1
F0.00076452599388379206
I1
I0
I1
tp2553
sS'these,drugs,may'
p2554
(F0
F0
I1
I1
I0
tp2555
sS'of,subsequent,sessions'
p2556
(F1
F0.00076452599388379206
I0
I1
I-1
tp2557
sS'and,serum,concentrations'
p2558
(F1
F0.00076452599388379206
I1
I0
I1
tp2559
sS'chickens,intramuscularly,injected'
p2560
(F1
F0.00076452599388379206
I0
I1
I-1
tp2561
sS'daily,dose,of'
p2562
(F1
F0.0015290519877675841
I2
I0
I2
tp2563
sS'these,behavioural,observations'
p2564
(F1
F0.00076452599388379206
I1
I0
I1
tp2565
sS'to,the,pregnancy'
p2566
(F1
F0.00076452599388379206
I0
I1
I-1
tp2567
sS'co-,administered,with'
p2568
(F1
F0.00076452599388379206
I1
I0
I1
tp2569
sS'after,other,nondepolarizing'
p2570
(F1
F0.00076452599388379206
I0
I1
I-1
tp2571
sS'been,reports,of'
p2572
(F0.59999999999999998
F0.0022935779816513763
I4
I1
I3
tp2573
sS'drug,metabolizing,enzyme'
p2574
(F0
F0
I1
I1
I0
tp2575
sS'of,mivacron,may'
p2576
(F0
F0
I1
I1
I0
tp2577
sS'mephenytoin,may,interact'
p2578
(F1
F0.00076452599388379206
I1
I0
I1
tp2579
sS'concomitantly,should,be'
p2580
(F1
F0.0022935779816513763
I3
I0
I3
tp2581
sS'of,ketoconazole-mediated,cyp3a4'
p2582
(F1
F0.00076452599388379206
I0
I1
I-1
tp2583
sS'that,may,prolong'
p2584
(F1
F0.00076452599388379206
I1
I0
I1
tp2585
sS'at,different,conditions'
p2586
(F1
F0.00076452599388379206
I0
I1
I-1
tp2587
sS'also,had,a'
p2588
(F1
F0.00076452599388379206
I1
I0
I1
tp2589
sS'influence,locomotion,in'
p2590
(F1
F0.00076452599388379206
I1
I0
I1
tp2591
sS'observed,following,concomitant'
p2592
(F1
F0.00076452599388379206
I0
I1
I-1
tp2593
sS'dosage,of,or'
p2594
(F1
F0.00076452599388379206
I0
I1
I-1
tp2595
sS'formal,drug,interaction'
p2596
(F1
F0.00076452599388379206
I0
I1
I-1
tp2597
sS'in,patients,on'
p2598
(F0
F0
I1
I1
I0
tp2599
sS'lithium,serum,levels'
p2600
(F1
F0.00076452599388379206
I0
I1
I-1
tp2601
sS'premixed,formulations,of'
p2602
(F1
F0.00076452599388379206
I1
I0
I1
tp2603
sS'an,effect,of'
p2604
(F1
F0.00076452599388379206
I1
I0
I1
tp2605
sS'with,water,wheel'
p2606
(F1
F0.00076452599388379206
I0
I1
I-1
tp2607
sS'inr,and,an'
p2608
(F1
F0.00076452599388379206
I1
I0
I1
tp2609
sS'mpag,concentrations,are'
p2610
(F1
F0.00076452599388379206
I0
I1
I-1
tp2611
sS'reductase,inhibitor,in'
p2612
(F1
F0.00076452599388379206
I0
I1
I-1
tp2613
sS'prolonging,effect,appeared'
p2614
(F1
F0.00076452599388379206
I0
I1
I-1
tp2615
sS'ng,hr,ml'
p2616
(F1
F0.00076452599388379206
I1
I0
I1
tp2617
sS'was,also,increased'
p2618
(F1
F0.00076452599388379206
I1
I0
I1
tp2619
sS'when,ditropan,xl'
p2620
(F1
F0.00076452599388379206
I1
I0
I1
tp2621
sS'bcl-2,family,inhibitor'
p2622
(F1
F0.00076452599388379206
I1
I0
I1
tp2623
sS'employ,appropriate,clinical'
p2624
(F1
F0.0015290519877675841
I2
I0
I2
tp2625
sS'doses,lower,than'
p2626
(F1
F0.00076452599388379206
I1
I0
I1
tp2627
sS'inhibitors,of,cyp3a4'
p2628
(F1
F0.00076452599388379206
I1
I0
I1
tp2629
sS'coadministration,of,tritec'
p2630
(F1
F0.00076452599388379206
I1
I0
I1
tp2631
sS'be,provided,with'
p2632
(F1
F0.00076452599388379206
I1
I0
I1
tp2633
sS'with,ropivacaine,leading'
p2634
(F1
F0.00076452599388379206
I1
I0
I1
tp2635
sS'causal,relationship,between'
p2636
(F1
F0.00076452599388379206
I1
I0
I1
tp2637
sS'the,first,few'
p2638
(F1
F0.00076452599388379206
I1
I0
I1
tp2639
sS'acquired,qt,prolongation'
p2640
(F1
F0.00076452599388379206
I0
I1
I-1
tp2641
sS'minimized,by,discontinuing'
p2642
(F1
F0.00076452599388379206
I0
I1
I-1
tp2643
sS'in,women,and'
p2644
(F1
F0.00076452599388379206
I1
I0
I1
tp2645
sS'in,requirement,in'
p2646
(F1
F0.00076452599388379206
I0
I1
I-1
tp2647
sS'are,also,tubularly'
p2648
(F1
F0.00076452599388379206
I1
I0
I1
tp2649
sS'acidic,media,whereas'
p2650
(F1
F0.00076452599388379206
I1
I0
I1
tp2651
sS'retention,and,or'
p2652
(F1
F0.00076452599388379206
I1
I0
I1
tp2653
sS'of,beta,adrenergic'
p2654
(F1
F0.00076452599388379206
I1
I0
I1
tp2655
sS'tetrahydropyridine,vehicle-treated,animals'
p2656
(F1
F0.0015290519877675841
I2
I0
I2
tp2657
sS'blockers,increase,the'
p2658
(F1
F0.00076452599388379206
I1
I0
I1
tp2659
sS'kg,plus,mg'
p2660
(F1
F0.00076452599388379206
I0
I1
I-1
tp2661
sS'due,to,adding'
p2662
(F1
F0.00076452599388379206
I1
I0
I1
tp2663
sS'cns,depression-producing,drugs'
p2664
(F1
F0.00076452599388379206
I1
I0
I1
tp2665
sS'provided,as,nonheme'
p2666
(F1
F0.00076452599388379206
I1
I0
I1
tp2667
sS'with,a,variety'
p2668
(F1
F0.00076452599388379206
I0
I1
I-1
tp2669
sS'be,similar,to'
p2670
(F1
F0.00076452599388379206
I1
I0
I1
tp2671
sS'are,incompatible,with'
p2672
(F1
F0.00076452599388379206
I1
I0
I1
tp2673
sS'time,induced,by'
p2674
(F1
F0.00076452599388379206
I0
I1
I-1
tp2675
sS'gastrointestinal,motility,are'
p2676
(F1
F0.00076452599388379206
I1
I0
I1
tp2677
sS'the,pharmacokinetics,of'
p2678
(F1
F0.0068807339449541288
I0
I9
I-9
tp2679
sS'enzyme,inducer,and'
p2680
(F1
F0.00076452599388379206
I1
I0
I1
tp2681
sS'while,their,combination'
p2682
(F1
F0.00076452599388379206
I1
I0
I1
tp2683
sS'increases,in,dose'
p2684
(F1
F0.00076452599388379206
I1
I0
I1
tp2685
sS'for,mice,group'
p2686
(F1
F0.00076452599388379206
I0
I1
I-1
tp2687
sS'the,pharmacokinetics,or'
p2688
(F1
F0.00076452599388379206
I0
I1
I-1
tp2689
sS'may,occur,in'
p2690
(F1
F0.00076452599388379206
I0
I1
I-1
tp2691
sS'be,metabolized,by'
p2692
(F0
F0
I1
I1
I0
tp2693
sS'agent,is,a'
p2694
(F1
F0.00076452599388379206
I1
I0
I1
tp2695
sS'chloride,supplements,absorbent-type'
p2696
(F1
F0.00076452599388379206
I1
I0
I1
tp2697
sS'inhibition,such,as'
p2698
(F1
F0.00076452599388379206
I0
I1
I-1
tp2699
sS'with,female,rats'
p2700
(F1
F0.00076452599388379206
I0
I1
I-1
tp2701
sS'interaction,studies,between'
p2702
(F1
F0.00076452599388379206
I0
I1
I-1
tp2703
sS'of,concealed,inefficacy'
p2704
(F1
F0.00076452599388379206
I1
I0
I1
tp2705
sS'of,was,carried'
p2706
(F1
F0.00076452599388379206
I0
I1
I-1
tp2707
sS'may,bind,bile'
p2708
(F1
F0.00076452599388379206
I1
I0
I1
tp2709
sS'increased,fold,in'
p2710
(F1
F0.00076452599388379206
I1
I0
I1
tp2711
sS'may,prolong,the'
p2712
(F1
F0.00076452599388379206
I1
I0
I1
tp2713
sS'alter,gastrointestinal,motility'
p2714
(F1
F0.0015290519877675841
I2
I0
I2
tp2715
sS'nsaids,with,longer'
p2716
(F1
F0.00076452599388379206
I1
I0
I1
tp2717
sS'peak,concentration,and'
p2718
(F1
F0.00076452599388379206
I1
I0
I1
tp2719
sS'gastrointestinal,effects,and'
p2720
(F1
F0.00076452599388379206
I0
I1
I-1
tp2721
sS'an,is,considered'
p2722
(F1
F0.00076452599388379206
I1
I0
I1
tp2723
sS'heart,medicines,birth'
p2724
(F1
F0.00076452599388379206
I1
I0
I1
tp2725
sS'mofetil,inhibit,purine'
p2726
(F1
F0.00076452599388379206
I1
I0
I1
tp2727
sS'agitation,in,seven'
p2728
(F1
F0.00076452599388379206
I0
I1
I-1
tp2729
sS'apoptosis,and,dna'
p2730
(F1
F0.00076452599388379206
I0
I1
I-1
tp2731
sS'family,st,johns'
p2732
(F1
F0.00076452599388379206
I1
I0
I1
tp2733
sS'with,high-dose,intravenous'
p2734
(F1
F0.0015290519877675841
I2
I0
I2
tp2735
sS'the,dosage,if'
p2736
(F1
F0.00076452599388379206
I1
I0
I1
tp2737
sS'were,ingested,on'
p2738
(F1
F0.00076452599388379206
I0
I1
I-1
tp2739
sS'between,and,proton'
p2740
(F1
F0.00076452599388379206
I0
I1
I-1
tp2741
sS'of,with,phentermine'
p2742
(F1
F0.00076452599388379206
I1
I0
I1
tp2743
sS'is,no,information'
p2744
(F1
F0.00076452599388379206
I0
I1
I-1
tp2745
sS'its,potential,to'
p2746
(F1
F0.00076452599388379206
I0
I1
I-1
tp2747
sS'respect,to,toxicity'
p2748
(F1
F0.00076452599388379206
I0
I1
I-1
tp2749
sS'depressants,effects,should'
p2750
(F1
F0.00076452599388379206
I1
I0
I1
tp2751
sS'b-acetyldigoxin,administration,for'
p2752
(F1
F0.00076452599388379206
I0
I1
I-1
tp2753
sS'given,that,and'
p2754
(F1
F0.00076452599388379206
I1
I0
I1
tp2755
sS'currently,recommended,dose'
p2756
(F1
F0.00076452599388379206
I1
I0
I1
tp2757
sS'alpha-adrenergic,blocking,agents'
p2758
(F0
F0
I1
I1
I0
tp2759
sS'to,healthy,volunteers'
p2760
(F1
F0.00076452599388379206
I1
I0
I1
tp2761
sS'alter,the,kinetics'
p2762
(F1
F0.00076452599388379206
I0
I1
I-1
tp2763
sS'closely,for,changes'
p2764
(F1
F0.00076452599388379206
I1
I0
I1
tp2765
sS'during,maintenance,with'
p2766
(F1
F0.00076452599388379206
I0
I1
I-1
tp2767
sS'the,combined,administration'
p2768
(F1
F0.00076452599388379206
I1
I0
I1
tp2769
sS'identify,any,clinically'
p2770
(F1
F0.00076452599388379206
I0
I1
I-1
tp2771
sS'tachycardia,dryness,of'
p2772
(F1
F0.00076452599388379206
I1
I0
I1
tp2773
sS'these,include,sympathomimetic'
p2774
(F1
F0.00076452599388379206
I0
I1
I-1
tp2775
sS'acetate,and,results'
p2776
(F1
F0.00076452599388379206
I1
I0
I1
tp2777
sS'hormonal,agents,may'
p2778
(F1
F0.00076452599388379206
I1
I0
I1
tp2779
sS'regulatory,agencies,state'
p2780
(F1
F0.00076452599388379206
I1
I0
I1
tp2781
sS'affect,gastrointestinal,absorption'
p2782
(F1
F0.00076452599388379206
I1
I0
I1
tp2783
sS'on,gastric,emptying'
p2784
(F1
F0.00076452599388379206
I1
I0
I1
tp2785
sS'tracheal,intubation,the'
p2786
(F1
F0.00076452599388379206
I0
I1
I-1
tp2787
sS'the,plasma,clearance'
p2788
(F1
F0.00076452599388379206
I1
I0
I1
tp2789
sS'incidence,of,bradycardia'
p2790
(F1
F0.00076452599388379206
I1
I0
I1
tp2791
sS'treating,urinary,and'
p2792
(F1
F0.00076452599388379206
I0
I1
I-1
tp2793
sS'induced,by,and'
p2794
(F1
F0.00076452599388379206
I0
I1
I-1
tp2795
sS'inhibitor,of,renal'
p2796
(F0
F0
I1
I1
I0
tp2797
sS'is,contraindicated,pending'
p2798
(F1
F0.00076452599388379206
I1
I0
I1
tp2799
sS'induction,of,either'
p2800
(F1
F0.00076452599388379206
I0
I1
I-1
tp2801
sS'increased,by,with'
p2802
(F1
F0.00076452599388379206
I1
I0
I1
tp2803
sS'possibility,of,interaction'
p2804
(F1
F0.00076452599388379206
I1
I0
I1
tp2805
sS'between,any,of'
p2806
(F1
F0.00076452599388379206
I0
I1
I-1
tp2807
sS'monitoring,of,serum'
p2808
(F1
F0.00076452599388379206
I1
I0
I1
tp2809
sS'killed,virus,vaccines'
p2810
(F1
F0.00076452599388379206
I1
I0
I1
tp2811
sS'patients,since,the'
p2812
(F1
F0.00076452599388379206
I1
I0
I1
tp2813
sS'only,and,showed'
p2814
(F1
F0.00076452599388379206
I0
I1
I-1
tp2815
sS'sedative,effects,and'
p2816
(F1
F0.00076452599388379206
I1
I0
I1
tp2817
sS'exposure,were,efficiently'
p2818
(F1
F0.00076452599388379206
I1
I0
I1
tp2819
sS'when,coadministered,to'
p2820
(F1
F0.00076452599388379206
I1
I0
I1
tp2821
sS'patient,receiving,multiple'
p2822
(F1
F0.00076452599388379206
I1
I0
I1
tp2823
sS'administration,of,low-dose'
p2824
(F1
F0.00076452599388379206
I1
I0
I1
tp2825
sS'loss,in,monkeys'
p2826
(F1
F0.00076452599388379206
I0
I1
I-1
tp2827
sS'meq,results,in'
p2828
(F1
F0.00076452599388379206
I1
I0
I1
tp2829
sS'the,ovulation-suppressing,action'
p2830
(F1
F0.00076452599388379206
I0
I1
I-1
tp2831
sS'the,following,drugs'
p2832
(F0
F0
I1
I1
I0
tp2833
sS'hazardous,when,taken'
p2834
(F1
F0.00076452599388379206
I1
I0
I1
tp2835
sS'on,effects,of'
p2836
(F1
F0.00076452599388379206
I0
I1
I-1
tp2837
sS'flushes,linked,to'
p2838
(F1
F0.00076452599388379206
I0
I1
I-1
tp2839
sS'type,may,counteract'
p2840
(F1
F0.00076452599388379206
I1
I0
I1
tp2841
sS'with,other,centrally'
p2842
(F1
F0.00076452599388379206
I1
I0
I1
tp2843
sS'of,an,inhibitor'
p2844
(F0
F0
I1
I1
I0
tp2845
sS'absorption,of,drugs'
p2846
(F1
F0.0015290519877675841
I2
I0
I2
tp2847
sS'that,the,pharmacokinetics'
p2848
(F1
F0.00076452599388379206
I0
I1
I-1
tp2849
sS'of,mg,per'
p2850
(F1
F0.00076452599388379206
I1
I0
I1
tp2851
sS'kip1,in,dasatinib-enhanced'
p2852
(F1
F0.00076452599388379206
I1
I0
I1
tp2853
sS'been,postmarketing,reports'
p2854
(F1
F0.00076452599388379206
I1
I0
I1
tp2855
sS'alcohol,due,to'
p2856
(F1
F0.00076452599388379206
I1
I0
I1
tp2857
sS'significant,synergism,was'
p2858
(F1
F0.00076452599388379206
I1
I0
I1
tp2859
sS'a7,noradrenaline,cell'
p2860
(F1
F0.00076452599388379206
I1
I0
I1
tp2861
sS'guanethidine,although,does'
p2862
(F1
F0.00076452599388379206
I1
I0
I1
tp2863
sS'important,effects,on'
p2864
(F1
F0.00076452599388379206
I0
I1
I-1
tp2865
sS'are,given,concomitantly'
p2866
(F1
F0.00076452599388379206
I1
I0
I1
tp2867
sS'or,on,the'
p2868
(F1
F0.00076452599388379206
I0
I1
I-1
tp2869
sS'concomitantly,with,ethacrynic'
p2870
(F1
F0.00076452599388379206
I1
I0
I1
tp2871
sS'following,seven,groups'
p2872
(F1
F0.00076452599388379206
I0
I1
I-1
tp2873
sS'of,in,combination'
p2874
(F1
F0.0015290519877675841
I2
I0
I2
tp2875
sS'the,salt,intake'
p2876
(F1
F0.00076452599388379206
I1
I0
I1
tp2877
sS'if,administered,prior'
p2878
(F1
F0.0015290519877675841
I2
I0
I2
tp2879
sS'are,potentiated,by'
p2880
(F1
F0.0015290519877675841
I2
I0
I2
tp2881
sS'male,rats,demonstrated'
p2882
(F1
F0.00076452599388379206
I0
I1
I-1
tp2883
sS'receiving,mg,three'
p2884
(F1
F0.00076452599388379206
I0
I1
I-1
tp2885
sS'concomitantly,with,can'
p2886
(F1
F0.00076452599388379206
I1
I0
I1
tp2887
sS'as,slowly,dissolving'
p2888
(F1
F0.00076452599388379206
I1
I0
I1
tp2889
sS'scopolamine,should,be'
p2890
(F1
F0.00076452599388379206
I1
I0
I1
tp2891
sS'short-acting,benzodiazepines,which'
p2892
(F1
F0.00076452599388379206
I1
I0
I1
tp2893
sS'max,and,auc'
p2894
(F1
F0.0022935779816513763
I3
I0
I3
tp2895
sS'randomized,either,to'
p2896
(F1
F0.00076452599388379206
I0
I1
I-1
tp2897
sS'may,have,the'
p2898
(F1
F0.00076452599388379206
I0
I1
I-1
tp2899
sS'reduced,dosage,in'
p2900
(F1
F0.00076452599388379206
I1
I0
I1
tp2901
sS'thus,the,rate'
p2902
(F1
F0.00076452599388379206
I1
I0
I1
tp2903
sS'tubular,secretion,and'
p2904
(F0
F0
I1
I1
I0
tp2905
sS'recommended,that,plasma'
p2906
(F1
F0.00076452599388379206
I1
I0
I1
tp2907
sS'to,less,mpa'
p2908
(F1
F0.00076452599388379206
I0
I1
I-1
tp2909
sS'total,clearance,of'
p2910
(F1
F0.00076452599388379206
I1
I0
I1
tp2911
sS'as,anorexia,tachypnea'
p2912
(F1
F0.00076452599388379206
I1
I0
I1
tp2913
sS'should,be,monitored'
p2914
(F1
F0.0053516819571865441
I7
I0
I7
tp2915
sS'according,to,the'
p2916
(F0
F0
I1
I1
I0
tp2917
sS'clinical,monitoring,when'
p2918
(F1
F0.0015290519877675841
I2
I0
I2
tp2919
sS'as,general,or'
p2920
(F1
F0.00076452599388379206
I0
I1
I-1
tp2921
sS'phenothiazine-type,should,be'
p2922
(F1
F0.00076452599388379206
I0
I1
I-1
tp2923
sS'daily,for,days'
p2924
(F1
F0.0015290519877675841
I0
I2
I-2
tp2925
sS'lines,except,for'
p2926
(F1
F0.00076452599388379206
I1
I0
I1
tp2927
sS'with,erythema,and'
p2928
(F1
F0.00076452599388379206
I1
I0
I1
tp2929
sS'probenecid,probenecid,a'
p2930
(F1
F0.00076452599388379206
I0
I1
I-1
tp2931
sS'vitamin,k,absorption'
p2932
(F1
F0.00076452599388379206
I1
I0
I1
tp2933
sS'mg,kg,p'
p2934
(F1
F0.00076452599388379206
I0
I1
I-1
tp2935
sS'interaction,study,indicate'
p2936
(F1
F0.00076452599388379206
I1
I0
I1
tp2937
sS'inducer,and,decreased'
p2938
(F1
F0.00076452599388379206
I1
I0
I1
tp2939
sS'volume,per,mouse'
p2940
(F1
F0.00076452599388379206
I1
I0
I1
tp2941
sS'drugs,beta,blockers'
p2942
(F1
F0.00076452599388379206
I0
I1
I-1
tp2943
sS'no,information,available'
p2944
(F1
F0.00076452599388379206
I0
I1
I-1
tp2945
sS'mg,kg,g'
p2946
(F1
F0.00076452599388379206
I0
I1
I-1
tp2947
sS'administered,after,a'
p2948
(F1
F0.00076452599388379206
I0
I1
I-1
tp2949
sS'some,can,enhance'
p2950
(F1
F0.00076452599388379206
I1
I0
I1
tp2951
sS'adverse,experience,profiles'
p2952
(F1
F0.00076452599388379206
I1
I0
I1
tp2953
sS'the,abraded,skin'
p2954
(F1
F0.00076452599388379206
I1
I0
I1
tp2955
sS'increase,the,clearance'
p2956
(F1
F0.0038226299694189602
I5
I0
I5
tp2957
sS'more,potent,cyp'
p2958
(F1
F0.00076452599388379206
I0
I1
I-1
tp2959
sS'other,antihypertensives,when'
p2960
(F1
F0.00076452599388379206
I1
I0
I1
tp2961
sS'to,a,small'
p2962
(F1
F0.00076452599388379206
I1
I0
I1
tp2963
sS'when,administering,mobic'
p2964
(F1
F0.00076452599388379206
I1
I0
I1
tp2965
sS'in,patients,taking'
p2966
(F1
F0.0015290519877675841
I2
I0
I2
tp2967
sS'warfarin,in,normal-weight'
p2968
(F1
F0.00076452599388379206
I0
I1
I-1
tp2969
sS'the,susceptibility,results'
p2970
(F1
F0.00076452599388379206
I0
I1
I-1
tp2971
sS'purine,metabolism,it'
p2972
(F1
F0.00076452599388379206
I1
I0
I1
tp2973
sS'eliminated,via,renal'
p2974
(F1
F0.00076452599388379206
I1
I0
I1
tp2975
sS'vitro,studies,show'
p2976
(F1
F0.00076452599388379206
I0
I1
I-1
tp2977
sS'control,pills,medicines'
p2978
(F1
F0.00076452599388379206
I0
I1
I-1
tp2979
sS'the,auc,and'
p2980
(F1
F0.00076452599388379206
I1
I0
I1
tp2981
sS'study,of,normal-weight'
p2982
(F1
F0.00076452599388379206
I0
I1
I-1
tp2983
sS'of,both,nonheme'
p2984
(F1
F0.00076452599388379206
I1
I0
I1
tp2985
sS'as,suxamethonium,chloride'
p2986
(F1
F0.00076452599388379206
I1
I0
I1
tp2987
sS'standard,hormone,treatment'
p2988
(F1
F0.00076452599388379206
I0
I1
I-1
tp2989
sS'up-regulation,of,the'
p2990
(F1
F0.00076452599388379206
I0
I1
I-1
tp2991
sS'as,vitamin,k'
p2992
(F1
F0.00076452599388379206
I1
I0
I1
tp2993
sS'anticoagulants,oral,the'
p2994
(F1
F0.00076452599388379206
I1
I0
I1
tp2995
sS'containing,cdna,encoding'
p2996
(F1
F0.00076452599388379206
I0
I1
I-1
tp2997
sS'to,followed,by'
p2998
(F1
F0.0015290519877675841
I2
I0
I2
tp2999
sS'and,sympathomimetic,amines'
p3000
(F1
F0.00076452599388379206
I1
I0
I1
tp3001
sS'reduce,mpa,exposure'
p3002
(F1
F0.00076452599388379206
I0
I1
I-1
tp3003
sS'when,coadministered,coadministration'
p3004
(F1
F0.00076452599388379206
I1
I0
I1
tp3005
sS'suggests,that,ascorbic'
p3006
(F1
F0.00076452599388379206
I1
I0
I1
tp3007
sS'use,of,aggrastat'
p3008
(F1
F0.00076452599388379206
I1
I0
I1
tp3009
sS'and,n,and'
p3010
(F1
F0.00076452599388379206
I0
I1
I-1
tp3011
sS'decreased,in,the'
p3012
(F1
F0.00076452599388379206
I0
I1
I-1
tp3013
sS'and,increase,salt'
p3014
(F1
F0.00076452599388379206
I0
I1
I-1
tp3015
sS'phenyl-1,tetrahydropyridine-induced,loss'
p3016
(F1
F0.00076452599388379206
I1
I0
I1
tp3017
sS'all,significantly,higher'
p3018
(F1
F0.00076452599388379206
I1
I0
I1
tp3019
sS'other,azole,antifungals'
p3020
(F1
F0.0015290519877675841
I2
I0
I2
tp3021
sS'receiving,indicating,that'
p3022
(F1
F0.00076452599388379206
I0
I1
I-1
tp3023
sS'not,reproduce,the'
p3024
(F1
F0.00076452599388379206
I0
I1
I-1
tp3025
sS'remeron,soltab,orally'
p3026
(F1
F0.00076452599388379206
I0
I1
I-1
tp3027
sS'significantly,affect,the'
p3028
(F1
F0.00076452599388379206
I0
I1
I-1
tp3029
sS'administration,of,equivalent'
p3030
(F1
F0.00076452599388379206
I1
I0
I1
tp3031
sS'has,been,described'
p3032
(F1
F0.00076452599388379206
I1
I0
I1
tp3033
sS'and,incoordination,when'
p3034
(F1
F0.00076452599388379206
I1
I0
I1
tp3035
sS'well,as,and'
p3036
(F1
F0.00076452599388379206
I0
I1
I-1
tp3037
sS'acute,myocardial,infarction'
p3038
(F1
F0.00076452599388379206
I0
I1
I-1
tp3039
sS'in,some,individual'
p3040
(F1
F0.00076452599388379206
I0
I1
I-1
tp3041
sS'n,channel,blockers'
p3042
(F1
F0.00076452599388379206
I0
I1
I-1
tp3043
sS'when,mobic,is'
p3044
(F1
F0.00076452599388379206
I1
I0
I1
tp3045
sS'it,is,advisable'
p3046
(F1
F0.00076452599388379206
I1
I0
I1
tp3047
sS'large,and,the'
p3048
(F1
F0.00076452599388379206
I0
I1
I-1
tp3049
sS'combined,use,of'
p3050
(F1
F0.0015290519877675841
I2
I0
I2
tp3051
sS'findings,suggest,that'
p3052
(F1
F0.00076452599388379206
I1
I0
I1
tp3053
sS'which,induces,hepatic'
p3054
(F1
F0.0015290519877675841
I0
I2
I-2
tp3055
sS'and,theophylline-containing,drugs'
p3056
(F1
F0.00076452599388379206
I1
I0
I1
tp3057
sS'significant,decrease,in'
p3058
(F1
F0.00076452599388379206
I1
I0
I1
tp3059
sS'performed,until,the'
p3060
(F1
F0.00076452599388379206
I0
I1
I-1
tp3061
sS'inhibitors,ketoconazole,an'
p3062
(F1
F0.00076452599388379206
I1
I0
I1
tp3063
sS'oral,the,activity'
p3064
(F1
F0.00076452599388379206
I1
I0
I1
tp3065
sS'by,discontinuing,therapy'
p3066
(F1
F0.00076452599388379206
I0
I1
I-1
tp3067
sS'of,patients,in'
p3068
(F1
F0.00076452599388379206
I0
I1
I-1
tp3069
sS'in,the,pharmacokinetic'
p3070
(F1
F0.00076452599388379206
I1
I0
I1
tp3071
sS'studies,of,given'
p3072
(F1
F0.00076452599388379206
I0
I1
I-1
tp3073
sS'and,hydrochloride,may'
p3074
(F1
F0.00076452599388379206
I1
I0
I1
tp3075
sS'sodium,colistimethate,salts'
p3076
(F1
F0.00076452599388379206
I1
I0
I1
tp3077
sS'not,to,affect'
p3078
(F1
F0.00076452599388379206
I0
I1
I-1
tp3079
sS'strong,inhibitor,of'
p3080
(F1
F0.00076452599388379206
I1
I0
I1
tp3081
sS'non-small,lung,cancer'
p3082
(F1
F0.00076452599388379206
I1
I0
I1
tp3083
sS'occur,in,patients'
p3084
(F1
F0.00076452599388379206
I0
I1
I-1
tp3085
sS'may,be,anticipated'
p3086
(F1
F0.00076452599388379206
I1
I0
I1
tp3087
sS'basis,that,these'
p3088
(F1
F0.00076452599388379206
I1
I0
I1
tp3089
sS'a,few,spontaneous'
p3090
(F1
F0.00076452599388379206
I0
I1
I-1
tp3091
sS'subjects,who,were'
p3092
(F1
F0.00076452599388379206
I1
I0
I1
tp3093
sS'be,prolonged,by'
p3094
(F1
F0.00076452599388379206
I1
I0
I1
tp3095
sS'the,risk,of'
p3096
(F0.59999999999999998
F0.0045871559633027525
I8
I2
I6
tp3097
sS'with,and,other'
p3098
(F0
F0
I1
I1
I0
tp3099
sS'is,approximately,bound'
p3100
(F1
F0.00076452599388379206
I0
I1
I-1
tp3101
sS'cyp3a4,inhibitors,ketoconazole'
p3102
(F1
F0.00076452599388379206
I1
I0
I1
tp3103
sS'of,thrombopenia,with'
p3104
(F1
F0.00076452599388379206
I0
I1
I-1
tp3105
sS'in,rats,and'
p3106
(F1
F0.00076452599388379206
I0
I1
I-1
tp3107
sS'and,the,patients'
p3108
(F1
F0.00076452599388379206
I1
I0
I1
tp3109
sS'significantly,decreased,in'
p3110
(F1
F0.00076452599388379206
I0
I1
I-1
tp3111
sS'food,interaction,oral'
p3112
(F1
F0.00076452599388379206
I0
I1
I-1
tp3113
sS'the,marked,shrinkage'
p3114
(F1
F0.00076452599388379206
I1
I0
I1
tp3115
sS'occur,earlier,than'
p3116
(F1
F0.00076452599388379206
I1
I0
I1
tp3117
sS'serotonin,and,catecholamines'
p3118
(F1
F0.00076452599388379206
I0
I1
I-1
tp3119
sS'other,potent,cyp3a4'
p3120
(F1
F0.00076452599388379206
I1
I0
I1
tp3121
sS'no,pharmacokinetic,drug'
p3122
(F1
F0.00076452599388379206
I1
I0
I1
tp3123
sS'less,with,mg'
p3124
(F1
F0.00076452599388379206
I0
I1
I-1
tp3125
sS'agent,alone,average'
p3126
(F1
F0.00076452599388379206
I1
I0
I1
tp3127
sS'of,fertility,a'
p3128
(F1
F0.00076452599388379206
I0
I1
I-1
tp3129
sS'can,inhibit,ovarian'
p3130
(F1
F0.00076452599388379206
I1
I0
I1
tp3131
sS'symptoms,due,to'
p3132
(F1
F0.00076452599388379206
I1
I0
I1
tp3133
sS'dosage,adjustment,of'
p3134
(F1
F0.00076452599388379206
I0
I1
I-1
tp3135
sS'interaction,study,mean'
p3136
(F1
F0.00076452599388379206
I1
I0
I1
tp3137
sS'the,primary,cns'
p3138
(F1
F0.00076452599388379206
I1
I0
I1
tp3139
sS'to,avoid,and'
p3140
(F1
F0.00076452599388379206
I1
I0
I1
tp3141
sS'hepatotoxicity,has,been'
p3142
(F1
F0.00076452599388379206
I1
I0
I1
tp3143
sS'with,drugs,that'
p3144
(F0.33333333333333331
F0.00076452599388379206
I1
I2
I-1
tp3145
sS'also,noted,when'
p3146
(F1
F0.00076452599388379206
I1
I0
I1
tp3147
sS'bleeding,if,administered'
p3148
(F1
F0.0015290519877675841
I2
I0
I2
tp3149
sS'hmg-coa,reductase,inhibitor'
p3150
(F1
F0.00076452599388379206
I0
I1
I-1
tp3151
sS'and,after,months'
p3152
(F1
F0.00076452599388379206
I0
I1
I-1
tp3153
sS'on,herceptin-mediated,antibody-dependent'
p3154
(F1
F0.00076452599388379206
I0
I1
I-1
tp3155
sS'mpa,were,and'
p3156
(F1
F0.00076452599388379206
I1
I0
I1
tp3157
sS'in,any,of'
p3158
(F1
F0.00076452599388379206
I0
I1
I-1
tp3159
sS'to,the,intestines'
p3160
(F1
F0.00076452599388379206
I1
I0
I1
tp3161
sS'of,hydrochloride,resulting'
p3162
(F1
F0.00076452599388379206
I1
I0
I1
tp3163
sS'n,extensive,and'
p3164
(F1
F0.00076452599388379206
I0
I1
I-1
tp3165
sS'aruonic,transporter,did'
p3166
(F1
F0.00076452599388379206
I0
I1
I-1
tp3167
sS'with,other,nondepolarizing'
p3168
(F1
F0.00076452599388379206
I0
I1
I-1
tp3169
sS'as,other,azole'
p3170
(F1
F0.00076452599388379206
I1
I0
I1
tp3171
sS'with,ferrous,sulfate'
p3172
(F1
F0.0015290519877675841
I2
I0
I2
tp3173
sS'with,anticholinergic,activity'
p3174
(F1
F0.00076452599388379206
I1
I0
I1
tp3175
sS'administration,of,ropivacaine'
p3176
(F1
F0.00076452599388379206
I1
I0
I1
tp3177
sS'and,symptoms,of'
p3178
(F0
F0
I1
I1
I0
tp3179
sS'evidence,of,a'
p3180
(F1
F0.00076452599388379206
I0
I1
I-1
tp3181
sS'a,decrease,in'
p3182
(F0.59999999999999998
F0.0022935779816513763
I4
I1
I3
tp3183
sS'bid,in,healthy'
p3184
(F1
F0.00076452599388379206
I1
I0
I1
tp3185
sS'the,cyp2c19,inhibitors'
p3186
(F1
F0.00076452599388379206
I1
I0
I1
tp3187
sS'with,ethinyl,estradiol-'
p3188
(F1
F0.00076452599388379206
I1
I0
I1
tp3189
sS'decline,in,subjects'
p3190
(F1
F0.00076452599388379206
I0
I1
I-1
tp3191
sS'by,active,renal'
p3192
(F1
F0.00076452599388379206
I0
I1
I-1
tp3193
sS'delivery,of,adeno-associated'
p3194
(F1
F0.00076452599388379206
I0
I1
I-1
tp3195
sS'aluminum-,or,magnesium-containing'
p3196
(F1
F0.00076452599388379206
I1
I0
I1
tp3197
sS'supplements,or,other'
p3198
(F1
F0.00076452599388379206
I0
I1
I-1
tp3199
sS'activity,when,used'
p3200
(F1
F0.00076452599388379206
I1
I0
I1
tp3201
sS'can,enhance,toxicity'
p3202
(F1
F0.00076452599388379206
I1
I0
I1
tp3203
sS'vitro,in,nsclc'
p3204
(F1
F0.00076452599388379206
I1
I0
I1
tp3205
sS'in,dznep,insensitive'
p3206
(F1
F0.00076452599388379206
I1
I0
I1
tp3207
sS'alteration,of,pharmacokinetics'
p3208
(F1
F0.00076452599388379206
I0
I1
I-1
tp3209
sS'therapy,which,corresponded'
p3210
(F1
F0.00076452599388379206
I0
I1
I-1
tp3211
sS'addition,to,and'
p3212
(F1
F0.00076452599388379206
I0
I1
I-1
tp3213
sS'effects,of,these'
p3214
(F0.33333333333333331
F0.00076452599388379206
I2
I1
I1
tp3215
sS'did,not,alter'
p3216
(F1
F0.0068807339449541288
I0
I9
I-9
tp3217
sS'childbearing,potential,refer'
p3218
(F1
F0.00076452599388379206
I0
I1
I-1
tp3219
sS'have,shown,that'
p3220
(F0.33333333333333331
F0.00076452599388379206
I2
I1
I1
tp3221
sS'soltab,with,most'
p3222
(F1
F0.00076452599388379206
I0
I1
I-1
tp3223
sS'knockdown,of,bcl-2'
p3224
(F1
F0.00076452599388379206
I1
I0
I1
tp3225
sS'a,woman,of'
p3226
(F1
F0.00076452599388379206
I0
I1
I-1
tp3227
sS'for,tubular,secretion'
p3228
(F1
F0.00076452599388379206
I0
I1
I-1
tp3229
sS'to,be,an'
p3230
(F1
F0.00076452599388379206
I1
I0
I1
tp3231
sS'are,not,conclusive'
p3232
(F1
F0.00076452599388379206
I1
I0
I1
tp3233
sS'lower,in,patients'
p3234
(F1
F0.00076452599388379206
I0
I1
I-1
tp3235
sS'as,acetylsalicylic,acid'
p3236
(F1
F0.00076452599388379206
I1
I0
I1
tp3237
sS'lead,to,further'
p3238
(F1
F0.00076452599388379206
I0
I1
I-1
tp3239
sS'demonstrated,sensitization,to'
p3240
(F1
F0.00076452599388379206
I0
I1
I-1
tp3241
sS'ai,vaccination,was'
p3242
(F1
F0.00076452599388379206
I1
I0
I1
tp3243
sS'while,no,formal'
p3244
(F1
F0.00076452599388379206
I0
I1
I-1
tp3245
sS'as,a,bioenhancer'
p3246
(F1
F0.00076452599388379206
I1
I0
I1
tp3247
sS'extensive,and,n'
p3248
(F1
F0.00076452599388379206
I0
I1
I-1
tp3249
sS'concomitant,drugs,were'
p3250
(F1
F0.00076452599388379206
I0
I1
I-1
tp3251
sS'clinically,significant,changes'
p3252
(F1
F0.0015290519877675841
I0
I2
I-2
tp3253
sS'this,drug,s'
p3254
(F1
F0.00076452599388379206
I1
I0
I1
tp3255
sS'days,resulted,in'
p3256
(F1
F0.00076452599388379206
I0
I1
I-1
tp3257
sS'qid,can,be'
p3258
(F1
F0.00076452599388379206
I1
I0
I1
tp3259
sS'increased,the,half-life'
p3260
(F1
F0.00076452599388379206
I1
I0
I1
tp3261
sS'increase,the,c'
p3262
(F1
F0.00076452599388379206
I1
I0
I1
tp3263
sS'sulfate,usp,because'
p3264
(F1
F0.00076452599388379206
I1
I0
I1
tp3265
sS'agents,analgesic,agents'
p3266
(F1
F0.00076452599388379206
I0
I1
I-1
tp3267
sS'once,weekly,for'
p3268
(F1
F0.00076452599388379206
I1
I0
I1
tp3269
sS'cyp,a4,it'
p3270
(F1
F0.00076452599388379206
I1
I0
I1
tp3271
sS'use,of,zemuron'
p3272
(F1
F0.0015290519877675841
I0
I2
I-2
tp3273
sS'an,overall,mean'
p3274
(F1
F0.00076452599388379206
I1
I0
I1
tp3275
sS'confirmed,in-vivo,indicate'
p3276
(F1
F0.00076452599388379206
I0
I1
I-1
tp3277
sS'immunocompromised,individuals,nalidixic'
p3278
(F1
F0.00076452599388379206
I1
I0
I1
tp3279
sS'prolongation,and,rare'
p3280
(F1
F0.00076452599388379206
I1
I0
I1
tp3281
sS'a,proof,opioid'
p3282
(F1
F0.00076452599388379206
I1
I0
I1
tp3283
sS'inhibitors,is,feasible'
p3284
(F1
F0.00076452599388379206
I0
I1
I-1
tp3285
sS'and,or,dosage'
p3286
(F1
F0.00076452599388379206
I1
I0
I1
tp3287
sS'inhibitors,on,platelet'
p3288
(F1
F0.00076452599388379206
I0
I1
I-1
tp3289
sS'with,either,or'
p3290
(F1
F0.00076452599388379206
I0
I1
I-1
tp3291
sS'inhibitors,include,grapefruit'
p3292
(F1
F0.00076452599388379206
I0
I1
I-1
tp3293
sS'the,like,activity'
p3294
(F1
F0.00076452599388379206
I0
I1
I-1
tp3295
sS'sensitization,compared,with'
p3296
(F1
F0.00076452599388379206
I1
I0
I1
tp3297
sS'alone,or,in'
p3298
(F0.33333333333333331
F0.00076452599388379206
I1
I2
I-1
tp3299
sS'the,presence,of'
p3300
(F0.7142857142857143
F0.0038226299694189602
I6
I1
I5
tp3301
sS'levels,therapeutic,range'
p3302
(F1
F0.00076452599388379206
I1
I0
I1
tp3303
sS'xenical,and,drug'
p3304
(F1
F0.00076452599388379206
I1
I0
I1
tp3305
sS'agonist,it,is'
p3306
(F1
F0.00076452599388379206
I1
I0
I1
tp3307
sS'toxicity,and,or'
p3308
(F1
F0.00076452599388379206
I1
I0
I1
tp3309
sS'not,generally,recommended'
p3310
(F1
F0.00076452599388379206
I1
I0
I1
tp3311
sS'and,may,require'
p3312
(F1
F0.0015290519877675841
I2
I0
I2
tp3313
sS'of,hiv-protease,inhibitors'
p3314
(F1
F0.00076452599388379206
I0
I1
I-1
tp3315
sS'a,significant,reduction'
p3316
(F1
F0.00076452599388379206
I1
I0
I1
tp3317
sS'use,with,anticholinergics'
p3318
(F1
F0.00076452599388379206
I1
I0
I1
tp3319
sS'been,taken,concurrently'
p3320
(F1
F0.00076452599388379206
I1
I0
I1
tp3321
sS'significantly,decrease,the'
p3322
(F1
F0.00076452599388379206
I1
I0
I1
tp3323
sS'cycling,of,and'
p3324
(F1
F0.00076452599388379206
I1
I0
I1
tp3325
sS'and,in,chronic'
p3326
(F1
F0.00076452599388379206
I0
I1
I-1
tp3327
sS'of,other,azole-type'
p3328
(F1
F0.00076452599388379206
I1
I0
I1
tp3329
sS'inactivated,nd,and'
p3330
(F1
F0.00076452599388379206
I0
I1
I-1
tp3331
sS'adjoining,a5,and'
p3332
(F1
F0.00076452599388379206
I1
I0
I1
tp3333
sS'antidepressant,such,as'
p3334
(F1
F0.00076452599388379206
I0
I1
I-1
tp3335
sS'plasma,concentration,was'
p3336
(F1
F0.00076452599388379206
I1
I0
I1
tp3337
sS'decrease,when,hyperthyroid'
p3338
(F1
F0.00076452599388379206
I0
I1
I-1
tp3339
sS'to,the,desired'
p3340
(F1
F0.00076452599388379206
I1
I0
I1
tp3341
sS'for,patients,on'
p3342
(F1
F0.00076452599388379206
I1
I0
I1
tp3343
sS'administered,oral,or'
p3344
(F1
F0.00076452599388379206
I1
I0
I1
tp3345
sS'certain,monoamine,oxidase'
p3346
(F1
F0.00076452599388379206
I1
I0
I1
tp3347
sS'dry,mouth,constipation'
p3348
(F1
F0.0015290519877675841
I2
I0
I2
tp3349
sS'are,no,known'
p3350
(F1
F0.00076452599388379206
I1
I0
I1
tp3351
sS'perfusion,of,isolated'
p3352
(F1
F0.00076452599388379206
I1
I0
I1
tp3353
sS'much,weaker,effect'
p3354
(F1
F0.00076452599388379206
I1
I0
I1
tp3355
sS'sedation,and,an'
p3356
(F1
F0.00076452599388379206
I1
I0
I1
tp3357
sS'respiratory,depression,due'
p3358
(F1
F0.00076452599388379206
I1
I0
I1
tp3359
sS'addition,to,bleeding'
p3360
(F1
F0.00076452599388379206
I1
I0
I1
tp3361
sS'or,similar,agents'
p3362
(F1
F0.00076452599388379206
I1
I0
I1
tp3363
sS'as,and,other'
p3364
(F1
F0.00076452599388379206
I0
I1
I-1
tp3365
sS'cyps,a6,c9'
p3366
(F1
F0.00076452599388379206
I0
I1
I-1
tp3367
sS'of,qt,interval'
p3368
(F1
F0.00076452599388379206
I0
I1
I-1
tp3369
sS'qid,did,not'
p3370
(F1
F0.00076452599388379206
I0
I1
I-1
tp3371
sS'patients,receiving,the'
p3372
(F1
F0.0015290519877675841
I2
I0
I2
tp3373
sS'in,elderly,patients'
p3374
(F1
F0.00076452599388379206
I0
I1
I-1
tp3375
sS'alcohol,in,a'
p3376
(F1
F0.00076452599388379206
I0
I1
I-1
tp3377
sS'if,a,patient'
p3378
(F1
F0.00076452599388379206
I1
I0
I1
tp3379
sS'of,approximately,following'
p3380
(F1
F0.0015290519877675841
I0
I2
I-2
tp3381
sS'be,used,in'
p3382
(F0
F0
I1
I1
I0
tp3383
sS'or,certain,monoamine'
p3384
(F1
F0.00076452599388379206
I1
I0
I1
tp3385
sS'be,used,if'
p3386
(F1
F0.00076452599388379206
I1
I0
I1
tp3387
sS'increased,in,the'
p3388
(F1
F0.00076452599388379206
I0
I1
I-1
tp3389
sS'example,bile,acid'
p3390
(F1
F0.00076452599388379206
I1
I0
I1
tp3391
sS'anti-resorptive,response,to'
p3392
(F1
F0.00076452599388379206
I1
I0
I1
tp3393
sS'effect-time,curves,self-reported'
p3394
(F1
F0.00076452599388379206
I0
I1
I-1
tp3395
sS'blinded,crossover,study'
p3396
(F1
F0.00076452599388379206
I0
I1
I-1
tp3397
sS'action,of,and'
p3398
(F1
F0.00076452599388379206
I0
I1
I-1
tp3399
sS'or,severe,constipation'
p3400
(F1
F0.00076452599388379206
I1
I0
I1
tp3401
sS'of,nutrients,alpha'
p3402
(F1
F0.00076452599388379206
I1
I0
I1
tp3403
sS'and,dna,strand'
p3404
(F1
F0.00076452599388379206
I0
I1
I-1
tp3405
sS'and,an,inducer'
p3406
(F1
F0.00076452599388379206
I1
I0
I1
tp3407
sS'testing,found,no'
p3408
(F1
F0.00076452599388379206
I0
I1
I-1
tp3409
sS'initiated,the,dose'
p3410
(F1
F0.00076452599388379206
I0
I1
I-1
tp3411
sS'taking,oral,and'
p3412
(F1
F0.00076452599388379206
I1
I0
I1
tp3413
sS'these,enzymes,has'
p3414
(F1
F0.00076452599388379206
I0
I1
I-1
tp3415
sS'from,its,binding'
p3416
(F1
F0.00076452599388379206
I0
I1
I-1
tp3417
sS'were,tested,therapeutically'
p3418
(F1
F0.00076452599388379206
I1
I0
I1
tp3419
sS'metabolism,and,pharmacokinetics'
p3420
(F1
F0.00076452599388379206
I0
I1
I-1
tp3421
sS'on,treatment,should'
p3422
(F1
F0.00076452599388379206
I1
I0
I1
tp3423
sS'an,elevation,of'
p3424
(F1
F0.00076452599388379206
I1
I0
I1
tp3425
sS'some,individual,ethinyl'
p3426
(F1
F0.00076452599388379206
I0
I1
I-1
tp3427
sS'antinociceptive,effect,of'
p3428
(F1
F0.00076452599388379206
I1
I0
I1
tp3429
sS'liver,slices,do'
p3430
(F1
F0.00076452599388379206
I0
I1
I-1
tp3431
sS'and,first-pass,cyp3a'
p3432
(F1
F0.00076452599388379206
I0
I1
I-1
tp3433
sS'these,cytochrome,p450'
p3434
(F1
F0.00076452599388379206
I0
I1
I-1
tp3435
sS'at,doses,higher'
p3436
(F1
F0.00076452599388379206
I1
I0
I1
tp3437
sS'beta,adrenergic,blockers'
p3438
(F1
F0.00076452599388379206
I1
I0
I1
tp3439
sS'aav2,containing,cdna'
p3440
(F1
F0.00076452599388379206
I0
I1
I-1
tp3441
sS'that,of,and'
p3442
(F1
F0.00076452599388379206
I0
I1
I-1
tp3443
sS'place,preference,in'
p3444
(F1
F0.00076452599388379206
I0
I1
I-1
tp3445
sS'by,inhibition,of'
p3446
(F1
F0.00076452599388379206
I1
I0
I1
tp3447
sS'benzodiazepines,oral,clinically'
p3448
(F1
F0.00076452599388379206
I1
I0
I1
tp3449
sS'supplements,absorbent-type,anti-diarrhea'
p3450
(F1
F0.00076452599388379206
I1
I0
I1
tp3451
sS'the,locomotor,inhibitory'
p3452
(F1
F0.00076452599388379206
I1
I0
I1
tp3453
sS'half-life,and,auc'
p3454
(F1
F0.00076452599388379206
I1
I0
I1
tp3455
sS'both,the,gastrointestinal'
p3456
(F1
F0.00076452599388379206
I0
I1
I-1
tp3457
sS'effects,can,occur'
p3458
(F1
F0.00076452599388379206
I1
I0
I1
tp3459
sS'cardiac,arrythmias,typically'
p3460
(F1
F0.00076452599388379206
I1
I0
I1
tp3461
sS'of,a,potent'
p3462
(F1
F0.00076452599388379206
I0
I1
I-1
tp3463
sS'fresh,human,serum'
p3464
(F1
F0.00076452599388379206
I1
I0
I1
tp3465
sS'increase,the,frequency'
p3466
(F1
F0.0015290519877675841
I2
I0
I2
tp3467
sS'been,observed,with'
p3468
(F1
F0.00076452599388379206
I1
I0
I1
tp3469
sS'bile,acid,sequestrates'
p3470
(F1
F0.00076452599388379206
I1
I0
I1
tp3471
sS'or,other,hepatic'
p3472
(F1
F0.00076452599388379206
I1
I0
I1
tp3473
sS'primarily,an,increased'
p3474
(F1
F0.00076452599388379206
I0
I1
I-1
tp3475
sS'this,study,examined'
p3476
(F1
F0.00076452599388379206
I0
I1
I-1
tp3477
sS'the,signs,of'
p3478
(F1
F0.00076452599388379206
I1
I0
I1
tp3479
sS'enhancement,of,humoral'
p3480
(F1
F0.00076452599388379206
I0
I1
I-1
tp3481
sS'no,protein,binding'
p3482
(F1
F0.00076452599388379206
I0
I1
I-1
tp3483
sS'on,a,stable'
p3484
(F1
F0.0015290519877675841
I0
I2
I-2
tp3485
sS'would,be,respiratory'
p3486
(F1
F0.00076452599388379206
I1
I0
I1
tp3487
sS'meloxicam,mg,once'
p3488
(F1
F0.00076452599388379206
I0
I1
I-1
tp3489
sS'dose,of,when'
p3490
(F1
F0.00076452599388379206
I0
I1
I-1
tp3491
sS'and,u251,to'
p3492
(F1
F0.00076452599388379206
I0
I1
I-1
tp3493
sS'including,barbiturates,tricyclic'
p3494
(F1
F0.00076452599388379206
I1
I0
I1
tp3495
sS'swimming,test,fst'
p3496
(F1
F0.00076452599388379206
I0
I1
I-1
tp3497
sS'and,because,patients'
p3498
(F1
F0.00076452599388379206
I1
I0
I1
tp3499
sS'all,patients,had'
p3500
(F1
F0.00076452599388379206
I0
I1
I-1
tp3501
sS'each,group,drugs'
p3502
(F1
F0.00076452599388379206
I0
I1
I-1
tp3503
sS'target,bp,with'
p3504
(F1
F0.00076452599388379206
I0
I1
I-1
tp3505
sS'associated,with,refer'
p3506
(F1
F0.00076452599388379206
I0
I1
I-1
tp3507
sS'administration,of,bacteriostatic'
p3508
(F1
F0.00076452599388379206
I1
I0
I1
tp3509
sS'except,for,two'
p3510
(F1
F0.00076452599388379206
I1
I0
I1
tp3511
sS'as,compared,with'
p3512
(F1
F0.00076452599388379206
I0
I1
I-1
tp3513
sS'adjustment,when,megestrol'
p3514
(F1
F0.00076452599388379206
I0
I1
I-1
tp3515
sS'by,exposure,were'
p3516
(F1
F0.00076452599388379206
I1
I0
I1
tp3517
sS'hepatic,enzymes,such'
p3518
(F1
F0.0015290519877675841
I2
I0
I2
tp3519
sS'randomized,blinded,crossover'
p3520
(F1
F0.00076452599388379206
I0
I1
I-1
tp3521
sS'evidence,that,is'
p3522
(F1
F0.00076452599388379206
I1
I0
I1
tp3523
sS'acids,for,example'
p3524
(F1
F0.00076452599388379206
I1
I0
I1
tp3525
sS'with,fixed,combination'
p3526
(F1
F0.00076452599388379206
I0
I1
I-1
tp3527
sS'cotreatment,with,dznep'
p3528
(F1
F0.00076452599388379206
I1
I0
I1
tp3529
sS'kg,day,in'
p3530
(F1
F0.00076452599388379206
I0
I1
I-1
tp3531
sS'in,a,study'
p3532
(F0.5
F0.0015290519877675841
I3
I1
I2
tp3533
sS'patients,receiving,most'
p3534
(F1
F0.00076452599388379206
I0
I1
I-1
tp3535
sS'the,peak,concentration'
p3536
(F1
F0.00076452599388379206
I1
I0
I1
tp3537
sS'incubations,were,performed'
p3538
(F1
F0.00076452599388379206
I0
I1
I-1
tp3539
sS'interactions,inhibitors,of'
p3540
(F0
F0
I1
I1
I0
tp3541
sS'possible,should,be'
p3542
(F1
F0.00076452599388379206
I1
I0
I1
tp3543
sS'interactions,with,commonly'
p3544
(F1
F0.00076452599388379206
I0
I1
I-1
tp3545
sS'following,enzyme,inhibition'
p3546
(F1
F0.00076452599388379206
I0
I1
I-1
tp3547
sS'paliperidone,may,antagonize'
p3548
(F1
F0.00076452599388379206
I1
I0
I1
tp3549
sS'of,this,synergism'
p3550
(F1
F0.00076452599388379206
I1
I0
I1
tp3551
sS'be,respiratory,depression'
p3552
(F1
F0.00076452599388379206
I1
I0
I1
tp3553
sS'azole,antifungals,eg'
p3554
(F1
F0.00076452599388379206
I1
I0
I1
tp3555
sS'p450,a6,and'
p3556
(F1
F0.00076452599388379206
I0
I1
I-1
tp3557
sS'diminished,effects,of'
p3558
(F1
F0.0015290519877675841
I2
I0
I2
tp3559
sS'physicians,should,closely'
p3560
(F1
F0.0015290519877675841
I2
I0
I2
tp3561
sS'can,occur,when'
p3562
(F1
F0.00076452599388379206
I1
I0
I1
tp3563
sS'resistance,to,the'
p3564
(F1
F0.00076452599388379206
I1
I0
I1
tp3565
sS'and,neuromuscular,blocking'
p3566
(F1
F0.00076452599388379206
I1
I0
I1
tp3567
sS'enhanced,by,the'
p3568
(F1
F0.00076452599388379206
I1
I0
I1
tp3569
sS'induction,or,inhibition'
p3570
(F1
F0.00076452599388379206
I0
I1
I-1
tp3571
sS'of,valproic,acid'
p3572
(F1
F0.0015290519877675841
I2
I0
I2
tp3573
sS'a,clinically-relevant,interaction'
p3574
(F1
F0.00076452599388379206
I0
I1
I-1
tp3575
sS'with,doses,of'
p3576
(F1
F0.00076452599388379206
I1
I0
I1
tp3577
sS'eg,may,increase'
p3578
(F1
F0.00076452599388379206
I1
I0
I1
tp3579
sS'breast,cancer,especially'
p3580
(F1
F0.00076452599388379206
I1
I0
I1
tp3581
sS'the,fact,that'
p3582
(F1
F0.00076452599388379206
I0
I1
I-1
tp3583
sS'acid,decreases,oral'
p3584
(F1
F0.00076452599388379206
I1
I0
I1
tp3585
sS'p27,kip1,in'
p3586
(F1
F0.00076452599388379206
I1
I0
I1
tp3587
sS'required,for,optimal'
p3588
(F1
F0.00076452599388379206
I0
I1
I-1
tp3589
sS'associated,with,qt'
p3590
(F1
F0.00076452599388379206
I1
I0
I1
tp3591
sS'protease,inhibitors,there'
p3592
(F1
F0.00076452599388379206
I0
I1
I-1
tp3593
sS'injectable,emulsion,does'
p3594
(F1
F0.00076452599388379206
I0
I1
I-1
tp3595
sS'of,cyp3a4,mg'
p3596
(F1
F0.00076452599388379206
I1
I0
I1
tp3597
sS'nutritional,status,was'
p3598
(F1
F0.00076452599388379206
I0
I1
I-1
tp3599
sS'potentiate,the,replication'
p3600
(F1
F0.00076452599388379206
I1
I0
I1
tp3601
sS'cancer,cells,and'
p3602
(F1
F0.00076452599388379206
I0
I1
I-1
tp3603
sS'hyperreflexia,and,incoordination'
p3604
(F1
F0.00076452599388379206
I1
I0
I1
tp3605
sS'nifedipine,auc,and'
p3606
(F1
F0.00076452599388379206
I1
I0
I1
tp3607
sS'monitoring,of,concentrations'
p3608
(F1
F0.0015290519877675841
I2
I0
I2
tp3609
sS'of,some,of'
p3610
(F1
F0.00076452599388379206
I0
I1
I-1
tp3611
sS'with,concomitant,use'
p3612
(F0.33333333333333331
F0.00076452599388379206
I2
I1
I1
tp3613
sS'loop,diuretics,oral'
p3614
(F1
F0.00076452599388379206
I1
I0
I1
tp3615
sS'gastric,ph,is'
p3616
(F1
F0.00076452599388379206
I1
I0
I1
tp3617
sS'with,alcohol,due'
p3618
(F1
F0.00076452599388379206
I1
I0
I1
tp3619
sS'by,cp450,liver'
p3620
(F1
F0.00076452599388379206
I1
I0
I1
tp3621
sS'not,a,substitute'
p3622
(F1
F0.00076452599388379206
I0
I1
I-1
tp3623
sS'or,pharmacokinetics,were'
p3624
(F1
F0.00076452599388379206
I0
I1
I-1
tp3625
sS'result,of,decreased'
p3626
(F1
F0.00076452599388379206
I0
I1
I-1
tp3627
sS'nutritionally-derived,vitamin,k'
p3628
(F1
F0.00076452599388379206
I0
I1
I-1
tp3629
sS'studied,the,potent'
p3630
(F1
F0.00076452599388379206
I1
I0
I1
tp3631
sS'it,may,also'
p3632
(F1
F0.0015290519877675841
I0
I2
I-2
tp3633
sS'on,the,absorption'
p3634
(F1
F0.00076452599388379206
I0
I1
I-1
tp3635
sS'other,chemotherapeutic,agents'
p3636
(F1
F0.00076452599388379206
I0
I1
I-1
tp3637
sS'and,particularly,the'
p3638
(F1
F0.00076452599388379206
I1
I0
I1
tp3639
sS'mivacron,include,certain'
p3640
(F1
F0.00076452599388379206
I1
I0
I1
tp3641
sS'and,chondroitin,abc'
p3642
(F1
F0.00076452599388379206
I0
I1
I-1
tp3643
sS'delivered,by,intravitreal'
p3644
(F1
F0.00076452599388379206
I0
I1
I-1
tp3645
sS'when,was,administered'
p3646
(F1
F0.00076452599388379206
I0
I1
I-1
tp3647
sS'pharmacokinetic,profile,of'
p3648
(F1
F0.00076452599388379206
I0
I1
I-1
tp3649
sS'recommended,that,myfortic'
p3650
(F1
F0.0015290519877675841
I2
I0
I2
tp3651
sS'interactions,with,sanctura'
p3652
(F1
F0.00076452599388379206
I1
I0
I1
tp3653
sS'studied,and,is'
p3654
(F1
F0.00076452599388379206
I1
I0
I1
tp3655
sS'neuronal,loss,was'
p3656
(F1
F0.00076452599388379206
I1
I0
I1
tp3657
sS'inhibitors,is,contraindicated'
p3658
(F1
F0.00076452599388379206
I1
I0
I1
tp3659
sS'effect,of,concomitant'
p3660
(F1
F0.00076452599388379206
I0
I1
I-1
tp3661
sS'you,are,taking'
p3662
(F1
F0.00076452599388379206
I0
I1
I-1
tp3663
sS'tell,your,doctor'
p3664
(F1
F0.00076452599388379206
I0
I1
I-1
tp3665
sS'we,present,a'
p3666
(F1
F0.00076452599388379206
I1
I0
I1
tp3667
sS'presence,of,renal'
p3668
(F1
F0.00076452599388379206
I0
I1
I-1
tp3669
sS'digitalized,patients,since'
p3670
(F1
F0.00076452599388379206
I1
I0
I1
tp3671
sS'when,potent,cytochrome'
p3672
(F1
F0.0015290519877675841
I2
I0
I2
tp3673
sS'cns,depressants,including'
p3674
(F1
F0.00076452599388379206
I0
I1
I-1
tp3675
sS'astemizole,rifabutin,tacrolimus'
p3676
(F1
F0.00076452599388379206
I1
I0
I1
tp3677
sS'of,action,of'
p3678
(F1
F0.0015290519877675841
I0
I2
I-2
tp3679
sS'no,change,in'
p3680
(F1
F0.0015290519877675841
I0
I2
I-2
tp3681
sS'together,with,high-dose'
p3682
(F1
F0.00076452599388379206
I1
I0
I1
tp3683
sS'mg,kg,significantly'
p3684
(F1
F0.00076452599388379206
I1
I0
I1
tp3685
sS'liver,microsomes,showed'
p3686
(F1
F0.00076452599388379206
I0
I1
I-1
tp3687
sS'markedly,decreased,c'
p3688
(F1
F0.00076452599388379206
I1
I0
I1
tp3689
sS'and,in,nsclc'
p3690
(F1
F0.00076452599388379206
I0
I1
I-1
tp3691
sS'of,curariform,drugs'
p3692
(F1
F0.00076452599388379206
I1
I0
I1
tp3693
sS'bradycardia,was,increased'
p3694
(F1
F0.00076452599388379206
I1
I0
I1
tp3695
sS'orally,administered,agent'
p3696
(F1
F0.00076452599388379206
I1
I0
I1
tp3697
sS'eldepryl,and,selective'
p3698
(F1
F0.00076452599388379206
I1
I0
I1
tp3699
sS'of,anticholinergic,agents'
p3700
(F1
F0.00076452599388379206
I1
I0
I1
tp3701
sS'centrally,acting,alpha-2'
p3702
(F1
F0.00076452599388379206
I0
I1
I-1
tp3703
sS'anticholinergic,drugs,and'
p3704
(F1
F0.00076452599388379206
I1
I0
I1
tp3705
sS'd6,inhibitors,to'
p3706
(F1
F0.00076452599388379206
I1
I0
I1
tp3707
sS'did,not,influence'
p3708
(F1
F0.00076452599388379206
I0
I1
I-1
tp3709
sS'with,a,database'
p3710
(F1
F0.00076452599388379206
I0
I1
I-1
tp3711
sS'in,achieving,adequate'
p3712
(F1
F0.00076452599388379206
I0
I1
I-1
tp3713
sS'bactericidal,effects,of'
p3714
(F1
F0.00076452599388379206
I1
I0
I1
tp3715
sS'are,co-,administered'
p3716
(F1
F0.00076452599388379206
I1
I0
I1
tp3717
sS'the,neuromuscular,blocking'
p3718
(F0.5
F0.0015290519877675841
I3
I1
I2
tp3719
sS'has,displayed,synergy'
p3720
(F1
F0.00076452599388379206
I1
I0
I1
tp3721
sS'been,reported,during'
p3722
(F1
F0.00076452599388379206
I1
I0
I1
tp3723
sS'anticoagulation,test,should'
p3724
(F1
F0.00076452599388379206
I1
I0
I1
tp3725
sS'the,clinical,effects'
p3726
(F1
F0.00076452599388379206
I0
I1
I-1
tp3727
sS'reduce,the,dosage'
p3728
(F1
F0.00076452599388379206
I1
I0
I1
tp3729
sS'of,when,given'
p3730
(F1
F0.0015290519877675841
I2
I0
I2
tp3731
sS'administered,with,consideration'
p3732
(F1
F0.00076452599388379206
I1
I0
I1
tp3733
sS'nervous,system,particularly'
p3734
(F1
F0.00076452599388379206
I1
I0
I1
tp3735
sS'compared,with,alone'
p3736
(F1
F0.00076452599388379206
I1
I0
I1
tp3737
sS'initiation,of,or'
p3738
(F1
F0.00076452599388379206
I1
I0
I1
tp3739
sS'that,did,not'
p3740
(F1
F0.00076452599388379206
I1
I0
I1
tp3741
sS'or,discontinues,therapy'
p3742
(F1
F0.00076452599388379206
I1
I0
I1
tp3743
sS'not,occurred,in'
p3744
(F1
F0.00076452599388379206
I1
I0
I1
tp3745
sS'and,coadministration,of'
p3746
(F1
F0.00076452599388379206
I1
I0
I1
tp3747
sS'studies,with,human'
p3748
(F1
F0.00076452599388379206
I0
I1
I-1
tp3749
sS'with,low,doses'
p3750
(F1
F0.00076452599388379206
I0
I1
I-1
tp3751
sS'ropivacaine,should,be'
p3752
(F1
F0.00076452599388379206
I1
I0
I1
tp3753
sS'have,more,frequent'
p3754
(F1
F0.00076452599388379206
I1
I0
I1
tp3755
sS'necessary,to,maintain'
p3756
(F1
F0.00076452599388379206
I0
I1
I-1
tp3757
sS'of,urinary,retention'
p3758
(F1
F0.00076452599388379206
I1
I0
I1
tp3759
sS'detail,below,oral'
p3760
(F1
F0.00076452599388379206
I1
I0
I1
tp3761
sS'probenecid,competes,with'
p3762
(F1
F0.00076452599388379206
I1
I0
I1
tp3763
sS'medicines,and,please'
p3764
(F1
F0.00076452599388379206
I1
I0
I1
tp3765
sS'a,single,intravenous'
p3766
(F1
F0.00076452599388379206
I0
I1
I-1
tp3767
sS'iii,and,chondroitin'
p3768
(F1
F0.00076452599388379206
I0
I1
I-1
tp3769
sS'studies,to,assess'
p3770
(F1
F0.00076452599388379206
I1
I0
I1
tp3771
sS'may,affect,absorption'
p3772
(F1
F0.00076452599388379206
I1
I0
I1
tp3773
sS'not,significantly,alter'
p3774
(F1
F0.00076452599388379206
I0
I1
I-1
tp3775
sS'change,in,plasma'
p3776
(F1
F0.00076452599388379206
I0
I1
I-1
tp3777
sS'cytochrome,p450,enzyme'
p3778
(F1
F0.0015290519877675841
I2
I0
I2
tp3779
sS'including,ergot,alkaloids'
p3780
(F1
F0.00076452599388379206
I0
I1
I-1
tp3781
sS'for,two,combinations'
p3782
(F1
F0.00076452599388379206
I1
I0
I1
tp3783
sS'expected,and,flomax'
p3784
(F1
F0.00076452599388379206
I1
I0
I1
tp3785
sS'vitro,binding,of'
p3786
(F1
F0.00076452599388379206
I0
I1
I-1
tp3787
sS'with,trental,with'
p3788
(F1
F0.00076452599388379206
I1
I0
I1
tp3789
sS'of,either,tolectin'
p3790
(F1
F0.00076452599388379206
I0
I1
I-1
tp3791
sS'kip1,enhanced,paclitaxel-induced'
p3792
(F1
F0.00076452599388379206
I1
I0
I1
tp3793
sS'the,serum,concentration'
p3794
(F0
F0
I1
I1
I0
tp3795
sS'tranquilizers,sedative-hypnotics,including'
p3796
(F1
F0.00076452599388379206
I1
I0
I1
tp3797
sS'subjects,did,not'
p3798
(F1
F0.00076452599388379206
I0
I1
I-1
tp3799
sS'the,breakdown,of'
p3800
(F1
F0.00076452599388379206
I1
I0
I1
tp3801
sS'of,agents,including'
p3802
(F1
F0.00076452599388379206
I0
I1
I-1
tp3803
sS'concomitantly,during,administration'
p3804
(F1
F0.00076452599388379206
I1
I0
I1
tp3805
sS'of,the,contraception'
p3806
(F1
F0.00076452599388379206
I1
I0
I1
tp3807
sS'on,the,action'
p3808
(F1
F0.00076452599388379206
I1
I0
I1
tp3809
sS'injectable,emulsion,has'
p3810
(F1
F0.00076452599388379206
I0
I1
I-1
tp3811
sS'such,as,general'
p3812
(F1
F0.00076452599388379206
I0
I1
I-1
tp3813
sS'mephenytoin,may,also'
p3814
(F1
F0.00076452599388379206
I1
I0
I1
tp3815
sS'result,in,delayed'
p3816
(F1
F0.00076452599388379206
I1
I0
I1
tp3817
sS'antagonized,by,anticholinergic'
p3818
(F1
F0.00076452599388379206
I1
I0
I1
tp3819
sS'not,be,given'
p3820
(F1
F0.00076452599388379206
I1
I0
I1
tp3821
sS'time,spent,in'
p3822
(F1
F0.00076452599388379206
I0
I1
I-1
tp3823
sS'dosed,to,pharmacokinetic'
p3824
(F1
F0.0015290519877675841
I0
I2
I-2
tp3825
sS'assay,sirna,knockdown'
p3826
(F1
F0.00076452599388379206
I0
I1
I-1
tp3827
sS'effect,of,mivacron'
p3828
(F1
F0.00076452599388379206
I1
I0
I1
tp3829
sS'blockers,selective,serotonin'
p3830
(F1
F0.00076452599388379206
I0
I1
I-1
tp3831
sS'mg,kg,body'
p3832
(F1
F0.00076452599388379206
I0
I1
I-1
tp3833
sS'effects,and,stimulant'
p3834
(F1
F0.00076452599388379206
I0
I1
I-1
tp3835
sS'metabolism,in,the'
p3836
(F1
F0.00076452599388379206
I1
I0
I1
tp3837
sS'in,the,clinical'
p3838
(F1
F0.00076452599388379206
I0
I1
I-1
tp3839
sS'has,been,large'
p3840
(F1
F0.00076452599388379206
I0
I1
I-1
tp3841
sS'cytochrome,p450,enzymes'
p3842
(F1
F0.0015290519877675841
I0
I2
I-2
tp3843
sS'and,are,incompatible'
p3844
(F1
F0.00076452599388379206
I1
I0
I1
tp3845
sS'of,drugs,and'
p3846
(F1
F0.00076452599388379206
I1
I0
I1
tp3847
sS'prothrombin,activity,patients'
p3848
(F1
F0.00076452599388379206
I1
I0
I1
tp3849
sS'metabolism,increasing,serum'
p3850
(F1
F0.00076452599388379206
I1
I0
I1
tp3851
sS'suggested,the,possibility'
p3852
(F1
F0.00076452599388379206
I1
I0
I1
tp3853
sS'drugs,and,days'
p3854
(F1
F0.00076452599388379206
I1
I0
I1
tp3855
sS'central,nervous,system'
p3856
(F1
F0.0030581039755351682
I4
I0
I4
tp3857
sS'serum,and,symptoms'
p3858
(F1
F0.00076452599388379206
I0
I1
I-1
tp3859
sS'no,changes,in'
p3860
(F1
F0.00076452599388379206
I0
I1
I-1
tp3861
sS'dornase,alfa,pulmozyme'
p3862
(F1
F0.00076452599388379206
I1
I0
I1
tp3863
sS'oxidase,inhibitors,or'
p3864
(F1
F0.0022935779816513763
I3
I0
I3
tp3865
sS'time,may,be'
p3866
(F1
F0.00076452599388379206
I1
I0
I1
tp3867
sS'm2,eloxatin,dosed'
p3868
(F1
F0.00076452599388379206
I1
I0
I1
tp3869
sS'blocking,agents,may'
p3870
(F1
F0.00076452599388379206
I1
I0
I1
tp3871
sS'of,midbrain,dopaminergic'
p3872
(F1
F0.00076452599388379206
I1
I0
I1
tp3873
sS'subsequent,to,interaction'
p3874
(F1
F0.00076452599388379206
I1
I0
I1
tp3875
sS'could,elicit,this'
p3876
(F1
F0.00076452599388379206
I1
I0
I1
tp3877
sS'inhibit,this,drug'
p3878
(F1
F0.00076452599388379206
I0
I1
I-1
tp3879
sS'of,inhibition,by'
p3880
(F1
F0.00076452599388379206
I1
I0
I1
tp3881
sS'co-administration,of,oral'
p3882
(F1
F0.00076452599388379206
I1
I0
I1
tp3883
sS'variety,of,agents'
p3884
(F1
F0.00076452599388379206
I0
I1
I-1
tp3885
sS'the,co-injection,of'
p3886
(F1
F0.00076452599388379206
I0
I1
I-1
tp3887
sS'pharmacokinetics,of,single'
p3888
(F1
F0.00076452599388379206
I0
I1
I-1
tp3889
sS'a,patient,initiates'
p3890
(F1
F0.00076452599388379206
I1
I0
I1
tp3891
sS'hey,cells,treated'
p3892
(F1
F0.00076452599388379206
I1
I0
I1
tp3893
sS'reports,of,nephrotoxicity'
p3894
(F1
F0.00076452599388379206
I1
I0
I1
tp3895
sS'to,pharmacokinetic,steady'
p3896
(F1
F0.0015290519877675841
I0
I2
I-2
tp3897
sS'was,unaltered,with'
p3898
(F1
F0.00076452599388379206
I0
I1
I-1
tp3899
sS'effect,of,on'
p3900
(F0.33333333333333331
F0.0015290519877675841
I2
I4
I-2
tp3901
sS'who,are,concurrently'
p3902
(F1
F0.00076452599388379206
I1
I0
I1
tp3903
sS'use,of,with'
p3904
(F1
F0.0030581039755351682
I4
I0
I4
tp3905
sS'with,concomitant,administration'
p3906
(F1
F0.0015290519877675841
I2
I0
I2
tp3907
sS'have,a,narrow'
p3908
(F1
F0.00076452599388379206
I0
I1
I-1
tp3909
sS'may,elicit,important'
p3910
(F1
F0.00076452599388379206
I0
I1
I-1
tp3911
sS'absorption,relative,to'
p3912
(F1
F0.00076452599388379206
I0
I1
I-1
tp3913
sS'or,topical,use'
p3914
(F1
F0.00076452599388379206
I0
I1
I-1
tp3915
sS'women,the,qt'
p3916
(F1
F0.00076452599388379206
I0
I1
I-1
tp3917
sS'administered,following,administration'
p3918
(F1
F0.00076452599388379206
I1
I0
I1
tp3919
sS'test,of,forced'
p3920
(F1
F0.00076452599388379206
I0
I1
I-1
tp3921
sS'for,are,unnecessary'
p3922
(F1
F0.00076452599388379206
I0
I1
I-1
tp3923
sS'in,normal,volunteer'
p3924
(F1
F0.00076452599388379206
I0
I1
I-1
tp3925
sS'beta,agonists,inhaled'
p3926
(F1
F0.00076452599388379206
I1
I0
I1
tp3927
sS'p450,a4,or'
p3928
(F1
F0.00076452599388379206
I0
I1
I-1
tp3929
sS'with,or,other'
p3930
(F0.33333333333333331
F0.00076452599388379206
I2
I1
I1
tp3931
sS'patients,with,end-stage'
p3932
(F1
F0.00076452599388379206
I0
I1
I-1
tp3933
sS'because,they,may'
p3934
(F1
F0.0015290519877675841
I2
I0
I2
tp3935
sS'skelaxin,may,enhance'
p3936
(F1
F0.00076452599388379206
I1
I0
I1
tp3937
sS'produce,a,corresponding'
p3938
(F1
F0.00076452599388379206
I1
I0
I1
tp3939
sS'transcriptase,inhibitors,or'
p3940
(F1
F0.00076452599388379206
I0
I1
I-1
tp3941
sS'and,noradrenergic,cell'
p3942
(F1
F0.00076452599388379206
I1
I0
I1
tp3943
sS'sirna,knockdown,of'
p3944
(F0.33333333333333331
F0.00076452599388379206
I1
I2
I-1
tp3945
sS'mitotane,to,patients'
p3946
(F1
F0.00076452599388379206
I1
I0
I1
tp3947
sS'the,type,may'
p3948
(F1
F0.00076452599388379206
I1
I0
I1
tp3949
sS'increased,response,increased'
p3950
(F1
F0.0015290519877675841
I0
I2
I-2
tp3951
sS'displayed,synergy,in'
p3952
(F1
F0.00076452599388379206
I1
I0
I1
tp3953
sS'action,of,it'
p3954
(F1
F0.00076452599388379206
I1
I0
I1
tp3955
sS'of,from,that'
p3956
(F1
F0.00076452599388379206
I1
I0
I1
tp3957
sS'potential,for,interaction'
p3958
(F1
F0.00076452599388379206
I0
I1
I-1
tp3959
sS'this,study,evaluated'
p3960
(F1
F0.00076452599388379206
I0
I1
I-1
tp3961
sS'increased,thrombocytopenia,increased'
p3962
(F1
F0.0015290519877675841
I0
I2
I-2
tp3963
sS'take,both,and'
p3964
(F1
F0.00076452599388379206
I1
I0
I1
tp3965
sS'metabolizing,enzyme,system'
p3966
(F1
F0.00076452599388379206
I0
I1
I-1
tp3967
sS'antihypertensive,effects,of'
p3968
(F1
F0.0015290519877675841
I2
I0
I2
tp3969
sS'elimination,half-lives,for'
p3970
(F1
F0.00076452599388379206
I1
I0
I1
tp3971
sS'systemic,exposure,to'
p3972
(F1
F0.00076452599388379206
I0
I1
I-1
tp3973
sS'reduction,in,the'
p3974
(F0
F0
I1
I1
I0
tp3975
sS'is,used,concomitantly'
p3976
(F1
F0.00076452599388379206
I1
I0
I1
tp3977
sS'xanthine,derivatives,is'
p3978
(F1
F0.00076452599388379206
I1
I0
I1
tp3979
sS'depression,hypotension,and'
p3980
(F1
F0.00076452599388379206
I1
I0
I1
tp3981
sS'with,live,organism'
p3982
(F1
F0.00076452599388379206
I1
I0
I1
tp3983
sS'the,pregnancy,category'
p3984
(F1
F0.00076452599388379206
I0
I1
I-1
tp3985
sS'was,increased,when'
p3986
(F1
F0.00076452599388379206
I1
I0
I1
tp3987
sS'g,kg,with'
p3988
(F1
F0.00076452599388379206
I1
I0
I1
tp3989
sS'saponins,gsls,on'
p3990
(F1
F0.00076452599388379206
I0
I1
I-1
tp3991
sS'in,vitro,but'
p3992
(F1
F0.00076452599388379206
I1
I0
I1
tp3993
sS'for,example,bile'
p3994
(F1
F0.00076452599388379206
I1
I0
I1
tp3995
sS'auc,values,for'
p3996
(F1
F0.00076452599388379206
I1
I0
I1
tp3997
sS'also,displace,from'
p3998
(F1
F0.00076452599388379206
I1
I0
I1
tp3999
sS'a4,enzyme,system'
p4000
(F1
F0.0015290519877675841
I2
I0
I2
tp4001
sS'additive,with,that'
p4002
(F1
F0.0015290519877675841
I2
I0
I2
tp4003
sS'has,not,yet'
p4004
(F1
F0.00076452599388379206
I0
I1
I-1
tp4005
sS'of,concomitantly,administered'
p4006
(F1
F0.00076452599388379206
I1
I0
I1
tp4007
sS'saline,g,kg'
p4008
(F1
F0.00076452599388379206
I0
I1
I-1
tp4009
sS'precipitated,by,the'
p4010
(F1
F0.00076452599388379206
I1
I0
I1
tp4011
sS'doses,between,and'
p4012
(F1
F0.0015290519877675841
I0
I2
I-2
tp4013
sS'supplements,and,analogues'
p4014
(F1
F0.00076452599388379206
I1
I0
I1
tp4015
sS'to,approximately,of'
p4016
(F1
F0.00076452599388379206
I1
I0
I1
tp4017
sS'pharmacologic,studies,have'
p4018
(F1
F0.00076452599388379206
I1
I0
I1
tp4019
sS'were,exposed,to'
p4020
(F0
F0
I1
I1
I0
tp4021
sS'this,may,be'
p4022
(F1
F0.00076452599388379206
I0
I1
I-1
tp4023
sS'azathioprine,mycophenolate,mofetil'
p4024
(F1
F0.00076452599388379206
I1
I0
I1
tp4025
sS'cytochromes,p450,a6'
p4026
(F1
F0.00076452599388379206
I0
I1
I-1
tp4027
sS'to,increased,serum'
p4028
(F1
F0.00076452599388379206
I1
I0
I1
tp4029
sS'little,effect,on'
p4030
(F1
F0.00076452599388379206
I1
I0
I1
tp4031
sS'in,studies,in'
p4032
(F1
F0.00076452599388379206
I0
I1
I-1
tp4033
sS'either,discontinuing,the'
p4034
(F1
F0.00076452599388379206
I1
I0
I1
tp4035
sS'patients,taking,beta'
p4036
(F1
F0.00076452599388379206
I1
I0
I1
tp4037
sS'by,remeron,has'
p4038
(F1
F0.00076452599388379206
I1
I0
I1
tp4039
sS'described,in,bone'
p4040
(F1
F0.00076452599388379206
I1
I0
I1
tp4041
sS'before,for,the'
p4042
(F1
F0.00076452599388379206
I0
I1
I-1
tp4043
sS'administered,with,caution'
p4044
(F1
F0.0022935779816513763
I3
I0
I3
tp4045
sS'in,children,with'
p4046
(F1
F0.00076452599388379206
I1
I0
I1
tp4047
sS'did,not,recur'
p4048
(F1
F0.00076452599388379206
I0
I1
I-1
tp4049
sS'in,inr,and'
p4050
(F1
F0.0015290519877675841
I2
I0
I2
tp4051
sS'antimycotic,agents,and'
p4052
(F1
F0.00076452599388379206
I1
I0
I1
tp4053
sS'investigated,in,adequately'
p4054
(F1
F0.00076452599388379206
I0
I1
I-1
tp4055
sS'nitrous,oxide,to'
p4056
(F1
F0.00076452599388379206
I0
I1
I-1
tp4057
sS'absorption,dosage,or'
p4058
(F1
F0.00076452599388379206
I1
I0
I1
tp4059
sS'university,of,wales'
p4060
(F1
F0.00076452599388379206
I1
I0
I1
tp4061
sS'addition,dznep,insensitivity'
p4062
(F1
F0.00076452599388379206
I1
I0
I1
tp4063
sS'stimulantes,of,the'
p4064
(F1
F0.00076452599388379206
I1
I0
I1
tp4065
sS'noradrenergic,cell,groups'
p4066
(F1
F0.00076452599388379206
I1
I0
I1
tp4067
sS'onset,but,an'
p4068
(F1
F0.00076452599388379206
I1
I0
I1
tp4069
sS'in,clinical,practice'
p4070
(F1
F0.00076452599388379206
I0
I1
I-1
tp4071
sS'counts,of,midbrain'
p4072
(F1
F0.00076452599388379206
I1
I0
I1
tp4073
sS'chemotherapy,in,the'
p4074
(F1
F0.00076452599388379206
I1
I0
I1
tp4075
sS'important,effect,on'
p4076
(F1
F0.00076452599388379206
I0
I1
I-1
tp4077
sS'anticoagulants,such,as'
p4078
(F1
F0.00076452599388379206
I1
I0
I1
tp4079
sS'medicines,birth,control'
p4080
(F1
F0.00076452599388379206
I1
I0
I1
tp4081
sS'myelotoxicity,radiation,therapy'
p4082
(F1
F0.00076452599388379206
I1
I0
I1
tp4083
sS'receiving,methadone-maintenance,therapy'
p4084
(F1
F0.00076452599388379206
I1
I0
I1
tp4085
sS'an,approach,allowing'
p4086
(F1
F0.00076452599388379206
I1
I0
I1
tp4087
sS'ganglion,cell,layer'
p4088
(F1
F0.00076452599388379206
I0
I1
I-1
tp4089
sS'by,in,subjects'
p4090
(F1
F0.00076452599388379206
I1
I0
I1
tp4091
sS'its,active,metabolite'
p4092
(F1
F0.00076452599388379206
I0
I1
I-1
tp4093
sS'mycamine,should,be'
p4094
(F1
F0.00076452599388379206
I1
I0
I1
tp4095
sS'drugs,can,be'
p4096
(F1
F0.00076452599388379206
I1
I0
I1
tp4097
sS'anticholinergic,drugs,may'
p4098
(F1
F0.00076452599388379206
I1
I0
I1
tp4099
sS'some,of,the'
p4100
(F0.5
F0.0015290519877675841
I1
I3
I-2
tp4101
sS'considered,when,anticholinergic'
p4102
(F1
F0.00076452599388379206
I0
I1
I-1
tp4103
sS'of,there,was'
p4104
(F1
F0.00076452599388379206
I1
I0
I1
tp4105
sS'the,active,metabolite'
p4106
(F1
F0.00076452599388379206
I0
I1
I-1
tp4107
sS'a,mechanism,which'
p4108
(F1
F0.00076452599388379206
I1
I0
I1
tp4109
sS'patients,have,been'
p4110
(F1
F0.00076452599388379206
I0
I1
I-1
tp4111
sS'of,gene,expression'
p4112
(F1
F0.00076452599388379206
I0
I1
I-1
tp4113
sS'or,changing,mobic'
p4114
(F1
F0.00076452599388379206
I1
I0
I1
tp4115
sS'possible,although,there'
p4116
(F1
F0.00076452599388379206
I1
I0
I1
tp4117
sS'decrease,the,exposure'
p4118
(F1
F0.00076452599388379206
I1
I0
I1
tp4119
sS'to,the,zantac'
p4120
(F1
F0.00076452599388379206
I0
I1
I-1
tp4121
sS'cytochrome,p-450,drug-metabolizing'
p4122
(F1
F0.00076452599388379206
I0
I1
I-1
tp4123
sS'the,recommended,clinical'
p4124
(F1
F0.00076452599388379206
I0
I1
I-1
tp4125
sS'and,mycophenolate,mofetil'
p4126
(F1
F0.00076452599388379206
I1
I0
I1
tp4127
sS'nephrotoxic,drugs,such'
p4128
(F1
F0.00076452599388379206
I0
I1
I-1
tp4129
sS'johns,wort,may'
p4130
(F1
F0.00076452599388379206
I1
I0
I1
tp4131
sS'known,to,be'
p4132
(F0.33333333333333331
F0.00076452599388379206
I2
I1
I1
tp4133
sS'combination,was,comparable'
p4134
(F1
F0.00076452599388379206
I0
I1
I-1
tp4135
sS'a,markedly,decreased'
p4136
(F1
F0.00076452599388379206
I1
I0
I1
tp4137
sS'and,oral,no'
p4138
(F1
F0.00076452599388379206
I0
I1
I-1
tp4139
sS'be,anticipated,and'
p4140
(F1
F0.00076452599388379206
I1
I0
I1
tp4141
sS'with,failed,to'
p4142
(F1
F0.00076452599388379206
I0
I1
I-1
tp4143
sS'and,duration,of'
p4144
(F1
F0.00076452599388379206
I1
I0
I1
tp4145
sS'concentrations,in,serum'
p4146
(F1
F0.00076452599388379206
I1
I0
I1
tp4147
sS'dosage,increased,the'
p4148
(F1
F0.00076452599388379206
I1
I0
I1
tp4149
sS'levels,of,mometasone'
p4150
(F1
F0.00076452599388379206
I1
I0
I1
tp4151
sS'users,who,initiated'
p4152
(F1
F0.00076452599388379206
I1
I0
I1
tp4153
sS'there,was,no'
p4154
(F1
F0.0022935779816513763
I0
I3
I-3
tp4155
sS'used,concurrently,with'
p4156
(F0
F0
I2
I2
I0
tp4157
sS'concomitantly,with,maxair'
p4158
(F1
F0.00076452599388379206
I1
I0
I1
tp4159
sS'in,digitalized,patients'
p4160
(F1
F0.00076452599388379206
I1
I0
I1
tp4161
sS'in,onset,intensity'
p4162
(F1
F0.00076452599388379206
I0
I1
I-1
tp4163
sS'a,synergistic,effect'
p4164
(F1
F0.00076452599388379206
I1
I0
I1
tp4165
sS'avoid,prescribing,isoenzyme'
p4166
(F1
F0.00076452599388379206
I1
I0
I1
tp4167
sS'recommended,for,patients'
p4168
(F1
F0.00076452599388379206
I1
I0
I1
tp4169
sS'ovarian,cancer,cells'
p4170
(F0
F0
I1
I1
I0
tp4171
sS'coadministered,with,aceon'
p4172
(F1
F0.00076452599388379206
I1
I0
I1
tp4173
sS'from,hypoglycemia,in'
p4174
(F1
F0.00076452599388379206
I1
I0
I1
tp4175
sS'of,panobinostat-related,adverse'
p4176
(F1
F0.00076452599388379206
I0
I1
I-1
tp4177
sS'the,proton,pump'
p4178
(F1
F0.00076452599388379206
I0
I1
I-1
tp4179
sS'clearance,is,increased'
p4180
(F1
F0.00076452599388379206
I1
I0
I1
tp4181
sS'that,the,phosphorylation'
p4182
(F1
F0.00076452599388379206
I1
I0
I1
tp4183
sS'of,this,drug'
p4184
(F1
F0.00076452599388379206
I1
I0
I1
tp4185
sS'when,taken,concurrently'
p4186
(F1
F0.00076452599388379206
I1
I0
I1
tp4187
sS'inhibitors,or,certain'
p4188
(F1
F0.00076452599388379206
I0
I1
I-1
tp4189
sS'found,throughout,the'
p4190
(F1
F0.00076452599388379206
I0
I1
I-1
tp4191
sS'of,as,an'
p4192
(F1
F0.00076452599388379206
I1
I0
I1
tp4193
sS'is,not,likely'
p4194
(F1
F0.00076452599388379206
I0
I1
I-1
tp4195
sS'drugs,of,the'
p4196
(F1
F0.00076452599388379206
I1
I0
I1
tp4197
sS'dose,of,the'
p4198
(F1
F0.00076452599388379206
I1
I0
I1
tp4199
sS'with,caution,to'
p4200
(F1
F0.0022935779816513763
I3
I0
I3
tp4201
sS'patients,who,received'
p4202
(F1
F0.00076452599388379206
I0
I1
I-1
tp4203
sS'when,myfortic,was'
p4204
(F1
F0.00076452599388379206
I1
I0
I1
tp4205
sS'as,and,can'
p4206
(F1
F0.00076452599388379206
I1
I0
I1
tp4207
sS'metabotropic,glutamate,receptor'
p4208
(F0
F0
I1
I1
I0
tp4209
sS'of,followed,by'
p4210
(F1
F0.00076452599388379206
I1
I0
I1
tp4211
sS'alter,the,plasma'
p4212
(F1
F0.0015290519877675841
I0
I2
I-2
tp4213
sS'concomitantly,receiving,treatment'
p4214
(F1
F0.00076452599388379206
I1
I0
I1
tp4215
sS'with,has,not'
p4216
(F1
F0.0015290519877675841
I0
I2
I-2
tp4217
sS'shown,to,significantly'
p4218
(F1
F0.00076452599388379206
I1
I0
I1
tp4219
sS'determinant,of,their'
p4220
(F1
F0.00076452599388379206
I1
I0
I1
tp4221
sS'to,be,more'
p4222
(F1
F0.00076452599388379206
I1
I0
I1
tp4223
sS'used,in,treating'
p4224
(F1
F0.00076452599388379206
I0
I1
I-1
tp4225
sS'potent,cyp3a4,inhibitors'
p4226
(F1
F0.00076452599388379206
I1
I0
I1
tp4227
sS'sulfate,levothyroxine,sodium'
p4228
(F1
F0.00076452599388379206
I0
I1
I-1
tp4229
sS'appropriate,model,for'
p4230
(F1
F0.00076452599388379206
I0
I1
I-1
tp4231
sS'alupent,metaproterenol,sulfate'
p4232
(F1
F0.00076452599388379206
I1
I0
I1
tp4233
sS'agents,and,have'
p4234
(F1
F0.00076452599388379206
I0
I1
I-1
tp4235
sS'side,effects,of'
p4236
(F0
F0
I2
I2
I0
tp4237
sS'one,hour,after'
p4238
(F1
F0.00076452599388379206
I1
I0
I1
tp4239
sS'reverse,the,analgesic'
p4240
(F1
F0.00076452599388379206
I1
I0
I1
tp4241
sS'rate,and,extent'
p4242
(F1
F0.00076452599388379206
I0
I1
I-1
tp4243
sS'to,rheumatoid,arthritis'
p4244
(F1
F0.0015290519877675841
I0
I2
I-2
tp4245
sS'loop,given,concomitantly'
p4246
(F1
F0.00076452599388379206
I1
I0
I1
tp4247
sS'was,similar,to'
p4248
(F1
F0.00076452599388379206
I0
I1
I-1
tp4249
sS'cyclosporine-treated,as,compared'
p4250
(F1
F0.00076452599388379206
I0
I1
I-1
tp4251
sS'phenyl-1,tetrahydropyridine,toxicity'
p4252
(F1
F0.00076452599388379206
I1
I0
I1
tp4253
sS'compared,to,subjects'
p4254
(F1
F0.00076452599388379206
I1
I0
I1
tp4255
sS'treated,with,potent'
p4256
(F1
F0.00076452599388379206
I1
I0
I1
tp4257
sS'doses,and,h'
p4258
(F1
F0.00076452599388379206
I0
I1
I-1
tp4259
sS'of,invega,should'
p4260
(F1
F0.00076452599388379206
I1
I0
I1
tp4261
sS'mg,oral,dose'
p4262
(F1
F0.00076452599388379206
I0
I1
I-1
tp4263
sS'maximum,recommended,dose'
p4264
(F1
F0.00076452599388379206
I0
I1
I-1
tp4265
sS'and,respectively,in'
p4266
(F1
F0.00076452599388379206
I1
I0
I1
tp4267
sS'uptake,cellular,thiol'
p4268
(F1
F0.00076452599388379206
I0
I1
I-1
tp4269
sS'rifabutin,there,have'
p4270
(F1
F0.00076452599388379206
I1
I0
I1
tp4271
sS'as,and,induce'
p4272
(F1
F0.00076452599388379206
I1
I0
I1
tp4273
sS'because,there,is'
p4274
(F1
F0.00076452599388379206
I1
I0
I1
tp4275
sS'on,the,precocene'
p4276
(F1
F0.00076452599388379206
I0
I1
I-1
tp4277
sS'interactions,the,use'
p4278
(F1
F0.00076452599388379206
I0
I1
I-1
tp4279
sS'other,oral,hypoglycemic'
p4280
(F1
F0.00076452599388379206
I1
I0
I1
tp4281
sS'also,added,sometimes'
p4282
(F1
F0.00076452599388379206
I0
I1
I-1
tp4283
sS'between,tamsulosin,hci'
p4284
(F1
F0.00076452599388379206
I0
I1
I-1
tp4285
sS'dasatinib-mediated,induction,of'
p4286
(F1
F0.00076452599388379206
I1
I0
I1
tp4287
sS'taking,this,medication'
p4288
(F1
F0.00076452599388379206
I0
I1
I-1
tp4289
sS'patients,with,hypertensive'
p4290
(F1
F0.00076452599388379206
I0
I1
I-1
tp4291
sS'saline,saline,mg'
p4292
(F1
F0.00076452599388379206
I0
I1
I-1
tp4293
sS'in,humans,and'
p4294
(F1
F0.00076452599388379206
I0
I1
I-1
tp4295
sS'however,a,potent'
p4296
(F1
F0.00076452599388379206
I1
I0
I1
tp4297
sS'interact,with,cns'
p4298
(F1
F0.00076452599388379206
I1
I0
I1
tp4299
sS'and,pharmacokinetics,of'
p4300
(F1
F0.00076452599388379206
I0
I1
I-1
tp4301
sS'therapy,with,cerezyme'
p4302
(F1
F0.00076452599388379206
I1
I0
I1
tp4303
sS'maximum,mg,were'
p4304
(F1
F0.00076452599388379206
I0
I1
I-1
tp4305
sS'patients,receiving,zolinza'
p4306
(F1
F0.00076452599388379206
I1
I0
I1
tp4307
sS'and,in,clinical'
p4308
(F1
F0.00076452599388379206
I1
I0
I1
tp4309
sS'generally,recommended,because'
p4310
(F1
F0.00076452599388379206
I1
I0
I1
tp4311
sS'for,therapy,and'
p4312
(F1
F0.00076452599388379206
I0
I1
I-1
tp4313
sS'prothrombin,time,induced'
p4314
(F1
F0.00076452599388379206
I0
I1
I-1
tp4315
sS'inhibitor,on,the'
p4316
(F1
F0.00076452599388379206
I0
I1
I-1
tp4317
sS'with,daily,administration'
p4318
(F1
F0.00076452599388379206
I0
I1
I-1
tp4319
sS'of,streptase,streptokinase'
p4320
(F1
F0.00076452599388379206
I0
I1
I-1
tp4321
sS'when,cholinesterase,inhibitors'
p4322
(F1
F0.00076452599388379206
I1
I0
I1
tp4323
sS'and,related,compounds'
p4324
(F1
F0.00076452599388379206
I1
I0
I1
tp4325
sS'reduction,of,the'
p4326
(F1
F0.0015290519877675841
I2
I0
I2
tp4327
sS'when,ace,inhibitors'
p4328
(F1
F0.00076452599388379206
I0
I1
I-1
tp4329
sS'decrease,the,serum'
p4330
(F1
F0.00076452599388379206
I1
I0
I1
tp4331
sS'observation,of,the'
p4332
(F1
F0.00076452599388379206
I1
I0
I1
tp4333
sS'system,such,as'
p4334
(F1
F0.00076452599388379206
I1
I0
I1
tp4335
sS'like,activity,of'
p4336
(F1
F0.0015290519877675841
I0
I2
I-2
tp4337
sS'ipth,and,serum'
p4338
(F1
F0.00076452599388379206
I1
I0
I1
tp4339
sS'be,monitored,for'
p4340
(F1
F0.0015290519877675841
I2
I0
I2
tp4341
sS'other,proton,pump'
p4342
(F1
F0.00076452599388379206
I0
I1
I-1
tp4343
sS'the,total,level'
p4344
(F1
F0.00076452599388379206
I1
I0
I1
tp4345
sS'observed,in,administering'
p4346
(F1
F0.00076452599388379206
I1
I0
I1
tp4347
sS'as,elavil,asendin'
p4348
(F1
F0.00076452599388379206
I0
I1
I-1
tp4349
sS'clinical,relevance,for'
p4350
(F1
F0.00076452599388379206
I0
I1
I-1
tp4351
sS'levels,should,be'
p4352
(F1
F0.00076452599388379206
I1
I0
I1
tp4353
sS'not,cause,a'
p4354
(F1
F0.00076452599388379206
I0
I1
I-1
tp4355
sS'decreased,seizure,threshold'
p4356
(F1
F0.00076452599388379206
I1
I0
I1
tp4357
sS'that,are,metabolized'
p4358
(F0
F0
I1
I1
I0
tp4359
sS'was,no,evidence'
p4360
(F1
F0.00076452599388379206
I0
I1
I-1
tp4361
sS'dosage,in,patients'
p4362
(F1
F0.00076452599388379206
I1
I0
I1
tp4363
sS'subsequent,sessions,during'
p4364
(F1
F0.00076452599388379206
I0
I1
I-1
tp4365
sS'individual,ethinyl,estradiol'
p4366
(F1
F0.00076452599388379206
I0
I1
I-1
tp4367
sS'reduced,by,during'
p4368
(F1
F0.00076452599388379206
I1
I0
I1
tp4369
sS'montelukast,at,doses'
p4370
(F1
F0.00076452599388379206
I0
I1
I-1
tp4371
sS'patients,should,be'
p4372
(F1
F0.0038226299694189602
I5
I0
I5
tp4373
sS'necessary,to,monitor'
p4374
(F1
F0.00076452599388379206
I1
I0
I1
tp4375
sS'caused,a,markedly'
p4376
(F1
F0.00076452599388379206
I1
I0
I1
tp4377
sS'a,study,of'
p4378
(F0
F0
I1
I1
I0
tp4379
sS'increased,when,it'
p4380
(F1
F0.00076452599388379206
I1
I0
I1
tp4381
sS'anticholinergic,drugs,antiarrhythmic'
p4382
(F1
F0.00076452599388379206
I1
I0
I1
tp4383
sS'organic,bases,via'
p4384
(F1
F0.00076452599388379206
I1
I0
I1
tp4385
sS'paget,s,disease'
p4386
(F1
F0.00076452599388379206
I1
I0
I1
tp4387
sS'responsiveness,to,but'
p4388
(F1
F0.00076452599388379206
I1
I0
I1
tp4389
sS'kg,p,o'
p4390
(F1
F0.00076452599388379206
I0
I1
I-1
tp4391
sS'it,is,ingested'
p4392
(F1
F0.00076452599388379206
I1
I0
I1
tp4393
sS'of,mivacron,are'
p4394
(F1
F0.00076452599388379206
I1
I0
I1
tp4395
sS'kg,s-ketamine,after'
p4396
(F1
F0.00076452599388379206
I0
I1
I-1
tp4397
sS'patients,receiving,xenical'
p4398
(F1
F0.00076452599388379206
I0
I1
I-1
tp4399
sS'given,to,decreasing'
p4400
(F1
F0.00076452599388379206
I1
I0
I1
tp4401
sS'macrolide,including,is'
p4402
(F1
F0.00076452599388379206
I1
I0
I1
tp4403
sS'in,the,presence'
p4404
(F0.66666666666666663
F0.0030581039755351682
I5
I1
I4
tp4405
sS'of,doses,between'
p4406
(F1
F0.0015290519877675841
I0
I2
I-2
tp4407
sS'of,and,cci-779'
p4408
(F1
F0.00076452599388379206
I0
I1
I-1
tp4409
sS'extrapyramidal,effects,of'
p4410
(F1
F0.00076452599388379206
I1
I0
I1
tp4411
sS'be,observed,in'
p4412
(F1
F0.00076452599388379206
I1
I0
I1
tp4413
sS'some,anti-proliferative,effects'
p4414
(F1
F0.00076452599388379206
I1
I0
I1
tp4415
sS'vitro,p450,inhibition'
p4416
(F1
F0.00076452599388379206
I0
I1
I-1
tp4417
sS'reduce,the,effects'
p4418
(F1
F0.0015290519877675841
I2
I0
I2
tp4419
sS'significant,inhibitors,of'
p4420
(F1
F0.00076452599388379206
I1
I0
I1
tp4421
sS'in,in,vitro'
p4422
(F1
F0.00076452599388379206
I1
I0
I1
tp4423
sS'of,src,family'
p4424
(F1
F0.00076452599388379206
I1
I0
I1
tp4425
sS'and,temperature,were'
p4426
(F1
F0.00076452599388379206
I0
I1
I-1
tp4427
sS'to,initiation,of'
p4428
(F1
F0.00076452599388379206
I1
I0
I1
tp4429
sS'at,doses,of'
p4430
(F0
F0
I1
I1
I0
tp4431
sS'of,false-positive,urine'
p4432
(F1
F0.00076452599388379206
I0
I1
I-1
tp4433
sS'cortical,steroids,or'
p4434
(F1
F0.00076452599388379206
I0
I1
I-1
tp4435
sS'reduced,approximately,resulting'
p4436
(F1
F0.00076452599388379206
I0
I1
I-1
tp4437
sS'in,greater,detail'
p4438
(F1
F0.00076452599388379206
I1
I0
I1
tp4439
sS'commonly,employed,antianginal'
p4440
(F1
F0.00076452599388379206
I0
I1
I-1
tp4441
sS'distinct,and,statistically'
p4442
(F1
F0.00076452599388379206
I1
I0
I1
tp4443
sS'agents,tricyclic,antidepressants'
p4444
(F1
F0.00076452599388379206
I1
I0
I1
tp4445
sS'displace,from,plasma'
p4446
(F1
F0.00076452599388379206
I1
I0
I1
tp4447
sS'combining,with,other'
p4448
(F1
F0.00076452599388379206
I1
I0
I1
tp4449
sS'anesthesia,other,antihypertensive'
p4450
(F1
F0.00076452599388379206
I1
I0
I1
tp4451
sS'of,cyp2d6,coadministration'
p4452
(F1
F0.00076452599388379206
I0
I1
I-1
tp4453
sS'demonstrated,that,approximately'
p4454
(F1
F0.00076452599388379206
I1
I0
I1
tp4455
sS'none,of,the'
p4456
(F1
F0.00076452599388379206
I1
I0
I1
tp4457
sS'those,receiving,a'
p4458
(F1
F0.00076452599388379206
I0
I1
I-1
tp4459
sS'administered,with,nitrous'
p4460
(F1
F0.00076452599388379206
I0
I1
I-1
tp4461
sS'a,stable,target'
p4462
(F1
F0.00076452599388379206
I1
I0
I1
tp4463
sS'or,inhibit,this'
p4464
(F1
F0.00076452599388379206
I0
I1
I-1
tp4465
sS'itraconazole,torsades,de'
p4466
(F1
F0.00076452599388379206
I1
I0
I1
tp4467
sS'an,increased,risk'
p4468
(F1
F0.0022935779816513763
I3
I0
I3
tp4469
sS'be,precipitated,by'
p4470
(F1
F0.00076452599388379206
I1
I0
I1
tp4471
sS'or,of,such'
p4472
(F1
F0.00076452599388379206
I0
I1
I-1
tp4473
sS'qt,prolongation,in'
p4474
(F1
F0.00076452599388379206
I0
I1
I-1
tp4475
sS'xl,was,administered'
p4476
(F1
F0.00076452599388379206
I1
I0
I1
tp4477
sS'substituted,imidazole,drugs'
p4478
(F1
F0.00076452599388379206
I1
I0
I1
tp4479
sS'we,present,an'
p4480
(F1
F0.00076452599388379206
I1
I0
I1
tp4481
sS'inducers,of,these'
p4482
(F1
F0.00076452599388379206
I0
I1
I-1
tp4483
sS'concurrent,administration,of'
p4484
(F0.5
F0.0015290519877675841
I3
I1
I2
tp4485
sS'with,mixed,agonist'
p4486
(F1
F0.00076452599388379206
I1
I0
I1
tp4487
sS'plasma,protein-binding,sites'
p4488
(F1
F0.00076452599388379206
I1
I0
I1
tp4489
sS'time,and,serum'
p4490
(F1
F0.00076452599388379206
I0
I1
I-1
tp4491
sS'drug-drug,interactions,of'
p4492
(F1
F0.00076452599388379206
I0
I1
I-1
tp4493
sS'dose,of,aceon'
p4494
(F1
F0.00076452599388379206
I1
I0
I1
tp4495
sS'with,human,liver'
p4496
(F1
F0.00076452599388379206
I0
I1
I-1
tp4497
sS'tnkase,were,routinely'
p4498
(F1
F0.00076452599388379206
I0
I1
I-1
tp4499
sS'concomitantly,with,proamatine'
p4500
(F1
F0.00076452599388379206
I1
I0
I1
tp4501
sS'and,or,macrolide'
p4502
(F1
F0.00076452599388379206
I1
I0
I1
tp4503
sS'cells,and,cotreatment'
p4504
(F1
F0.00076452599388379206
I1
I0
I1
tp4505
sS'cns,effects,of'
p4506
(F1
F0.00076452599388379206
I1
I0
I1
tp4507
sS'ranging,from,to'
p4508
(F1
F0.00076452599388379206
I1
I0
I1
tp4509
sS'by,concurrent,mexitil'
p4510
(F1
F0.00076452599388379206
I0
I1
I-1
tp4511
sS'of,wine,did'
p4512
(F1
F0.00076452599388379206
I0
I1
I-1
tp4513
sS'suggest,that,the'
p4514
(F1
F0.00076452599388379206
I1
I0
I1
tp4515
sS'not,significantly,affect'
p4516
(F1
F0.00076452599388379206
I0
I1
I-1
tp4517
sS'did,not,result'
p4518
(F1
F0.0015290519877675841
I0
I2
I-2
tp4519
sS'and,insulin,the'
p4520
(F1
F0.00076452599388379206
I1
I0
I1
tp4521
sS'produced,a,slight'
p4522
(F1
F0.00076452599388379206
I1
I0
I1
tp4523
sS'subjects,showed,that'
p4524
(F1
F0.00076452599388379206
I0
I1
I-1
tp4525
sS'effects,of,multiple'
p4526
(F1
F0.00076452599388379206
I0
I1
I-1
tp4527
sS'not,lead,to'
p4528
(F1
F0.00076452599388379206
I0
I1
I-1
tp4529
sS'could,potentially,result'
p4530
(F1
F0.00076452599388379206
I1
I0
I1
tp4531
sS'bioavailability,of,skelid'
p4532
(F1
F0.0022935779816513763
I3
I0
I3
tp4533
sS'chicken,actin,promoter'
p4534
(F1
F0.00076452599388379206
I0
I1
I-1
tp4535
sS'mg,three,times'
p4536
(F1
F0.0061162079510703364
I0
I8
I-8
tp4537
sS'enhanced,time,spent'
p4538
(F1
F0.00076452599388379206
I0
I1
I-1
tp4539
sS'serum,because,of'
p4540
(F1
F0.00076452599388379206
I0
I1
I-1
tp4541
sS'and,or,severe'
p4542
(F1
F0.00076452599388379206
I1
I0
I1
tp4543
sS'in,herceptin,clearance'
p4544
(F1
F0.00076452599388379206
I1
I0
I1
tp4545
sS'maximum,g,and'
p4546
(F1
F0.00076452599388379206
I0
I1
I-1
tp4547
sS'evaluated,the,effects'
p4548
(F1
F0.0022935779816513763
I0
I3
I-3
tp4549
sS'increased,exposure,to'
p4550
(F1
F0.00076452599388379206
I1
I0
I1
tp4551
sS'recovery,from,should'
p4552
(F1
F0.00076452599388379206
I1
I0
I1
tp4553
sS'be,treated,with'
p4554
(F1
F0.00076452599388379206
I1
I0
I1
tp4555
sS'gemfibrozil,in,a'
p4556
(F1
F0.00076452599388379206
I0
I1
I-1
tp4557
sS'polymyxin,b,or'
p4558
(F1
F0.0015290519877675841
I0
I2
I-2
tp4559
sS'between,alimta,and'
p4560
(F1
F0.00076452599388379206
I1
I0
I1
tp4561
sS'a4,it,is'
p4562
(F1
F0.00076452599388379206
I1
I0
I1
tp4563
sS'bacteriostatic,drugs,may'
p4564
(F1
F0.00076452599388379206
I1
I0
I1
tp4565
sS'at,the,cell'
p4566
(F1
F0.00076452599388379206
I1
I0
I1
tp4567
sS'glycosides,may,enhance'
p4568
(F1
F0.00076452599388379206
I1
I0
I1
tp4569
sS'is,typical,of'
p4570
(F1
F0.00076452599388379206
I1
I0
I1
tp4571
sS'of,gsls,because'
p4572
(F1
F0.00076452599388379206
I0
I1
I-1
tp4573
sS'elderly,may,develop'
p4574
(F1
F0.00076452599388379206
I1
I0
I1
tp4575
sS'all,in,patients'
p4576
(F1
F0.00076452599388379206
I1
I0
I1
tp4577
sS'we,also,evaluated'
p4578
(F1
F0.00076452599388379206
I0
I1
I-1
tp4579
sS'thc,in,patients'
p4580
(F1
F0.00076452599388379206
I0
I1
I-1
tp4581
sS'and,richens,at'
p4582
(F1
F0.00076452599388379206
I1
I0
I1
tp4583
sS'given,consideration,in'
p4584
(F1
F0.00076452599388379206
I1
I0
I1
tp4585
sS'or,reverse,transcriptase'
p4586
(F1
F0.00076452599388379206
I0
I1
I-1
tp4587
sS'with,tacrolimus-treated,renal'
p4588
(F1
F0.00076452599388379206
I0
I1
I-1
tp4589
sS'four,drugs,in'
p4590
(F1
F0.00076452599388379206
I1
I0
I1
tp4591
sS'cause,a,clinically'
p4592
(F1
F0.00076452599388379206
I0
I1
I-1
tp4593
sS'mutual,inhibition,of'
p4594
(F1
F0.00076452599388379206
I1
I0
I1
tp4595
sS'pointes,have,been'
p4596
(F1
F0.00076452599388379206
I0
I1
I-1
tp4597
sS'anesthesia,and,therefore'
p4598
(F1
F0.0015290519877675841
I2
I0
I2
tp4599
sS'in,no,changes'
p4600
(F1
F0.00076452599388379206
I0
I1
I-1
tp4601
sS'with,and,an'
p4602
(F0
F0
I1
I1
I0
tp4603
sS'dosage,if,indicated'
p4604
(F1
F0.00076452599388379206
I1
I0
I1
tp4605
sS'do,not,reproduce'
p4606
(F1
F0.00076452599388379206
I0
I1
I-1
tp4607
sS'who,received,low-dose'
p4608
(F1
F0.00076452599388379206
I0
I1
I-1
tp4609
sS'due,to,active'
p4610
(F1
F0.00076452599388379206
I1
I0
I1
tp4611
sS'is,improved,by'
p4612
(F1
F0.00076452599388379206
I1
I0
I1
tp4613
sS'larger,cohorts,of'
p4614
(F1
F0.00076452599388379206
I0
I1
I-1
tp4615
sS'relevant,concentrations,of'
p4616
(F1
F0.00076452599388379206
I1
I0
I1
tp4617
sS'to,investigate,whether'
p4618
(F1
F0.00076452599388379206
I0
I1
I-1
tp4619
sS'during,organogenesis,result'
p4620
(F1
F0.00076452599388379206
I0
I1
I-1
tp4621
sS'of,with,has'
p4622
(F1
F0.00076452599388379206
I0
I1
I-1
tp4623
sS'a,patient,already'
p4624
(F1
F0.00076452599388379206
I1
I0
I1
tp4625
sS'aspirin,rimantadine,hcl'
p4626
(F1
F0.00076452599388379206
I0
I1
I-1
tp4627
sS'stem-and,leaf,saponins'
p4628
(F1
F0.0015290519877675841
I0
I2
I-2
tp4629
sS'anti-vitamin,k,activity'
p4630
(F1
F0.00076452599388379206
I1
I0
I1
tp4631
sS'vesicare,when,administered'
p4632
(F1
F0.00076452599388379206
I1
I0
I1
tp4633
sS'renal,excretion,of'
p4634
(F1
F0.0015290519877675841
I0
I2
I-2
tp4635
sS'laboratory,tests,there'
p4636
(F1
F0.00076452599388379206
I0
I1
I-1
tp4637
sS'in,monkeys,rendered'
p4638
(F1
F0.00076452599388379206
I0
I1
I-1
tp4639
sS'especially,true,if'
p4640
(F1
F0.00076452599388379206
I0
I1
I-1
tp4641
sS'neuromuscular,block,may'
p4642
(F1
F0.00076452599388379206
I1
I0
I1
tp4643
sS'risk,of,bleeding'
p4644
(F1
F0.0022935779816513763
I3
I0
I3
tp4645
sS'of,ml,of'
p4646
(F1
F0.00076452599388379206
I0
I1
I-1
tp4647
sS'for,patients,receiving'
p4648
(F1
F0.0015290519877675841
I2
I0
I2
tp4649
sS'in,two,controlled'
p4650
(F1
F0.00076452599388379206
I0
I1
I-1
tp4651
sS'in,departments,of'
p4652
(F1
F0.00076452599388379206
I0
I1
I-1
tp4653
sS'effect,decreased,renal'
p4654
(F1
F0.0015290519877675841
I0
I2
I-2
tp4655
sS'conditioned,with,spent'
p4656
(F1
F0.00076452599388379206
I0
I1
I-1
tp4657
sS'plasma,levels,nonsteroidal'
p4658
(F1
F0.00076452599388379206
I1
I0
I1
tp4659
sS'hypoglycemic,agents,blood'
p4660
(F1
F0.00076452599388379206
I1
I0
I1
tp4661
sS'were,reduced,approximately'
p4662
(F1
F0.00076452599388379206
I1
I0
I1
tp4663
sS'close,medical,supervision'
p4664
(F1
F0.00076452599388379206
I1
I0
I1
tp4665
sS'is,the,standard'
p4666
(F1
F0.00076452599388379206
I0
I1
I-1
tp4667
sS'effect,of,mg'
p4668
(F1
F0.0015290519877675841
I0
I2
I-2
tp4669
sS'exposure,at,mg'
p4670
(F1
F0.0030581039755351682
I0
I4
I-4
tp4671
sS'adrenal,cortical,steroids'
p4672
(F1
F0.00076452599388379206
I0
I1
I-1
tp4673
sS'releases,catecholamines,in'
p4674
(F1
F0.00076452599388379206
I1
I0
I1
tp4675
sS'or,did,not'
p4676
(F1
F0.00076452599388379206
I0
I1
I-1
tp4677
sS'and,other,anticholinergic'
p4678
(F1
F0.00076452599388379206
I1
I0
I1
tp4679
sS'from,plasma,protein-binding'
p4680
(F1
F0.00076452599388379206
I1
I0
I1
tp4681
sS'sulfonamides,can,also'
p4682
(F1
F0.00076452599388379206
I1
I0
I1
tp4683
sS'anticoagulant,effect,of'
p4684
(F1
F0.0015290519877675841
I0
I2
I-2
tp4685
sS'tetrahydropyridine,mptp,x'
p4686
(F1
F0.00076452599388379206
I0
I1
I-1
tp4687
sS'was,comparable,with'
p4688
(F1
F0.00076452599388379206
I0
I1
I-1
tp4689
sS'ephedrine,enhances,the'
p4690
(F1
F0.00076452599388379206
I1
I0
I1
tp4691
sS'in,the,kinetics'
p4692
(F1
F0.00076452599388379206
I0
I1
I-1
tp4693
sS'component,in,the'
p4694
(F1
F0.00076452599388379206
I1
I0
I1
tp4695
sS'metabolism,of,by'
p4696
(F1
F0.00076452599388379206
I1
I0
I1
tp4697
sS'sought,to,evaluate'
p4698
(F1
F0.00076452599388379206
I0
I1
I-1
tp4699
sS'that,may,interfere'
p4700
(F1
F0.00076452599388379206
I1
I0
I1
tp4701
sS'may,decrease,plasma'
p4702
(F1
F0.00076452599388379206
I1
I0
I1
tp4703
sS'affect,the,metabolism'
p4704
(F1
F0.00076452599388379206
I0
I1
I-1
tp4705
sS'growth,and,induced'
p4706
(F1
F0.00076452599388379206
I1
I0
I1
tp4707
sS'neurotoxin,methyl-4,phenyl-1'
p4708
(F1
F0.00076452599388379206
I0
I1
I-1
tp4709
sS'metopirone,inhibits,the'
p4710
(F1
F0.00076452599388379206
I1
I0
I1
tp4711
sS'effect,of,ketoconazole-mediated'
p4712
(F1
F0.00076452599388379206
I0
I1
I-1
tp4713
sS'oral,is,increased'
p4714
(F1
F0.00076452599388379206
I1
I0
I1
tp4715
sS'is,recommended,when'
p4716
(F1
F0.0015290519877675841
I2
I0
I2
tp4717
sS'model,is,not'
p4718
(F1
F0.00076452599388379206
I1
I0
I1
tp4719
sS'the,isoform-specific,cyp'
p4720
(F1
F0.00076452599388379206
I0
I1
I-1
tp4721
sS'of,sanctura,and'
p4722
(F1
F0.00076452599388379206
I0
I1
I-1
tp4723
sS'dose,of,demonstrated'
p4724
(F1
F0.00076452599388379206
I1
I0
I1
tp4725
sS'nick-end,labeling,tunel'
p4726
(F1
F0.00076452599388379206
I0
I1
I-1
tp4727
sS'of,demonstrated,that'
p4728
(F1
F0.00076452599388379206
I1
I0
I1
tp4729
sS'serotonin,reuptake,inhibitors'
p4730
(F0.33333333333333331
F0.00076452599388379206
I2
I1
I1
tp4731
sS'acetyl-l,carnitine,elicits'
p4732
(F1
F0.00076452599388379206
I1
I0
I1
tp4733
sS'of,on,gastrointestinal'
p4734
(F1
F0.00076452599388379206
I1
I0
I1
tp4735
sS'chronic,use,on'
p4736
(F1
F0.00076452599388379206
I0
I1
I-1
tp4737
sS'once,daily,dosed'
p4738
(F1
F0.00076452599388379206
I0
I1
I-1
tp4739
sS'reported,in,a'
p4740
(F1
F0.00076452599388379206
I1
I0
I1
tp4741
sS'was,given,twice'
p4742
(F1
F0.0015290519877675841
I0
I2
I-2
tp4743
sS'by,concurrent,administration'
p4744
(F0
F0
I1
I1
I0
tp4745
sS'significantly,increased,the'
p4746
(F1
F0.0015290519877675841
I2
I0
I2
tp4747
sS'pyridine,or,vehicle'
p4748
(F1
F0.00076452599388379206
I0
I1
I-1
tp4749
sS'detrol,la,is'
p4750
(F1
F0.00076452599388379206
I1
I0
I1
tp4751
sS'slightly,shorter,durations'
p4752
(F1
F0.00076452599388379206
I1
I0
I1
tp4753
sS'glucose,concentrations,should'
p4754
(F1
F0.00076452599388379206
I1
I0
I1
tp4755
sS'level,of,anesthesia'
p4756
(F1
F0.00076452599388379206
I1
I0
I1
tp4757
sS'the,safety,and'
p4758
(F1
F0.00076452599388379206
I0
I1
I-1
tp4759
sS'when,megestrol,acetate'
p4760
(F1
F0.00076452599388379206
I0
I1
I-1
tp4761
sS'inhibitors,ssris,have'
p4762
(F1
F0.00076452599388379206
I1
I0
I1
tp4763
sS'severe,agitation,and'
p4764
(F1
F0.00076452599388379206
I1
I0
I1
tp4765
sS'antagonize,the,effects'
p4766
(F1
F0.0022935779816513763
I3
I0
I3
tp4767
sS'media,and,in'
p4768
(F1
F0.00076452599388379206
I1
I0
I1
tp4769
sS'increase,seizure,activity'
p4770
(F1
F0.00076452599388379206
I1
I0
I1
tp4771
sS'as,other,thiazide-like'
p4772
(F1
F0.00076452599388379206
I1
I0
I1
tp4773
sS'do,not,exceed'
p4774
(F1
F0.00076452599388379206
I1
I0
I1
tp4775
sS'apoptosis,and,furthermore'
p4776
(F1
F0.00076452599388379206
I1
I0
I1
tp4777
sS'medication,tell,your'
p4778
(F1
F0.00076452599388379206
I0
I1
I-1
tp4779
sS'on,induced,antinociception'
p4780
(F1
F0.00076452599388379206
I0
I1
I-1
tp4781
sS'but,the,use'
p4782
(F1
F0.00076452599388379206
I1
I0
I1
tp4783
sS'of,diflucan,with'
p4784
(F1
F0.00076452599388379206
I1
I0
I1
tp4785
sS'patients,when,and'
p4786
(F1
F0.00076452599388379206
I1
I0
I1
tp4787
sS'anticholinesterases,concurrent,use'
p4788
(F1
F0.00076452599388379206
I1
I0
I1
tp4789
sS'further,increase,in'
p4790
(F1
F0.00076452599388379206
I0
I1
I-1
tp4791
sS'in,vitro,p450'
p4792
(F1
F0.00076452599388379206
I0
I1
I-1
tp4793
sS'coma,and,death'
p4794
(F1
F0.00076452599388379206
I1
I0
I1
tp4795
sS'in,association,with'
p4796
(F0.33333333333333331
F0.00076452599388379206
I2
I1
I1
tp4797
sS'drugs,or,with'
p4798
(F1
F0.00076452599388379206
I1
I0
I1
tp4799
sS'of,the,retinal'
p4800
(F1
F0.00076452599388379206
I0
I1
I-1
tp4801
sS'of,are,depressed'
p4802
(F1
F0.00076452599388379206
I1
I0
I1
tp4803
sS'clearance,in,a'
p4804
(F1
F0.00076452599388379206
I1
I0
I1
tp4805
sS'an,interaction,with'
p4806
(F1
F0.00076452599388379206
I0
I1
I-1
tp4807
sS'metabolized,by,the'
p4808
(F1
F0.0015290519877675841
I2
I0
I2
tp4809
sS'aminoglutethimide,administered,concomitantly'
p4810
(F1
F0.00076452599388379206
I1
I0
I1
tp4811
sS'and,hence,the'
p4812
(F1
F0.00076452599388379206
I0
I1
I-1
tp4813
sS'impact,on,hot'
p4814
(F1
F0.00076452599388379206
I0
I1
I-1
tp4815
sS'with,intramuscular,or'
p4816
(F1
F0.00076452599388379206
I1
I0
I1
tp4817
sS'azole-type,antifungal,agents'
p4818
(F1
F0.00076452599388379206
I1
I0
I1
tp4819
sS'hormone,control,by'
p4820
(F1
F0.00076452599388379206
I0
I1
I-1
tp4821
sS'reduce,the,plasma'
p4822
(F1
F0.00076452599388379206
I1
I0
I1
tp4823
sS'presence,of,increased'
p4824
(F1
F0.00076452599388379206
I1
I0
I1
tp4825
sS'the,evidence,for'
p4826
(F1
F0.00076452599388379206
I1
I0
I1
tp4827
sS'oral,contraceptives,in'
p4828
(F1
F0.0015290519877675841
I0
I2
I-2
tp4829
sS'interactions,that,may'
p4830
(F1
F0.00076452599388379206
I0
I1
I-1
tp4831
sS'inhibitors,other,potassium'
p4832
(F1
F0.00076452599388379206
I1
I0
I1
tp4833
sS'containing,hydroxide,hydroxide'
p4834
(F1
F0.00076452599388379206
I0
I1
I-1
tp4835
sS'incidence,of,adverse'
p4836
(F1
F0.00076452599388379206
I1
I0
I1
tp4837
sS'receiving,diflucan,and'
p4838
(F1
F0.0022935779816513763
I3
I0
I3
tp4839
sS'use,with,cholinomimetics'
p4840
(F1
F0.00076452599388379206
I1
I0
I1
tp4841
sS'clinical,and,self'
p4842
(F1
F0.00076452599388379206
I1
I0
I1
tp4843
sS'warfarin,anticoagulant,activity'
p4844
(F1
F0.00076452599388379206
I1
I0
I1
tp4845
sS'will,influence,the'
p4846
(F1
F0.00076452599388379206
I1
I0
I1
tp4847
sS'in,adolescent,male'
p4848
(F1
F0.00076452599388379206
I0
I1
I-1
tp4849
sS'effect,on,cmax'
p4850
(F1
F0.00076452599388379206
I1
I0
I1
tp4851
sS'in,cellular,glutathione'
p4852
(F1
F0.00076452599388379206
I0
I1
I-1
tp4853
sS'pain,without,causing'
p4854
(F1
F0.00076452599388379206
I1
I0
I1
tp4855
sS'to,an,increase'
p4856
(F1
F0.00076452599388379206
I1
I0
I1
tp4857
sS'a,formal,single-dose'
p4858
(F1
F0.00076452599388379206
I1
I0
I1
tp4859
sS'for,days,did'
p4860
(F1
F0.0022935779816513763
I0
I3
I-3
tp4861
sS'monitoring,when,potent'
p4862
(F1
F0.0015290519877675841
I2
I0
I2
tp4863
sS'those,receiving,indicating'
p4864
(F1
F0.00076452599388379206
I0
I1
I-1
tp4865
sS'significantly,alter,the'
p4866
(F1
F0.00076452599388379206
I0
I1
I-1
tp4867
sS'exercised,if,pergolide'
p4868
(F1
F0.00076452599388379206
I0
I1
I-1
tp4869
sS'and,neulasta,should'
p4870
(F1
F0.00076452599388379206
I1
I0
I1
tp4871
sS'may,also,affect'
p4872
(F1
F0.00076452599388379206
I1
I0
I1
tp4873
sS'demser,with,or'
p4874
(F1
F0.00076452599388379206
I1
I0
I1
tp4875
sS'but,concomitant,administration'
p4876
(F1
F0.00076452599388379206
I1
I0
I1
tp4877
sS'induce,metabolism,and'
p4878
(F1
F0.00076452599388379206
I1
I0
I1
tp4879
sS'vma,vanillylmandelic,acid'
p4880
(F1
F0.00076452599388379206
I0
I1
I-1
tp4881
sS'cause,orthostatic,hypotension'
p4882
(F1
F0.00076452599388379206
I1
I0
I1
tp4883
sS'with,drugs,beta'
p4884
(F1
F0.00076452599388379206
I0
I1
I-1
tp4885
sS'causing,cns,effects'
p4886
(F1
F0.00076452599388379206
I1
I0
I1
tp4887
sS'the,study,population'
p4888
(F1
F0.00076452599388379206
I1
I0
I1
tp4889
sS'with,post-mortem,stereological'
p4890
(F1
F0.00076452599388379206
I1
I0
I1
tp4891
sS'patients,n,than'
p4892
(F1
F0.00076452599388379206
I1
I0
I1
tp4893
sS'decreases,the,elimination'
p4894
(F1
F0.00076452599388379206
I1
I0
I1
tp4895
sS'used,with,great'
p4896
(F1
F0.00076452599388379206
I1
I0
I1
tp4897
sS'vaccines,should,be'
p4898
(F1
F0.00076452599388379206
I1
I0
I1
tp4899
sS'patients,on,treatment'
p4900
(F1
F0.00076452599388379206
I1
I0
I1
tp4901
sS'vitamins,such,as'
p4902
(F1
F0.00076452599388379206
I1
I0
I1
tp4903
sS'may,potentiate,the'
p4904
(F1
F0.0022935779816513763
I3
I0
I3
tp4905
sS'alter,the,clearance'
p4906
(F1
F0.00076452599388379206
I1
I0
I1
tp4907
sS'pt,and,inr'
p4908
(F1
F0.00076452599388379206
I1
I0
I1
tp4909
sS'during,administration,of'
p4910
(F1
F0.00076452599388379206
I1
I0
I1
tp4911
sS'mexitil,if,mexitil'
p4912
(F1
F0.00076452599388379206
I1
I0
I1
tp4913
sS'carnitine,elicits,a'
p4914
(F1
F0.00076452599388379206
I1
I0
I1
tp4915
sS'known,to,affect'
p4916
(F1
F0.00076452599388379206
I0
I1
I-1
tp4917
sS'montelukast,at,a'
p4918
(F1
F0.00076452599388379206
I0
I1
I-1
tp4919
sS'presence,of,there'
p4920
(F1
F0.00076452599388379206
I1
I0
I1
tp4921
sS'with,regular,nph'
p4922
(F1
F0.00076452599388379206
I1
I0
I1
tp4923
sS'not,produce,a'
p4924
(F1
F0.00076452599388379206
I1
I0
I1
tp4925
sS'be,expected,to'
p4926
(F0.33333333333333331
F0.00076452599388379206
I1
I2
I-1
tp4927
sS'to,although,this'
p4928
(F1
F0.00076452599388379206
I0
I1
I-1
tp4929
sS'content,hplc,and'
p4930
(F1
F0.00076452599388379206
I0
I1
I-1
tp4931
sS'group,drugs,being'
p4932
(F1
F0.00076452599388379206
I0
I1
I-1
tp4933
sS'by,when,coadministered'
p4934
(F1
F0.00076452599388379206
I1
I0
I1
tp4935
sS'no,adverse,effect'
p4936
(F1
F0.00076452599388379206
I0
I1
I-1
tp4937
sS'of,with,ferrous'
p4938
(F1
F0.00076452599388379206
I1
I0
I1
tp4939
sS'drug,interactions,there'
p4940
(F1
F0.00076452599388379206
I1
I0
I1
tp4941
sS'there,is,a'
p4942
(F1
F0.00076452599388379206
I1
I0
I1
tp4943
sS'paclitaxel-induced,apoptosis,by'
p4944
(F1
F0.00076452599388379206
I1
I0
I1
tp4945
sS'auc,to,s'
p4946
(F1
F0.00076452599388379206
I1
I0
I1
tp4947
sS'drug,uptake,cellular'
p4948
(F1
F0.00076452599388379206
I0
I1
I-1
tp4949
sS'systemic,or,topical'
p4950
(F1
F0.00076452599388379206
I0
I1
I-1
tp4951
sS'study,published,in'
p4952
(F1
F0.00076452599388379206
I1
I0
I1
tp4953
sS'that,is,a'
p4954
(F1
F0.00076452599388379206
I1
I0
I1
tp4955
sS'depressants,can,increase'
p4956
(F1
F0.00076452599388379206
I1
I0
I1
tp4957
sS'already,receiving,treatment'
p4958
(F1
F0.00076452599388379206
I1
I0
I1
tp4959
sS'in,ethinyl,estradiol'
p4960
(F1
F0.00076452599388379206
I1
I0
I1
tp4961
sS'until,blood,pressure'
p4962
(F1
F0.00076452599388379206
I1
I0
I1
tp4963
sS'when,initiating,adjusting'
p4964
(F1
F0.00076452599388379206
I1
I0
I1
tp4965
sS'in,prothrombin,time'
p4966
(F1
F0.00076452599388379206
I1
I0
I1
tp4967
sS'neurons,was,found'
p4968
(F1
F0.00076452599388379206
I1
I0
I1
tp4969
sS'receiving,and,concomitantly'
p4970
(F1
F0.0015290519877675841
I2
I0
I2
tp4971
sS'the,alkyating,agent'
p4972
(F1
F0.00076452599388379206
I0
I1
I-1
tp4973
sS'tacrolimus,short-acting,benzodiazepines'
p4974
(F1
F0.00076452599388379206
I1
I0
I1
tp4975
sS'tablets,but,an'
p4976
(F1
F0.00076452599388379206
I1
I0
I1
tp4977
sS'also,found,that'
p4978
(F1
F0.00076452599388379206
I1
I0
I1
tp4979
sS'the,effect-time,curves'
p4980
(F1
F0.00076452599388379206
I0
I1
I-1
tp4981
sS'context,compared,with'
p4982
(F1
F0.00076452599388379206
I0
I1
I-1
tp4983
sS'alter,serum,levels'
p4984
(F1
F0.00076452599388379206
I1
I0
I1
tp4985
sS'influence,the,effect'
p4986
(F1
F0.00076452599388379206
I0
I1
I-1
tp4987
sS'drug-paired,context,compared'
p4988
(F1
F0.00076452599388379206
I0
I1
I-1
tp4989
sS'fluconazole,tablets,coadministered'
p4990
(F1
F0.00076452599388379206
I1
I0
I1
tp4991
sS'risk,of,toxicity'
p4992
(F1
F0.0022935779816513763
I3
I0
I3
tp4993
sS'with,traditional,therapy'
p4994
(F1
F0.00076452599388379206
I1
I0
I1
tp4995
sS'may,significantly,decrease'
p4996
(F1
F0.00076452599388379206
I1
I0
I1
tp4997
sS'ratio,inr,were'
p4998
(F1
F0.00076452599388379206
I1
I0
I1
tp4999
sS'concomitantly,administered,medication'
p5000
(F1
F0.00076452599388379206
I1
I0
I1
tp5001
sS'not,be,coadministered'
p5002
(F1
F0.00076452599388379206
I1
I0
I1
tp5003
sS'inhibitor,in,a'
p5004
(F1
F0.00076452599388379206
I0
I1
I-1
tp5005
sS'in,chickens,intramuscularly'
p5006
(F1
F0.00076452599388379206
I0
I1
I-1
tp5007
sS'interaction,with,significant'
p5008
(F1
F0.00076452599388379206
I1
I0
I1
tp5009
sS'exhibits,some,monoamine'
p5010
(F1
F0.00076452599388379206
I1
I0
I1
tp5011
sS'exposure,when,coadministered'
p5012
(F1
F0.00076452599388379206
I0
I1
I-1
tp5013
sS'be,hazardous,when'
p5014
(F1
F0.00076452599388379206
I1
I0
I1
tp5015
sS'metabolizing,enzyme,cyp3a4'
p5016
(F1
F0.00076452599388379206
I1
I0
I1
tp5017
sS'metabolism,of,and'
p5018
(F1
F0.0022935779816513763
I3
I0
I3
tp5019
sS'for,pheochromocytoma,by'
p5020
(F1
F0.00076452599388379206
I0
I1
I-1
tp5021
sS'with,longer,half-lives'
p5022
(F1
F0.00076452599388379206
I1
I0
I1
tp5023
sS'prothrombin,time,pt'
p5024
(F1
F0.0015290519877675841
I2
I0
I2
tp5025
sS'concluded,that,the'
p5026
(F1
F0.00076452599388379206
I1
I0
I1
tp5027
sS'of,a,clinically-relevant'
p5028
(F1
F0.00076452599388379206
I0
I1
I-1
tp5029
sS'strong,cyp3a4,inhibitor'
p5030
(F1
F0.00076452599388379206
I1
I0
I1
tp5031
sS'this,study,aimed'
p5032
(F1
F0.00076452599388379206
I0
I1
I-1
tp5033
sS'reduce,the,efficacy'
p5034
(F1
F0.00076452599388379206
I1
I0
I1
tp5035
sS'and,in,combination'
p5036
(F1
F0.00076452599388379206
I0
I1
I-1
tp5037
sS'anticoagulants,prolongation,of'
p5038
(F1
F0.00076452599388379206
I1
I0
I1
tp5039
sS'and,effectiveness,of'
p5040
(F1
F0.00076452599388379206
I0
I1
I-1
tp5041
sS'that,plasma,levels'
p5042
(F1
F0.00076452599388379206
I1
I0
I1
tp5043
sS'serum,because,it'
p5044
(F1
F0.00076452599388379206
I0
I1
I-1
tp5045
sS'are,to,be'
p5046
(F1
F0.00076452599388379206
I1
I0
I1
tp5047
sS'maintenance,with,diprivan'
p5048
(F1
F0.00076452599388379206
I0
I1
I-1
tp5049
sS'proamatine,potential,for'
p5050
(F1
F0.00076452599388379206
I1
I0
I1
tp5051
sS'on,the,vascular'
p5052
(F1
F0.00076452599388379206
I1
I0
I1
tp5053
sS'enzymes,would,be'
p5054
(F1
F0.00076452599388379206
I0
I1
I-1
tp5055
sS'analysis,suggests,that'
p5056
(F0
F0
I1
I1
I0
tp5057
sS'p,but,its'
p5058
(F1
F0.00076452599388379206
I0
I1
I-1
tp5059
sS'to,have,a'
p5060
(F1
F0.00076452599388379206
I0
I1
I-1
tp5061
sS'control,was,minutes'
p5062
(F1
F0.00076452599388379206
I0
I1
I-1
tp5063
sS'cancer,by,up-regulation'
p5064
(F1
F0.00076452599388379206
I0
I1
I-1
tp5065
sS'suxamethonium,chloride,concurrent'
p5066
(F1
F0.00076452599388379206
I1
I0
I1
tp5067
sS'nonsteroidal,anti-inflammatory,agents'
p5068
(F1
F0.00076452599388379206
I1
I0
I1
tp5069
sS'when,metrogel,gel'
p5070
(F1
F0.00076452599388379206
I0
I1
I-1
tp5071
sS'system,depressants,meperidine'
p5072
(F1
F0.00076452599388379206
I1
I0
I1
tp5073
sS'hmg-coa,reductase,inhibitors'
p5074
(F1
F0.0015290519877675841
I0
I2
I-2
tp5075
sS'drug,adamantyl,hexamethylenimine'
p5076
(F1
F0.00076452599388379206
I0
I1
I-1
tp5077
sS'theophylline,theophylline,clearance'
p5078
(F1
F0.00076452599388379206
I0
I1
I-1
tp5079
sS'p450,a4,inhibitors'
p5080
(F1
F0.00076452599388379206
I1
I0
I1
tp5081
sS'reduction,in,in-vivo'
p5082
(F1
F0.00076452599388379206
I1
I0
I1
tp5083
sS'certain,heart,medicines'
p5084
(F1
F0.00076452599388379206
I1
I0
I1
tp5085
sS'has,shown,antitumor'
p5086
(F1
F0.00076452599388379206
I0
I1
I-1
tp5087
sS'altered,when,mixed'
p5088
(F1
F0.00076452599388379206
I1
I0
I1
tp5089
sS'the,dosage,of'
p5090
(F0.33333333333333331
F0.00076452599388379206
I2
I1
I1
tp5091
sS'oral,has,been'
p5092
(F1
F0.00076452599388379206
I1
I0
I1
tp5093
sS'reported,confusion,disorientation'
p5094
(F1
F0.00076452599388379206
I1
I0
I1
tp5095
sS'decrease,in,plasma'
p5096
(F0.33333333333333331
F0.00076452599388379206
I2
I1
I1
tp5097
sS'h,before,test'
p5098
(F1
F0.00076452599388379206
I0
I1
I-1
tp5099
sS'agents,that,produce'
p5100
(F1
F0.00076452599388379206
I1
I0
I1
tp5101
sS'constipation,which,may'
p5102
(F1
F0.00076452599388379206
I1
I0
I1
tp5103
sS'or,sequential,systemic'
p5104
(F1
F0.00076452599388379206
I0
I1
I-1
tp5105
sS'have,clinically,important'
p5106
(F1
F0.00076452599388379206
I0
I1
I-1
tp5107
sS'effect,of,exelon'
p5108
(F1
F0.00076452599388379206
I0
I1
I-1
tp5109
sS'receiving,can,result'
p5110
(F1
F0.00076452599388379206
I1
I0
I1
tp5111
sS'certain,actions,or'
p5112
(F1
F0.00076452599388379206
I1
I0
I1
tp5113
sS'macrolides,clinical,drug'
p5114
(F1
F0.00076452599388379206
I1
I0
I1
tp5115
sS'levels,of,when'
p5116
(F1
F0.00076452599388379206
I1
I0
I1
tp5117
sS'of,bw,for'
p5118
(F1
F0.00076452599388379206
I0
I1
I-1
tp5119
sS'most,other,drugs'
p5120
(F1
F0.00076452599388379206
I0
I1
I-1
tp5121
sS'changes,of,qrs'
p5122
(F1
F0.00076452599388379206
I0
I1
I-1
tp5123
sS'in,a,decrease'
p5124
(F1
F0.00076452599388379206
I1
I0
I1
tp5125
sS'to,competition,for'
p5126
(F1
F0.00076452599388379206
I0
I1
I-1
tp5127
sS'in,the,rate'
p5128
(F1
F0.00076452599388379206
I0
I1
I-1
tp5129
sS'with,concurrent,use'
p5130
(F1
F0.0015290519877675841
I2
I0
I2
tp5131
sS'indicate,that,the'
p5132
(F0
F0
I1
I1
I0
tp5133
sS'or,should,not'
p5134
(F1
F0.00076452599388379206
I1
I0
I1
tp5135
sS'of,metabolism,in'
p5136
(F1
F0.00076452599388379206
I1
I0
I1
tp5137
sS'oxidase,inhibitors,mao-is'
p5138
(F1
F0.00076452599388379206
I0
I1
I-1
tp5139
sS'and,k-ras,mutation'
p5140
(F1
F0.00076452599388379206
I0
I1
I-1
tp5141
sS'by,is,not'
p5142
(F1
F0.00076452599388379206
I0
I1
I-1
tp5143
sS'dtic,and,alone'
p5144
(F1
F0.00076452599388379206
I0
I1
I-1
tp5145
sS'of,chemet,with'
p5146
(F1
F0.00076452599388379206
I1
I0
I1
tp5147
sS'interactions,associated,with'
p5148
(F1
F0.00076452599388379206
I0
I1
I-1
tp5149
sS'of,or,did'
p5150
(F1
F0.00076452599388379206
I0
I1
I-1
tp5151
sS'the,median,duration'
p5152
(F1
F0.00076452599388379206
I0
I1
I-1
tp5153
sS'requirement,in,patients'
p5154
(F1
F0.00076452599388379206
I0
I1
I-1
tp5155
sS'significantly,increased,and'
p5156
(F1
F0.00076452599388379206
I1
I0
I1
tp5157
sS'following,topical,application'
p5158
(F1
F0.0015290519877675841
I0
I2
I-2
tp5159
sS'exposure,to,oral'
p5160
(F1
F0.00076452599388379206
I1
I0
I1
tp5161
sS'of,transduction,into'
p5162
(F1
F0.00076452599388379206
I0
I1
I-1
tp5163
sS'rr,and,pr'
p5164
(F1
F0.00076452599388379206
I0
I1
I-1
tp5165
sS'a,test,for'
p5166
(F1
F0.00076452599388379206
I0
I1
I-1
tp5167
sS'not,recur,in'
p5168
(F1
F0.00076452599388379206
I0
I1
I-1
tp5169
sS'and,patients,should'
p5170
(F1
F0.00076452599388379206
I1
I0
I1
tp5171
sS'approximately,fold,higher'
p5172
(F1
F0.00076452599388379206
I1
I0
I1
tp5173
sS'but,not,in'
p5174
(F1
F0.0015290519877675841
I2
I0
I2
tp5175
sS'decreased,by,following'
p5176
(F1
F0.00076452599388379206
I1
I0
I1
tp5177
sS'in,a,pharmacokinetic'
p5178
(F0.33333333333333331
F0.00076452599388379206
I2
I1
I1
tp5179
sS'human,liver,microsomes'
p5180
(F1
F0.00076452599388379206
I0
I1
I-1
tp5181
sS'plasma,protein,binding'
p5182
(F1
F0.00076452599388379206
I0
I1
I-1
tp5183
sS'on,sensitivity,was'
p5184
(F1
F0.00076452599388379206
I0
I1
I-1
tp5185
sS'or,or,the'
p5186
(F0
F0
I1
I1
I0
tp5187
sS'adverse,effects,and'
p5188
(F1
F0.00076452599388379206
I1
I0
I1
tp5189
sS'from,adequate,drug-drug'
p5190
(F1
F0.00076452599388379206
I0
I1
I-1
tp5191
sS'two,hours,and'
p5192
(F1
F0.00076452599388379206
I1
I0
I1
tp5193
sS'as,with,other'
p5194
(F1
F0.0015290519877675841
I2
I0
I2
tp5195
sS'and,is,not'
p5196
(F0
F0
I1
I1
I0
tp5197
sS'should,be,carefully'
p5198
(F1
F0.0015290519877675841
I2
I0
I2
tp5199
sS'sanctura,has,the'
p5200
(F1
F0.00076452599388379206
I1
I0
I1
tp5201
sS'patients,treated,with'
p5202
(F1
F0.0022935779816513763
I3
I0
I3
tp5203
sS'when,administered,concomitantly'
p5204
(F1
F0.00076452599388379206
I1
I0
I1
tp5205
sS'of,anti-parkinsonian,drug'
p5206
(F1
F0.00076452599388379206
I0
I1
I-1
tp5207
sS'any,of,the'
p5208
(F1
F0.00076452599388379206
I0
I1
I-1
tp5209
sS'of,mg,bid'
p5210
(F1
F0.00076452599388379206
I1
I0
I1
tp5211
sS'effectiveness,such,as'
p5212
(F1
F0.00076452599388379206
I1
I0
I1
tp5213
sS'with,purpura,has'
p5214
(F1
F0.00076452599388379206
I0
I1
I-1
tp5215
sS'administered,to,patients'
p5216
(F0
F0
I1
I1
I0
tp5217
sS'failed,to,influence'
p5218
(F1
F0.00076452599388379206
I1
I0
I1
tp5219
sS'c,max,and'
p5220
(F1
F0.0022935779816513763
I3
I0
I3
tp5221
sS'monoamine,oxidase,mao'
p5222
(F1
F0.00076452599388379206
I0
I1
I-1
tp5223
sS'succinylcholine-facilitated,tracheal,intubation'
p5224
(F1
F0.00076452599388379206
I0
I1
I-1
tp5225
sS'using,a,shimadzu'
p5226
(F1
F0.00076452599388379206
I0
I1
I-1
tp5227
sS'effects,the,sequential'
p5228
(F1
F0.00076452599388379206
I1
I0
I1
tp5229
sS'knockdown,of,p27'
p5230
(F1
F0.00076452599388379206
I0
I1
I-1
tp5231
sS'n,and,to'
p5232
(F1
F0.00076452599388379206
I0
I1
I-1
tp5233
sS'steady-state,mycamine,compared'
p5234
(F1
F0.0015290519877675841
I2
I0
I2
tp5235
sS'onset,of,a'
p5236
(F1
F0.00076452599388379206
I1
I0
I1
tp5237
sS'a4,inhibitors,and'
p5238
(F1
F0.00076452599388379206
I1
I0
I1
tp5239
sS'auc,of,oral'
p5240
(F1
F0.0015290519877675841
I2
I0
I2
tp5241
sS'n,or,to'
p5242
(F1
F0.00076452599388379206
I0
I1
I-1
tp5243
sS'parameters,changes,of'
p5244
(F1
F0.00076452599388379206
I0
I1
I-1
tp5245
sS'concomitant,orally,administered'
p5246
(F1
F0.00076452599388379206
I1
I0
I1
tp5247
sS'histamine-like,flushing,and'
p5248
(F1
F0.00076452599388379206
I1
I0
I1
tp5249
sS'should,be,avoided'
p5250
(F0.33333333333333331
F0.00076452599388379206
I1
I2
I-1
tp5251
sS'inhospital,administration,of'
p5252
(F1
F0.00076452599388379206
I1
I0
I1
tp5253
sS'prescribed,medications,such'
p5254
(F1
F0.00076452599388379206
I0
I1
I-1
tp5255
sS'levels,be,monitored'
p5256
(F1
F0.00076452599388379206
I1
I0
I1
tp5257
sS'and,have,no'
p5258
(F1
F0.00076452599388379206
I0
I1
I-1
tp5259
sS'ischemia,and,or'
p5260
(F1
F0.00076452599388379206
I0
I1
I-1
tp5261
sS'inhibition,or,induction'
p5262
(F1
F0.00076452599388379206
I0
I1
I-1
tp5263
sS'limited,evidence,suggests'
p5264
(F1
F0.00076452599388379206
I1
I0
I1
tp5265
sS'days,did,not'
p5266
(F1
F0.0022935779816513763
I0
I3
I-3
tp5267
sS'conducted,in,mice'
p5268
(F1
F0.00076452599388379206
I0
I1
I-1
tp5269
sS'pharmacokinetic,disposition,of'
p5270
(F1
F0.00076452599388379206
I0
I1
I-1
tp5271
sS'to,sensitize,cells'
p5272
(F1
F0.00076452599388379206
I0
I1
I-1
tp5273
sS'dosing,for,at'
p5274
(F1
F0.00076452599388379206
I1
I0
I1
tp5275
sS'drug,interactions,the'
p5276
(F1
F0.00076452599388379206
I0
I1
I-1
tp5277
sS'i,or,should'
p5278
(F1
F0.00076452599388379206
I1
I0
I1
tp5279
sS'promoter,was,delivered'
p5280
(F1
F0.00076452599388379206
I0
I1
I-1
tp5281
sS'interactions,women,on'
p5282
(F1
F0.00076452599388379206
I1
I0
I1
tp5283
sS'inhibited,tumor,growth'
p5284
(F1
F0.00076452599388379206
I1
I0
I1
tp5285
sS'causes,a,reduction'
p5286
(F1
F0.00076452599388379206
I1
I0
I1
tp5287
sS'have,an,additive'
p5288
(F1
F0.0015290519877675841
I2
I0
I2
tp5289
sS'studies,have,been'
p5290
(F1
F0.0015290519877675841
I0
I2
I-2
tp5291
sS'be,expected,and'
p5292
(F1
F0.00076452599388379206
I1
I0
I1
tp5293
sS'capsules,and,other'
p5294
(F1
F0.00076452599388379206
I0
I1
I-1
tp5295
sS'given,orally,doses'
p5296
(F1
F0.00076452599388379206
I0
I1
I-1
tp5297
sS'to,or,pharmacokinetics'
p5298
(F1
F0.00076452599388379206
I0
I1
I-1
tp5299
sS'normal-weight,female,subjects'
p5300
(F1
F0.00076452599388379206
I0
I1
I-1
tp5301
sS'is,additive,with'
p5302
(F1
F0.00076452599388379206
I1
I0
I1
tp5303
sS'depressant,medications,concurrent'
p5304
(F1
F0.00076452599388379206
I1
I0
I1
tp5305
sS'function,such,as'
p5306
(F1
F0.0015290519877675841
I2
I0
I2
tp5307
sS'safely,following,succinylcholine-facilitated'
p5308
(F1
F0.00076452599388379206
I0
I1
I-1
tp5309
sS'performed,to,assess'
p5310
(F1
F0.00076452599388379206
I0
I1
I-1
tp5311
sS'total,intravenous,anesthesia'
p5312
(F1
F0.00076452599388379206
I0
I1
I-1
tp5313
sS'compared,with,a'
p5314
(F1
F0.00076452599388379206
I0
I1
I-1
tp5315
sS'amantadine,population,pharmacokinetic'
p5316
(F1
F0.00076452599388379206
I0
I1
I-1
tp5317
sS'reduced,by,compared'
p5318
(F1
F0.00076452599388379206
I1
I0
I1
tp5319
sS'which,corresponded,to'
p5320
(F1
F0.00076452599388379206
I0
I1
I-1
tp5321
sS'effects,of,and'
p5322
(F1
F0.0022935779816513763
I3
I0
I3
tp5323
sS'contraceptives,in,healthy'
p5324
(F1
F0.00076452599388379206
I0
I1
I-1
tp5325
sS'if,pergolide,mesylate'
p5326
(F1
F0.00076452599388379206
I0
I1
I-1
tp5327
sS'a,enzyme,care'
p5328
(F1
F0.00076452599388379206
I1
I0
I1
tp5329
sS'a,novel,combination'
p5330
(F1
F0.00076452599388379206
I1
I0
I1
tp5331
sS'due,to,competition'
p5332
(F1
F0.00076452599388379206
I0
I1
I-1
tp5333
sS'interaction,between,alimta'
p5334
(F1
F0.00076452599388379206
I1
I0
I1
tp5335
sS'and,mpag,concentrations'
p5336
(F1
F0.00076452599388379206
I0
I1
I-1
tp5337
sS'range,of,muscle'
p5338
(F1
F0.00076452599388379206
I0
I1
I-1
tp5339
sS'be,expected,with'
p5340
(F1
F0.00076452599388379206
I0
I1
I-1
tp5341
sS'receiving,other,local'
p5342
(F1
F0.00076452599388379206
I1
I0
I1
tp5343
sS'the,pressor,agent'
p5344
(F1
F0.00076452599388379206
I1
I0
I1
tp5345
sS'potential,to,decrease'
p5346
(F1
F0.00076452599388379206
I0
I1
I-1
tp5347
sS'compared,with,tacrolimus-treated'
p5348
(F1
F0.00076452599388379206
I0
I1
I-1
tp5349
sS'exelon,tartrate,on'
p5350
(F1
F0.00076452599388379206
I0
I1
I-1
tp5351
sS'vivo,cyp3a,activity'
p5352
(F1
F0.00076452599388379206
I0
I1
I-1
tp5353
sS'tests,when,compared'
p5354
(F1
F0.00076452599388379206
I1
I0
I1
tp5355
sS'in,the,breast'
p5356
(F1
F0.00076452599388379206
I1
I0
I1
tp5357
sS'and,induce,metabolism'
p5358
(F1
F0.00076452599388379206
I1
I0
I1
tp5359
sS'sirolimus,auc,was'
p5360
(F1
F0.00076452599388379206
I1
I0
I1
tp5361
sS'pth,by,is'
p5362
(F1
F0.00076452599388379206
I1
I0
I1
tp5363
sS'study,it,can'
p5364
(F1
F0.00076452599388379206
I1
I0
I1
tp5365
sS'proteins,caution,should'
p5366
(F1
F0.00076452599388379206
I0
I1
I-1
tp5367
sS'with,essential,hypertension'
p5368
(F1
F0.00076452599388379206
I1
I0
I1
tp5369
sS'probably,other,loop'
p5370
(F1
F0.00076452599388379206
I1
I0
I1
tp5371
sS'oral,administration,of'
p5372
(F0.33333333333333331
F0.0015290519877675841
I2
I4
I-2
tp5373
sS'to,increase,decrease'
p5374
(F1
F0.00076452599388379206
I1
I0
I1
tp5375
sS'proton,pump,inhibitors'
p5376
(F0.20000000000000001
F0.00076452599388379206
I2
I3
I-1
tp5377
sS'relevance,for,compounds'
p5378
(F1
F0.00076452599388379206
I0
I1
I-1
tp5379
sS'bone,marrow,transplant'
p5380
(F1
F0.00076452599388379206
I1
I0
I1
tp5381
sS'other,anticholinergic,pharmacological'
p5382
(F1
F0.00076452599388379206
I1
I0
I1
tp5383
sS'the,human,a375'
p5384
(F1
F0.00076452599388379206
I0
I1
I-1
tp5385
sS'low-dose,added,to'
p5386
(F1
F0.00076452599388379206
I1
I0
I1
tp5387
sS'a,calcineurin,inhibitor-free'
p5388
(F1
F0.00076452599388379206
I0
I1
I-1
tp5389
sS'have,received,or'
p5390
(F1
F0.00076452599388379206
I1
I0
I1
tp5391
sS'prothrombin,times,in'
p5392
(F1
F0.00076452599388379206
I1
I0
I1
tp5393
sS'to,disalcid,and'
p5394
(F1
F0.00076452599388379206
I1
I0
I1
tp5395
sS'in,these,subjects'
p5396
(F1
F0.00076452599388379206
I0
I1
I-1
tp5397
sS'kip1,decreased,dasatinib-'
p5398
(F1
F0.00076452599388379206
I0
I1
I-1
tp5399
sS'and,increased,hydroxy-'
p5400
(F1
F0.00076452599388379206
I1
I0
I1
tp5401
sS'one,renal,transplant'
p5402
(F1
F0.00076452599388379206
I1
I0
I1
tp5403
sS'constipation,somnolence,drowsiness'
p5404
(F1
F0.00076452599388379206
I1
I0
I1
tp5405
sS'patients,concurrently,taking'
p5406
(F1
F0.00076452599388379206
I1
I0
I1
tp5407
sS'auc0-,since,is'
p5408
(F1
F0.00076452599388379206
I1
I0
I1
tp5409
sS'following,all,incubation'
p5410
(F1
F0.00076452599388379206
I1
I0
I1
tp5411
sS'clinically,significant,inhibitory'
p5412
(F1
F0.00076452599388379206
I0
I1
I-1
tp5413
sS'and,international,normalized'
p5414
(F1
F0.00076452599388379206
I1
I0
I1
tp5415
sS'gavage,fertility,studies'
p5416
(F1
F0.00076452599388379206
I0
I1
I-1
tp5417
sS'not,in,vivo'
p5418
(F1
F0.00076452599388379206
I1
I0
I1
tp5419
sS'high,renal,clearance'
p5420
(F1
F0.00076452599388379206
I1
I0
I1
tp5421
sS'further,electrocardiographic,parameters'
p5422
(F1
F0.00076452599388379206
I0
I1
I-1
tp5423
sS'vaccinations,with,live'
p5424
(F1
F0.00076452599388379206
I1
I0
I1
tp5425
sS'tests,were,carried'
p5426
(F1
F0.00076452599388379206
I0
I1
I-1
tp5427
sS'in,blood,pressure'
p5428
(F1
F0.00076452599388379206
I0
I1
I-1
tp5429
sS'inhaled,other,anti-pseudomonal'
p5430
(F1
F0.00076452599388379206
I1
I0
I1
tp5431
sS'limits,the,use'
p5432
(F1
F0.00076452599388379206
I1
I0
I1
tp5433
sS'interactions,with,oral'
p5434
(F1
F0.00076452599388379206
I1
I0
I1
tp5435
sS'co-administration,with,mg'
p5436
(F1
F0.00076452599388379206
I0
I1
I-1
tp5437
sS'phenobarbital,which,induces'
p5438
(F1
F0.0015290519877675841
I0
I2
I-2
tp5439
sS'in,vivo,drug-drug'
p5440
(F1
F0.0015290519877675841
I0
I2
I-2
tp5441
sS'antianginal,and,drugs'
p5442
(F1
F0.00076452599388379206
I0
I1
I-1
tp5443
sS'drugs,were,tested'
p5444
(F1
F0.00076452599388379206
I1
I0
I1
tp5445
sS'hcl,and,other'
p5446
(F1
F0.00076452599388379206
I1
I0
I1
tp5447
sS'patients,with,herceptin-refractory'
p5448
(F1
F0.00076452599388379206
I1
I0
I1
tp5449
sS'adrenergic,agonists,should'
p5450
(F1
F0.00076452599388379206
I1
I0
I1
tp5451
sS'effect,of,sympathomimetic'
p5452
(F1
F0.0015290519877675841
I2
I0
I2
tp5453
sS'appear,as,large'
p5454
(F1
F0.00076452599388379206
I0
I1
I-1
tp5455
sS'affect,elimination,because'
p5456
(F1
F0.00076452599388379206
I0
I1
I-1
tp5457
sS'has,also,been'
p5458
(F1
F0.00076452599388379206
I1
I0
I1
tp5459
sS'one,fatality,has'
p5460
(F1
F0.00076452599388379206
I1
I0
I1
tp5461
sS'complications,when,a'
p5462
(F1
F0.00076452599388379206
I1
I0
I1
tp5463
sS'to,use,of'
p5464
(F1
F0.00076452599388379206
I1
I0
I1
tp5465
sS'evista,and,has'
p5466
(F1
F0.00076452599388379206
I0
I1
I-1
tp5467
sS'can,cause,neurologic'
p5468
(F1
F0.00076452599388379206
I1
I0
I1
tp5469
sS'or,macrolide,eg'
p5470
(F1
F0.00076452599388379206
I1
I0
I1
tp5471
sS'however,in,patients'
p5472
(F1
F0.00076452599388379206
I1
I0
I1
tp5473
sS'time,in,patients'
p5474
(F1
F0.0038226299694189602
I5
I0
I5
tp5475
sS'the,control,of'
p5476
(F1
F0.00076452599388379206
I0
I1
I-1
tp5477
sS'with,consideration,should'
p5478
(F1
F0.00076452599388379206
I1
I0
I1
tp5479
sS'patients,with,essential'
p5480
(F1
F0.00076452599388379206
I1
I0
I1
tp5481
sS'leukemia,model,is'
p5482
(F1
F0.00076452599388379206
I1
I0
I1
tp5483
sS'digitalis,glycosides,diuretic-induced'
p5484
(F1
F0.00076452599388379206
I1
I0
I1
tp5485
sS'metabolism,of,resulting'
p5486
(F1
F0.00076452599388379206
I1
I0
I1
tp5487
sS'up,to,and'
p5488
(F1
F0.00076452599388379206
I0
I1
I-1
tp5489
sS'or,potentiate,the'
p5490
(F1
F0.0015290519877675841
I2
I0
I2
tp5491
sS'behavior,violations,in'
p5492
(F1
F0.00076452599388379206
I0
I1
I-1
tp5493
sS'previously,reported,that'
p5494
(F1
F0.00076452599388379206
I1
I0
I1
tp5495
sS'system,and,decreases'
p5496
(F1
F0.00076452599388379206
I1
I0
I1
tp5497
sS'used,when,evista'
p5498
(F1
F0.00076452599388379206
I1
I0
I1
tp5499
sS'contributing,to,the'
p5500
(F1
F0.00076452599388379206
I0
I1
I-1
tp5501
sS'on,platelet,reactivity'
p5502
(F0
F0
I1
I1
I0
tp5503
sS'lung,cancer,with'
p5504
(F1
F0.00076452599388379206
I1
I0
I1
tp5505
sS'at,least,two'
p5506
(F1
F0.00076452599388379206
I1
I0
I1
tp5507
sS'to,those,receiving'
p5508
(F1
F0.00076452599388379206
I0
I1
I-1
tp5509
sS'a,decreased,time'
p5510
(F1
F0.00076452599388379206
I1
I0
I1
tp5511
sS'by,the,volume'
p5512
(F1
F0.00076452599388379206
I0
I1
I-1
tp5513
sS'to,cause,clinically'
p5514
(F1
F0.00076452599388379206
I0
I1
I-1
tp5515
sS'sessions,during,which'
p5516
(F1
F0.00076452599388379206
I0
I1
I-1
tp5517
sS'of,high-dose,and'
p5518
(F1
F0.00076452599388379206
I1
I0
I1
tp5519
sS'signs,were,observed'
p5520
(F1
F0.00076452599388379206
I0
I1
I-1
tp5521
sS'of,blood,pressure'
p5522
(F1
F0.00076452599388379206
I1
I0
I1
tp5523
sS'mind,in,the'
p5524
(F1
F0.00076452599388379206
I1
I0
I1
tp5525
sS'and,potassium-sparing,diuretics'
p5526
(F1
F0.0015290519877675841
I0
I2
I-2
tp5527
sS'p,as,compared'
p5528
(F1
F0.00076452599388379206
I0
I1
I-1
tp5529
sS'thiabendazole,may,compete'
p5530
(F1
F0.00076452599388379206
I1
I0
I1
tp5531
sS'in,the,drug-paired'
p5532
(F1
F0.00076452599388379206
I0
I1
I-1
tp5533
sS'or,supplements,concomitantly'
p5534
(F1
F0.00076452599388379206
I1
I0
I1
tp5535
sS'considered,to,be'
p5536
(F1
F0.00076452599388379206
I1
I0
I1
tp5537
sS'not,likely,to'
p5538
(F1
F0.00076452599388379206
I0
I1
I-1
tp5539
sS'patients,there,were'
p5540
(F1
F0.00076452599388379206
I0
I1
I-1
tp5541
sS'shown,no,effect'
p5542
(F1
F0.00076452599388379206
I1
I0
I1
tp5543
sS'and,or,reduce'
p5544
(F1
F0.00076452599388379206
I1
I0
I1
tp5545
sS'is,effective,in'
p5546
(F1
F0.00076452599388379206
I0
I1
I-1
tp5547
sS'terfenadine,because,of'
p5548
(F1
F0.00076452599388379206
I1
I0
I1
tp5549
sS'and,vitamin,k'
p5550
(F1
F0.0015290519877675841
I2
I0
I2
tp5551
sS'that,are,substrates'
p5552
(F1
F0.00076452599388379206
I0
I1
I-1
tp5553
sS'for,patients,with'
p5554
(F1
F0.00076452599388379206
I1
I0
I1
tp5555
sS'secreted,by,the'
p5556
(F1
F0.00076452599388379206
I1
I0
I1
tp5557
sS'obstipation,even,ileus'
p5558
(F1
F0.00076452599388379206
I1
I0
I1
tp5559
sS'a,minimal,effect'
p5560
(F1
F0.0015290519877675841
I2
I0
I2
tp5561
sS'to,analyze,the'
p5562
(F1
F0.00076452599388379206
I0
I1
I-1
tp5563
sS'its,effect,on'
p5564
(F1
F0.00076452599388379206
I0
I1
I-1
tp5565
sS'shorter,time,with'
p5566
(F1
F0.00076452599388379206
I1
I0
I1
tp5567
sS'univasc,was,administered'
p5568
(F1
F0.00076452599388379206
I0
I1
I-1
tp5569
sS'emulsion,may,be'
p5570
(F1
F0.00076452599388379206
I1
I0
I1
tp5571
sS'have,been,associated'
p5572
(F1
F0.00076452599388379206
I1
I0
I1
tp5573
sS'either,tolectin,or'
p5574
(F1
F0.00076452599388379206
I0
I1
I-1
tp5575
sS'to,patients,with'
p5576
(F1
F0.00076452599388379206
I1
I0
I1
tp5577
sS'treatment,although,they'
p5578
(F1
F0.00076452599388379206
I0
I1
I-1
tp5579
sS'reported,to,prolong'
p5580
(F1
F0.00076452599388379206
I1
I0
I1
tp5581
sS'of,data,regarding'
p5582
(F1
F0.00076452599388379206
I1
I0
I1
tp5583
sS'lyase,greatly,enhanced'
p5584
(F1
F0.00076452599388379206
I0
I1
I-1
tp5585
sS'type,mao,inhibitors'
p5586
(F1
F0.00076452599388379206
I1
I0
I1
tp5587
sS'reductase,inhibitors,in'
p5588
(F1
F0.00076452599388379206
I0
I1
I-1
tp5589
sS'of,chronic,use'
p5590
(F1
F0.00076452599388379206
I0
I1
I-1
tp5591
sS'may,be,enhanced'
p5592
(F1
F0.0015290519877675841
I2
I0
I2
tp5593
sS'flushing,mydriasis,tachycardia'
p5594
(F1
F0.00076452599388379206
I1
I0
I1
tp5595
sS'toxicity,towards,dopaminergic'
p5596
(F1
F0.00076452599388379206
I1
I0
I1
tp5597
sS'a4,inhibitors,include'
p5598
(F1
F0.00076452599388379206
I0
I1
I-1
tp5599
sS'used,with,and'
p5600
(F1
F0.00076452599388379206
I0
I1
I-1
tp5601
sS'reported,to,result'
p5602
(F1
F0.00076452599388379206
I1
I0
I1
tp5603
sS'other,potassium,chloride'
p5604
(F1
F0.00076452599388379206
I1
I0
I1
tp5605
sS'until,recovery,from'
p5606
(F1
F0.00076452599388379206
I1
I0
I1
tp5607
sS'to,decreased,serum'
p5608
(F1
F0.0015290519877675841
I2
I0
I2
tp5609
sS'at,an,increased'
p5610
(F1
F0.00076452599388379206
I1
I0
I1
tp5611
sS'that,chronic,treatment'
p5612
(F1
F0.00076452599388379206
I1
I0
I1
tp5613
sS'due,to,urinary'
p5614
(F1
F0.00076452599388379206
I1
I0
I1
tp5615
sS'activities,in,a'
p5616
(F1
F0.00076452599388379206
I0
I1
I-1
tp5617
sS'been,reported,to'
p5618
(F1
F0.0068807339449541288
I9
I0
I9
tp5619
sS'significantly,modified,by'
p5620
(F1
F0.00076452599388379206
I0
I1
I-1
tp5621
sS'vitamin,k,is'
p5622
(F1
F0.00076452599388379206
I0
I1
I-1
tp5623
sS'thoracic,ribs,was'
p5624
(F1
F0.00076452599388379206
I0
I1
I-1
tp5625
sS'discontinuing,the,or'
p5626
(F1
F0.00076452599388379206
I1
I0
I1
tp5627
sS'the,hypotensive,effects'
p5628
(F1
F0.00076452599388379206
I0
I1
I-1
tp5629
sS'short-acting,benzodiazepines,following'
p5630
(F1
F0.00076452599388379206
I1
I0
I1
tp5631
sS'data,indicate,that'
p5632
(F1
F0.0022935779816513763
I3
I0
I3
tp5633
sS'studies,that,did'
p5634
(F1
F0.00076452599388379206
I1
I0
I1
tp5635
sS'of,food,to'
p5636
(F1
F0.00076452599388379206
I1
I0
I1
tp5637
sS'temperature,were,noted'
p5638
(F1
F0.00076452599388379206
I0
I1
I-1
tp5639
sS'theophylline,terfenadine,cisapride'
p5640
(F1
F0.00076452599388379206
I1
I0
I1
tp5641
sS'duration,of,action'
p5642
(F1
F0.0015290519877675841
I0
I2
I-2
tp5643
sS'the,agent,should'
p5644
(F1
F0.00076452599388379206
I1
I0
I1
tp5645
sS'impair,intestinal,absorption'
p5646
(F1
F0.00076452599388379206
I1
I0
I1
tp5647
sS'increase,in,overall'
p5648
(F1
F0.00076452599388379206
I1
I0
I1
tp5649
sS'mg,qid,did'
p5650
(F1
F0.00076452599388379206
I0
I1
I-1
tp5651
sS'patients,on,therapy'
p5652
(F1
F0.00076452599388379206
I0
I1
I-1
tp5653
sS'concentration,cmax,of'
p5654
(F1
F0.00076452599388379206
I1
I0
I1
tp5655
sS'sympathomimetic,drugs,antidepressant'
p5656
(F1
F0.00076452599388379206
I1
I0
I1
tp5657
sS'of,acetate,and'
p5658
(F1
F0.00076452599388379206
I0
I1
I-1
tp5659
sS'potential,interactions,concomitant'
p5660
(F1
F0.00076452599388379206
I1
I0
I1
tp5661
sS'and,concomitantly,should'
p5662
(F1
F0.0022935779816513763
I3
I0
I3
tp5663
sS'avoided,and,patients'
p5664
(F1
F0.00076452599388379206
I1
I0
I1
tp5665
sS'there,are,reports'
p5666
(F1
F0.0015290519877675841
I2
I0
I2
tp5667
sS'is,administered,following'
p5668
(F1
F0.00076452599388379206
I1
I0
I1
tp5669
sS'lithium,in,clinical'
p5670
(F1
F0.00076452599388379206
I1
I0
I1
tp5671
sS'including,general,other'
p5672
(F1
F0.00076452599388379206
I0
I1
I-1
tp5673
sS'day,females,times'
p5674
(F1
F0.00076452599388379206
I0
I1
I-1
tp5675
sS'vivo,biotransformation,of'
p5676
(F1
F0.00076452599388379206
I0
I1
I-1
tp5677
sS'to,women,treated'
p5678
(F1
F0.00076452599388379206
I1
I0
I1
tp5679
sS'inhibition,of,gastric'
p5680
(F1
F0.00076452599388379206
I1
I0
I1
tp5681
sS'diuretic-induced,hypokalemia,can'
p5682
(F1
F0.00076452599388379206
I1
I0
I1
tp5683
sS'with,herceptin-refractory,her2-positive'
p5684
(F1
F0.00076452599388379206
I1
I0
I1
tp5685
sS'in,breast,but'
p5686
(F1
F0.00076452599388379206
I1
I0
I1
tp5687
sS'effect,may,be'
p5688
(F1
F0.00076452599388379206
I1
I0
I1
tp5689
sS'dose,is,changed'
p5690
(F1
F0.00076452599388379206
I1
I0
I1
tp5691
sS'the,pharmacokinetic,and'
p5692
(F1
F0.00076452599388379206
I0
I1
I-1
tp5693
sS'by,injection,polymyxin'
p5694
(F1
F0.00076452599388379206
I0
I1
I-1
tp5695
sS'of,crm197,on'
p5696
(F1
F0.00076452599388379206
I0
I1
I-1
tp5697
sS'suspension,test,tst'
p5698
(F1
F0.00076452599388379206
I0
I1
I-1
tp5699
sS'of,their,bioavailability'
p5700
(F1
F0.00076452599388379206
I1
I0
I1
tp5701
sS'agents,simultaneous,use'
p5702
(F1
F0.00076452599388379206
I1
I0
I1
tp5703
sS'studies,between,tamsulosin'
p5704
(F1
F0.00076452599388379206
I0
I1
I-1
tp5705
sS'for,is,recommended'
p5706
(F1
F0.00076452599388379206
I1
I0
I1
tp5707
sS'that,could,elicit'
p5708
(F1
F0.00076452599388379206
I1
I0
I1
tp5709
sS'inhibits,some,of'
p5710
(F1
F0.00076452599388379206
I1
I0
I1
tp5711
sS'neonatal,treatment,enhanced'
p5712
(F1
F0.00076452599388379206
I1
I0
I1
tp5713
sS'or,drugs,that'
p5714
(F1
F0.00076452599388379206
I1
I0
I1
tp5715
sS'can,inhibit,the'
p5716
(F1
F0.00076452599388379206
I1
I0
I1
tp5717
sS'properties,of,were'
p5718
(F1
F0.00076452599388379206
I0
I1
I-1
tp5719
sS'with,univasc,can'
p5720
(F1
F0.00076452599388379206
I0
I1
I-1
tp5721
sS'aggrastat,in,combination'
p5722
(F1
F0.00076452599388379206
I1
I0
I1
tp5723
sS'of,the,side'
p5724
(F1
F0.0015290519877675841
I0
I2
I-2
tp5725
sS'enzymes,would,not'
p5726
(F1
F0.00076452599388379206
I0
I1
I-1
tp5727
sS'an,isolated,effect'
p5728
(F1
F0.00076452599388379206
I1
I0
I1
tp5729
sS'pergolide,mesylate,is'
p5730
(F1
F0.00076452599388379206
I0
I1
I-1
tp5731
sS'although,not,studied'
p5732
(F1
F0.00076452599388379206
I1
I0
I1
tp5733
sS'induces,hepatic,metabolism'
p5734
(F1
F0.0015290519877675841
I0
I2
I-2
tp5735
sS'of,or,ci'
p5736
(F1
F0.00076452599388379206
I1
I0
I1
tp5737
sS'seven,patients,the'
p5738
(F1
F0.00076452599388379206
I1
I0
I1
tp5739
sS'eg,or,or'
p5740
(F1
F0.00076452599388379206
I1
I0
I1
tp5741
sS'this,study,was'
p5742
(F1
F0.0022935779816513763
I0
I3
I-3
tp5743
sS'add,to,or'
p5744
(F1
F0.00076452599388379206
I1
I0
I1
tp5745
sS'therapy,for,several'
p5746
(F1
F0.00076452599388379206
I0
I1
I-1
tp5747
sS'and,lower,respectively'
p5748
(F1
F0.00076452599388379206
I1
I0
I1
tp5749
sS'dna,damage,of'
p5750
(F1
F0.00076452599388379206
I0
I1
I-1
tp5751
sS'and,dna,damage'
p5752
(F1
F0.00076452599388379206
I0
I1
I-1
tp5753
sS'the,plasma,concentration'
p5754
(F0.20000000000000001
F0.00076452599388379206
I3
I2
I1
tp5755
sS'inhibits,metabolism,and'
p5756
(F1
F0.00076452599388379206
I1
I0
I1
tp5757
sS'including,and,to'
p5758
(F1
F0.00076452599388379206
I1
I0
I1
tp5759
sS'creatinine,clearance,ml'
p5760
(F1
F0.00076452599388379206
I1
I0
I1
tp5761
sS'to,be,metabolized'
p5762
(F0
F0
I1
I1
I0
tp5763
sS'day,approximately,reduction'
p5764
(F1
F0.00076452599388379206
I0
I1
I-1
tp5765
sS'certain,given,by'
p5766
(F1
F0.00076452599388379206
I0
I1
I-1
tp5767
sS'seven,groups,n'
p5768
(F1
F0.00076452599388379206
I0
I1
I-1
tp5769
sS'accounts,of,qt'
p5770
(F1
F0.00076452599388379206
I0
I1
I-1
tp5771
sS'in,the,mean'
p5772
(F1
F0.00076452599388379206
I0
I1
I-1
tp5773
sS'anticholinergics,because,of'
p5774
(F1
F0.00076452599388379206
I1
I0
I1
tp5775
sS'been,shown,to'
p5776
(F0.5
F0.0015290519877675841
I3
I1
I2
tp5777
sS'salicylates,given,concomitantly'
p5778
(F1
F0.00076452599388379206
I1
I0
I1
tp5779
sS'or,should,be'
p5780
(F1
F0.00076452599388379206
I0
I1
I-1
tp5781
sS'competes,with,a'
p5782
(F1
F0.00076452599388379206
I1
I0
I1
tp5783
sS'and,vs,ml'
p5784
(F1
F0.00076452599388379206
I1
I0
I1
tp5785
sS'toxicity,has,been'
p5786
(F1
F0.00076452599388379206
I1
I0
I1
tp5787
sS'therapies,may,be'
p5788
(F1
F0.00076452599388379206
I1
I0
I1
tp5789
sS'common,clinical,dosage'
p5790
(F1
F0.00076452599388379206
I1
I0
I1
tp5791
sS'responses,to,inactivated'
p5792
(F1
F0.00076452599388379206
I0
I1
I-1
tp5793
sS'ketoconazole-mediated,cyp3a4,inhibition'
p5794
(F1
F0.00076452599388379206
I0
I1
I-1
tp5795
sS'five,different,cancer'
p5796
(F1
F0.00076452599388379206
I0
I1
I-1
tp5797
sS'in,one,renal'
p5798
(F1
F0.00076452599388379206
I1
I0
I1
tp5799
sS'are,significantly,lower'
p5800
(F1
F0.00076452599388379206
I0
I1
I-1
tp5801
sS'demonstrated,in,patients'
p5802
(F1
F0.00076452599388379206
I1
I0
I1
tp5803
sS'mg,daily,based'
p5804
(F1
F0.0030581039755351682
I0
I4
I-4
tp5805
sS'have,suggested,the'
p5806
(F1
F0.00076452599388379206
I1
I0
I1
tp5807
sS'may,require,increases'
p5808
(F1
F0.00076452599388379206
I1
I0
I1
tp5809
sS'crossover,study,of'
p5810
(F1
F0.00076452599388379206
I0
I1
I-1
tp5811
sS'treatment,with,nexavar'
p5812
(F1
F0.00076452599388379206
I1
I0
I1
tp5813
sS'of,and,resulting'
p5814
(F1
F0.00076452599388379206
I1
I0
I1
tp5815
sS'the,more,potent'
p5816
(F1
F0.00076452599388379206
I0
I1
I-1
tp5817
sS'at,a,dose'
p5818
(F1
F0.0015290519877675841
I0
I2
I-2
tp5819
sS'that,is,unlikely'
p5820
(F1
F0.00076452599388379206
I0
I1
I-1
tp5821
sS'co,administration,of'
p5822
(F1
F0.00076452599388379206
I1
I0
I1
tp5823
sS'as,determined,by'
p5824
(F1
F0.00076452599388379206
I0
I1
I-1
tp5825
sS'single,and,multiple'
p5826
(F1
F0.00076452599388379206
I0
I1
I-1
tp5827
sS'may,require,increased'
p5828
(F1
F0.00076452599388379206
I1
I0
I1
tp5829
sS'to,affect,invega'
p5830
(F1
F0.00076452599388379206
I0
I1
I-1
tp5831
sS'sodium,bicarbonate,to'
p5832
(F1
F0.00076452599388379206
I0
I1
I-1
tp5833
sS'for,compounds,predominantly'
p5834
(F1
F0.00076452599388379206
I0
I1
I-1
tp5835
sS'kg,and,group'
p5836
(F1
F0.00076452599388379206
I0
I1
I-1
tp5837
sS'plasma,bismuth,trough'
p5838
(F1
F0.00076452599388379206
I1
I0
I1
tp5839
sS'their,bioavailability,eg'
p5840
(F1
F0.00076452599388379206
I1
I0
I1
tp5841
sS'or,pt,and'
p5842
(F1
F0.00076452599388379206
I1
I0
I1
tp5843
sS'pharmacokinetic,data,indicate'
p5844
(F1
F0.00076452599388379206
I1
I0
I1
tp5845
sS'demonstrated,that,diflucan'
p5846
(F1
F0.00076452599388379206
I1
I0
I1
tp5847
sS'and,other,cholinesterase'
p5848
(F1
F0.00076452599388379206
I1
I0
I1
tp5849
sS'therefore,caution,should'
p5850
(F0.5
F0.0015290519877675841
I3
I1
I2
tp5851
sS'concealed,inefficacy,of'
p5852
(F1
F0.00076452599388379206
I1
I0
I1
tp5853
sS'may,decrease,bioavailability'
p5854
(F1
F0.00076452599388379206
I1
I0
I1
tp5855
sS'roles,of,p27'
p5856
(F1
F0.00076452599388379206
I0
I1
I-1
tp5857
sS'model,three,doses'
p5858
(F1
F0.00076452599388379206
I0
I1
I-1
tp5859
sS'univasc,can,increase'
p5860
(F1
F0.00076452599388379206
I0
I1
I-1
tp5861
sS'or,increasing,the'
p5862
(F1
F0.00076452599388379206
I1
I0
I1
tp5863
sS'of,versed,syrup'
p5864
(F1
F0.00076452599388379206
I1
I0
I1
tp5865
sS'in,pk,parameters'
p5866
(F1
F0.00076452599388379206
I0
I1
I-1
tp5867
sS'birth,control,pills'
p5868
(F0
F0
I1
I1
I0
tp5869
sS'thrombopenia,with,purpura'
p5870
(F1
F0.00076452599388379206
I0
I1
I-1
tp5871
sS'action,of,other'
p5872
(F1
F0.00076452599388379206
I1
I0
I1
tp5873
sS'cytochrome,p450,a4'
p5874
(F0.59999999999999998
F0.0022935779816513763
I4
I1
I3
tp5875
sS'cmax,in,the'
p5876
(F1
F0.00076452599388379206
I1
I0
I1
tp5877
sS'skin,of,healthy'
p5878
(F1
F0.00076452599388379206
I1
I0
I1
tp5879
sS'date,there,is'
p5880
(F1
F0.00076452599388379206
I0
I1
I-1
tp5881
sS'and,elevated,parent'
p5882
(F1
F0.00076452599388379206
I1
I0
I1
tp5883
sS'infant,with,confirmed'
p5884
(F1
F0.00076452599388379206
I1
I0
I1
tp5885
sS'may,cause,shortness'
p5886
(F1
F0.00076452599388379206
I1
I0
I1
tp5887
sS'increased,levels,and'
p5888
(F1
F0.00076452599388379206
I1
I0
I1
tp5889
sS'or,when,indicated'
p5890
(F1
F0.00076452599388379206
I0
I1
I-1
tp5891
sS'cyp3a4,isozymes,cytochrome'
p5892
(F1
F0.00076452599388379206
I1
I0
I1
tp5893
sS'methergine,maleate,is'
p5894
(F1
F0.00076452599388379206
I1
I0
I1
tp5895
sS'curariform,drugs,diuretic-induced'
p5896
(F1
F0.00076452599388379206
I1
I0
I1
tp5897
sS'in,human,ovarian'
p5898
(F1
F0.00076452599388379206
I1
I0
I1
tp5899
sS'should,interrupt,dosing'
p5900
(F1
F0.00076452599388379206
I1
I0
I1
tp5901
sS'available,from,adequate'
p5902
(F1
F0.00076452599388379206
I0
I1
I-1
tp5903
sS'to,reduce,the'
p5904
(F0.59999999999999998
F0.0022935779816513763
I4
I1
I3
tp5905
sS'target,inr,or'
p5906
(F1
F0.00076452599388379206
I1
I0
I1
tp5907
sS'is,advised,for'
p5908
(F1
F0.00076452599388379206
I1
I0
I1
tp5909
sS'other,potentially,neurotoxic'
p5910
(F1
F0.00076452599388379206
I0
I1
I-1
tp5911
sS'clearance,of,a'
p5912
(F1
F0.00076452599388379206
I1
I0
I1
tp5913
sS'and,skelid,are'
p5914
(F1
F0.00076452599388379206
I1
I0
I1
tp5915
sS'mitomycin-c,may,cause'
p5916
(F1
F0.00076452599388379206
I1
I0
I1
tp5917
sS'enzyme,system,drugs'
p5918
(F1
F0.00076452599388379206
I0
I1
I-1
tp5919
sS'in,hospitalized,patients'
p5920
(F1
F0.00076452599388379206
I0
I1
I-1
tp5921
sS'mg,kg,saline'
p5922
(F1
F0.00076452599388379206
I0
I1
I-1
tp5923
sS'fold,in,one'
p5924
(F1
F0.00076452599388379206
I1
I0
I1
tp5925
sS'vitro,rat,liver'
p5926
(F1
F0.00076452599388379206
I1
I0
I1
tp5927
sS'hot,flushes,linked'
p5928
(F1
F0.00076452599388379206
I0
I1
I-1
tp5929
sS'and,an,increased'
p5930
(F1
F0.0015290519877675841
I2
I0
I2
tp5931
sS'changing,mobic,therapy'
p5932
(F1
F0.00076452599388379206
I1
I0
I1
tp5933
sS'interactions,of,with'
p5934
(F1
F0.0015290519877675841
I0
I2
I-2
tp5935
sS'nexavar,with,compounds'
p5936
(F1
F0.00076452599388379206
I1
I0
I1
tp5937
sS'and,caused,a'
p5938
(F1
F0.00076452599388379206
I1
I0
I1
tp5939
sS'to,or,potentiate'
p5940
(F1
F0.00076452599388379206
I1
I0
I1
tp5941
sS'interaction,between,and'
p5942
(F0
F0
I2
I2
I0
tp5943
sS'hiv-protease,inhibitors,or'
p5944
(F1
F0.00076452599388379206
I0
I1
I-1
tp5945
sS'the,drug-paired,context'
p5946
(F1
F0.00076452599388379206
I0
I1
I-1
tp5947
sS'interaction,between,any'
p5948
(F1
F0.00076452599388379206
I0
I1
I-1
tp5949
sS'either,of,these'
p5950
(F1
F0.0015290519877675841
I0
I2
I-2
tp5951
sS'marrow,transplant,patients'
p5952
(F1
F0.00076452599388379206
I1
I0
I1
tp5953
sS'a5,a7,noradrenaline'
p5954
(F1
F0.00076452599388379206
I1
I0
I1
tp5955
sS'other,drugs,no'
p5956
(F1
F0.00076452599388379206
I0
I1
I-1
tp5957
sS'neonatal,enhanced,time'
p5958
(F1
F0.00076452599388379206
I0
I1
I-1
tp5959
sS'otherwise,contraindicated,should'
p5960
(F1
F0.00076452599388379206
I0
I1
I-1
tp5961
sS'potentiate,the,effect'
p5962
(F1
F0.00076452599388379206
I1
I0
I1
tp5963
sS'objective,of,this'
p5964
(F1
F0.00076452599388379206
I0
I1
I-1
tp5965
sS'is,no,change'
p5966
(F1
F0.00076452599388379206
I0
I1
I-1
tp5967
sS'also,used,the'
p5968
(F1
F0.00076452599388379206
I1
I0
I1
tp5969
sS'metabolite,levels,in'
p5970
(F1
F0.00076452599388379206
I1
I0
I1
tp5971
sS'inhibit,its,metabolism'
p5972
(F1
F0.00076452599388379206
I1
I0
I1
tp5973
sS'agents,after,the'
p5974
(F1
F0.00076452599388379206
I1
I0
I1
tp5975
sS'of,free,in'
p5976
(F1
F0.00076452599388379206
I0
I1
I-1
tp5977
sS'infinity,auc,of'
p5978
(F1
F0.00076452599388379206
I1
I0
I1
tp5979
sS'may,decrease,the'
p5980
(F1
F0.0038226299694189602
I5
I0
I5
tp5981
sS'including,hyaluronan,lyase'
p5982
(F1
F0.00076452599388379206
I0
I1
I-1
tp5983
sS'ribs,was,observed'
p5984
(F1
F0.00076452599388379206
I0
I1
I-1
tp5985
sS'be,advised,to'
p5986
(F1
F0.0015290519877675841
I2
I0
I2
tp5987
sS'to,be,potentiated'
p5988
(F1
F0.00076452599388379206
I1
I0
I1
tp5989
sS'aimed,to,evaluate'
p5990
(F1
F0.00076452599388379206
I0
I1
I-1
tp5991
sS'in,a,way'
p5992
(F1
F0.00076452599388379206
I0
I1
I-1
tp5993
sS'syrup,is,accentuated'
p5994
(F1
F0.00076452599388379206
I1
I0
I1
tp5995
sS'the,difference,in'
p5996
(F1
F0.00076452599388379206
I0
I1
I-1
tp5997
sS'cyp3a4,cyp2d6,cyp1a2'
p5998
(F1
F0.00076452599388379206
I0
I1
I-1
tp5999
sS'of,conducted,in'
p6000
(F1
F0.00076452599388379206
I0
I1
I-1
tp6001
sS'be,a,strong'
p6002
(F1
F0.00076452599388379206
I1
I0
I1
tp6003
sS'blood,levels,should'
p6004
(F1
F0.00076452599388379206
I1
I0
I1
tp6005
sS'taking,or,other'
p6006
(F1
F0.00076452599388379206
I1
I0
I1
tp6007
sS'rare,reports,of'
p6008
(F1
F0.00076452599388379206
I0
I1
I-1
tp6009
sS'coumarin-type,and,other'
p6010
(F1
F0.00076452599388379206
I1
I0
I1
tp6011
sS'of,was,significantly'
p6012
(F1
F0.00076452599388379206
I1
I0
I1
tp6013
sS'relaxants,or,local'
p6014
(F1
F0.00076452599388379206
I0
I1
I-1
tp6015
sS'of,the,two'
p6016
(F1
F0.0015290519877675841
I0
I2
I-2
tp6017
sS'by,but,greatly'
p6018
(F1
F0.00076452599388379206
I1
I0
I1
tp6019
sS'overall,exposure,the'
p6020
(F1
F0.00076452599388379206
I1
I0
I1
tp6021
sS'and,diminishing,concealed'
p6022
(F1
F0.00076452599388379206
I1
I0
I1
tp6023
sS'regimen,of,gsls'
p6024
(F1
F0.00076452599388379206
I1
I0
I1
tp6025
sS'of,gi,ulceration'
p6026
(F1
F0.00076452599388379206
I1
I0
I1
tp6027
sS'a,variety,of'
p6028
(F1
F0.0015290519877675841
I0
I2
I-2
tp6029
sS'therapeutically,relevant,concentrations'
p6030
(F1
F0.00076452599388379206
I1
I0
I1
tp6031
sS'antiarrhythmic,agents,of'
p6032
(F1
F0.00076452599388379206
I1
I0
I1
tp6033
sS'of,and,related'
p6034
(F1
F0.00076452599388379206
I1
I0
I1
tp6035
sS'required,the,dose'
p6036
(F1
F0.00076452599388379206
I0
I1
I-1
tp6037
sS'earlier,than,might'
p6038
(F1
F0.00076452599388379206
I1
I0
I1
tp6039
sS'of,proamatine,potential'
p6040
(F1
F0.00076452599388379206
I1
I0
I1
tp6041
sS'at,a,common'
p6042
(F1
F0.00076452599388379206
I1
I0
I1
tp6043
sS'or,greater,with'
p6044
(F1
F0.00076452599388379206
I1
I0
I1
tp6045
sS'animals,almost,loss'
p6046
(F1
F0.00076452599388379206
I1
I0
I1
tp6047
sS'eg,or,macrolide'
p6048
(F1
F0.00076452599388379206
I1
I0
I1
tp6049
sS'range,considered,to'
p6050
(F1
F0.00076452599388379206
I1
I0
I1
tp6051
sS'hepatic,cyp3a,isozymes'
p6052
(F1
F0.00076452599388379206
I1
I0
I1
tp6053
sS'of,potentiating,cns'
p6054
(F1
F0.00076452599388379206
I1
I0
I1
tp6055
sS'two,combinations,in'
p6056
(F1
F0.00076452599388379206
I1
I0
I1
tp6057
sS'ml,min,caution'
p6058
(F1
F0.00076452599388379206
I1
I0
I1
tp6059
sS'b6,inhibitor,and'
p6060
(F1
F0.00076452599388379206
I0
I1
I-1
tp6061
sS'other,agents,that'
p6062
(F1
F0.0015290519877675841
I2
I0
I2
tp6063
sS'be,observed,before'
p6064
(F1
F0.00076452599388379206
I1
I0
I1
tp6065
sS'similar,to,that'
p6066
(F0
F0
I1
I1
I0
tp6067
sS'protein-bound,drugs,such'
p6068
(F1
F0.00076452599388379206
I1
I0
I1
tp6069
sS'of,the,action'
p6070
(F1
F0.00076452599388379206
I1
I0
I1
tp6071
sS'in,pharmacokinetic,parameters'
p6072
(F1
F0.00076452599388379206
I0
I1
I-1
tp6073
sS'in,one,case'
p6074
(F1
F0.00076452599388379206
I1
I0
I1
tp6075
sS'vivo,positron,emission'
p6076
(F1
F0.00076452599388379206
I1
I0
I1
tp6077
sS'penicillin,blood,levels'
p6078
(F1
F0.00076452599388379206
I1
I0
I1
tp6079
sS'of,ea,in'
p6080
(F1
F0.00076452599388379206
I1
I0
I1
tp6081
sS'acetaminophen,rimantadine,hcl'
p6082
(F1
F0.00076452599388379206
I0
I1
I-1
tp6083
sS'weekly,doses,of'
p6084
(F1
F0.0015290519877675841
I0
I2
I-2
tp6085
sS'to,be,used'
p6086
(F1
F0.00076452599388379206
I1
I0
I1
tp6087
sS'medical,treatment,with'
p6088
(F1
F0.00076452599388379206
I0
I1
I-1
tp6089
sS'day,times,the'
p6090
(F1
F0.0015290519877675841
I0
I2
I-2
tp6091
sS'cancer,or,with'
p6092
(F1
F0.00076452599388379206
I0
I1
I-1
tp6093
sS'in,higher,and'
p6094
(F1
F0.00076452599388379206
I0
I1
I-1
tp6095
sS's-enantiomers,or,pharmacodynamics'
p6096
(F1
F0.00076452599388379206
I0
I1
I-1
tp6097
sS'interaction,with,co-administered'
p6098
(F1
F0.00076452599388379206
I0
I1
I-1
tp6099
sS'agent,dtic,and'
p6100
(F1
F0.00076452599388379206
I0
I1
I-1
tp6101
sS'and,locomotor,inhibitor'
p6102
(F1
F0.00076452599388379206
I0
I1
I-1
tp6103
sS'cells,alone,or'
p6104
(F1
F0.00076452599388379206
I0
I1
I-1
tp6105
sS'were,resistant,to'
p6106
(F1
F0.00076452599388379206
I0
I1
I-1
tp6107
sS'with,xenical,administration'
p6108
(F1
F0.00076452599388379206
I0
I1
I-1
tp6109
sS'dznep,insensitivity,might'
p6110
(F1
F0.00076452599388379206
I1
I0
I1
tp6111
sS'is,used,concurrently'
p6112
(F1
F0.00076452599388379206
I1
I0
I1
tp6113
sS'use,of,a'
p6114
(F1
F0.00076452599388379206
I0
I1
I-1
tp6115
sS'of,spontaneous,recovery'
p6116
(F1
F0.00076452599388379206
I1
I0
I1
tp6117
sS'and,should,be'
p6118
(F1
F0.0015290519877675841
I2
I0
I2
tp6119
sS'to,both,the'
p6120
(F1
F0.00076452599388379206
I0
I1
I-1
tp6121
sS'not,increase,blood'
p6122
(F1
F0.00076452599388379206
I0
I1
I-1
tp6123
sS'effects,of,oxycodone'
p6124
(F1
F0.00076452599388379206
I1
I0
I1
tp6125
sS'was,significantly,increased'
p6126
(F1
F0.00076452599388379206
I1
I0
I1
tp6127
sS'of,in,healthy'
p6128
(F1
F0.00076452599388379206
I0
I1
I-1
tp6129
sS'decrease,arterial,responsiveness'
p6130
(F1
F0.00076452599388379206
I1
I0
I1
tp6131
sS'that,mephenytoin,may'
p6132
(F1
F0.00076452599388379206
I1
I0
I1
tp6133
sS'with,is,not'
p6134
(F1
F0.0015290519877675841
I2
I0
I2
tp6135
sS'in,the,first'
p6136
(F1
F0.00076452599388379206
I1
I0
I1
tp6137
sS'interactions,it,appears'
p6138
(F1
F0.00076452599388379206
I1
I0
I1
tp6139
sS'that,of,neurotoxin'
p6140
(F1
F0.00076452599388379206
I0
I1
I-1
tp6141
sS'by,co-injection,of'
p6142
(F1
F0.00076452599388379206
I1
I0
I1
tp6143
sS'antacids,absorption,of'
p6144
(F1
F0.00076452599388379206
I1
I0
I1
tp6145
sS'up,to,mg'
p6146
(F1
F0.0022935779816513763
I0
I3
I-3
tp6147
sS'sirna,sub-g1,fraction'
p6148
(F1
F0.00076452599388379206
I0
I1
I-1
tp6149
sS'the,drugs,was'
p6150
(F1
F0.00076452599388379206
I0
I1
I-1
tp6151
sS'sequestrates,or,oral'
p6152
(F1
F0.00076452599388379206
I1
I0
I1
tp6153
sS'levels,of,such'
p6154
(F1
F0.00076452599388379206
I1
I0
I1
tp6155
sS'retinal,transduction,following'
p6156
(F1
F0.00076452599388379206
I0
I1
I-1
tp6157
sS'xenical,should,be'
p6158
(F1
F0.00076452599388379206
I1
I0
I1
tp6159
sS'methods,which,convert'
p6160
(F1
F0.00076452599388379206
I0
I1
I-1
tp6161
sS'for,information,on'
p6162
(F1
F0.00076452599388379206
I0
I1
I-1
tp6163
sS'patients,taking,concomitant'
p6164
(F1
F0.00076452599388379206
I1
I0
I1
tp6165
sS'to,significantly,increase'
p6166
(F1
F0.00076452599388379206
I1
I0
I1
tp6167
sS'and,avian,influenza'
p6168
(F1
F0.00076452599388379206
I0
I1
I-1
tp6169
sS'enzyme,system,such'
p6170
(F1
F0.00076452599388379206
I1
I0
I1
tp6171
sS'mind,when,metrogel'
p6172
(F1
F0.00076452599388379206
I0
I1
I-1
tp6173
sS'had,a,significant'
p6174
(F1
F0.00076452599388379206
I1
I0
I1
tp6175
sS'premedications,such,as'
p6176
(F1
F0.00076452599388379206
I0
I1
I-1
tp6177
sS'tail,suspension,test'
p6178
(F1
F0.00076452599388379206
I0
I1
I-1
tp6179
sS'of,methicillin-resistant,staphylococcus'
p6180
(F1
F0.00076452599388379206
I0
I1
I-1
tp6181
sS'on,two,separate'
p6182
(F1
F0.00076452599388379206
I1
I0
I1
tp6183
sS'occurrence,of,serious'
p6184
(F1
F0.00076452599388379206
I1
I0
I1
tp6185
sS'values,when,feldene'
p6186
(F1
F0.00076452599388379206
I1
I0
I1
tp6187
sS'studied,in,clinical'
p6188
(F1
F0.00076452599388379206
I0
I1
I-1
tp6189
sS'with,mycamine,should'
p6190
(F1
F0.00076452599388379206
I1
I0
I1
tp6191
sS'has,been,administered'
p6192
(F1
F0.00076452599388379206
I0
I1
I-1
tp6193
sS'an,increase,in'
p6194
(F1
F0.0053516819571865441
I7
I0
I7
tp6195
sS'given,as,or'
p6196
(F1
F0.00076452599388379206
I1
I0
I1
tp6197
sS'whereas,arrested,at'
p6198
(F1
F0.00076452599388379206
I0
I1
I-1
tp6199
sS'drugs,on,the'
p6200
(F1
F0.00076452599388379206
I0
I1
I-1
tp6201
sS'drug,interactions,drugs'
p6202
(F1
F0.00076452599388379206
I0
I1
I-1
tp6203
sS'such,as,suxamethonium'
p6204
(F1
F0.00076452599388379206
I1
I0
I1
tp6205
sS'i,antipsychotic,agents'
p6206
(F1
F0.00076452599388379206
I1
I0
I1
tp6207
sS'of,ropivacaine,can'
p6208
(F1
F0.00076452599388379206
I1
I0
I1
tp6209
sS'in,the,plasma'
p6210
(F1
F0.0015290519877675841
I0
I2
I-2
tp6211
sS'displayed,parkinsonian,symptoms'
p6212
(F1
F0.00076452599388379206
I1
I0
I1
tp6213
sS'kinetics,of,in'
p6214
(F1
F0.00076452599388379206
I0
I1
I-1
tp6215
sS'trial,of,and'
p6216
(F1
F0.00076452599388379206
I0
I1
I-1
tp6217
sS'receiving,and,neulasta'
p6218
(F1
F0.00076452599388379206
I1
I0
I1
tp6219
sS'aim,of,the'
p6220
(F1
F0.00076452599388379206
I0
I1
I-1
tp6221
sS'our,data,demonstrate'
p6222
(F1
F0.00076452599388379206
I1
I0
I1
tp6223
sS'for,an,effect'
p6224
(F1
F0.00076452599388379206
I0
I1
I-1
tp6225
sS'heparinase,iii,and'
p6226
(F1
F0.00076452599388379206
I0
I1
I-1
tp6227
sS'tablets,with,food'
p6228
(F1
F0.00076452599388379206
I0
I1
I-1
tp6229
sS'seizures,following,coadministration'
p6230
(F1
F0.00076452599388379206
I1
I0
I1
tp6231
sS'cyp3a4,family,may'
p6232
(F1
F0.00076452599388379206
I1
I0
I1
tp6233
sS'significantly,increased,plasma'
p6234
(F1
F0.00076452599388379206
I1
I0
I1
tp6235
sS'analgesics,may,result'
p6236
(F1
F0.00076452599388379206
I1
I0
I1
tp6237
sS'may,influence,the'
p6238
(F1
F0.00076452599388379206
I1
I0
I1
tp6239
sS'reported,that,the'
p6240
(F1
F0.00076452599388379206
I1
I0
I1
tp6241
sS'subjects,concurrently,treated'
p6242
(F1
F0.00076452599388379206
I1
I0
I1
tp6243
sS'by,these,results'
p6244
(F1
F0.00076452599388379206
I1
I0
I1
tp6245
sS'to,interfere,with'
p6246
(F1
F0.00076452599388379206
I1
I0
I1
tp6247
sS'sedative,effects,can'
p6248
(F1
F0.00076452599388379206
I1
I0
I1
tp6249
sS'intensity,or,duration'
p6250
(F1
F0.00076452599388379206
I0
I1
I-1
tp6251
sS'influence,of,on'
p6252
(F1
F0.00076452599388379206
I0
I1
I-1
tp6253
sS'vitamin,supplements,and'
p6254
(F1
F0.00076452599388379206
I1
I0
I1
tp6255
sS'inhibitor,of,any'
p6256
(F1
F0.00076452599388379206
I0
I1
I-1
tp6257
sS'as,wine,yogurt'
p6258
(F1
F0.00076452599388379206
I1
I0
I1
tp6259
sS'increasing,the,salt'
p6260
(F1
F0.00076452599388379206
I1
I0
I1
tp6261
sS'if,replacement,is'
p6262
(F1
F0.00076452599388379206
I0
I1
I-1
tp6263
sS'possible,that,dopamine'
p6264
(F1
F0.00076452599388379206
I1
I0
I1
tp6265
sS'in,vitro,activity'
p6266
(F1
F0.0015290519877675841
I0
I2
I-2
tp6267
sS'unlikely,to,alter'
p6268
(F1
F0.00076452599388379206
I0
I1
I-1
tp6269
sS'or,extent,of'
p6270
(F0
F0
I1
I1
I0
tp6271
sS'cause,any,clinically'
p6272
(F1
F0.00076452599388379206
I0
I1
I-1
tp6273
sS'peak,drug,concentration'
p6274
(F1
F0.00076452599388379206
I1
I0
I1
tp6275
sS'in,combination,was'
p6276
(F1
F0.00076452599388379206
I0
I1
I-1
tp6277
sS'this,study,it'
p6278
(F1
F0.00076452599388379206
I1
I0
I1
tp6279
sS'experiments,gsls,may'
p6280
(F1
F0.00076452599388379206
I0
I1
I-1
tp6281
sS'renal,clearance,of'
p6282
(F1
F0.00076452599388379206
I1
I0
I1
tp6283
sS'k-ras,mutation,were'
p6284
(F1
F0.00076452599388379206
I0
I1
I-1
tp6285
sS'of,mg,of'
p6286
(F1
F0.00076452599388379206
I1
I0
I1
tp6287
sS'considered,in,patients'
p6288
(F1
F0.00076452599388379206
I1
I0
I1
tp6289
sS'effect,on,plasma'
p6290
(F1
F0.0030581039755351682
I4
I0
I4
tp6291
sS'study,of,and'
p6292
(F1
F0.00076452599388379206
I0
I1
I-1
tp6293
sS'of,mg,or'
p6294
(F1
F0.00076452599388379206
I1
I0
I1
tp6295
sS'with,in,aids'
p6296
(F1
F0.00076452599388379206
I1
I0
I1
tp6297
sS'a,way,crossover'
p6298
(F1
F0.00076452599388379206
I0
I1
I-1
tp6299
sS'decrease,or,leave'
p6300
(F1
F0.00076452599388379206
I1
I0
I1
tp6301
sS'rats,and,rabbits'
p6302
(F1
F0.00076452599388379206
I0
I1
I-1
tp6303
sS'has,been,studied'
p6304
(F1
F0.00076452599388379206
I0
I1
I-1
tp6305
sS'abacavir,has,no'
p6306
(F1
F0.00076452599388379206
I0
I1
I-1
tp6307
sS'including,feldene,have'
p6308
(F1
F0.00076452599388379206
I1
I0
I1
tp6309
sS'coadministration,of,drugs'
p6310
(F1
F0.00076452599388379206
I1
I0
I1
tp6311
sS'receptors,or,may'
p6312
(F1
F0.00076452599388379206
I1
I0
I1
tp6313
sS'the,same,time'
p6314
(F1
F0.0015290519877675841
I2
I0
I2
tp6315
sS'hypotension,that,may'
p6316
(F1
F0.00076452599388379206
I1
I0
I1
tp6317
sS'slowing,the,rate'
p6318
(F1
F0.00076452599388379206
I1
I0
I1
tp6319
sS'of,and,the'
p6320
(F1
F0.00076452599388379206
I1
I0
I1
tp6321
sS'the,following,concomitant'
p6322
(F1
F0.00076452599388379206
I0
I1
I-1
tp6323
sS'when,xenical,was'
p6324
(F1
F0.00076452599388379206
I1
I0
I1
tp6325
sS'treatment,with,peg-intron'
p6326
(F1
F0.00076452599388379206
I1
I0
I1
tp6327
sS'ace,inhibitors,can'
p6328
(F1
F0.00076452599388379206
I1
I0
I1
tp6329
sS'affected,by,the'
p6330
(F1
F0.00076452599388379206
I0
I1
I-1
tp6331
sS'acid,a,test'
p6332
(F1
F0.00076452599388379206
I0
I1
I-1
tp6333
sS'diuretics,patients,on'
p6334
(F1
F0.00076452599388379206
I1
I0
I1
tp6335
sS'study,we,tested'
p6336
(F1
F0.00076452599388379206
I0
I1
I-1
tp6337
sS'sensitization,to,although'
p6338
(F1
F0.00076452599388379206
I0
I1
I-1
tp6339
sS'and,showed,resistances'
p6340
(F1
F0.00076452599388379206
I0
I1
I-1
tp6341
sS'acetylsalicylic,acid,artificial'
p6342
(F1
F0.00076452599388379206
I0
I1
I-1
tp6343
sS'minimal,increase,in'
p6344
(F1
F0.00076452599388379206
I1
I0
I1
tp6345
sS'although,they,do'
p6346
(F1
F0.00076452599388379206
I1
I0
I1
tp6347
sS'of,predominantly,a'
p6348
(F1
F0.00076452599388379206
I0
I1
I-1
tp6349
sS'the,authors,report'
p6350
(F1
F0.00076452599388379206
I1
I0
I1
tp6351
sS'to,drugs,having'
p6352
(F1
F0.00076452599388379206
I0
I1
I-1
tp6353
sS'drugs,at,high'
p6354
(F1
F0.00076452599388379206
I0
I1
I-1
tp6355
sS'monitored,closely,and'
p6356
(F1
F0.00076452599388379206
I1
I0
I1
tp6357
sS'on,the,pharmacokinetic'
p6358
(F0
F0
I1
I1
I0
tp6359
sS'such,as,mivacron'
p6360
(F1
F0.00076452599388379206
I1
I0
I1
tp6361
sS'compounds,predominantly,metabolized'
p6362
(F1
F0.00076452599388379206
I0
I1
I-1
tp6363
sS'under,the,plasma'
p6364
(F1
F0.00076452599388379206
I1
I0
I1
tp6365
sS'possible,potentiation,hypotensive'
p6366
(F1
F0.00076452599388379206
I0
I1
I-1
tp6367
sS'macrolide,hiv,protease'
p6368
(F1
F0.00076452599388379206
I0
I1
I-1
tp6369
sS'taken,while,dosing'
p6370
(F1
F0.00076452599388379206
I1
I0
I1
tp6371
sS'the,highly,specific'
p6372
(F1
F0.00076452599388379206
I0
I1
I-1
tp6373
sS'typically,torsades,de'
p6374
(F1
F0.00076452599388379206
I1
I0
I1
tp6375
sS'should,be,adjusted'
p6376
(F1
F0.0015290519877675841
I2
I0
I2
tp6377
sS'of,a,may'
p6378
(F1
F0.00076452599388379206
I0
I1
I-1
tp6379
sS'by,anesthesia,other'
p6380
(F1
F0.00076452599388379206
I1
I0
I1
tp6381
sS'a,non-human,primate'
p6382
(F1
F0.00076452599388379206
I1
I0
I1
tp6383
sS'found,antagonism,between'
p6384
(F1
F0.00076452599388379206
I1
I0
I1
tp6385
sS'interactions,of,oral'
p6386
(F1
F0.00076452599388379206
I0
I1
I-1
tp6387
sS'be,affected,by'
p6388
(F1
F0.00076452599388379206
I0
I1
I-1
tp6389
sS'a,potent,inhibitor'
p6390
(F0
F0
I1
I1
I0
tp6391
sS'in,delayed,clearance'
p6392
(F1
F0.00076452599388379206
I1
I0
I1
tp6393
sS'data,from,small'
p6394
(F1
F0.00076452599388379206
I1
I0
I1
tp6395
sS'drugs,may,not'
p6396
(F1
F0.00076452599388379206
I0
I1
I-1
tp6397
sS'day,treatment,periods'
p6398
(F1
F0.00076452599388379206
I0
I1
I-1
tp6399
sS'likely,to,occur'
p6400
(F1
F0.00076452599388379206
I0
I1
I-1
tp6401
sS'and,mg,daily'
p6402
(F1
F0.0015290519877675841
I2
I0
I2
tp6403
sS'and,other,and'
p6404
(F1
F0.00076452599388379206
I0
I1
I-1
tp6405
sS'blocking,effects,of'
p6406
(F0.33333333333333331
F0.00076452599388379206
I2
I1
I1
tp6407
sS'in,at,least'
p6408
(F1
F0.00076452599388379206
I0
I1
I-1
tp6409
sS'because,is,not'
p6410
(F1
F0.00076452599388379206
I0
I1
I-1
tp6411
sS'while,those,secreted'
p6412
(F1
F0.00076452599388379206
I1
I0
I1
tp6413
sS'be,used,as'
p6414
(F1
F0.00076452599388379206
I1
I0
I1
tp6415
sS'evaluate,potential,interactions'
p6416
(F1
F0.00076452599388379206
I0
I1
I-1
tp6417
sS'methenamine,efficacy,may'
p6418
(F1
F0.00076452599388379206
I1
I0
I1
tp6419
sS'with,in,vivo'
p6420
(F1
F0.00076452599388379206
I1
I0
I1
tp6421
sS'motility,anticholinergic,agents'
p6422
(F1
F0.00076452599388379206
I1
I0
I1
tp6423
sS'and,rifampicin,in'
p6424
(F1
F0.00076452599388379206
I1
I0
I1
tp6425
sS'drugs,rivastigmine,is'
p6426
(F1
F0.00076452599388379206
I0
I1
I-1
tp6427
sS'limited,in,vitro'
p6428
(F1
F0.00076452599388379206
I0
I1
I-1
tp6429
sS'concomitant,diflucan,and'
p6430
(F1
F0.00076452599388379206
I1
I0
I1
tp6431
sS'by,negatively,regulating'
p6432
(F1
F0.00076452599388379206
I1
I0
I1
tp6433
sS'absence,and,presence'
p6434
(F1
F0.00076452599388379206
I0
I1
I-1
tp6435
sS'ziagen,twice,daily'
p6436
(F1
F0.00076452599388379206
I1
I0
I1
tp6437
sS'human,serum,to'
p6438
(F1
F0.00076452599388379206
I1
I0
I1
tp6439
sS'the,tubular,secretion'
p6440
(F1
F0.00076452599388379206
I1
I0
I1
tp6441
sS'supplement,absorption,when'
p6442
(F1
F0.00076452599388379206
I1
I0
I1
tp6443
sS'has,been,associated'
p6444
(F1
F0.0015290519877675841
I2
I0
I2
tp6445
sS'combination,with,other'
p6446
(F1
F0.0022935779816513763
I3
I0
I3
tp6447
sS'of,hypokalemia,and'
p6448
(F1
F0.00076452599388379206
I0
I1
I-1
tp6449
sS'aspirin,may,decrease'
p6450
(F1
F0.00076452599388379206
I1
I0
I1
tp6451
sS'and,however,a'
p6452
(F1
F0.00076452599388379206
I1
I0
I1
tp6453
sS'depression-producing,drugs,may'
p6454
(F1
F0.00076452599388379206
I1
I0
I1
tp6455
sS'sympathomimetic,agents,tricyclic'
p6456
(F1
F0.00076452599388379206
I1
I0
I1
tp6457
sS'on,therapy,when'
p6458
(F1
F0.00076452599388379206
I0
I1
I-1
tp6459
sS'coexistence,may,compete'
p6460
(F1
F0.00076452599388379206
I0
I1
I-1
tp6461
sS'and,probably,other'
p6462
(F1
F0.00076452599388379206
I1
I0
I1
tp6463
sS'did,not,displace'
p6464
(F1
F0.00076452599388379206
I0
I1
I-1
tp6465
sS'associated,with,an'
p6466
(F1
F0.0015290519877675841
I2
I0
I2
tp6467
sS'and,adjoining,a5'
p6468
(F1
F0.00076452599388379206
I1
I0
I1
tp6469
sS'concurrently,receiving,other'
p6470
(F1
F0.00076452599388379206
I1
I0
I1
tp6471
sS'inhibit,plasma,cholinesterase'
p6472
(F1
F0.00076452599388379206
I1
I0
I1
tp6473
sS'decreasing,the,dosage'
p6474
(F1
F0.00076452599388379206
I1
I0
I1
tp6475
sS'experience,an,excessive'
p6476
(F1
F0.00076452599388379206
I1
I0
I1
tp6477
sS'concomitantly,with,agents'
p6478
(F1
F0.00076452599388379206
I1
I0
I1
tp6479
sS'control,at,its'
p6480
(F1
F0.00076452599388379206
I0
I1
I-1
tp6481
sS'in,increased,plasma'
p6482
(F1
F0.0015290519877675841
I2
I0
I2
tp6483
sS'dose-related,myelotoxicity,radiation'
p6484
(F1
F0.00076452599388379206
I1
I0
I1
tp6485
sS'mean,pharmacokinetic,parameters'
p6486
(F1
F0.00076452599388379206
I1
I0
I1
tp6487
sS'study,healthy,volunteers'
p6488
(F1
F0.00076452599388379206
I0
I1
I-1
tp6489
sS'than,when,myfortic'
p6490
(F1
F0.00076452599388379206
I1
I0
I1
tp6491
sS'p450,system,are'
p6492
(F1
F0.00076452599388379206
I1
I0
I1
tp6493
sS'the,cyp3a4,family'
p6494
(F1
F0.0015290519877675841
I2
I0
I2
tp6495
sS'decreases,oral,clearance'
p6496
(F1
F0.00076452599388379206
I1
I0
I1
tp6497
sS'that,approximately,doubled'
p6498
(F1
F0.00076452599388379206
I1
I0
I1
tp6499
sS'evaluated,for,growth'
p6500
(F1
F0.00076452599388379206
I0
I1
I-1
tp6501
sS'interact,with,type'
p6502
(F1
F0.00076452599388379206
I1
I0
I1
tp6503
sS'these,are,described'
p6504
(F1
F0.00076452599388379206
I1
I0
I1
tp6505
sS'in,a,slight'
p6506
(F1
F0.00076452599388379206
I0
I1
I-1
tp6507
sS'eliminated,by,active'
p6508
(F0
F0
I1
I1
I0
tp6509
sS'to,patients,on'
p6510
(F0
F0
I1
I1
I0
tp6511
sS'described,in,greater'
p6512
(F1
F0.00076452599388379206
I1
I0
I1
tp6513
sS'for,days,at'
p6514
(F1
F0.00076452599388379206
I0
I1
I-1
tp6515
sS'inhibitors,such,as'
p6516
(F1
F0.00076452599388379206
I1
I0
I1
tp6517
sS'infarction,in,the'
p6518
(F1
F0.00076452599388379206
I0
I1
I-1
tp6519
sS'when,a,single'
p6520
(F1
F0.00076452599388379206
I1
I0
I1
tp6521
sS'interaction,of,streptase'
p6522
(F1
F0.00076452599388379206
I0
I1
I-1
tp6523
sS'p27,kip1,enhanced'
p6524
(F1
F0.00076452599388379206
I1
I0
I1
tp6525
sS'not,a,suitable'
p6526
(F1
F0.00076452599388379206
I0
I1
I-1
tp6527
sS'cytochrome,p4501a2,such'
p6528
(F1
F0.00076452599388379206
I1
I0
I1
tp6529
sS'by,commonly,prescribed'
p6530
(F1
F0.00076452599388379206
I0
I1
I-1
tp6531
sS'body,weight,in'
p6532
(F1
F0.00076452599388379206
I0
I1
I-1
tp6533
sS'weekly,intramuscular,methyl-4'
p6534
(F1
F0.00076452599388379206
I0
I1
I-1
tp6535
sS'potential,interaction,between'
p6536
(F1
F0.00076452599388379206
I1
I0
I1
tp6537
sS'as,the,observed'
p6538
(F1
F0.00076452599388379206
I0
I1
I-1
tp6539
sS'required,and,ipth'
p6540
(F1
F0.00076452599388379206
I1
I0
I1
tp6541
sS'relaxants,inhalational,agents'
p6542
(F1
F0.00076452599388379206
I0
I1
I-1
tp6543
sS'of,mg,maximum'
p6544
(F1
F0.00076452599388379206
I0
I1
I-1
tp6545
sS'the,inr,international'
p6546
(F1
F0.00076452599388379206
I0
I1
I-1
tp6547
sS'values,with,treatment'
p6548
(F1
F0.00076452599388379206
I0
I1
I-1
tp6549
sS'data,regarding,potential'
p6550
(F1
F0.00076452599388379206
I1
I0
I1
tp6551
sS'the,amphetamine-paired,context'
p6552
(F1
F0.00076452599388379206
I0
I1
I-1
tp6553
sS'in,human,non-small'
p6554
(F1
F0.00076452599388379206
I1
I0
I1
tp6555
sS'in,five,normal'
p6556
(F1
F0.00076452599388379206
I1
I0
I1
tp6557
sS'at,least,hour'
p6558
(F1
F0.00076452599388379206
I1
I0
I1
tp6559
sS'the,concomitant,use'
p6560
(F0.20000000000000001
F0.00076452599388379206
I2
I3
I-1
tp6561
sS'increases,the,serum'
p6562
(F1
F0.00076452599388379206
I1
I0
I1
tp6563
sS'in,dosage,requirements'
p6564
(F1
F0.0015290519877675841
I2
I0
I2
tp6565
sS'the,p,mouse'
p6566
(F1
F0.00076452599388379206
I1
I0
I1
tp6567
sS'of,auc,to'
p6568
(F1
F0.00076452599388379206
I0
I1
I-1
tp6569
sS'prolonged,losses,of'
p6570
(F1
F0.00076452599388379206
I1
I0
I1
tp6571
sS'study,of,chronic'
p6572
(F1
F0.00076452599388379206
I1
I0
I1
tp6573
sS'increasing,serum,and'
p6574
(F1
F0.00076452599388379206
I0
I1
I-1
tp6575
sS'can,be,synergistic'
p6576
(F1
F0.00076452599388379206
I1
I0
I1
tp6577
sS'but,its,effect'
p6578
(F1
F0.00076452599388379206
I0
I1
I-1
tp6579
sS'was,administered,with'
p6580
(F1
F0.00076452599388379206
I1
I0
I1
tp6581
sS'administration,decreased,the'
p6582
(F1
F0.00076452599388379206
I1
I0
I1
tp6583
sS'isoform-specific,cyp,inhibitors'
p6584
(F1
F0.00076452599388379206
I0
I1
I-1
tp6585
sS'mice,co-administration,of'
p6586
(F1
F0.00076452599388379206
I1
I0
I1
tp6587
sS'effect,of,other'
p6588
(F1
F0.00076452599388379206
I0
I1
I-1
tp6589
sS'receiving,a,course'
p6590
(F1
F0.00076452599388379206
I1
I0
I1
tp6591
sS'of,absorption,dosage'
p6592
(F1
F0.00076452599388379206
I1
I0
I1
tp6593
sS'cannot,be,interrupted'
p6594
(F1
F0.00076452599388379206
I1
I0
I1
tp6595
sS'were,initially,activated'
p6596
(F1
F0.00076452599388379206
I1
I0
I1
tp6597
sS'diminished,absorption,of'
p6598
(F1
F0.00076452599388379206
I1
I0
I1
tp6599
sS'by,up,to'
p6600
(F1
F0.00076452599388379206
I1
I0
I1
tp6601
sS'of,sympathomimetic,pressor'
p6602
(F1
F0.0015290519877675841
I2
I0
I2
tp6603
sS'neuromuscular,blocking,action'
p6604
(F1
F0.0015290519877675841
I2
I0
I2
tp6605
sS'metabolism,of,coumarin'
p6606
(F1
F0.00076452599388379206
I1
I0
I1
tp6607
sS'are,unnecessary,when'
p6608
(F1
F0.00076452599388379206
I0
I1
I-1
tp6609
sS'with,but,only'
p6610
(F1
F0.00076452599388379206
I0
I1
I-1
tp6611
sS'lead,to,less'
p6612
(F1
F0.00076452599388379206
I0
I1
I-1
tp6613
sS'in,a,patient'
p6614
(F1
F0.0015290519877675841
I2
I0
I2
tp6615
sS'in,rats,there'
p6616
(F1
F0.00076452599388379206
I0
I1
I-1
tp6617
sS'depression,neurotoxic,medications'
p6618
(F1
F0.00076452599388379206
I1
I0
I1
tp6619
sS'nonheme,and,heme'
p6620
(F1
F0.00076452599388379206
I0
I1
I-1
tp6621
sS'therapies,thiazide,beta'
p6622
(F1
F0.00076452599388379206
I0
I1
I-1
tp6623
sS'of,oral,is'
p6624
(F1
F0.00076452599388379206
I1
I0
I1
tp6625
sS'these,enzymes,may'
p6626
(F1
F0.00076452599388379206
I0
I1
I-1
tp6627
sS'zetia,with,is'
p6628
(F1
F0.00076452599388379206
I1
I0
I1
tp6629
sS'that,dopamine,antagonists'
p6630
(F1
F0.00076452599388379206
I1
I0
I1
tp6631
sS'drugs,that,stimulate'
p6632
(F1
F0.00076452599388379206
I1
I0
I1
tp6633
sS'that,ascorbic,acid'
p6634
(F1
F0.00076452599388379206
I1
I0
I1
tp6635
sS'binding,sites,notably'
p6636
(F1
F0.00076452599388379206
I1
I0
I1
tp6637
sS'drugs,such,as'
p6638
(F0.77777777777777779
F0.0053516819571865441
I8
I1
I7
tp6639
sS'other,drugs,paliperidone'
p6640
(F1
F0.00076452599388379206
I0
I1
I-1
tp6641
sS'study,of,hiv-infected'
p6642
(F1
F0.00076452599388379206
I1
I0
I1
tp6643
sS'practice,is,the'
p6644
(F1
F0.00076452599388379206
I0
I1
I-1
tp6645
sS'and,mg,on'
p6646
(F1
F0.0015290519877675841
I0
I2
I-2
tp6647
sS'were,observed,following'
p6648
(F1
F0.00076452599388379206
I0
I1
I-1
tp6649
sS'nsaids,with,short'
p6650
(F1
F0.00076452599388379206
I1
I0
I1
tp6651
sS'has,caused,deaths'
p6652
(F1
F0.00076452599388379206
I1
I0
I1
tp6653
sS'the,human,exposure'
p6654
(F1
F0.0030581039755351682
I0
I4
I-4
tp6655
sS'antinociceptive,activity,of'
p6656
(F1
F0.00076452599388379206
I1
I0
I1
tp6657
sS'a,study,in'
p6658
(F0
F0
I1
I1
I0
tp6659
sS'gastrointestinal,bleeding,hematuria'
p6660
(F1
F0.00076452599388379206
I1
I0
I1
tp6661
sS'ferrous,sulfate,or'
p6662
(F1
F0.0015290519877675841
I2
I0
I2
tp6663
sS'isolates,of,methicillin-resistant'
p6664
(F1
F0.0015290519877675841
I0
I2
I-2
tp6665
sS'inhibitory,effect,on'
p6666
(F1
F0.00076452599388379206
I0
I1
I-1
tp6667
sS'one,month,after'
p6668
(F1
F0.00076452599388379206
I1
I0
I1
tp6669
sS'p450,inhibition,studies'
p6670
(F1
F0.00076452599388379206
I0
I1
I-1
tp6671
sS'mecamylamine,may,be'
p6672
(F1
F0.00076452599388379206
I1
I0
I1
tp6673
sS'of,class,i'
p6674
(F1
F0.00076452599388379206
I1
I0
I1
tp6675
sS'been,observed,in'
p6676
(F1
F0.00076452599388379206
I0
I1
I-1
tp6677
sS'in,a,broad'
p6678
(F1
F0.00076452599388379206
I0
I1
I-1
tp6679
sS'of,gsls,at'
p6680
(F1
F0.00076452599388379206
I0
I1
I-1
tp6681
sS'content,such,as'
p6682
(F1
F0.00076452599388379206
I1
I0
I1
tp6683
sS'bromide,injection,before'
p6684
(F1
F0.00076452599388379206
I0
I1
I-1
tp6685
sS'with,agents,that'
p6686
(F1
F0.00076452599388379206
I1
I0
I1
tp6687
sS'of,pediatric,oncology'
p6688
(F1
F0.00076452599388379206
I0
I1
I-1
tp6689
sS'of,adjusted,as'
p6690
(F1
F0.00076452599388379206
I1
I0
I1
tp6691
sS'excretion,of,decreased'
p6692
(F1
F0.0015290519877675841
I0
I2
I-2
tp6693
sS'the,induction,or'
p6694
(F1
F0.00076452599388379206
I0
I1
I-1
tp6695
sS'day,for,days'
p6696
(F1
F0.0053516819571865441
I0
I7
I-7
tp6697
sS'interaction,study,n'
p6698
(F1
F0.00076452599388379206
I1
I0
I1
tp6699
sS'are,used,together'
p6700
(F1
F0.00076452599388379206
I1
I0
I1
tp6701
sS'by,is,associated'
p6702
(F0
F0
I1
I1
I0
tp6703
sS'not,influence,the'
p6704
(F1
F0.0015290519877675841
I0
I2
I-2
tp6705
sS'values,for,mpa'
p6706
(F1
F0.00076452599388379206
I1
I0
I1
tp6707
sS'supporting,experimental,evidence'
p6708
(F1
F0.00076452599388379206
I1
I0
I1
tp6709
sS'assess,the,effect'
p6710
(F1
F0.00076452599388379206
I0
I1
I-1
tp6711
sS'initiation,of,aceon'
p6712
(F1
F0.00076452599388379206
I1
I0
I1
tp6713
sS'metabolism,decreased,the'
p6714
(F1
F0.0015290519877675841
I0
I2
I-2
tp6715
sS'for,the,secretion'
p6716
(F1
F0.00076452599388379206
I1
I0
I1
tp6717
sS'symlin,on,the'
p6718
(F1
F0.00076452599388379206
I0
I1
I-1
tp6719
sS'oral,gavage,fertility'
p6720
(F1
F0.00076452599388379206
I0
I1
I-1
tp6721
sS'showed,that,the'
p6722
(F1
F0.00076452599388379206
I0
I1
I-1
tp6723
sS'renal,insufficiency,should'
p6724
(F1
F0.00076452599388379206
I1
I0
I1
tp6725
sS'so,that,an'
p6726
(F1
F0.00076452599388379206
I0
I1
I-1
tp6727
sS'at,the,doses'
p6728
(F1
F0.00076452599388379206
I0
I1
I-1
tp6729
sS'greater,significantly,increases'
p6730
(F1
F0.00076452599388379206
I1
I0
I1
tp6731
sS'anticoagulants,prothrombin,time'
p6732
(F1
F0.00076452599388379206
I1
I0
I1
tp6733
sS'salicylates,may,enhance'
p6734
(F1
F0.00076452599388379206
I1
I0
I1
tp6735
sS'be,necessary,to'
p6736
(F1
F0.00076452599388379206
I1
I0
I1
tp6737
sS'muscle,relaxants,or'
p6738
(F1
F0.00076452599388379206
I0
I1
I-1
tp6739
sS'enzymes,improves,retinal'
p6740
(F1
F0.00076452599388379206
I0
I1
I-1
tp6741
sS'vehicle,group,mg'
p6742
(F1
F0.00076452599388379206
I0
I1
I-1
tp6743
sS'deazaneplanocin,a,dznep'
p6744
(F1
F0.00076452599388379206
I0
I1
I-1
tp6745
sS'or,food,interactions'
p6746
(F1
F0.00076452599388379206
I1
I0
I1
tp6747
sS'women,treated,with'
p6748
(F1
F0.00076452599388379206
I1
I0
I1
tp6749
sS'as,for,sites'
p6750
(F1
F0.00076452599388379206
I1
I0
I1
tp6751
sS'of,its,potential'
p6752
(F1
F0.00076452599388379206
I0
I1
I-1
tp6753
sS'but,magnesium-aluminum,hydroxide'
p6754
(F1
F0.00076452599388379206
I1
I0
I1
tp6755
sS'significantly,higher,than'
p6756
(F1
F0.00076452599388379206
I0
I1
I-1
tp6757
sS'that,alter,platelet'
p6758
(F1
F0.0015290519877675841
I2
I0
I2
tp6759
sS'may,reduce,serum'
p6760
(F1
F0.00076452599388379206
I1
I0
I1
tp6761
sS'conducted,in,rats'
p6762
(F1
F0.0015290519877675841
I0
I2
I-2
tp6763
sS'g,kg,intraperitoneally'
p6764
(F1
F0.00076452599388379206
I0
I1
I-1
tp6765
sS'strains,were,resistant'
p6766
(F1
F0.00076452599388379206
I0
I1
I-1
tp6767
sS'inhibitor,of,the'
p6768
(F1
F0.00076452599388379206
I1
I0
I1
tp6769
sS'blocking,action,of'
p6770
(F1
F0.0015290519877675841
I2
I0
I2
tp6771
sS'increases,in,prothrombin'
p6772
(F1
F0.00076452599388379206
I1
I0
I1
tp6773
sS'cyp3a4,significantly,increased'
p6774
(F1
F0.00076452599388379206
I1
I0
I1
tp6775
sS'an,orally,active'
p6776
(F1
F0.00076452599388379206
I0
I1
I-1
tp6777
sS'patients,being,treated'
p6778
(F1
F0.00076452599388379206
I1
I0
I1
tp6779
sS'given,concomitantly,with'
p6780
(F1
F0.0015290519877675841
I2
I0
I2
tp6781
sS'include,certain,and'
p6782
(F1
F0.00076452599388379206
I1
I0
I1
tp6783
sS'dosage,adjustment,when'
p6784
(F1
F0.00076452599388379206
I0
I1
I-1
tp6785
sS'may,enhance,neuromuscular'
p6786
(F1
F0.00076452599388379206
I1
I0
I1
tp6787
sS'duration,of,antinociception'
p6788
(F1
F0.00076452599388379206
I1
I0
I1
tp6789
sS'of,drugs,where'
p6790
(F1
F0.00076452599388379206
I1
I0
I1
tp6791
sS'possible,interactions,with'
p6792
(F1
F0.00076452599388379206
I0
I1
I-1
tp6793
sS'with,have,not'
p6794
(F0
F0
I1
I1
I0
tp6795
sS'chloride,plasma,concentrations'
p6796
(F1
F0.00076452599388379206
I1
I0
I1
tp6797
sS'and,does,not'
p6798
(F1
F0.00076452599388379206
I0
I1
I-1
tp6799
sS'diminution,is,not'
p6800
(F1
F0.00076452599388379206
I1
I0
I1
tp6801
sS'study,and,in'
p6802
(F1
F0.00076452599388379206
I1
I0
I1
tp6803
sS'the,effectiveness,of'
p6804
(F1
F0.0015290519877675841
I2
I0
I2
tp6805
sS'increase,decrease,or'
p6806
(F1
F0.00076452599388379206
I1
I0
I1
tp6807
sS'advised,for,patients'
p6808
(F1
F0.00076452599388379206
I1
I0
I1
tp6809
sS'activity,of,oral'
p6810
(F1
F0.00076452599388379206
I1
I0
I1
tp6811
sS'or,prolonged,losses'
p6812
(F1
F0.00076452599388379206
I1
I0
I1
tp6813
sS'atropinization,flushing,mydriasis'
p6814
(F1
F0.00076452599388379206
I1
I0
I1
tp6815
sS'subsequently,received,to'
p6816
(F1
F0.00076452599388379206
I1
I0
I1
tp6817
sS'and,thiazide,diuretics'
p6818
(F1
F0.00076452599388379206
I1
I0
I1
tp6819
sS'because,matulane,exhibits'
p6820
(F1
F0.00076452599388379206
I1
I0
I1
tp6821
sS'a,mg,kg'
p6822
(F1
F0.00076452599388379206
I0
I1
I-1
tp6823
sS'with,measurement,of'
p6824
(F1
F0.00076452599388379206
I0
I1
I-1
tp6825
sS'renal,transplant,patients'
p6826
(F0.33333333333333331
F0.00076452599388379206
I2
I1
I1
tp6827
sS'following,administration,of'
p6828
(F0.33333333333333331
F0.00076452599388379206
I1
I2
I-1
tp6829
sS'de,pointes,have'
p6830
(F1
F0.00076452599388379206
I0
I1
I-1
tp6831
sS'by,the,use'
p6832
(F1
F0.00076452599388379206
I1
I0
I1
tp6833
sS'cautiously,in,conjunction'
p6834
(F1
F0.0015290519877675841
I2
I0
I2
tp6835
sS'causes,a,minimal'
p6836
(F1
F0.00076452599388379206
I1
I0
I1
tp6837
sS'agents,and,or'
p6838
(F1
F0.00076452599388379206
I1
I0
I1
tp6839
sS'or,ischemia,of'
p6840
(F1
F0.00076452599388379206
I0
I1
I-1
tp6841
sS'dznep,insensitive,cells'
p6842
(F1
F0.00076452599388379206
I1
I0
I1
tp6843
sS'warfarin,users,had'
p6844
(F1
F0.00076452599388379206
I1
I0
I1
tp6845
sS'vaccines,may,decrease'
p6846
(F1
F0.00076452599388379206
I1
I0
I1
tp6847
sS'metabolite,and,did'
p6848
(F1
F0.00076452599388379206
I0
I1
I-1
tp6849
sS'and,the,interaction'
p6850
(F1
F0.00076452599388379206
I0
I1
I-1
tp6851
sS'of,either,or'
p6852
(F1
F0.00076452599388379206
I0
I1
I-1
tp6853
sS'study,in,five'
p6854
(F1
F0.00076452599388379206
I1
I0
I1
tp6855
sS'lamisil,tablets,and'
p6856
(F1
F0.00076452599388379206
I1
I0
I1
tp6857
sS'sanctura,and,or'
p6858
(F1
F0.00076452599388379206
I0
I1
I-1
tp6859
sS'co-administration,of,zetia'
p6860
(F1
F0.00076452599388379206
I1
I0
I1
tp6861
sS'compatibility,has,been'
p6862
(F1
F0.00076452599388379206
I0
I1
I-1
tp6863
sS'may,have,been'
p6864
(F1
F0.00076452599388379206
I0
I1
I-1
tp6865
sS'and,nose,may'
p6866
(F1
F0.00076452599388379206
I1
I0
I1
tp6867
sS'will,compete,with'
p6868
(F1
F0.00076452599388379206
I0
I1
I-1
tp6869
sS'some,patients,there'
p6870
(F1
F0.00076452599388379206
I0
I1
I-1
tp6871
sS'either,component,of'
p6872
(F1
F0.00076452599388379206
I0
I1
I-1
tp6873
sS'of,and,eldepryl'
p6874
(F1
F0.00076452599388379206
I1
I0
I1
tp6875
sS'of,diprivan,injectable'
p6876
(F1
F0.0015290519877675841
I2
I0
I2
tp6877
sS'levels,and,prolongation'
p6878
(F1
F0.00076452599388379206
I1
I0
I1
tp6879
sS'on,may,experience'
p6880
(F1
F0.00076452599388379206
I1
I0
I1
tp6881
sS'the,anticoagulant,effect'
p6882
(F1
F0.00076452599388379206
I0
I1
I-1
tp6883
sS'primarily,metabolized,through'
p6884
(F1
F0.00076452599388379206
I0
I1
I-1
tp6885
sS'used,concomitantly,with'
p6886
(F1
F0.0022935779816513763
I3
I0
I3
tp6887
sS'parent,levels,have'
p6888
(F1
F0.00076452599388379206
I1
I0
I1
tp6889
sS'administered,alone,under'
p6890
(F1
F0.00076452599388379206
I1
I0
I1
tp6891
sS'reported,from,hypoglycemia'
p6892
(F1
F0.00076452599388379206
I1
I0
I1
tp6893
sS'dose,response,for'
p6894
(F1
F0.00076452599388379206
I0
I1
I-1
tp6895
sS'cycle,apoptosis,and'
p6896
(F1
F0.00076452599388379206
I0
I1
I-1
tp6897
sS'those,include,divalproex'
p6898
(F1
F0.00076452599388379206
I0
I1
I-1
tp6899
sS'bleeding,hematuria,and'
p6900
(F1
F0.00076452599388379206
I1
I0
I1
tp6901
sS'both,r-,and'
p6902
(F1
F0.00076452599388379206
I0
I1
I-1
tp6903
sS'and,or,sequential'
p6904
(F1
F0.00076452599388379206
I0
I1
I-1
tp6905
sS'peak,plasma,concentrations'
p6906
(F1
F0.00076452599388379206
I1
I0
I1
tp6907
sS'that,coadministration,of'
p6908
(F1
F0.0015290519877675841
I2
I0
I2
tp6909
sS'drugs,were,used'
p6910
(F1
F0.00076452599388379206
I0
I1
I-1
tp6911
sS'dopamine,antagonists,such'
p6912
(F1
F0.0015290519877675841
I2
I0
I2
tp6913
sS'increases,in,concentrations'
p6914
(F1
F0.00076452599388379206
I1
I0
I1
tp6915
sS'given,concomitantly,during'
p6916
(F1
F0.00076452599388379206
I1
I0
I1
tp6917
sS'matulane,exhibits,some'
p6918
(F1
F0.00076452599388379206
I1
I0
I1
tp6919
sS'cause,unusually,large'
p6920
(F1
F0.00076452599388379206
I1
I0
I1
tp6921
sS'in,acidic,media'
p6922
(F1
F0.00076452599388379206
I1
I0
I1
tp6923
sS'state,that,the'
p6924
(F1
F0.00076452599388379206
I1
I0
I1
tp6925
sS'unlikely,to,affect'
p6926
(F1
F0.00076452599388379206
I0
I1
I-1
tp6927
sS'expression,at,the'
p6928
(F1
F0.00076452599388379206
I1
I0
I1
tp6929
sS'hospitalized,patients,with'
p6930
(F1
F0.00076452599388379206
I0
I1
I-1
tp6931
sS'on,an,in'
p6932
(F1
F0.00076452599388379206
I1
I0
I1
tp6933
sS'bases,via,the'
p6934
(F1
F0.00076452599388379206
I1
I0
I1
tp6935
sS'interactions,are,birth'
p6936
(F1
F0.00076452599388379206
I0
I1
I-1
tp6937
sS'pharmacokinetics,of,a'
p6938
(F1
F0.0015290519877675841
I0
I2
I-2
tp6939
sS'injectable,emulsion,may'
p6940
(F1
F0.00076452599388379206
I1
I0
I1
tp6941
sS'and,therefore,may'
p6942
(F1
F0.00076452599388379206
I0
I1
I-1
tp6943
sS'reported,in,vivo'
p6944
(F1
F0.00076452599388379206
I0
I1
I-1
tp6945
sS'as,acetylcholine,chloride'
p6946
(F1
F0.00076452599388379206
I1
I0
I1
tp6947
sS'following,drugs,and'
p6948
(F1
F0.00076452599388379206
I1
I0
I1
tp6949
sS'concentrations,to,achieve'
p6950
(F1
F0.00076452599388379206
I1
I0
I1
tp6951
sS'the,cell,surface'
p6952
(F0
F0
I1
I1
I0
tp6953
sS'drug,drug,interactions'
p6954
(F1
F0.00076452599388379206
I1
I0
I1
tp6955
sS'alter,platelet,function'
p6956
(F1
F0.0015290519877675841
I2
I0
I2
tp6957
sS'such,as,or'
p6958
(F0.33333333333333331
F0.0015290519877675841
I4
I2
I2
tp6959
sS'of,nonheme,or'
p6960
(F1
F0.00076452599388379206
I0
I1
I-1
tp6961
sS'because,pergolide,mesylate'
p6962
(F1
F0.00076452599388379206
I0
I1
I-1
tp6963
sS'alone,average,tumor'
p6964
(F1
F0.00076452599388379206
I1
I0
I1
tp6965
sS'the,mtor,inhibitor'
p6966
(F1
F0.00076452599388379206
I1
I0
I1
tp6967
sS'g,maximum,g'
p6968
(F1
F0.00076452599388379206
I0
I1
I-1
tp6969
sS'contraceptives,in,normal-weight'
p6970
(F1
F0.00076452599388379206
I0
I1
I-1
tp6971
sS'rifampicin,in,patients'
p6972
(F1
F0.00076452599388379206
I1
I0
I1
tp6973
sS'results,in,a'
p6974
(F0.33333333333333331
F0.00076452599388379206
I2
I1
I1
tp6975
sS'should,be,closely'
p6976
(F1
F0.0015290519877675841
I2
I0
I2
tp6977
sS'not,interfere,with'
p6978
(F1
F0.00076452599388379206
I0
I1
I-1
tp6979
sS'action,of,mivacron'
p6980
(F1
F0.00076452599388379206
I1
I0
I1
tp6981
sS'of,hiv-infected,patients'
p6982
(F1
F0.00076452599388379206
I1
I0
I1
tp6983
sS'general,or,other'
p6984
(F1
F0.00076452599388379206
I0
I1
I-1
tp6985
sS'use,of,mexitil'
p6986
(F1
F0.00076452599388379206
I1
I0
I1
tp6987
sS'adolescent,rats,using'
p6988
(F1
F0.00076452599388379206
I0
I1
I-1
tp6989
sS'the,strains,were'
p6990
(F1
F0.00076452599388379206
I0
I1
I-1
tp6991
sS'of,the,commonly'
p6992
(F1
F0.00076452599388379206
I0
I1
I-1
tp6993
sS'for,sites,of'
p6994
(F1
F0.00076452599388379206
I1
I0
I1
tp6995
sS'doses,of,that'
p6996
(F1
F0.00076452599388379206
I0
I1
I-1
tp6997
sS'of,are,not'
p6998
(F1
F0.00076452599388379206
I0
I1
I-1
tp6999
sS'dose,and,the'
p7000
(F1
F0.00076452599388379206
I0
I1
I-1
tp7001
sS'antagonist,analgesics,i'
p7002
(F1
F0.00076452599388379206
I1
I0
I1
tp7003
sS'and,by,some'
p7004
(F1
F0.00076452599388379206
I1
I0
I1
tp7005
sS'clearance,is,reduced'
p7006
(F1
F0.00076452599388379206
I1
I0
I1
tp7007
sS'in,mind,when'
p7008
(F1
F0.00076452599388379206
I0
I1
I-1
tp7009
sS'renal,insufficiency,creatinine'
p7010
(F1
F0.00076452599388379206
I1
I0
I1
tp7011
sS'between,lamisil,tablets'
p7012
(F1
F0.00076452599388379206
I1
I0
I1
tp7013
sS'irreversibly,inhibit,plasma'
p7014
(F1
F0.00076452599388379206
I1
I0
I1
tp7015
sS'women,the,pharmacokinetic'
p7016
(F1
F0.00076452599388379206
I0
I1
I-1
tp7017
sS'some,monoamine,oxidase'
p7018
(F1
F0.00076452599388379206
I1
I0
I1
tp7019
sS'serum,concentration,in'
p7020
(F1
F0.00076452599388379206
I1
I0
I1
tp7021
sS'were,and,lower'
p7022
(F1
F0.00076452599388379206
I1
I0
I1
tp7023
sS'other,short-acting,beta'
p7024
(F1
F0.00076452599388379206
I1
I0
I1
tp7025
sS'of,general,internal'
p7026
(F1
F0.00076452599388379206
I0
I1
I-1
tp7027
sS'when,cells,were'
p7028
(F1
F0.00076452599388379206
I1
I0
I1
tp7029
sS'combination,of,crm197'
p7030
(F1
F0.00076452599388379206
I1
I0
I1
tp7031
sS'dose,to,achieve'
p7032
(F1
F0.0015290519877675841
I2
I0
I2
tp7033
sS'with,alone,for'
p7034
(F1
F0.00076452599388379206
I1
I0
I1
tp7035
sS'on,therapy,may'
p7036
(F1
F0.00076452599388379206
I1
I0
I1
tp7037
sS'of,mg,in'
p7038
(F1
F0.0015290519877675841
I2
I0
I2
tp7039
sS'to,hours,and'
p7040
(F1
F0.00076452599388379206
I1
I0
I1
tp7041
sS'that,the,decreases'
p7042
(F1
F0.00076452599388379206
I0
I1
I-1
tp7043
sS'may,accentuate,the'
p7044
(F1
F0.00076452599388379206
I1
I0
I1
tp7045
sS'replacement,is,required'
p7046
(F1
F0.00076452599388379206
I0
I1
I-1
tp7047
sS'knockdown,of,gene'
p7048
(F1
F0.00076452599388379206
I0
I1
I-1
tp7049
sS'when,it,is'
p7050
(F1
F0.0015290519877675841
I2
I0
I2
tp7051
sS'elimination,of,causing'
p7052
(F1
F0.00076452599388379206
I1
I0
I1
tp7053
sS'fluorescent,protein,gfp'
p7054
(F1
F0.00076452599388379206
I0
I1
I-1
tp7055
sS'cns,depressants,effects'
p7056
(F1
F0.00076452599388379206
I1
I0
I1
tp7057
sS's,response,to'
p7058
(F1
F0.00076452599388379206
I1
I0
I1
tp7059
sS'shown,to,depress'
p7060
(F1
F0.00076452599388379206
I1
I0
I1
tp7061
sS'inhibitors,and,may'
p7062
(F0
F0
I1
I1
I0
tp7063
sS'time,in,the'
p7064
(F1
F0.00076452599388379206
I0
I1
I-1
tp7065
sS'antiepileptic,drugs,periodic'
p7066
(F1
F0.00076452599388379206
I1
I0
I1
tp7067
sS'activated,charcoal,because'
p7068
(F1
F0.00076452599388379206
I1
I0
I1
tp7069
sS'a,and,nutritionally-derived'
p7070
(F1
F0.00076452599388379206
I0
I1
I-1
tp7071
sS'concurrently,may,increase'
p7072
(F1
F0.00076452599388379206
I1
I0
I1
tp7073
sS'investigate,the,efficacy'
p7074
(F1
F0.00076452599388379206
I0
I1
I-1
tp7075
sS'and,a,increase'
p7076
(F1
F0.00076452599388379206
I1
I0
I1
tp7077
sS'hb-egf,in,t-all'
p7078
(F1
F0.00076452599388379206
I0
I1
I-1
tp7079
sS'qd,as,compared'
p7080
(F1
F0.00076452599388379206
I1
I0
I1
tp7081
sS'had,no,effect'
p7082
(F1
F0.00076452599388379206
I1
I0
I1
tp7083
sS'ritalin,may,inhibit'
p7084
(F1
F0.00076452599388379206
I1
I0
I1
tp7085
sS'concomitantly,with,alupent'
p7086
(F1
F0.00076452599388379206
I1
I0
I1
tp7087
sS'the,myeloproliferative,effects'
p7088
(F1
F0.00076452599388379206
I1
I0
I1
tp7089
sS'rate,of,achievement'
p7090
(F1
F0.00076452599388379206
I0
I1
I-1
tp7091
sS'convulsions,have,been'
p7092
(F1
F0.00076452599388379206
I1
I0
I1
tp7093
sS'compared,with,patients'
p7094
(F1
F0.00076452599388379206
I1
I0
I1
tp7095
sS'within,hours,of'
p7096
(F1
F0.00076452599388379206
I1
I0
I1
tp7097
sS'mutation,were,exposed'
p7098
(F1
F0.00076452599388379206
I0
I1
I-1
tp7099
sS'in,the,treatment'
p7100
(F0
F0
I2
I2
I0
tp7101
sS'monitor,blood,levels'
p7102
(F1
F0.00076452599388379206
I1
I0
I1
tp7103
sS'that,in,vivo'
p7104
(F1
F0.00076452599388379206
I0
I1
I-1
tp7105
sS'slight,increase,in'
p7106
(F1
F0.00076452599388379206
I1
I0
I1
tp7107
sS'of,and,eg'
p7108
(F1
F0.00076452599388379206
I0
I1
I-1
tp7109
sS'of,absorption,relative'
p7110
(F1
F0.00076452599388379206
I0
I1
I-1
tp7111
sS'taking,remeron,soltab'
p7112
(F1
F0.00076452599388379206
I1
I0
I1
tp7113
sS'other,nondepolarizing,neuromuscular'
p7114
(F1
F0.00076452599388379206
I0
I1
I-1
tp7115
sS'be,exercised,with'
p7116
(F1
F0.00076452599388379206
I1
I0
I1
tp7117
sS'other,drugs,and'
p7118
(F1
F0.00076452599388379206
I1
I0
I1
tp7119
sS'combination,to,rheumatoid'
p7120
(F1
F0.00076452599388379206
I0
I1
I-1
tp7121
sS'case,to,result'
p7122
(F1
F0.00076452599388379206
I1
I0
I1
tp7123
sS'mexitil,does,not'
p7124
(F1
F0.00076452599388379206
I1
I0
I1
tp7125
sS'inhibitory,effect,of'
p7126
(F1
F0.00076452599388379206
I1
I0
I1
tp7127
sS'patients,with,paget'
p7128
(F1
F0.00076452599388379206
I1
I0
I1
tp7129
sS'concomitantly,the,patient'
p7130
(F1
F0.00076452599388379206
I1
I0
I1
tp7131
sS'mg,qd,as'
p7132
(F1
F0.00076452599388379206
I1
I0
I1
tp7133
sS'cns,depressants,can'
p7134
(F1
F0.00076452599388379206
I1
I0
I1
tp7135
sS'when,was,co-administered'
p7136
(F1
F0.00076452599388379206
I0
I1
I-1
tp7137
sS'were,all,significantly'
p7138
(F1
F0.00076452599388379206
I1
I0
I1
tp7139
sS'a,common,clinical'
p7140
(F1
F0.00076452599388379206
I1
I0
I1
tp7141
sS'other,agents,no'
p7142
(F1
F0.00076452599388379206
I0
I1
I-1
tp7143
sS'disintegrating,tablets,may'
p7144
(F1
F0.00076452599388379206
I0
I1
I-1
tp7145
sS'this,synergism,is'
p7146
(F1
F0.00076452599388379206
I1
I0
I1
tp7147
sS'taking,other,drugs'
p7148
(F1
F0.00076452599388379206
I1
I0
I1
tp7149
sS'administration,of,chemet'
p7150
(F1
F0.00076452599388379206
I1
I0
I1
tp7151
sS'plus,enhanced,cytotoxicity'
p7152
(F1
F0.00076452599388379206
I1
I0
I1
tp7153
sS'or,the,inr'
p7154
(F1
F0.00076452599388379206
I0
I1
I-1
tp7155
sS'of,and,and'
p7156
(F1
F0.00076452599388379206
I1
I0
I1
tp7157
sS'two,controlled,week'
p7158
(F1
F0.00076452599388379206
I0
I1
I-1
tp7159
sS'the,potent,cytochrome'
p7160
(F1
F0.00076452599388379206
I1
I0
I1
tp7161
sS'use,of,succinate'
p7162
(F1
F0.00076452599388379206
I1
I0
I1
tp7163
sS'mg,diminished,absorption'
p7164
(F1
F0.00076452599388379206
I1
I0
I1
tp7165
sS'clinical,drug,interaction'
p7166
(F1
F0.00076452599388379206
I1
I0
I1
tp7167
sS'a4,or,its'
p7168
(F1
F0.00076452599388379206
I0
I1
I-1
tp7169
sS'those,started,recently'
p7170
(F1
F0.00076452599388379206
I1
I0
I1
tp7171
sS'published,in,found'
p7172
(F1
F0.00076452599388379206
I1
I0
I1
tp7173
sS'that,the,signaling'
p7174
(F1
F0.00076452599388379206
I1
I0
I1
tp7175
sS'reports,suggest,that'
p7176
(F1
F0.00076452599388379206
I1
I0
I1
tp7177
sS'of,or,on'
p7178
(F1
F0.00076452599388379206
I0
I1
I-1
tp7179
sS'dosing,with,and'
p7180
(F1
F0.00076452599388379206
I1
I0
I1
tp7181
sS'and,may,produce'
p7182
(F1
F0.00076452599388379206
I0
I1
I-1
tp7183
sS'effect,was,found'
p7184
(F1
F0.00076452599388379206
I0
I1
I-1
tp7185
sS'elavil,asendin,sinequan'
p7186
(F1
F0.00076452599388379206
I0
I1
I-1
tp7187
sS'and,results,in'
p7188
(F1
F0.00076452599388379206
I1
I0
I1
tp7189
sS'other,azole-type,antifungal'
p7190
(F1
F0.00076452599388379206
I1
I0
I1
tp7191
sS'inhibit,the,breakdown'
p7192
(F1
F0.00076452599388379206
I1
I0
I1
tp7193
sS'other,agents,which'
p7194
(F1
F0.00076452599388379206
I1
I0
I1
tp7195
sS'of,gastric,acid'
p7196
(F1
F0.00076452599388379206
I1
I0
I1
tp7197
sS'activated,by,exposure'
p7198
(F1
F0.00076452599388379206
I1
I0
I1
tp7199
sS'sedation,including,a'
p7200
(F1
F0.00076452599388379206
I0
I1
I-1
tp7201
sS'of,in,patients'
p7202
(F1
F0.00076452599388379206
I1
I0
I1
tp7203
sS'cytochrome,p450,inducers'
p7204
(F1
F0.00076452599388379206
I1
I0
I1
tp7205
sS'of,decreased,absorption'
p7206
(F1
F0.00076452599388379206
I0
I1
I-1
tp7207
sS'clinical,outcome,in'
p7208
(F1
F0.00076452599388379206
I0
I1
I-1
tp7209
sS'oral,antidiabetic,drugs'
p7210
(F1
F0.00076452599388379206
I1
I0
I1
tp7211
sS'or,failed,to'
p7212
(F1
F0.00076452599388379206
I1
I0
I1
tp7213
sS'times,in,patients'
p7214
(F1
F0.00076452599388379206
I1
I0
I1
tp7215
sS'is,the,stronger'
p7216
(F1
F0.00076452599388379206
I0
I1
I-1
tp7217
sS'examples,of,some'
p7218
(F1
F0.00076452599388379206
I0
I1
I-1
tp7219
sS'improved,parathyroid,hormone'
p7220
(F1
F0.00076452599388379206
I0
I1
I-1
tp7221
sS'rat,liver,model'
p7222
(F1
F0.00076452599388379206
I1
I0
I1
tp7223
sS'significantly,lower,the'
p7224
(F1
F0.00076452599388379206
I0
I1
I-1
tp7225
sS'and,in,vitro'
p7226
(F1
F0.00076452599388379206
I0
I1
I-1
tp7227
sS'tachypnea,lethargy,coma'
p7228
(F1
F0.00076452599388379206
I1
I0
I1
tp7229
sS'of,provided,as'
p7230
(F1
F0.00076452599388379206
I1
I0
I1
tp7231
sS'be,monitored,particularly'
p7232
(F1
F0.0015290519877675841
I2
I0
I2
tp7233
sS'inducers,such,as'
p7234
(F1
F0.0030581039755351682
I4
I0
I4
tp7235
sS'function,has,been'
p7236
(F1
F0.00076452599388379206
I1
I0
I1
tp7237
sS'sutent,with,strong'
p7238
(F1
F0.00076452599388379206
I1
I0
I1
tp7239
sS'shown,to,be'
p7240
(F1
F0.0015290519877675841
I2
I0
I2
tp7241
sS'rats,and,were'
p7242
(F1
F0.00076452599388379206
I0
I1
I-1
tp7243
sS'vasopressors,particularly,may'
p7244
(F1
F0.0015290519877675841
I2
I0
I2
tp7245
sS'antidepressant,drugs,hcl'
p7246
(F1
F0.00076452599388379206
I1
I0
I1
tp7247
sS'hypokalemia,may,enhance'
p7248
(F1
F0.00076452599388379206
I1
I0
I1
tp7249
sS'of,is,impaired'
p7250
(F1
F0.00076452599388379206
I1
I0
I1
tp7251
sS'studies,acetylsalicylic,acid'
p7252
(F1
F0.00076452599388379206
I0
I1
I-1
tp7253
sS'spontaneous,accounts,of'
p7254
(F1
F0.00076452599388379206
I0
I1
I-1
tp7255
sS'who,are,prescribed'
p7256
(F1
F0.00076452599388379206
I1
I0
I1
tp7257
sS'first-pass,cyp3a,activities'
p7258
(F1
F0.00076452599388379206
I0
I1
I-1
tp7259
sS'with,the,following'
p7260
(F0
F0
I1
I1
I0
tp7261
sS'evaluation,of,like'
p7262
(F1
F0.00076452599388379206
I0
I1
I-1
tp7263
sS'to,or,after'
p7264
(F1
F0.00076452599388379206
I1
I0
I1
tp7265
sS'presence,of,supplemental'
p7266
(F1
F0.00076452599388379206
I1
I0
I1
tp7267
sS'the,anti-resorptive,response'
p7268
(F1
F0.00076452599388379206
I1
I0
I1
tp7269
sS'level,of,free'
p7270
(F1
F0.00076452599388379206
I0
I1
I-1
tp7271
sS'pharmacokinetics,pharmacodynamics,fecal'
p7272
(F1
F0.00076452599388379206
I0
I1
I-1
tp7273
sS'and,g,of'
p7274
(F1
F0.00076452599388379206
I0
I1
I-1
tp7275
sS'to,and,did'
p7276
(F1
F0.00076452599388379206
I0
I1
I-1
tp7277
sS'healthy,subjects,receiving'
p7278
(F1
F0.00076452599388379206
I0
I1
I-1
tp7279
sS'were,efficiently,suppressed'
p7280
(F1
F0.00076452599388379206
I1
I0
I1
tp7281
sS'and,without,unexpected'
p7282
(F1
F0.00076452599388379206
I0
I1
I-1
tp7283
sS'or,causing,too'
p7284
(F1
F0.00076452599388379206
I1
I0
I1
tp7285
sS'of,it,should'
p7286
(F1
F0.00076452599388379206
I1
I0
I1
tp7287
sS'because,have,been'
p7288
(F1
F0.00076452599388379206
I1
I0
I1
tp7289
sS'whether,the,highly'
p7290
(F1
F0.00076452599388379206
I0
I1
I-1
tp7291
sS'that,low-dose,added'
p7292
(F1
F0.00076452599388379206
I1
I0
I1
tp7293
sS'of,patients,showed'
p7294
(F1
F0.00076452599388379206
I0
I1
I-1
tp7295
sS'administering,feldene,to'
p7296
(F1
F0.00076452599388379206
I1
I0
I1
tp7297
sS'severe,obstipation,even'
p7298
(F1
F0.00076452599388379206
I1
I0
I1
tp7299
sS'solid,tumors,and'
p7300
(F1
F0.00076452599388379206
I0
I1
I-1
tp7301
sS'of,multiple,doses'
p7302
(F1
F0.00076452599388379206
I0
I1
I-1
tp7303
sS'is,primarily,metabolized'
p7304
(F1
F0.00076452599388379206
I0
I1
I-1
tp7305
sS'at,mg,daily'
p7306
(F1
F0.0030581039755351682
I0
I4
I-4
tp7307
sS'dosage,requirements,when'
p7308
(F1
F0.0015290519877675841
I2
I0
I2
tp7309
sS'with,agents,and'
p7310
(F1
F0.00076452599388379206
I0
I1
I-1
tp7311
sS'days,after,initiating'
p7312
(F1
F0.00076452599388379206
I1
I0
I1
tp7313
sS'took,variable,doses'
p7314
(F1
F0.00076452599388379206
I1
I0
I1
tp7315
sS'administrations,not,recommended'
p7316
(F1
F0.00076452599388379206
I1
I0
I1
tp7317
sS'and,cci-779,in'
p7318
(F1
F0.00076452599388379206
I0
I1
I-1
tp7319
sS'of,ointment,on'
p7320
(F1
F0.00076452599388379206
I1
I0
I1
tp7321
sS'live,vaccines,during'
p7322
(F1
F0.00076452599388379206
I1
I0
I1
tp7323
sS'short-acting,beta,adrenergic'
p7324
(F1
F0.00076452599388379206
I1
I0
I1
tp7325
sS'nonheme,as,sulfate'
p7326
(F1
F0.00076452599388379206
I1
I0
I1
tp7327
sS'too,great,a'
p7328
(F1
F0.00076452599388379206
I1
I0
I1
tp7329
sS'case,report,in'
p7330
(F1
F0.00076452599388379206
I1
I0
I1
tp7331
sS'systemic,and,apparent'
p7332
(F1
F0.00076452599388379206
I1
I0
I1
tp7333
sS'increases,the,clearance'
p7334
(F1
F0.00076452599388379206
I1
I0
I1
tp7335
sS'effects,may,be'
p7336
(F1
F0.00076452599388379206
I1
I0
I1
tp7337
sS'the,desired,level'
p7338
(F1
F0.00076452599388379206
I1
I0
I1
tp7339
sS'sometimes,with,improved'
p7340
(F1
F0.00076452599388379206
I0
I1
I-1
tp7341
sS'is,anticipated,it'
p7342
(F1
F0.00076452599388379206
I1
I0
I1
tp7343
sS'bcl-2,and,cdk1'
p7344
(F0
F0
I1
I1
I0
tp7345
sS'depressants,meperidine,should'
p7346
(F1
F0.00076452599388379206
I1
I0
I1
tp7347
sS'in,additive,sedation'
p7348
(F1
F0.00076452599388379206
I1
I0
I1
tp7349
sS'test,for,pheochromocytoma'
p7350
(F1
F0.00076452599388379206
I0
I1
I-1
tp7351
sS'parameters,of,are'
p7352
(F1
F0.00076452599388379206
I0
I1
I-1
tp7353
sS'drops,before,feeds'
p7354
(F1
F0.00076452599388379206
I0
I1
I-1
tp7355
sS'that,are,also'
p7356
(F1
F0.00076452599388379206
I1
I0
I1
tp7357
sS'action,of,will'
p7358
(F1
F0.00076452599388379206
I1
I0
I1
tp7359
sS'parathyroidism,causes,bone'
p7360
(F1
F0.00076452599388379206
I0
I1
I-1
tp7361
sS'secretion,of,organic'
p7362
(F0
F0
I1
I1
I0
tp7363
sS'and,decreased,metabolite'
p7364
(F1
F0.00076452599388379206
I1
I0
I1
tp7365
sS'capsules,should,not'
p7366
(F1
F0.00076452599388379206
I1
I0
I1
tp7367
sS'in,a,increase'
p7368
(F1
F0.00076452599388379206
I1
I0
I1
tp7369
sS'and,on,mptp-evoked'
p7370
(F1
F0.00076452599388379206
I0
I1
I-1
tp7371
sS'of,various,drugs'
p7372
(F1
F0.00076452599388379206
I1
I0
I1
tp7373
sS'of,either,oral'
p7374
(F1
F0.00076452599388379206
I0
I1
I-1
tp7375
sS'mg,m2,eloxatin'
p7376
(F0
F0
I1
I1
I0
tp7377
sS'and,cmax,by'
p7378
(F1
F0.00076452599388379206
I1
I0
I1
tp7379
sS'not,recommended,terfenadine'
p7380
(F1
F0.00076452599388379206
I1
I0
I1
tp7381
sS'for,and,were'
p7382
(F1
F0.00076452599388379206
I0
I1
I-1
tp7383
sS'may,be,a'
p7384
(F1
F0.00076452599388379206
I0
I1
I-1
tp7385
sS'due,to,mexitil'
p7386
(F1
F0.00076452599388379206
I1
I0
I1
tp7387
sS'it,may,be'
p7388
(F1
F0.0015290519877675841
I2
I0
I2
tp7389
sS'oral,have,shown'
p7390
(F1
F0.00076452599388379206
I1
I0
I1
tp7391
sS'and,further,increase'
p7392
(F1
F0.00076452599388379206
I0
I1
I-1
tp7393
sS'evidence,that,the'
p7394
(F1
F0.00076452599388379206
I1
I0
I1
tp7395
sS'absorption,and,enterohepatic'
p7396
(F1
F0.00076452599388379206
I1
I0
I1
tp7397
sS'advised,when,is'
p7398
(F1
F0.00076452599388379206
I1
I0
I1
tp7399
sS'are,secreted,by'
p7400
(F1
F0.00076452599388379206
I1
I0
I1
tp7401
sS'in,s-warfarin,half-life'
p7402
(F1
F0.00076452599388379206
I1
I0
I1
tp7403
sS'or,after,other'
p7404
(F1
F0.00076452599388379206
I0
I1
I-1
tp7405
sS'and,administered,with'
p7406
(F1
F0.00076452599388379206
I0
I1
I-1
tp7407
sS'reduction,of,pth'
p7408
(F1
F0.00076452599388379206
I1
I0
I1
tp7409
sS'elicit,this,activity'
p7410
(F1
F0.00076452599388379206
I1
I0
I1
tp7411
sS'be,interrupted,close'
p7412
(F1
F0.00076452599388379206
I1
I0
I1
tp7413
sS'be,reduced,by'
p7414
(F1
F0.0015290519877675841
I2
I0
I2
tp7415
sS'terminal,deoxynucleotidyl,transferase-mediated'
p7416
(F1
F0.00076452599388379206
I0
I1
I-1
tp7417
sS'analgesics,general,anesthetics'
p7418
(F1
F0.00076452599388379206
I1
I0
I1
tp7419
sS'oral,clearance,of'
p7420
(F1
F0.0015290519877675841
I2
I0
I2
tp7421
sS'reproductive,toxicity,at'
p7422
(F1
F0.00076452599388379206
I0
I1
I-1
tp7423
sS'on,this,experience'
p7424
(F1
F0.00076452599388379206
I1
I0
I1
tp7425
sS'intraperitoneally,min,before'
p7426
(F1
F0.00076452599388379206
I0
I1
I-1
tp7427
sS'other,nonsteroidal,anti-inflammatory'
p7428
(F1
F0.00076452599388379206
I1
I0
I1
tp7429
sS'cmax,and,auc'
p7430
(F1
F0.00076452599388379206
I1
I0
I1
tp7431
sS'concomitantly,with,ace'
p7432
(F1
F0.00076452599388379206
I1
I0
I1
tp7433
sS'ganglionic,or,peripheral'
p7434
(F1
F0.00076452599388379206
I0
I1
I-1
tp7435
sS'bone,marrow,fibrosis'
p7436
(F1
F0.00076452599388379206
I0
I1
I-1
tp7437
sS'of,zetia,with'
p7438
(F1
F0.00076452599388379206
I1
I0
I1
tp7439
sS'hour,after,the'
p7440
(F1
F0.00076452599388379206
I1
I0
I1
tp7441
sS'although,no,pharmacokinetic'
p7442
(F1
F0.00076452599388379206
I1
I0
I1
tp7443
sS'and,prothrombin,time'
p7444
(F1
F0.00076452599388379206
I1
I0
I1
tp7445
sS'other,belladonna,alkaloids'
p7446
(F1
F0.00076452599388379206
I0
I1
I-1
tp7447
sS'may,diminish,the'
p7448
(F1
F0.0022935779816513763
I3
I0
I3
tp7449
sS'liver,s,ability'
p7450
(F1
F0.00076452599388379206
I1
I0
I1
tp7451
sS'is,initiated,in'
p7452
(F1
F0.00076452599388379206
I1
I0
I1
tp7453
sS'healthy,subjects,mean'
p7454
(F1
F0.00076452599388379206
I1
I0
I1
tp7455
sS'meperidine,should,be'
p7456
(F1
F0.00076452599388379206
I1
I0
I1
tp7457
sS'in,plasma,profiles'
p7458
(F1
F0.00076452599388379206
I0
I1
I-1
tp7459
sS'and,reduce,the'
p7460
(F1
F0.00076452599388379206
I1
I0
I1
tp7461
sS'in,methyl-4,phenyl-1'
p7462
(F1
F0.0015290519877675841
I2
I0
I2
tp7463
sS'or,ferrous,gluconate'
p7464
(F1
F0.00076452599388379206
I1
I0
I1
tp7465
sS'acetyl-l,carnitine,and'
p7466
(F1
F0.00076452599388379206
I0
I1
I-1
tp7467
sS'amphetamine-paired,context,compared'
p7468
(F1
F0.00076452599388379206
I0
I1
I-1
tp7469
sS'are,no,controlled'
p7470
(F1
F0.00076452599388379206
I0
I1
I-1
tp7471
sS'higher,dose,of'
p7472
(F1
F0.00076452599388379206
I1
I0
I1
tp7473
sS'events,in,connection'
p7474
(F1
F0.00076452599388379206
I0
I1
I-1
tp7475
sS'lower,in,cyclosporine-treated'
p7476
(F0
F0
I1
I1
I0
tp7477
sS'should,closely,monitor'
p7478
(F1
F0.0015290519877675841
I2
I0
I2
tp7479
sS'were,unaffected,by'
p7480
(F1
F0.00076452599388379206
I0
I1
I-1
tp7481
sS'ropivacaine,leading,to'
p7482
(F1
F0.00076452599388379206
I1
I0
I1
tp7483
sS'initiation,of,an'
p7484
(F1
F0.00076452599388379206
I0
I1
I-1
tp7485
sS'dose,pharmacokinetic,studies'
p7486
(F1
F0.00076452599388379206
I0
I1
I-1
tp7487
sS'daily,mg,once'
p7488
(F1
F0.00076452599388379206
I0
I1
I-1
tp7489
sS'the,preclinical,combination'
p7490
(F1
F0.00076452599388379206
I1
I0
I1
tp7491
sS'ace,inhibitors,reports'
p7492
(F1
F0.00076452599388379206
I1
I0
I1
tp7493
sS'and,can,antagonize'
p7494
(F1
F0.00076452599388379206
I1
I0
I1
tp7495
sS'an,effect,on'
p7496
(F0
F0
I1
I1
I0
tp7497
sS'than,in,methyl-4'
p7498
(F1
F0.00076452599388379206
I1
I0
I1
tp7499
sS'auc,to,auc'
p7500
(F1
F0.00076452599388379206
I0
I1
I-1
tp7501
sS'of,was,observed'
p7502
(F1
F0.00076452599388379206
I1
I0
I1
tp7503
sS'was,decreased,following'
p7504
(F1
F0.00076452599388379206
I1
I0
I1
tp7505
sS'all,incubation,schedules'
p7506
(F1
F0.00076452599388379206
I1
I0
I1
tp7507
sS'drugs,tramadol,although'
p7508
(F1
F0.00076452599388379206
I1
I0
I1
tp7509
sS'fibrates,the,safety'
p7510
(F1
F0.00076452599388379206
I0
I1
I-1
tp7511
sS'of,with,different'
p7512
(F1
F0.00076452599388379206
I1
I0
I1
tp7513
sS'the,synergistic,antinociception'
p7514
(F1
F0.00076452599388379206
I1
I0
I1
tp7515
sS'increased,effect,decreased'
p7516
(F1
F0.0015290519877675841
I0
I2
I-2
tp7517
sS'crm197,induced,apoptosis'
p7518
(F1
F0.00076452599388379206
I1
I0
I1
tp7519
sS'considered,for,patients'
p7520
(F1
F0.00076452599388379206
I1
I0
I1
tp7521
sS'dopaminergic,neurons,as'
p7522
(F1
F0.00076452599388379206
I1
I0
I1
tp7523
sS'depth,of,transduction'
p7524
(F1
F0.00076452599388379206
I0
I1
I-1
tp7525
sS'b,or,local'
p7526
(F1
F0.00076452599388379206
I0
I1
I-1
tp7527
sS'studies,with,forced'
p7528
(F1
F0.00076452599388379206
I1
I0
I1
tp7529
sS'tablets,and,these'
p7530
(F1
F0.00076452599388379206
I1
I0
I1
tp7531
sS'of,other,cns'
p7532
(F0.33333333333333331
F0.00076452599388379206
I2
I1
I1
tp7533
sS'nsaids,concomitant,administration'
p7534
(F1
F0.00076452599388379206
I1
I0
I1
tp7535
sS'showed,a,reduction'
p7536
(F1
F0.00076452599388379206
I1
I0
I1
tp7537
sS'in,drug-interaction,studies'
p7538
(F1
F0.00076452599388379206
I0
I1
I-1
tp7539
sS'in,concentrations,and'
p7540
(F1
F0.00076452599388379206
I1
I0
I1
tp7541
sS'a,corresponding,decrease'
p7542
(F1
F0.00076452599388379206
I1
I0
I1
tp7543
sS'on,the,kinetics'
p7544
(F1
F0.00076452599388379206
I0
I1
I-1
tp7545
sS'ticagrelor,brilinta,better'
p7546
(F1
F0.00076452599388379206
I0
I1
I-1
tp7547
sS'inhibits,the,metabolism'
p7548
(F1
F0.00076452599388379206
I1
I0
I1
tp7549
sS'it,has,been'
p7550
(F1
F0.0015290519877675841
I2
I0
I2
tp7551
sS'increase,in,dosage'
p7552
(F1
F0.00076452599388379206
I1
I0
I1
tp7553
sS'rivastigmine,is,primarily'
p7554
(F1
F0.00076452599388379206
I0
I1
I-1
tp7555
sS'fold,higher,when'
p7556
(F1
F0.00076452599388379206
I1
I0
I1
tp7557
sS'treated,with,proton'
p7558
(F1
F0.00076452599388379206
I1
I0
I1
tp7559
sS'with,nexavar,resulted'
p7560
(F1
F0.00076452599388379206
I1
I0
I1
tp7561
sS'myfortic,the,use'
p7562
(F1
F0.00076452599388379206
I1
I0
I1
tp7563
sS'normal-weight,mildly,hypercholesterolemic'
p7564
(F1
F0.00076452599388379206
I0
I1
I-1
tp7565
sS'of,thrombotic,cardiovascular'
p7566
(F1
F0.00076452599388379206
I1
I0
I1
tp7567
sS'that,may,bind'
p7568
(F1
F0.00076452599388379206
I1
I0
I1
tp7569
sS'or,with,for'
p7570
(F1
F0.00076452599388379206
I0
I1
I-1
tp7571
sS'cell,cycle,at'
p7572
(F1
F0.00076452599388379206
I0
I1
I-1
tp7573
sS'injection,to,patients'
p7574
(F1
F0.00076452599388379206
I0
I1
I-1
tp7575
sS'potentiate,the,pressor'
p7576
(F1
F0.00076452599388379206
I1
I0
I1
tp7577
sS'insufficiency,should,avoid'
p7578
(F1
F0.00076452599388379206
I1
I0
I1
tp7579
sS'protease,inhibitors,calcium'
p7580
(F1
F0.00076452599388379206
I1
I0
I1
tp7581
sS'corticosteroids,or,acth'
p7582
(F1
F0.00076452599388379206
I0
I1
I-1
tp7583
sS'a,substrate,of'
p7584
(F1
F0.0022935779816513763
I0
I3
I-3
tp7585
sS'increase,in,intracellular'
p7586
(F1
F0.00076452599388379206
I1
I0
I1
tp7587
sS'present,study,we'
p7588
(F1
F0.00076452599388379206
I0
I1
I-1
tp7589
sS'with,either,sirnas'
p7590
(F1
F0.00076452599388379206
I1
I0
I1
tp7591
sS'timing,of,dosage'
p7592
(F1
F0.00076452599388379206
I1
I0
I1
tp7593
sS'different,cancer,cell'
p7594
(F1
F0.00076452599388379206
I0
I1
I-1
tp7595
sS'and,especially,those'
p7596
(F1
F0.00076452599388379206
I1
I0
I1
tp7597
sS'are,eliminated,by'
p7598
(F0
F0
I1
I1
I0
tp7599
sS'hydroxychloroquine,sulfate,levothyroxine'
p7600
(F1
F0.00076452599388379206
I0
I1
I-1
tp7601
sS'to,mg,day'
p7602
(F1
F0.00076452599388379206
I0
I1
I-1
tp7603
sS'sensitivity,cell,cycle'
p7604
(F1
F0.00076452599388379206
I0
I1
I-1
tp7605
sS'active,tubular,secretion'
p7606
(F1
F0.0022935779816513763
I3
I0
I3
tp7607
sS'furafylline,and,had'
p7608
(F1
F0.00076452599388379206
I1
I0
I1
tp7609
sS'or,oral,agents'
p7610
(F1
F0.00076452599388379206
I1
I0
I1
tp7611
sS'higher,than,those'
p7612
(F1
F0.00076452599388379206
I0
I1
I-1
tp7613
sS'administered,with,a'
p7614
(F1
F0.00076452599388379206
I1
I0
I1
tp7615
sS'mobic,may,result'
p7616
(F1
F0.00076452599388379206
I1
I0
I1
tp7617
sS'vivo,the,plasma'
p7618
(F1
F0.00076452599388379206
I1
I0
I1
tp7619
sS'the,fda,has'
p7620
(F1
F0.00076452599388379206
I1
I0
I1
tp7621
sS'markedly,potentiated,in'
p7622
(F1
F0.0015290519877675841
I2
I0
I2
tp7623
sS'receiving,other,narcotic'
p7624
(F1
F0.00076452599388379206
I1
I0
I1
tp7625
sS'vumon,injection,to'
p7626
(F1
F0.00076452599388379206
I0
I1
I-1
tp7627
sS'demonstrate,that,chronic'
p7628
(F1
F0.00076452599388379206
I1
I0
I1
tp7629
sS'impairs,the,intestinal'
p7630
(F1
F0.00076452599388379206
I1
I0
I1
tp7631
sS'drowsiness,and,or'
p7632
(F1
F0.00076452599388379206
I1
I0
I1
tp7633
sS'of,a,concomitant'
p7634
(F1
F0.00076452599388379206
I1
I0
I1
tp7635
sS'drug,interaction,between'
p7636
(F0.33333333333333331
F0.00076452599388379206
I1
I2
I-1
tp7637
sS'effect,appeared,less'
p7638
(F1
F0.00076452599388379206
I0
I1
I-1
tp7639
sS'patients,receiving,these'
p7640
(F1
F0.00076452599388379206
I0
I1
I-1
tp7641
sS'pharmacokinetic,interaction,was'
p7642
(F1
F0.00076452599388379206
I0
I1
I-1
tp7643
sS'of,diflucan,when'
p7644
(F1
F0.00076452599388379206
I1
I0
I1
tp7645
sS'a,fold,decrease'
p7646
(F1
F0.00076452599388379206
I0
I1
I-1
tp7647
sS'receiving,high-dose,and'
p7648
(F1
F0.00076452599388379206
I1
I0
I1
tp7649
sS'no,supporting,experimental'
p7650
(F1
F0.00076452599388379206
I1
I0
I1
tp7651
sS'or,high,blood'
p7652
(F1
F0.00076452599388379206
I0
I1
I-1
tp7653
sS'related,to,amide-type'
p7654
(F1
F0.00076452599388379206
I1
I0
I1
tp7655
sS'terbinafine,increases,the'
p7656
(F1
F0.00076452599388379206
I1
I0
I1
tp7657
sS'changes,in,inr'
p7658
(F1
F0.00076452599388379206
I1
I0
I1
tp7659
sS'dependent,in,human'
p7660
(F1
F0.00076452599388379206
I1
I0
I1
tp7661
sS'was,lower,than'
p7662
(F1
F0.00076452599388379206
I1
I0
I1
tp7663
sS'as,or,certain'
p7664
(F1
F0.00076452599388379206
I0
I1
I-1
tp7665
sS'nephrotoxicity,in,patients'
p7666
(F1
F0.00076452599388379206
I1
I0
I1
tp7667
sS'pamelor,tofranil,anafranil'
p7668
(F1
F0.00076452599388379206
I0
I1
I-1
tp7669
sS'evidence,that,can'
p7670
(F1
F0.00076452599388379206
I1
I0
I1
tp7671
sS'origins,to,several'
p7672
(F1
F0.00076452599388379206
I0
I1
I-1
tp7673
sS'please,note,that'
p7674
(F1
F0.00076452599388379206
I1
I0
I1
tp7675
sS'anticoagulant,activity,should'
p7676
(F1
F0.00076452599388379206
I1
I0
I1
tp7677
sS'levels,but,magnesium-aluminum'
p7678
(F1
F0.00076452599388379206
I1
I0
I1
tp7679
sS'fertility,studies,of'
p7680
(F1
F0.00076452599388379206
I0
I1
I-1
tp7681
sS'purpose,of,this'
p7682
(F1
F0.00076452599388379206
I0
I1
I-1
tp7683
sS'reported,in,some'
p7684
(F1
F0.0015290519877675841
I2
I0
I2
tp7685
sS'a,slight,decrease'
p7686
(F1
F0.00076452599388379206
I0
I1
I-1
tp7687
sS'pharmacokinetics,and,on'
p7688
(F1
F0.00076452599388379206
I1
I0
I1
tp7689
sS'mg,kg,and'
p7690
(F1
F0.00076452599388379206
I0
I1
I-1
tp7691
sS'other,loop,given'
p7692
(F1
F0.00076452599388379206
I1
I0
I1
tp7693
sS'drugs,remarkably,enhanced'
p7694
(F1
F0.00076452599388379206
I1
I0
I1
tp7695
sS'the,volume,contraction'
p7696
(F1
F0.00076452599388379206
I0
I1
I-1
tp7697
sS'therefore,do,not'
p7698
(F1
F0.00076452599388379206
I1
I0
I1
tp7699
sS'injection,polymyxin,b'
p7700
(F1
F0.00076452599388379206
I0
I1
I-1
tp7701
sS'of,hey,xenograft-bearing'
p7702
(F1
F0.00076452599388379206
I1
I0
I1
tp7703
sS'the,safety,of'
p7704
(F1
F0.0015290519877675841
I0
I2
I-2
tp7705
sS'pharmacokinetics,were,observed'
p7706
(F1
F0.00076452599388379206
I0
I1
I-1
tp7707
sS'affect,the,clearance'
p7708
(F1
F0.00076452599388379206
I0
I1
I-1
tp7709
sS'cholestyramine,pretreatment,for'
p7710
(F1
F0.00076452599388379206
I1
I0
I1
tp7711
sS'chronic,treatment,with'
p7712
(F0
F0
I1
I1
I0
tp7713
sS'of,parkinsonian,motor'
p7714
(F1
F0.00076452599388379206
I0
I1
I-1
tp7715
sS'of,the,cytochrome'
p7716
(F1
F0.00076452599388379206
I1
I0
I1
tp7717
sS'application,in,patients'
p7718
(F1
F0.00076452599388379206
I0
I1
I-1
tp7719
sS'xenical,did,not'
p7720
(F1
F0.0030581039755351682
I0
I4
I-4
tp7721
sS'blocking,agents,h2'
p7722
(F1
F0.00076452599388379206
I0
I1
I-1
tp7723
sS'to,occur,with'
p7724
(F1
F0.00076452599388379206
I0
I1
I-1
tp7725
sS'cytotoxicity,in,a'
p7726
(F1
F0.00076452599388379206
I1
I0
I1
tp7727
sS'and,adjustment,of'
p7728
(F1
F0.00076452599388379206
I1
I0
I1
tp7729
sS'wine,yogurt,ripe'
p7730
(F1
F0.00076452599388379206
I1
I0
I1
tp7731
sS'enhanced,locomotor,sensitization'
p7732
(F1
F0.00076452599388379206
I1
I0
I1
tp7733
sS'of,on,prothrombin'
p7734
(F1
F0.00076452599388379206
I0
I1
I-1
tp7735
sS'separate,occasions,with'
p7736
(F1
F0.00076452599388379206
I1
I0
I1
tp7737
sS'sanctura,have,not'
p7738
(F1
F0.00076452599388379206
I1
I0
I1
tp7739
sS'on,clinical,outcome'
p7740
(F1
F0.00076452599388379206
I0
I1
I-1
tp7741
sS'intravitreal,delivery,of'
p7742
(F1
F0.00076452599388379206
I0
I1
I-1
tp7743
sS'following,succinylcholine-facilitated,tracheal'
p7744
(F1
F0.00076452599388379206
I0
I1
I-1
tp7745
sS'locomotor,sensitization,and'
p7746
(F1
F0.0015290519877675841
I0
I2
I-2
tp7747
sS'a,drug-drug,interaction'
p7748
(F0
F0
I1
I1
I0
tp7749
sS'diabetic,patients,under'
p7750
(F1
F0.00076452599388379206
I0
I1
I-1
tp7751
sS'been,rare,reports'
p7752
(F1
F0.00076452599388379206
I0
I1
I-1
tp7753
sS'with,and,in'
p7754
(F1
F0.00076452599388379206
I1
I0
I1
tp7755
sS'gfp,under,the'
p7756
(F1
F0.00076452599388379206
I0
I1
I-1
tp7757
sS'vitro,evidence,that'
p7758
(F1
F0.00076452599388379206
I1
I0
I1
tp7759
sS'of,mg,kg'
p7760
(F1
F0.0015290519877675841
I0
I2
I-2
tp7761
sS'does,not,alter'
p7762
(F0
F0
I1
I1
I0
tp7763
sS'of,methyl-1,thiazol-4'
p7764
(F1
F0.00076452599388379206
I0
I1
I-1
tp7765
sS'concurrently,with,similar'
p7766
(F1
F0.00076452599388379206
I1
I0
I1
tp7767
sS'an,additive,effect'
p7768
(F1
F0.0015290519877675841
I2
I0
I2
tp7769
sS'pregnancies,on,two'
p7770
(F1
F0.00076452599388379206
I1
I0
I1
tp7771
sS'post-marketing,experience,as'
p7772
(F1
F0.00076452599388379206
I1
I0
I1
tp7773
sS'under,the,effect-time'
p7774
(F1
F0.00076452599388379206
I0
I1
I-1
tp7775
sS'for,interaction,between'
p7776
(F1
F0.00076452599388379206
I0
I1
I-1
tp7777
sS'increased,plasma,levels'
p7778
(F1
F0.00076452599388379206
I1
I0
I1
tp7779
sS'benzodiazepines,following,oral'
p7780
(F1
F0.00076452599388379206
I1
I0
I1
tp7781
sS'blocks,the,renal'
p7782
(F1
F0.00076452599388379206
I1
I0
I1
tp7783
sS'than,in,matched'
p7784
(F1
F0.00076452599388379206
I1
I0
I1
tp7785
sS'cohorts,of,nonmatched'
p7786
(F1
F0.00076452599388379206
I0
I1
I-1
tp7787
sS'and,cmax,were'
p7788
(F1
F0.00076452599388379206
I1
I0
I1
tp7789
sS'hy-per,parathyroidism,causes'
p7790
(F1
F0.00076452599388379206
I0
I1
I-1
tp7791
sS'cimetidine,the,effects'
p7792
(F1
F0.00076452599388379206
I0
I1
I-1
tp7793
sS'from,studies,that'
p7794
(F1
F0.00076452599388379206
I1
I0
I1
tp7795
sS'divalproex,sodium,valproic'
p7796
(F1
F0.00076452599388379206
I0
I1
I-1
tp7797
sS'the,serum,concentrations'
p7798
(F0
F0
I1
I1
I0
tp7799
sS'bronchospasm,killed,virus'
p7800
(F1
F0.00076452599388379206
I1
I0
I1
tp7801
sS'drugs,may,decrease'
p7802
(F1
F0.00076452599388379206
I1
I0
I1
tp7803
sS'with,significantly,increased'
p7804
(F1
F0.00076452599388379206
I1
I0
I1
tp7805
sS'of,her2-positive,breast'
p7806
(F1
F0.00076452599388379206
I1
I0
I1
tp7807
sS'the,serum,levels'
p7808
(F1
F0.00076452599388379206
I1
I0
I1
tp7809
sS'until,normal,hematopoiesis'
p7810
(F1
F0.00076452599388379206
I0
I1
I-1
tp7811
sS'cells,from,different'
p7812
(F1
F0.00076452599388379206
I0
I1
I-1
tp7813
sS'oral,mg,twice'
p7814
(F0
F0
I1
I1
I0
tp7815
sS'the,elimination,of'
p7816
(F1
F0.00076452599388379206
I1
I0
I1
tp7817
sS'a,increase,in'
p7818
(F1
F0.0015290519877675841
I2
I0
I2
tp7819
sS'auc,was,increased'
p7820
(F1
F0.00076452599388379206
I1
I0
I1
tp7821
sS'serum,and,others'
p7822
(F1
F0.00076452599388379206
I0
I1
I-1
tp7823
sS'rarely,to,cause'
p7824
(F1
F0.00076452599388379206
I1
I0
I1
tp7825
sS'weight,in,combination'
p7826
(F1
F0.00076452599388379206
I0
I1
I-1
tp7827
sS'effectiveness,of,oral'
p7828
(F1
F0.00076452599388379206
I1
I0
I1
tp7829
sS'ovarian,function,in'
p7830
(F1
F0.00076452599388379206
I1
I0
I1
tp7831
sS'diuretic-induced,hypokalemia,may'
p7832
(F1
F0.00076452599388379206
I1
I0
I1
tp7833
sS'results,in,increased'
p7834
(F1
F0.00076452599388379206
I1
I0
I1
tp7835
sS'tolerability,of,fixed'
p7836
(F1
F0.00076452599388379206
I0
I1
I-1
tp7837
sS'be,monitored,closely'
p7838
(F1
F0.0015290519877675841
I2
I0
I2
tp7839
sS'of,the,following'
p7840
(F0.33333333333333331
F0.00076452599388379206
I1
I2
I-1
tp7841
sS'reduction,of,blood'
p7842
(F1
F0.00076452599388379206
I1
I0
I1
tp7843
sS'primate,study,and'
p7844
(F1
F0.00076452599388379206
I1
I0
I1
tp7845
sS't790m,and,k-ras'
p7846
(F1
F0.00076452599388379206
I1
I0
I1
tp7847
sS'with,a,potent'
p7848
(F1
F0.00076452599388379206
I1
I0
I1
tp7849
sS'metabolism,of,other'
p7850
(F1
F0.0022935779816513763
I0
I3
I-3
tp7851
sS'oral,are,co-'
p7852
(F1
F0.00076452599388379206
I1
I0
I1
tp7853
sS'population,pk,analysis'
p7854
(F1
F0.00076452599388379206
I0
I1
I-1
tp7855
sS'adverse,reaction,reports'
p7856
(F1
F0.00076452599388379206
I1
I0
I1
tp7857
sS'these,drugs,should'
p7858
(F1
F0.0015290519877675841
I2
I0
I2
tp7859
sS'volunteer,subjects,showed'
p7860
(F1
F0.00076452599388379206
I0
I1
I-1
tp7861
sS'may,significantly,increase'
p7862
(F1
F0.00076452599388379206
I1
I0
I1
tp7863
sS'with,inactivated,ai'
p7864
(F1
F0.00076452599388379206
I1
I0
I1
tp7865
sS'dna,strand,breaks'
p7866
(F1
F0.00076452599388379206
I0
I1
I-1
tp7867
sS'role,of,cyps'
p7868
(F1
F0.00076452599388379206
I0
I1
I-1
tp7869
sS'induced,by,is'
p7870
(F1
F0.00076452599388379206
I0
I1
I-1
tp7871
sS'mg,daily,dosed'
p7872
(F1
F0.00076452599388379206
I0
I1
I-1
tp7873
sS'induce,metabolism,lowering'
p7874
(F1
F0.00076452599388379206
I1
I0
I1
tp7875
sS'patients,taking,other'
p7876
(F1
F0.00076452599388379206
I1
I0
I1
tp7877
sS'melena,have,been'
p7878
(F1
F0.00076452599388379206
I1
I0
I1
tp7879
sS'enhances,the,antinociceptive'
p7880
(F1
F0.00076452599388379206
I1
I0
I1
tp7881
sS'single,mg,dose'
p7882
(F1
F0.00076452599388379206
I1
I0
I1
tp7883
sS'receiving,ace,inhibitors'
p7884
(F1
F0.00076452599388379206
I1
I0
I1
tp7885
sS'not,affect,the'
p7886
(F1
F0.0030581039755351682
I0
I4
I-4
tp7887
sS'decrease,plasma,concentrations'
p7888
(F1
F0.00076452599388379206
I1
I0
I1
tp7889
sS'focus,on,herceptin-mediated'
p7890
(F1
F0.00076452599388379206
I0
I1
I-1
tp7891
sS'with,concurrently,administered'
p7892
(F1
F0.00076452599388379206
I1
I0
I1
tp7893
sS'evista,is,given'
p7894
(F1
F0.00076452599388379206
I1
I0
I1
tp7895
sS'arthritis,ra,patients'
p7896
(F1
F0.00076452599388379206
I0
I1
I-1
tp7897
sS'time,pt,should'
p7898
(F1
F0.00076452599388379206
I1
I0
I1
tp7899
sS'increase,the,diffusion'
p7900
(F1
F0.00076452599388379206
I1
I0
I1
tp7901
sS'of,substances,that'
p7902
(F1
F0.00076452599388379206
I1
I0
I1
tp7903
sS'chloride,miochol,and'
p7904
(F1
F0.00076452599388379206
I1
I0
I1
tp7905
sS'electrocardiographic,parameters,changes'
p7906
(F1
F0.00076452599388379206
I0
I1
I-1
tp7907
sS'of,other,dietary'
p7908
(F1
F0.00076452599388379206
I1
I0
I1
tp7909
sS'bronchodilators,should,not'
p7910
(F1
F0.0015290519877675841
I2
I0
I2
tp7911
sS'used,together,the'
p7912
(F1
F0.00076452599388379206
I1
I0
I1
tp7913
sS'been,reported,with'
p7914
(F1
F0.0030581039755351682
I4
I0
I4
tp7915
sS'hours,after,discontinuing'
p7916
(F1
F0.00076452599388379206
I1
I0
I1
tp7917
sS'of,action,cholinesterase'
p7918
(F1
F0.00076452599388379206
I1
I0
I1
tp7919
sS'parameters,of,symlin'
p7920
(F1
F0.00076452599388379206
I1
I0
I1
tp7921
sS'a,therapeutic,target'
p7922
(F1
F0.00076452599388379206
I0
I1
I-1
tp7923
sS'cholinesterase,activity,chronically'
p7924
(F1
F0.00076452599388379206
I1
I0
I1
tp7925
sS'mg,bid,in'
p7926
(F1
F0.00076452599388379206
I1
I0
I1
tp7927
sS'an,oral,containing'
p7928
(F1
F0.00076452599388379206
I0
I1
I-1
tp7929
sS'diminishing,concealed,inefficacy'
p7930
(F1
F0.00076452599388379206
I1
I0
I1
tp7931
sS'of,metabolism,occurs'
p7932
(F1
F0.00076452599388379206
I1
I0
I1
tp7933
sS'may,decrease,when'
p7934
(F1
F0.00076452599388379206
I0
I1
I-1
tp7935
sS'response,to,chemotherapy'
p7936
(F1
F0.00076452599388379206
I1
I0
I1
tp7937
sS'of,organic,bases'
p7938
(F1
F0.00076452599388379206
I1
I0
I1
tp7939
sS'herceptin,clearance,in'
p7940
(F1
F0.00076452599388379206
I1
I0
I1
tp7941
sS'in-vivo,indicate,that'
p7942
(F1
F0.00076452599388379206
I0
I1
I-1
tp7943
sS'of,oral,antidiabetic'
p7944
(F1
F0.00076452599388379206
I1
I0
I1
tp7945
sS'hiv-positive,woman,on'
p7946
(F1
F0.0015290519877675841
I2
I0
I2
tp7947
sS'and,cns,depressant'
p7948
(F1
F0.00076452599388379206
I1
I0
I1
tp7949
sS'potassium,supplements,and'
p7950
(F1
F0.0015290519877675841
I0
I2
I-2
tp7951
sS'pharmacokinetics,of,megestrol'
p7952
(F1
F0.00076452599388379206
I0
I1
I-1
tp7953
sS'a,negative,control'
p7954
(F1
F0.00076452599388379206
I0
I1
I-1
tp7955
sS'serum,levels,and'
p7956
(F1
F0.00076452599388379206
I1
I0
I1
tp7957
sS'oxidase,mao,inhibitors'
p7958
(F1
F0.00076452599388379206
I0
I1
I-1
tp7959
sS'p450,a,enzyme'
p7960
(F1
F0.00076452599388379206
I1
I0
I1
tp7961
sS'reduce,serum,levels'
p7962
(F1
F0.00076452599388379206
I1
I0
I1
tp7963
sS'for,increases,in'
p7964
(F1
F0.00076452599388379206
I1
I0
I1
tp7965
sS'under,the,control'
p7966
(F1
F0.00076452599388379206
I0
I1
I-1
tp7967
sS'may,affect,the'
p7968
(F1
F0.00076452599388379206
I1
I0
I1
tp7969
sS'coadministration,with,results'
p7970
(F1
F0.00076452599388379206
I0
I1
I-1
tp7971
sS'p27,kip1,bcl-2'
p7972
(F1
F0.00076452599388379206
I0
I1
I-1
tp7973
sS'has,been,observed'
p7974
(F0
F0
I1
I1
I0
tp7975
sS'thus,elevating,the'
p7976
(F1
F0.00076452599388379206
I1
I0
I1
tp7977
sS'may,induce,metabolism'
p7978
(F1
F0.00076452599388379206
I1
I0
I1
tp7979
sS'following,intravitreal,delivery'
p7980
(F1
F0.00076452599388379206
I0
I1
I-1
tp7981
sS'causes,a,statistically'
p7982
(F1
F0.00076452599388379206
I1
I0
I1
tp7983
sS's,pharmacokinetics,and'
p7984
(F1
F0.00076452599388379206
I1
I0
I1
tp7985
sS'lethargy,coma,and'
p7986
(F1
F0.00076452599388379206
I1
I0
I1
tp7987
sS'measured,in,ovarian'
p7988
(F1
F0.00076452599388379206
I0
I1
I-1
tp7989
sS'pending,full,examination'
p7990
(F1
F0.00076452599388379206
I1
I0
I1
tp7991
sS'of,is,additive'
p7992
(F1
F0.00076452599388379206
I1
I0
I1
tp7993
sS'of,and,sympathomimetic'
p7994
(F1
F0.00076452599388379206
I1
I0
I1
tp7995
sS'human,exposure,at'
p7996
(F1
F0.0030581039755351682
I0
I4
I-4
tp7997
sS'in,cases,which'
p7998
(F1
F0.00076452599388379206
I0
I1
I-1
tp7999
sS'normal,volunteer,subjects'
p8000
(F1
F0.00076452599388379206
I0
I1
I-1
tp8001
sS'carefully,monitored,and'
p8002
(F1
F0.00076452599388379206
I1
I0
I1
tp8003
sS'may,be,associated'
p8004
(F0.5
F0.0015290519877675841
I3
I1
I2
tp8005
sS'increased,incidence,of'
p8006
(F0.33333333333333331
F0.00076452599388379206
I1
I2
I-1
tp8007
sS'pantoprazole,has,a'
p8008
(F1
F0.00076452599388379206
I1
I0
I1
tp8009
sS'intubation,the,interaction'
p8010
(F1
F0.00076452599388379206
I0
I1
I-1
tp8011
sS'concentration,and,auc'
p8012
(F1
F0.0015290519877675841
I2
I0
I2
tp8013
sS'of,the,drug'
p8014
(F1
F0.00076452599388379206
I1
I0
I1
tp8015
sS'azole,antifungals,in'
p8016
(F1
F0.00076452599388379206
I1
I0
I1
tp8017
sS'serious,adverse,events'
p8018
(F1
F0.00076452599388379206
I0
I1
I-1
tp8019
sS'metastatic,tumors,in'
p8020
(F1
F0.00076452599388379206
I1
I0
I1
tp8021
sS'muscle,relaxants,inhalational'
p8022
(F1
F0.00076452599388379206
I0
I1
I-1
tp8023
sS'tumors,and,acute'
p8024
(F1
F0.00076452599388379206
I0
I1
I-1
tp8025
sS'of,the,due'
p8026
(F1
F0.00076452599388379206
I0
I1
I-1
tp8027
sS'undercarboxylated,osteocalcin,a'
p8028
(F1
F0.00076452599388379206
I0
I1
I-1
tp8029
sS'sensitize,cells,from'
p8030
(F1
F0.00076452599388379206
I0
I1
I-1
tp8031
sS'agents,blood,glucose'
p8032
(F1
F0.00076452599388379206
I1
I0
I1
tp8033
sS'in,administering,demser'
p8034
(F1
F0.00076452599388379206
I1
I0
I1
tp8035
sS'increase,in,auc'
p8036
(F1
F0.00076452599388379206
I1
I0
I1
tp8037
sS'with,xenical,patients'
p8038
(F1
F0.00076452599388379206
I1
I0
I1
tp8039
sS'proamatine,alpha-adrenergic,blocking'
p8040
(F1
F0.00076452599388379206
I1
I0
I1
tp8041
sS'although,mivacron,a'
p8042
(F1
F0.00076452599388379206
I0
I1
I-1
tp8043
sS'antagonists,such,as'
p8044
(F1
F0.0015290519877675841
I2
I0
I2
tp8045
sS'elevated,parent,levels'
p8046
(F1
F0.00076452599388379206
I1
I0
I1
tp8047
sS'taking,nsaids,with'
p8048
(F1
F0.00076452599388379206
I1
I0
I1
tp8049
sS'cyp3a4,inhibitors,such'
p8050
(F1
F0.00076452599388379206
I1
I0
I1
tp8051
sS'mg,four,times'
p8052
(F1
F0.0015290519877675841
I2
I0
I2
tp8053
sS'p450,enzymes,would'
p8054
(F1
F0.00076452599388379206
I0
I1
I-1
tp8055
sS'transport,system,caused'
p8056
(F1
F0.00076452599388379206
I1
I0
I1
tp8057
sS'based,on,in'
p8058
(F1
F0.00076452599388379206
I0
I1
I-1
tp8059
sS'cerebral,ischemia,and'
p8060
(F1
F0.00076452599388379206
I0
I1
I-1
tp8061
sS'meloxicam,did,not'
p8062
(F1
F0.00076452599388379206
I0
I1
I-1
tp8063
sS'to,s,active'
p8064
(F1
F0.00076452599388379206
I1
I0
I1
tp8065
sS'and,alpha,lipoic'
p8066
(F1
F0.00076452599388379206
I0
I1
I-1
tp8067
sS'increase,the,incidence'
p8068
(F1
F0.00076452599388379206
I1
I0
I1
tp8069
sS'as,or,mg'
p8070
(F1
F0.00076452599388379206
I1
I0
I1
tp8071
sS'studied,on,a'
p8072
(F1
F0.00076452599388379206
I0
I1
I-1
tp8073
sS'vitro,activity,of'
p8074
(F1
F0.0015290519877675841
I0
I2
I-2
tp8075
sS'substrates,for,these'
p8076
(F1
F0.00076452599388379206
I0
I1
I-1
tp8077
sS'of,minor,bleeding'
p8078
(F1
F0.00076452599388379206
I1
I0
I1
tp8079
sS'cyclosporine,preliminary,data'
p8080
(F1
F0.00076452599388379206
I1
I0
I1
tp8081
sS'normal,renal,function'
p8082
(F1
F0.00076452599388379206
I1
I0
I1
tp8083
sS'hepatic,and,first-pass'
p8084
(F1
F0.00076452599388379206
I0
I1
I-1
tp8085
sS'model,possibly,enhancing'
p8086
(F1
F0.00076452599388379206
I1
I0
I1
tp8087
sS'with,other,azole'
p8088
(F1
F0.00076452599388379206
I1
I0
I1
tp8089
sS'fst,with,water'
p8090
(F1
F0.00076452599388379206
I0
I1
I-1
tp8091
sS'minimal,effect,on'
p8092
(F1
F0.0015290519877675841
I2
I0
I2
tp8093
sS'furthermore,the,combination'
p8094
(F1
F0.00076452599388379206
I1
I0
I1
tp8095
sS'association,with,tiva'
p8096
(F1
F0.00076452599388379206
I0
I1
I-1
tp8097
sS'to,increasing,the'
p8098
(F1
F0.00076452599388379206
I1
I0
I1
tp8099
sS'or,were,also'
p8100
(F1
F0.00076452599388379206
I0
I1
I-1
tp8101
sS'sirnas,or,enhances'
p8102
(F1
F0.00076452599388379206
I1
I0
I1
tp8103
sS'mycamine,on,mycophenolate'
p8104
(F1
F0.00076452599388379206
I0
I1
I-1
tp8105
sS'mao,inhibitors,narcotic'
p8106
(F1
F0.00076452599388379206
I1
I0
I1
tp8107
sS'profile,of,a'
p8108
(F1
F0.0015290519877675841
I0
I2
I-2
tp8109
sS'on,s,pharmacokinetics'
p8110
(F1
F0.00076452599388379206
I1
I0
I1
tp8111
sS'these,effects,may'
p8112
(F1
F0.00076452599388379206
I1
I0
I1
tp8113
sS'not,been,reported'
p8114
(F1
F0.00076452599388379206
I0
I1
I-1
tp8115
sS'is,due,to'
p8116
(F1
F0.00076452599388379206
I1
I0
I1
tp8117
sS'used,in,at'
p8118
(F1
F0.00076452599388379206
I0
I1
I-1
tp8119
sS'ability,to,metabolize'
p8120
(F1
F0.00076452599388379206
I1
I0
I1
tp8121
sS'of,both,drugs'
p8122
(F1
F0.00076452599388379206
I1
I0
I1
tp8123
sS'clearance,of,was'
p8124
(F1
F0.0030581039755351682
I4
I0
I4
tp8125
sS'or,inhibitors,of'
p8126
(F1
F0.00076452599388379206
I0
I1
I-1
tp8127
sS'tended,to,decline'
p8128
(F1
F0.00076452599388379206
I0
I1
I-1
tp8129
sS'with,against,clinical'
p8130
(F1
F0.00076452599388379206
I0
I1
I-1
tp8131
sS'cancer,the,mechanism'
p8132
(F1
F0.00076452599388379206
I1
I0
I1
tp8133
sS'of,evista,and'
p8134
(F1
F0.00076452599388379206
I0
I1
I-1
tp8135
sS'and,mg,kg'
p8136
(F1
F0.0015290519877675841
I0
I2
I-2
tp8137
sS'decreased,the,toxicity'
p8138
(F1
F0.00076452599388379206
I1
I0
I1
tp8139
sS'amphetamine,locomotor,sensitization'
p8140
(F1
F0.00076452599388379206
I0
I1
I-1
tp8141
sS'the,glucuronidation,of'
p8142
(F1
F0.00076452599388379206
I1
I0
I1
tp8143
sS'oral,by,fold'
p8144
(F1
F0.00076452599388379206
I1
I0
I1
tp8145
sS'therapy,may,cause'
p8146
(F1
F0.00076452599388379206
I1
I0
I1
tp8147
sS'reported,during,concomitant'
p8148
(F1
F0.00076452599388379206
I1
I0
I1
tp8149
sS'sulfamethoxazole,may,inhibit'
p8150
(F1
F0.00076452599388379206
I1
I0
I1
tp8151
sS'therapy,on,the'
p8152
(F1
F0.00076452599388379206
I1
I0
I1
tp8153
sS'in,human,a375'
p8154
(F0
F0
I1
I1
I0
tp8155
sS'treatment,also,had'
p8156
(F1
F0.00076452599388379206
I1
I0
I1
tp8157
sS'compared,with,female'
p8158
(F1
F0.00076452599388379206
I0
I1
I-1
tp8159
sS'patients,receiving,concomitant'
p8160
(F0
F0
I1
I1
I0
tp8161
sS'drugs,and,and'
p8162
(F1
F0.00076452599388379206
I0
I1
I-1
tp8163
sS'high-dose,and,carbonic'
p8164
(F1
F0.00076452599388379206
I1
I0
I1
tp8165
sS'of,drugs,from'
p8166
(F1
F0.00076452599388379206
I1
I0
I1
tp8167
sS'in,rheumatoid,arthritis'
p8168
(F1
F0.00076452599388379206
I0
I1
I-1
tp8169
sS'the,immune,response'
p8170
(F1
F0.00076452599388379206
I0
I1
I-1
tp8171
sS'mykrox,tablets,are'
p8172
(F1
F0.00076452599388379206
I1
I0
I1
tp8173
sS'dietary,carcinogenicity,study'
p8174
(F1
F0.0015290519877675841
I0
I2
I-2
tp8175
sS'proamatine,therefore,caution'
p8176
(F1
F0.00076452599388379206
I1
I0
I1
tp8177
sS'competes,with,for'
p8178
(F1
F0.00076452599388379206
I1
I0
I1
tp8179
sS'parameters,i,cmax'
p8180
(F1
F0.00076452599388379206
I1
I0
I1
tp8181
sS'resulted,in,the'
p8182
(F1
F0.00076452599388379206
I1
I0
I1
tp8183
sS'pharmacokinetics,of,remeron'
p8184
(F1
F0.00076452599388379206
I0
I1
I-1
tp8185
sS'qtc,rr,and'
p8186
(F1
F0.00076452599388379206
I0
I1
I-1
tp8187
sS'were,performed,until'
p8188
(F1
F0.00076452599388379206
I0
I1
I-1
tp8189
sS'inr,and,prothrombin'
p8190
(F1
F0.00076452599388379206
I1
I0
I1
tp8191
sS'such,drugs,may'
p8192
(F1
F0.00076452599388379206
I0
I1
I-1
tp8193
sS'the,pressor,effects'
p8194
(F1
F0.00076452599388379206
I1
I0
I1
tp8195
sS'pre-mexitil,values,within'
p8196
(F1
F0.00076452599388379206
I1
I0
I1
tp8197
sS'secondary,to,prolongation'
p8198
(F1
F0.00076452599388379206
I1
I0
I1
tp8199
sS'affect,absorption,of'
p8200
(F1
F0.00076452599388379206
I1
I0
I1
tp8201
sS'to,further,electrocardiographic'
p8202
(F1
F0.00076452599388379206
I0
I1
I-1
tp8203
sS'the,intestinal,absorption'
p8204
(F1
F0.00076452599388379206
I1
I0
I1
tp8205
sS'objective,was,to'
p8206
(F1
F0.0015290519877675841
I0
I2
I-2
tp8207
sS'kinases,on,sensitivity'
p8208
(F1
F0.00076452599388379206
I0
I1
I-1
tp8209
sS'dopamine,transporter,imaging'
p8210
(F1
F0.00076452599388379206
I1
I0
I1
tp8211
sS'in,a,significant'
p8212
(F1
F0.00076452599388379206
I1
I0
I1
tp8213
sS'longer,half-lives,all'
p8214
(F1
F0.00076452599388379206
I1
I0
I1
tp8215
sS'by,fold,whereas'
p8216
(F1
F0.00076452599388379206
I1
I0
I1
tp8217
sS'a,marker,of'
p8218
(F1
F0.00076452599388379206
I0
I1
I-1
tp8219
sS'lbh589,an,orally'
p8220
(F1
F0.00076452599388379206
I0
I1
I-1
tp8221
sS'the,sedative,effects'
p8222
(F1
F0.00076452599388379206
I1
I0
I1
tp8223
sS'presence,of,steady-state'
p8224
(F1
F0.0015290519877675841
I2
I0
I2
tp8225
sS'of,stupor,muscular'
p8226
(F1
F0.00076452599388379206
I1
I0
I1
tp8227
sS'great,caution,and'
p8228
(F1
F0.00076452599388379206
I1
I0
I1
tp8229
sS'time,or,the'
p8230
(F1
F0.00076452599388379206
I0
I1
I-1
tp8231
sS'doses,of,mycamine'
p8232
(F1
F0.00076452599388379206
I0
I1
I-1
tp8233
sS'events,bruising,epistaxis'
p8234
(F1
F0.00076452599388379206
I1
I0
I1
tp8235
sS'useful,especially,in'
p8236
(F1
F0.00076452599388379206
I0
I1
I-1
tp8237
sS'on,in,vitro'
p8238
(F1
F0.00076452599388379206
I0
I1
I-1
tp8239
sS'clinically,warranted,appropriate'
p8240
(F1
F0.00076452599388379206
I1
I0
I1
tp8241
sS'interfere,with,the'
p8242
(F1
F0.0038226299694189602
I5
I0
I5
tp8243
sS'the,commonly,used'
p8244
(F1
F0.00076452599388379206
I0
I1
I-1
tp8245
sS'with,lowered,the'
p8246
(F1
F0.00076452599388379206
I1
I0
I1
tp8247
sS'effect,of,crm197'
p8248
(F1
F0.00076452599388379206
I0
I1
I-1
tp8249
sS'agents,have,not'
p8250
(F1
F0.00076452599388379206
I0
I1
I-1
tp8251
sS'vitro,studies,with'
p8252
(F0
F0
I1
I1
I0
tp8253
sS'and,were,assessed'
p8254
(F1
F0.00076452599388379206
I0
I1
I-1
tp8255
sS'of,serious,cardiac'
p8256
(F1
F0.00076452599388379206
I1
I0
I1
tp8257
sS'k,antagonists,drugs'
p8258
(F1
F0.00076452599388379206
I1
I0
I1
tp8259
sS'cdk1,in,apoptosis'
p8260
(F1
F0.00076452599388379206
I0
I1
I-1
tp8261
sS'of,the,pressor'
p8262
(F1
F0.00076452599388379206
I1
I0
I1
tp8263
sS'behavioural,observations,were'
p8264
(F1
F0.00076452599388379206
I1
I0
I1
tp8265
sS'of,ginseng,stem-and'
p8266
(F1
F0.0015290519877675841
I0
I2
I-2
tp8267
sS'significant,reduction,in'
p8268
(F1
F0.00076452599388379206
I1
I0
I1
tp8269
sS'intestinal,absorption,of'
p8270
(F1
F0.0015290519877675841
I2
I0
I2
tp8271
sS'mice,while,their'
p8272
(F1
F0.00076452599388379206
I1
I0
I1
tp8273
sS'study,population,as'
p8274
(F1
F0.00076452599388379206
I1
I0
I1
tp8275
sS'data,suggest,that'
p8276
(F1
F0.00076452599388379206
I1
I0
I1
tp8277
sS'monitoring,of,the'
p8278
(F1
F0.00076452599388379206
I1
I0
I1
tp8279
sS'apoptosis,of,dznep'
p8280
(F1
F0.00076452599388379206
I1
I0
I1
tp8281
sS'of,resulted,in'
p8282
(F1
F0.00076452599388379206
I1
I0
I1
tp8283
sS'cyp,b6,inhibitor'
p8284
(F1
F0.00076452599388379206
I0
I1
I-1
tp8285
sS'of,oral,administration'
p8286
(F1
F0.00076452599388379206
I0
I1
I-1
tp8287
sS'disease,prior,use'
p8288
(F1
F0.00076452599388379206
I1
I0
I1
tp8289
sS'treatment,of,hey'
p8290
(F1
F0.00076452599388379206
I1
I0
I1
tp8291
sS'for,invega,to'
p8292
(F1
F0.00076452599388379206
I0
I1
I-1
tp8293
sS'family,inhibitor,synergistically'
p8294
(F1
F0.00076452599388379206
I1
I0
I1
tp8295
sS'effects,of,doses'
p8296
(F1
F0.0015290519877675841
I0
I2
I-2
tp8297
sS'disorientation,respiratory,depression'
p8298
(F1
F0.00076452599388379206
I1
I0
I1
tp8299
sS'achieve,target,bp'
p8300
(F1
F0.00076452599388379206
I1
I0
I1
tp8301
sS'of,are,potentiated'
p8302
(F1
F0.00076452599388379206
I1
I0
I1
tp8303
sS'of,tritec,with'
p8304
(F1
F0.00076452599388379206
I1
I0
I1
tp8305
sS'of,control,was'
p8306
(F1
F0.00076452599388379206
I0
I1
I-1
tp8307
sS'mg,had,a'
p8308
(F1
F0.00076452599388379206
I1
I0
I1
tp8309
sS'administered,at,the'
p8310
(F1
F0.00076452599388379206
I1
I0
I1
tp8311
sS'not,alter,pharmacokinetics'
p8312
(F1
F0.00076452599388379206
I0
I1
I-1
tp8313
sS'amphotericin,b,polymyxin'
p8314
(F1
F0.00076452599388379206
I0
I1
I-1
tp8315
sS'and,pharmacodynamic,interactions'
p8316
(F1
F0.00076452599388379206
I0
I1
I-1
tp8317
sS'few,spontaneous,accounts'
p8318
(F1
F0.00076452599388379206
I0
I1
I-1
tp8319
sS'effect,on,the'
p8320
(F0.25
F0.0015290519877675841
I3
I5
I-2
tp8321
sS'beta,blockers,antidiabetic'
p8322
(F1
F0.00076452599388379206
I0
I1
I-1
tp8323
sS'treatment,increases,cytochrome'
p8324
(F1
F0.00076452599388379206
I1
I0
I1
tp8325
sS'such,as,may'
p8326
(F1
F0.0015290519877675841
I2
I0
I2
tp8327
sS'between,the,alkyating'
p8328
(F1
F0.00076452599388379206
I0
I1
I-1
tp8329
sS'concentrations,of,sodium'
p8330
(F1
F0.00076452599388379206
I1
I0
I1
tp8331
sS'calcium,doses,mg'
p8332
(F1
F0.00076452599388379206
I1
I0
I1
tp8333
sS'are,known,to'
p8334
(F1
F0.00076452599388379206
I1
I0
I1
tp8335
sS'latter,displayed,clearances'
p8336
(F1
F0.00076452599388379206
I0
I1
I-1
tp8337
sS'drug,interactions,are'
p8338
(F1
F0.00076452599388379206
I0
I1
I-1
tp8339
sS'sedation,which,limits'
p8340
(F1
F0.00076452599388379206
I1
I0
I1
tp8341
sS'adverse,event,profile'
p8342
(F1
F0.00076452599388379206
I0
I1
I-1
tp8343
sS'and,may,increase'
p8344
(F1
F0.0030581039755351682
I4
I0
I4
tp8345
sS'inactivated,newcastle,disease'
p8346
(F1
F0.00076452599388379206
I0
I1
I-1
tp8347
sS'patients,receiving,than'
p8348
(F1
F0.00076452599388379206
I0
I1
I-1
tp8349
sS'as,nonheme,as'
p8350
(F1
F0.00076452599388379206
I1
I0
I1
tp8351
sS'maleate,is,used'
p8352
(F1
F0.00076452599388379206
I1
I0
I1
tp8353
sS'on,the,anticoagulant'
p8354
(F1
F0.00076452599388379206
I0
I1
I-1
tp8355
sS'feasible,as,the'
p8356
(F1
F0.00076452599388379206
I0
I1
I-1
tp8357
sS'iii,or,chondroitin'
p8358
(F0.33333333333333331
F0.00076452599388379206
I1
I2
I-1
tp8359
sS'is,not,believed'
p8360
(F1
F0.00076452599388379206
I1
I0
I1
tp8361
sS'transporter,imaging,data'
p8362
(F1
F0.00076452599388379206
I1
I0
I1
tp8363
sS'although,such,a'
p8364
(F0
F0
I1
I1
I0
tp8365
sS'of,the,isozyme'
p8366
(F1
F0.00076452599388379206
I1
I0
I1
tp8367
sS'periodic,serum,level'
p8368
(F1
F0.00076452599388379206
I1
I0
I1
tp8369
sS'with,either,agent'
p8370
(F1
F0.00076452599388379206
I1
I0
I1
tp8371
sS'the,retinal,ganglion'
p8372
(F1
F0.00076452599388379206
I0
I1
I-1
tp8373
sS'reactivity,and,on'
p8374
(F1
F0.00076452599388379206
I0
I1
I-1
tp8375
sS'serum,levels,but'
p8376
(F1
F0.00076452599388379206
I1
I0
I1
tp8377
sS'the,first,test'
p8378
(F1
F0.00076452599388379206
I1
I0
I1
tp8379
sS'groups,methyl-4,phenyl-1'
p8380
(F1
F0.00076452599388379206
I0
I1
I-1
tp8381
sS'was,administered,as'
p8382
(F1
F0.00076452599388379206
I0
I1
I-1
tp8383
sS'a,dopamine,agonist'
p8384
(F1
F0.00076452599388379206
I1
I0
I1
tp8385
sS'pressor,effects,of'
p8386
(F1
F0.00076452599388379206
I1
I0
I1
tp8387
sS'extra,thoracic,ribs'
p8388
(F1
F0.00076452599388379206
I0
I1
I-1
tp8389
sS'authors,report,the'
p8390
(F1
F0.00076452599388379206
I1
I0
I1
tp8391
sS'bleeding,and,or'
p8392
(F1
F0.00076452599388379206
I1
I0
I1
tp8393
sS'these,nsaids,should'
p8394
(F1
F0.00076452599388379206
I1
I0
I1
tp8395
sS'sunitinib,as,a'
p8396
(F1
F0.00076452599388379206
I1
I0
I1
tp8397
sS'non-thalidomide,drug,interactions'
p8398
(F1
F0.00076452599388379206
I0
I1
I-1
tp8399
sS'administered,until,normal'
p8400
(F1
F0.00076452599388379206
I0
I1
I-1
tp8401
sS'with,the,cytochrome'
p8402
(F1
F0.00076452599388379206
I0
I1
I-1
tp8403
sS'concentrations,and,increased'
p8404
(F1
F0.00076452599388379206
I1
I0
I1
tp8405
sS'synergism,was,also'
p8406
(F1
F0.00076452599388379206
I1
I0
I1
tp8407
sS'highly,specific,metabotropic'
p8408
(F1
F0.00076452599388379206
I0
I1
I-1
tp8409
sS'human,pharmacologic,studies'
p8410
(F1
F0.00076452599388379206
I1
I0
I1
tp8411
sS'when,it,was'
p8412
(F1
F0.0015290519877675841
I2
I0
I2
tp8413
sS'of,an,increases'
p8414
(F1
F0.00076452599388379206
I0
I1
I-1
tp8415
sS'cyclosporine,when,studied'
p8416
(F1
F0.00076452599388379206
I0
I1
I-1
tp8417
sS'been,reported,rarely'
p8418
(F1
F0.00076452599388379206
I1
I0
I1
tp8419
sS'inhibitors,mao-is,type'
p8420
(F1
F0.00076452599388379206
I0
I1
I-1
tp8421
sS'thiazide,beta,blockers'
p8422
(F1
F0.00076452599388379206
I0
I1
I-1
tp8423
sS'be,advised,that'
p8424
(F1
F0.00076452599388379206
I1
I0
I1
tp8425
sS'food,interactions,with'
p8426
(F1
F0.00076452599388379206
I1
I0
I1
tp8427
sS'all,patients,taking'
p8428
(F1
F0.00076452599388379206
I1
I0
I1
tp8429
sS'solutions,containing,should'
p8430
(F1
F0.00076452599388379206
I0
I1
I-1
tp8431
sS'a,risk,is'
p8432
(F1
F0.00076452599388379206
I0
I1
I-1
tp8433
sS'in,two,larger'
p8434
(F1
F0.00076452599388379206
I0
I1
I-1
tp8435
sS'antagonists,since,is'
p8436
(F1
F0.00076452599388379206
I1
I0
I1
tp8437
sS'magnesium-aluminum,containing,ml'
p8438
(F1
F0.00076452599388379206
I1
I0
I1
tp8439
sS'tetrahydropyridine-induced,loss,of'
p8440
(F1
F0.00076452599388379206
I1
I0
I1
tp8441
sS'effective,indicating,a'
p8442
(F1
F0.00076452599388379206
I0
I1
I-1
tp8443
sS'shortness,of,breath'
p8444
(F1
F0.00076452599388379206
I1
I0
I1
tp8445
sS'leading,to,the'
p8446
(F1
F0.00076452599388379206
I1
I0
I1
tp8447
sS'or,both,based'
p8448
(F1
F0.00076452599388379206
I0
I1
I-1
tp8449
sS'bioavailability,eg,esters'
p8450
(F1
F0.00076452599388379206
I1
I0
I1
tp8451
sS'inhibits,the,intracellular'
p8452
(F1
F0.00076452599388379206
I1
I0
I1
tp8453
sS'tears,conjugated,estrogens'
p8454
(F1
F0.00076452599388379206
I0
I1
I-1
tp8455
sS'multidose,study,of'
p8456
(F1
F0.00076452599388379206
I1
I0
I1
tp8457
sS'terbinafine,clearance,is'
p8458
(F0
F0
I1
I1
I0
tp8459
sS'combinations,of,and'
p8460
(F1
F0.00076452599388379206
I0
I1
I-1
tp8461
sS'sunitinib,exhibited,dose-dependent'
p8462
(F1
F0.00076452599388379206
I0
I1
I-1
tp8463
sS'resulting,in,elevated'
p8464
(F1
F0.00076452599388379206
I1
I0
I1
tp8465
sS'ea,in,children'
p8466
(F1
F0.00076452599388379206
I1
I0
I1
tp8467
sS'therapy,such,as'
p8468
(F1
F0.00076452599388379206
I1
I0
I1
tp8469
sS'or,multiple,doses'
p8470
(F1
F0.00076452599388379206
I0
I1
I-1
tp8471
sS'administered,with,streptokinase'
p8472
(F1
F0.00076452599388379206
I0
I1
I-1
tp8473
sS'that,chronic,dosing'
p8474
(F1
F0.00076452599388379206
I0
I1
I-1
tp8475
sS'of,and,has'
p8476
(F1
F0.0022935779816513763
I3
I0
I3
tp8477
sS'induced,apoptosis,and'
p8478
(F1
F0.00076452599388379206
I1
I0
I1
tp8479
sS'with,and,or'
p8480
(F1
F0.00076452599388379206
I1
I0
I1
tp8481
sS'vivo,hepatic,and'
p8482
(F1
F0.00076452599388379206
I0
I1
I-1
tp8483
sS'patients,taking,these'
p8484
(F1
F0.00076452599388379206
I1
I0
I1
tp8485
sS'that,nsaids,can'
p8486
(F1
F0.00076452599388379206
I1
I0
I1
tp8487
sS'drugs,that,irreversibly'
p8488
(F1
F0.00076452599388379206
I1
I0
I1
tp8489
sS'to,pre-mexitil,values'
p8490
(F1
F0.00076452599388379206
I1
I0
I1
tp8491
sS'receiving,monoamine,oxidase'
p8492
(F1
F0.0015290519877675841
I2
I0
I2
tp8493
sS'or,local,have'
p8494
(F1
F0.00076452599388379206
I0
I1
I-1
tp8495
sS'and,in,vivo'
p8496
(F1
F0.0015290519877675841
I0
I2
I-2
tp8497
sS'anticipated,it,may'
p8498
(F1
F0.00076452599388379206
I1
I0
I1
tp8499
sS'antinociception,and,locomotor'
p8500
(F1
F0.00076452599388379206
I0
I1
I-1
tp8501
sS'bcl-2,was,overexpressed'
p8502
(F1
F0.00076452599388379206
I1
I0
I1
tp8503
sS'univasc,can,be'
p8504
(F1
F0.00076452599388379206
I0
I1
I-1
tp8505
sS'administered,with,therapeutic'
p8506
(F1
F0.00076452599388379206
I1
I0
I1
tp8507
sS'complete,cross-resistance,between'
p8508
(F1
F0.00076452599388379206
I1
I0
I1
tp8509
sS'arrested,cell,cycle'
p8510
(F1
F0.00076452599388379206
I0
I1
I-1
tp8511
sS'ascertain,the,difference'
p8512
(F1
F0.00076452599388379206
I0
I1
I-1
tp8513
sS'be,given,to'
p8514
(F1
F0.0015290519877675841
I2
I0
I2
tp8515
sS'regular,nph,and'
p8516
(F1
F0.00076452599388379206
I1
I0
I1
tp8517
sS'and,or,oral'
p8518
(F1
F0.00076452599388379206
I1
I0
I1
tp8519
sS'a,effect,on'
p8520
(F1
F0.00076452599388379206
I1
I0
I1
tp8521
sS'twice,daily,for'
p8522
(F1
F0.00076452599388379206
I0
I1
I-1
tp8523
sS'phases,p,as'
p8524
(F1
F0.00076452599388379206
I0
I1
I-1
tp8525
sS'and,alone,and'
p8526
(F1
F0.00076452599388379206
I0
I1
I-1
tp8527
sS'it,is,reasonable'
p8528
(F1
F0.0015290519877675841
I2
I0
I2
tp8529
sS'patients,taking,nsaids'
p8530
(F1
F0.00076452599388379206
I1
I0
I1
tp8531
sS'that,ritalin,may'
p8532
(F1
F0.00076452599388379206
I1
I0
I1
tp8533
sS'methadone-maintenance,therapy,mg'
p8534
(F1
F0.00076452599388379206
I1
I0
I1
tp8535
sS'ml,min,p'
p8536
(F1
F0.00076452599388379206
I1
I0
I1
tp8537
sS'displacement,of,from'
p8538
(F1
F0.00076452599388379206
I0
I1
I-1
tp8539
sS'the,same,regimen'
p8540
(F1
F0.00076452599388379206
I1
I0
I1
tp8541
sS'mechanism,of,hepatic'
p8542
(F1
F0.00076452599388379206
I1
I0
I1
tp8543
sS'curves,self-reported,drowsiness'
p8544
(F1
F0.00076452599388379206
I0
I1
I-1
tp8545
sS'possible,interactions,of'
p8546
(F1
F0.00076452599388379206
I0
I1
I-1
tp8547
sS'media,whereas,with'
p8548
(F1
F0.00076452599388379206
I1
I0
I1
tp8549
sS'stereoisomers,has,been'
p8550
(F1
F0.00076452599388379206
I0
I1
I-1
tp8551
sS'of,succinate,tablets'
p8552
(F1
F0.00076452599388379206
I1
I0
I1
tp8553
sS'the,metabolism,of'
p8554
(F0.25
F0.0030581039755351682
I10
I6
I4
tp8555
sS'of,and,an'
p8556
(F1
F0.00076452599388379206
I1
I0
I1
tp8557
sS'levels,of,valproic'
p8558
(F1
F0.00076452599388379206
I1
I0
I1
tp8559
sS'encoding,enhanced,green'
p8560
(F1
F0.00076452599388379206
I0
I1
I-1
tp8561
sS'a,substitute,for'
p8562
(F1
F0.00076452599388379206
I0
I1
I-1
tp8563
sS'may,increase,sensitivity'
p8564
(F1
F0.00076452599388379206
I1
I0
I1
tp8565
sS'the,patient,should'
p8566
(F1
F0.00076452599388379206
I1
I0
I1
tp8567
sS'demonstrated,that,the'
p8568
(F1
F0.00076452599388379206
I0
I1
I-1
tp8569
sS'mildly,hypercholesterolemic,patients'
p8570
(F1
F0.00076452599388379206
I0
I1
I-1
tp8571
sS'antagonism,between,and'
p8572
(F1
F0.00076452599388379206
I1
I0
I1
tp8573
sS'assay,induced,her2'
p8574
(F1
F0.00076452599388379206
I1
I0
I1
tp8575
sS'and,enterohepatic,cycling'
p8576
(F1
F0.00076452599388379206
I1
I0
I1
tp8577
sS'peg-intron,once,weekly'
p8578
(F1
F0.00076452599388379206
I1
I0
I1
tp8579
sS'to,g,had'
p8580
(F1
F0.00076452599388379206
I1
I0
I1
tp8581
sS'than,in,those'
p8582
(F1
F0.00076452599388379206
I0
I1
I-1
tp8583
sS'of,and,may'
p8584
(F1
F0.0038226299694189602
I5
I0
I5
tp8585
sS'treatment,with,univasc'
p8586
(F1
F0.00076452599388379206
I0
I1
I-1
tp8587
sS'adjuvant,to,improve'
p8588
(F1
F0.00076452599388379206
I0
I1
I-1
tp8589
sS'adult,mice,in'
p8590
(F1
F0.00076452599388379206
I0
I1
I-1
tp8591
sS'and,is,therefore'
p8592
(F1
F0.00076452599388379206
I1
I0
I1
tp8593
sS'administered,one,hour'
p8594
(F1
F0.00076452599388379206
I1
I0
I1
tp8595
sS'rats,at,doses'
p8596
(F1
F0.00076452599388379206
I0
I1
I-1
tp8597
sS'ropivacaine,can,interact'
p8598
(F1
F0.00076452599388379206
I1
I0
I1
tp8599
sS'substrate,of,cyp1a2'
p8600
(F1
F0.00076452599388379206
I0
I1
I-1
tp8601
sS'that,might,be'
p8602
(F1
F0.00076452599388379206
I1
I0
I1
tp8603
sS'following,agents,may'
p8604
(F1
F0.00076452599388379206
I1
I0
I1
tp8605
sS'of,mexitil,and'
p8606
(F1
F0.00076452599388379206
I1
I0
I1
tp8607
sS'blocking,effect,of'
p8608
(F1
F0.00076452599388379206
I1
I0
I1
tp8609
sS'the,subject,of'
p8610
(F1
F0.00076452599388379206
I0
I1
I-1
tp8611
sS'dosing,of,was'
p8612
(F1
F0.00076452599388379206
I0
I1
I-1
tp8613
sS'risk,of,minor'
p8614
(F1
F0.00076452599388379206
I1
I0
I1
tp8615
sS'through,p27,kip1'
p8616
(F1
F0.00076452599388379206
I1
I0
I1
tp8617
sS'be,decreased,with'
p8618
(F1
F0.00076452599388379206
I1
I0
I1
tp8619
sS'results,suggest,that'
p8620
(F1
F0.00076452599388379206
I0
I1
I-1
tp8621
sS'effects,of,drugs'
p8622
(F1
F0.0015290519877675841
I2
I0
I2
tp8623
sS'skelid,is,increased'
p8624
(F1
F0.00076452599388379206
I1
I0
I1
tp8625
sS'data,no,dosage'
p8626
(F1
F0.00076452599388379206
I1
I0
I1
tp8627
sS'sj,grens,efficacy'
p8628
(F1
F0.00076452599388379206
I0
I1
I-1
tp8629
sS'patients,under,treatment'
p8630
(F1
F0.00076452599388379206
I0
I1
I-1
tp8631
sS'the,patients,should'
p8632
(F1
F0.00076452599388379206
I1
I0
I1
tp8633
sS'chronic,model,day'
p8634
(F1
F0.00076452599388379206
I0
I1
I-1
tp8635
sS'cholestyramine,causes,a'
p8636
(F1
F0.00076452599388379206
I1
I0
I1
tp8637
sS'co-administration,of,sutent'
p8638
(F1
F0.0015290519877675841
I2
I0
I2
tp8639
sS'mouth,and,nose'
p8640
(F1
F0.00076452599388379206
I1
I0
I1
tp8641
sS'intensity,measurements,of'
p8642
(F1
F0.00076452599388379206
I1
I0
I1
tp8643
sS'were,required,for'
p8644
(F1
F0.00076452599388379206
I0
I1
I-1
tp8645
sS'with,the,bactericidal'
p8646
(F1
F0.00076452599388379206
I1
I0
I1
tp8647
sS'in,conclusion,we'
p8648
(F1
F0.00076452599388379206
I1
I0
I1
tp8649
sS'in,cyclosporine-treated,as'
p8650
(F1
F0.00076452599388379206
I0
I1
I-1
tp8651
sS'expression,transfection,with'
p8652
(F1
F0.00076452599388379206
I0
I1
I-1
tp8653
sS'of,mg,once'
p8654
(F1
F0.00076452599388379206
I0
I1
I-1
tp8655
sS'prior,to,initiation'
p8656
(F1
F0.00076452599388379206
I1
I0
I1
tp8657
sS'after,initiation,of'
p8658
(F1
F0.00076452599388379206
I1
I0
I1
tp8659
sS'may,not,be'
p8660
(F1
F0.00076452599388379206
I0
I1
I-1
tp8661
sS'competitively,inhibits,the'
p8662
(F1
F0.00076452599388379206
I1
I0
I1
tp8663
sS'mycophenolate,mofetil,inhibit'
p8664
(F1
F0.00076452599388379206
I1
I0
I1
tp8665
sS'other,monoamine,oxidase'
p8666
(F1
F0.00076452599388379206
I0
I1
I-1
tp8667
sS'of,on,induced'
p8668
(F1
F0.00076452599388379206
I0
I1
I-1
tp8669
sS'purinethol,and,tabloid'
p8670
(F1
F0.00076452599388379206
I1
I0
I1
tp8671
sS'weeks,was,associated'
p8672
(F1
F0.00076452599388379206
I1
I0
I1
tp8673
sS'interaction,studies,conducted'
p8674
(F1
F0.00076452599388379206
I0
I1
I-1
tp8675
sS'number,of,drugs'
p8676
(F1
F0.0015290519877675841
I2
I0
I2
tp8677
sS'azole,antifungals,bleeding'
p8678
(F1
F0.00076452599388379206
I1
I0
I1
tp8679
sS'respectively,in,the'
p8680
(F1
F0.00076452599388379206
I1
I0
I1
tp8681
sS'evidence,for,lenalidomide-cci'
p8682
(F1
F0.00076452599388379206
I0
I1
I-1
tp8683
sS'symlin,were,altered'
p8684
(F1
F0.00076452599388379206
I1
I0
I1
tp8685
sS'may,cause,serious'
p8686
(F1
F0.0015290519877675841
I2
I0
I2
tp8687
sS'not,sufficient,to'
p8688
(F1
F0.00076452599388379206
I1
I0
I1
tp8689
sS'such,as,and'
p8690
(F0.73333333333333328
F0.0084097859327217118
I13
I2
I11
tp8691
sS'tablets,may,increase'
p8692
(F1
F0.00076452599388379206
I0
I1
I-1
tp8693
sS'which,may,enhance'
p8694
(F1
F0.00076452599388379206
I1
I0
I1
tp8695
sS'extent,of,biotransformation'
p8696
(F1
F0.00076452599388379206
I0
I1
I-1
tp8697
sS'expression,vectors,and'
p8698
(F1
F0.00076452599388379206
I0
I1
I-1
tp8699
sS'since,these,patients'
p8700
(F1
F0.00076452599388379206
I1
I0
I1
tp8701
sS'zemuron,is,administered'
p8702
(F1
F0.00076452599388379206
I1
I0
I1
tp8703
sS'in,total,users'
p8704
(F1
F0.00076452599388379206
I0
I1
I-1
tp8705
sS'of,g,maximum'
p8706
(F1
F0.00076452599388379206
I0
I1
I-1
tp8707
sS'monitored,for,increases'
p8708
(F1
F0.00076452599388379206
I1
I0
I1
tp8709
sS'and,with,post-mortem'
p8710
(F1
F0.00076452599388379206
I1
I0
I1
tp8711
sS'is,markedly,potentiated'
p8712
(F1
F0.0015290519877675841
I2
I0
I2
tp8713
sS'enzyme,such,as'
p8714
(F1
F0.00076452599388379206
I0
I1
I-1
tp8715
sS'sequential,systemic,or'
p8716
(F1
F0.00076452599388379206
I0
I1
I-1
tp8717
sS'mg,of,provided'
p8718
(F1
F0.00076452599388379206
I1
I0
I1
tp8719
sS'sulfate,and,heme'
p8720
(F1
F0.00076452599388379206
I1
I0
I1
tp8721
sS'to,increase,the'
p8722
(F1
F0.0022935779816513763
I3
I0
I3
tp8723
sS'cm3,difference,cm3'
p8724
(F1
F0.00076452599388379206
I1
I0
I1
tp8725
sS'supplements,concomitantly,with'
p8726
(F1
F0.00076452599388379206
I1
I0
I1
tp8727
sS'and,in,all'
p8728
(F1
F0.00076452599388379206
I1
I0
I1
tp8729
sS'toxicity,the,order'
p8730
(F1
F0.00076452599388379206
I0
I1
I-1
tp8731
sS'activity,in,mice'
p8732
(F1
F0.00076452599388379206
I0
I1
I-1
tp8733
sS'oral,produced,an'
p8734
(F1
F0.00076452599388379206
I1
I0
I1
tp8735
sS'ra,patients,evaluated'
p8736
(F1
F0.00076452599388379206
I0
I1
I-1
tp8737
sS'rifampin,rifampin,enhances'
p8738
(F1
F0.00076452599388379206
I1
I0
I1
tp8739
sS'lipoic,acid,against'
p8740
(F1
F0.00076452599388379206
I0
I1
I-1
tp8741
sS'on,hot,flushes'
p8742
(F1
F0.00076452599388379206
I0
I1
I-1
tp8743
sS'clinical,circumstances,consideration'
p8744
(F1
F0.00076452599388379206
I1
I0
I1
tp8745
sS'are,receiving,treatment'
p8746
(F1
F0.00076452599388379206
I0
I1
I-1
tp8747
sS'once,daily,for'
p8748
(F1
F0.00076452599388379206
I0
I1
I-1
tp8749
sS'appropriate,clinical,monitoring'
p8750
(F1
F0.0015290519877675841
I2
I0
I2
tp8751
sS'observed,following,topical'
p8752
(F1
F0.00076452599388379206
I0
I1
I-1
tp8753
sS'blood,pressure,after'
p8754
(F1
F0.00076452599388379206
I1
I0
I1
tp8755
sS'most,proton,pump'
p8756
(F1
F0.00076452599388379206
I0
I1
I-1
tp8757
sS'motility,are,antagonized'
p8758
(F1
F0.00076452599388379206
I1
I0
I1
tp8759
sS'may,occur,earlier'
p8760
(F1
F0.00076452599388379206
I1
I0
I1
tp8761
sS'cautiously,increasing,salt'
p8762
(F1
F0.00076452599388379206
I0
I1
I-1
tp8763
sS'subjects,receiving,mg'
p8764
(F1
F0.00076452599388379206
I0
I1
I-1
tp8765
sS'any,change,in'
p8766
(F1
F0.00076452599388379206
I0
I1
I-1
tp8767
sS'uveitis,in,patients'
p8768
(F1
F0.00076452599388379206
I1
I0
I1
tp8769
sS'given,the,primary'
p8770
(F1
F0.00076452599388379206
I1
I0
I1
tp8771
sS'increase,plasma,concentrations'
p8772
(F1
F0.00076452599388379206
I1
I0
I1
tp8773
sS'present,an,interesting'
p8774
(F1
F0.00076452599388379206
I1
I0
I1
tp8775
sS'tablets,for,at'
p8776
(F1
F0.00076452599388379206
I1
I0
I1
tp8777
sS'pyridine-treated,animals,than'
p8778
(F1
F0.00076452599388379206
I1
I0
I1
tp8779
sS'heme,as,concentrated'
p8780
(F1
F0.00076452599388379206
I0
I1
I-1
tp8781
sS'our,objective,was'
p8782
(F1
F0.00076452599388379206
I0
I1
I-1
tp8783
sS'daily,administration,of'
p8784
(F1
F0.00076452599388379206
I0
I1
I-1
tp8785
sS'hepatic,cytochrome,p-450'
p8786
(F1
F0.00076452599388379206
I0
I1
I-1
tp8787
sS'for,the,hmg-coa'
p8788
(F1
F0.00076452599388379206
I0
I1
I-1
tp8789
sS'and,up,to'
p8790
(F1
F0.00076452599388379206
I1
I0
I1
tp8791
sS'could,lead,to'
p8792
(F1
F0.0015290519877675841
I2
I0
I2
tp8793
sS'selegiline,in,healthy'
p8794
(F1
F0.00076452599388379206
I0
I1
I-1
tp8795
sS'pharmacokinetic,parameters,for'
p8796
(F1
F0.00076452599388379206
I1
I0
I1
tp8797
sS'children,receiving,low-dose'
p8798
(F1
F0.00076452599388379206
I0
I1
I-1
tp8799
sS'compound,and,decreased'
p8800
(F1
F0.00076452599388379206
I1
I0
I1
tp8801
sS'drugs,care,must'
p8802
(F1
F0.00076452599388379206
I1
I0
I1
tp8803
sS'cana,edta,is'
p8804
(F1
F0.00076452599388379206
I1
I0
I1
tp8805
sS'anticoagulants,and,antiplatelet'
p8806
(F1
F0.00076452599388379206
I1
I0
I1
tp8807
sS'with,increased,risk'
p8808
(F1
F0.00076452599388379206
I0
I1
I-1
tp8809
sS'an,increases,the'
p8810
(F1
F0.00076452599388379206
I0
I1
I-1
tp8811
sS'and,the,effect'
p8812
(F1
F0.00076452599388379206
I0
I1
I-1
tp8813
sS'approximately,bound,to'
p8814
(F1
F0.00076452599388379206
I0
I1
I-1
tp8815
sS'radiolabeled,drug,uptake'
p8816
(F1
F0.00076452599388379206
I0
I1
I-1
tp8817
sS'doses,of,methyl-4'
p8818
(F1
F0.00076452599388379206
I0
I1
I-1
tp8819
sS'a,fold,increase'
p8820
(F1
F0.00076452599388379206
I1
I0
I1
tp8821
sS'the,elevation,of'
p8822
(F1
F0.00076452599388379206
I0
I1
I-1
tp8823
sS'least,of,patients'
p8824
(F1
F0.00076452599388379206
I0
I1
I-1
tp8825
sS'reduced,in,patients'
p8826
(F1
F0.00076452599388379206
I1
I0
I1
tp8827
sS'effects,on,serotonin'
p8828
(F1
F0.00076452599388379206
I0
I1
I-1
tp8829
sS'have,produced,an'
p8830
(F1
F0.00076452599388379206
I1
I0
I1
tp8831
sS'the,isozyme,including'
p8832
(F1
F0.00076452599388379206
I1
I0
I1
tp8833
sS'exposure,to,following'
p8834
(F1
F0.00076452599388379206
I0
I1
I-1
tp8835
sS'to,prolongation,of'
p8836
(F1
F0.00076452599388379206
I1
I0
I1
tp8837
sS'multiple-dose,study,in'
p8838
(F1
F0.00076452599388379206
I0
I1
I-1
tp8839
sS'when,a,new'
p8840
(F1
F0.00076452599388379206
I1
I0
I1
tp8841
sS'the,renal,tubular'
p8842
(F1
F0.00076452599388379206
I1
I0
I1
tp8843
sS'interactions,with,common'
p8844
(F1
F0.00076452599388379206
I0
I1
I-1
tp8845
sS'can,interact,with'
p8846
(F1
F0.0022935779816513763
I3
I0
I3
tp8847
sS'igf-i,suppression,compared'
p8848
(F1
F0.00076452599388379206
I1
I0
I1
tp8849
sS'and,drug,interaction'
p8850
(F1
F0.00076452599388379206
I1
I0
I1
tp8851
sS'approximately,half,because'
p8852
(F1
F0.00076452599388379206
I1
I0
I1
tp8853
sS'herceptin,treatment,following'
p8854
(F1
F0.00076452599388379206
I1
I0
I1
tp8855
sS'control,values,in'
p8856
(F1
F0.00076452599388379206
I1
I0
I1
tp8857
sS'we,evaluated,how'
p8858
(F1
F0.00076452599388379206
I0
I1
I-1
tp8859
sS'closely,monitored,when'
p8860
(F1
F0.00076452599388379206
I1
I0
I1
tp8861
sS'interacts,with,herceptin'
p8862
(F1
F0.00076452599388379206
I0
I1
I-1
tp8863
sS'there,is,no'
p8864
(F0.20000000000000001
F0.00076452599388379206
I2
I3
I-1
tp8865
sS'twice,daily,increased'
p8866
(F1
F0.00076452599388379206
I1
I0
I1
tp8867
sS'molecular,basis,of'
p8868
(F1
F0.00076452599388379206
I1
I0
I1
tp8869
sS'of,to,the'
p8870
(F1
F0.00076452599388379206
I0
I1
I-1
tp8871
sS'inhibitors,have,the'
p8872
(F1
F0.00076452599388379206
I1
I0
I1
tp8873
sS'that,may,reduce'
p8874
(F1
F0.00076452599388379206
I1
I0
I1
tp8875
sS'inhibitor,of,hb-egf'
p8876
(F1
F0.00076452599388379206
I0
I1
I-1
tp8877
sS'auc,and,mean'
p8878
(F1
F0.00076452599388379206
I1
I0
I1
tp8879
sS'amide-type,local,since'
p8880
(F1
F0.00076452599388379206
I1
I0
I1
tp8881
sS'interaction,between,proton'
p8882
(F1
F0.00076452599388379206
I0
I1
I-1
tp8883
sS'an,hmg-coa,reductase'
p8884
(F1
F0.00076452599388379206
I0
I1
I-1
tp8885
sS'quicker,achievement,of'
p8886
(F1
F0.00076452599388379206
I1
I0
I1
tp8887
sS'the,synergism,of'
p8888
(F1
F0.00076452599388379206
I1
I0
I1
tp8889
sS'carboxylated,metabolite,and'
p8890
(F1
F0.00076452599388379206
I0
I1
I-1
tp8891
sS'doses,up,to'
p8892
(F1
F0.0022935779816513763
I0
I3
I-3
tp8893
sS'ergot-type,medications,like'
p8894
(F1
F0.00076452599388379206
I1
I0
I1
tp8895
sS'alkyating,agent,dtic'
p8896
(F1
F0.00076452599388379206
I0
I1
I-1
tp8897
sS'wales,reported,that'
p8898
(F1
F0.00076452599388379206
I1
I0
I1
tp8899
sS'critical,determinant,of'
p8900
(F1
F0.00076452599388379206
I1
I0
I1
tp8901
sS'these,two,drugs'
p8902
(F1
F0.00076452599388379206
I0
I1
I-1
tp8903
sS'alimta,in,patients'
p8904
(F1
F0.00076452599388379206
I1
I0
I1
tp8905
sS'with,refer,to'
p8906
(F1
F0.00076452599388379206
I0
I1
I-1
tp8907
sS'between,mycamine,and'
p8908
(F1
F0.00076452599388379206
I0
I1
I-1
tp8909
sS'vehicle-treated,animals,almost'
p8910
(F1
F0.00076452599388379206
I1
I0
I1
tp8911
sS'between,and,by'
p8912
(F1
F0.00076452599388379206
I1
I0
I1
tp8913
sS'clinical,practice,is'
p8914
(F1
F0.00076452599388379206
I0
I1
I-1
tp8915
sS'starting,dose,of'
p8916
(F1
F0.00076452599388379206
I0
I1
I-1
tp8917
sS'are,less,likely'
p8918
(F1
F0.00076452599388379206
I0
I1
I-1
tp8919
sS'of,g,kg'
p8920
(F1
F0.00076452599388379206
I1
I0
I1
tp8921
sS'reuptake,inhibitors,ssris'
p8922
(F0
F0
I1
I1
I0
tp8923
sS'of,mivacron,with'
p8924
(F1
F0.00076452599388379206
I0
I1
I-1
tp8925
sS'that,oral,are'
p8926
(F1
F0.00076452599388379206
I1
I0
I1
tp8927
sS'anti-proliferative,effects,the'
p8928
(F1
F0.00076452599388379206
I1
I0
I1
tp8929
sS'and,sirna,knockdown'
p8930
(F1
F0.00076452599388379206
I1
I0
I1
tp8931
sS'risk,in,a'
p8932
(F1
F0.00076452599388379206
I0
I1
I-1
tp8933
sS'of,concentrations,and'
p8934
(F1
F0.00076452599388379206
I1
I0
I1
tp8935
sS'as,that,of'
p8936
(F1
F0.0015290519877675841
I0
I2
I-2
tp8937
sS'a,critical,determinant'
p8938
(F1
F0.00076452599388379206
I1
I0
I1
tp8939
sS's,active,metabolite'
p8940
(F1
F0.00076452599388379206
I1
I0
I1
tp8941
sS'a,single,mg'
p8942
(F0.59999999999999998
F0.0022935779816513763
I1
I4
I-3
tp8943
sS'a4,may,increase'
p8944
(F1
F0.00076452599388379206
I1
I0
I1
tp8945
sS'pharmacodynamics,and,pharmacokinetics'
p8946
(F1
F0.00076452599388379206
I0
I1
I-1
tp8947
sS'use,of,has'
p8948
(F1
F0.00076452599388379206
I0
I1
I-1
tp8949
sS'or,there,is'
p8950
(F1
F0.00076452599388379206
I0
I1
I-1
tp8951
sS'in,vitro,assay'
p8952
(F1
F0.00076452599388379206
I1
I0
I1
tp8953
sS'which,may,potentiate'
p8954
(F1
F0.00076452599388379206
I1
I0
I1
tp8955
sS'full,characterization,of'
p8956
(F1
F0.00076452599388379206
I1
I0
I1
tp8957
sS'or,which,are'
p8958
(F1
F0.00076452599388379206
I1
I0
I1
tp8959
sS'stomach,may,be'
p8960
(F1
F0.00076452599388379206
I1
I0
I1
tp8961
sS'many,drugs,at'
p8962
(F1
F0.00076452599388379206
I0
I1
I-1
tp8963
sS'are,administered,at'
p8964
(F1
F0.00076452599388379206
I1
I0
I1
tp8965
sS'the,and,phases'
p8966
(F1
F0.00076452599388379206
I0
I1
I-1
tp8967
sS'medications,such,as'
p8968
(F0
F0
I1
I1
I0
tp8969
sS'related,compounds,may'
p8970
(F1
F0.00076452599388379206
I1
I0
I1
tp8971
sS'vitro,perfusion,of'
p8972
(F1
F0.00076452599388379206
I1
I0
I1
tp8973
sS'report,in,which'
p8974
(F1
F0.00076452599388379206
I1
I0
I1
tp8975
sS'glyburide,in,normal-weight'
p8976
(F1
F0.00076452599388379206
I0
I1
I-1
tp8977
sS'tubular,secretion,by'
p8978
(F1
F0.00076452599388379206
I1
I0
I1
tp8979
sS'may,be,of'
p8980
(F1
F0.00076452599388379206
I0
I1
I-1
tp8981
sS'vaccines,by,oral'
p8982
(F1
F0.00076452599388379206
I0
I1
I-1
tp8983
sS'mobic,patients,should'
p8984
(F1
F0.00076452599388379206
I1
I0
I1
tp8985
sS'agents,that,slow'
p8986
(F1
F0.00076452599388379206
I1
I0
I1
tp8987
sS'cyp,d6,inhibitors'
p8988
(F1
F0.00076452599388379206
I1
I0
I1
tp8989
sS'of,nondepolarizing,agents'
p8990
(F1
F0.00076452599388379206
I1
I0
I1
tp8991
sS'animal,model,possibly'
p8992
(F1
F0.00076452599388379206
I1
I0
I1
tp8993
sS'inducers,of,the'
p8994
(F1
F0.00076452599388379206
I1
I0
I1
tp8995
sS'transduction,of,the'
p8996
(F1
F0.00076452599388379206
I0
I1
I-1
tp8997
sS'pharmacokinetic,study,demonstrated'
p8998
(F1
F0.00076452599388379206
I1
I0
I1
tp8999
sS'of,or,following'
p9000
(F1
F0.00076452599388379206
I0
I1
I-1
tp9001
sS'qt,interval,in'
p9002
(F1
F0.00076452599388379206
I0
I1
I-1
tp9003
sS'and,could,possibly'
p9004
(F1
F0.00076452599388379206
I1
I0
I1
tp9005
sS'half-life,by,and'
p9006
(F1
F0.00076452599388379206
I1
I0
I1
tp9007
sS'by,any,concomitantly'
p9008
(F1
F0.00076452599388379206
I1
I0
I1
tp9009
sS'or,placebo,in'
p9010
(F1
F0.00076452599388379206
I0
I1
I-1
tp9011
sS'of,salicylic,acid'
p9012
(F1
F0.00076452599388379206
I1
I0
I1
tp9013
sS'study,of,fst'
p9014
(F1
F0.00076452599388379206
I0
I1
I-1
tp9015
sS'increasing,the,risk'
p9016
(F1
F0.00076452599388379206
I1
I0
I1
tp9017
sS'administration,increased,total'
p9018
(F0
F0
I1
I1
I0
tp9019
sS'of,absorption,and'
p9020
(F1
F0.00076452599388379206
I0
I1
I-1
tp9021
sS'increased,by,a'
p9022
(F1
F0.00076452599388379206
I1
I0
I1
tp9023
sS'of,humoral,immune'
p9024
(F1
F0.00076452599388379206
I0
I1
I-1
tp9025
sS'acth,may,increase'
p9026
(F1
F0.0015290519877675841
I0
I2
I-2
tp9027
sS'of,on,absorption'
p9028
(F1
F0.00076452599388379206
I0
I1
I-1
tp9029
sS'slowly,titrated,to'
p9030
(F1
F0.00076452599388379206
I0
I1
I-1
tp9031
sS'this,implies,that'
p9032
(F1
F0.00076452599388379206
I0
I1
I-1
tp9033
sS'of,tnkase,were'
p9034
(F1
F0.00076452599388379206
I0
I1
I-1
tp9035
sS'any,clinically,important'
p9036
(F1
F0.00076452599388379206
I0
I1
I-1
tp9037
sS'reproduce,the,reported'
p9038
(F1
F0.00076452599388379206
I0
I1
I-1
tp9039
sS'inhibitors,tested,for'
p9040
(F1
F0.00076452599388379206
I0
I1
I-1
tp9041
sS'or,therapy,on'
p9042
(F1
F0.00076452599388379206
I1
I0
I1
tp9043
sS'inhibitors,of,cytochrome'
p9044
(F0
F0
I1
I1
I0
tp9045
sS'vitamin,b1,thiamine'
p9046
(F1
F0.00076452599388379206
I1
I0
I1
tp9047
sS'hyaluronidase,may,increase'
p9048
(F1
F0.00076452599388379206
I1
I0
I1
tp9049
sS'doses,of,and'
p9050
(F1
F0.00076452599388379206
I1
I0
I1
tp9051
sS'apparent,total,clearance'
p9052
(F1
F0.00076452599388379206
I1
I0
I1
tp9053
sS'the,diffusion,rate'
p9054
(F1
F0.00076452599388379206
I1
I0
I1
tp9055
sS'mg,day,with'
p9056
(F1
F0.00076452599388379206
I1
I0
I1
tp9057
sS'with,and,without'
p9058
(F1
F0.00076452599388379206
I1
I0
I1
tp9059
sS'other,indications,that'
p9060
(F1
F0.00076452599388379206
I1
I0
I1
tp9061
sS'carcinogenicity,study,with'
p9062
(F1
F0.0015290519877675841
I0
I2
I-2
tp9063
sS'of,mg,tid'
p9064
(F1
F0.00076452599388379206
I1
I0
I1
tp9065
sS'sites,thus,increasing'
p9066
(F1
F0.00076452599388379206
I1
I0
I1
tp9067
sS'of,the,cell'
p9068
(F1
F0.00076452599388379206
I0
I1
I-1
tp9069
sS'being,given,orally'
p9070
(F1
F0.00076452599388379206
I0
I1
I-1
tp9071
sS'caused,a,reduction'
p9072
(F1
F0.00076452599388379206
I1
I0
I1
tp9073
sS'and,mg,four'
p9074
(F1
F0.00076452599388379206
I1
I0
I1
tp9075
sS'because,of,its'
p9076
(F1
F0.00076452599388379206
I0
I1
I-1
tp9077
sS'when,evista,is'
p9078
(F1
F0.00076452599388379206
I1
I0
I1
tp9079
sS'sedating,drugs,may'
p9080
(F1
F0.00076452599388379206
I1
I0
I1
tp9081
sS'including,and,without'
p9082
(F1
F0.00076452599388379206
I0
I1
I-1
tp9083
sS'products,with,is'
p9084
(F1
F0.00076452599388379206
I1
I0
I1
tp9085
sS'of,detrol,la'
p9086
(F1
F0.00076452599388379206
I1
I0
I1
tp9087
sS'in,post-marketing,experience'
p9088
(F1
F0.00076452599388379206
I1
I0
I1
tp9089
sS'is,required,the'
p9090
(F1
F0.00076452599388379206
I0
I1
I-1
tp9091
sS'reduction,in,requirement'
p9092
(F1
F0.00076452599388379206
I0
I1
I-1
tp9093
sS'curve,auc,and'
p9094
(F1
F0.00076452599388379206
I1
I0
I1
tp9095
sS'by,either,discontinuing'
p9096
(F1
F0.00076452599388379206
I1
I0
I1
tp9097
sS'against,the,acute'
p9098
(F1
F0.00076452599388379206
I0
I1
I-1
tp9099
sS's,metabolism,by'
p9100
(F1
F0.00076452599388379206
I1
I0
I1
tp9101
sS'be,slowly,titrated'
p9102
(F1
F0.00076452599388379206
I0
I1
I-1
tp9103
sS'be,administered,with'
p9104
(F0.59999999999999998
F0.0022935779816513763
I4
I1
I3
tp9105
sS'be,considered,in'
p9106
(F1
F0.00076452599388379206
I1
I0
I1
tp9107
sS'rheumatoid,arthritis,ra'
p9108
(F1
F0.00076452599388379206
I0
I1
I-1
tp9109
sS'or,cautiously,increasing'
p9110
(F1
F0.00076452599388379206
I0
I1
I-1
tp9111
sS'international,normalized,ratio'
p9112
(F0
F0
I1
I1
I0
tp9113
sS'insensitivity,might,be'
p9114
(F1
F0.00076452599388379206
I1
I0
I1
tp9115
sS'administered,concurrently,with'
p9116
(F1
F0.00076452599388379206
I1
I0
I1
tp9117
sS'with,opioid,analgesics'
p9118
(F1
F0.00076452599388379206
I1
I0
I1
tp9119
sS'pharmacodynamics,prothrombin,time'
p9120
(F1
F0.00076452599388379206
I0
I1
I-1
tp9121
sS'with,a,negative'
p9122
(F1
F0.00076452599388379206
I0
I1
I-1
tp9123
sS'human,immediately,prior'
p9124
(F1
F0.00076452599388379206
I1
I0
I1
tp9125
sS'anticholinergic,drugs,tricyclic'
p9126
(F1
F0.00076452599388379206
I1
I0
I1
tp9127
sS'administering,mitotane,to'
p9128
(F1
F0.00076452599388379206
I1
I0
I1
tp9129
sS'starting,mexitil,theophylline'
p9130
(F1
F0.00076452599388379206
I1
I0
I1
tp9131
sS'or,dosage,should'
p9132
(F1
F0.00076452599388379206
I1
I0
I1
tp9133
sS'children,with,a'
p9134
(F1
F0.00076452599388379206
I1
I0
I1
tp9135
sS'class,i,antipsychotic'
p9136
(F1
F0.00076452599388379206
I1
I0
I1
tp9137
sS'of,or,to'
p9138
(F1
F0.00076452599388379206
I0
I1
I-1
tp9139
sS'use,appears,to'
p9140
(F1
F0.00076452599388379206
I1
I0
I1
tp9141
sS'vitamin,k,antagonists'
p9142
(F1
F0.0015290519877675841
I2
I0
I2
tp9143
sS'liver,model,nitrogen'
p9144
(F1
F0.00076452599388379206
I1
I0
I1
tp9145
sS'that,concomitant,mg'
p9146
(F1
F0.00076452599388379206
I1
I0
I1
tp9147
sS'metabolism,of,myfortic'
p9148
(F1
F0.00076452599388379206
I0
I1
I-1
tp9149
sS'administered,in,conjunction'
p9150
(F1
F0.00076452599388379206
I1
I0
I1
tp9151
sS'pharmacology,variability,in'
p9152
(F1
F0.00076452599388379206
I1
I0
I1
tp9153
sS'that,are,capable'
p9154
(F1
F0.00076452599388379206
I1
I0
I1
tp9155
sS'when,co-administered,with'
p9156
(F1
F0.00076452599388379206
I0
I1
I-1
tp9157
sS'neuromuscular,blocking,effects'
p9158
(F0.33333333333333331
F0.00076452599388379206
I2
I1
I1
tp9159
sS'does,not,interfere'
p9160
(F1
F0.00076452599388379206
I0
I1
I-1
tp9161
sS'with,dznep,and'
p9162
(F1
F0.00076452599388379206
I1
I0
I1
tp9163
sS'thus,inhibits,the'
p9164
(F1
F0.00076452599388379206
I1
I0
I1
tp9165
sS'studies,evaluating,possible'
p9166
(F1
F0.00076452599388379206
I0
I1
I-1
tp9167
sS'effect,on,absorption'
p9168
(F1
F0.00076452599388379206
I1
I0
I1
tp9169
sS'hydrochloride,and,may'
p9170
(F1
F0.00076452599388379206
I1
I0
I1
tp9171
sS'use,of,and'
p9172
(F0.77777777777777779
F0.0053516819571865441
I8
I1
I7
tp9173
sS'and,may,alter'
p9174
(F1
F0.00076452599388379206
I1
I0
I1
tp9175
sS'and,noradrenergic,neuronal'
p9176
(F1
F0.00076452599388379206
I0
I1
I-1
tp9177
sS'diflucan,increases,the'
p9178
(F1
F0.0015290519877675841
I2
I0
I2
tp9179
sS'trials,the,concomitant'
p9180
(F1
F0.00076452599388379206
I0
I1
I-1
tp9181
sS'accordingly,patients,should'
p9182
(F1
F0.0015290519877675841
I2
I0
I2
tp9183
sS'on,day,a'
p9184
(F1
F0.00076452599388379206
I0
I1
I-1
tp9185
sS'respectively,lesser,number'
p9186
(F1
F0.00076452599388379206
I1
I0
I1
tp9187
sS'false-positive,urine,screening'
p9188
(F1
F0.00076452599388379206
I0
I1
I-1
tp9189
sS'colonies,than,did'
p9190
(F1
F0.00076452599388379206
I1
I0
I1
tp9191
sS'not,been,assessed'
p9192
(F1
F0.00076452599388379206
I0
I1
I-1
tp9193
sS'well,as,diminished'
p9194
(F1
F0.0015290519877675841
I2
I0
I2
tp9195
sS'of,patients,taking'
p9196
(F1
F0.00076452599388379206
I1
I0
I1
tp9197
sS'and,thus,inhibits'
p9198
(F1
F0.00076452599388379206
I1
I0
I1
tp9199
sS'hiv,protease,or'
p9200
(F1
F0.00076452599388379206
I0
I1
I-1
tp9201
sS'subjects,in,the'
p9202
(F1
F0.00076452599388379206
I1
I0
I1
tp9203
sS'and,blood,concentrations'
p9204
(F1
F0.00076452599388379206
I1
I0
I1
tp9205
sS'followed,by,and'
p9206
(F1
F0.00076452599388379206
I1
I0
I1
tp9207
sS'antifungals,bleeding,events'
p9208
(F1
F0.00076452599388379206
I1
I0
I1
tp9209
sS'and,lomefloxacin,reacts'
p9210
(F1
F0.00076452599388379206
I1
I0
I1
tp9211
sS'of,respiratory,depression'
p9212
(F1
F0.00076452599388379206
I1
I0
I1
tp9213
sS'study,in,which'
p9214
(F1
F0.00076452599388379206
I1
I0
I1
tp9215
sS'it,was,detected'
p9216
(F1
F0.00076452599388379206
I1
I0
I1
tp9217
sS'toxicity,by,altering'
p9218
(F1
F0.00076452599388379206
I1
I0
I1
tp9219
sS'interaction,study,showed'
p9220
(F1
F0.00076452599388379206
I1
I0
I1
tp9221
sS'is,not,verified'
p9222
(F1
F0.00076452599388379206
I0
I1
I-1
tp9223
sS'either,or,or'
p9224
(F1
F0.0015290519877675841
I0
I2
I-2
tp9225
sS'weaker,effect,on'
p9226
(F1
F0.00076452599388379206
I1
I0
I1
tp9227
sS'and,increases,the'
p9228
(F1
F0.00076452599388379206
I1
I0
I1
tp9229
sS'acute,mi,when'
p9230
(F1
F0.00076452599388379206
I0
I1
I-1
tp9231
sS'aimed,to,investigate'
p9232
(F1
F0.00076452599388379206
I0
I1
I-1
tp9233
sS'serum,concentrations,in'
p9234
(F1
F0.00076452599388379206
I1
I0
I1
tp9235
sS'two,separate,occasions'
p9236
(F1
F0.00076452599388379206
I1
I0
I1
tp9237
sS'coadministered,with,adjustment'
p9238
(F1
F0.00076452599388379206
I0
I1
I-1
tp9239
sS'be,advisable,to'
p9240
(F1
F0.00076452599388379206
I1
I0
I1
tp9241
sS'in,patients,concurrently'
p9242
(F1
F0.0015290519877675841
I2
I0
I2
tp9243
sS'of,a,selective'
p9244
(F1
F0.00076452599388379206
I1
I0
I1
tp9245
sS'of,interaction,between'
p9246
(F1
F0.00076452599388379206
I0
I1
I-1
tp9247
sS'forced,expression,and'
p9248
(F1
F0.00076452599388379206
I1
I0
I1
tp9249
sS'and,prolongation,of'
p9250
(F1
F0.00076452599388379206
I1
I0
I1
tp9251
sS'of,acute,mi'
p9252
(F1
F0.00076452599388379206
I0
I1
I-1
tp9253
sS'tpmt,enzyme,they'
p9254
(F1
F0.00076452599388379206
I1
I0
I1
tp9255
sS'active,metabolite,is'
p9256
(F1
F0.00076452599388379206
I0
I1
I-1
tp9257
sS'in,acute,model'
p9258
(F1
F0.00076452599388379206
I0
I1
I-1
tp9259
sS'studies,with,coumarin-type'
p9260
(F1
F0.00076452599388379206
I1
I0
I1
tp9261
sS'that,dasatinib-mediated,induction'
p9262
(F1
F0.00076452599388379206
I1
I0
I1
tp9263
sS'of,mg,diminished'
p9264
(F1
F0.00076452599388379206
I1
I0
I1
tp9265
sS'pk,parameters,was'
p9266
(F1
F0.00076452599388379206
I0
I1
I-1
tp9267
sS'experimental,groups,methyl-4'
p9268
(F1
F0.00076452599388379206
I0
I1
I-1
tp9269
sS'or,sedation,and'
p9270
(F1
F0.00076452599388379206
I1
I0
I1
tp9271
sS'exercised,with,concomitant'
p9272
(F1
F0.00076452599388379206
I1
I0
I1
tp9273
sS'liver,has,shown'
p9274
(F1
F0.00076452599388379206
I1
I0
I1
tp9275
sS'to,subjects,who'
p9276
(F1
F0.00076452599388379206
I1
I0
I1
tp9277
sS'cns,effects,such'
p9278
(F1
F0.00076452599388379206
I1
I0
I1
tp9279
sS'the,inr,or'
p9280
(F1
F0.0015290519877675841
I2
I0
I2
tp9281
sS'prior,to,during'
p9282
(F1
F0.00076452599388379206
I1
I0
I1
tp9283
sS'approach,allowing,to'
p9284
(F1
F0.00076452599388379206
I1
I0
I1
tp9285
sS'in,each,group'
p9286
(F1
F0.00076452599388379206
I0
I1
I-1
tp9287
sS'as,n,n'
p9288
(F1
F0.00076452599388379206
I0
I1
I-1
tp9289
sS'anesthetic,agents,have'
p9290
(F1
F0.00076452599388379206
I0
I1
I-1
tp9291
sS'the,extrapyramidal,effects'
p9292
(F1
F0.00076452599388379206
I1
I0
I1
tp9293
sS'in,the,metabolic'
p9294
(F1
F0.00076452599388379206
I1
I0
I1
tp9295
sS'noradrenergic,neuronal,loss'
p9296
(F1
F0.00076452599388379206
I0
I1
I-1
tp9297
sS'drugs,eliminated,via'
p9298
(F1
F0.00076452599388379206
I1
I0
I1
tp9299
sS'by,the,anionic'
p9300
(F1
F0.00076452599388379206
I1
I0
I1
tp9301
sS'cisapride,other,drugs'
p9302
(F1
F0.00076452599388379206
I1
I0
I1
tp9303
sS'severe,toxicity,has'
p9304
(F1
F0.00076452599388379206
I1
I0
I1
tp9305
sS'from,mg,day'
p9306
(F1
F0.00076452599388379206
I0
I1
I-1
tp9307
sS'if,mexitil,and'
p9308
(F1
F0.00076452599388379206
I1
I0
I1
tp9309
sS'therapy,mg,and'
p9310
(F1
F0.00076452599388379206
I1
I0
I1
tp9311
sS'of,is,not'
p9312
(F1
F0.00076452599388379206
I0
I1
I-1
tp9313
sS'apoptosis,by,negatively'
p9314
(F1
F0.00076452599388379206
I1
I0
I1
tp9315
sS'plasma,concentrations,increased'
p9316
(F1
F0.00076452599388379206
I1
I0
I1
tp9317
sS'xenical,administration,vitamin'
p9318
(F1
F0.00076452599388379206
I0
I1
I-1
tp9319
sS'survival,rate,compared'
p9320
(F1
F0.00076452599388379206
I1
I0
I1
tp9321
sS'decreased,with,xenical'
p9322
(F1
F0.00076452599388379206
I1
I0
I1
tp9323
sS'coadministered,with,other'
p9324
(F0
F0
I1
I1
I0
tp9325
sS'i,fludrocortisone,acetate'
p9326
(F1
F0.00076452599388379206
I0
I1
I-1
tp9327
sS'of,the,or'
p9328
(F1
F0.00076452599388379206
I0
I1
I-1
tp9329
sS'crm197,on,these'
p9330
(F1
F0.00076452599388379206
I0
I1
I-1
tp9331
sS'the,drugs,of'
p9332
(F1
F0.00076452599388379206
I1
I0
I1
tp9333
sS'additive,effects,in'
p9334
(F1
F0.00076452599388379206
I1
I0
I1
tp9335
sS'small,number,of'
p9336
(F1
F0.00076452599388379206
I1
I0
I1
tp9337
sS'cause,clinically,significant'
p9338
(F1
F0.00076452599388379206
I0
I1
I-1
tp9339
sS'chronic,dosing,of'
p9340
(F1
F0.00076452599388379206
I0
I1
I-1
tp9341
sS'severe,constipation,which'
p9342
(F1
F0.00076452599388379206
I1
I0
I1
tp9343
sS'mivacron,may,be'
p9344
(F0
F0
I1
I1
I0
tp9345
sS'if,in,certain'
p9346
(F1
F0.00076452599388379206
I1
I0
I1
tp9347
sS'interval,in,healthy'
p9348
(F1
F0.00076452599388379206
I0
I1
I-1
tp9349
sS'mg,per,day'
p9350
(F1
F0.00076452599388379206
I1
I0
I1
tp9351
sS'nsaids,should,interrupt'
p9352
(F1
F0.00076452599388379206
I1
I0
I1
tp9353
sS'or,to,therapy'
p9354
(F1
F0.00076452599388379206
I0
I1
I-1
tp9355
sS'patients,to,whom'
p9356
(F1
F0.0022935779816513763
I3
I0
I3
tp9357
sS'reduced,doses,of'
p9358
(F1
F0.00076452599388379206
I1
I0
I1
tp9359
sS'clearance,of,cerezyme'
p9360
(F1
F0.00076452599388379206
I1
I0
I1
tp9361
sS'urinary,and,respiratory'
p9362
(F1
F0.00076452599388379206
I0
I1
I-1
tp9363
sS'effects,of,a'
p9364
(F1
F0.00076452599388379206
I0
I1
I-1
tp9365
sS'these,patients,are'
p9366
(F1
F0.00076452599388379206
I1
I0
I1
tp9367
sS'a,monoamine,oxidase'
p9368
(F1
F0.00076452599388379206
I1
I0
I1
tp9369
sS'lt,and,phases'
p9370
(F1
F0.00076452599388379206
I0
I1
I-1
tp9371
sS'to,warrant,dosage'
p9372
(F1
F0.00076452599388379206
I0
I1
I-1
tp9373
sS'active,metabolite,by'
p9374
(F1
F0.00076452599388379206
I1
I0
I1
tp9375
sS'mixed,with,regular'
p9376
(F1
F0.00076452599388379206
I1
I0
I1
tp9377
sS'metrogel,gel,is'
p9378
(F1
F0.00076452599388379206
I0
I1
I-1
tp9379
sS'cholestyramine,cholestyramine,causes'
p9380
(F1
F0.00076452599388379206
I1
I0
I1
tp9381
sS'concomitant,administration,decreased'
p9382
(F1
F0.00076452599388379206
I1
I0
I1
tp9383
sS'to,increase,serum'
p9384
(F1
F0.00076452599388379206
I1
I0
I1
tp9385
sS'decreased,time,of'
p9386
(F1
F0.00076452599388379206
I1
I0
I1
tp9387
sS'induction,of,p27'
p9388
(F1
F0.00076452599388379206
I1
I0
I1
tp9389
sS'in,adult,diabetic'
p9390
(F1
F0.00076452599388379206
I0
I1
I-1
tp9391
sS'fu,and,following'
p9392
(F1
F0.00076452599388379206
I0
I1
I-1
tp9393
sS'the,plasma,concentrations'
p9394
(F0
F0
I1
I1
I0
tp9395
sS'in,the,risk'
p9396
(F1
F0.00076452599388379206
I1
I0
I1
tp9397
sS'antihypertensive,drugs,potentiation'
p9398
(F1
F0.00076452599388379206
I1
I0
I1
tp9399
sS'medicines,to,control'
p9400
(F1
F0.00076452599388379206
I0
I1
I-1
tp9401
sS'profiles,similar,to'
p9402
(F1
F0.00076452599388379206
I1
I0
I1
tp9403
sS'metabolized,by,a'
p9404
(F1
F0.00076452599388379206
I0
I1
I-1
tp9405
sS'evidence,suggests,that'
p9406
(F1
F0.0015290519877675841
I2
I0
I2
tp9407
sS'you,have,taken'
p9408
(F1
F0.00076452599388379206
I1
I0
I1
tp9409
sS'skills,produced,by'
p9410
(F1
F0.0015290519877675841
I2
I0
I2
tp9411
sS'fat,excretion,or'
p9412
(F1
F0.00076452599388379206
I0
I1
I-1
tp9413
sS'when,univasc,was'
p9414
(F1
F0.00076452599388379206
I0
I1
I-1
tp9415
sS'administration,of,which'
p9416
(F1
F0.00076452599388379206
I1
I0
I1
tp9417
sS'experiment,the,same'
p9418
(F1
F0.00076452599388379206
I1
I0
I1
tp9419
sS'antagonize,the,bactericidal'
p9420
(F1
F0.00076452599388379206
I1
I0
I1
tp9421
sS'kip1,bcl-2,and'
p9422
(F1
F0.00076452599388379206
I0
I1
I-1
tp9423
sS'of,or,januvia'
p9424
(F1
F0.00076452599388379206
I0
I1
I-1
tp9425
sS'injection,before,for'
p9426
(F1
F0.00076452599388379206
I0
I1
I-1
tp9427
sS'breast,cancer,or'
p9428
(F1
F0.00076452599388379206
I0
I1
I-1
tp9429
sS'on,the,pharmacokinetics'
p9430
(F1
F0.0038226299694189602
I0
I5
I-5
tp9431
sS'tricyclic,antidepressants,may'
p9432
(F1
F0.00076452599388379206
I1
I0
I1
tp9433
sS'or,severity,of'
p9434
(F1
F0.0015290519877675841
I2
I0
I2
tp9435
sS'concomitant,and,ace'
p9436
(F1
F0.00076452599388379206
I0
I1
I-1
tp9437
sS'in,the,same'
p9438
(F1
F0.00076452599388379206
I1
I0
I1
tp9439
sS'recommended,terfenadine,and'
p9440
(F1
F0.00076452599388379206
I1
I0
I1
tp9441
sS'of,cardiac,events'
p9442
(F1
F0.00076452599388379206
I1
I0
I1
tp9443
sS'the,sedative,activity'
p9444
(F1
F0.00076452599388379206
I1
I0
I1
tp9445
sS'of,cyp3a4,i'
p9446
(F1
F0.00076452599388379206
I1
I0
I1
tp9447
sS'coadministration,of,at'
p9448
(F1
F0.00076452599388379206
I1
I0
I1
tp9449
sS'other,drugs,which'
p9450
(F1
F0.0015290519877675841
I2
I0
I2
tp9451
sS'a,net,inducer'
p9452
(F1
F0.00076452599388379206
I1
I0
I1
tp9453
sS'newcastle,disease,and'
p9454
(F1
F0.00076452599388379206
I0
I1
I-1
tp9455
sS'increase,the,effects'
p9456
(F1
F0.0022935779816513763
I3
I0
I3
tp9457
sS'in,r-warfarin,half-life'
p9458
(F1
F0.00076452599388379206
I1
I0
I1
tp9459
sS'and,do,not'
p9460
(F1
F0.00076452599388379206
I0
I1
I-1
tp9461
sS'as,may,decrease'
p9462
(F1
F0.00076452599388379206
I1
I0
I1
tp9463
sS'are,likely,to'
p9464
(F1
F0.00076452599388379206
I1
I0
I1
tp9465
sS'myeloproliferative,effects,of'
p9466
(F1
F0.00076452599388379206
I1
I0
I1
tp9467
sS'modified,pharmacokinetics,were'
p9468
(F1
F0.00076452599388379206
I0
I1
I-1
tp9469
sS'inhibitors,a,synergistic'
p9470
(F1
F0.00076452599388379206
I1
I0
I1
tp9471
sS'from,the,small'
p9472
(F1
F0.00076452599388379206
I1
I0
I1
tp9473
sS'due,to,its'
p9474
(F1
F0.00076452599388379206
I1
I0
I1
tp9475
sS'these,products,with'
p9476
(F1
F0.00076452599388379206
I1
I0
I1
tp9477
sS'interact,with,and'
p9478
(F1
F0.00076452599388379206
I1
I0
I1
tp9479
sS'demser,to,patients'
p9480
(F1
F0.00076452599388379206
I1
I0
I1
tp9481
sS'investigates,the,ability'
p9482
(F1
F0.00076452599388379206
I0
I1
I-1
tp9483
sS'drugs,diuretic-induced,hypokalemia'
p9484
(F1
F0.00076452599388379206
I1
I0
I1
tp9485
sS'and,the,low'
p9486
(F1
F0.00076452599388379206
I0
I1
I-1
tp9487
sS'ethynyl,pyridine,significantly'
p9488
(F1
F0.00076452599388379206
I1
I0
I1
tp9489
sS'and,nsaids,with'
p9490
(F1
F0.00076452599388379206
I1
I0
I1
tp9491
sS'not,been,studied'
p9492
(F0.33333333333333331
F0.00076452599388379206
I2
I1
I1
tp9493
sS'treated,with,salt-retaining'
p9494
(F1
F0.00076452599388379206
I0
I1
I-1
tp9495
sS'clearance,of,compounds'
p9496
(F1
F0.00076452599388379206
I1
I0
I1
tp9497
sS'nexavar,resulted,in'
p9498
(F1
F0.00076452599388379206
I1
I0
I1
tp9499
sS'an,increased,rate'
p9500
(F1
F0.00076452599388379206
I1
I0
I1
tp9501
sS'oral,may,be'
p9502
(F1
F0.00076452599388379206
I1
I0
I1
tp9503
sS'these,data,suggest'
p9504
(F1
F0.00076452599388379206
I1
I0
I1
tp9505
sS'use,in,patients'
p9506
(F1
F0.00076452599388379206
I1
I0
I1
tp9507
sS'locomotion,in,mice'
p9508
(F1
F0.00076452599388379206
I1
I0
I1
tp9509
sS'who,subsequently,received'
p9510
(F1
F0.00076452599388379206
I1
I0
I1
tp9511
sS'absence,of,data'
p9512
(F1
F0.00076452599388379206
I1
I0
I1
tp9513
sS'effects,of,when'
p9514
(F1
F0.0015290519877675841
I2
I0
I2
tp9515
sS'or,chondroitin,abc'
p9516
(F1
F0.00076452599388379206
I0
I1
I-1
tp9517
sS'significantly,lower,in'
p9518
(F1
F0.0015290519877675841
I0
I2
I-2
tp9519
sS'acting,alpha-2,agonists'
p9520
(F1
F0.00076452599388379206
I0
I1
I-1
tp9521
sS'increased,the,depth'
p9522
(F1
F0.00076452599388379206
I0
I1
I-1
tp9523
sS'containing,should,be'
p9524
(F1
F0.00076452599388379206
I0
I1
I-1
tp9525
sS'pharmacokinetics,or,pharmacodynamics'
p9526
(F1
F0.00076452599388379206
I0
I1
I-1
tp9527
sS'transfection,with,bcl-2'
p9528
(F1
F0.00076452599388379206
I0
I1
I-1
tp9529
sS'vasoconstrictor,agents,including'
p9530
(F1
F0.00076452599388379206
I0
I1
I-1
tp9531
sS'clinical,trials,nsaids'
p9532
(F1
F0.00076452599388379206
I1
I0
I1
tp9533
sS'questioning,revealed,the'
p9534
(F1
F0.00076452599388379206
I0
I1
I-1
tp9535
sS'not,a,substrate'
p9536
(F1
F0.00076452599388379206
I0
I1
I-1
tp9537
sS'ferrous,gluconate,is'
p9538
(F1
F0.00076452599388379206
I1
I0
I1
tp9539
sS'a,two-fold,decrease'
p9540
(F1
F0.00076452599388379206
I1
I0
I1
tp9541
sS'nsaids,may,diminish'
p9542
(F1
F0.00076452599388379206
I1
I0
I1
tp9543
sS'there,is,usually'
p9544
(F1
F0.00076452599388379206
I1
I0
I1
tp9545
sS'after,the,initiation'
p9546
(F1
F0.0015290519877675841
I2
I0
I2
tp9547
sS'd,vitamin,a'
p9548
(F1
F0.00076452599388379206
I0
I1
I-1
tp9549
sS'treatment,periods,at'
p9550
(F1
F0.00076452599388379206
I0
I1
I-1
tp9551
sS'patients,who,were'
p9552
(F1
F0.00076452599388379206
I1
I0
I1
tp9553
sS'that,irreversibly,inhibit'
p9554
(F1
F0.00076452599388379206
I1
I0
I1
tp9555
sS'ethynyl,pyridine-treated,animals'
p9556
(F1
F0.00076452599388379206
I1
I0
I1
tp9557
sS'a,minimal,increase'
p9558
(F1
F0.00076452599388379206
I1
I0
I1
tp9559
sS'acid,and,have'
p9560
(F1
F0.00076452599388379206
I1
I0
I1
tp9561
sS'males,the,clearance'
p9562
(F1
F0.00076452599388379206
I1
I0
I1
tp9563
sS'whereas,none,of'
p9564
(F1
F0.00076452599388379206
I1
I0
I1
tp9565
sS'acid,secretion,may'
p9566
(F1
F0.00076452599388379206
I1
I0
I1
tp9567
sS'toxicity,phenytoin,can'
p9568
(F1
F0.00076452599388379206
I1
I0
I1
tp9569
sS'certain,ergot,alkaloid'
p9570
(F1
F0.00076452599388379206
I0
I1
I-1
tp9571
sS'fold,increase,in'
p9572
(F1
F0.0015290519877675841
I2
I0
I2
tp9573
sS'that,are,known'
p9574
(F1
F0.00076452599388379206
I1
I0
I1
tp9575
sS'organism,vaccines,are'
p9576
(F1
F0.00076452599388379206
I1
I0
I1
tp9577
sS'the,single-dose,pharmacokinetics'
p9578
(F1
F0.00076452599388379206
I0
I1
I-1
tp9579
sS'to,or,hours'
p9580
(F1
F0.00076452599388379206
I1
I0
I1
tp9581
sS'interactions,there,are'
p9582
(F1
F0.00076452599388379206
I1
I0
I1
tp9583
sS'mg,daily,dose'
p9584
(F1
F0.0015290519877675841
I2
I0
I2
tp9585
sS'as,may,interfere'
p9586
(F1
F0.00076452599388379206
I1
I0
I1
tp9587
sS'study,has,shown'
p9588
(F1
F0.00076452599388379206
I1
I0
I1
tp9589
sS'in,vivo,positron'
p9590
(F1
F0.00076452599388379206
I1
I0
I1
tp9591
sS'a,range,of'
p9592
(F1
F0.00076452599388379206
I0
I1
I-1
tp9593
sS'published,data,indicate'
p9594
(F1
F0.00076452599388379206
I1
I0
I1
tp9595
sS'postmarketing,reports,of'
p9596
(F1
F0.00076452599388379206
I1
I0
I1
tp9597
sS'more,than,treatment'
p9598
(F1
F0.00076452599388379206
I1
I0
I1
tp9599
sS'of,such,drugs'
p9600
(F0
F0
I1
I1
I0
tp9601
sS'no,effect,while'
p9602
(F1
F0.00076452599388379206
I1
I0
I1
tp9603
sS'low-dose,to,reduce'
p9604
(F1
F0.00076452599388379206
I1
I0
I1
tp9605
sS'was,muted,compared'
p9606
(F1
F0.00076452599388379206
I0
I1
I-1
tp9607
sS'profound,and,long'
p9608
(F1
F0.00076452599388379206
I1
I0
I1
tp9609
sS'may,require,reduced'
p9610
(F1
F0.00076452599388379206
I1
I0
I1
tp9611
sS'to,many,drugs'
p9612
(F1
F0.00076452599388379206
I0
I1
I-1
tp9613
sS'that,induce,hepatic'
p9614
(F1
F0.0015290519877675841
I2
I0
I2
tp9615
sS'dosages,of,concomitantly'
p9616
(F1
F0.00076452599388379206
I1
I0
I1
tp9617
sS'of,sodium,bicarbonate'
p9618
(F1
F0.00076452599388379206
I0
I1
I-1
tp9619
sS'they,have,a'
p9620
(F1
F0.00076452599388379206
I0
I1
I-1
tp9621
sS'by,the,concomitant'
p9622
(F1
F0.00076452599388379206
I1
I0
I1
tp9623
sS'during,anesthesia,or'
p9624
(F1
F0.00076452599388379206
I0
I1
I-1
tp9625
sS'contraindicated,selective,serotonin'
p9626
(F1
F0.00076452599388379206
I1
I0
I1
tp9627
sS'evidence,that,may'
p9628
(F1
F0.00076452599388379206
I1
I0
I1
tp9629
sS'not,displace,from'
p9630
(F1
F0.0015290519877675841
I0
I2
I-2
tp9631
sS'alter,the,single-dose'
p9632
(F1
F0.00076452599388379206
I0
I1
I-1
tp9633
sS'treatment,with,either'
p9634
(F0
F0
I1
I1
I0
tp9635
sS'in,patients,suffering'
p9636
(F1
F0.0015290519877675841
I2
I0
I2
tp9637
sS'be,considered,when'
p9638
(F0
F0
I1
I1
I0
tp9639
sS'lyase,heparinase,iii'
p9640
(F1
F0.00076452599388379206
I0
I1
I-1
tp9641
sS'substrate,of,cytochromes'
p9642
(F1
F0.00076452599388379206
I0
I1
I-1
tp9643
sS'or,nephrotoxic,drugs'
p9644
(F1
F0.00076452599388379206
I0
I1
I-1
tp9645
sS'inhibitor,cci-779,has'
p9646
(F1
F0.00076452599388379206
I1
I0
I1
tp9647
sS'when,the,mexitil'
p9648
(F1
F0.00076452599388379206
I1
I0
I1
tp9649
sS'until,the,development'
p9650
(F1
F0.00076452599388379206
I0
I1
I-1
tp9651
sS'between,and,or'
p9652
(F1
F0.00076452599388379206
I0
I1
I-1
tp9653
sS'concurrently,blood,levels'
p9654
(F1
F0.00076452599388379206
I1
I0
I1
tp9655
sS'zidovudine,competitively,inhibits'
p9656
(F1
F0.00076452599388379206
I1
I0
I1
tp9657
sS'records,of,pediatric'
p9658
(F1
F0.00076452599388379206
I0
I1
I-1
tp9659
sS'suggest,that,dasatinib-mediated'
p9660
(F1
F0.00076452599388379206
I1
I0
I1
tp9661
sS'hormones,sedative,non-steroidal'
p9662
(F1
F0.00076452599388379206
I0
I1
I-1
tp9663
sS'drugs,capable,of'
p9664
(F1
F0.00076452599388379206
I0
I1
I-1
tp9665
sS'and,on,platelet'
p9666
(F1
F0.00076452599388379206
I1
I0
I1
tp9667
sS'on,these,cells'
p9668
(F1
F0.00076452599388379206
I0
I1
I-1
tp9669
sS'retrospectively,reviewed,the'
p9670
(F1
F0.00076452599388379206
I0
I1
I-1
tp9671
sS'agents,of,class'
p9672
(F1
F0.00076452599388379206
I1
I0
I1
tp9673
sS'sulfate,or,ferrous'
p9674
(F1
F0.00076452599388379206
I1
I0
I1
tp9675
sS'reduced,approximately,in'
p9676
(F1
F0.00076452599388379206
I1
I0
I1
tp9677
sS'treatment,of,acute'
p9678
(F1
F0.0015290519877675841
I0
I2
I-2
tp9679
sS'in,a,two-fold'
p9680
(F1
F0.00076452599388379206
I1
I0
I1
tp9681
sS'efficacy,may,be'
p9682
(F1
F0.00076452599388379206
I1
I0
I1
tp9683
sS'drugs,no,dosage'
p9684
(F1
F0.00076452599388379206
I0
I1
I-1
tp9685
sS'feldene,have,been'
p9686
(F1
F0.00076452599388379206
I1
I0
I1
tp9687
sS'hey,xenograft-bearing,mice'
p9688
(F1
F0.00076452599388379206
I1
I0
I1
tp9689
sS'significant,protective,effect'
p9690
(F1
F0.00076452599388379206
I1
I0
I1
tp9691
sS'administration,of,aceon'
p9692
(F1
F0.00076452599388379206
I0
I1
I-1
tp9693
sS'nalidixic,acid,together'
p9694
(F1
F0.00076452599388379206
I1
I0
I1
tp9695
sS'concomitant,with,recommended'
p9696
(F1
F0.00076452599388379206
I1
I0
I1
tp9697
sS'flomax,capsules,should'
p9698
(F1
F0.0015290519877675841
I2
I0
I2
tp9699
sS'but,also,prolonged'
p9700
(F1
F0.00076452599388379206
I1
I0
I1
tp9701
sS'leukine,such,as'
p9702
(F1
F0.00076452599388379206
I1
I0
I1
tp9703
sS'concentrations,and,auc'
p9704
(F1
F0.00076452599388379206
I1
I0
I1
tp9705
sS'some,drugs,in'
p9706
(F1
F0.00076452599388379206
I1
I0
I1
tp9707
sS'received,or,are'
p9708
(F1
F0.00076452599388379206
I1
I0
I1
tp9709
sS'agents,eg,nitrous'
p9710
(F1
F0.00076452599388379206
I1
I0
I1
tp9711
sS'was,evaluated,for'
p9712
(F1
F0.00076452599388379206
I0
I1
I-1
tp9713
sS'monitored,and,the'
p9714
(F1
F0.00076452599388379206
I1
I0
I1
tp9715
sS'shown,that,is'
p9716
(F1
F0.00076452599388379206
I0
I1
I-1
tp9717
sS'although,there,is'
p9718
(F1
F0.00076452599388379206
I1
I0
I1
tp9719
sS'antitumor,activities,in'
p9720
(F1
F0.00076452599388379206
I0
I1
I-1
tp9721
sS'of,such,as'
p9722
(F1
F0.00076452599388379206
I0
I1
I-1
tp9723
sS'with,and,was'
p9724
(F1
F0.00076452599388379206
I0
I1
I-1
tp9725
sS'lithium,renal,clearance'
p9726
(F1
F0.00076452599388379206
I1
I0
I1
tp9727
sS'vanillylmandelic,acid,a'
p9728
(F1
F0.00076452599388379206
I0
I1
I-1
tp9729
sS'metabolized,by,these'
p9730
(F1
F0.0015290519877675841
I0
I2
I-2
tp9731
sS'concentrations,of,the'
p9732
(F1
F0.00076452599388379206
I0
I1
I-1
tp9733
sS'deoxynucleotidyl,transferase-mediated,dutp'
p9734
(F1
F0.00076452599388379206
I0
I1
I-1
tp9735
sS'and,there,is'
p9736
(F1
F0.00076452599388379206
I1
I0
I1
tp9737
sS'inhibitors,to,sensitize'
p9738
(F1
F0.00076452599388379206
I0
I1
I-1
tp9739
sS'myelotoxicity,bone,marrow'
p9740
(F1
F0.00076452599388379206
I1
I0
I1
tp9741
sS'the,p,lt'
p9742
(F1
F0.00076452599388379206
I0
I1
I-1
tp9743
sS'the,pharmacokinetics,and'
p9744
(F1
F0.00076452599388379206
I0
I1
I-1
tp9745
sS'may,further,increase'
p9746
(F1
F0.00076452599388379206
I0
I1
I-1
tp9747
sS'systemic,exposure,observed'
p9748
(F1
F0.00076452599388379206
I0
I1
I-1
tp9749
sS'of,mycamine,on'
p9750
(F1
F0.00076452599388379206
I0
I1
I-1
tp9751
sS'effects,of,chronic'
p9752
(F0
F0
I1
I1
I0
tp9753
sS'furosemide,and,probably'
p9754
(F1
F0.00076452599388379206
I1
I0
I1
tp9755
sS'bleeding,vs,but'
p9756
(F1
F0.00076452599388379206
I1
I0
I1
tp9757
sS'rabbits,treated,with'
p9758
(F1
F0.00076452599388379206
I0
I1
I-1
tp9759
sS'been,the,subject'
p9760
(F1
F0.00076452599388379206
I0
I1
I-1
tp9761
sS'a,potent,cyp3a'
p9762
(F1
F0.00076452599388379206
I0
I1
I-1
tp9763
sS'bcl-2,and,the'
p9764
(F1
F0.00076452599388379206
I1
I0
I1
tp9765
sS'plus,inhibited,tumor'
p9766
(F1
F0.00076452599388379206
I1
I0
I1
tp9767
sS'or,had,an'
p9768
(F1
F0.00076452599388379206
I1
I0
I1
tp9769
sS'toxicity,since,inhibit'
p9770
(F1
F0.00076452599388379206
I1
I0
I1
tp9771
sS'does,not,cause'
p9772
(F1
F0.00076452599388379206
I0
I1
I-1
tp9773
sS'sodium,and,displaced'
p9774
(F1
F0.00076452599388379206
I1
I0
I1
tp9775
sS'has,no,clinically'
p9776
(F1
F0.00076452599388379206
I1
I0
I1
tp9777
sS'of,increase,or'
p9778
(F1
F0.00076452599388379206
I1
I0
I1
tp9779
sS'is,coadministered,with'
p9780
(F0
F0
I1
I1
I0
tp9781
sS'wine,did,not'
p9782
(F1
F0.00076452599388379206
I0
I1
I-1
tp9783
sS'up,to,when'
p9784
(F1
F0.00076452599388379206
I1
I0
I1
tp9785
sS'in,doses,of'
p9786
(F1
F0.00076452599388379206
I1
I0
I1
tp9787
sS'anticoagulants,anabolic,may'
p9788
(F1
F0.00076452599388379206
I1
I0
I1
tp9789
sS'system,may,be'
p9790
(F1
F0.00076452599388379206
I1
I0
I1
tp9791
sS'at,g1,phase'
p9792
(F1
F0.00076452599388379206
I0
I1
I-1
tp9793
sS'suppression,compared,with'
p9794
(F1
F0.00076452599388379206
I1
I0
I1
tp9795
sS'decreases,in,some'
p9796
(F1
F0.00076452599388379206
I0
I1
I-1
tp9797
sS'it,appears,possible'
p9798
(F1
F0.00076452599388379206
I1
I0
I1
tp9799
sS'analgesics,agonist,antagonist'
p9800
(F1
F0.00076452599388379206
I1
I0
I1
tp9801
sS'increased,with,coadministration'
p9802
(F1
F0.00076452599388379206
I1
I0
I1
tp9803
sS'mechanisms,of,interaction'
p9804
(F1
F0.00076452599388379206
I0
I1
I-1
tp9805
sS'oral,may,render'
p9806
(F1
F0.0015290519877675841
I2
I0
I2
tp9807
sS'variety,of,such'
p9808
(F1
F0.00076452599388379206
I0
I1
I-1
tp9809
sS'auc,were,increased'
p9810
(F1
F0.00076452599388379206
I1
I0
I1
tp9811
sS'be,an,appropriate'
p9812
(F1
F0.00076452599388379206
I0
I1
I-1
tp9813
sS'oral,agents,may'
p9814
(F1
F0.00076452599388379206
I1
I0
I1
tp9815
sS'serum,antibody,response'
p9816
(F1
F0.00076452599388379206
I1
I0
I1
tp9817
sS'vitro,in,the'
p9818
(F1
F0.00076452599388379206
I1
I0
I1
tp9819
sS'we,tested,whether'
p9820
(F1
F0.00076452599388379206
I0
I1
I-1
tp9821
sS'enzymes,including,hyaluronan'
p9822
(F1
F0.00076452599388379206
I0
I1
I-1
tp9823
sS'impairment,of,fertility'
p9824
(F1
F0.00076452599388379206
I0
I1
I-1
tp9825
sS'if,the,total'
p9826
(F1
F0.00076452599388379206
I0
I1
I-1
tp9827
sS'available,indicate,that'
p9828
(F1
F0.00076452599388379206
I0
I1
I-1
tp9829
sS'placebo,in,day'
p9830
(F1
F0.00076452599388379206
I0
I1
I-1
tp9831
sS'to,affect,mexitil'
p9832
(F1
F0.00076452599388379206
I0
I1
I-1
tp9833
sS'of,in,conjunction'
p9834
(F1
F0.00076452599388379206
I1
I0
I1
tp9835
sS'and,infusional,fu'
p9836
(F1
F0.00076452599388379206
I0
I1
I-1
tp9837
sS'as,diminished,effects'
p9838
(F1
F0.0015290519877675841
I2
I0
I2
tp9839
sS'was,carried,out'
p9840
(F1
F0.00076452599388379206
I0
I1
I-1
tp9841
sS'because,patients,took'
p9842
(F1
F0.00076452599388379206
I1
I0
I1
tp9843
sS'without,or,platelet'
p9844
(F1
F0.00076452599388379206
I1
I0
I1
tp9845
sS'parameters,was,not'
p9846
(F1
F0.00076452599388379206
I0
I1
I-1
tp9847
sS'affected,by,multiple'
p9848
(F1
F0.00076452599388379206
I0
I1
I-1
tp9849
sS'for,days,xenical'
p9850
(F1
F0.0030581039755351682
I0
I4
I-4
tp9851
sS'antagonize,the,effect'
p9852
(F1
F0.00076452599388379206
I1
I0
I1
tp9853
sS'care,should,be'
p9854
(F1
F0.00076452599388379206
I1
I0
I1
tp9855
sS'agents,no,clinically'
p9856
(F1
F0.00076452599388379206
I0
I1
I-1
tp9857
sS'serum,concentrations,of'
p9858
(F0
F0
I1
I1
I0
tp9859
sS'or,may,diminish'
p9860
(F1
F0.00076452599388379206
I1
I0
I1
tp9861
sS'and,its,active'
p9862
(F1
F0.00076452599388379206
I0
I1
I-1
tp9863
sS'improved,the,progression-free'
p9864
(F1
F0.00076452599388379206
I1
I0
I1
tp9865
sS'to,assess,the'
p9866
(F1
F0.00076452599388379206
I0
I1
I-1
tp9867
sS'oral,activated,charcoal'
p9868
(F1
F0.00076452599388379206
I1
I0
I1
tp9869
sS'when,those,agents'
p9870
(F1
F0.00076452599388379206
I1
I0
I1
tp9871
sS'univasc,has,been'
p9872
(F1
F0.00076452599388379206
I0
I1
I-1
tp9873
sS'and,other,hdac'
p9874
(F1
F0.00076452599388379206
I1
I0
I1
tp9875
sS'therapy,and,have'
p9876
(F1
F0.00076452599388379206
I0
I1
I-1
tp9877
sS'addition,of,either'
p9878
(F1
F0.00076452599388379206
I0
I1
I-1
tp9879
sS'intracellular,levels,of'
p9880
(F1
F0.00076452599388379206
I1
I0
I1
tp9881
sS'since,is,metabolized'
p9882
(F1
F0.00076452599388379206
I0
I1
I-1
tp9883
sS'unpredictable,myelotoxicity,bone'
p9884
(F1
F0.00076452599388379206
I1
I0
I1
tp9885
sS'was,a,reduction'
p9886
(F1
F0.00076452599388379206
I0
I1
I-1
tp9887
sS'to,parenteral,solutions'
p9888
(F1
F0.00076452599388379206
I0
I1
I-1
tp9889
sS'alcohol,impairs,the'
p9890
(F1
F0.00076452599388379206
I1
I0
I1
tp9891
sS'chemet,with,other'
p9892
(F1
F0.00076452599388379206
I1
I0
I1
tp9893
sS'the,incremental,ldl-c'
p9894
(F1
F0.00076452599388379206
I1
I0
I1
tp9895
sS'increase,platelet,reactivity'
p9896
(F1
F0.00076452599388379206
I1
I0
I1
tp9897
sS'grapefruit,juice,may'
p9898
(F1
F0.00076452599388379206
I1
I0
I1
tp9899
sS'that,gh,administration'
p9900
(F1
F0.00076452599388379206
I1
I0
I1
tp9901
sS'promising,oral,adjuvant'
p9902
(F1
F0.00076452599388379206
I0
I1
I-1
tp9903
sS'common,premedications,such'
p9904
(F1
F0.00076452599388379206
I0
I1
I-1
tp9905
sS'pravastatin,in,a'
p9906
(F1
F0.00076452599388379206
I0
I1
I-1
tp9907
sS'use,of,zolinza'
p9908
(F1
F0.00076452599388379206
I1
I0
I1
tp9909
sS'being,treated,with'
p9910
(F1
F0.0015290519877675841
I2
I0
I2
tp9911
sS'interaction,of,and'
p9912
(F1
F0.00076452599388379206
I0
I1
I-1
tp9913
sS'cardiac,dysrhythmias,secondary'
p9914
(F1
F0.00076452599388379206
I1
I0
I1
tp9915
sS'doctor,if,you'
p9916
(F1
F0.00076452599388379206
I0
I1
I-1
tp9917
sS'ssris,have,been'
p9918
(F1
F0.00076452599388379206
I1
I0
I1
tp9919
sS'monitored,for,symptoms'
p9920
(F1
F0.00076452599388379206
I1
I0
I1
tp9921
sS'of,target,bp'
p9922
(F0
F0
I1
I1
I0
tp9923
sS'of,psychotic,episodes'
p9924
(F1
F0.00076452599388379206
I1
I0
I1
tp9925
sS'on,dexmedetomidine-induced,antinociception'
p9926
(F1
F0.00076452599388379206
I0
I1
I-1
tp9927
sS'gene,expression,transfection'
p9928
(F1
F0.00076452599388379206
I0
I1
I-1
tp9929
sS'since,are,potentiated'
p9930
(F1
F0.00076452599388379206
I1
I0
I1
tp9931
sS'phentermine,hydrochloride,may'
p9932
(F1
F0.00076452599388379206
I1
I0
I1
tp9933
sS'metabolism,by,a'
p9934
(F1
F0.00076452599388379206
I1
I0
I1
tp9935
sS'in,alteration,of'
p9936
(F1
F0.00076452599388379206
I0
I1
I-1
tp9937
sS'or,acquired,qt'
p9938
(F1
F0.00076452599388379206
I0
I1
I-1
tp9939
sS'isolate,the,effect'
p9940
(F1
F0.00076452599388379206
I1
I0
I1
tp9941
sS'the,small,bowel'
p9942
(F1
F0.00076452599388379206
I1
I0
I1
tp9943
sS'change,in,the'
p9944
(F1
F0.0015290519877675841
I0
I2
I-2
tp9945
sS'in,vitro,binding'
p9946
(F1
F0.00076452599388379206
I0
I1
I-1
tp9947
sS'administration,of,a'
p9948
(F0
F0
I1
I1
I0
tp9949
sS'of,approximately,probably'
p9950
(F1
F0.00076452599388379206
I0
I1
I-1
tp9951
sS'point,which,was'
p9952
(F1
F0.00076452599388379206
I1
I0
I1
tp9953
sS'antifungals,in,conjunction'
p9954
(F1
F0.00076452599388379206
I1
I0
I1
tp9955
sS'to,control,seizures'
p9956
(F1
F0.00076452599388379206
I0
I1
I-1
tp9957
sS'streptase,streptokinase,alone'
p9958
(F1
F0.00076452599388379206
I1
I0
I1
tp9959
sS'min,before,hot'
p9960
(F1
F0.00076452599388379206
I0
I1
I-1
tp9961
sS'of,concentrations,in'
p9962
(F1
F0.00076452599388379206
I1
I0
I1
tp9963
sS'c9,or,influence'
p9964
(F1
F0.00076452599388379206
I0
I1
I-1
tp9965
sS'patients,on,concomitant'
p9966
(F1
F0.00076452599388379206
I1
I0
I1
tp9967
sS'in,serum,levels'
p9968
(F1
F0.00076452599388379206
I1
I0
I1
tp9969
sS'investigate,whether,hb-egf'
p9970
(F1
F0.00076452599388379206
I0
I1
I-1
tp9971
sS'concomitantly,with,dornase'
p9972
(F1
F0.00076452599388379206
I1
I0
I1
tp9973
sS'lasting,inhibition,of'
p9974
(F1
F0.00076452599388379206
I1
I0
I1
tp9975
sS'renal,tubular,secretion'
p9976
(F0.33333333333333331
F0.00076452599388379206
I1
I2
I-1
tp9977
sS'and,or,the'
p9978
(F1
F0.00076452599388379206
I0
I1
I-1
tp9979
sS'fold,decrease,in'
p9980
(F1
F0.00076452599388379206
I0
I1
I-1
tp9981
sS'azole,antimycotics,protease'
p9982
(F1
F0.00076452599388379206
I1
I0
I1
tp9983
sS'some,patients,when'
p9984
(F1
F0.00076452599388379206
I1
I0
I1
tp9985
sS'tobi,patients,taking'
p9986
(F1
F0.00076452599388379206
I1
I0
I1
tp9987
sS'receiving,zolinza,concomitantly'
p9988
(F1
F0.00076452599388379206
I1
I0
I1
tp9989
sS'cells,were,exposed'
p9990
(F1
F0.00076452599388379206
I1
I0
I1
tp9991
sS'and,ethinyl,following'
p9992
(F1
F0.00076452599388379206
I0
I1
I-1
tp9993
sS'loss,of,tyrosine'
p9994
(F1
F0.00076452599388379206
I1
I0
I1
tp9995
sS'the,sulfonylurea,should'
p9996
(F1
F0.00076452599388379206
I1
I0
I1
tp9997
sS'when,coadministering,with'
p9998
(F1
F0.00076452599388379206
I1
I0
I1
tp9999
sS'increase,in,pk'
p10000
(F1
F0.00076452599388379206
I0
I1
I-1
tp10001
sS'hypoglycemic,agents,oxandrolone'
p10002
(F1
F0.00076452599388379206
I1
I0
I1
tp10003
sS'shown,that,caused'
p10004
(F1
F0.00076452599388379206
I1
I0
I1
tp10005
sS'plasma,levels,of'
p10006
(F1
F0.0045871559633027525
I6
I0
I6
tp10007
sS'of,at,doses'
p10008
(F1
F0.0015290519877675841
I2
I0
I2
tp10009
sS'remeron,soltab,with'
p10010
(F1
F0.00076452599388379206
I0
I1
I-1
tp10011
sS'thiamine,loop,diuretics'
p10012
(F1
F0.00076452599388379206
I1
I0
I1
tp10013
sS'caution,in,combination'
p10014
(F1
F0.0015290519877675841
I2
I0
I2
tp10015
sS'the,following,classes'
p10016
(F1
F0.00076452599388379206
I0
I1
I-1
tp10017
sS'patients,with,relapsed'
p10018
(F1
F0.00076452599388379206
I0
I1
I-1
tp10019
sS'a,higher,dose'
p10020
(F1
F0.00076452599388379206
I1
I0
I1
tp10021
sS'not,possible,the'
p10022
(F1
F0.00076452599388379206
I0
I1
I-1
tp10023
sS'adrenergic,agonists,on'
p10024
(F1
F0.00076452599388379206
I1
I0
I1
tp10025
sS'therefore,may,not'
p10026
(F1
F0.00076452599388379206
I0
I1
I-1
tp10027
sS'alimta,and,nsaids'
p10028
(F1
F0.00076452599388379206
I1
I0
I1
tp10029
sS'ripe,cheese,and'
p10030
(F1
F0.00076452599388379206
I1
I0
I1
tp10031
sS'than,were,required'
p10032
(F1
F0.00076452599388379206
I0
I1
I-1
tp10033
sS'n,and,n'
p10034
(F1
F0.00076452599388379206
I0
I1
I-1
tp10035
sS'cholinesterase,resistance,to'
p10036
(F1
F0.00076452599388379206
I1
I0
I1
tp10037
sS'changes,in,the'
p10038
(F1
F0.0015290519877675841
I0
I2
I-2
tp10039
sS'well,as,that'
p10040
(F1
F0.00076452599388379206
I0
I1
I-1
tp10041
sS'because,no,adverse'
p10042
(F1
F0.00076452599388379206
I0
I1
I-1
tp10043
sS'ingested,with,ferrous'
p10044
(F1
F0.00076452599388379206
I1
I0
I1
tp10045
sS'k,levels,tended'
p10046
(F1
F0.00076452599388379206
I0
I1
I-1
tp10047
sS'therapy,with,a'
p10048
(F1
F0.0015290519877675841
I2
I0
I2
tp10049
sS'of,concurrent,or'
p10050
(F1
F0.00076452599388379206
I0
I1
I-1
tp10051
sS'vs,p27,kip1'
p10052
(F1
F0.00076452599388379206
I0
I1
I-1
tp10053
sS'daily,twice,the'
p10054
(F1
F0.00076452599388379206
I1
I0
I1
tp10055
sS'for,a,period'
p10056
(F1
F0.00076452599388379206
I1
I0
I1
tp10057
sS'inhibit,the,metabolism'
p10058
(F0.66666666666666663
F0.0030581039755351682
I5
I1
I4
tp10059
sS'of,after,b-acetyldigoxin'
p10060
(F1
F0.00076452599388379206
I0
I1
I-1
tp10061
sS'with,reduction,in'
p10062
(F1
F0.00076452599388379206
I0
I1
I-1
tp10063
sS'of,precocene,i'
p10064
(F0
F0
I1
I1
I0
tp10065
sS'patients,on,or'
p10066
(F1
F0.00076452599388379206
I0
I1
I-1
tp10067
sS'treatment,with,is'
p10068
(F1
F0.00076452599388379206
I0
I1
I-1
tp10069
sS'creatinine,is,recommended'
p10070
(F1
F0.00076452599388379206
I1
I0
I1
tp10071
sS'depo-subq,provera,may'
p10072
(F1
F0.00076452599388379206
I1
I0
I1
tp10073
sS'do,not,bear'
p10074
(F1
F0.00076452599388379206
I1
I0
I1
tp10075
sS'be,adjusted,according'
p10076
(F1
F0.00076452599388379206
I1
I0
I1
tp10077
sS'female,rats,times'
p10078
(F1
F0.00076452599388379206
I0
I1
I-1
tp10079
sS'or,acth,may'
p10080
(F1
F0.0015290519877675841
I0
I2
I-2
tp10081
sS'activity,of,combined'
p10082
(F1
F0.0015290519877675841
I0
I2
I-2
tp10083
sS'compounds,that,are'
p10084
(F1
F0.00076452599388379206
I1
I0
I1
tp10085
sS'a,study,conducted'
p10086
(F1
F0.00076452599388379206
I1
I0
I1
tp10087
sS'expected,to,cause'
p10088
(F1
F0.00076452599388379206
I0
I1
I-1
tp10089
sS'base-secreting,system,also'
p10090
(F1
F0.00076452599388379206
I1
I0
I1
tp10091
sS'panobinostat-related,adverse,events'
p10092
(F1
F0.00076452599388379206
I0
I1
I-1
tp10093
sS'tablets,coadministered,with'
p10094
(F1
F0.00076452599388379206
I1
I0
I1
tp10095
sS'mediated,suppression,of'
p10096
(F1
F0.00076452599388379206
I1
I0
I1
tp10097
sS'the,low,systemic'
p10098
(F1
F0.00076452599388379206
I0
I1
I-1
tp10099
sS'with,coumarin-type,interactions'
p10100
(F1
F0.00076452599388379206
I1
I0
I1
tp10101
sS'both,and,should'
p10102
(F1
F0.00076452599388379206
I1
I0
I1
tp10103
sS'significantly,higher,in'
p10104
(F1
F0.00076452599388379206
I1
I0
I1
tp10105
sS'type,b,if'
p10106
(F1
F0.00076452599388379206
I0
I1
I-1
tp10107
sS'transduction,into,the'
p10108
(F1
F0.00076452599388379206
I0
I1
I-1
tp10109
sS'the,findings,suggest'
p10110
(F1
F0.00076452599388379206
I1
I0
I1
tp10111
sS'addition,cns,toxicity'
p10112
(F1
F0.00076452599388379206
I1
I0
I1
tp10113
sS'develop,during,concomitant'
p10114
(F1
F0.00076452599388379206
I0
I1
I-1
tp10115
sS'agents,that,might'
p10116
(F1
F0.00076452599388379206
I1
I0
I1
tp10117
sS'administration,of,gsls'
p10118
(F1
F0.00076452599388379206
I0
I1
I-1
tp10119
sS'caution,in,combining'
p10120
(F1
F0.00076452599388379206
I1
I0
I1
tp10121
sS'been,observed,data'
p10122
(F1
F0.00076452599388379206
I1
I0
I1
tp10123
sS'when,methergine,maleate'
p10124
(F1
F0.00076452599388379206
I1
I0
I1
tp10125
sS'used,with,a'
p10126
(F1
F0.00076452599388379206
I0
I1
I-1
tp10127
sS'exposure,to,parent'
p10128
(F1
F0.00076452599388379206
I1
I0
I1
tp10129
sS'p450,enzyme,system'
p10130
(F1
F0.00076452599388379206
I0
I1
I-1
tp10131
sS'study,of,the'
p10132
(F1
F0.00076452599388379206
I0
I1
I-1
tp10133
sS'produced,an,overall'
p10134
(F1
F0.00076452599388379206
I1
I0
I1
tp10135
sS'mazindol,may,reduce'
p10136
(F1
F0.00076452599388379206
I1
I0
I1
tp10137
sS'emergence,agitation,in'
p10138
(F1
F0.00076452599388379206
I0
I1
I-1
tp10139
sS'develop,delirium,high'
p10140
(F1
F0.00076452599388379206
I1
I0
I1
tp10141
sS'channel,blockers,n'
p10142
(F1
F0.00076452599388379206
I0
I1
I-1
tp10143
sS'thiazide-like,may,affect'
p10144
(F1
F0.00076452599388379206
I1
I0
I1
tp10145
sS'enhanced,green,fluorescent'
p10146
(F1
F0.00076452599388379206
I0
I1
I-1
tp10147
sS'particularly,at,doses'
p10148
(F1
F0.00076452599388379206
I1
I0
I1
tp10149
sS'other,central,nervous'
p10150
(F1
F0.0015290519877675841
I2
I0
I2
tp10151
sS'it,was,previously'
p10152
(F1
F0.00076452599388379206
I1
I0
I1
tp10153
sS'interact,with,or'
p10154
(F1
F0.00076452599388379206
I1
I0
I1
tp10155
sS'increases,plasma,levels'
p10156
(F1
F0.00076452599388379206
I1
I0
I1
tp10157
sS'together,the,signs'
p10158
(F1
F0.00076452599388379206
I1
I0
I1
tp10159
sS'of,oral,mg'
p10160
(F1
F0.00076452599388379206
I1
I0
I1
tp10161
sS'other,dietary,components'
p10162
(F1
F0.00076452599388379206
I1
I0
I1
tp10163
sS'during,or,after'
p10164
(F1
F0.00076452599388379206
I1
I0
I1
tp10165
sS'kg,dose,of'
p10166
(F1
F0.00076452599388379206
I0
I1
I-1
tp10167
sS'inhibit,the,tpmt'
p10168
(F1
F0.00076452599388379206
I1
I0
I1
tp10169
sS'following,different,incubation'
p10170
(F1
F0.00076452599388379206
I0
I1
I-1
tp10171
sS'and,statistically,significant'
p10172
(F1
F0.00076452599388379206
I1
I0
I1
tp10173
sS'preference,in,adolescent'
p10174
(F1
F0.00076452599388379206
I0
I1
I-1
tp10175
sS'such,a,reaction'
p10176
(F1
F0.00076452599388379206
I1
I0
I1
tp10177
sS'tested,whether,the'
p10178
(F1
F0.00076452599388379206
I0
I1
I-1
tp10179
sS'amines,is,markedly'
p10180
(F1
F0.0015290519877675841
I2
I0
I2
tp10181
sS'sulfonylurea,should,be'
p10182
(F1
F0.00076452599388379206
I1
I0
I1
tp10183
sS'and,from,foreign'
p10184
(F1
F0.00076452599388379206
I1
I0
I1
tp10185
sS'of,a,chicken'
p10186
(F1
F0.00076452599388379206
I0
I1
I-1
tp10187
sS'interrupted,close,medical'
p10188
(F1
F0.00076452599388379206
I1
I0
I1
tp10189
sS'similarity,of,other'
p10190
(F1
F0.00076452599388379206
I1
I0
I1
tp10191
sS'mequitazine,can,interact'
p10192
(F1
F0.00076452599388379206
I1
I0
I1
tp10193
sS'survived,with,higher'
p10194
(F1
F0.00076452599388379206
I0
I1
I-1
tp10195
sS'with,ventricular,arrhythmia'
p10196
(F1
F0.00076452599388379206
I0
I1
I-1
tp10197
sS'anesthetics,phenothiazines,other'
p10198
(F1
F0.00076452599388379206
I1
I0
I1
tp10199
sS'of,the,study'
p10200
(F1
F0.00076452599388379206
I0
I1
I-1
tp10201
sS'therefore,use,of'
p10202
(F1
F0.00076452599388379206
I1
I0
I1
tp10203
sS'coumarin-derivative,anticoagulants,prolongation'
p10204
(F1
F0.00076452599388379206
I1
I0
I1
tp10205
sS'interaction,with,guanethidine'
p10206
(F1
F0.00076452599388379206
I1
I0
I1
tp10207
sS'increased,prothrombin,time'
p10208
(F1
F0.00076452599388379206
I1
I0
I1
tp10209
sS'may,be,counteracted'
p10210
(F1
F0.00076452599388379206
I1
I0
I1
tp10211
sS'from,to,mg'
p10212
(F1
F0.00076452599388379206
I1
I0
I1
tp10213
sS'intravenous,anesthesia,tiva'
p10214
(F1
F0.00076452599388379206
I0
I1
I-1
tp10215
sS'that,an,interaction'
p10216
(F1
F0.00076452599388379206
I0
I1
I-1
tp10217
sS'is,considered,necessary'
p10218
(F1
F0.00076452599388379206
I1
I0
I1
tp10219
sS'adrenal,or,acth'
p10220
(F1
F0.00076452599388379206
I0
I1
I-1
tp10221
sS'days,xenical,did'
p10222
(F1
F0.0030581039755351682
I0
I4
I-4
tp10223
sS'the,drug,classes'
p10224
(F1
F0.00076452599388379206
I1
I0
I1
tp10225
sS'alone,and,in'
p10226
(F1
F0.00076452599388379206
I0
I1
I-1
tp10227
sS'estradiol,and,there'
p10228
(F1
F0.00076452599388379206
I1
I0
I1
tp10229
sS'other,hepatic,enzyme'
p10230
(F1
F0.00076452599388379206
I1
I0
I1
tp10231
sS'may,occasionally,experience'
p10232
(F1
F0.00076452599388379206
I1
I0
I1
tp10233
sS'while,there,is'
p10234
(F1
F0.00076452599388379206
I1
I0
I1
tp10235
sS'as,and,have'
p10236
(F1
F0.00076452599388379206
I1
I0
I1
tp10237
sS'narcotic,analgesics,and'
p10238
(F1
F0.00076452599388379206
I1
I0
I1
tp10239
sS'of,meq,results'
p10240
(F1
F0.00076452599388379206
I1
I0
I1
tp10241
sS'or,tricyclic,antidepressants'
p10242
(F1
F0.00076452599388379206
I1
I0
I1
tp10243
sS'using,a,terminal'
p10244
(F1
F0.00076452599388379206
I0
I1
I-1
tp10245
sS'and,displaced,protein-bound'
p10246
(F1
F0.00076452599388379206
I1
I0
I1
tp10247
sS'cyp2c19,inhibitors,and'
p10248
(F1
F0.00076452599388379206
I1
I0
I1
tp10249
sS'subtherapeutic,levels,therapeutic'
p10250
(F1
F0.00076452599388379206
I1
I0
I1
tp10251
sS'of,mg,had'
p10252
(F1
F0.00076452599388379206
I1
I0
I1
tp10253
sS'ketoconazole,spontaneous,adverse'
p10254
(F1
F0.00076452599388379206
I1
I0
I1
tp10255
sS'with,forced,expression'
p10256
(F1
F0.00076452599388379206
I1
I0
I1
tp10257
sS'such,as,marplan'
p10258
(F1
F0.00076452599388379206
I1
I0
I1
tp10259
sS'mesylate,is,approximately'
p10260
(F1
F0.00076452599388379206
I0
I1
I-1
tp10261
sS'clearance,may,decrease'
p10262
(F1
F0.00076452599388379206
I0
I1
I-1
tp10263
sS'mechanism,is,purported'
p10264
(F1
F0.00076452599388379206
I1
I0
I1
tp10265
sS'of,extra,thoracic'
p10266
(F1
F0.00076452599388379206
I0
I1
I-1
tp10267
sS'vs,vs,cm3'
p10268
(F1
F0.00076452599388379206
I1
I0
I1
tp10269
sS'pathways,that,were'
p10270
(F1
F0.00076452599388379206
I1
I0
I1
tp10271
sS'in,children,due'
p10272
(F1
F0.00076452599388379206
I1
I0
I1
tp10273
sS'of,these,products'
p10274
(F1
F0.00076452599388379206
I1
I0
I1
tp10275
sS'associated,with,elevations'
p10276
(F1
F0.00076452599388379206
I1
I0
I1
tp10277
sS'aav2-mediated,retinal,transduction'
p10278
(F1
F0.00076452599388379206
I1
I0
I1
tp10279
sS'coadministered,with,in'
p10280
(F1
F0.00076452599388379206
I1
I0
I1
tp10281
sS'while,co-administration,of'
p10282
(F1
F0.00076452599388379206
I1
I0
I1
tp10283
sS'with,co-administered,drugs'
p10284
(F1
F0.00076452599388379206
I0
I1
I-1
tp10285
sS'cellular,glutathione,and'
p10286
(F1
F0.00076452599388379206
I0
I1
I-1
tp10287
sS'with,a,mean'
p10288
(F1
F0.00076452599388379206
I1
I0
I1
tp10289
sS'of,hospitalization,for'
p10290
(F0
F0
I1
I1
I0
tp10291
sS'a,greater,potentiation'
p10292
(F1
F0.00076452599388379206
I0
I1
I-1
tp10293
sS'liver,thus,elevating'
p10294
(F1
F0.00076452599388379206
I1
I0
I1
tp10295
sS'her2-positive,metastatic,breast'
p10296
(F1
F0.00076452599388379206
I1
I0
I1
tp10297
sS'analgesics,i,or'
p10298
(F1
F0.00076452599388379206
I1
I0
I1
tp10299
sS'parkinsonian,motor,symptoms'
p10300
(F1
F0.00076452599388379206
I0
I1
I-1
tp10301
sS'until,use,in'
p10302
(F1
F0.00076452599388379206
I1
I0
I1
tp10303
sS'and,antiplatelet,agents'
p10304
(F1
F0.00076452599388379206
I1
I0
I1
tp10305
sS'with,mg,kg'
p10306
(F1
F0.00076452599388379206
I1
I0
I1
tp10307
sS'and,cdk1,in'
p10308
(F1
F0.00076452599388379206
I0
I1
I-1
tp10309
sS'blocking,agents,eg'
p10310
(F1
F0.00076452599388379206
I0
I1
I-1
tp10311
sS'subjects,the,treatment'
p10312
(F1
F0.00076452599388379206
I0
I1
I-1
tp10313
sS'in,patients,chronically'
p10314
(F1
F0.00076452599388379206
I1
I0
I1
tp10315
sS'with,zerit,should'
p10316
(F1
F0.00076452599388379206
I1
I0
I1
tp10317
sS'and,fold,increase'
p10318
(F1
F0.00076452599388379206
I1
I0
I1
tp10319
sS'the,antitumor,effects'
p10320
(F1
F0.00076452599388379206
I0
I1
I-1
tp10321
sS'conditioned,place,preference'
p10322
(F1
F0.00076452599388379206
I0
I1
I-1
tp10323
sS'hydrolysis,may,lead'
p10324
(F1
F0.00076452599388379206
I0
I1
I-1
tp10325
sS'sympathomimetic,bronchodilators,and'
p10326
(F1
F0.00076452599388379206
I0
I1
I-1
tp10327
sS'levels,returned,to'
p10328
(F1
F0.00076452599388379206
I1
I0
I1
tp10329
sS'show,additive,effects'
p10330
(F1
F0.00076452599388379206
I1
I0
I1
tp10331
sS'mexitil,lowered,mexitil'
p10332
(F1
F0.00076452599388379206
I1
I0
I1
tp10333
sS'the,enhancement,of'
p10334
(F1
F0.00076452599388379206
I1
I0
I1
tp10335
sS'pulmozyme,genentech,beta'
p10336
(F1
F0.00076452599388379206
I1
I0
I1
tp10337
sS'absorption,of,a'
p10338
(F1
F0.0015290519877675841
I2
I0
I2
tp10339
sS'of,oral,by'
p10340
(F1
F0.00076452599388379206
I1
I0
I1
tp10341
sS'effect,on,dexmedetomidine-induced'
p10342
(F1
F0.00076452599388379206
I0
I1
I-1
tp10343
sS'control,by,is'
p10344
(F1
F0.00076452599388379206
I0
I1
I-1
tp10345
sS'recommended,because,of'
p10346
(F1
F0.00076452599388379206
I1
I0
I1
tp10347
sS'drugs,known,to'
p10348
(F1
F0.0015290519877675841
I0
I2
I-2
tp10349
sS'transplant,patients,with'
p10350
(F1
F0.00076452599388379206
I1
I0
I1
tp10351
sS'and,grams,of'
p10352
(F1
F0.00076452599388379206
I0
I1
I-1
tp10353
sS'proven,preventive,impact'
p10354
(F1
F0.00076452599388379206
I0
I1
I-1
tp10355
sS'results,are,not'
p10356
(F1
F0.00076452599388379206
I1
I0
I1
tp10357
sS'oral,containing,mg'
p10358
(F1
F0.00076452599388379206
I0
I1
I-1
tp10359
sS'or,prolonged,prothrombin'
p10360
(F1
F0.00076452599388379206
I1
I0
I1
tp10361
sS'organic,acids,via'
p10362
(F1
F0.00076452599388379206
I0
I1
I-1
tp10363
sS'were,decreases,up'
p10364
(F1
F0.00076452599388379206
I0
I1
I-1
tp10365
sS'both,based,on'
p10366
(F1
F0.00076452599388379206
I0
I1
I-1
tp10367
sS'interactions,with,have'
p10368
(F1
F0.00076452599388379206
I1
I0
I1
tp10369
sS'diflucan,and,coumarin-type'
p10370
(F1
F0.00076452599388379206
I1
I0
I1
tp10371
sS'before,to,attenuate'
p10372
(F1
F0.00076452599388379206
I0
I1
I-1
tp10373
sS'a,reduction,of'
p10374
(F1
F0.0015290519877675841
I2
I0
I2
tp10375
sS'with,caution,and'
p10376
(F1
F0.00076452599388379206
I1
I0
I1
tp10377
sS'did,not,affect'
p10378
(F1
F0.0015290519877675841
I0
I2
I-2
tp10379
sS'diminished,nonheme,absorption'
p10380
(F1
F0.00076452599388379206
I1
I0
I1
tp10381
sS'have,beneficial,effects'
p10382
(F1
F0.00076452599388379206
I1
I0
I1
tp10383
sS'the,different,metabolism'
p10384
(F1
F0.00076452599388379206
I0
I1
I-1
tp10385
sS'on,gastrointestinal,motility'
p10386
(F1
F0.00076452599388379206
I1
I0
I1
tp10387
sS'transporter,did,not'
p10388
(F1
F0.00076452599388379206
I0
I1
I-1
tp10389
sS'requirements,when,administering'
p10390
(F1
F0.0015290519877675841
I2
I0
I2
tp10391
sS'of,chickens,to'
p10392
(F1
F0.00076452599388379206
I0
I1
I-1
tp10393
sS'discontinuing,therapy,for'
p10394
(F1
F0.00076452599388379206
I0
I1
I-1
tp10395
sS'inhibitors,and,concomitantly'
p10396
(F1
F0.00076452599388379206
I1
I0
I1
tp10397
sS'altabax,is,unlikely'
p10398
(F1
F0.00076452599388379206
I0
I1
I-1
tp10399
sS'sulfamethizole,may,increase'
p10400
(F1
F0.00076452599388379206
I1
I0
I1
tp10401
sS'who,have,received'
p10402
(F1
F0.00076452599388379206
I1
I0
I1
tp10403
sS'is,antagonistic,in'
p10404
(F1
F0.00076452599388379206
I1
I0
I1
tp10405
sS'drugs,leads,to'
p10406
(F1
F0.00076452599388379206
I1
I0
I1
tp10407
sS'immune,response,in'
p10408
(F1
F0.00076452599388379206
I0
I1
I-1
tp10409
sS'clearance,of,and'
p10410
(F1
F0.0015290519877675841
I2
I0
I2
tp10411
sS'vitamin,k,nutritional'
p10412
(F1
F0.00076452599388379206
I0
I1
I-1
tp10413
sS'or,with,other'
p10414
(F1
F0.00076452599388379206
I1
I0
I1
tp10415
sS'to,subtherapeutic,levels'
p10416
(F1
F0.00076452599388379206
I1
I0
I1
tp10417
sS'to,prevent,graft-versus'
p10418
(F1
F0.00076452599388379206
I1
I0
I1
tp10419
sS'in,a,prolongation'
p10420
(F1
F0.00076452599388379206
I1
I0
I1
tp10421
sS'between,mivacron,and'
p10422
(F1
F0.00076452599388379206
I0
I1
I-1
tp10423
sS'decreases,up,to'
p10424
(F1
F0.00076452599388379206
I0
I1
I-1
tp10425
sS'dose,of,should'
p10426
(F0.33333333333333331
F0.00076452599388379206
I1
I2
I-1
tp10427
sS'performed,the,following'
p10428
(F1
F0.00076452599388379206
I0
I1
I-1
tp10429
sS'of,single,use'
p10430
(F1
F0.00076452599388379206
I0
I1
I-1
tp10431
sS'cardiac,glycosides,may'
p10432
(F1
F0.00076452599388379206
I1
I0
I1
tp10433
sS'constipation,and,other'
p10434
(F1
F0.00076452599388379206
I1
I0
I1
tp10435
sS'generally,used,in'
p10436
(F1
F0.00076452599388379206
I0
I1
I-1
tp10437
sS'because,of,the'
p10438
(F1
F0.0038226299694189602
I5
I0
I5
tp10439
sS'drugs,paliperidone,is'
p10440
(F1
F0.00076452599388379206
I0
I1
I-1
tp10441
sS'clinical,data,on'
p10442
(F1
F0.00076452599388379206
I0
I1
I-1
tp10443
sS'be,administered,to'
p10444
(F1
F0.00076452599388379206
I1
I0
I1
tp10445
sS'median,duration,of'
p10446
(F1
F0.00076452599388379206
I0
I1
I-1
tp10447
sS'amplifies,the,therapeutic'
p10448
(F1
F0.00076452599388379206
I1
I0
I1
tp10449
sS'after,b-acetyldigoxin,administration'
p10450
(F1
F0.00076452599388379206
I0
I1
I-1
tp10451
sS'hormone,treatment,for'
p10452
(F1
F0.00076452599388379206
I0
I1
I-1
tp10453
sS'association,with,increases'
p10454
(F1
F0.00076452599388379206
I1
I0
I1
tp10455
sS'avoid,while,taking'
p10456
(F1
F0.00076452599388379206
I1
I0
I1
tp10457
sS'studies,documenting,the'
p10458
(F1
F0.00076452599388379206
I0
I1
I-1
tp10459
sS'not,recommended,until'
p10460
(F1
F0.00076452599388379206
I1
I0
I1
tp10461
sS'that,the,incidence'
p10462
(F1
F0.00076452599388379206
I1
I0
I1
tp10463
sS'is,superior,to'
p10464
(F1
F0.00076452599388379206
I1
I0
I1
tp10465
sS'administration,of,resulted'
p10466
(F1
F0.00076452599388379206
I1
I0
I1
tp10467
sS'only,was,noticeably'
p10468
(F1
F0.00076452599388379206
I0
I1
I-1
tp10469
sS'in,clinical,trials'
p10470
(F0.20000000000000001
F0.00076452599388379206
I2
I3
I-1
tp10471
sS'a,result,of'
p10472
(F1
F0.0015290519877675841
I2
I0
I2
tp10473
sS'negatively,regulating,bcl-2'
p10474
(F1
F0.00076452599388379206
I1
I0
I1
tp10475
sS'of,forced,swimming'
p10476
(F1
F0.00076452599388379206
I0
I1
I-1
tp10477
sS'who,were,poor'
p10478
(F1
F0.00076452599388379206
I1
I0
I1
tp10479
sS'produced,an,elevation'
p10480
(F1
F0.00076452599388379206
I1
I0
I1
tp10481
sS'monoamine,oxidase,inhibitory'
p10482
(F1
F0.00076452599388379206
I1
I0
I1
tp10483
sS'actin,promoter,was'
p10484
(F1
F0.00076452599388379206
I0
I1
I-1
tp10485
sS'elucidated,the,expression'
p10486
(F1
F0.00076452599388379206
I0
I1
I-1
tp10487
sS'the,plasma,concentration-time'
p10488
(F1
F0.00076452599388379206
I1
I0
I1
tp10489
sS'mixing,symlin,and'
p10490
(F1
F0.00076452599388379206
I1
I0
I1
tp10491
sS'be,avoided,except'
p10492
(F1
F0.00076452599388379206
I0
I1
I-1
tp10493
sS'lines,with,egfr'
p10494
(F0
F0
I1
I1
I0
tp10495
sS'recovery,from,has'
p10496
(F1
F0.00076452599388379206
I1
I0
I1
tp10497
sS'decrease,the,effectiveness'
p10498
(F1
F0.00076452599388379206
I1
I0
I1
tp10499
sS'breast,cancer,with'
p10500
(F1
F0.00076452599388379206
I0
I1
I-1
tp10501
sS'during,coadministration,of'
p10502
(F1
F0.00076452599388379206
I1
I0
I1
tp10503
sS'mg,twice,daily'
p10504
(F0
F0
I1
I1
I0
tp10505
sS'levels,in,a'
p10506
(F1
F0.00076452599388379206
I1
I0
I1
tp10507
sS'and,to,those'
p10508
(F1
F0.00076452599388379206
I0
I1
I-1
tp10509
sS'and,qt,were'
p10510
(F1
F0.00076452599388379206
I0
I1
I-1
tp10511
sS'when,was,combined'
p10512
(F1
F0.0015290519877675841
I2
I0
I2
tp10513
sS'of,and,its'
p10514
(F1
F0.0015290519877675841
I0
I2
I-2
tp10515
sS'a5,and,a7'
p10516
(F1
F0.00076452599388379206
I1
I0
I1
tp10517
sS'administer,myfortic,with'
p10518
(F1
F0.00076452599388379206
I1
I0
I1
tp10519
sS'interact,with,the'
p10520
(F1
F0.0015290519877675841
I2
I0
I2
tp10521
sS'include,macrolide,hiv'
p10522
(F1
F0.00076452599388379206
I0
I1
I-1
tp10523
sS'results,regarding,the'
p10524
(F1
F0.00076452599388379206
I0
I1
I-1
tp10525
sS'or,holed,open'
p10526
(F1
F0.00076452599388379206
I0
I1
I-1
tp10527
sS'to,ai,vaccination'
p10528
(F1
F0.00076452599388379206
I1
I0
I1
tp10529
sS'and,gp,iib'
p10530
(F1
F0.00076452599388379206
I1
I0
I1
tp10531
sS'herceptin-mediated,antibody-dependent,cellular'
p10532
(F0
F0
I1
I1
I0
tp10533
sS'anticholinergic,agents,simultaneous'
p10534
(F1
F0.00076452599388379206
I1
I0
I1
tp10535
sS'who,are,on'
p10536
(F1
F0.00076452599388379206
I1
I0
I1
tp10537
sS'daily,dosed,to'
p10538
(F1
F0.0015290519877675841
I0
I2
I-2
tp10539
sS'in,the,placebo'
p10540
(F1
F0.00076452599388379206
I0
I1
I-1
tp10541
sS'crm197,plus,enhanced'
p10542
(F1
F0.00076452599388379206
I1
I0
I1
tp10543
sS'day,after,starting'
p10544
(F1
F0.00076452599388379206
I1
I0
I1
tp10545
sS'with,proton,pump'
p10546
(F1
F0.00076452599388379206
I1
I0
I1
tp10547
sS'saline,saline,g'
p10548
(F1
F0.00076452599388379206
I0
I1
I-1
tp10549
sS'significant,change,in'
p10550
(F1
F0.0015290519877675841
I0
I2
I-2
tp10551
sS'possibly,by,competing'
p10552
(F1
F0.00076452599388379206
I1
I0
I1
tp10553
sS'short-acting,benzodiazepines,oral'
p10554
(F1
F0.00076452599388379206
I1
I0
I1
tp10555
sS'methyl-4,phenyl-1,tetrahydropyridine-induced'
p10556
(F1
F0.00076452599388379206
I1
I0
I1
tp10557
sS'delivery,of,food'
p10558
(F1
F0.00076452599388379206
I1
I0
I1
tp10559
sS'with,plus,formed'
p10560
(F1
F0.00076452599388379206
I1
I0
I1
tp10561
sS'sensitivity,of,the'
p10562
(F1
F0.00076452599388379206
I1
I0
I1
tp10563
sS'marker,of,vitamin'
p10564
(F1
F0.00076452599388379206
I0
I1
I-1
tp10565
sS'other,chelation,therapy'
p10566
(F1
F0.00076452599388379206
I1
I0
I1
tp10567
sS'capable,of,potentiating'
p10568
(F1
F0.00076452599388379206
I1
I0
I1
tp10569
sS'blocking,agents,such'
p10570
(F1
F0.0015290519877675841
I2
I0
I2
tp10571
sS'of,megestrol,acetate'
p10572
(F0
F0
I1
I1
I0
tp10573
sS'few,days,after'
p10574
(F1
F0.00076452599388379206
I1
I0
I1
tp10575
sS'the,role,of'
p10576
(F1
F0.00076452599388379206
I1
I0
I1
tp10577
sS'curariform,drugs,such'
p10578
(F1
F0.00076452599388379206
I1
I0
I1
tp10579
sS'of,mg,heme'
p10580
(F1
F0.00076452599388379206
I0
I1
I-1
tp10581
sS'vindesine,can,interact'
p10582
(F1
F0.00076452599388379206
I1
I0
I1
tp10583
sS'and,to,and'
p10584
(F1
F0.00076452599388379206
I1
I0
I1
tp10585
sS'at,least,of'
p10586
(F1
F0.00076452599388379206
I0
I1
I-1
tp10587
sS'a6,and,c9'
p10588
(F1
F0.00076452599388379206
I0
I1
I-1
tp10589
sS'their,mechanism,of'
p10590
(F1
F0.00076452599388379206
I1
I0
I1
tp10591
sS'glycosides,serum,levels'
p10592
(F1
F0.00076452599388379206
I0
I1
I-1
tp10593
sS'or,pharmacodynamics,prothrombin'
p10594
(F1
F0.00076452599388379206
I0
I1
I-1
tp10595
sS'bear,directly,on'
p10596
(F1
F0.00076452599388379206
I1
I0
I1
tp10597
sS'for,myocardial,infarction'
p10598
(F1
F0.00076452599388379206
I0
I1
I-1
tp10599
sS'that,are,not'
p10600
(F1
F0.00076452599388379206
I1
I0
I1
tp10601
sS'these,subjects,did'
p10602
(F1
F0.00076452599388379206
I0
I1
I-1
tp10603
sS'associated,with,prevention'
p10604
(F1
F0.00076452599388379206
I1
I0
I1
tp10605
sS'potential,effects,of'
p10606
(F1
F0.00076452599388379206
I0
I1
I-1
tp10607
sS'intravenous,and,who'
p10608
(F1
F0.00076452599388379206
I1
I0
I1
tp10609
sS'note,that,mephenytoin'
p10610
(F1
F0.00076452599388379206
I1
I0
I1
tp10611
sS'profiles,of,or'
p10612
(F1
F0.00076452599388379206
I0
I1
I-1
tp10613
sS'change,the,clearance'
p10614
(F1
F0.00076452599388379206
I0
I1
I-1
tp10615
sS'component,of,an'
p10616
(F1
F0.00076452599388379206
I0
I1
I-1
tp10617
sS'administration,of,chemotherapy'
p10618
(F1
F0.00076452599388379206
I1
I0
I1
tp10619
sS'the,elimination,half-life'
p10620
(F1
F0.00076452599388379206
I1
I0
I1
tp10621
sS'was,reduced,by'
p10622
(F0.33333333333333331
F0.00076452599388379206
I2
I1
I1
tp10623
sS'sutent,with,inducers'
p10624
(F1
F0.00076452599388379206
I1
I0
I1
tp10625
sS'of,gi,bleeding'
p10626
(F1
F0.00076452599388379206
I1
I0
I1
tp10627
sS'from,its,human'
p10628
(F1
F0.00076452599388379206
I0
I1
I-1
tp10629
sS'by,a,p450'
p10630
(F1
F0.00076452599388379206
I0
I1
I-1
tp10631
sS'maintenance,of,anesthesia'
p10632
(F1
F0.00076452599388379206
I1
I0
I1
tp10633
sS'exposure,the,addition'
p10634
(F1
F0.00076452599388379206
I1
I0
I1
tp10635
sS'toxicity,of,diepoxybutane'
p10636
(F1
F0.00076452599388379206
I0
I1
I-1
tp10637
sS'insensitive,cells,and'
p10638
(F1
F0.00076452599388379206
I1
I0
I1
tp10639
sS'enzymes,an,indication'
p10640
(F1
F0.00076452599388379206
I0
I1
I-1
tp10641
sS'secretion,may,interfere'
p10642
(F1
F0.00076452599388379206
I1
I0
I1
tp10643
sS'to,decline,in'
p10644
(F1
F0.00076452599388379206
I0
I1
I-1
tp10645
sS'studied,and,because'
p10646
(F1
F0.00076452599388379206
I1
I0
I1
tp10647
sS'approximately,resulting,in'
p10648
(F1
F0.00076452599388379206
I0
I1
I-1
tp10649
sS'exposure,following,enzyme'
p10650
(F1
F0.00076452599388379206
I0
I1
I-1
tp10651
sS'multiple,myeloma,evidence'
p10652
(F1
F0.00076452599388379206
I0
I1
I-1
tp10653
sS'doses,of,mg'
p10654
(F0
F0
I3
I3
I0
tp10655
sS'calcium,channel,antagonists'
p10656
(F1
F0.00076452599388379206
I1
I0
I1
tp10657
sS'administration,of,with'
p10658
(F1
F0.0030581039755351682
I4
I0
I4
tp10659
sS'may,be,contributing'
p10660
(F1
F0.00076452599388379206
I0
I1
I-1
tp10661
sS'with,a,history'
p10662
(F1
F0.00076452599388379206
I1
I0
I1
tp10663
sS'insufficiency,creatinine,clearance'
p10664
(F1
F0.00076452599388379206
I1
I0
I1
tp10665
sS'receiving,concomitant,diflucan'
p10666
(F1
F0.00076452599388379206
I1
I0
I1
tp10667
sS'important,non-thalidomide,drug'
p10668
(F1
F0.00076452599388379206
I0
I1
I-1
tp10669
sS'mobic,therapy,in'
p10670
(F1
F0.00076452599388379206
I1
I0
I1
tp10671
sS'combination,with,daily'
p10672
(F1
F0.00076452599388379206
I0
I1
I-1
tp10673
sS'occurrence,of,stupor'
p10674
(F1
F0.00076452599388379206
I1
I0
I1
tp10675
sS'was,combined,with'
p10676
(F1
F0.00076452599388379206
I1
I0
I1
tp10677
sS'slowly,dissolving,dosage'
p10678
(F1
F0.00076452599388379206
I1
I0
I1
tp10679
sS'taken,especially,during'
p10680
(F1
F0.00076452599388379206
I1
I0
I1
tp10681
sS'with,egfr,t790m'
p10682
(F0
F0
I1
I1
I0
tp10683
sS'exceed,a,mg'
p10684
(F1
F0.00076452599388379206
I1
I0
I1
tp10685
sS'radiation,therapy,may'
p10686
(F1
F0.00076452599388379206
I1
I0
I1
tp10687
sS'exposure,auc,to'
p10688
(F1
F0.00076452599388379206
I1
I0
I1
tp10689
sS'enzymes,inhibition,or'
p10690
(F1
F0.00076452599388379206
I0
I1
I-1
tp10691
sS'however,the,impairment'
p10692
(F1
F0.0015290519877675841
I2
I0
I2
tp10693
sS'therapy,when,ace'
p10694
(F1
F0.00076452599388379206
I0
I1
I-1
tp10695
sS'a,useful,especially'
p10696
(F1
F0.00076452599388379206
I0
I1
I-1
tp10697
sS'data,on,the'
p10698
(F1
F0.00076452599388379206
I0
I1
I-1
tp10699
sS'vitamin,k,levels'
p10700
(F1
F0.00076452599388379206
I0
I1
I-1
tp10701
sS'in,matched,tacrolimus-treated'
p10702
(F1
F0.00076452599388379206
I1
I0
I1
tp10703
sS'hiv-infected,patients,receiving'
p10704
(F1
F0.00076452599388379206
I1
I0
I1
tp10705
sS'evaluate,whether,initiation'
p10706
(F1
F0.00076452599388379206
I0
I1
I-1
tp10707
sS'use,with,low-dose'
p10708
(F1
F0.00076452599388379206
I1
I0
I1
tp10709
sS'additive,to,disalcid'
p10710
(F1
F0.00076452599388379206
I1
I0
I1
tp10711
sS'should,be,observed'
p10712
(F1
F0.0022935779816513763
I3
I0
I3
tp10713
sS'patients,are,at'
p10714
(F1
F0.00076452599388379206
I1
I0
I1
tp10715
sS'stable,renal,transplant'
p10716
(F0
F0
I1
I1
I0
tp10717
sS'combination,therapy,with'
p10718
(F1
F0.00076452599388379206
I1
I0
I1
tp10719
sS'although,does,not'
p10720
(F1
F0.00076452599388379206
I1
I0
I1
tp10721
sS'caused,a,significant'
p10722
(F1
F0.00076452599388379206
I1
I0
I1
tp10723
sS'diabetes,drug,therapies'
p10724
(F1
F0.00076452599388379206
I1
I0
I1
tp10725
sS'of,childbearing,potential'
p10726
(F1
F0.00076452599388379206
I0
I1
I-1
tp10727
sS'patients,receiving,ace'
p10728
(F1
F0.00076452599388379206
I1
I0
I1
tp10729
sS'reports,of,increase'
p10730
(F1
F0.00076452599388379206
I1
I0
I1
tp10731
sS'dyscrasia,can,cause'
p10732
(F1
F0.00076452599388379206
I1
I0
I1
tp10733
sS'zadaxin,therapy,in'
p10734
(F1
F0.00076452599388379206
I1
I0
I1
tp10735
sS'gastric,acid,secretion'
p10736
(F1
F0.00076452599388379206
I1
I0
I1
tp10737
sS'stable,digitalis,glycoside'
p10738
(F1
F0.00076452599388379206
I0
I1
I-1
tp10739
sS'be,considered,for'
p10740
(F1
F0.00076452599388379206
I1
I0
I1
tp10741
sS'of,and,on'
p10742
(F1
F0.00076452599388379206
I0
I1
I-1
tp10743
sS'as,cana,edta'
p10744
(F1
F0.00076452599388379206
I1
I0
I1
tp10745
sS'therefore,flomax,capsules'
p10746
(F1
F0.00076452599388379206
I1
I0
I1
tp10747
sS'oral,certain,and'
p10748
(F1
F0.00076452599388379206
I1
I0
I1
tp10749
sS'are,receiving,a'
p10750
(F1
F0.00076452599388379206
I1
I0
I1
tp10751
sS'against,isolates,of'
p10752
(F1
F0.00076452599388379206
I0
I1
I-1
tp10753
sS'therefore,it,is'
p10754
(F1
F0.00076452599388379206
I1
I0
I1
tp10755
sS'was,potentiated,by'
p10756
(F1
F0.00076452599388379206
I1
I0
I1
tp10757
sS'beta,adrenergic,aerosol'
p10758
(F1
F0.0015290519877675841
I2
I0
I2
tp10759
sS'cyp3a,activity,is'
p10760
(F1
F0.00076452599388379206
I0
I1
I-1
tp10761
sS'anesthesia,tiva,repeatedly'
p10762
(F1
F0.00076452599388379206
I0
I1
I-1
tp10763
sS'with,great,caution'
p10764
(F1
F0.0022935779816513763
I3
I0
I3
tp10765
sS'vitro,testing,found'
p10766
(F1
F0.00076452599388379206
I0
I1
I-1
tp10767
sS'wort,and,certain'
p10768
(F1
F0.00076452599388379206
I1
I0
I1
tp10769
sS'after,treatment,for'
p10770
(F1
F0.00076452599388379206
I0
I1
I-1
tp10771
sS'depresses,the,central'
p10772
(F1
F0.00076452599388379206
I1
I0
I1
tp10773
sS'on,drug,interactions'
p10774
(F1
F0.00076452599388379206
I0
I1
I-1
tp10775
sS'with,other,chemotherapeutic'
p10776
(F1
F0.00076452599388379206
I0
I1
I-1
tp10777
sS'to,active,tubular'
p10778
(F1
F0.00076452599388379206
I1
I0
I1
tp10779
sS'emulsion,has,not'
p10780
(F1
F0.00076452599388379206
I0
I1
I-1
tp10781
sS'diprivan,injectable,emulsion'
p10782
(F0
F0
I2
I2
I0
tp10783
sS'effect,of,from'
p10784
(F1
F0.00076452599388379206
I1
I0
I1
tp10785
sS'tiva,repeatedly,for'
p10786
(F1
F0.00076452599388379206
I0
I1
I-1
tp10787
sS'in,patients,to'
p10788
(F1
F0.0022935779816513763
I3
I0
I3
tp10789
sS'breast,cancer,by'
p10790
(F1
F0.00076452599388379206
I0
I1
I-1
tp10791
sS'evidence,that,aminosalicylate'
p10792
(F1
F0.00076452599388379206
I1
I0
I1
tp10793
sS'alter,the,adverse'
p10794
(F1
F0.00076452599388379206
I0
I1
I-1
tp10795
sS'auc,was,significantly'
p10796
(F1
F0.00076452599388379206
I0
I1
I-1
tp10797
sS'carried,out,in'
p10798
(F1
F0.00076452599388379206
I0
I1
I-1
tp10799
sS'cancer,cells,through'
p10800
(F1
F0.00076452599388379206
I1
I0
I1
tp10801
sS'test,in,mice'
p10802
(F1
F0.00076452599388379206
I1
I0
I1
tp10803
sS'enzyme,cyp3a4,significantly'
p10804
(F1
F0.00076452599388379206
I1
I0
I1
tp10805
sS'secretion,and,further'
p10806
(F1
F0.00076452599388379206
I0
I1
I-1
tp10807
sS'were,poor,metabolizers'
p10808
(F1
F0.00076452599388379206
I1
I0
I1
tp10809
sS'as,post-marketing,observations'
p10810
(F1
F0.00076452599388379206
I1
I0
I1
tp10811
sS'implanon,failure,in'
p10812
(F1
F0.00076452599388379206
I1
I0
I1
tp10813
sS'fact,that,chronic'
p10814
(F1
F0.00076452599388379206
I0
I1
I-1
tp10815
sS'the,sequential,administrations'
p10816
(F1
F0.00076452599388379206
I1
I0
I1
tp10817
sS'with,commonly,used'
p10818
(F1
F0.00076452599388379206
I0
I1
I-1
tp10819
sS'cyp2d6,and,cyp1a2'
p10820
(F1
F0.00076452599388379206
I0
I1
I-1
tp10821
sS'ingested,on,an'
p10822
(F1
F0.00076452599388379206
I0
I1
I-1
tp10823
sS'cerezyme,and,zavesca'
p10824
(F1
F0.00076452599388379206
I1
I0
I1
tp10825
sS'pharmacodynamic,interactions,between'
p10826
(F1
F0.00076452599388379206
I0
I1
I-1
tp10827
sS'should,be,given'
p10828
(F1
F0.0022935779816513763
I3
I0
I3
tp10829
sS'with,confirmed,congenital'
p10830
(F1
F0.00076452599388379206
I1
I0
I1
tp10831
sS'and,is,sequence'
p10832
(F1
F0.00076452599388379206
I1
I0
I1
tp10833
sS'of,zemplar,capsules'
p10834
(F1
F0.00076452599388379206
I1
I0
I1
tp10835
sS'maintain,a,target'
p10836
(F1
F0.00076452599388379206
I0
I1
I-1
tp10837
sS'excessive,reductions,in'
p10838
(F1
F0.00076452599388379206
I0
I1
I-1
tp10839
sS'following,a,single'
p10840
(F1
F0.0015290519877675841
I0
I2
I-2
tp10841
sS'dose,of,hcl'
p10842
(F1
F0.00076452599388379206
I1
I0
I1
tp10843
sS'by,the,induction'
p10844
(F1
F0.00076452599388379206
I0
I1
I-1
tp10845
sS'due,to,a'
p10846
(F1
F0.00076452599388379206
I1
I0
I1
tp10847
sS'receiving,most,proton'
p10848
(F1
F0.00076452599388379206
I0
I1
I-1
tp10849
sS'and,resulting,in'
p10850
(F1
F0.00076452599388379206
I1
I0
I1
tp10851
sS'apnea,seizures,following'
p10852
(F1
F0.00076452599388379206
I1
I0
I1
tp10853
sS'cancer,cells,mcf7'
p10854
(F1
F0.00076452599388379206
I1
I0
I1
tp10855
sS'for,pharmacokinetic,interactions'
p10856
(F1
F0.00076452599388379206
I1
I0
I1
tp10857
sS'such,compounds,to'
p10858
(F1
F0.00076452599388379206
I1
I0
I1
tp10859
sS'of,xenical,mg'
p10860
(F1
F0.0015290519877675841
I0
I2
I-2
tp10861
sS'for,other,indications'
p10862
(F1
F0.00076452599388379206
I1
I0
I1
tp10863
sS'increased,by,and'
p10864
(F1
F0.00076452599388379206
I1
I0
I1
tp10865
sS'is,recommended,for'
p10866
(F1
F0.00076452599388379206
I1
I0
I1
tp10867
sS'biotransformation,of,precocene'
p10868
(F1
F0.00076452599388379206
I0
I1
I-1
tp10869
sS'was,increased,by'
p10870
(F1
F0.00076452599388379206
I1
I0
I1
tp10871
sS'of,the,small'
p10872
(F1
F0.00076452599388379206
I1
I0
I1
tp10873
sS'oral,antiplatelet,drug'
p10874
(F1
F0.00076452599388379206
I1
I0
I1
tp10875
sS'kg,group,mg'
p10876
(F1
F0.00076452599388379206
I0
I1
I-1
tp10877
sS'by,increasing,the'
p10878
(F1
F0.00076452599388379206
I1
I0
I1
tp10879
sS'not,be,considered'
p10880
(F1
F0.00076452599388379206
I1
I0
I1
tp10881
sS'toxicity,have,been'
p10882
(F0
F0
I1
I1
I0
tp10883
sS'sympathomimetic,pressor,amines'
p10884
(F1
F0.0015290519877675841
I2
I0
I2
tp10885
sS'change,in,onset'
p10886
(F1
F0.00076452599388379206
I0
I1
I-1
tp10887
sS'in,chronic,model'
p10888
(F1
F0.00076452599388379206
I0
I1
I-1
tp10889
sS'and,the,four'
p10890
(F1
F0.00076452599388379206
I1
I0
I1
tp10891
sS'agonists,on,the'
p10892
(F1
F0.00076452599388379206
I1
I0
I1
tp10893
sS'chemical,similarity,of'
p10894
(F1
F0.00076452599388379206
I1
I0
I1
tp10895
sS'appeared,less,with'
p10896
(F1
F0.00076452599388379206
I0
I1
I-1
tp10897
sS'of,attenuating,some'
p10898
(F1
F0.00076452599388379206
I0
I1
I-1
tp10899
sS'with,univasc,if'
p10900
(F1
F0.00076452599388379206
I0
I1
I-1
tp10901
sS'ability,of,cyclooxygenase-2'
p10902
(F1
F0.00076452599388379206
I0
I1
I-1
tp10903
sS'in,a,large'
p10904
(F1
F0.00076452599388379206
I0
I1
I-1
tp10905
sS'the,concentrations,of'
p10906
(F1
F0.00076452599388379206
I0
I1
I-1
tp10907
sS'sedation,the,rate'
p10908
(F1
F0.00076452599388379206
I1
I0
I1
tp10909
sS'the,child,was'
p10910
(F1
F0.00076452599388379206
I0
I1
I-1
tp10911
sS'inhibitors,or,tricyclic'
p10912
(F1
F0.00076452599388379206
I1
I0
I1
tp10913
sS'the,plasma,ace'
p10914
(F1
F0.00076452599388379206
I0
I1
I-1
tp10915
sS'evista,is,coadministered'
p10916
(F1
F0.00076452599388379206
I1
I0
I1
tp10917
sS'inhibitors,when,used'
p10918
(F1
F0.00076452599388379206
I0
I1
I-1
tp10919
sS'dasatinib-,and,paclitaxel-induced'
p10920
(F1
F0.00076452599388379206
I0
I1
I-1
tp10921
sS'however,as,with'
p10922
(F1
F0.00076452599388379206
I1
I0
I1
tp10923
sS'effect,of,versed'
p10924
(F1
F0.00076452599388379206
I1
I0
I1
tp10925
sS'a,week,dietary'
p10926
(F1
F0.0015290519877675841
I0
I2
I-2
tp10927
sS'neurons,in,the'
p10928
(F1
F0.00076452599388379206
I1
I0
I1
tp10929
sS'these,drugs,interrupt'
p10930
(F1
F0.00076452599388379206
I0
I1
I-1
tp10931
sS'of,this,single'
p10932
(F1
F0.00076452599388379206
I1
I0
I1
tp10933
sS'be,associated,with'
p10934
(F1
F0.0030581039755351682
I4
I0
I4
tp10935
sS'agents,including,and'
p10936
(F0
F0
I1
I1
I0
tp10937
sS'drugs,that,induce'
p10938
(F0
F0
I2
I2
I0
tp10939
sS'pre-dose,concentration,and'
p10940
(F1
F0.00076452599388379206
I1
I0
I1
tp10941
sS'may,increase,certain'
p10942
(F1
F0.00076452599388379206
I1
I0
I1
tp10943
sS'they,should,be'
p10944
(F1
F0.0015290519877675841
I2
I0
I2
tp10945
sS'dose,or,multiple'
p10946
(F1
F0.00076452599388379206
I0
I1
I-1
tp10947
sS'drug,therapy,and'
p10948
(F1
F0.00076452599388379206
I0
I1
I-1
tp10949
sS'should,be,discontinued'
p10950
(F1
F0.00076452599388379206
I1
I0
I1
tp10951
sS'is,partially,metabolized'
p10952
(F1
F0.00076452599388379206
I1
I0
I1
tp10953
sS'coadministration,of,mg'
p10954
(F1
F0.00076452599388379206
I1
I0
I1
tp10955
sS'effect,on,s'
p10956
(F1
F0.00076452599388379206
I1
I0
I1
tp10957
sS'may,alter,mean'
p10958
(F1
F0.00076452599388379206
I1
I0
I1
tp10959
sS'use,of,other'
p10960
(F1
F0.0015290519877675841
I0
I2
I-2
tp10961
sS'paclitaxel-induced,apoptosis,compared'
p10962
(F1
F0.00076452599388379206
I0
I1
I-1
tp10963
sS'hypertension,suggests,that'
p10964
(F1
F0.00076452599388379206
I1
I0
I1
tp10965
sS'elimination,because,is'
p10966
(F1
F0.00076452599388379206
I0
I1
I-1
tp10967
sS'agents,streptase,streptokinase'
p10968
(F1
F0.00076452599388379206
I1
I0
I1
tp10969
sS'based,on,an'
p10970
(F1
F0.00076452599388379206
I1
I0
I1
tp10971
sS'difficulty,in,achieving'
p10972
(F1
F0.00076452599388379206
I0
I1
I-1
tp10973
sS'in,a,t-all'
p10974
(F1
F0.00076452599388379206
I1
I0
I1
tp10975
sS'potentiate,the,action'
p10976
(F1
F0.0015290519877675841
I2
I0
I2
tp10977
sS'same,subjects,in'
p10978
(F1
F0.00076452599388379206
I1
I0
I1
tp10979
sS'of,in,adolescent'
p10980
(F1
F0.00076452599388379206
I0
I1
I-1
tp10981
sS'treatment,increased,the'
p10982
(F1
F0.00076452599388379206
I1
I0
I1
tp10983
sS'increases,in,r-warfarin'
p10984
(F1
F0.00076452599388379206
I1
I0
I1
tp10985
sS'giving,class,drugs'
p10986
(F1
F0.00076452599388379206
I1
I0
I1
tp10987
sS'mg,on,absorption'
p10988
(F1
F0.0015290519877675841
I0
I2
I-2
tp10989
sS'three,times,the'
p10990
(F1
F0.00076452599388379206
I0
I1
I-1
tp10991
sS'patients,receiving,high-dose'
p10992
(F1
F0.00076452599388379206
I1
I0
I1
tp10993
sS'or,reduce,the'
p10994
(F1
F0.00076452599388379206
I1
I0
I1
tp10995
sS'this,increase,was'
p10996
(F1
F0.00076452599388379206
I1
I0
I1
tp10997
sS'similar,neuromuscular,blocking'
p10998
(F1
F0.00076452599388379206
I1
I0
I1
tp10999
sS'resulted,in,increased'
p11000
(F1
F0.00076452599388379206
I1
I0
I1
tp11001
sS'antiproliferative,effect,relating'
p11002
(F1
F0.00076452599388379206
I1
I0
I1
tp11003
sS'however,in,a'
p11004
(F1
F0.00076452599388379206
I1
I0
I1
tp11005
sS'interval,following,co-administration'
p11006
(F1
F0.00076452599388379206
I0
I1
I-1
tp11007
sS'levels,in,renal'
p11008
(F1
F0.00076452599388379206
I1
I0
I1
tp11009
sS'when,is,administered'
p11010
(F1
F0.00076452599388379206
I1
I0
I1
tp11011
sS'for,cmax,and'
p11012
(F1
F0.00076452599388379206
I1
I0
I1
tp11013
sS'magnesium-aluminum,hydroxide,when'
p11014
(F1
F0.00076452599388379206
I1
I0
I1
tp11015
sS'of,when,administered'
p11016
(F1
F0.00076452599388379206
I1
I0
I1
tp11017
sS'pharmacokinetic,studies,show'
p11018
(F1
F0.00076452599388379206
I0
I1
I-1
tp11019
sS'patients,concomitantly,receiving'
p11020
(F1
F0.00076452599388379206
I1
I0
I1
tp11021
sS'levels,and,toxicity'
p11022
(F1
F0.00076452599388379206
I1
I0
I1
tp11023
sS'oncology,patients,who'
p11024
(F1
F0.00076452599388379206
I0
I1
I-1
tp11025
sS'taken,a,monoamine'
p11026
(F1
F0.00076452599388379206
I1
I0
I1
tp11027
sS'may,cause,intense'
p11028
(F1
F0.00076452599388379206
I1
I0
I1
tp11029
sS'the,qt,interval'
p11030
(F1
F0.00076452599388379206
I0
I1
I-1
tp11031
sS'cyp,inhibitor,aminobenzotriazole'
p11032
(F1
F0.00076452599388379206
I0
I1
I-1
tp11033
sS'of,in,an'
p11034
(F1
F0.00076452599388379206
I1
I0
I1
tp11035
sS'b1,thiamine,loop'
p11036
(F1
F0.00076452599388379206
I1
I0
I1
tp11037
sS'before,and,after'
p11038
(F1
F0.00076452599388379206
I0
I1
I-1
tp11039
sS'lapatinib,may,have'
p11040
(F1
F0.00076452599388379206
I0
I1
I-1
tp11041
sS'triprolidine,may,enhance'
p11042
(F1
F0.00076452599388379206
I1
I0
I1
tp11043
sS'low-dose,with,mobic'
p11044
(F1
F0.00076452599388379206
I1
I0
I1
tp11045
sS'blood,pressure,may'
p11046
(F1
F0.00076452599388379206
I0
I1
I-1
tp11047
sS'and,other,muscle'
p11048
(F1
F0.00076452599388379206
I0
I1
I-1
tp11049
sS'and,analogues,a'
p11050
(F1
F0.00076452599388379206
I1
I0
I1
tp11051
sS'tricyclic,antidepressant,such'
p11052
(F1
F0.00076452599388379206
I0
I1
I-1
tp11053
sS'may,be,required'
p11054
(F1
F0.00076452599388379206
I1
I0
I1
tp11055
sS'bile,acids,for'
p11056
(F1
F0.00076452599388379206
I1
I0
I1
tp11057
sS'is,accentuated,by'
p11058
(F1
F0.00076452599388379206
I1
I0
I1
tp11059
sS'acute,administration,of'
p11060
(F1
F0.00076452599388379206
I1
I0
I1
tp11061
sS'which,may,lead'
p11062
(F1
F0.00076452599388379206
I1
I0
I1
tp11063
sS'especially,in,cases'
p11064
(F1
F0.00076452599388379206
I0
I1
I-1
tp11065
sS'since,inhibit,the'
p11066
(F1
F0.00076452599388379206
I1
I0
I1
tp11067
sS'normal,values,when'
p11068
(F1
F0.00076452599388379206
I1
I0
I1
tp11069
sS'diflucan,reduces,the'
p11070
(F1
F0.00076452599388379206
I1
I0
I1
tp11071
sS'to,increased,plasma'
p11072
(F1
F0.00076452599388379206
I1
I0
I1
tp11073
sS'growth,inhibition,mtt'
p11074
(F1
F0.00076452599388379206
I0
I1
I-1
tp11075
sS'beta,blockers,and'
p11076
(F1
F0.00076452599388379206
I0
I1
I-1
tp11077
sS'antagonists,and,drugs'
p11078
(F1
F0.00076452599388379206
I1
I0
I1
tp11079
sS'from,to,hours'
p11080
(F1
F0.00076452599388379206
I1
I0
I1
tp11081
sS'was,administered,to'
p11082
(F0
F0
I1
I1
I0
tp11083
sS'kg,intraperitoneally,not'
p11084
(F1
F0.00076452599388379206
I1
I0
I1
tp11085
sS'belladonna,alkaloids,including'
p11086
(F1
F0.00076452599388379206
I0
I1
I-1
tp11087
sS'adrenergic,aerosol,bronchodilators'
p11088
(F1
F0.0015290519877675841
I2
I0
I2
tp11089
sS'males,and,mg'
p11090
(F1
F0.00076452599388379206
I0
I1
I-1
tp11091
sS'in,stable,renal'
p11092
(F1
F0.00076452599388379206
I0
I1
I-1
tp11093
sS'with,mobic,may'
p11094
(F1
F0.00076452599388379206
I1
I0
I1
tp11095
sS'interact,with,other'
p11096
(F0
F0
I1
I1
I0
tp11097
sS'increased,geometric,mean'
p11098
(F1
F0.00076452599388379206
I1
I0
I1
tp11099
sS'but,this,diminution'
p11100
(F1
F0.00076452599388379206
I1
I0
I1
tp11101
sS'of,anticholinergic,drugs'
p11102
(F1
F0.00076452599388379206
I1
I0
I1
tp11103
sS'hepatic,metabolism,decreased'
p11104
(F1
F0.0015290519877675841
I0
I2
I-2
tp11105
sS'counteract,the,specific'
p11106
(F1
F0.00076452599388379206
I1
I0
I1
tp11107
sS'tetrahydropyridine,toxicity,towards'
p11108
(F1
F0.00076452599388379206
I1
I0
I1
tp11109
sS'drugs,n,n'
p11110
(F1
F0.00076452599388379206
I0
I1
I-1
tp11111
sS'the,drug,interaction'
p11112
(F1
F0.00076452599388379206
I0
I1
I-1
tp11113
sS'of,who,are'
p11114
(F1
F0.00076452599388379206
I1
I0
I1
tp11115
sS'is,increased,by'
p11116
(F1
F0.00076452599388379206
I1
I0
I1
tp11117
sS'and,are,fluoroquinolone'
p11118
(F1
F0.00076452599388379206
I0
I1
I-1
tp11119
sS'significantly,altered,by'
p11120
(F1
F0.00076452599388379206
I1
I0
I1
tp11121
sS'of,enhanced,as'
p11122
(F1
F0.0015290519877675841
I2
I0
I2
tp11123
sS'microsomes,showed,that'
p11124
(F1
F0.00076452599388379206
I0
I1
I-1
tp11125
sS'inhibitors,close,monitoring'
p11126
(F1
F0.00076452599388379206
I0
I1
I-1
tp11127
sS'population,pharmacokinetic,analysis'
p11128
(F0
F0
I1
I1
I0
tp11129
sS'of,zolinza,and'
p11130
(F1
F0.00076452599388379206
I1
I0
I1
tp11131
sS'patient,initiates,or'
p11132
(F1
F0.00076452599388379206
I1
I0
I1
tp11133
sS'decrease,patient,s'
p11134
(F1
F0.00076452599388379206
I1
I0
I1
tp11135
sS'was,detected,in'
p11136
(F1
F0.00076452599388379206
I1
I0
I1
tp11137
sS'intestines,and,thus'
p11138
(F1
F0.00076452599388379206
I1
I0
I1
tp11139
sS'plasma,profiles,of'
p11140
(F1
F0.00076452599388379206
I0
I1
I-1
tp11141
sS'with,alimta,to'
p11142
(F1
F0.00076452599388379206
I1
I0
I1
tp11143
sS'other,highly,protein-bound'
p11144
(F1
F0.00076452599388379206
I1
I0
I1
tp11145
sS'the,contraception,and'
p11146
(F1
F0.00076452599388379206
I1
I0
I1
tp11147
sS'effects,of,by'
p11148
(F1
F0.00076452599388379206
I1
I0
I1
tp11149
sS'of,fat-soluble,vitamins'
p11150
(F1
F0.00076452599388379206
I1
I0
I1
tp11151
sS'that,can,inhibit'
p11152
(F1
F0.00076452599388379206
I1
I0
I1
tp11153
sS'bacteriostatic,may,antagonize'
p11154
(F1
F0.00076452599388379206
I1
I0
I1
tp11155
sS'cdna,encoding,enhanced'
p11156
(F1
F0.00076452599388379206
I0
I1
I-1
tp11157
sS'damage,of,five'
p11158
(F1
F0.00076452599388379206
I0
I1
I-1
tp11159
sS'given,by,injection'
p11160
(F1
F0.00076452599388379206
I0
I1
I-1
tp11161
sS'after,pretreatments,with'
p11162
(F1
F0.00076452599388379206
I0
I1
I-1
tp11163
sS'patients,receiving,and'
p11164
(F1
F0.0030581039755351682
I4
I0
I4
tp11165
sS'should,be,administered'
p11166
(F0.33333333333333331
F0.0015290519877675841
I4
I2
I2
tp11167
sS'were,potent,non-competitive'
p11168
(F1
F0.00076452599388379206
I1
I0
I1
tp11169
sS'with,nitrous,oxide'
p11170
(F1
F0.00076452599388379206
I0
I1
I-1
tp11171
sS'particularly,when,the'
p11172
(F1
F0.00076452599388379206
I1
I0
I1
tp11173
sS'with,oral,may'
p11174
(F1
F0.0022935779816513763
I3
I0
I3
tp11175
sS'approved,brilinta-astrazeneca,an'
p11176
(F1
F0.00076452599388379206
I1
I0
I1
tp11177
sS'narcotic,analgesics,general'
p11178
(F1
F0.00076452599388379206
I1
I0
I1
tp11179
sS'was,overexpressed,in'
p11180
(F1
F0.00076452599388379206
I1
I0
I1
tp11181
sS'combined,with,herceptin'
p11182
(F1
F0.00076452599388379206
I1
I0
I1
tp11183
sS'humans,and,do'
p11184
(F1
F0.00076452599388379206
I0
I1
I-1
tp11185
sS'inhibitors,the,pressor'
p11186
(F1
F0.0015290519877675841
I2
I0
I2
tp11187
sS'inhibition,and,the'
p11188
(F1
F0.00076452599388379206
I0
I1
I-1
tp11189
sS'potentiation,of,the'
p11190
(F1
F0.00076452599388379206
I0
I1
I-1
tp11191
sS'with,plavix,and'
p11192
(F1
F0.00076452599388379206
I0
I1
I-1
tp11193
sS'fat-soluble,vitamins,such'
p11194
(F1
F0.00076452599388379206
I1
I0
I1
tp11195
sS'glucuronidation,of,and'
p11196
(F1
F0.00076452599388379206
I1
I0
I1
tp11197
sS'xenical,patients,on'
p11198
(F1
F0.00076452599388379206
I1
I0
I1
tp11199
sS'plasma,proteins,caution'
p11200
(F1
F0.00076452599388379206
I0
I1
I-1
tp11201
sS'confidence,interval,ci'
p11202
(F1
F0.00076452599388379206
I1
I0
I1
tp11203
sS'other,drugs,having'
p11204
(F1
F0.00076452599388379206
I1
I0
I1
tp11205
sS'have,been,postmarketing'
p11206
(F1
F0.00076452599388379206
I1
I0
I1
tp11207
sS'of,emergence,agitation'
p11208
(F1
F0.00076452599388379206
I0
I1
I-1
tp11209
sS'action,cholinesterase,inhibitors'
p11210
(F1
F0.00076452599388379206
I1
I0
I1
tp11211
sS'similar,drugs,while'
p11212
(F1
F0.00076452599388379206
I1
I0
I1
tp11213
sS'being,and,the'
p11214
(F1
F0.00076452599388379206
I0
I1
I-1
tp11215
sS'available,data,no'
p11216
(F1
F0.00076452599388379206
I1
I0
I1
tp11217
sS'combination,was,evaluated'
p11218
(F1
F0.00076452599388379206
I0
I1
I-1
tp11219
sS'emission,tomography,dopamine'
p11220
(F1
F0.00076452599388379206
I1
I0
I1
tp11221
sS'digoxin,in,normal-weight'
p11222
(F1
F0.00076452599388379206
I0
I1
I-1
tp11223
sS'midbrain,dopaminergic,neurons'
p11224
(F1
F0.00076452599388379206
I1
I0
I1
tp11225
sS'artificial,tears,conjugated'
p11226
(F1
F0.00076452599388379206
I0
I1
I-1
tp11227
sS'increased,when,was'
p11228
(F1
F0.00076452599388379206
I1
I0
I1
tp11229
sS'antihypertensive,drugs,care'
p11230
(F1
F0.00076452599388379206
I1
I0
I1
tp11231
sS'other,cholinesterase,inhibitors'
p11232
(F1
F0.00076452599388379206
I1
I0
I1
tp11233
sS'with,recommended,doses'
p11234
(F1
F0.00076452599388379206
I1
I0
I1
tp11235
sS'phenyl-1,tetrahydropyridine,treatment'
p11236
(F1
F0.00076452599388379206
I1
I0
I1
tp11237
sS'times,a,day'
p11238
(F0.55555555555555558
F0.0038226299694189602
I2
I7
I-5
tp11239
sS'rate,of,hydrochloride'
p11240
(F1
F0.00076452599388379206
I1
I0
I1
tp11241
sS'to,patients,being'
p11242
(F1
F0.00076452599388379206
I1
I0
I1
tp11243
sS'impaired,renal,function'
p11244
(F1
F0.00076452599388379206
I1
I0
I1
tp11245
sS'coadministration,of,megestrol'
p11246
(F1
F0.00076452599388379206
I1
I0
I1
tp11247
sS'moxifloxacin,and,are'
p11248
(F1
F0.00076452599388379206
I0
I1
I-1
tp11249
sS'patients,with,mild'
p11250
(F1
F0.0015290519877675841
I2
I0
I2
tp11251
sS'one,of,s-adenosylhomocysteine'
p11252
(F1
F0.00076452599388379206
I0
I1
I-1
tp11253
sS'cause,serious,cardiac'
p11254
(F1
F0.0015290519877675841
I2
I0
I2
tp11255
sS'the,present,study'
p11256
(F0.5
F0.0015290519877675841
I1
I3
I-2
tp11257
sS'this,enzyme,such'
p11258
(F1
F0.00076452599388379206
I0
I1
I-1
tp11259
sS'topical,application,of'
p11260
(F0
F0
I1
I1
I0
tp11261
sS'of,should,be'
p11262
(F0
F0
I1
I1
I0
tp11263
sS'the,occurrence,of'
p11264
(F1
F0.0015290519877675841
I2
I0
I2
tp11265
sS'thiazides,may,add'
p11266
(F1
F0.00076452599388379206
I1
I0
I1
tp11267
sS'with,compounds,that'
p11268
(F1
F0.00076452599388379206
I1
I0
I1
tp11269
sS'exercised,when,methergine'
p11270
(F1
F0.00076452599388379206
I1
I0
I1
tp11271
sS'anorexia,tachypnea,lethargy'
p11272
(F1
F0.00076452599388379206
I1
I0
I1
tp11273
sS'with,a,strong'
p11274
(F1
F0.00076452599388379206
I1
I0
I1
tp11275
sS'or,nardil,in'
p11276
(F1
F0.00076452599388379206
I1
I0
I1
tp11277
sS'during,concomitant,use'
p11278
(F0
F0
I1
I1
I0
tp11279
sS'been,described,in'
p11280
(F1
F0.00076452599388379206
I1
I0
I1
tp11281
sS'in,reducing,plasma'
p11282
(F1
F0.00076452599388379206
I0
I1
I-1
tp11283
sS'self-reported,drowsiness,and'
p11284
(F1
F0.00076452599388379206
I0
I1
I-1
tp11285
sS'coadministration,of,xenical'
p11286
(F1
F0.00076452599388379206
I0
I1
I-1
tp11287
sS'serious,cardiac,arrhythmias'
p11288
(F1
F0.0015290519877675841
I2
I0
I2
tp11289
sS'considered,necessary,it'
p11290
(F1
F0.00076452599388379206
I1
I0
I1
tp11291
sS'adult,diabetic,patients'
p11292
(F1
F0.00076452599388379206
I0
I1
I-1
tp11293
sS'remeron,soltab,diazepam'
p11294
(F1
F0.00076452599388379206
I1
I0
I1
tp11295
sS'to,when,taken'
p11296
(F1
F0.00076452599388379206
I1
I0
I1
tp11297
sS'towards,dopaminergic,and'
p11298
(F1
F0.00076452599388379206
I1
I0
I1
tp11299
sS'alimta,to,patients'
p11300
(F1
F0.00076452599388379206
I1
I0
I1
tp11301
sS'susceptibility,results,for'
p11302
(F1
F0.00076452599388379206
I0
I1
I-1
tp11303
sS'against,clinical,isolates'
p11304
(F1
F0.00076452599388379206
I0
I1
I-1
tp11305
sS'inhibit,the,hepatic'
p11306
(F1
F0.0015290519877675841
I2
I0
I2
tp11307
sS'response,of,adrenergic'
p11308
(F1
F0.0015290519877675841
I2
I0
I2
tp11309
sS'after,initiating,or'
p11310
(F1
F0.00076452599388379206
I1
I0
I1
tp11311
sS'administration,of,either'
p11312
(F1
F0.0015290519877675841
I0
I2
I-2
tp11313
sS'mpa,exposure,when'
p11314
(F1
F0.00076452599388379206
I0
I1
I-1
tp11315
sS'administration,of,followed'
p11316
(F1
F0.00076452599388379206
I1
I0
I1
tp11317
sS'administration,of,substances'
p11318
(F1
F0.00076452599388379206
I1
I0
I1
tp11319
sS't,returned,to'
p11320
(F1
F0.00076452599388379206
I0
I1
I-1
tp11321
sS'cycle,at,g1'
p11322
(F1
F0.00076452599388379206
I0
I1
I-1
tp11323
sS'role,of,p27'
p11324
(F1
F0.00076452599388379206
I1
I0
I1
tp11325
sS'effect,while,appeared'
p11326
(F1
F0.00076452599388379206
I1
I0
I1
tp11327
sS'in,their,serum'
p11328
(F1
F0.00076452599388379206
I1
I0
I1
tp11329
sS'but,its,addition'
p11330
(F1
F0.00076452599388379206
I0
I1
I-1
tp11331
sS'studies,show,that'
p11332
(F1
F0.0015290519877675841
I0
I2
I-2
tp11333
sS'in,female,rats'
p11334
(F1
F0.00076452599388379206
I1
I0
I1
tp11335
sS'likely,the,result'
p11336
(F1
F0.00076452599388379206
I0
I1
I-1
tp11337
sS'significant,hypoglycemia,may'
p11338
(F1
F0.00076452599388379206
I1
I0
I1
tp11339
sS'report,the,case'
p11340
(F1
F0.00076452599388379206
I1
I0
I1
tp11341
sS'in,vitro,rat'
p11342
(F1
F0.00076452599388379206
I1
I0
I1
tp11343
sS'with,short,elimination'
p11344
(F1
F0.00076452599388379206
I1
I0
I1
tp11345
sS'phenyl-1,tetrahydropyridine,vehicle-treated'
p11346
(F1
F0.0015290519877675841
I2
I0
I2
tp11347
sS'effects,of,the'
p11348
(F1
F0.00076452599388379206
I1
I0
I1
tp11349
sS'rate,of,thrombotic'
p11350
(F1
F0.00076452599388379206
I1
I0
I1
tp11351
sS'carbachol,may,decrease'
p11352
(F1
F0.00076452599388379206
I1
I0
I1
tp11353
sS'is,not,known'
p11354
(F1
F0.0015290519877675841
I0
I2
I-2
tp11355
sS'cholinesterase,inhibitors,have'
p11356
(F1
F0.00076452599388379206
I1
I0
I1
tp11357
sS'effects,and,coadministration'
p11358
(F1
F0.00076452599388379206
I1
I0
I1
tp11359
sS'displaced,protein-bound,in'
p11360
(F1
F0.00076452599388379206
I1
I0
I1
tp11361
sS'not,change,the'
p11362
(F1
F0.0015290519877675841
I0
I2
I-2
tp11363
sS'drugs,may,increase'
p11364
(F1
F0.0015290519877675841
I2
I0
I2
tp11365
sS'unnecessary,when,co-administered'
p11366
(F1
F0.00076452599388379206
I0
I1
I-1
tp11367
sS'formal,interaction,studies'
p11368
(F1
F0.00076452599388379206
I0
I1
I-1
tp11369
sS'influence,of,the'
p11370
(F1
F0.00076452599388379206
I0
I1
I-1
tp11371
sS'i,trial,of'
p11372
(F1
F0.00076452599388379206
I0
I1
I-1
tp11373
sS'agents,including,feldene'
p11374
(F1
F0.00076452599388379206
I1
I0
I1
tp11375
sS'cardiovascular,events,in'
p11376
(F1
F0.00076452599388379206
I1
I0
I1
tp11377
sS'been,large,and'
p11378
(F1
F0.00076452599388379206
I0
I1
I-1
tp11379
sS'drugs,that,reduce'
p11380
(F1
F0.00076452599388379206
I1
I0
I1
tp11381
sS'tamsulosin,hci,and'
p11382
(F1
F0.00076452599388379206
I0
I1
I-1
tp11383
sS'mean,dose,from'
p11384
(F1
F0.00076452599388379206
I0
I1
I-1
tp11385
sS'the,latter,displayed'
p11386
(F1
F0.00076452599388379206
I0
I1
I-1
tp11387
sS'interfere,with,hormonal'
p11388
(F1
F0.00076452599388379206
I0
I1
I-1
tp11389
sS'blood,pressure,medicines'
p11390
(F1
F0.00076452599388379206
I0
I1
I-1
tp11391
sS'a,study,published'
p11392
(F1
F0.00076452599388379206
I1
I0
I1
tp11393
sS'and,on,clinical'
p11394
(F1
F0.00076452599388379206
I0
I1
I-1
tp11395
sS'interrupt,enterohepatic,recirculation'
p11396
(F1
F0.00076452599388379206
I0
I1
I-1
tp11397
sS'intervals,pr,qrs'
p11398
(F1
F0.00076452599388379206
I0
I1
I-1
tp11399
sS'of,ethinyl,estradiol'
p11400
(F0.33333333333333331
F0.00076452599388379206
I1
I2
I-1
tp11401
sS'a,specific,inhibitor'
p11402
(F1
F0.00076452599388379206
I0
I1
I-1
tp11403
sS'organogenesis,result,in'
p11404
(F1
F0.00076452599388379206
I0
I1
I-1
tp11405
sS'death,have,been'
p11406
(F1
F0.00076452599388379206
I1
I0
I1
tp11407
sS'these,results,if'
p11408
(F1
F0.00076452599388379206
I0
I1
I-1
tp11409
sS'administered,prior,to'
p11410
(F1
F0.0015290519877675841
I2
I0
I2
tp11411
sS'sequence,dependent,in'
p11412
(F1
F0.00076452599388379206
I1
I0
I1
tp11413
sS'doses,of,or'
p11414
(F1
F0.00076452599388379206
I1
I0
I1
tp11415
sS'not,believed,to'
p11416
(F1
F0.00076452599388379206
I1
I0
I1
tp11417
sS'with,coumarin-type,have'
p11418
(F1
F0.00076452599388379206
I1
I0
I1
tp11419
sS'doses,of,on'
p11420
(F1
F0.00076452599388379206
I0
I1
I-1
tp11421
sS'a,predictable,dose-related'
p11422
(F1
F0.00076452599388379206
I1
I0
I1
tp11423
sS'may,be,prolonged'
p11424
(F1
F0.00076452599388379206
I1
I0
I1
tp11425
sS'anti-inflammatory,agents,including'
p11426
(F1
F0.00076452599388379206
I1
I0
I1
tp11427
sS'administration,because,of'
p11428
(F1
F0.00076452599388379206
I0
I1
I-1
tp11429
sS'prevention,of,emergence'
p11430
(F1
F0.00076452599388379206
I0
I1
I-1
tp11431
sS'by,hepatic,cytochrome'
p11432
(F1
F0.00076452599388379206
I0
I1
I-1
tp11433
sS'acid,and,gp'
p11434
(F1
F0.00076452599388379206
I1
I0
I1
tp11435
sS'macrolide,antibiotics,and'
p11436
(F1
F0.00076452599388379206
I0
I1
I-1
tp11437
sS'receiving,xenical,mg'
p11438
(F1
F0.0030581039755351682
I0
I4
I-4
tp11439
sS'cns,depressants,such'
p11440
(F1
F0.00076452599388379206
I1
I0
I1
tp11441
sS'increased,fold,by'
p11442
(F1
F0.00076452599388379206
I1
I0
I1
tp11443
sS'studied,in,patients'
p11444
(F1
F0.00076452599388379206
I0
I1
I-1
tp11445
sS'associated,with,erythema'
p11446
(F1
F0.00076452599388379206
I1
I0
I1
tp11447
sS'may,add,to'
p11448
(F1
F0.00076452599388379206
I1
I0
I1
tp11449
sS'change,in,dosage'
p11450
(F1
F0.0015290519877675841
I2
I0
I2
tp11451
sS'streptokinase,with,other'
p11452
(F1
F0.00076452599388379206
I0
I1
I-1
tp11453
sS'with,can,inhibit'
p11454
(F1
F0.00076452599388379206
I1
I0
I1
tp11455
sS'that,causes,a'
p11456
(F1
F0.00076452599388379206
I1
I0
I1
tp11457
sS'warfarin,users,who'
p11458
(F1
F0.00076452599388379206
I1
I0
I1
tp11459
sS'studies,to,evaluate'
p11460
(F1
F0.00076452599388379206
I0
I1
I-1
tp11461
sS'or,pharmacodynamics,blood'
p11462
(F1
F0.00076452599388379206
I0
I1
I-1
tp11463
sS'appear,to,increase'
p11464
(F1
F0.00076452599388379206
I1
I0
I1
tp11465
sS'with,that,on'
p11466
(F1
F0.00076452599388379206
I0
I1
I-1
tp11467
sS'clearance,in,the'
p11468
(F1
F0.00076452599388379206
I1
I0
I1
tp11469
sS'pathways,involving,cyp2d6'
p11470
(F1
F0.00076452599388379206
I0
I1
I-1
tp11471
sS'anticoagulants,phenytoin,cyclosporine'
p11472
(F1
F0.00076452599388379206
I1
I0
I1
tp11473
sS'by,but,is'
p11474
(F1
F0.00076452599388379206
I1
I0
I1
tp11475
sS'administration,of,fixed'
p11476
(F1
F0.00076452599388379206
I1
I0
I1
tp11477
sS'in,this,randomized'
p11478
(F1
F0.00076452599388379206
I0
I1
I-1
tp11479
sS'for,gastrointestinal,bleeding'
p11480
(F1
F0.00076452599388379206
I0
I1
I-1
tp11481
sS'of,hb-egf,in'
p11482
(F1
F0.00076452599388379206
I0
I1
I-1
tp11483
sS'a,number,of'
p11484
(F1
F0.00076452599388379206
I1
I0
I1
tp11485
sS'whereas,with,in'
p11486
(F1
F0.00076452599388379206
I1
I0
I1
tp11487
sS'level,determinations,of'
p11488
(F1
F0.00076452599388379206
I1
I0
I1
tp11489
sS'of,dopamine,transporter'
p11490
(F1
F0.00076452599388379206
I1
I0
I1
tp11491
sS'in,herceptin,serum'
p11492
(F1
F0.00076452599388379206
I1
I0
I1
tp11493
sS'used,simultaneously,with'
p11494
(F1
F0.00076452599388379206
I0
I1
I-1
tp11495
sS'tolectin,is,administered'
p11496
(F1
F0.00076452599388379206
I1
I0
I1
tp11497
sS'hydrolase,inhibitors,has'
p11498
(F1
F0.00076452599388379206
I0
I1
I-1
tp11499
sS'of,and,is'
p11500
(F1
F0.00076452599388379206
I1
I0
I1
tp11501
sS'closely,for,signs'
p11502
(F1
F0.00076452599388379206
I1
I0
I1
tp11503
sS'of,and,in'
p11504
(F0.33333333333333331
F0.00076452599388379206
I1
I2
I-1
tp11505
sS'change,in,either'
p11506
(F1
F0.00076452599388379206
I0
I1
I-1
tp11507
sS'pyridine,reduces,dopaminergic'
p11508
(F1
F0.00076452599388379206
I0
I1
I-1
tp11509
sS'or,magnesium-containing,when'
p11510
(F1
F0.00076452599388379206
I1
I0
I1
tp11511
sS'celontin,may,interact'
p11512
(F1
F0.00076452599388379206
I1
I0
I1
tp11513
sS'ergot,alkaloid,drugs'
p11514
(F1
F0.00076452599388379206
I0
I1
I-1
tp11515
sS'causing,an,increase'
p11516
(F1
F0.00076452599388379206
I1
I0
I1
tp11517
sS't-all,and,to'
p11518
(F1
F0.00076452599388379206
I0
I1
I-1
tp11519
sS'hct116,hepg2,mcf7'
p11520
(F1
F0.00076452599388379206
I0
I1
I-1
tp11521
sS'and,k-ras,mutations'
p11522
(F1
F0.00076452599388379206
I1
I0
I1
tp11523
sS'for,or,toxicity'
p11524
(F1
F0.00076452599388379206
I1
I0
I1
tp11525
sS'decrease,in,the'
p11526
(F0.20000000000000001
F0.00076452599388379206
I3
I2
I1
tp11527
sS'gel,is,prescribed'
p11528
(F1
F0.00076452599388379206
I0
I1
I-1
tp11529
sS'combination,compared,with'
p11530
(F1
F0.00076452599388379206
I1
I0
I1
tp11531
sS'absorption,of,nonheme'
p11532
(F1
F0.00076452599388379206
I0
I1
I-1
tp11533
sS'and,induced,apoptosis'
p11534
(F1
F0.00076452599388379206
I1
I0
I1
tp11535
sS'clinically,important,effect'
p11536
(F1
F0.00076452599388379206
I0
I1
I-1
tp11537
sS'the,interaction,between'
p11538
(F1
F0.00076452599388379206
I0
I1
I-1
tp11539
sS'require,increases,in'
p11540
(F1
F0.00076452599388379206
I1
I0
I1
tp11541
sS'have,been,reports'
p11542
(F0.59999999999999998
F0.0022935779816513763
I4
I1
I3
tp11543
sS'a,reduction,in'
p11544
(F0.25
F0.0015290519877675841
I5
I3
I2
tp11545
sS'additional,birth,control'
p11546
(F1
F0.00076452599388379206
I1
I0
I1
tp11547
sS'blood,dyscrasia,can'
p11548
(F1
F0.00076452599388379206
I1
I0
I1
tp11549
sS'feldene,is,administered'
p11550
(F1
F0.00076452599388379206
I1
I0
I1
tp11551
sS'drug,for,use'
p11552
(F1
F0.00076452599388379206
I1
I0
I1
tp11553
sS'used,in,administering'
p11554
(F1
F0.00076452599388379206
I0
I1
I-1
tp11555
sS'and,self,measured'
p11556
(F1
F0.00076452599388379206
I1
I0
I1
tp11557
sS'to,chickens,inoculated'
p11558
(F1
F0.00076452599388379206
I1
I0
I1
tp11559
sS'anticholinergics,or,other'
p11560
(F1
F0.00076452599388379206
I1
I0
I1
tp11561
sS'ratio,of,auc'
p11562
(F1
F0.00076452599388379206
I0
I1
I-1
tp11563
sS'abt,decreased,the'
p11564
(F1
F0.00076452599388379206
I1
I0
I1
tp11565
sS'therapy,was,associated'
p11566
(F1
F0.00076452599388379206
I1
I0
I1
tp11567
sS'intravenous,premedication,particularly'
p11568
(F1
F0.00076452599388379206
I1
I0
I1
tp11569
sS'affected,by,administration'
p11570
(F1
F0.00076452599388379206
I0
I1
I-1
tp11571
sS'conducted,in,normal'
p11572
(F1
F0.00076452599388379206
I0
I1
I-1
tp11573
sS'mg,tid,to'
p11574
(F1
F0.00076452599388379206
I1
I0
I1
tp11575
sS'opioid,analgesics,agonist'
p11576
(F1
F0.00076452599388379206
I1
I0
I1
tp11577
sS'ethynyl,pyridine,reduces'
p11578
(F1
F0.00076452599388379206
I0
I1
I-1
tp11579
sS'inhibitors,ssris,and'
p11580
(F1
F0.00076452599388379206
I0
I1
I-1
tp11581
sS'prolong,the,qtc'
p11582
(F1
F0.00076452599388379206
I0
I1
I-1
tp11583
sS'while,the,effects'
p11584
(F1
F0.00076452599388379206
I1
I0
I1
tp11585
sS'metabolized,by,cytochrome'
p11586
(F1
F0.00076452599388379206
I0
I1
I-1
tp11587
sS'levels,when,both'
p11588
(F1
F0.00076452599388379206
I1
I0
I1
tp11589
sS'present,study,was'
p11590
(F1
F0.00076452599388379206
I0
I1
I-1
tp11591
sS'between,proton,pump'
p11592
(F1
F0.00076452599388379206
I0
I1
I-1
tp11593
sS'the,gastrointestinal,effects'
p11594
(F1
F0.00076452599388379206
I0
I1
I-1
tp11595
sS'bioavailability,of,oral'
p11596
(F1
F0.00076452599388379206
I1
I0
I1
tp11597
sS'this,medication,tell'
p11598
(F1
F0.00076452599388379206
I0
I1
I-1
tp11599
sS'by,anti-vitamin,k'
p11600
(F1
F0.00076452599388379206
I1
I0
I1
tp11601
sS'hcl,mg,was'
p11602
(F1
F0.0015290519877675841
I0
I2
I-2
tp11603
sS'since,mexitil,is'
p11604
(F1
F0.00076452599388379206
I0
I1
I-1
tp11605
sS'cyclooxygenase-2,inhibitors,to'
p11606
(F1
F0.00076452599388379206
I0
I1
I-1
tp11607
sS'metabolized,through,hydrolysis'
p11608
(F1
F0.00076452599388379206
I0
I1
I-1
tp11609
sS'reduction,in,plasma'
p11610
(F1
F0.00076452599388379206
I1
I0
I1
tp11611
sS'with,the,absorption'
p11612
(F1
F0.0015290519877675841
I2
I0
I2
tp11613
sS'and,other,strong'
p11614
(F1
F0.00076452599388379206
I1
I0
I1
tp11615
sS'potential,for,invega'
p11616
(F1
F0.00076452599388379206
I0
I1
I-1
tp11617
sS'dose,of,has'
p11618
(F1
F0.00076452599388379206
I0
I1
I-1
tp11619
sS'and,potent,inhibitor'
p11620
(F1
F0.00076452599388379206
I1
I0
I1
tp11621
sS'diuretics,excessive,reductions'
p11622
(F1
F0.00076452599388379206
I0
I1
I-1
tp11623
sS'by,compared,to'
p11624
(F1
F0.00076452599388379206
I1
I0
I1
tp11625
sS'streptase,streptokinase,with'
p11626
(F1
F0.00076452599388379206
I0
I1
I-1
tp11627
sS'the,sensitivity,cell'
p11628
(F1
F0.00076452599388379206
I0
I1
I-1
tp11629
sS'show,that,does'
p11630
(F1
F0.00076452599388379206
I0
I1
I-1
tp11631
sS'other,drugs,that'
p11632
(F0.5
F0.0015290519877675841
I3
I1
I2
tp11633
sS'with,antiplatelet,agents'
p11634
(F1
F0.00076452599388379206
I1
I0
I1
tp11635
sS'be,enhanced,by'
p11636
(F1
F0.0015290519877675841
I2
I0
I2
tp11637
sS'minimize,cns,depression'
p11638
(F1
F0.00076452599388379206
I0
I1
I-1
tp11639
sS'other,thiazide-like,may'
p11640
(F1
F0.00076452599388379206
I1
I0
I1
tp11641
sS'of,but,did'
p11642
(F1
F0.00076452599388379206
I1
I0
I1
tp11643
sS'vs,but,does'
p11644
(F1
F0.00076452599388379206
I1
I0
I1
tp11645
sS'analgesic,agents,eg'
p11646
(F1
F0.00076452599388379206
I1
I0
I1
tp11647
sS'acid,sequestrates,or'
p11648
(F1
F0.00076452599388379206
I1
I0
I1
tp11649
sS'the,methyl-1,thiazol-4'
p11650
(F1
F0.00076452599388379206
I1
I0
I1
tp11651
sS'when,indicated,requires'
p11652
(F1
F0.00076452599388379206
I0
I1
I-1
tp11653
sS'used,only,with'
p11654
(F1
F0.0015290519877675841
I2
I0
I2
tp11655
sS'administered,to,chickens'
p11656
(F1
F0.00076452599388379206
I1
I0
I1
tp11657
sS'poor,metabolizers,see'
p11658
(F1
F0.00076452599388379206
I1
I0
I1
tp11659
sS'in,and,other'
p11660
(F1
F0.00076452599388379206
I1
I0
I1
tp11661
sS'parenteral,solutions,containing'
p11662
(F1
F0.00076452599388379206
I0
I1
I-1
tp11663
sS'monkeys,rendered,parkinsonian'
p11664
(F1
F0.00076452599388379206
I0
I1
I-1
tp11665
sS'digoxin,there,was'
p11666
(F1
F0.00076452599388379206
I1
I0
I1
tp11667
sS'isozymes,have,been'
p11668
(F1
F0.00076452599388379206
I1
I0
I1
tp11669
sS'for,drug,interactions'
p11670
(F1
F0.00076452599388379206
I1
I0
I1
tp11671
sS'pharmacokinetic,parameters,i'
p11672
(F1
F0.00076452599388379206
I1
I0
I1
tp11673
sS'of,the,effect'
p11674
(F1
F0.00076452599388379206
I0
I1
I-1
tp11675
sS'between,and,the'
p11676
(F1
F0.00076452599388379206
I1
I0
I1
tp11677
sS'cells,mcf7,following'
p11678
(F1
F0.00076452599388379206
I1
I0
I1
tp11679
sS'and,these,changes'
p11680
(F1
F0.00076452599388379206
I1
I0
I1
tp11681
sS'ml,the,mean'
p11682
(F1
F0.00076452599388379206
I1
I0
I1
tp11683
sS'of,oral,in'
p11684
(F1
F0.00076452599388379206
I1
I0
I1
tp11685
sS'changes,has,not'
p11686
(F1
F0.00076452599388379206
I1
I0
I1
tp11687
sS'other,drugs,on'
p11688
(F1
F0.00076452599388379206
I0
I1
I-1
tp11689
sS'to,maintain,a'
p11690
(F1
F0.00076452599388379206
I0
I1
I-1
tp11691
sS'p450,a,inhibitors'
p11692
(F1
F0.00076452599388379206
I1
I0
I1
tp11693
sS'out,in,the'
p11694
(F1
F0.00076452599388379206
I0
I1
I-1
tp11695
sS'all,possible,should'
p11696
(F1
F0.00076452599388379206
I1
I0
I1
tp11697
sS'the,duration,of'
p11698
(F1
F0.00076452599388379206
I1
I0
I1
tp11699
sS'monitored,particularly,when'
p11700
(F1
F0.00076452599388379206
I1
I0
I1
tp11701
sS'and,after,interaction'
p11702
(F1
F0.00076452599388379206
I0
I1
I-1
tp11703
sS'purported,to,be'
p11704
(F1
F0.00076452599388379206
I1
I0
I1
tp11705
sS'classes,of,drug'
p11706
(F1
F0.00076452599388379206
I0
I1
I-1
tp11707
sS'mg,day,but'
p11708
(F1
F0.00076452599388379206
I1
I0
I1
tp11709
sS'plasma,cholinesterase,activity'
p11710
(F1
F0.00076452599388379206
I1
I0
I1
tp11711
sS'events,in,patients'
p11712
(F1
F0.00076452599388379206
I1
I0
I1
tp11713
sS'the,high,renal'
p11714
(F1
F0.00076452599388379206
I1
I0
I1
tp11715
sS'elucidate,the,antitumor'
p11716
(F1
F0.00076452599388379206
I0
I1
I-1
tp11717
sS'vaccines,are,not'
p11718
(F1
F0.00076452599388379206
I1
I0
I1
tp11719
sS'and,carboptic,isopto'
p11720
(F1
F0.00076452599388379206
I1
I0
I1
tp11721
sS'receiving,or,other'
p11722
(F1
F0.00076452599388379206
I1
I0
I1
tp11723
sS'fecal,fat,excretion'
p11724
(F1
F0.00076452599388379206
I0
I1
I-1
tp11725
sS'megestrol,acetate,and'
p11726
(F1
F0.00076452599388379206
I1
I0
I1
tp11727
sS'methotrexate,a,study'
p11728
(F1
F0.00076452599388379206
I0
I1
I-1
tp11729
sS'in,prothrombin,times'
p11730
(F1
F0.00076452599388379206
I1
I0
I1
tp11731
sS'such,drugs,is'
p11732
(F1
F0.00076452599388379206
I0
I1
I-1
tp11733
sS'throughout,the,experiments'
p11734
(F1
F0.00076452599388379206
I0
I1
I-1
tp11735
sS'to,the,synergism'
p11736
(F1
F0.00076452599388379206
I1
I0
I1
tp11737
sS'spent,more,time'
p11738
(F1
F0.00076452599388379206
I0
I1
I-1
tp11739
sS'combined,administration,of'
p11740
(F1
F0.00076452599388379206
I1
I0
I1
tp11741
sS'are,at,an'
p11742
(F1
F0.00076452599388379206
I1
I0
I1
tp11743
sS'that,at,the'
p11744
(F1
F0.00076452599388379206
I0
I1
I-1
tp11745
sS'gastrointestinal,motility,anticholinergic'
p11746
(F1
F0.00076452599388379206
I1
I0
I1
tp11747
sS'interaction,oral,administration'
p11748
(F1
F0.00076452599388379206
I0
I1
I-1
tp11749
sS'of,oral,may'
p11750
(F1
F0.00076452599388379206
I1
I0
I1
tp11751
sS'agents,may,result'
p11752
(F1
F0.0015290519877675841
I2
I0
I2
tp11753
sS'have,not,been'
p11754
(F1
F0.0015290519877675841
I2
I0
I2
tp11755
sS'of,mg,m2'
p11756
(F1
F0.00076452599388379206
I1
I0
I1
tp11757
sS'demonstrate,qt,interval'
p11758
(F1
F0.00076452599388379206
I1
I0
I1
tp11759
sS'male,and,female'
p11760
(F1
F0.00076452599388379206
I0
I1
I-1
tp11761
sS'preliminary,evidence,suggests'
p11762
(F1
F0.00076452599388379206
I1
I0
I1
tp11763
sS'ganciclovir,may,be'
p11764
(F1
F0.00076452599388379206
I0
I1
I-1
tp11765
sS'were,vs,ml'
p11766
(F1
F0.00076452599388379206
I1
I0
I1
tp11767
sS't790m,mutation,and'
p11768
(F1
F0.00076452599388379206
I0
I1
I-1
tp11769
sS'potent,inhibitor,of'
p11770
(F0.33333333333333331
F0.00076452599388379206
I2
I1
I1
tp11771
sS'is,impaired,by'
p11772
(F1
F0.00076452599388379206
I1
I0
I1
tp11773
sS'binding,of,to'
p11774
(F1
F0.00076452599388379206
I0
I1
I-1
tp11775
sS'influence,the,delivery'
p11776
(F1
F0.00076452599388379206
I1
I0
I1
tp11777
sS'positive,control,at'
p11778
(F1
F0.00076452599388379206
I0
I1
I-1
tp11779
sS'of,dznep,insensitive'
p11780
(F1
F0.00076452599388379206
I1
I0
I1
tp11781
sS'the,delivery,of'
p11782
(F1
F0.00076452599388379206
I1
I0
I1
tp11783
sS'and,cdk1,suggest'
p11784
(F1
F0.00076452599388379206
I1
I0
I1
tp11785
sS'potential,to,convert'
p11786
(F1
F0.00076452599388379206
I0
I1
I-1
tp11787
sS'to,avoid,while'
p11788
(F1
F0.00076452599388379206
I1
I0
I1
tp11789
sS'with,similar,neuromuscular'
p11790
(F1
F0.00076452599388379206
I1
I0
I1
tp11791
sS'gi,ulceration,or'
p11792
(F1
F0.00076452599388379206
I1
I0
I1
tp11793
sS'achieving,adequate,sedation'
p11794
(F1
F0.00076452599388379206
I0
I1
I-1
tp11795
sS'the,interaction,of'
p11796
(F0.33333333333333331
F0.00076452599388379206
I1
I2
I-1
tp11797
sS'and,were,interpreted'
p11798
(F1
F0.00076452599388379206
I0
I1
I-1
tp11799
sS'oral,s-ketamine,is'
p11800
(F1
F0.00076452599388379206
I1
I0
I1
tp11801
sS'can,increase,serum'
p11802
(F1
F0.00076452599388379206
I0
I1
I-1
tp11803
sS'likely,to,have'
p11804
(F0
F0
I1
I1
I0
tp11805
sS'patients,for,other'
p11806
(F1
F0.00076452599388379206
I1
I0
I1
tp11807
sS'crisis,has,been'
p11808
(F1
F0.00076452599388379206
I1
I0
I1
tp11809
sS'compete,with,other'
p11810
(F1
F0.00076452599388379206
I1
I0
I1
tp11811
sS'gastrointestinal,bleeding,risk'
p11812
(F1
F0.00076452599388379206
I0
I1
I-1
tp11813
sS'physicians,should,carefully'
p11814
(F1
F0.00076452599388379206
I1
I0
I1
tp11815
sS'to,adding,to'
p11816
(F1
F0.00076452599388379206
I1
I0
I1
tp11817
sS'of,anticholinesterase,poisoning'
p11818
(F1
F0.00076452599388379206
I1
I0
I1
tp11819
sS'with,mg,of'
p11820
(F1
F0.00076452599388379206
I1
I0
I1
tp11821
sS'resulted,in,substantial'
p11822
(F1
F0.00076452599388379206
I1
I0
I1
tp11823
sS'by,the,subsequent'
p11824
(F1
F0.00076452599388379206
I1
I0
I1
tp11825
sS'and,of,ethinyl'
p11826
(F1
F0.00076452599388379206
I0
I1
I-1
tp11827
sS'that,may,alter'
p11828
(F1
F0.00076452599388379206
I0
I1
I-1
tp11829
sS'potassium-sparing,or,supplements'
p11830
(F1
F0.00076452599388379206
I1
I0
I1
tp11831
sS'renal,clearance,is'
p11832
(F1
F0.00076452599388379206
I1
I0
I1
tp11833
sS'coadministration,with,reduced'
p11834
(F1
F0.00076452599388379206
I1
I0
I1
tp11835
sS'tablets,in,normal-weight'
p11836
(F1
F0.00076452599388379206
I0
I1
I-1
tp11837
sS'in,either,pharmacokinetics'
p11838
(F1
F0.00076452599388379206
I0
I1
I-1
tp11839
sS'qrs,and,qt'
p11840
(F1
F0.00076452599388379206
I0
I1
I-1
tp11841
sS'initially,activated,by'
p11842
(F1
F0.00076452599388379206
I1
I0
I1
tp11843
sS'effect,on,deb'
p11844
(F1
F0.00076452599388379206
I1
I0
I1
tp11845
sS'asendin,sinequan,pamelor'
p11846
(F1
F0.00076452599388379206
I0
I1
I-1
tp11847
sS'antiplatelet,agents,streptase'
p11848
(F1
F0.00076452599388379206
I1
I0
I1
tp11849
sS'neonatal,treatment,on'
p11850
(F1
F0.00076452599388379206
I0
I1
I-1
tp11851
sS'to,infinity,auc'
p11852
(F1
F0.00076452599388379206
I1
I0
I1
tp11853
sS'mg,once,daily'
p11854
(F0.5
F0.0015290519877675841
I1
I3
I-2
tp11855
sS'nifedipine,extended-release,tablets'
p11856
(F1
F0.00076452599388379206
I0
I1
I-1
tp11857
sS'the,psychostimulant,drug'
p11858
(F1
F0.00076452599388379206
I0
I1
I-1
tp11859
sS'to,the,active'
p11860
(F1
F0.00076452599388379206
I0
I1
I-1
tp11861
sS'enzyme,inducers,such'
p11862
(F1
F0.0022935779816513763
I3
I0
I3
tp11863
sS'twice,daily,fro'
p11864
(F1
F0.00076452599388379206
I0
I1
I-1
tp11865
sS'plus,mg,kg'
p11866
(F1
F0.00076452599388379206
I0
I1
I-1
tp11867
sS'certain,may,induce'
p11868
(F1
F0.00076452599388379206
I1
I0
I1
tp11869
sS'of,causing,an'
p11870
(F1
F0.00076452599388379206
I1
I0
I1
tp11871
sS'excretion,or,systemic'
p11872
(F1
F0.00076452599388379206
I0
I1
I-1
tp11873
sS'these,two,classes'
p11874
(F1
F0.00076452599388379206
I0
I1
I-1
tp11875
sS'yielded,a,significant'
p11876
(F1
F0.00076452599388379206
I1
I0
I1
tp11877
sS'those,in,the'
p11878
(F1
F0.00076452599388379206
I0
I1
I-1
tp11879
sS'cholestyramine,concomitant,administration'
p11880
(F1
F0.00076452599388379206
I1
I0
I1
tp11881
sS'cyp2c19,a,cytochrome'
p11882
(F1
F0.00076452599388379206
I1
I0
I1
tp11883
sS'because,it,decreases'
p11884
(F1
F0.00076452599388379206
I0
I1
I-1
tp11885
sS'mutation,and,k-ras'
p11886
(F1
F0.00076452599388379206
I0
I1
I-1
tp11887
sS'been,demonstrated,in'
p11888
(F1
F0.00076452599388379206
I1
I0
I1
tp11889
sS'markedly,inhibits,the'
p11890
(F1
F0.00076452599388379206
I1
I0
I1
tp11891
sS'biotransformation,of,to'
p11892
(F1
F0.00076452599388379206
I0
I1
I-1
tp11893
sS'was,administered,one'
p11894
(F1
F0.00076452599388379206
I1
I0
I1
tp11895
sS'chloride,in,all'
p11896
(F1
F0.00076452599388379206
I0
I1
I-1
tp11897
sS'have,demonstrated,appropriateness'
p11898
(F1
F0.00076452599388379206
I1
I0
I1
tp11899
sS'aceon,tablets,may'
p11900
(F1
F0.00076452599388379206
I0
I1
I-1
tp11901
sS'study,in,rheumatoid'
p11902
(F1
F0.00076452599388379206
I0
I1
I-1
tp11903
sS'inhibit,the,cytochrome'
p11904
(F1
F0.00076452599388379206
I1
I0
I1
tp11905
sS'and,other,nonsteroidal'
p11906
(F1
F0.00076452599388379206
I1
I0
I1
tp11907
sS'drugs,that,may'
p11908
(F1
F0.00076452599388379206
I1
I0
I1
tp11909
sS'been,reported,confusion'
p11910
(F1
F0.00076452599388379206
I1
I0
I1
tp11911
sS'declining,renal,function'
p11912
(F1
F0.00076452599388379206
I1
I0
I1
tp11913
sS'child,was,taking'
p11914
(F1
F0.00076452599388379206
I0
I1
I-1
tp11915
sS'blocking,agents,has'
p11916
(F1
F0.00076452599388379206
I1
I0
I1
tp11917
sS'are,on,therapy'
p11918
(F1
F0.00076452599388379206
I1
I0
I1
tp11919
sS'the,incidence,of'
p11920
(F0.33333333333333331
F0.00076452599388379206
I2
I1
I1
tp11921
sS'however,and,this'
p11922
(F1
F0.00076452599388379206
I0
I1
I-1
tp11923
sS'isolated,rat,liver'
p11924
(F1
F0.00076452599388379206
I1
I0
I1
tp11925
sS'in,the,p'
p11926
(F0
F0
I1
I1
I0
tp11927
sS'considered,when,coadministering'
p11928
(F1
F0.00076452599388379206
I1
I0
I1
tp11929
sS'with,the,mtor'
p11930
(F1
F0.00076452599388379206
I1
I0
I1
tp11931
sS'other,strong,p450'
p11932
(F1
F0.00076452599388379206
I1
I0
I1
tp11933
sS'of,anesthesia,or'
p11934
(F1
F0.00076452599388379206
I1
I0
I1
tp11935
sS'on,coumarin-type,and'
p11936
(F1
F0.00076452599388379206
I1
I0
I1
tp11937
sS'tacrolimus-treated,patients,n'
p11938
(F1
F0.00076452599388379206
I0
I1
I-1
tp11939
sS'transduction,is,improved'
p11940
(F1
F0.00076452599388379206
I1
I0
I1
tp11941
sS'with,a,decrease'
p11942
(F0
F0
I1
I1
I0
tp11943
sS'via,renal,secretion'
p11944
(F1
F0.00076452599388379206
I1
I0
I1
tp11945
sS'post-mortem,stereological,counts'
p11946
(F1
F0.00076452599388379206
I1
I0
I1
tp11947
sS'therefore,should,be'
p11948
(F1
F0.0015290519877675841
I2
I0
I2
tp11949
sS'if,indicated,are'
p11950
(F1
F0.00076452599388379206
I1
I0
I1
tp11951
sS'increases,cytochrome,p450'
p11952
(F1
F0.00076452599388379206
I1
I0
I1
tp11953
sS'src,and,abl'
p11954
(F1
F0.00076452599388379206
I0
I1
I-1
tp11955
sS'on,and,especially'
p11956
(F1
F0.00076452599388379206
I1
I0
I1
tp11957
sS'mg,or,greater'
p11958
(F1
F0.00076452599388379206
I1
I0
I1
tp11959
sS'influence,the,intensity'
p11960
(F1
F0.00076452599388379206
I1
I0
I1
tp11961
sS'pending,full,characterization'
p11962
(F1
F0.00076452599388379206
I1
I0
I1
tp11963
sS'local,such,as'
p11964
(F1
F0.00076452599388379206
I0
I1
I-1
tp11965
sS'a,base,is'
p11966
(F1
F0.00076452599388379206
I1
I0
I1
tp11967
sS'are,used,with'
p11968
(F1
F0.00076452599388379206
I1
I0
I1
tp11969
sS'the,effects,of'
p11970
(F0.125
F0.0015290519877675841
I9
I7
I2
tp11971
sS'are,reports,of'
p11972
(F1
F0.0015290519877675841
I2
I0
I2
tp11973
sS'inr,or,pt'
p11974
(F1
F0.0015290519877675841
I2
I0
I2
tp11975
sS'agents,oxandrolone,may'
p11976
(F1
F0.00076452599388379206
I1
I0
I1
tp11977
sS'until,a,stable'
p11978
(F1
F0.00076452599388379206
I1
I0
I1
tp11979
sS'and,other,salicylate'
p11980
(F1
F0.00076452599388379206
I1
I0
I1
tp11981
sS'with,aceon,tablets'
p11982
(F1
F0.00076452599388379206
I1
I0
I1
tp11983
sS'effects,of,proamatine'
p11984
(F1
F0.0015290519877675841
I2
I0
I2
tp11985
sS'of,given,in'
p11986
(F1
F0.00076452599388379206
I0
I1
I-1
tp11987
sS'absorption,of,anticholinergic'
p11988
(F1
F0.00076452599388379206
I1
I0
I1
tp11989
sS'antimycotics,protease,inhibitors'
p11990
(F1
F0.00076452599388379206
I1
I0
I1
tp11991
sS'evaluate,the,effect'
p11992
(F1
F0.00076452599388379206
I0
I1
I-1
tp11993
sS'however,the,co'
p11994
(F1
F0.00076452599388379206
I1
I0
I1
tp11995
sS'mg,daily,with'
p11996
(F1
F0.00076452599388379206
I1
I0
I1
tp11997
sS'should,not,be'
p11998
(F0.81818181818181823
F0.0068807339449541288
I10
I1
I9
tp11999
sS'inhibition,on,clinical'
p12000
(F1
F0.00076452599388379206
I0
I1
I-1
tp12001
sS't,values,for'
p12002
(F1
F0.00076452599388379206
I1
I0
I1
tp12003
sS'the,standard,hormone'
p12004
(F1
F0.00076452599388379206
I0
I1
I-1
tp12005
sS'is,reduced,approximately'
p12006
(F1
F0.00076452599388379206
I0
I1
I-1
tp12007
sS'given,concomitantly,the'
p12008
(F1
F0.00076452599388379206
I1
I0
I1
tp12009
sS'cause,clinically,important'
p12010
(F1
F0.00076452599388379206
I0
I1
I-1
tp12011
sS'result,in,prolongation'
p12012
(F1
F0.00076452599388379206
I1
I0
I1
tp12013
sS'with,mg,day'
p12014
(F1
F0.00076452599388379206
I1
I0
I1
tp12015
sS'to,fu,and'
p12016
(F1
F0.00076452599388379206
I0
I1
I-1
tp12017
sS'tartrate,on,the'
p12018
(F1
F0.00076452599388379206
I0
I1
I-1
tp12019
sS'coadministration,of,evista'
p12020
(F1
F0.00076452599388379206
I0
I1
I-1
tp12021
sS'hydroxide,and,did'
p12022
(F1
F0.00076452599388379206
I0
I1
I-1
tp12023
sS'inhibit,the,absorption'
p12024
(F1
F0.00076452599388379206
I0
I1
I-1
tp12025
sS'remeron,has,been'
p12026
(F1
F0.00076452599388379206
I1
I0
I1
tp12027
sS'of,ovarian,cancer'
p12028
(F1
F0.00076452599388379206
I1
I0
I1
tp12029
sS'were,used,in'
p12030
(F1
F0.00076452599388379206
I0
I1
I-1
tp12031
sS'oral,clearance,increased'
p12032
(F1
F0.00076452599388379206
I1
I0
I1
tp12033
sS'in,which,a'
p12034
(F1
F0.00076452599388379206
I1
I0
I1
tp12035
sS'control,sirna,vs'
p12036
(F1
F0.00076452599388379206
I0
I1
I-1
tp12037
sS'relationship,between,lamisil'
p12038
(F1
F0.00076452599388379206
I1
I0
I1
tp12039
sS'caution,is,advised'
p12040
(F1
F0.0015290519877675841
I2
I0
I2
tp12041
sS'inefficacy,of,treatment'
p12042
(F1
F0.00076452599388379206
I1
I0
I1
tp12043
sS'invega,to,affect'
p12044
(F1
F0.00076452599388379206
I0
I1
I-1
tp12045
sS'topical,application,in'
p12046
(F1
F0.00076452599388379206
I0
I1
I-1
tp12047
sS'of,remeron,soltab'
p12048
(F1
F0.0015290519877675841
I0
I2
I-2
tp12049
sS'reported,rarely,to'
p12050
(F1
F0.00076452599388379206
I1
I0
I1
tp12051
sS'cases,which,respond'
p12052
(F1
F0.00076452599388379206
I0
I1
I-1
tp12053
sS'with,interaction,studies'
p12054
(F1
F0.00076452599388379206
I1
I0
I1
tp12055
sS'such,as,other'
p12056
(F1
F0.00076452599388379206
I1
I0
I1
tp12057
sS'ci,or,ci'
p12058
(F1
F0.00076452599388379206
I1
I0
I1
tp12059
sS'coadministered,coadministration,of'
p12060
(F1
F0.00076452599388379206
I1
I0
I1
tp12061
sS'or,drugs,used'
p12062
(F1
F0.00076452599388379206
I0
I1
I-1
tp12063
sS'electroretinograms,survived,with'
p12064
(F1
F0.00076452599388379206
I0
I1
I-1
tp12065
sS'hot,plate,or'
p12066
(F1
F0.00076452599388379206
I0
I1
I-1
tp12067
sS'such,as,acetylsalicylic'
p12068
(F1
F0.00076452599388379206
I1
I0
I1
tp12069
sS'symptoms,whereas,none'
p12070
(F1
F0.00076452599388379206
I1
I0
I1
tp12071
sS'g,and,weekly'
p12072
(F1
F0.0015290519877675841
I0
I2
I-2
tp12073
sS'o,as,well'
p12074
(F1
F0.00076452599388379206
I0
I1
I-1
tp12075
sS'control,seizures,such'
p12076
(F1
F0.00076452599388379206
I0
I1
I-1
tp12077
sS'outcome,in,clopidogrel-treated'
p12078
(F1
F0.00076452599388379206
I0
I1
I-1
tp12079
sS'mg,qid,can'
p12080
(F1
F0.00076452599388379206
I1
I0
I1
tp12081
sS'recur,in,any'
p12082
(F1
F0.00076452599388379206
I0
I1
I-1
tp12083
sS'exposed,to,followed'
p12084
(F1
F0.00076452599388379206
I1
I0
I1
tp12085
sS'and,drugs,without'
p12086
(F1
F0.00076452599388379206
I0
I1
I-1
tp12087
sS'drugs,and,other'
p12088
(F1
F0.00076452599388379206
I1
I0
I1
tp12089
sS'oral,clinically,significant'
p12090
(F1
F0.00076452599388379206
I1
I0
I1
tp12091
sS'suggest,that,gh'
p12092
(F1
F0.00076452599388379206
I1
I0
I1
tp12093
sS'drugs,to,affect'
p12094
(F1
F0.00076452599388379206
I0
I1
I-1
tp12095
sS'program,mexitil,has'
p12096
(F1
F0.00076452599388379206
I0
I1
I-1
tp12097
sS'in,day,treatment'
p12098
(F1
F0.00076452599388379206
I0
I1
I-1
tp12099
sS'to,whom,and'
p12100
(F1
F0.0022935779816513763
I3
I0
I3
tp12101
sS'should,carefully,monitor'
p12102
(F1
F0.00076452599388379206
I1
I0
I1
tp12103
sS'compared,to,use'
p12104
(F1
F0.00076452599388379206
I1
I0
I1
tp12105
sS'of,s-adenosylhomocysteine,adohcy'
p12106
(F1
F0.00076452599388379206
I0
I1
I-1
tp12107
sS'after,caused,a'
p12108
(F1
F0.00076452599388379206
I1
I0
I1
tp12109
sS'that,of,concurrent'
p12110
(F1
F0.00076452599388379206
I0
I1
I-1
tp12111
sS'noted,using,a'
p12112
(F1
F0.00076452599388379206
I0
I1
I-1
tp12113
sS'of,and,other'
p12114
(F1
F0.0022935779816513763
I3
I0
I3
tp12115
sS'hr,ml,similar'
p12116
(F1
F0.00076452599388379206
I1
I0
I1
tp12117
sS'anticholinergic,properties,may'
p12118
(F1
F0.00076452599388379206
I0
I1
I-1
tp12119
sS'due,to,the'
p12120
(F1
F0.0015290519877675841
I2
I0
I2
tp12121
sS'aerosol,bronchodilators,should'
p12122
(F1
F0.0015290519877675841
I2
I0
I2
tp12123
sS'and,can,be'
p12124
(F1
F0.00076452599388379206
I1
I0
I1
tp12125
sS'well,as,post-marketing'
p12126
(F1
F0.00076452599388379206
I1
I0
I1
tp12127
sS'particular,caution,in'
p12128
(F1
F0.00076452599388379206
I1
I0
I1
tp12129
sS'were,conducted,in'
p12130
(F1
F0.00076452599388379206
I0
I1
I-1
tp12131
sS'such,as,wine'
p12132
(F1
F0.00076452599388379206
I1
I0
I1
tp12133
sS'of,g,and'
p12134
(F1
F0.00076452599388379206
I0
I1
I-1
tp12135
sS'interaction,studies,indicate'
p12136
(F1
F0.00076452599388379206
I1
I0
I1
tp12137
sS'women,on,oral'
p12138
(F1
F0.00076452599388379206
I1
I0
I1
tp12139
sS'low-dose,and,total'
p12140
(F1
F0.00076452599388379206
I0
I1
I-1
tp12141
sS'interactions,with,other'
p12142
(F1
F0.00076452599388379206
I1
I0
I1
tp12143
sS'concomitantly,as,anorexia'
p12144
(F1
F0.00076452599388379206
I1
I0
I1
tp12145
sS'may,be,diminished'
p12146
(F1
F0.00076452599388379206
I1
I0
I1
tp12147
sS'appears,possible,although'
p12148
(F1
F0.00076452599388379206
I1
I0
I1
tp12149
sS'concentration,profile,of'
p12150
(F1
F0.0015290519877675841
I0
I2
I-2
tp12151
sS'study,evaluated,the'
p12152
(F1
F0.00076452599388379206
I0
I1
I-1
tp12153
sS'from,limited,in'
p12154
(F1
F0.00076452599388379206
I0
I1
I-1
tp12155
sS'group,vehicle,group'
p12156
(F1
F0.00076452599388379206
I0
I1
I-1
tp12157
sS'treatment,all,methyl-4'
p12158
(F1
F0.00076452599388379206
I1
I0
I1
tp12159
sS'of,neurotoxin,methyl-4'
p12160
(F1
F0.00076452599388379206
I0
I1
I-1
tp12161
sS'its,binding,site'
p12162
(F1
F0.00076452599388379206
I0
I1
I-1
tp12163
sS'chondroitin,abc,lyase'
p12164
(F1
F0.0015290519877675841
I0
I2
I-2
tp12165
sS'in,the,locus'
p12166
(F1
F0.00076452599388379206
I1
I0
I1
tp12167
sS'a,broad,range'
p12168
(F1
F0.00076452599388379206
I0
I1
I-1
tp12169
sS'interactions,between,flomax'
p12170
(F1
F0.00076452599388379206
I0
I1
I-1
tp12171
sS'not,known,at'
p12172
(F1
F0.00076452599388379206
I0
I1
I-1
tp12173
sS'gsls,on,the'
p12174
(F1
F0.00076452599388379206
I0
I1
I-1
tp12175
sS'compared,to,and'
p12176
(F1
F0.00076452599388379206
I1
I0
I1
tp12177
sS'single,dose,containing'
p12178
(F1
F0.00076452599388379206
I0
I1
I-1
tp12179
sS'fixed,combination,in'
p12180
(F1
F0.00076452599388379206
I0
I1
I-1
tp12181
sS'barbiturates,tricyclic,antidepressants'
p12182
(F1
F0.00076452599388379206
I1
I0
I1
tp12183
sS'experimental,evidence,that'
p12184
(F1
F0.00076452599388379206
I1
I0
I1
tp12185
sS'reduce,the,anti-resorptive'
p12186
(F1
F0.00076452599388379206
I1
I0
I1
tp12187
sS'function,in,women'
p12188
(F1
F0.00076452599388379206
I1
I0
I1
tp12189
sS'slight,but,significant'
p12190
(F1
F0.00076452599388379206
I1
I0
I1
tp12191
sS'decrease,bioavailability,of'
p12192
(F1
F0.00076452599388379206
I1
I0
I1
tp12193
sS'result,in,an'
p12194
(F1
F0.0022935779816513763
I3
I0
I3
tp12195
sS'that,the,metabolism'
p12196
(F1
F0.00076452599388379206
I0
I1
I-1
tp12197
sS'of,nondepolarizing,neuromuscular'
p12198
(F1
F0.00076452599388379206
I1
I0
I1
tp12199
sS'to,one,month'
p12200
(F1
F0.00076452599388379206
I1
I0
I1
tp12201
sS'is,metabolized,by'
p12202
(F1
F0.0015290519877675841
I0
I2
I-2
tp12203
sS'agents,eg,and'
p12204
(F1
F0.0015290519877675841
I0
I2
I-2
tp12205
sS'taking,concomitant,with'
p12206
(F1
F0.00076452599388379206
I1
I0
I1
tp12207
sS'heme,at,doses'
p12208
(F1
F0.00076452599388379206
I0
I1
I-1
tp12209
sS'in,vasospasm,leading'
p12210
(F1
F0.00076452599388379206
I0
I1
I-1
tp12211
sS'nsclc,cell,lines'
p12212
(F0.5
F0.0015290519877675841
I1
I3
I-2
tp12213
sS'mg,did,not'
p12214
(F1
F0.00076452599388379206
I0
I1
I-1
tp12215
sS'hormone,pth,levels'
p12216
(F1
F0.00076452599388379206
I0
I1
I-1
tp12217
sS'toxicity,has,also'
p12218
(F1
F0.00076452599388379206
I1
I0
I1
tp12219
sS'the,records,of'
p12220
(F1
F0.00076452599388379206
I0
I1
I-1
tp12221
sS'of,and,ethinyl'
p12222
(F1
F0.00076452599388379206
I0
I1
I-1
tp12223
sS'although,specific,drug'
p12224
(F1
F0.00076452599388379206
I1
I0
I1
tp12225
sS'formalin,test,when'
p12226
(F1
F0.00076452599388379206
I1
I0
I1
tp12227
sS'that,nsaids,may'
p12228
(F1
F0.00076452599388379206
I1
I0
I1
tp12229
sS'reported,with,concomitant'
p12230
(F1
F0.0015290519877675841
I2
I0
I2
tp12231
sS'salicylates,and,other'
p12232
(F1
F0.00076452599388379206
I1
I0
I1
tp12233
sS'used,neuromuscular,blocking'
p12234
(F1
F0.00076452599388379206
I0
I1
I-1
tp12235
sS'prescribed,for,patients'
p12236
(F1
F0.00076452599388379206
I0
I1
I-1
tp12237
sS'phenothiazines,other,tranquilizers'
p12238
(F1
F0.00076452599388379206
I1
I0
I1
tp12239
sS'for,may,be'
p12240
(F1
F0.00076452599388379206
I1
I0
I1
tp12241
sS'avoid,and,other'
p12242
(F1
F0.00076452599388379206
I1
I0
I1
tp12243
sS'arrhythmia,including,torsades'
p12244
(F1
F0.00076452599388379206
I0
I1
I-1
tp12245
sS'well,as,other'
p12246
(F1
F0.00076452599388379206
I1
I0
I1
tp12247
sS'of,absorption,of'
p12248
(F1
F0.00076452599388379206
I1
I0
I1
tp12249
sS'up,to,one'
p12250
(F1
F0.00076452599388379206
I1
I0
I1
tp12251
sS'isolated,effect,of'
p12252
(F1
F0.00076452599388379206
I1
I0
I1
tp12253
sS'benzodiazepines,which,are'
p12254
(F1
F0.00076452599388379206
I1
I0
I1
tp12255
sS'clinical,effects,of'
p12256
(F1
F0.00076452599388379206
I0
I1
I-1
tp12257
sS'in,a,reduction'
p12258
(F0
F0
I1
I1
I0
tp12259
sS'oxidase,inhibitor,maoi'
p12260
(F1
F0.00076452599388379206
I1
I0
I1
tp12261
sS'indicating,that,at'
p12262
(F1
F0.00076452599388379206
I0
I1
I-1
tp12263
sS'with,inducers,of'
p12264
(F1
F0.00076452599388379206
I1
I0
I1
tp12265
sS'a,promising,oral'
p12266
(F1
F0.00076452599388379206
I0
I1
I-1
tp12267
sS'metabolize,some,other'
p12268
(F1
F0.00076452599388379206
I1
I0
I1
tp12269
sS'following,co-administration,with'
p12270
(F1
F0.00076452599388379206
I0
I1
I-1
tp12271
sS'daily,increased,geometric'
p12272
(F1
F0.00076452599388379206
I1
I0
I1
tp12273
sS'and,cdk1,expression'
p12274
(F1
F0.00076452599388379206
I0
I1
I-1
tp12275
sS'inhibited,at,relevant'
p12276
(F1
F0.00076452599388379206
I1
I0
I1
tp12277
sS'following,and,its'
p12278
(F1
F0.00076452599388379206
I0
I1
I-1
tp12279
sS'the,depressant,effects'
p12280
(F1
F0.00076452599388379206
I1
I0
I1
tp12281
sS'concurrently,with,other'
p12282
(F1
F0.00076452599388379206
I1
I0
I1
tp12283
sS'require,dose,reductions'
p12284
(F1
F0.00076452599388379206
I1
I0
I1
tp12285
sS'in,vitro,did'
p12286
(F1
F0.0015290519877675841
I0
I2
I-2
tp12287
sS'n,than,in'
p12288
(F1
F0.00076452599388379206
I1
I0
I1
tp12289
sS'british,national,formulary'
p12290
(F1
F0.00076452599388379206
I0
I1
I-1
tp12291
sS'associated,with,increased'
p12292
(F1
F0.00076452599388379206
I0
I1
I-1
tp12293
sS'decreased,metabolite,levels'
p12294
(F1
F0.00076452599388379206
I1
I0
I1
tp12295
sS'observations,have,shown'
p12296
(F1
F0.00076452599388379206
I1
I0
I1
tp12297
sS'short,elimination,half-lives'
p12298
(F1
F0.00076452599388379206
I1
I0
I1
tp12299
sS'without,causing,sedation'
p12300
(F1
F0.00076452599388379206
I1
I0
I1
tp12301
sS'fat-soluble,vitamin,supplements'
p12302
(F1
F0.00076452599388379206
I1
I0
I1
tp12303
sS'plasma,concentrations,were'
p12304
(F1
F0.00076452599388379206
I1
I0
I1
tp12305
sS'antitumor,effects,of'
p12306
(F1
F0.00076452599388379206
I0
I1
I-1
tp12307
sS'flomax,capsules,and'
p12308
(F1
F0.00076452599388379206
I0
I1
I-1
tp12309
sS'dose,of,on'
p12310
(F1
F0.00076452599388379206
I0
I1
I-1
tp12311
sS'acid,may,influence'
p12312
(F1
F0.00076452599388379206
I1
I0
I1
tp12313
sS'study,mean,auc'
p12314
(F1
F0.00076452599388379206
I1
I0
I1
tp12315
sS'similar,agents,since'
p12316
(F1
F0.00076452599388379206
I1
I0
I1
tp12317
sS'patients,evaluated,the'
p12318
(F1
F0.00076452599388379206
I0
I1
I-1
tp12319
sS'in,patients,concomitantly'
p12320
(F0
F0
I1
I1
I0
tp12321
sS'since,the,combination'
p12322
(F1
F0.00076452599388379206
I1
I0
I1
tp12323
sS'woman,on,therapy'
p12324
(F1
F0.0015290519877675841
I2
I0
I2
tp12325
sS'phenytoin,in,normal-weight'
p12326
(F1
F0.00076452599388379206
I0
I1
I-1
tp12327
sS'drug,interactions,women'
p12328
(F1
F0.00076452599388379206
I1
I0
I1
tp12329
sS'and,auc,t'
p12330
(F1
F0.00076452599388379206
I1
I0
I1
tp12331
sS'and,or,severity'
p12332
(F1
F0.0015290519877675841
I2
I0
I2
tp12333
sS'and,elimination,are'
p12334
(F1
F0.00076452599388379206
I0
I1
I-1
tp12335
sS'interval,ci,to'
p12336
(F1
F0.00076452599388379206
I1
I0
I1
tp12337
sS'juice,may,inhibit'
p12338
(F1
F0.00076452599388379206
I1
I0
I1
tp12339
sS'urinary,retention,and'
p12340
(F1
F0.00076452599388379206
I1
I0
I1
tp12341
sS'with,oral,alkeran'
p12342
(F1
F0.00076452599388379206
I1
I0
I1
tp12343
sS'care,must,be'
p12344
(F1
F0.00076452599388379206
I1
I0
I1
tp12345
sS'decrease,the,antihypertensive'
p12346
(F1
F0.00076452599388379206
I1
I0
I1
tp12347
sS'the,mean,area'
p12348
(F1
F0.00076452599388379206
I1
I0
I1
tp12349
sS'pointes,and,elevated'
p12350
(F1
F0.00076452599388379206
I1
I0
I1
tp12351
sS'kg,significantly,increased'
p12352
(F1
F0.00076452599388379206
I1
I0
I1
tp12353
sS'food,does,not'
p12354
(F1
F0.00076452599388379206
I0
I1
I-1
tp12355
sS'three,doses,and'
p12356
(F1
F0.00076452599388379206
I0
I1
I-1
tp12357
sS'tunel,assay,sirna'
p12358
(F1
F0.00076452599388379206
I0
I1
I-1
tp12359
sS'eloxatin,and,infusional'
p12360
(F1
F0.00076452599388379206
I0
I1
I-1
tp12361
sS'the,impairment,of'
p12362
(F1
F0.0015290519877675841
I2
I0
I2
tp12363
sS'digoxin,meloxicam,mg'
p12364
(F1
F0.00076452599388379206
I0
I1
I-1
tp12365
sS'the,or,may'
p12366
(F1
F0.00076452599388379206
I1
I0
I1
tp12367
sS'an,inr,international'
p12368
(F1
F0.00076452599388379206
I0
I1
I-1
tp12369
sS'concentrations,when,coadministered'
p12370
(F1
F0.00076452599388379206
I1
I0
I1
tp12371
sS'dose,of,detrol'
p12372
(F1
F0.00076452599388379206
I1
I0
I1
tp12373
sS'was,observed,between'
p12374
(F0
F0
I1
I1
I0
tp12375
sS'tritec,with,resulted'
p12376
(F1
F0.00076452599388379206
I1
I0
I1
tp12377
sS'that,and,mycophenolate'
p12378
(F1
F0.00076452599388379206
I1
I0
I1
tp12379
sS'expression,and,sirna'
p12380
(F1
F0.00076452599388379206
I1
I0
I1
tp12381
sS'diflucan,taken,in'
p12382
(F1
F0.00076452599388379206
I1
I0
I1
tp12383
sS'vehicle,were,performed'
p12384
(F1
F0.00076452599388379206
I0
I1
I-1
tp12385
sS'chemotherapeutic,agents,radiotherapy'
p12386
(F1
F0.00076452599388379206
I0
I1
I-1
tp12387
sS'be,used,concurrently'
p12388
(F1
F0.00076452599388379206
I1
I0
I1
tp12389
sS'or,concurrent,use'
p12390
(F1
F0.00076452599388379206
I1
I0
I1
tp12391
sS'administered,concurrently,may'
p12392
(F1
F0.00076452599388379206
I1
I0
I1
tp12393
sS'avoid,giving,class'
p12394
(F1
F0.00076452599388379206
I1
I0
I1
tp12395
sS'and,that,of'
p12396
(F1
F0.00076452599388379206
I0
I1
I-1
tp12397
sS'an,infant,with'
p12398
(F1
F0.00076452599388379206
I1
I0
I1
tp12399
sS'neurons,as,well'
p12400
(F1
F0.00076452599388379206
I1
I0
I1
tp12401
sS'and,other,sedating'
p12402
(F1
F0.00076452599388379206
I1
I0
I1
tp12403
sS'the,or,on'
p12404
(F1
F0.00076452599388379206
I0
I1
I-1
tp12405
sS'prolongation,of,the'
p12406
(F1
F0.00076452599388379206
I1
I0
I1
tp12407
sS'of,bradycardia,was'
p12408
(F1
F0.00076452599388379206
I1
I0
I1
tp12409
sS'fewer,colonies,than'
p12410
(F1
F0.00076452599388379206
I1
I0
I1
tp12411
sS'the,sedative,effect'
p12412
(F1
F0.00076452599388379206
I1
I0
I1
tp12413
sS'effectiveness,of,the'
p12414
(F1
F0.0015290519877675841
I2
I0
I2
tp12415
sS'potential,for,increased'
p12416
(F1
F0.0015290519877675841
I2
I0
I2
tp12417
sS'a,slight,increase'
p12418
(F1
F0.00076452599388379206
I1
I0
I1
tp12419
sS'as,compared,to'
p12420
(F1
F0.00076452599388379206
I1
I0
I1
tp12421
sS'each,other,should'
p12422
(F1
F0.00076452599388379206
I1
I0
I1
tp12423
sS'or,certain,herbal'
p12424
(F1
F0.00076452599388379206
I0
I1
I-1
tp12425
sS'indicate,that,markedly'
p12426
(F1
F0.00076452599388379206
I1
I0
I1
tp12427
sS'reported,to,increase'
p12428
(F1
F0.0015290519877675841
I2
I0
I2
tp12429
sS'drugs,eliminated,by'
p12430
(F1
F0.00076452599388379206
I1
I0
I1
tp12431
sS'n,n,nonsteroidal'
p12432
(F1
F0.00076452599388379206
I0
I1
I-1
tp12433
sS'application,of,ointment'
p12434
(F1
F0.00076452599388379206
I1
I0
I1
tp12435
sS'close,monitoring,of'
p12436
(F1
F0.00076452599388379206
I0
I1
I-1
tp12437
sS'b,polymyxin,b'
p12438
(F1
F0.00076452599388379206
I0
I1
I-1
tp12439
sS'increased,systemic,toxicity'
p12440
(F1
F0.00076452599388379206
I1
I0
I1
tp12441
sS'we,retrospectively,reviewed'
p12442
(F1
F0.00076452599388379206
I0
I1
I-1
tp12443
sS'pretreatment,for,four'
p12444
(F1
F0.00076452599388379206
I1
I0
I1
tp12445
sS'levels,nonsteroidal,anti-inflammatory'
p12446
(F1
F0.00076452599388379206
I1
I0
I1
tp12447
sS'are,recommended,when'
p12448
(F1
F0.00076452599388379206
I1
I0
I1
tp12449
sS'and,decreased,the'
p12450
(F1
F0.00076452599388379206
I1
I0
I1
tp12451
sS'in,a,drug-drug'
p12452
(F0
F0
I1
I1
I0
tp12453
sS'to,either,or'
p12454
(F1
F0.00076452599388379206
I0
I1
I-1
tp12455
sS'for,pain,medicines'
p12456
(F1
F0.00076452599388379206
I0
I1
I-1
tp12457
sS'digitalis,glycoside,regimen'
p12458
(F1
F0.00076452599388379206
I0
I1
I-1
tp12459
sS'effect,would,be'
p12460
(F1
F0.00076452599388379206
I1
I0
I1
tp12461
sS'acetazolamide,concurrent,use'
p12462
(F1
F0.00076452599388379206
I1
I0
I1
tp12463
sS'drugs,may,interfere'
p12464
(F1
F0.00076452599388379206
I1
I0
I1
tp12465
sS'gastrointestinal,bleeding,have'
p12466
(F1
F0.00076452599388379206
I1
I0
I1
tp12467
sS'or,side,effects'
p12468
(F1
F0.00076452599388379206
I1
I0
I1
tp12469
sS'reported,that,combined'
p12470
(F1
F0.00076452599388379206
I1
I0
I1
tp12471
sS'and,may,cause'
p12472
(F1
F0.0015290519877675841
I2
I0
I2
tp12473
sS'compounds,to,potentially'
p12474
(F1
F0.00076452599388379206
I1
I0
I1
tp12475
sS'increasing,the,dose'
p12476
(F1
F0.00076452599388379206
I1
I0
I1
tp12477
sS'antiplatelet,agents,and'
p12478
(F1
F0.00076452599388379206
I1
I0
I1
tp12479
sS'and,elevated,temperature'
p12480
(F1
F0.00076452599388379206
I1
I0
I1
tp12481
sS'noted,when,was'
p12482
(F1
F0.00076452599388379206
I1
I0
I1
tp12483
sS'a,suitable,chemosensitizer'
p12484
(F1
F0.00076452599388379206
I0
I1
I-1
tp12485
sS'of,extracellular,matrix'
p12486
(F1
F0.00076452599388379206
I0
I1
I-1
tp12487
sS'with,and,mobic'
p12488
(F1
F0.00076452599388379206
I1
I0
I1
tp12489
sS'cell,lines,hela'
p12490
(F1
F0.00076452599388379206
I0
I1
I-1
tp12491
sS'ketoconazole,an,inhibitor'
p12492
(F1
F0.00076452599388379206
I1
I0
I1
tp12493
sS'enhance,toxicity,by'
p12494
(F1
F0.00076452599388379206
I1
I0
I1
tp12495
sS'of,by,about'
p12496
(F1
F0.00076452599388379206
I1
I0
I1
tp12497
sS'invega,paliperidone,is'
p12498
(F1
F0.00076452599388379206
I0
I1
I-1
tp12499
sS'prolongation,and,or'
p12500
(F1
F0.00076452599388379206
I1
I0
I1
tp12501
sS'it,is,possible'
p12502
(F1
F0.0015290519877675841
I2
I0
I2
tp12503
sS'activity,patients,who'
p12504
(F1
F0.00076452599388379206
I1
I0
I1
tp12505
sS'before,initiation,of'
p12506
(F1
F0.00076452599388379206
I0
I1
I-1
tp12507
sS'of,methyl-4,phenyl-1'
p12508
(F1
F0.00076452599388379206
I1
I0
I1
tp12509
sS'coadministration,of,and'
p12510
(F1
F0.00076452599388379206
I1
I0
I1
tp12511
sS'and,serum,creatinine'
p12512
(F1
F0.00076452599388379206
I1
I0
I1
tp12513
sS'which,respond,to'
p12514
(F1
F0.00076452599388379206
I0
I1
I-1
tp12515
sS'the,finding,that'
p12516
(F1
F0.00076452599388379206
I1
I0
I1
tp12517
sS'adjusted,as,necessary'
p12518
(F1
F0.00076452599388379206
I1
I0
I1
tp12519
sS'not,a,potent'
p12520
(F1
F0.00076452599388379206
I0
I1
I-1
tp12521
sS'interactions,for,vitamin'
p12522
(F1
F0.0015290519877675841
I2
I0
I2
tp12523
sS'as,necessary,until'
p12524
(F1
F0.00076452599388379206
I1
I0
I1
tp12525
sS'intravitreal,injection,to'
p12526
(F1
F0.00076452599388379206
I0
I1
I-1
tp12527
sS'rifampin,enhances,the'
p12528
(F1
F0.00076452599388379206
I1
I0
I1
tp12529
sS'when,administering,nexavar'
p12530
(F1
F0.00076452599388379206
I1
I0
I1
tp12531
sS'cns,toxicity,has'
p12532
(F1
F0.00076452599388379206
I1
I0
I1
tp12533
sS'sinequan,pamelor,tofranil'
p12534
(F1
F0.00076452599388379206
I0
I1
I-1
tp12535
sS'bronchodilators,and,oral'
p12536
(F1
F0.00076452599388379206
I0
I1
I-1
tp12537
sS'of,serum,concentrations'
p12538
(F1
F0.00076452599388379206
I1
I0
I1
tp12539
sS'performed,in,the'
p12540
(F1
F0.00076452599388379206
I0
I1
I-1
tp12541
sS'the,potential,to'
p12542
(F0.33333333333333331
F0.00076452599388379206
I2
I1
I1
tp12543
sS'the,efficacy,of'
p12544
(F1
F0.00076452599388379206
I0
I1
I-1
tp12545
sS'metabolism,of,concurrently'
p12546
(F1
F0.00076452599388379206
I1
I0
I1
tp12547
sS'anti-parkinsonian,drug,adamantyl'
p12548
(F1
F0.00076452599388379206
I0
I1
I-1
tp12549
sS'certain,cases,an'
p12550
(F1
F0.00076452599388379206
I1
I0
I1
tp12551
sS'of,any,of'
p12552
(F1
F0.00076452599388379206
I0
I1
I-1
tp12553
sS'nervous,system,depressants'
p12554
(F1
F0.0022935779816513763
I3
I0
I3
tp12555
sS'plasma,concentration-time,curve'
p12556
(F1
F0.00076452599388379206
I1
I0
I1
tp12557
sS'subjects,and,seven'
p12558
(F1
F0.00076452599388379206
I1
I0
I1
tp12559
sS'decreased,the,mean'
p12560
(F1
F0.00076452599388379206
I1
I0
I1
tp12561
sS'use,decreases,gastrointestinal'
p12562
(F1
F0.00076452599388379206
I1
I0
I1
tp12563
sS'which,was,potentiated'
p12564
(F1
F0.00076452599388379206
I1
I0
I1
tp12565
sS'female,controls,conditioned'
p12566
(F1
F0.00076452599388379206
I0
I1
I-1
tp12567
sS'symptoms,in,either'
p12568
(F1
F0.00076452599388379206
I0
I1
I-1
tp12569
sS'drug-metabolizing,enzymes,cyp3a4'
p12570
(F1
F0.00076452599388379206
I0
I1
I-1
tp12571
sS'adjustments,for,are'
p12572
(F1
F0.00076452599388379206
I0
I1
I-1
tp12573
sS'observed,closely,for'
p12574
(F1
F0.00076452599388379206
I1
I0
I1
tp12575
sS'pressor,agent,for'
p12576
(F1
F0.00076452599388379206
I1
I0
I1
tp12577
sS'no,drug,interaction'
p12578
(F1
F0.00076452599388379206
I0
I1
I-1
tp12579
sS'receiving,concomitant,and'
p12580
(F1
F0.00076452599388379206
I0
I1
I-1
tp12581
sS'locomotor,inhibitory,effect'
p12582
(F1
F0.00076452599388379206
I1
I0
I1
tp12583
sS'enterohepatic,cycling,of'
p12584
(F1
F0.00076452599388379206
I1
I0
I1
tp12585
sS'not,demonstrated,a'
p12586
(F1
F0.00076452599388379206
I0
I1
I-1
tp12587
sS'studies,demonstrate,a'
p12588
(F1
F0.00076452599388379206
I1
I0
I1
tp12589
sS'adults,was,reduced'
p12590
(F1
F0.00076452599388379206
I1
I0
I1
tp12591
sS'with,type,mao'
p12592
(F1
F0.00076452599388379206
I1
I0
I1
tp12593
sS'while,in,vitro'
p12594
(F1
F0.00076452599388379206
I0
I1
I-1
tp12595
sS'concomitantly,taking,oral'
p12596
(F1
F0.00076452599388379206
I1
I0
I1
tp12597
sS'inhibitor,of,cytochrome'
p12598
(F1
F0.0015290519877675841
I2
I0
I2
tp12599
sS'case,of,an'
p12600
(F1
F0.0015290519877675841
I2
I0
I2
tp12601
sS'h2,blockers,oral'
p12602
(F1
F0.00076452599388379206
I0
I1
I-1
tp12603
sS'between,flomax,capsules'
p12604
(F1
F0.00076452599388379206
I0
I1
I-1
tp12605
sS'cross-resistance,between,purinethol'
p12606
(F1
F0.00076452599388379206
I1
I0
I1
tp12607
sS'test,when,it'
p12608
(F1
F0.00076452599388379206
I1
I0
I1
tp12609
sS'administering,mobic,with'
p12610
(F1
F0.00076452599388379206
I1
I0
I1
tp12611
sS'oral,clearance,were'
p12612
(F1
F0.00076452599388379206
I1
I0
I1
tp12613
sS'be,exercised,if'
p12614
(F1
F0.00076452599388379206
I0
I1
I-1
tp12615
sS'of,by,slowing'
p12616
(F1
F0.00076452599388379206
I1
I0
I1
tp12617
sS'coadministration,of,a'
p12618
(F1
F0.00076452599388379206
I1
I0
I1
tp12619
sS'drugs,where,gastric'
p12620
(F1
F0.00076452599388379206
I1
I0
I1
tp12621
sS'in,vivo,cyp3a'
p12622
(F1
F0.00076452599388379206
I0
I1
I-1
tp12623
sS'rendered,parkinsonian,by'
p12624
(F1
F0.00076452599388379206
I0
I1
I-1
tp12625
sS'with,mg,qd'
p12626
(F1
F0.00076452599388379206
I1
I0
I1
tp12627
sS'clearance,of,this'
p12628
(F1
F0.00076452599388379206
I1
I0
I1
tp12629
sS'of,and,was'
p12630
(F1
F0.00076452599388379206
I1
I0
I1
tp12631
sS'pump,inhibitors,including'
p12632
(F1
F0.00076452599388379206
I1
I0
I1
tp12633
sS'is,unaffected,by'
p12634
(F0
F0
I1
I1
I0
tp12635
sS'in,reduced,dosage'
p12636
(F1
F0.00076452599388379206
I1
I0
I1
tp12637
sS'pk,analysis,with'
p12638
(F1
F0.00076452599388379206
I0
I1
I-1
tp12639
sS'large,compassionate,use'
p12640
(F1
F0.00076452599388379206
I0
I1
I-1
tp12641
sS'those,secreted,by'
p12642
(F1
F0.00076452599388379206
I1
I0
I1
tp12643
sS'enhanced,as,well'
p12644
(F1
F0.0015290519877675841
I2
I0
I2
tp12645
sS'genentech,beta,agonists'
p12646
(F1
F0.00076452599388379206
I1
I0
I1
tp12647
sS'concomitantly,with,depo-subq'
p12648
(F1
F0.00076452599388379206
I1
I0
I1
tp12649
sS'formulations,of,recombinant'
p12650
(F1
F0.00076452599388379206
I1
I0
I1
tp12651
sS'this,was,associated'
p12652
(F1
F0.00076452599388379206
I0
I1
I-1
tp12653
sS'anticholinesterase,poisoning,although'
p12654
(F1
F0.00076452599388379206
I1
I0
I1
tp12655
sS'objective,of,the'
p12656
(F1
F0.00076452599388379206
I0
I1
I-1
tp12657
sS'and,must,be'
p12658
(F1
F0.00076452599388379206
I0
I1
I-1
tp12659
sS'may,be,hazardous'
p12660
(F1
F0.00076452599388379206
I1
I0
I1
tp12661
sS'cell,groups,whereas'
p12662
(F1
F0.00076452599388379206
I1
I0
I1
tp12663
sS'and,were,randomized'
p12664
(F1
F0.00076452599388379206
I0
I1
I-1
tp12665
sS'cytochrome,p450,cyp'
p12666
(F1
F0.00076452599388379206
I0
I1
I-1
tp12667
sS'one,case,to'
p12668
(F1
F0.00076452599388379206
I1
I0
I1
tp12669
sS'combination,of,abt-737'
p12670
(F1
F0.00076452599388379206
I1
I0
I1
tp12671
sS'combination,with,particularly'
p12672
(F1
F0.00076452599388379206
I1
I0
I1
tp12673
sS'day,study,of'
p12674
(F1
F0.00076452599388379206
I0
I1
I-1
tp12675
sS'steroid,medications,certain'
p12676
(F1
F0.00076452599388379206
I1
I0
I1
tp12677
sS'sanctura,with,drugs'
p12678
(F1
F0.00076452599388379206
I0
I1
I-1
tp12679
sS'and,are,likely'
p12680
(F1
F0.00076452599388379206
I1
I0
I1
tp12681
sS'animals,than,in'
p12682
(F1
F0.00076452599388379206
I1
I0
I1
tp12683
sS'of,mg,nonheme'
p12684
(F1
F0.00076452599388379206
I0
I1
I-1
tp12685
sS'inr,in,patients'
p12686
(F1
F0.00076452599388379206
I1
I0
I1
tp12687
sS'drugs,may,have'
p12688
(F1
F0.0015290519877675841
I2
I0
I2
tp12689
sS'exposed,to,either'
p12690
(F1
F0.00076452599388379206
I0
I1
I-1
tp12691
sS'having,tubal,pregnancies'
p12692
(F1
F0.00076452599388379206
I1
I0
I1
tp12693
sS'anti-proliferative,effects,in'
p12694
(F1
F0.00076452599388379206
I1
I0
I1
tp12695
sS'be,minimized,by'
p12696
(F0
F0
I1
I1
I0
tp12697
sS'gastrointestinal,absorption,of'
p12698
(F1
F0.00076452599388379206
I1
I0
I1
tp12699
sS'when,therapy,is'
p12700
(F1
F0.00076452599388379206
I1
I0
I1
tp12701
sS'myocardial,infarction,in'
p12702
(F1
F0.00076452599388379206
I0
I1
I-1
tp12703
sS'after,a,mg'
p12704
(F1
F0.00076452599388379206
I0
I1
I-1
tp12705
sS'plasma,prothrombin,activity'
p12706
(F1
F0.00076452599388379206
I1
I0
I1
tp12707
sS'cimetidine,concomitant,administration'
p12708
(F1
F0.00076452599388379206
I0
I1
I-1
tp12709
sS'anabolic,may,increase'
p12710
(F1
F0.00076452599388379206
I1
I0
I1
tp12711
sS'spontaneous,recovery,from'
p12712
(F1
F0.00076452599388379206
I1
I0
I1
tp12713
sS'mouth,constipation,somnolence'
p12714
(F1
F0.00076452599388379206
I1
I0
I1
tp12715
sS'substitute,for,for'
p12716
(F1
F0.00076452599388379206
I0
I1
I-1
tp12717
sS'leave,unchanged,mexitil'
p12718
(F1
F0.00076452599388379206
I1
I0
I1
tp12719
sS'for,active,tubular'
p12720
(F1
F0.00076452599388379206
I1
I0
I1
tp12721
sS'it,should,be'
p12722
(F1
F0.00076452599388379206
I1
I0
I1
tp12723
sS'depressants,including,general'
p12724
(F1
F0.00076452599388379206
I0
I1
I-1
tp12725
sS'that,the,dosage'
p12726
(F1
F0.00076452599388379206
I1
I0
I1
tp12727
sS'kg,day,times'
p12728
(F1
F0.0015290519877675841
I0
I2
I-2
tp12729
sS'administered,safely,following'
p12730
(F1
F0.00076452599388379206
I0
I1
I-1
tp12731
sS'human,plasma,proteins'
p12732
(F1
F0.00076452599388379206
I0
I1
I-1
tp12733
sS'imidazole,drugs,were'
p12734
(F1
F0.00076452599388379206
I1
I0
I1
tp12735
sS'to,patients,taking'
p12736
(F1
F0.00076452599388379206
I1
I0
I1
tp12737
sS'agents,structurally,related'
p12738
(F1
F0.00076452599388379206
I1
I0
I1
tp12739
sS'with,increased,the'
p12740
(F1
F0.00076452599388379206
I1
I0
I1
tp12741
sS'g,kg,and'
p12742
(F1
F0.00076452599388379206
I0
I1
I-1
tp12743
sS'oxycodone,hydrochloride,may'
p12744
(F1
F0.00076452599388379206
I1
I0
I1
tp12745
sS'a,multiple,dose'
p12746
(F1
F0.00076452599388379206
I1
I0
I1
tp12747
sS'of,increasing,serum'
p12748
(F1
F0.00076452599388379206
I0
I1
I-1
tp12749
sS'antibody,response,to'
p12750
(F1
F0.00076452599388379206
I1
I0
I1
tp12751
sS'methscopolamine,may,interact'
p12752
(F1
F0.00076452599388379206
I1
I0
I1
tp12753
sS'agents,such,as'
p12754
(F1
F0.0030581039755351682
I4
I0
I4
tp12755
sS'the,clearance,and'
p12756
(F1
F0.00076452599388379206
I0
I1
I-1
tp12757
sS'one,controlled,study'
p12758
(F1
F0.00076452599388379206
I1
I0
I1
tp12759
sS'grams,of,approximately'
p12760
(F1
F0.00076452599388379206
I0
I1
I-1
tp12761
sS'any,clinically,significant'
p12762
(F1
F0.00076452599388379206
I0
I1
I-1
tp12763
sS'from,that,of'
p12764
(F1
F0.00076452599388379206
I1
I0
I1
tp12765
sS'ticlopidine,treatment,increased'
p12766
(F1
F0.00076452599388379206
I1
I0
I1
tp12767
sS'superior,to,followed'
p12768
(F1
F0.00076452599388379206
I1
I0
I1
tp12769
sS'inhibitors,narcotic,analgesics'
p12770
(F1
F0.00076452599388379206
I1
I0
I1
tp12771
sS'reduced,the,peak'
p12772
(F1
F0.00076452599388379206
I1
I0
I1
tp12773
sS'metastatic,breast,cancer'
p12774
(F1
F0.00076452599388379206
I1
I0
I1
tp12775
sS'least,two,hours'
p12776
(F1
F0.00076452599388379206
I1
I0
I1
tp12777
sS'poor,metabolizers,of'
p12778
(F1
F0.00076452599388379206
I0
I1
I-1
tp12779
sS'with,should,be'
p12780
(F1
F0.00076452599388379206
I1
I0
I1
tp12781
sS'doses,of,g'
p12782
(F1
F0.0015290519877675841
I0
I2
I-2
tp12783
sS'forced,swimming,test'
p12784
(F1
F0.00076452599388379206
I0
I1
I-1
tp12785
sS'the,second,day'
p12786
(F1
F0.00076452599388379206
I1
I0
I1
tp12787
sS'chemosensitizer,for,breast'
p12788
(F1
F0.00076452599388379206
I0
I1
I-1
tp12789
sS'has,not,occurred'
p12790
(F1
F0.00076452599388379206
I1
I0
I1
tp12791
sS'patients,who,have'
p12792
(F1
F0.00076452599388379206
I1
I0
I1
tp12793
sS'from,this,study'
p12794
(F1
F0.00076452599388379206
I1
I0
I1
tp12795
sS'which,is,not'
p12796
(F1
F0.00076452599388379206
I1
I0
I1
tp12797
sS'we,demonstrated,an'
p12798
(F1
F0.00076452599388379206
I1
I0
I1
tp12799
sS'combination,was,studied'
p12800
(F1
F0.00076452599388379206
I0
I1
I-1
tp12801
sS'recommended,in,patients'
p12802
(F1
F0.00076452599388379206
I1
I0
I1
tp12803
sS'cell,surface,expression'
p12804
(F1
F0.00076452599388379206
I0
I1
I-1
tp12805
sS'fibrosis,leading,to'
p12806
(F1
F0.00076452599388379206
I0
I1
I-1
tp12807
sS'for,weeks,was'
p12808
(F1
F0.00076452599388379206
I1
I0
I1
tp12809
sS'in,the,hot'
p12810
(F1
F0.00076452599388379206
I1
I0
I1
tp12811
sS'recombinant,human,immediately'
p12812
(F1
F0.00076452599388379206
I1
I0
I1
tp12813
sS'similar,to,those'
p12814
(F1
F0.00076452599388379206
I0
I1
I-1
tp12815
sS'agents,and,without'
p12816
(F1
F0.00076452599388379206
I0
I1
I-1
tp12817
sS'advised,that,vaccinations'
p12818
(F1
F0.00076452599388379206
I1
I0
I1
tp12819
sS'contraceptives,concomitant,use'
p12820
(F1
F0.00076452599388379206
I0
I1
I-1
tp12821
sS'not,affected,by'
p12822
(F1
F0.0022935779816513763
I0
I3
I-3
tp12823
sS'also,tubularly,secreted'
p12824
(F1
F0.00076452599388379206
I1
I0
I1
tp12825
sS'the,antihypertensive,effect'
p12826
(F1
F0.00076452599388379206
I1
I0
I1
tp12827
sS'potent,cyp,a4'
p12828
(F1
F0.0015290519877675841
I0
I2
I-2
tp12829
sS'epistaxis,gastrointestinal,bleeding'
p12830
(F1
F0.00076452599388379206
I1
I0
I1
tp12831
sS'the,mechanism,of'
p12832
(F1
F0.00076452599388379206
I1
I0
I1
tp12833
sS'sympathomimetics,metolazone,may'
p12834
(F1
F0.00076452599388379206
I1
I0
I1
tp12835
sS'apoptosis,compared,with'
p12836
(F1
F0.00076452599388379206
I0
I1
I-1
tp12837
sS'but,an,increase'
p12838
(F1
F0.00076452599388379206
I1
I0
I1
tp12839
sS'the,level,of'
p12840
(F1
F0.00076452599388379206
I0
I1
I-1
tp12841
sS'lead,to,decreased'
p12842
(F1
F0.0015290519877675841
I2
I0
I2
tp12843
sS'revealed,the,child'
p12844
(F1
F0.00076452599388379206
I0
I1
I-1
tp12845
sS'sequential,administrations,of'
p12846
(F1
F0.00076452599388379206
I1
I0
I1
tp12847
sS'plasma,concentrations,by'
p12848
(F1
F0.00076452599388379206
I1
I0
I1
tp12849
sS'per,mouse,vs'
p12850
(F1
F0.00076452599388379206
I1
I0
I1
tp12851
sS'to,parent,compound'
p12852
(F1
F0.00076452599388379206
I1
I0
I1
tp12853
sS'to,a,decrease'
p12854
(F1
F0.00076452599388379206
I1
I0
I1
tp12855
sS'potentiated,in,patients'
p12856
(F1
F0.0015290519877675841
I2
I0
I2
tp12857
sS'not,be,administered'
p12858
(F1
F0.0030581039755351682
I4
I0
I4
tp12859
sS'used,as,a'
p12860
(F1
F0.00076452599388379206
I1
I0
I1
tp12861
sS'always,require,drug'
p12862
(F1
F0.00076452599388379206
I0
I1
I-1
tp12863
sS'first,dose,of'
p12864
(F1
F0.00076452599388379206
I1
I0
I1
tp12865
sS'are,metabolized,eliminated'
p12866
(F1
F0.00076452599388379206
I1
I0
I1
tp12867
sS'symptoms,of,toxicity'
p12868
(F0
F0
I1
I1
I0
tp12869
sS'antiplatelets,after,treatment'
p12870
(F1
F0.00076452599388379206
I0
I1
I-1
tp12871
sS'screening,tests,for'
p12872
(F1
F0.00076452599388379206
I0
I1
I-1
tp12873
sS'concomitantly,with,drugs'
p12874
(F1
F0.0015290519877675841
I2
I0
I2
tp12875
sS'daily,based,on'
p12876
(F1
F0.0030581039755351682
I0
I4
I-4
tp12877
sS'p,and,vs'
p12878
(F1
F0.00076452599388379206
I1
I0
I1
tp12879
sS'was,studied,in'
p12880
(F1
F0.0022935779816513763
I0
I3
I-3
tp12881
sS'and,in,a'
p12882
(F1
F0.00076452599388379206
I1
I0
I1
tp12883
sS'a6,c9,cl9'
p12884
(F1
F0.00076452599388379206
I0
I1
I-1
tp12885
sS'accentuate,the,orthostatic'
p12886
(F1
F0.00076452599388379206
I1
I0
I1
tp12887
sS'by,hepatic,cyp3a'
p12888
(F1
F0.00076452599388379206
I1
I0
I1
tp12889
sS'of,has,not'
p12890
(F0.33333333333333331
F0.00076452599388379206
I1
I2
I-1
tp12891
sS'and,death,have'
p12892
(F1
F0.00076452599388379206
I1
I0
I1
tp12893
sS'to,mg,bid'
p12894
(F1
F0.00076452599388379206
I1
I0
I1
tp12895
sS'hormone,replacement,therapies'
p12896
(F1
F0.00076452599388379206
I0
I1
I-1
tp12897
sS'weekly,for,weeks'
p12898
(F1
F0.00076452599388379206
I1
I0
I1
tp12899
sS'reports,of,patients'
p12900
(F1
F0.00076452599388379206
I1
I0
I1
tp12901
sS'based,on,this'
p12902
(F1
F0.00076452599388379206
I1
I0
I1
tp12903
sS'can,reduce,the'
p12904
(F1
F0.00076452599388379206
I1
I0
I1
tp12905
sS'herceptin,resulted,in'
p12906
(F1
F0.00076452599388379206
I1
I0
I1
tp12907
sS'poisoning,although,they'
p12908
(F1
F0.00076452599388379206
I1
I0
I1
tp12909
sS'of,and,with'
p12910
(F1
F0.00076452599388379206
I0
I1
I-1
tp12911
sS'monitored,when,mobic'
p12912
(F1
F0.00076452599388379206
I1
I0
I1
tp12913
sS'and,and,increases'
p12914
(F1
F0.00076452599388379206
I1
I0
I1
tp12915
sS'co-administration,of,mg'
p12916
(F1
F0.00076452599388379206
I1
I0
I1
tp12917
sS'with,other,agents'
p12918
(F1
F0.0015290519877675841
I2
I0
I2
tp12919
sS'with,for,active'
p12920
(F1
F0.00076452599388379206
I1
I0
I1
tp12921
sS'the,toxic,effects'
p12922
(F1
F0.00076452599388379206
I1
I0
I1
tp12923
sS'formed,fewer,colonies'
p12924
(F1
F0.00076452599388379206
I1
I0
I1
tp12925
sS'conclusive,evidence,of'
p12926
(F1
F0.00076452599388379206
I0
I1
I-1
tp12927
sS'less,mpa,available'
p12928
(F1
F0.00076452599388379206
I0
I1
I-1
tp12929
sS'require,increased,in'
p12930
(F1
F0.00076452599388379206
I1
I0
I1
tp12931
sS'oral,and,however'
p12932
(F1
F0.00076452599388379206
I1
I0
I1
tp12933
sS'of,biotransformation,of'
p12934
(F1
F0.00076452599388379206
I0
I1
I-1
tp12935
sS'pheochromocytoma,by,those'
p12936
(F1
F0.00076452599388379206
I0
I1
I-1
tp12937
sS'antidiabetic,agents,and'
p12938
(F1
F0.00076452599388379206
I0
I1
I-1
tp12939
sS'substantial,increases,in'
p12940
(F1
F0.00076452599388379206
I1
I0
I1
tp12941
sS'was,no,effect'
p12942
(F1
F0.00076452599388379206
I0
I1
I-1
tp12943
sS'patients,took,variable'
p12944
(F1
F0.00076452599388379206
I1
I0
I1
tp12945
sS'interrupt,dosing,for'
p12946
(F1
F0.00076452599388379206
I1
I0
I1
tp12947
sS'aspirin,should,be'
p12948
(F1
F0.0015290519877675841
I2
I0
I2
tp12949
sS'different,metabolism,of'
p12950
(F1
F0.00076452599388379206
I0
I1
I-1
tp12951
sS'not,be,treated'
p12952
(F1
F0.00076452599388379206
I1
I0
I1
tp12953
sS'by,and,respectively'
p12954
(F1
F0.00076452599388379206
I1
I0
I1
tp12955
sS'brilinta-astrazeneca,an,oral'
p12956
(F1
F0.00076452599388379206
I1
I0
I1
tp12957
sS'or,the,recommended'
p12958
(F1
F0.00076452599388379206
I1
I0
I1
tp12959
sS'preclude,effectiveness,of'
p12960
(F1
F0.00076452599388379206
I1
I0
I1
tp12961
sS'in,addition,to'
p12962
(F1
F0.00076452599388379206
I1
I0
I1
tp12963
sS'not,recommended,in'
p12964
(F1
F0.00076452599388379206
I1
I0
I1
tp12965
sS'considering,the,variability'
p12966
(F1
F0.00076452599388379206
I0
I1
I-1
tp12967
sS'such,as,for'
p12968
(F1
F0.00076452599388379206
I1
I0
I1
tp12969
sS'pilocarpine,should,be'
p12970
(F1
F0.00076452599388379206
I1
I0
I1
tp12971
sS'hepatic,microsomal,enzyme'
p12972
(F1
F0.00076452599388379206
I1
I0
I1
tp12973
sS'in,vitro,studies'
p12974
(F0.59999999999999998
F0.0022935779816513763
I1
I4
I-3
tp12975
sS'motor,symptoms,in'
p12976
(F1
F0.00076452599388379206
I0
I1
I-1
tp12977
sS'in,combining,with'
p12978
(F1
F0.00076452599388379206
I1
I0
I1
tp12979
sS'microsomal,enzyme,induction'
p12980
(F1
F0.00076452599388379206
I1
I0
I1
tp12981
sS'a,group,of'
p12982
(F1
F0.00076452599388379206
I0
I1
I-1
tp12983
sS'the,action,of'
p12984
(F1
F0.0045871559633027525
I6
I0
I6
tp12985
sS'vaccines,during,treatment'
p12986
(F1
F0.00076452599388379206
I1
I0
I1
tp12987
sS'of,drugs,for'
p12988
(F1
F0.00076452599388379206
I1
I0
I1
tp12989
sS'immune,responses,to'
p12990
(F1
F0.00076452599388379206
I0
I1
I-1
tp12991
sS'pyridine-treated,monkeys,were'
p12992
(F1
F0.00076452599388379206
I1
I0
I1
tp12993
sS'by,cyp1a2,via'
p12994
(F1
F0.00076452599388379206
I0
I1
I-1
tp12995
sS'and,cyp2c19,so'
p12996
(F1
F0.00076452599388379206
I0
I1
I-1
tp12997
sS'of,muscle,relaxants'
p12998
(F1
F0.00076452599388379206
I0
I1
I-1
tp12999
sS'risk,of,gi'
p13000
(F1
F0.00076452599388379206
I1
I0
I1
tp13001
sS'was,administered,alone'
p13002
(F1
F0.00076452599388379206
I1
I0
I1
tp13003
sS'in,treating,urinary'
p13004
(F1
F0.00076452599388379206
I0
I1
I-1
tp13005
sS'patients,on,a'
p13006
(F1
F0.0015290519877675841
I0
I2
I-2
tp13007
sS'history,of,ea'
p13008
(F1
F0.00076452599388379206
I1
I0
I1
tp13009
sS'by,slowing,the'
p13010
(F1
F0.00076452599388379206
I1
I0
I1
tp13011
sS'in,vitro,data'
p13012
(F1
F0.00076452599388379206
I1
I0
I1
tp13013
sS'cimetidine,a,known'
p13014
(F1
F0.00076452599388379206
I1
I0
I1
tp13015
sS'immunoreactivity,which,were'
p13016
(F1
F0.00076452599388379206
I1
I0
I1
tp13017
sS'results,from,limited'
p13018
(F1
F0.00076452599388379206
I0
I1
I-1
tp13019
sS'any,concomitantly,administered'
p13020
(F1
F0.00076452599388379206
I1
I0
I1
tp13021
sS'use,of,these'
p13022
(F1
F0.0022935779816513763
I3
I0
I3
tp13023
sS'the,qt,prolonging'
p13024
(F1
F0.00076452599388379206
I0
I1
I-1
tp13025
sS'mao,inhibitors,the'
p13026
(F1
F0.0015290519877675841
I2
I0
I2
tp13027
sS'depression,apnea,seizures'
p13028
(F1
F0.00076452599388379206
I1
I0
I1
tp13029
sS'terbinafine,decreases,the'
p13030
(F1
F0.00076452599388379206
I1
I0
I1
tp13031
sS'herceptin,in,her2-positive'
p13032
(F1
F0.00076452599388379206
I0
I1
I-1
tp13033
sS'transplant,patients,who'
p13034
(F1
F0.00076452599388379206
I1
I0
I1
tp13035
sS'and,others,supplements'
p13036
(F1
F0.00076452599388379206
I0
I1
I-1
tp13037
sS'hospitalized,in,departments'
p13038
(F1
F0.00076452599388379206
I0
I1
I-1
tp13039
sS'auc,of,were'
p13040
(F1
F0.00076452599388379206
I1
I0
I1
tp13041
sS'parkinsonian,by,chronic'
p13042
(F1
F0.00076452599388379206
I0
I1
I-1
tp13043
sS'was,to,establish'
p13044
(F1
F0.00076452599388379206
I0
I1
I-1
tp13045
sS'diflucan,with,oral'
p13046
(F1
F0.00076452599388379206
I1
I0
I1
tp13047
sS'prolongation,with,ventricular'
p13048
(F1
F0.00076452599388379206
I0
I1
I-1
tp13049
sS'treatment,with,myfortic'
p13050
(F1
F0.00076452599388379206
I1
I0
I1
tp13051
sS'p,mouse,leukemia'
p13052
(F1
F0.00076452599388379206
I1
I0
I1
tp13053
sS'the,qtc,interval'
p13054
(F0
F0
I1
I1
I0
tp13055
sS'appropriateness,of,inhospital'
p13056
(F1
F0.00076452599388379206
I1
I0
I1
tp13057
sS'in,a,multiple-dose'
p13058
(F1
F0.00076452599388379206
I0
I1
I-1
tp13059
sS'of,which,blocks'
p13060
(F1
F0.00076452599388379206
I1
I0
I1
tp13061
sS'with,potent,inducers'
p13062
(F1
F0.00076452599388379206
I1
I0
I1
tp13063
sS'the,dose,should'
p13064
(F1
F0.00076452599388379206
I0
I1
I-1
tp13065
sS'lesser,number,of'
p13066
(F1
F0.00076452599388379206
I1
I0
I1
tp13067
sS'cysteine,with,but'
p13068
(F1
F0.00076452599388379206
I0
I1
I-1
tp13069
sS'when,administered,to'
p13070
(F1
F0.00076452599388379206
I1
I0
I1
tp13071
sS'depression,which,could'
p13072
(F1
F0.00076452599388379206
I1
I0
I1
tp13073
sS'studied,in,acute'
p13074
(F1
F0.00076452599388379206
I0
I1
I-1
tp13075
sS'bleeding,compared,to'
p13076
(F1
F0.00076452599388379206
I1
I0
I1
tp13077
sS'steady,state,dosing'
p13078
(F1
F0.00076452599388379206
I0
I1
I-1
tp13079
sS'may,render,oral'
p13080
(F1
F0.0015290519877675841
I2
I0
I2
tp13081
sS'enzymes,the,concomitant'
p13082
(F1
F0.00076452599388379206
I0
I1
I-1
tp13083
sS'anti-inflammatory,drugs,may'
p13084
(F1
F0.00076452599388379206
I1
I0
I1
tp13085
sS'deaths,in,children'
p13086
(F1
F0.00076452599388379206
I1
I0
I1
tp13087
sS'metabolized,by,hepatic'
p13088
(F1
F0.00076452599388379206
I0
I1
I-1
tp13089
sS'study,demonstrated,that'
p13090
(F1
F0.0015290519877675841
I2
I0
I2
tp13091
sS'of,and,thus'
p13092
(F1
F0.0015290519877675841
I2
I0
I2
tp13093
sS'the,order,of'
p13094
(F1
F0.00076452599388379206
I0
I1
I-1
tp13095
sS'low,systemic,exposure'
p13096
(F1
F0.0015290519877675841
I0
I2
I-2
tp13097
sS'and,has,not'
p13098
(F1
F0.0015290519877675841
I0
I2
I-2
tp13099
sS'kip1,sirna,vs'
p13100
(F1
F0.00076452599388379206
I0
I1
I-1
tp13101
sS'of,bleeding,and'
p13102
(F1
F0.00076452599388379206
I1
I0
I1
tp13103
sS'nose,may,occur'
p13104
(F1
F0.00076452599388379206
I1
I0
I1
tp13105
sS'started,recently,may'
p13106
(F1
F0.00076452599388379206
I1
I0
I1
tp13107
sS'with,peg-intron,once'
p13108
(F1
F0.00076452599388379206
I1
I0
I1
tp13109
sS'subjects,studied,and'
p13110
(F1
F0.00076452599388379206
I1
I0
I1
tp13111
sS'the,metabolic,pathways'
p13112
(F1
F0.00076452599388379206
I0
I1
I-1
tp13113
sS'the,positive,control'
p13114
(F1
F0.00076452599388379206
I0
I1
I-1
tp13115
sS'pyridine,versus,methyl-4'
p13116
(F1
F0.00076452599388379206
I0
I1
I-1
tp13117
sS'week,dietary,carcinogenicity'
p13118
(F1
F0.0015290519877675841
I0
I2
I-2
tp13119
sS'de,pointes,in'
p13120
(F1
F0.00076452599388379206
I1
I0
I1
tp13121
sS'in,an,in'
p13122
(F1
F0.00076452599388379206
I1
I0
I1
tp13123
sS'receiving,certain,primarily'
p13124
(F1
F0.00076452599388379206
I0
I1
I-1
tp13125
sS'of,or,failed'
p13126
(F1
F0.00076452599388379206
I1
I0
I1
tp13127
sS'succinate,tablets,in'
p13128
(F1
F0.00076452599388379206
I1
I0
I1
tp13129
sS'of,these,enzymes'
p13130
(F1
F0.0022935779816513763
I0
I3
I-3
tp13131
sS'mixed,effects,on'
p13132
(F1
F0.00076452599388379206
I0
I1
I-1
tp13133
sS'xenical,and,grams'
p13134
(F1
F0.00076452599388379206
I0
I1
I-1
tp13135
sS'reduce,the,tubular'
p13136
(F1
F0.00076452599388379206
I1
I0
I1
tp13137
sS'confirmed,congenital,hypothyroidism'
p13138
(F1
F0.00076452599388379206
I1
I0
I1
tp13139
sS'in,rabbits,treated'
p13140
(F1
F0.00076452599388379206
I0
I1
I-1
tp13141
sS'respectively,lower,rate'
p13142
(F1
F0.00076452599388379206
I1
I0
I1
tp13143
sS'on,who,experienced'
p13144
(F1
F0.00076452599388379206
I1
I0
I1
tp13145
sS'the,small,number'
p13146
(F1
F0.00076452599388379206
I1
I0
I1
tp13147
sS'caused,deaths,in'
p13148
(F1
F0.00076452599388379206
I1
I0
I1
tp13149
sS'auc,of,approximately'
p13150
(F1
F0.0015290519877675841
I0
I2
I-2
tp13151
sS'partially,metabolized,by'
p13152
(F1
F0.00076452599388379206
I1
I0
I1
tp13153
sS'inhibitors,there,have'
p13154
(F1
F0.00076452599388379206
I0
I1
I-1
tp13155
sS'agitation,and,elevated'
p13156
(F1
F0.00076452599388379206
I1
I0
I1
tp13157
sS'myfortic,and,not'
p13158
(F1
F0.00076452599388379206
I1
I0
I1
tp13159
sS'nevertheless,during,concomitant'
p13160
(F1
F0.00076452599388379206
I1
I0
I1
tp13161
sS'post-marketing,observations,have'
p13162
(F1
F0.00076452599388379206
I1
I0
I1
tp13163
sS'found,in,locus'
p13164
(F1
F0.00076452599388379206
I1
I0
I1
tp13165
sS'target,bp,in'
p13166
(F1
F0.00076452599388379206
I1
I0
I1
tp13167
sS'we,sought,to'
p13168
(F1
F0.00076452599388379206
I0
I1
I-1
tp13169
sS'inhibitor,of,cyp3a4'
p13170
(F1
F0.00076452599388379206
I1
I0
I1
tp13171
sS'is,usually,complete'
p13172
(F1
F0.00076452599388379206
I1
I0
I1
tp13173
sS'on,therapy,resulting'
p13174
(F1
F0.00076452599388379206
I1
I0
I1
tp13175
sS'concentrations,should,be'
p13176
(F1
F0.0015290519877675841
I2
I0
I2
tp13177
sS'inhibition,curve,of'
p13178
(F1
F0.00076452599388379206
I0
I1
I-1
tp13179
sS'metabolizers,of,cyp2d6'
p13180
(F1
F0.00076452599388379206
I0
I1
I-1
tp13181
sS'intravenous,dose,of'
p13182
(F1
F0.00076452599388379206
I0
I1
I-1
tp13183
sS'values,in,methyl-4'
p13184
(F1
F0.00076452599388379206
I1
I0
I1
tp13185
sS'and,thus,decrease'
p13186
(F1
F0.0015290519877675841
I2
I0
I2
tp13187
sS'taking,magnesium-aluminum,containing'
p13188
(F1
F0.00076452599388379206
I1
I0
I1
tp13189
sS'on,plasma,levels'
p13190
(F1
F0.0022935779816513763
I3
I0
I3
tp13191
sS'a,day,yielded'
p13192
(F1
F0.00076452599388379206
I1
I0
I1
tp13193
sS'to,of,control'
p13194
(F1
F0.00076452599388379206
I0
I1
I-1
tp13195
sS'that,bcl-2,was'
p13196
(F1
F0.00076452599388379206
I1
I0
I1
tp13197
sS'metabolized,by,cp450'
p13198
(F1
F0.00076452599388379206
I1
I0
I1
tp13199
sS'daily,and,mg'
p13200
(F1
F0.00076452599388379206
I1
I0
I1
tp13201
sS'studies,have,identified'
p13202
(F1
F0.00076452599388379206
I0
I1
I-1
tp13203
sS'blood,levels,and'
p13204
(F1
F0.00076452599388379206
I1
I0
I1
tp13205
sS'effects,should,be'
p13206
(F0
F0
I1
I1
I0
tp13207
sS'had,indications,for'
p13208
(F1
F0.00076452599388379206
I0
I1
I-1
tp13209
sS'reduce,the,effectiveness'
p13210
(F1
F0.00076452599388379206
I1
I0
I1
tp13211
sS'by,is,superior'
p13212
(F1
F0.00076452599388379206
I1
I0
I1
tp13213
sS'to,achieve,appropriate'
p13214
(F1
F0.00076452599388379206
I1
I0
I1
tp13215
sS'with,improved,control'
p13216
(F1
F0.00076452599388379206
I0
I1
I-1
tp13217
sS'inhibitors,or,inducers'
p13218
(F1
F0.00076452599388379206
I0
I1
I-1
tp13219
sS'cyp3a,inhibitor,on'
p13220
(F1
F0.00076452599388379206
I0
I1
I-1
tp13221
sS'beta,adrenergic,agonists'
p13222
(F1
F0.00076452599388379206
I1
I0
I1
tp13223
sS'patients,on,often'
p13224
(F1
F0.00076452599388379206
I1
I0
I1
tp13225
sS'to,decreasing,the'
p13226
(F1
F0.00076452599388379206
I1
I0
I1
tp13227
sS'tumors,in,her2-positive'
p13228
(F0
F0
I1
I1
I0
tp13229
sS'oxidase,inhibitory,activity'
p13230
(F1
F0.00076452599388379206
I1
I0
I1
tp13231
sS'kg,with,mg'
p13232
(F1
F0.00076452599388379206
I1
I0
I1
tp13233
sS'p450,cp450,mediated'
p13234
(F1
F0.00076452599388379206
I1
I0
I1
tp13235
sS'of,and,xanthine'
p13236
(F1
F0.00076452599388379206
I1
I0
I1
tp13237
sS'and,or,extent'
p13238
(F1
F0.00076452599388379206
I1
I0
I1
tp13239
sS'inhibitors,calcium,channel'
p13240
(F1
F0.00076452599388379206
I1
I0
I1
tp13241
sS'phenotype,by,the'
p13242
(F1
F0.00076452599388379206
I0
I1
I-1
tp13243
sS'day,of,and'
p13244
(F1
F0.0015290519877675841
I2
I0
I2
tp13245
sS'cmax,of,with'
p13246
(F1
F0.00076452599388379206
I1
I0
I1
tp13247
sS'and,eldepryl,and'
p13248
(F1
F0.00076452599388379206
I1
I0
I1
tp13249
sS'a,significant,increase'
p13250
(F1
F0.0015290519877675841
I2
I0
I2
tp13251
sS'interaction,was,observed'
p13252
(F1
F0.00076452599388379206
I0
I1
I-1
tp13253
sS'interfere,with,measurement'
p13254
(F1
F0.00076452599388379206
I0
I1
I-1
tp13255
sS'given,the,different'
p13256
(F1
F0.00076452599388379206
I0
I1
I-1
tp13257
sS'demonstrate,a,decrease'
p13258
(F1
F0.00076452599388379206
I1
I0
I1
tp13259
sS'lead,to,increased'
p13260
(F1
F0.00076452599388379206
I1
I0
I1
tp13261
sS'improves,retinal,transduction'
p13262
(F1
F0.00076452599388379206
I0
I1
I-1
tp13263
sS'test,point,which'
p13264
(F1
F0.00076452599388379206
I1
I0
I1
tp13265
sS'are,not,significantly'
p13266
(F1
F0.00076452599388379206
I0
I1
I-1
tp13267
sS'expected,when,is'
p13268
(F1
F0.00076452599388379206
I1
I0
I1
tp13269
sS'in,an,hiv-positive'
p13270
(F1
F0.00076452599388379206
I1
I0
I1
tp13271
sS'can,cause,a'
p13272
(F1
F0.00076452599388379206
I1
I0
I1
tp13273
sS'via,the,cationic'
p13274
(F1
F0.00076452599388379206
I1
I0
I1
tp13275
sS'metabolites,possibly,by'
p13276
(F1
F0.00076452599388379206
I1
I0
I1
tp13277
sS'lyase,than,were'
p13278
(F1
F0.00076452599388379206
I0
I1
I-1
tp13279
sS'has,no,effect'
p13280
(F0
F0
I1
I1
I0
tp13281
sS'distinct,synergistic,action'
p13282
(F1
F0.00076452599388379206
I0
I1
I-1
tp13283
sS'antihypertensive,effect,of'
p13284
(F1
F0.00076452599388379206
I1
I0
I1
tp13285
sS'this,could,lead'
p13286
(F1
F0.0015290519877675841
I2
I0
I2
tp13287
sS'and,pr,intervals'
p13288
(F1
F0.00076452599388379206
I0
I1
I-1
tp13289
sS'qtc,interval,following'
p13290
(F1
F0.00076452599388379206
I0
I1
I-1
tp13291
sS'were,approximately,fold'
p13292
(F1
F0.00076452599388379206
I1
I0
I1
tp13293
sS'closely,and,the'
p13294
(F1
F0.00076452599388379206
I1
I0
I1
tp13295
sS'virus,vaccines,may'
p13296
(F1
F0.00076452599388379206
I1
I0
I1
tp13297
sS'function,creatinine,clearance'
p13298
(F1
F0.00076452599388379206
I1
I0
I1
tp13299
sS'implies,that,in'
p13300
(F1
F0.00076452599388379206
I0
I1
I-1
tp13301
sS'serum,levels,may'
p13302
(F1
F0.00076452599388379206
I0
I1
I-1
tp13303
sS'of,bleeding,if'
p13304
(F1
F0.0015290519877675841
I2
I0
I2
tp13305
sS'is,initiated,the'
p13306
(F1
F0.00076452599388379206
I0
I1
I-1
tp13307
sS'renal,secretion,population'
p13308
(F1
F0.00076452599388379206
I1
I0
I1
tp13309
sS'is,a,dopamine'
p13310
(F1
F0.00076452599388379206
I1
I0
I1
tp13311
sS'drug-drug,interactions,the'
p13312
(F1
F0.00076452599388379206
I0
I1
I-1
tp13313
sS'in,patients,receiving'
p13314
(F0.73913043478260865
F0.012996941896024464
I20
I3
I17
tp13315
sS'reviewed,the,records'
p13316
(F1
F0.00076452599388379206
I0
I1
I-1
tp13317
sS'effect,of,proton'
p13318
(F1
F0.00076452599388379206
I0
I1
I-1
tp13319
sS'ingested,mg,kg'
p13320
(F1
F0.00076452599388379206
I0
I1
I-1
tp13321
sS'interaction,of,with'
p13322
(F0
F0
I1
I1
I0
tp13323
sS'of,and,against'
p13324
(F1
F0.00076452599388379206
I0
I1
I-1
tp13325
sS'soltab,orally,disintegrating'
p13326
(F1
F0.00076452599388379206
I0
I1
I-1
tp13327
sS'trough,concentrations,and'
p13328
(F1
F0.00076452599388379206
I1
I0
I1
tp13329
sS'be,taken,while'
p13330
(F1
F0.00076452599388379206
I1
I0
I1
tp13331
sS'and,or,nephrotoxic'
p13332
(F1
F0.00076452599388379206
I0
I1
I-1
tp13333
sS'vitamin,e,acetate'
p13334
(F1
F0.00076452599388379206
I1
I0
I1
tp13335
sS'interaction,between,these'
p13336
(F1
F0.00076452599388379206
I0
I1
I-1
tp13337
sS'receiving,or,in'
p13338
(F1
F0.00076452599388379206
I1
I0
I1
tp13339
sS'of,gastrointestinal,bleeding'
p13340
(F1
F0.00076452599388379206
I1
I0
I1
tp13341
sS'or,heme,at'
p13342
(F1
F0.00076452599388379206
I0
I1
I-1
tp13343
sS'vaccines,may,potentiate'
p13344
(F1
F0.00076452599388379206
I1
I0
I1
tp13345
sS'cell,groups,in'
p13346
(F1
F0.00076452599388379206
I1
I0
I1
tp13347
sS'is,decreased,by'
p13348
(F1
F0.00076452599388379206
I1
I0
I1
tp13349
sS'in,aids,patients'
p13350
(F1
F0.00076452599388379206
I1
I0
I1
tp13351
sS'or,other,medications'
p13352
(F1
F0.00076452599388379206
I1
I0
I1
tp13353
sS'at,relevant,concentrations'
p13354
(F1
F0.00076452599388379206
I1
I0
I1
tp13355
sS'egfr,t790m,mutation'
p13356
(F1
F0.00076452599388379206
I0
I1
I-1
tp13357
sS'of,a,substrate'
p13358
(F1
F0.0015290519877675841
I0
I2
I-2
tp13359
sS'emulsion,does,not'
p13360
(F1
F0.00076452599388379206
I0
I1
I-1
tp13361
sS'compounds,known,to'
p13362
(F1
F0.00076452599388379206
I1
I0
I1
tp13363
sS'system,also,responsible'
p13364
(F1
F0.00076452599388379206
I1
I0
I1
tp13365
sS'antagonists,because,of'
p13366
(F1
F0.00076452599388379206
I1
I0
I1
tp13367
sS'of,were,unaffected'
p13368
(F1
F0.00076452599388379206
I0
I1
I-1
tp13369
sS'lowered,mexitil,plasma'
p13370
(F1
F0.00076452599388379206
I1
I0
I1
tp13371
sS'cancer,with,a'
p13372
(F1
F0.00076452599388379206
I0
I1
I-1
tp13373
sS'yet,been,investigated'
p13374
(F1
F0.00076452599388379206
I0
I1
I-1
tp13375
sS'co-administered,with,cyp3a4'
p13376
(F1
F0.00076452599388379206
I0
I1
I-1
tp13377
sS'function,as,well'
p13378
(F1
F0.00076452599388379206
I1
I0
I1
tp13379
sS'the,relative,concentration'
p13380
(F1
F0.00076452599388379206
I1
I0
I1
tp13381
sS'cells,through,p27'
p13382
(F1
F0.00076452599388379206
I1
I0
I1
tp13383
sS'potentiation,occurs,with'
p13384
(F1
F0.00076452599388379206
I0
I1
I-1
tp13385
sS'interact,with,ropivacaine'
p13386
(F1
F0.00076452599388379206
I1
I0
I1
tp13387
sS'drugs,have,been'
p13388
(F1
F0.00076452599388379206
I1
I0
I1
tp13389
sS'a,change,in'
p13390
(F1
F0.0015290519877675841
I2
I0
I2
tp13391
sS'all,patients,in'
p13392
(F1
F0.00076452599388379206
I0
I1
I-1
tp13393
sS'studies,with,the'
p13394
(F1
F0.00076452599388379206
I0
I1
I-1
tp13395
sS'concentrations,by,approximately'
p13396
(F1
F0.00076452599388379206
I1
I0
I1
tp13397
sS'indicate,that,may'
p13398
(F1
F0.00076452599388379206
I1
I0
I1
tp13399
sS'has,been,shown'
p13400
(F0.33333333333333331
F0.00076452599388379206
I2
I1
I1
tp13401
sS'with,lower,clinical'
p13402
(F1
F0.00076452599388379206
I1
I0
I1
tp13403
sS'may,also,be'
p13404
(F1
F0.0015290519877675841
I2
I0
I2
tp13405
sS'dose,oral,clearance'
p13406
(F1
F0.00076452599388379206
I1
I0
I1
tp13407
sS'k,absorption,may'
p13408
(F1
F0.00076452599388379206
I1
I0
I1
tp13409
sS'not,otherwise,contraindicated'
p13410
(F1
F0.00076452599388379206
I0
I1
I-1
tp13411
sS'normal,subjects,and'
p13412
(F1
F0.00076452599388379206
I1
I0
I1
tp13413
sS'to,amide-type,local'
p13414
(F1
F0.00076452599388379206
I1
I0
I1
tp13415
sS'cyclosporine,rifampin,theophylline'
p13416
(F1
F0.00076452599388379206
I1
I0
I1
tp13417
sS'control,pills,anti-infective'
p13418
(F1
F0.00076452599388379206
I1
I0
I1
tp13419
sS'we,suggest,that'
p13420
(F1
F0.00076452599388379206
I1
I0
I1
tp13421
sS'furthermore,we,present'
p13422
(F1
F0.00076452599388379206
I1
I0
I1
tp13423
sS'breast,cancer,cell'
p13424
(F1
F0.00076452599388379206
I1
I0
I1
tp13425
sS'accentuated,by,any'
p13426
(F1
F0.00076452599388379206
I1
I0
I1
tp13427
sS'tubular,secretion,although'
p13428
(F1
F0.00076452599388379206
I1
I0
I1
tp13429
sS'you,cannot,take'
p13430
(F1
F0.00076452599388379206
I1
I0
I1
tp13431
sS'relative,concentration,of'
p13432
(F1
F0.00076452599388379206
I1
I0
I1
tp13433
sS'were,interpreted,according'
p13434
(F1
F0.00076452599388379206
I0
I1
I-1
tp13435
sS'in,increased,risk'
p13436
(F1
F0.00076452599388379206
I1
I0
I1
tp13437
sS'cyp1a2,via,competitive'
p13438
(F1
F0.00076452599388379206
I0
I1
I-1
tp13439
sS'of,profound,and'
p13440
(F1
F0.00076452599388379206
I1
I0
I1
tp13441
sS'cause,intense,and'
p13442
(F1
F0.00076452599388379206
I1
I0
I1
tp13443
sS'was,a,slight'
p13444
(F1
F0.00076452599388379206
I1
I0
I1
tp13445
sS'model,day,study'
p13446
(F1
F0.00076452599388379206
I0
I1
I-1
tp13447
sS'more,frequent,monitoring'
p13448
(F1
F0.00076452599388379206
I1
I0
I1
tp13449
sS'phenytoin,cyclosporine,rifampin'
p13450
(F1
F0.00076452599388379206
I1
I0
I1
tp13451
sS'in,addition,cns'
p13452
(F1
F0.00076452599388379206
I1
I0
I1
tp13453
sS'contraception,and,up'
p13454
(F1
F0.00076452599388379206
I1
I0
I1
tp13455
sS'interaction,between,mivacron'
p13456
(F1
F0.00076452599388379206
I0
I1
I-1
tp13457
sS'de,pointes,and'
p13458
(F1
F0.00076452599388379206
I1
I0
I1
tp13459
sS'serum,concentrations,should'
p13460
(F1
F0.00076452599388379206
I1
I0
I1
tp13461
sS'parnate,or,nardil'
p13462
(F1
F0.00076452599388379206
I1
I0
I1
tp13463
sS'of,with,such'
p13464
(F1
F0.00076452599388379206
I0
I1
I-1
tp13465
sS'cholinesterase,inhibitors,are'
p13466
(F1
F0.00076452599388379206
I1
I0
I1
tp13467
sS'its,combination,with'
p13468
(F1
F0.0015290519877675841
I0
I2
I-2
tp13469
sS'responsible,for,the'
p13470
(F1
F0.00076452599388379206
I1
I0
I1
tp13471
sS'of,with,is'
p13472
(F1
F0.00076452599388379206
I1
I0
I1
tp13473
sS'that,slow,the'
p13474
(F1
F0.00076452599388379206
I1
I0
I1
tp13475
sS'healthy,volunteers,tended'
p13476
(F1
F0.00076452599388379206
I1
I0
I1
tp13477
sS'controls,conditioned,with'
p13478
(F1
F0.00076452599388379206
I0
I1
I-1
tp13479
sS'to,following,topical'
p13480
(F1
F0.00076452599388379206
I0
I1
I-1
tp13481
sS'groups,whereas,the'
p13482
(F1
F0.00076452599388379206
I1
I0
I1
tp13483
sS'antihypertensives,when,mykrox'
p13484
(F1
F0.00076452599388379206
I1
I0
I1
tp13485
sS'that,induce,or'
p13486
(F1
F0.0015290519877675841
I0
I2
I-2
tp13487
sS'initiated,in,a'
p13488
(F1
F0.00076452599388379206
I1
I0
I1
tp13489
sS'category,and,package'
p13490
(F1
F0.00076452599388379206
I0
I1
I-1
tp13491
sS'a,high,dose'
p13492
(F1
F0.00076452599388379206
I1
I0
I1
tp13493
sS'a,causal,relationship'
p13494
(F1
F0.0015290519877675841
I2
I0
I2
tp13495
sS'most,serious,effect'
p13496
(F1
F0.00076452599388379206
I1
I0
I1
tp13497
sS'is,no,conclusive'
p13498
(F1
F0.00076452599388379206
I0
I1
I-1
tp13499
sS'the,base-secreting,system'
p13500
(F1
F0.00076452599388379206
I1
I0
I1
tp13501
sS'same,regimen,of'
p13502
(F1
F0.00076452599388379206
I1
I0
I1
tp13503
sS'the,two,experimental'
p13504
(F1
F0.00076452599388379206
I0
I1
I-1
tp13505
sS'interaction,study,of'
p13506
(F1
F0.0015290519877675841
I0
I2
I-2
tp13507
sS'was,previously,reported'
p13508
(F1
F0.00076452599388379206
I1
I0
I1
tp13509
sS'studies,as,well'
p13510
(F1
F0.00076452599388379206
I1
I0
I1
tp13511
sS'significant,changes,to'
p13512
(F1
F0.00076452599388379206
I0
I1
I-1
tp13513
sS'a,multiple-dose,study'
p13514
(F1
F0.00076452599388379206
I0
I1
I-1
tp13515
sS'following,oral,administration'
p13516
(F1
F0.0015290519877675841
I2
I0
I2
tp13517
sS'efficacy,and,tolerability'
p13518
(F1
F0.00076452599388379206
I0
I1
I-1
tp13519
sS'were,noted,using'
p13520
(F1
F0.00076452599388379206
I0
I1
I-1
tp13521
sS'whether,the,co-injection'
p13522
(F1
F0.00076452599388379206
I0
I1
I-1
tp13523
sS'recirculation,and,reduce'
p13524
(F1
F0.00076452599388379206
I0
I1
I-1
tp13525
sS'can,cause,unpredictable'
p13526
(F1
F0.00076452599388379206
I1
I0
I1
tp13527
sS'toxicity,of,precocene'
p13528
(F1
F0.00076452599388379206
I1
I0
I1
tp13529
sS'pressure,medicines,for'
p13530
(F1
F0.00076452599388379206
I0
I1
I-1
tp13531
sS'of,the,liver'
p13532
(F1
F0.00076452599388379206
I1
I0
I1
tp13533
sS'patients,on,chronic'
p13534
(F1
F0.00076452599388379206
I1
I0
I1
tp13535
sS'cyp,inhibitors,tested'
p13536
(F1
F0.00076452599388379206
I0
I1
I-1
tp13537
sS'pth,levels,but'
p13538
(F1
F0.00076452599388379206
I0
I1
I-1
tp13539
sS'clearance,from,to'
p13540
(F1
F0.00076452599388379206
I1
I0
I1
tp13541
sS'the,stronger,of'
p13542
(F1
F0.00076452599388379206
I0
I1
I-1
tp13543
sS'occurs,with,concurrent'
p13544
(F1
F0.00076452599388379206
I1
I0
I1
tp13545
sS'agonists,inhaled,other'
p13546
(F1
F0.00076452599388379206
I1
I0
I1
tp13547
sS'for,patients,who'
p13548
(F1
F0.00076452599388379206
I0
I1
I-1
tp13549
sS'we,evaluated,mechanisms'
p13550
(F1
F0.00076452599388379206
I0
I1
I-1
tp13551
sS'that,vaccinations,may'
p13552
(F1
F0.00076452599388379206
I1
I0
I1
tp13553
sS'vaccinations,may,be'
p13554
(F1
F0.00076452599388379206
I1
I0
I1
tp13555
sS'edema,concomitant,administration'
p13556
(F1
F0.00076452599388379206
I0
I1
I-1
tp13557
sS'in,vivo,or'
p13558
(F1
F0.00076452599388379206
I0
I1
I-1
tp13559
sS'is,advised,when'
p13560
(F1
F0.00076452599388379206
I1
I0
I1
tp13561
sS'therefore,when,concomitant'
p13562
(F1
F0.00076452599388379206
I1
I0
I1
tp13563
sS'of,renal,impairment'
p13564
(F1
F0.00076452599388379206
I0
I1
I-1
tp13565
sS'volunteers,ingested,mg'
p13566
(F1
F0.00076452599388379206
I0
I1
I-1
tp13567
sS'is,recommended,that'
p13568
(F1
F0.0030581039755351682
I4
I0
I4
tp13569
sS'when,daily,doses'
p13570
(F1
F0.00076452599388379206
I0
I1
I-1
tp13571
sS'levels,when,xenical'
p13572
(F1
F0.00076452599388379206
I1
I0
I1
tp13573
sS'of,diepoxybutane,to'
p13574
(F1
F0.00076452599388379206
I0
I1
I-1
tp13575
sS'toxicity,which,was'
p13576
(F1
F0.00076452599388379206
I1
I0
I1
tp13577
sS'of,toxicity,may'
p13578
(F1
F0.00076452599388379206
I1
I0
I1
tp13579
sS'there,was,a'
p13580
(F0
F0
I1
I1
I0
tp13581
sS'appropriate,igf-i,suppression'
p13582
(F1
F0.00076452599388379206
I1
I0
I1
tp13583
sS'and,an,acute'
p13584
(F1
F0.00076452599388379206
I0
I1
I-1
tp13585
sS'may,be,expected'
p13586
(F0.33333333333333331
F0.00076452599388379206
I2
I1
I1
tp13587
sS'high,fever,severe'
p13588
(F1
F0.00076452599388379206
I1
I0
I1
tp13589
sS'the,pharmacokinetic,profile'
p13590
(F1
F0.00076452599388379206
I0
I1
I-1
tp13591
sS'enhance,neuromuscular,blocking'
p13592
(F1
F0.00076452599388379206
I1
I0
I1
tp13593
sS'capable,of,increasing'
p13594
(F1
F0.00076452599388379206
I0
I1
I-1
tp13595
sS'hypokalemia,and,increase'
p13596
(F1
F0.00076452599388379206
I0
I1
I-1
tp13597
sS'intake,before,initiation'
p13598
(F1
F0.00076452599388379206
I0
I1
I-1
tp13599
sS'the,plasma,kinetics'
p13600
(F1
F0.00076452599388379206
I0
I1
I-1
tp13601
sS'concentrations,increased,plasma'
p13602
(F1
F0.00076452599388379206
I1
I0
I1
tp13603
sS'might,be,coadministered'
p13604
(F1
F0.00076452599388379206
I1
I0
I1
tp13605
sS'with,feldene,since'
p13606
(F1
F0.00076452599388379206
I1
I0
I1
tp13607
sS'other,macrolide,including'
p13608
(F1
F0.00076452599388379206
I1
I0
I1
tp13609
sS'controlled,study,found'
p13610
(F1
F0.00076452599388379206
I1
I0
I1
tp13611
sS'receiving,or,similar'
p13612
(F1
F0.00076452599388379206
I1
I0
I1
tp13613
sS'avian,influenza,vaccines'
p13614
(F1
F0.00076452599388379206
I0
I1
I-1
tp13615
sS'and,le,is'
p13616
(F1
F0.00076452599388379206
I1
I0
I1
tp13617
sS'clopidogrel-treated,patients,have'
p13618
(F1
F0.00076452599388379206
I0
I1
I-1
tp13619
sS'that,interfere,with'
p13620
(F1
F0.00076452599388379206
I0
I1
I-1
tp13621
sS'did,not,significantly'
p13622
(F1
F0.0015290519877675841
I0
I2
I-2
tp13623
sS'following,the,administration'
p13624
(F1
F0.00076452599388379206
I1
I0
I1
tp13625
sS'concomitant,administration,with'
p13626
(F1
F0.00076452599388379206
I0
I1
I-1
tp13627
sS'serum,to,a'
p13628
(F1
F0.00076452599388379206
I1
I0
I1
tp13629
sS'stable,doses,of'
p13630
(F1
F0.00076452599388379206
I1
I0
I1
tp13631
sS'in,fresh,human'
p13632
(F1
F0.00076452599388379206
I1
I0
I1
tp13633
sS'and,levonorgestrel-containing,oral'
p13634
(F1
F0.00076452599388379206
I1
I0
I1
tp13635
sS'dose,requirements,of'
p13636
(F1
F0.00076452599388379206
I1
I0
I1
tp13637
sS'cancer,with,egfr'
p13638
(F1
F0.00076452599388379206
I1
I0
I1
tp13639
sS'absorption,of,both'
p13640
(F1
F0.00076452599388379206
I1
I0
I1
tp13641
sS'with,salt-retaining,steroid'
p13642
(F1
F0.00076452599388379206
I0
I1
I-1
tp13643
sS'levodopa,carbidopa,levodopa'
p13644
(F1
F0.00076452599388379206
I0
I1
I-1
tp13645
sS'desired,level,of'
p13646
(F1
F0.00076452599388379206
I1
I0
I1
tp13647
sS'exert,an,effect'
p13648
(F1
F0.00076452599388379206
I1
I0
I1
tp13649
sS'and,abt-737,a'
p13650
(F1
F0.00076452599388379206
I1
I0
I1
tp13651
sS'been,conducted,sanctura'
p13652
(F1
F0.00076452599388379206
I1
I0
I1
tp13653
sS'and,foods,with'
p13654
(F1
F0.00076452599388379206
I1
I0
I1
tp13655
sS'cancer,cell,lines'
p13656
(F0
F0
I1
I1
I0
tp13657
sS'enhance,or,precipitate'
p13658
(F1
F0.00076452599388379206
I1
I0
I1
tp13659
sS'mivacron,before,to'
p13660
(F1
F0.00076452599388379206
I0
I1
I-1
tp13661
sS'the,possibility,of'
p13662
(F0.5
F0.0015290519877675841
I3
I1
I2
tp13663
sS'be,taken,especially'
p13664
(F1
F0.00076452599388379206
I1
I0
I1
tp13665
sS'increase,in,the'
p13666
(F0.59999999999999998
F0.0022935779816513763
I4
I1
I3
tp13667
sS'is,given,concurrently'
p13668
(F1
F0.00076452599388379206
I1
I0
I1
tp13669
sS'is,also,used'
p13670
(F1
F0.00076452599388379206
I1
I0
I1
tp13671
sS'to,augment,precocene'
p13672
(F1
F0.00076452599388379206
I1
I0
I1
tp13673
sS'extended-release,tablets,in'
p13674
(F1
F0.00076452599388379206
I0
I1
I-1
tp13675
sS'vitro,did,not'
p13676
(F1
F0.0015290519877675841
I0
I2
I-2
tp13677
sS'not,been,conducted'
p13678
(F1
F0.00076452599388379206
I1
I0
I1
tp13679
sS'plasma,ace,inhibition'
p13680
(F1
F0.00076452599388379206
I0
I1
I-1
tp13681
sS'reported,to,reduce'
p13682
(F1
F0.00076452599388379206
I1
I0
I1
tp13683
sS'rate,of,absorption'
p13684
(F0
F0
I1
I1
I0
tp13685
sS'to,prolong,the'
p13686
(F1
F0.00076452599388379206
I1
I0
I1
tp13687
sS'as,given,concomitantly'
p13688
(F1
F0.00076452599388379206
I1
I0
I1
tp13689
sS'that,of,the'
p13690
(F1
F0.00076452599388379206
I0
I1
I-1
tp13691
sS'is,needed,with'
p13692
(F1
F0.00076452599388379206
I0
I1
I-1
tp13693
sS'with,hmg-coa,reductase'
p13694
(F1
F0.00076452599388379206
I0
I1
I-1
tp13695
sS'concomitantly,administered,with'
p13696
(F1
F0.00076452599388379206
I1
I0
I1
tp13697
sS'interactions,with,drugs'
p13698
(F1
F0.0015290519877675841
I0
I2
I-2
tp13699
sS'with,the,first'
p13700
(F1
F0.00076452599388379206
I1
I0
I1
tp13701
sS'mexitil,and,may'
p13702
(F1
F0.00076452599388379206
I1
I0
I1
tp13703
sS'an,increased,odds'
p13704
(F1
F0.00076452599388379206
I1
I0
I1
tp13705
sS'inhibit,ovarian,function'
p13706
(F1
F0.00076452599388379206
I1
I0
I1
tp13707
sS'and,zavesca,is'
p13708
(F1
F0.00076452599388379206
I1
I0
I1
tp13709
sS'sedation,may,have'
p13710
(F1
F0.00076452599388379206
I0
I1
I-1
tp13711
sS'be,additive,with'
p13712
(F1
F0.0022935779816513763
I3
I0
I3
tp13713
sS'and,heme,and'
p13714
(F1
F0.00076452599388379206
I0
I1
I-1
tp13715
sS'appreciably,metabolized,by'
p13716
(F1
F0.00076452599388379206
I0
I1
I-1
tp13717
sS'k,antagonists,and'
p13718
(F1
F0.00076452599388379206
I1
I0
I1
tp13719
sS'simultaneous,use,of'
p13720
(F1
F0.00076452599388379206
I1
I0
I1
tp13721
sS'of,a,vitamin'
p13722
(F1
F0.00076452599388379206
I1
I0
I1
tp13723
sS'in,substantial,increases'
p13724
(F1
F0.00076452599388379206
I1
I0
I1
tp13725
sS'appeared,to,increase'
p13726
(F1
F0.00076452599388379206
I1
I0
I1
tp13727
sS'classes,of,azole'
p13728
(F1
F0.00076452599388379206
I1
I0
I1
tp13729
sS'hydrochloride,and,neuromuscular'
p13730
(F1
F0.00076452599388379206
I1
I0
I1
tp13731
sS'and,presence,of'
p13732
(F1
F0.00076452599388379206
I0
I1
I-1
tp13733
sS'initiating,or,changing'
p13734
(F1
F0.00076452599388379206
I1
I0
I1
tp13735
sS'of,motor,skills'
p13736
(F1
F0.00076452599388379206
I1
I0
I1
tp13737
sS'have,been,shown'
p13738
(F1
F0.00076452599388379206
I1
I0
I1
tp13739
sS'in,vitro,and'
p13740
(F0.33333333333333331
F0.00076452599388379206
I1
I2
I-1
tp13741
sS'increases,the,plasma'
p13742
(F1
F0.0015290519877675841
I2
I0
I2
tp13743
sS'concurrently,administered,antiepileptic'
p13744
(F1
F0.00076452599388379206
I1
I0
I1
tp13745
sS'kg,day,males'
p13746
(F1
F0.00076452599388379206
I0
I1
I-1
tp13747
sS'been,reported,when'
p13748
(F0
F0
I1
I1
I0
tp13749
sS'oral,mg,ethinyl'
p13750
(F1
F0.00076452599388379206
I0
I1
I-1
tp13751
sS't-all,cell,lines'
p13752
(F1
F0.00076452599388379206
I0
I1
I-1
tp13753
sS'can,be,attributed'
p13754
(F1
F0.00076452599388379206
I1
I0
I1
tp13755
sS'drug,s,metabolism'
p13756
(F1
F0.00076452599388379206
I1
I0
I1
tp13757
sS'displayed,clearances,similar'
p13758
(F1
F0.00076452599388379206
I0
I1
I-1
tp13759
sS'administration,of,can'
p13760
(F1
F0.00076452599388379206
I1
I0
I1
tp13761
sS'serum,levels,when'
p13762
(F1
F0.00076452599388379206
I1
I0
I1
tp13763
sS'cause,unpredictable,myelotoxicity'
p13764
(F1
F0.00076452599388379206
I1
I0
I1
tp13765
sS'a,mg,and'
p13766
(F1
F0.00076452599388379206
I1
I0
I1
tp13767
sS'mi,when,not'
p13768
(F1
F0.00076452599388379206
I0
I1
I-1
tp13769
sS'of,and,anesthetic'
p13770
(F1
F0.00076452599388379206
I1
I0
I1
tp13771
sS'for,signs,of'
p13772
(F1
F0.00076452599388379206
I1
I0
I1
tp13773
sS'trimethoprim,may,inhibit'
p13774
(F1
F0.00076452599388379206
I1
I0
I1
tp13775
sS'interaction,between,mg'
p13776
(F1
F0.00076452599388379206
I0
I1
I-1
tp13777
sS'daily,with,mg'
p13778
(F1
F0.00076452599388379206
I1
I0
I1
tp13779
sS'in,rats,at'
p13780
(F1
F0.00076452599388379206
I0
I1
I-1
tp13781
sS'by,about,while'
p13782
(F1
F0.00076452599388379206
I1
I0
I1
tp13783
sS'agonists,has,not'
p13784
(F1
F0.00076452599388379206
I0
I1
I-1
tp13785
sS'elimination,half-life,of'
p13786
(F1
F0.00076452599388379206
I1
I0
I1
tp13787
sS'combination,as,an'
p13788
(F1
F0.00076452599388379206
I1
I0
I1
tp13789
sS'we,concluded,that'
p13790
(F1
F0.00076452599388379206
I1
I0
I1
tp13791
sS'locomotor,inhibitor,activity'
p13792
(F1
F0.00076452599388379206
I0
I1
I-1
tp13793
sS'two,experimental,groups'
p13794
(F1
F0.00076452599388379206
I0
I1
I-1
tp13795
sS'concomitantly,with,calcium-channel'
p13796
(F1
F0.00076452599388379206
I0
I1
I-1
tp13797
sS'study,the,like'
p13798
(F1
F0.00076452599388379206
I0
I1
I-1
tp13799
sS'furthermore,in,patients'
p13800
(F1
F0.00076452599388379206
I1
I0
I1
tp13801
sS'in,apoptosis,induced'
p13802
(F1
F0.00076452599388379206
I0
I1
I-1
tp13803
sS'antagonistic,in,breast'
p13804
(F1
F0.00076452599388379206
I1
I0
I1
tp13805
sS'by,chronic,treatment'
p13806
(F1
F0.00076452599388379206
I0
I1
I-1
tp13807
sS'parathyroid,hormone,pth'
p13808
(F1
F0.00076452599388379206
I0
I1
I-1
tp13809
sS'a,chicken,actin'
p13810
(F1
F0.00076452599388379206
I0
I1
I-1
tp13811
sS'lower,the,rate'
p13812
(F1
F0.00076452599388379206
I0
I1
I-1
tp13813
sS'in,bleeding,compared'
p13814
(F1
F0.00076452599388379206
I1
I0
I1
tp13815
sS'reports,of,enhanced'
p13816
(F1
F0.0015290519877675841
I2
I0
I2
tp13817
sS'in,vitro,perfusion'
p13818
(F1
F0.00076452599388379206
I1
I0
I1
tp13819
sS'have,shown,a'
p13820
(F1
F0.00076452599388379206
I1
I0
I1
tp13821
sS'concurrently,with,mexitil'
p13822
(F1
F0.00076452599388379206
I1
I0
I1
tp13823
sS'and,the,pro-oxidant'
p13824
(F1
F0.00076452599388379206
I0
I1
I-1
tp13825
sS'treatment,with,the'
p13826
(F1
F0.0015290519877675841
I2
I0
I2
tp13827
sS'other,anticholinergic-like,effects'
p13828
(F1
F0.00076452599388379206
I1
I0
I1
tp13829
sS'not,alter,serum'
p13830
(F1
F0.00076452599388379206
I1
I0
I1
tp13831
sS'such,as,blockers'
p13832
(F1
F0.00076452599388379206
I0
I1
I-1
tp13833
sS'at,all,possible'
p13834
(F1
F0.00076452599388379206
I1
I0
I1
tp13835
sS'as,chloride,on'
p13836
(F1
F0.00076452599388379206
I1
I0
I1
tp13837
sS'mean,auc,of'
p13838
(F1
F0.00076452599388379206
I1
I0
I1
tp13839
sS'serious,effect,would'
p13840
(F1
F0.00076452599388379206
I1
I0
I1
tp13841
sS'based,on,various'
p13842
(F1
F0.00076452599388379206
I0
I1
I-1
tp13843
sS'combination,with,herceptin'
p13844
(F1
F0.00076452599388379206
I1
I0
I1
tp13845
sS'infusion,administered,hour'
p13846
(F1
F0.00076452599388379206
I1
I0
I1
tp13847
sS'n,n,n'
p13848
(F1
F0.00076452599388379206
I0
I1
I-1
tp13849
sS'is,advisable,to'
p13850
(F1
F0.00076452599388379206
I1
I0
I1
tp13851
sS'model,for,precocene'
p13852
(F1
F0.00076452599388379206
I0
I1
I-1
tp13853
sS'the,doses,generally'
p13854
(F1
F0.00076452599388379206
I0
I1
I-1
tp13855
sS'further,increase,the'
p13856
(F1
F0.00076452599388379206
I0
I1
I-1
tp13857
sS'levels,may,be'
p13858
(F0
F0
I1
I1
I0
tp13859
sS'as,the,most'
p13860
(F1
F0.00076452599388379206
I1
I0
I1
tp13861
sS'in,metabolism,and'
p13862
(F1
F0.0015290519877675841
I2
I0
I2
tp13863
sS'and,inr,in'
p13864
(F1
F0.00076452599388379206
I1
I0
I1
tp13865
sS'although,a,causal'
p13866
(F1
F0.00076452599388379206
I1
I0
I1
tp13867
sS'threshold,has,been'
p13868
(F1
F0.00076452599388379206
I1
I0
I1
tp13869
sS'drugs,careful,monitoring'
p13870
(F1
F0.00076452599388379206
I1
I0
I1
tp13871
sS'concurrently,with,alimta'
p13872
(F1
F0.00076452599388379206
I1
I0
I1
tp13873
sS'of,fewer,drugs'
p13874
(F1
F0.00076452599388379206
I1
I0
I1
tp13875
sS'caution,and,additional'
p13876
(F1
F0.00076452599388379206
I1
I0
I1
tp13877
sS'non-human,primate,study'
p13878
(F1
F0.00076452599388379206
I1
I0
I1
tp13879
sS'cns,depressant,medications'
p13880
(F1
F0.00076452599388379206
I1
I0
I1
tp13881
sS'although,undercarboxylated,osteocalcin'
p13882
(F1
F0.00076452599388379206
I0
I1
I-1
tp13883
sS'result,in,higher'
p13884
(F1
F0.00076452599388379206
I0
I1
I-1
tp13885
sS'the,decreases,in'
p13886
(F1
F0.00076452599388379206
I0
I1
I-1
tp13887
sS'medications,concurrent,use'
p13888
(F1
F0.00076452599388379206
I1
I0
I1
tp13889
sS'cyp,interactions,inhibitors'
p13890
(F1
F0.00076452599388379206
I0
I1
I-1
tp13891
sS'receiving,a,calcineurin'
p13892
(F1
F0.00076452599388379206
I0
I1
I-1
tp13893
sS'a,selective,and'
p13894
(F1
F0.0015290519877675841
I2
I0
I2
tp13895
sS'pointes,in,patients'
p13896
(F1
F0.00076452599388379206
I1
I0
I1
tp13897
sS'of,days,before'
p13898
(F1
F0.00076452599388379206
I1
I0
I1
tp13899
sS'of,antihypertensive,effect'
p13900
(F1
F0.00076452599388379206
I1
I0
I1
tp13901
sS'as,the,agent'
p13902
(F1
F0.00076452599388379206
I1
I0
I1
tp13903
sS'the,or,ordinarily'
p13904
(F1
F0.00076452599388379206
I1
I0
I1
tp13905
sS'other,muscle,relaxants'
p13906
(F1
F0.00076452599388379206
I0
I1
I-1
tp13907
sS'in,ovarian,cancer'
p13908
(F1
F0.00076452599388379206
I0
I1
I-1
tp13909
sS'that,it,should'
p13910
(F1
F0.00076452599388379206
I1
I0
I1
tp13911
sS'be,used,with'
p13912
(F0.75
F0.0045871559633027525
I7
I1
I6
tp13913
sS'doses,of,who'
p13914
(F1
F0.00076452599388379206
I1
I0
I1
tp13915
sS'be,mixed,and'
p13916
(F1
F0.00076452599388379206
I0
I1
I-1
tp13917
sS'and,days,following'
p13918
(F1
F0.0015290519877675841
I2
I0
I2
tp13919
sS'is,not,sufficient'
p13920
(F1
F0.00076452599388379206
I1
I0
I1
tp13921
sS'pretreatments,with,oral'
p13922
(F1
F0.00076452599388379206
I0
I1
I-1
tp13923
sS'be,administered,at'
p13924
(F1
F0.00076452599388379206
I1
I0
I1
tp13925
sS's-ketamine,with,the'
p13926
(F1
F0.00076452599388379206
I0
I1
I-1
tp13927
sS'preventive,impact,on'
p13928
(F1
F0.00076452599388379206
I0
I1
I-1
tp13929
sS'hepatitis,c,patients'
p13930
(F1
F0.00076452599388379206
I1
I0
I1
tp13931
sS'medications,included,thyroid'
p13932
(F1
F0.00076452599388379206
I0
I1
I-1
tp13933
sS'with,drugs,known'
p13934
(F1
F0.00076452599388379206
I0
I1
I-1
tp13935
sS'matrix,degrading,enzymes'
p13936
(F1
F0.00076452599388379206
I0
I1
I-1
tp13937
sS'response,to,ai'
p13938
(F1
F0.00076452599388379206
I1
I0
I1
tp13939
sS'or,in,studies'
p13940
(F1
F0.00076452599388379206
I0
I1
I-1
tp13941
sS'when,mixed,with'
p13942
(F1
F0.00076452599388379206
I1
I0
I1
tp13943
sS'patients,receiving,cylert'
p13944
(F1
F0.00076452599388379206
I1
I0
I1
tp13945
sS'affect,invega,paliperidone'
p13946
(F1
F0.00076452599388379206
I0
I1
I-1
tp13947
sS'in,male,or'
p13948
(F1
F0.00076452599388379206
I0
I1
I-1
tp13949
sS'trental,has,been'
p13950
(F1
F0.00076452599388379206
I0
I1
I-1
tp13951
sS'to,affect,other'
p13952
(F1
F0.00076452599388379206
I0
I1
I-1
tp13953
sS'downward,adjustment,of'
p13954
(F1
F0.00076452599388379206
I1
I0
I1
tp13955
sS'increased,the,clearance'
p13956
(F1
F0.00076452599388379206
I1
I0
I1
tp13957
sS'causing,sedation,which'
p13958
(F1
F0.00076452599388379206
I1
I0
I1
tp13959
sS'acid,writhing,and'
p13960
(F1
F0.00076452599388379206
I1
I0
I1
tp13961
sS'similar,to,the'
p13962
(F1
F0.00076452599388379206
I1
I0
I1
tp13963
sS'plasma,levels,have'
p13964
(F1
F0.00076452599388379206
I1
I0
I1
tp13965
sS'at,the,first'
p13966
(F1
F0.00076452599388379206
I1
I0
I1
tp13967
sS'with,the,metabotropic'
p13968
(F1
F0.00076452599388379206
I1
I0
I1
tp13969
sS'users,contributed,person-years'
p13970
(F1
F0.00076452599388379206
I0
I1
I-1
tp13971
sS'inhibited,growth,and'
p13972
(F1
F0.00076452599388379206
I1
I0
I1
tp13973
sS'may,decrease,arterial'
p13974
(F1
F0.0015290519877675841
I2
I0
I2
tp13975
sS'reduction,in,cellular'
p13976
(F1
F0.00076452599388379206
I0
I1
I-1
tp13977
sS'and,or,cardiac'
p13978
(F1
F0.00076452599388379206
I1
I0
I1
tp13979
sS'megestrol,acetate,were'
p13980
(F1
F0.00076452599388379206
I0
I1
I-1
tp13981
sS'inhibitors,of,these'
p13982
(F1
F0.00076452599388379206
I0
I1
I-1
tp13983
sS'and,p,but'
p13984
(F1
F0.00076452599388379206
I0
I1
I-1
tp13985
sS'either,sirnas,or'
p13986
(F1
F0.00076452599388379206
I1
I0
I1
tp13987
sS'the,maximum,recommended'
p13988
(F1
F0.00076452599388379206
I0
I1
I-1
tp13989
sS'of,potent,inhalational'
p13990
(F1
F0.00076452599388379206
I0
I1
I-1
tp13991
sS'angina,or,high'
p13992
(F1
F0.00076452599388379206
I0
I1
I-1
tp13993
sS'in,a,group'
p13994
(F1
F0.00076452599388379206
I0
I1
I-1
tp13995
sS'oral,hormone,replacement'
p13996
(F1
F0.00076452599388379206
I0
I1
I-1
tp13997
sS'drugs,that,alter'
p13998
(F1
F0.0030581039755351682
I4
I0
I4
tp13999
sS'not,conclusive,because'
p14000
(F1
F0.00076452599388379206
I1
I0
I1
tp14001
sS'patients,usp,modified'
p14002
(F1
F0.00076452599388379206
I0
I1
I-1
tp14003
sS'symlin,and,insulin'
p14004
(F1
F0.00076452599388379206
I1
I0
I1
tp14005
sS'administration,of,than'
p14006
(F1
F0.00076452599388379206
I1
I0
I1
tp14007
sS'purpose,of,attenuating'
p14008
(F1
F0.00076452599388379206
I0
I1
I-1
tp14009
sS'volunteers,to,evaluate'
p14010
(F1
F0.00076452599388379206
I0
I1
I-1
tp14011
sS'as,amphotericin,b'
p14012
(F1
F0.00076452599388379206
I0
I1
I-1
tp14013
sS'in,a,decreased'
p14014
(F1
F0.00076452599388379206
I1
I0
I1
tp14015
sS'is,associated,with'
p14016
(F0.33333333333333331
F0.00076452599388379206
I1
I2
I-1
tp14017
sS'a,day,for'
p14018
(F1
F0.0053516819571865441
I0
I7
I-7
tp14019
sS'mixed,agonist,antagonist'
p14020
(F1
F0.00076452599388379206
I1
I0
I1
tp14021
sS'elevations,in,serum'
p14022
(F1
F0.00076452599388379206
I1
I0
I1
tp14023
sS'result,of,inhibition'
p14024
(F1
F0.00076452599388379206
I1
I0
I1
tp14025
sS'volunteers,n,did'
p14026
(F1
F0.00076452599388379206
I0
I1
I-1
tp14027
sS'elevating,the,serum'
p14028
(F1
F0.00076452599388379206
I1
I0
I1
tp14029
sS'advisable,to,avoid'
p14030
(F1
F0.00076452599388379206
I1
I0
I1
tp14031
sS'been,used,with'
p14032
(F1
F0.00076452599388379206
I0
I1
I-1
tp14033
sS'hydroxylase,immunoreactivity,which'
p14034
(F1
F0.00076452599388379206
I1
I0
I1
tp14035
sS'administration,of,potent'
p14036
(F1
F0.00076452599388379206
I0
I1
I-1
tp14037
sS'p450,inducers,such'
p14038
(F1
F0.00076452599388379206
I1
I0
I1
tp14039
sS'potent,inhibitors,include'
p14040
(F1
F0.00076452599388379206
I0
I1
I-1
tp14041
sS'may,have,beneficial'
p14042
(F1
F0.00076452599388379206
I1
I0
I1
tp14043
sS'decreases,the,oral'
p14044
(F1
F0.00076452599388379206
I1
I0
I1
tp14045
sS'of,causing,cns'
p14046
(F1
F0.00076452599388379206
I1
I0
I1
tp14047
sS'second,day,after'
p14048
(F1
F0.00076452599388379206
I1
I0
I1
tp14049
sS'enhance,the,neuromuscular'
p14050
(F1
F0.00076452599388379206
I1
I0
I1
tp14051
sS'concurrent,and,or'
p14052
(F1
F0.00076452599388379206
I0
I1
I-1
tp14053
sS'the,side,effects'
p14054
(F0.33333333333333331
F0.00076452599388379206
I1
I2
I-1
tp14055
sS'zolinza,and,other'
p14056
(F1
F0.00076452599388379206
I1
I0
I1
tp14057
sS'may,enhance,the'
p14058
(F1
F0.0030581039755351682
I4
I0
I4
tp14059
sS'these,drugs,can'
p14060
(F1
F0.00076452599388379206
I1
I0
I1
tp14061
sS'administration,of,ginseng'
p14062
(F1
F0.0015290519877675841
I0
I2
I-2
tp14063
sS'days,respectively,lower'
p14064
(F1
F0.00076452599388379206
I1
I0
I1
tp14065
sS'and,seven,patients'
p14066
(F1
F0.00076452599388379206
I1
I0
I1
tp14067
sS'bp,with,fixed'
p14068
(F1
F0.00076452599388379206
I0
I1
I-1
tp14069
sS'patient,taking,the'
p14070
(F1
F0.00076452599388379206
I1
I0
I1
tp14071
sS'occurrences,have,been'
p14072
(F1
F0.00076452599388379206
I0
I1
I-1
tp14073
sS'would,be,expected'
p14074
(F1
F0.00076452599388379206
I0
I1
I-1
tp14075
sS'to,calcitonin,salmon'
p14076
(F1
F0.00076452599388379206
I1
I0
I1
tp14077
sS'tests,there,have'
p14078
(F1
F0.00076452599388379206
I0
I1
I-1
tp14079
sS'decreased,serum,levels'
p14080
(F1
F0.0015290519877675841
I2
I0
I2
tp14081
sS'is,reduced,by'
p14082
(F1
F0.00076452599388379206
I1
I0
I1
tp14083
sS'with,the,co-administration'
p14084
(F1
F0.00076452599388379206
I1
I0
I1
tp14085
sS'not,administer,myfortic'
p14086
(F1
F0.00076452599388379206
I1
I0
I1
tp14087
sS'inhibitors,severe,thrombocytopenia'
p14088
(F1
F0.00076452599388379206
I1
I0
I1
tp14089
sS'agents,since,these'
p14090
(F1
F0.00076452599388379206
I1
I0
I1
tp14091
sS'astemizole,the,use'
p14092
(F1
F0.00076452599388379206
I1
I0
I1
tp14093
sS'administering,with,lowered'
p14094
(F1
F0.00076452599388379206
I1
I0
I1
tp14095
sS'rigidity,severe,agitation'
p14096
(F1
F0.00076452599388379206
I1
I0
I1
tp14097
sS'that,myfortic,and'
p14098
(F1
F0.00076452599388379206
I1
I0
I1
tp14099
sS'with,vasoconstrictor,agents'
p14100
(F1
F0.00076452599388379206
I0
I1
I-1
tp14101
sS'reduce,plasma,cholinesterase'
p14102
(F1
F0.00076452599388379206
I1
I0
I1
tp14103
sS'methylprednisolone,may,increase'
p14104
(F1
F0.00076452599388379206
I1
I0
I1
tp14105
sS'the,auc,of'
p14106
(F0.33333333333333331
F0.00076452599388379206
I1
I2
I-1
tp14107
sS'to,auc,was'
p14108
(F1
F0.00076452599388379206
I0
I1
I-1
tp14109
sS'plasma,clearance,of'
p14110
(F1
F0.00076452599388379206
I1
I0
I1
tp14111
sS'take,if,you'
p14112
(F1
F0.00076452599388379206
I1
I0
I1
tp14113
sS'of,cylert,with'
p14114
(F1
F0.00076452599388379206
I0
I1
I-1
tp14115
sS'group,of,healthy'
p14116
(F1
F0.00076452599388379206
I0
I1
I-1
tp14117
sS'does,not,appear'
p14118
(F1
F0.00076452599388379206
I1
I0
I1
tp14119
sS'absorption,and,elimination'
p14120
(F1
F0.00076452599388379206
I0
I1
I-1
tp14121
sS'administered,antiepileptic,drugs'
p14122
(F1
F0.00076452599388379206
I1
I0
I1
tp14123
sS'curcumin,can,be'
p14124
(F1
F0.00076452599388379206
I0
I1
I-1
tp14125
sS'unusually,large,or'
p14126
(F1
F0.00076452599388379206
I1
I0
I1
tp14127
sS'bismuth,trough,concentrations'
p14128
(F1
F0.00076452599388379206
I1
I0
I1
tp14129
sS'antagonist,methyl-1,thiazol-4'
p14130
(F0
F0
I1
I1
I0
tp14131
sS'pressure,may,be'
p14132
(F1
F0.00076452599388379206
I1
I0
I1
tp14133
sS'as,antimycotic,agents'
p14134
(F1
F0.00076452599388379206
I1
I0
I1
tp14135
sS'on,deb,induced'
p14136
(F1
F0.00076452599388379206
I1
I0
I1
tp14137
sS'to,assess,drug-drug'
p14138
(F1
F0.00076452599388379206
I1
I0
I1
tp14139
sS'high-dose,intravenous,and'
p14140
(F1
F0.00076452599388379206
I1
I0
I1
tp14141
sS'and,drugs,that'
p14142
(F0
F0
I1
I1
I0
tp14143
sS'more,time,in'
p14144
(F1
F0.00076452599388379206
I0
I1
I-1
tp14145
sS'several,days,or'
p14146
(F1
F0.00076452599388379206
I0
I1
I-1
tp14147
sS'aceon,tablets,with'
p14148
(F1
F0.00076452599388379206
I0
I1
I-1
tp14149
sS'the,recommended,dose'
p14150
(F1
F0.00076452599388379206
I1
I0
I1
tp14151
sS'administering,demser,to'
p14152
(F1
F0.00076452599388379206
I1
I0
I1
tp14153
sS'synergistic,interaction,between'
p14154
(F1
F0.00076452599388379206
I1
I0
I1
tp14155
sS'stupor,muscular,rigidity'
p14156
(F1
F0.00076452599388379206
I1
I0
I1
tp14157
sS'five,normal,subjects'
p14158
(F1
F0.00076452599388379206
I1
I0
I1
tp14159
sS'studied,with,cyp3a'
p14160
(F1
F0.00076452599388379206
I0
I1
I-1
tp14161
sS'general,internal,medicine'
p14162
(F1
F0.00076452599388379206
I0
I1
I-1
tp14163
sS'when,anticholinergic,properties'
p14164
(F1
F0.00076452599388379206
I0
I1
I-1
tp14165
sS'patients,in,a'
p14166
(F1
F0.00076452599388379206
I0
I1
I-1
tp14167
sS'decrease,levels,reports'
p14168
(F1
F0.00076452599388379206
I1
I0
I1
tp14169
sS'sanctura,with,other'
p14170
(F1
F0.00076452599388379206
I1
I0
I1
tp14171
sS'kip1,mediated,suppression'
p14172
(F1
F0.00076452599388379206
I1
I0
I1
tp14173
sS'drug,concentration,cmax'
p14174
(F1
F0.00076452599388379206
I1
I0
I1
tp14175
sS'conclusion,we,demonstrated'
p14176
(F1
F0.00076452599388379206
I1
I0
I1
tp14177
sS'increase,serum,because'
p14178
(F1
F0.0015290519877675841
I0
I2
I-2
tp14179
sS'hours,of,each'
p14180
(F1
F0.00076452599388379206
I1
I0
I1
tp14181
sS'with,therapeutic,doses'
p14182
(F1
F0.00076452599388379206
I1
I0
I1
tp14183
sS'ie,some,drugs'
p14184
(F1
F0.00076452599388379206
I1
I0
I1
tp14185
sS'patients,with,edema'
p14186
(F1
F0.00076452599388379206
I0
I1
I-1
tp14187
sS'receiving,both,drugs'
p14188
(F1
F0.00076452599388379206
I1
I0
I1
tp14189
sS'and,was,found'
p14190
(F1
F0.00076452599388379206
I1
I0
I1
tp14191
sS'or,local,such'
p14192
(F1
F0.00076452599388379206
I0
I1
I-1
tp14193
sS'of,the,drugs'
p14194
(F1
F0.00076452599388379206
I0
I1
I-1
tp14195
sS'and,concomitant,use'
p14196
(F1
F0.00076452599388379206
I1
I0
I1
tp14197
sS'alkaloids,including,and'
p14198
(F1
F0.00076452599388379206
I0
I1
I-1
tp14199
sS'with,adrenal,cortical'
p14200
(F1
F0.00076452599388379206
I0
I1
I-1
tp14201
sS'by,and,decreased'
p14202
(F1
F0.00076452599388379206
I1
I0
I1
tp14203
sS'used,if,tolectin'
p14204
(F1
F0.00076452599388379206
I1
I0
I1
tp14205
sS'or,duration,of'
p14206
(F1
F0.00076452599388379206
I0
I1
I-1
tp14207
sS'riboflavin,alcohol,impairs'
p14208
(F1
F0.00076452599388379206
I1
I0
I1
tp14209
sS'with,diprivan,injectable'
p14210
(F1
F0.00076452599388379206
I0
I1
I-1
tp14211
sS'recirculation,or,drugs'
p14212
(F1
F0.00076452599388379206
I1
I0
I1
tp14213
sS'taking,nsaids,concomitantly'
p14214
(F1
F0.00076452599388379206
I1
I0
I1
tp14215
sS'is,an,important'
p14216
(F1
F0.00076452599388379206
I1
I0
I1
tp14217
sS'vs,cm3,difference'
p14218
(F1
F0.00076452599388379206
I1
I0
I1
tp14219
sS'data,demonstrate,that'
p14220
(F1
F0.00076452599388379206
I1
I0
I1
tp14221
sS'in,vivo,in'
p14222
(F0
F0
I1
I1
I0
tp14223
sS'ethynyl,pyridine,versus'
p14224
(F1
F0.00076452599388379206
I0
I1
I-1
tp14225
sS'traditional,therapy,was'
p14226
(F1
F0.00076452599388379206
I1
I0
I1
tp14227
sS'of,the,inr'
p14228
(F1
F0.00076452599388379206
I1
I0
I1
tp14229
sS'contraindicated,should,be'
p14230
(F1
F0.00076452599388379206
I0
I1
I-1
tp14231
sS'impairment,their,coexistence'
p14232
(F1
F0.00076452599388379206
I0
I1
I-1
tp14233
sS'although,single,or'
p14234
(F1
F0.00076452599388379206
I1
I0
I1
tp14235
sS'the,mean,cmax'
p14236
(F1
F0.00076452599388379206
I1
I0
I1
tp14237
sS'recommended,in,immunocompromised'
p14238
(F1
F0.00076452599388379206
I1
I0
I1
tp14239
sS'reported,with,concurrent'
p14240
(F1
F0.00076452599388379206
I1
I0
I1
tp14241
sS'the,bioavailability,of'
p14242
(F0.20000000000000001
F0.00076452599388379206
I3
I2
I1
tp14243
sS'diet,that,may'
p14244
(F1
F0.00076452599388379206
I1
I0
I1
tp14245
sS'study,the,pharmacokinetic'
p14246
(F1
F0.00076452599388379206
I0
I1
I-1
tp14247
sS'of,cyp1a2,cyp2a6'
p14248
(F1
F0.00076452599388379206
I0
I1
I-1
tp14249
sS'to,during,or'
p14250
(F1
F0.00076452599388379206
I1
I0
I1
tp14251
sS'emulsion,administration,should'
p14252
(F1
F0.00076452599388379206
I1
I0
I1
tp14253
sS'competition,for,this'
p14254
(F1
F0.00076452599388379206
I0
I1
I-1
tp14255
sS'suitable,chemosensitizer,for'
p14256
(F1
F0.00076452599388379206
I0
I1
I-1
tp14257
sS'delirium,high,fever'
p14258
(F1
F0.00076452599388379206
I1
I0
I1
tp14259
sS'study,was,to'
p14260
(F1
F0.0030581039755351682
I0
I4
I-4
tp14261
sS'bioavailability,of,when'
p14262
(F1
F0.00076452599388379206
I1
I0
I1
tp14263
sS'blockers,antidiabetic,agents'
p14264
(F1
F0.00076452599388379206
I0
I1
I-1
tp14265
sS'neurotoxic,and,or'
p14266
(F1
F0.00076452599388379206
I0
I1
I-1
tp14267
sS'its,human,serum'
p14268
(F1
F0.00076452599388379206
I0
I1
I-1
tp14269
sS'arterial,responsiveness,to'
p14270
(F1
F0.00076452599388379206
I1
I0
I1
tp14271
sS'reduced,by,approximately'
p14272
(F1
F0.00076452599388379206
I1
I0
I1
tp14273
sS'and,should,not'
p14274
(F0
F0
I1
I1
I0
tp14275
sS'serum,level,subsequent'
p14276
(F1
F0.00076452599388379206
I1
I0
I1
tp14277
sS'caution,in,digitalized'
p14278
(F1
F0.00076452599388379206
I1
I0
I1
tp14279
sS'particularly,the,elderly'
p14280
(F1
F0.00076452599388379206
I1
I0
I1
tp14281
sS'k-ras,mutations,but'
p14282
(F1
F0.00076452599388379206
I1
I0
I1
tp14283
sS'and,other,alpha-adrenergic'
p14284
(F1
F0.00076452599388379206
I0
I1
I-1
tp14285
sS'by,and,does'
p14286
(F1
F0.00076452599388379206
I0
I1
I-1
tp14287
sS'with,myfortic,with'
p14288
(F1
F0.00076452599388379206
I1
I0
I1
tp14289
sS'drugs,at,different'
p14290
(F1
F0.00076452599388379206
I0
I1
I-1
tp14291
sS'dose,in,normal'
p14292
(F1
F0.00076452599388379206
I1
I0
I1
tp14293
sS'inhibitors,may,increase'
p14294
(F1
F0.00076452599388379206
I1
I0
I1
tp14295
sS'and,may,lead'
p14296
(F1
F0.0015290519877675841
I2
I0
I2
tp14297
sS'during,treatment,with'
p14298
(F1
F0.00076452599388379206
I1
I0
I1
tp14299
sS'day,to,mg'
p14300
(F1
F0.00076452599388379206
I0
I1
I-1
tp14301
sS'large,as,that'
p14302
(F1
F0.00076452599388379206
I0
I1
I-1
tp14303
sS'leading,to,cerebral'
p14304
(F1
F0.00076452599388379206
I0
I1
I-1
tp14305
sS'to,preclude,effectiveness'
p14306
(F1
F0.00076452599388379206
I1
I0
I1
tp14307
sS'theoretical,basis,that'
p14308
(F1
F0.00076452599388379206
I1
I0
I1
tp14309
sS'no,known,drug'
p14310
(F1
F0.00076452599388379206
I1
I0
I1
tp14311
sS'effects,of,invega'
p14312
(F1
F0.00076452599388379206
I1
I0
I1
tp14313
sS'is,significantly,lower'
p14314
(F1
F0.00076452599388379206
I0
I1
I-1
tp14315
sS'to,alter,the'
p14316
(F1
F0.0015290519877675841
I0
I2
I-2
tp14317
sS'dosage,should,be'
p14318
(F1
F0.0015290519877675841
I2
I0
I2
tp14319
sS'if,concomitant,treatment'
p14320
(F1
F0.00076452599388379206
I1
I0
I1
tp14321
sS'depressants,can,cause'
p14322
(F1
F0.00076452599388379206
I1
I0
I1
tp14323
sS'therapy,in,combination'
p14324
(F1
F0.00076452599388379206
I1
I0
I1
tp14325
sS'some,steroid,medications'
p14326
(F1
F0.00076452599388379206
I1
I0
I1
tp14327
sS'because,it,was'
p14328
(F1
F0.00076452599388379206
I1
I0
I1
tp14329
sS'four,days,with'
p14330
(F1
F0.00076452599388379206
I1
I0
I1
tp14331
sS'reduces,methyl-4,phenyl-1'
p14332
(F1
F0.00076452599388379206
I1
I0
I1
tp14333
sS'observed,at,the'
p14334
(F1
F0.00076452599388379206
I1
I0
I1
tp14335
sS'cause,marrow,depression'
p14336
(F1
F0.00076452599388379206
I1
I0
I1
tp14337
sS'serum,creatinine,is'
p14338
(F1
F0.00076452599388379206
I1
I0
I1
tp14339
sS'the,cationic,transport'
p14340
(F1
F0.0015290519877675841
I2
I0
I2
tp14341
sS'during,maintenance,of'
p14342
(F1
F0.00076452599388379206
I1
I0
I1
tp14343
sS'before,the,administration'
p14344
(F1
F0.00076452599388379206
I1
I0
I1
tp14345
sS'eg,and,nondepolarizing'
p14346
(F1
F0.00076452599388379206
I0
I1
I-1
tp14347
sS'agonist,antagonist,opioid'
p14348
(F1
F0.00076452599388379206
I1
I0
I1
tp14349
sS'to,result,in'
p14350
(F1
F0.0015290519877675841
I2
I0
I2
tp14351
sS'anti-cancer,drugs,is'
p14352
(F1
F0.00076452599388379206
I1
I0
I1
tp14353
sS'hours,and,until'
p14354
(F1
F0.00076452599388379206
I1
I0
I1
tp14355
sS'observed,in,vitro'
p14356
(F1
F0.00076452599388379206
I1
I0
I1
tp14357
sS'a,vitamin,e'
p14358
(F1
F0.00076452599388379206
I1
I0
I1
tp14359
sS'may,lead,to'
p14360
(F0.5
F0.0015290519877675841
I3
I1
I2
tp14361
sS'the,pharmacokinetic,parameters'
p14362
(F0.33333333333333331
F0.00076452599388379206
I2
I1
I1
tp14363
sS'serum,level,determinations'
p14364
(F1
F0.00076452599388379206
I1
I0
I1
tp14365
sS'dose,reductions,of'
p14366
(F1
F0.00076452599388379206
I1
I0
I1
tp14367
sS'treatment,are,likely'
p14368
(F1
F0.00076452599388379206
I0
I1
I-1
tp14369
sS'pharmacokinetics,are,not'
p14370
(F1
F0.00076452599388379206
I0
I1
I-1
tp14371
sS'or,hours,after'
p14372
(F1
F0.00076452599388379206
I1
I0
I1
tp14373
sS'mean,chloride,plasma'
p14374
(F1
F0.00076452599388379206
I1
I0
I1
tp14375
sS'a,small,but'
p14376
(F1
F0.00076452599388379206
I1
I0
I1
tp14377
sS'therapeutic,target,for'
p14378
(F1
F0.00076452599388379206
I0
I1
I-1
tp14379
sS'were,also,added'
p14380
(F1
F0.00076452599388379206
I0
I1
I-1
tp14381
sS'with,low-dose,to'
p14382
(F1
F0.00076452599388379206
I1
I0
I1
tp14383
sS'intravenous,has,caused'
p14384
(F1
F0.00076452599388379206
I1
I0
I1
tp14385
sS'oral,alkeran,vaccinations'
p14386
(F1
F0.00076452599388379206
I1
I0
I1
tp14387
sS'patients,with,normal'
p14388
(F1
F0.00076452599388379206
I1
I0
I1
tp14389
sS'that,is,not'
p14390
(F1
F0.0015290519877675841
I0
I2
I-2
tp14391
sS'of,equivalent,to'
p14392
(F1
F0.00076452599388379206
I1
I0
I1
tp14393
sS'of,dosage,may'
p14394
(F1
F0.00076452599388379206
I1
I0
I1
tp14395
sS'response,to,calcitonin'
p14396
(F1
F0.00076452599388379206
I1
I0
I1
tp14397
sS'complications,compared,to'
p14398
(F1
F0.00076452599388379206
I1
I0
I1
tp14399
sS'concomitant,mg,once'
p14400
(F1
F0.00076452599388379206
I1
I0
I1
tp14401
sS'study,of,given'
p14402
(F1
F0.00076452599388379206
I1
I0
I1
tp14403
sS'used,with,other'
p14404
(F1
F0.0015290519877675841
I2
I0
I2
tp14405
sS'levels,have,been'
p14406
(F1
F0.00076452599388379206
I1
I0
I1
tp14407
sS'a,significant,protective'
p14408
(F1
F0.00076452599388379206
I1
I0
I1
tp14409
sS'incidence,of,major'
p14410
(F1
F0.00076452599388379206
I1
I0
I1
tp14411
sS'with,particularly,at'
p14412
(F1
F0.00076452599388379206
I1
I0
I1
tp14413
sS'furosemide,clinical,studies'
p14414
(F1
F0.00076452599388379206
I1
I0
I1
tp14415
sS'consideration,in,patients'
p14416
(F1
F0.00076452599388379206
I1
I0
I1
tp14417
sS'cns,depressant,effects'
p14418
(F1
F0.0015290519877675841
I2
I0
I2
tp14419
sS'reports,of,false-positive'
p14420
(F1
F0.00076452599388379206
I0
I1
I-1
tp14421
sS'with,infusion,administered'
p14422
(F1
F0.00076452599388379206
I1
I0
I1
tp14423
sS'the,anionic,transport'
p14424
(F1
F0.00076452599388379206
I1
I0
I1
tp14425
sS'rats,demonstrated,sensitization'
p14426
(F1
F0.00076452599388379206
I0
I1
I-1
tp14427
sS'cell,lines,except'
p14428
(F1
F0.00076452599388379206
I1
I0
I1
tp14429
sS'treated,with,either'
p14430
(F1
F0.00076452599388379206
I1
I0
I1
tp14431
sS'the,university,of'
p14432
(F1
F0.00076452599388379206
I1
I0
I1
tp14433
sS'system,caused,a'
p14434
(F1
F0.00076452599388379206
I1
I0
I1
tp14435
sS'would,not,be'
p14436
(F1
F0.00076452599388379206
I0
I1
I-1
tp14437
sS'when,administering,mitotane'
p14438
(F1
F0.00076452599388379206
I1
I0
I1
tp14439
sS'thiazide,diuretics,in'
p14440
(F1
F0.00076452599388379206
I1
I0
I1
tp14441
sS'agent,should,be'
p14442
(F1
F0.00076452599388379206
I1
I0
I1
tp14443
sS'herceptin,serum,levels'
p14444
(F1
F0.00076452599388379206
I1
I0
I1
tp14445
sS'absorption,of,is'
p14446
(F1
F0.00076452599388379206
I1
I0
I1
tp14447
sS'administered,hour,after'
p14448
(F1
F0.00076452599388379206
I1
I0
I1
tp14449
sS'which,depresses,the'
p14450
(F1
F0.00076452599388379206
I1
I0
I1
tp14451
sS'a,single,dose'
p14452
(F0.5
F0.0015290519877675841
I1
I3
I-2
tp14453
sS'of,myfortic,and'
p14454
(F1
F0.00076452599388379206
I0
I1
I-1
tp14455
sS'this,is,especially'
p14456
(F1
F0.00076452599388379206
I0
I1
I-1
tp14457
sS'to,employ,appropriate'
p14458
(F1
F0.0015290519877675841
I2
I0
I2
tp14459
sS'if,cannot,be'
p14460
(F1
F0.00076452599388379206
I1
I0
I1
tp14461
sS'occurred,when,univasc'
p14462
(F1
F0.00076452599388379206
I0
I1
I-1
tp14463
sS'sedation,and,may'
p14464
(F1
F0.00076452599388379206
I1
I0
I1
tp14465
sS'reaction,has,not'
p14466
(F1
F0.00076452599388379206
I1
I0
I1
tp14467
sS'orthostatic,hypotension,that'
p14468
(F1
F0.00076452599388379206
I1
I0
I1
tp14469
sS'decreased,by,a'
p14470
(F1
F0.00076452599388379206
I1
I0
I1
tp14471
sS'indicate,that,and'
p14472
(F1
F0.00076452599388379206
I1
I0
I1
tp14473
sS'of,with,may'
p14474
(F1
F0.00076452599388379206
I1
I0
I1
tp14475
sS'such,as,cana'
p14476
(F1
F0.00076452599388379206
I1
I0
I1
tp14477
sS'in,the,amphetamine-paired'
p14478
(F1
F0.00076452599388379206
I0
I1
I-1
tp14479
sS'exhibits,anti-proliferative,effects'
p14480
(F1
F0.00076452599388379206
I1
I0
I1
tp14481
sS'metolazone,may,decrease'
p14482
(F1
F0.00076452599388379206
I1
I0
I1
tp14483
sS'might,be,associated'
p14484
(F1
F0.00076452599388379206
I1
I0
I1
tp14485
sS'and,in,acidic'
p14486
(F1
F0.00076452599388379206
I1
I0
I1
tp14487
sS'are,unknown,slightly'
p14488
(F1
F0.00076452599388379206
I1
I0
I1
tp14489
sS'fraction,control,sirna'
p14490
(F1
F0.00076452599388379206
I0
I1
I-1
tp14491
sS'of,tyrosine,hydroxylase-positive'
p14492
(F1
F0.00076452599388379206
I1
I0
I1
tp14493
sS'experiment,oral,administration'
p14494
(F1
F0.00076452599388379206
I0
I1
I-1
tp14495
sS'study,of,was'
p14496
(F1
F0.00076452599388379206
I0
I1
I-1
tp14497
sS'has,approved,brilinta-astrazeneca'
p14498
(F1
F0.00076452599388379206
I1
I0
I1
tp14499
sS'phases,the,areas'
p14500
(F1
F0.00076452599388379206
I0
I1
I-1
tp14501
sS'for,vitamin,b1'
p14502
(F1
F0.00076452599388379206
I1
I0
I1
tp14503
sS'for,vitamin,b2'
p14504
(F1
F0.00076452599388379206
I1
I0
I1
tp14505
sS'affect,the,effects'
p14506
(F1
F0.00076452599388379206
I1
I0
I1
tp14507
sS'growth,inhibition,in'
p14508
(F1
F0.00076452599388379206
I0
I1
I-1
tp14509
sS'renal,function,creatinine'
p14510
(F1
F0.00076452599388379206
I1
I0
I1
tp14511
sS'both,drugs,careful'
p14512
(F1
F0.00076452599388379206
I1
I0
I1
tp14513
sS'concentration-time,curve,extrapolated'
p14514
(F1
F0.00076452599388379206
I1
I0
I1
tp14515
sS'cyp,inhibitor,effectiveness'
p14516
(F1
F0.00076452599388379206
I0
I1
I-1
tp14517
sS'who,are,receiving'
p14518
(F1
F0.00076452599388379206
I0
I1
I-1
tp14519
sS'it,should,not'
p14520
(F1
F0.00076452599388379206
I1
I0
I1
tp14521
sS'b,or,when'
p14522
(F1
F0.00076452599388379206
I0
I1
I-1
tp14523
sS'thyroid,hormones,sedative'
p14524
(F1
F0.00076452599388379206
I0
I1
I-1
tp14525
sS'evaluated,mechanisms,of'
p14526
(F1
F0.00076452599388379206
I0
I1
I-1
tp14527
sS'when,studied,in'
p14528
(F1
F0.00076452599388379206
I0
I1
I-1
tp14529
sS'limited,effect,and'
p14530
(F1
F0.00076452599388379206
I0
I1
I-1
tp14531
sS'recommended,when,the'
p14532
(F1
F0.00076452599388379206
I1
I0
I1
tp14533
sS'conditioned,with,but'
p14534
(F1
F0.00076452599388379206
I0
I1
I-1
tp14535
sS'having,mixed,effects'
p14536
(F1
F0.00076452599388379206
I0
I1
I-1
tp14537
sS'appears,to,be'
p14538
(F1
F0.00076452599388379206
I1
I0
I1
tp14539
sS'drug,mg,kg'
p14540
(F1
F0.00076452599388379206
I0
I1
I-1
tp14541
sS'pharmacokinetic,profiles,of'
p14542
(F1
F0.00076452599388379206
I0
I1
I-1
tp14543
sS'and,following,different'
p14544
(F1
F0.00076452599388379206
I0
I1
I-1
tp14545
sS'mice,and,in'
p14546
(F1
F0.00076452599388379206
I0
I1
I-1
tp14547
sS'package,labeling,for'
p14548
(F1
F0.00076452599388379206
I0
I1
I-1
tp14549
sS'insulin,the,pharmacokinetic'
p14550
(F1
F0.00076452599388379206
I1
I0
I1
tp14551
sS'been,established,there'
p14552
(F1
F0.00076452599388379206
I1
I0
I1
tp14553
sS'doses,ranging,from'
p14554
(F1
F0.00076452599388379206
I1
I0
I1
tp14555
sS'that,can,be'
p14556
(F1
F0.00076452599388379206
I1
I0
I1
tp14557
sS'effects,of,leukine'
p14558
(F1
F0.00076452599388379206
I1
I0
I1
tp14559
sS'associated,with,and'
p14560
(F1
F0.00076452599388379206
I1
I0
I1
tp14561
sS'a,patient,taking'
p14562
(F1
F0.00076452599388379206
I1
I0
I1
tp14563
sS'when,proamatine,is'
p14564
(F1
F0.00076452599388379206
I1
I0
I1
tp14565
sS'jar,and,tail'
p14566
(F1
F0.00076452599388379206
I0
I1
I-1
tp14567
sS'with,respect,to'
p14568
(F1
F0.0015290519877675841
I0
I2
I-2
tp14569
sS'provided,with,the'
p14570
(F1
F0.00076452599388379206
I1
I0
I1
tp14571
sS'metabolism,and,caused'
p14572
(F1
F0.00076452599388379206
I1
I0
I1
tp14573
sS'doses,generally,used'
p14574
(F1
F0.00076452599388379206
I0
I1
I-1
tp14575
sS'and,h,before'
p14576
(F1
F0.00076452599388379206
I0
I1
I-1
tp14577
sS'or,is,contraindicated'
p14578
(F1
F0.00076452599388379206
I1
I0
I1
tp14579
sS'drugs,with,is'
p14580
(F1
F0.00076452599388379206
I0
I1
I-1
tp14581
sS'effect,on,dosing'
p14582
(F1
F0.00076452599388379206
I0
I1
I-1
tp14583
sS'cognitive,and,motor'
p14584
(F1
F0.00076452599388379206
I1
I0
I1
tp14585
sS'dose-dependent,antinociceptive,activity'
p14586
(F1
F0.00076452599388379206
I1
I0
I1
tp14587
sS'interaction,with,inhibitors'
p14588
(F1
F0.00076452599388379206
I0
I1
I-1
tp14589
sS'as,chloride,in'
p14590
(F1
F0.00076452599388379206
I0
I1
I-1
tp14591
sS'because,may,interfere'
p14592
(F1
F0.00076452599388379206
I1
I0
I1
tp14593
sS'co-administered,drugs,at'
p14594
(F1
F0.00076452599388379206
I0
I1
I-1
tp14595
sS'some,aluminum-,or'
p14596
(F1
F0.00076452599388379206
I1
I0
I1
tp14597
sS'a,period,of'
p14598
(F1
F0.00076452599388379206
I1
I0
I1
tp14599
sS'administration,of,spiriva'
p14600
(F1
F0.00076452599388379206
I1
I0
I1
tp14601
sS'on,clinical,pharmacokinetics'
p14602
(F1
F0.00076452599388379206
I0
I1
I-1
tp14603
sS'we,elucidated,the'
p14604
(F1
F0.00076452599388379206
I0
I1
I-1
tp14605
sS'theophylline,diflucan,increases'
p14606
(F1
F0.00076452599388379206
I1
I0
I1
tp14607
sS'mean,peak,drug'
p14608
(F1
F0.00076452599388379206
I1
I0
I1
tp14609
sS'receiving,than,in'
p14610
(F1
F0.00076452599388379206
I0
I1
I-1
tp14611
sS'reported,that,may'
p14612
(F1
F0.00076452599388379206
I1
I0
I1
tp14613
sS'used,in,patients'
p14614
(F1
F0.00076452599388379206
I0
I1
I-1
tp14615
sS'the,interaction,study'
p14616
(F1
F0.00076452599388379206
I0
I1
I-1
tp14617
sS'in,a,fold'
p14618
(F1
F0.00076452599388379206
I1
I0
I1
tp14619
sS'potent,inducers,of'
p14620
(F1
F0.00076452599388379206
I1
I0
I1
tp14621
sS'action,of,zemuron'
p14622
(F1
F0.00076452599388379206
I0
I1
I-1
tp14623
sS'dose-dependent,growth,inhibition'
p14624
(F1
F0.00076452599388379206
I0
I1
I-1
tp14625
sS'administration,may,alter'
p14626
(F1
F0.00076452599388379206
I1
I0
I1
tp14627
sS'not,always,require'
p14628
(F1
F0.00076452599388379206
I0
I1
I-1
tp14629
sS'concurrently,with,permax'
p14630
(F1
F0.00076452599388379206
I1
I0
I1
tp14631
sS'cationic,transport,system'
p14632
(F1
F0.0015290519877675841
I2
I0
I2
tp14633
sS'or,since,the'
p14634
(F1
F0.00076452599388379206
I1
I0
I1
tp14635
sS'moxifloxacin,and,lomefloxacin'
p14636
(F1
F0.00076452599388379206
I1
I0
I1
tp14637
sS'adrenergic,antagonists,because'
p14638
(F1
F0.00076452599388379206
I1
I0
I1
tp14639
sS'indicate,a,reduction'
p14640
(F1
F0.00076452599388379206
I1
I0
I1
tp14641
sS'with,paget,s'
p14642
(F1
F0.00076452599388379206
I1
I0
I1
tp14643
sS'congenital,or,acquired'
p14644
(F1
F0.00076452599388379206
I0
I1
I-1
tp14645
sS'studies,and,the'
p14646
(F1
F0.00076452599388379206
I0
I1
I-1
tp14647
sS'cisapride,there,have'
p14648
(F1
F0.00076452599388379206
I1
I0
I1
tp14649
sS'such,as,n'
p14650
(F1
F0.00076452599388379206
I0
I1
I-1
tp14651
sS'by,active,tubular'
p14652
(F1
F0.00076452599388379206
I1
I0
I1
tp14653
sS'in,which,different'
p14654
(F1
F0.00076452599388379206
I1
I0
I1
tp14655
sS'additive,sedation,and'
p14656
(F1
F0.00076452599388379206
I1
I0
I1
tp14657
sS'drs,rimmer,and'
p14658
(F1
F0.00076452599388379206
I1
I0
I1
tp14659
sS'although,they,are'
p14660
(F1
F0.00076452599388379206
I0
I1
I-1
tp14661
sS'a,course,of'
p14662
(F1
F0.00076452599388379206
I1
I0
I1
tp14663
sS'all,methyl-4,phenyl-1'
p14664
(F1
F0.00076452599388379206
I1
I0
I1
tp14665
sS'were,unaffected,in'
p14666
(F1
F0.00076452599388379206
I0
I1
I-1
tp14667
sS'of,the,neuromuscular'
p14668
(F1
F0.00076452599388379206
I0
I1
I-1
tp14669
sS'enzyme,system,may'
p14670
(F1
F0.00076452599388379206
I0
I1
I-1
tp14671
sS'to,and,of'
p14672
(F1
F0.00076452599388379206
I0
I1
I-1
tp14673
sS'by,up-regulation,of'
p14674
(F0
F0
I1
I1
I0
tp14675
sS'concentrations,of,heparinase'
p14676
(F1
F0.00076452599388379206
I0
I1
I-1
tp14677
sS'and,days,respectively'
p14678
(F1
F0.00076452599388379206
I1
I0
I1
tp14679
sS'at,mg,kg'
p14680
(F1
F0.00076452599388379206
I0
I1
I-1
tp14681
sS'that,bind,bile'
p14682
(F1
F0.00076452599388379206
I0
I1
I-1
tp14683
sS'single,mg,oral'
p14684
(F1
F0.00076452599388379206
I0
I1
I-1
tp14685
sS'directly,on,the'
p14686
(F1
F0.00076452599388379206
I1
I0
I1
tp14687
sS'nephrotoxicity,agents,increased'
p14688
(F1
F0.0015290519877675841
I0
I2
I-2
tp14689
sS'metabolite,is,reduced'
p14690
(F1
F0.00076452599388379206
I0
I1
I-1
tp14691
sS'which,low-dose,was'
p14692
(F1
F0.00076452599388379206
I0
I1
I-1
tp14693
sS'as,or,which'
p14694
(F1
F0.00076452599388379206
I1
I0
I1
tp14695
sS'with,commonly,employed'
p14696
(F1
F0.00076452599388379206
I0
I1
I-1
tp14697
sS'interfere,with,absorption'
p14698
(F1
F0.00076452599388379206
I1
I0
I1
tp14699
sS'did,not,improve'
p14700
(F1
F0.00076452599388379206
I0
I1
I-1
tp14701
sS'and,ipth,and'
p14702
(F1
F0.00076452599388379206
I1
I0
I1
tp14703
sS'ai,vaccines,and'
p14704
(F1
F0.00076452599388379206
I1
I0
I1
tp14705
sS'although,studies,to'
p14706
(F1
F0.00076452599388379206
I1
I0
I1
tp14707
sS'additive,effect,when'
p14708
(F1
F0.0015290519877675841
I2
I0
I2
tp14709
sS'hour,after,caused'
p14710
(F1
F0.00076452599388379206
I1
I0
I1
tp14711
sS'doses,mg,diminished'
p14712
(F1
F0.00076452599388379206
I1
I0
I1
tp14713
sS'eg,and,nitrous'
p14714
(F1
F0.00076452599388379206
I1
I0
I1
tp14715
sS'crossover,study,healthy'
p14716
(F1
F0.00076452599388379206
I0
I1
I-1
tp14717
sS'reported,with,feldene'
p14718
(F1
F0.00076452599388379206
I1
I0
I1
tp14719
sS'abl,kinases,on'
p14720
(F1
F0.00076452599388379206
I0
I1
I-1
tp14721
sS'acid,together,with'
p14722
(F1
F0.00076452599388379206
I1
I0
I1
tp14723
sS'discontinues,therapy,with'
p14724
(F1
F0.00076452599388379206
I1
I0
I1
tp14725
sS'alpha-2,agonists,has'
p14726
(F1
F0.00076452599388379206
I0
I1
I-1
tp14727
sS'which,are,metabolized'
p14728
(F1
F0.00076452599388379206
I1
I0
I1
tp14729
sS'primary,objective,of'
p14730
(F1
F0.00076452599388379206
I0
I1
I-1
tp14731
sS'and,had,no'
p14732
(F1
F0.00076452599388379206
I1
I0
I1
tp14733
sS'the,incubations,were'
p14734
(F1
F0.00076452599388379206
I0
I1
I-1
tp14735
sS'mptp,x,mg'
p14736
(F1
F0.00076452599388379206
I0
I1
I-1
tp14737
sS'decrease,in,prothrombin'
p14738
(F1
F0.00076452599388379206
I1
I0
I1
tp14739
sS'uncontrolled,hy-per,parathyroidism'
p14740
(F1
F0.00076452599388379206
I0
I1
I-1
tp14741
sS'be,reduced,in'
p14742
(F1
F0.0022935779816513763
I3
I0
I3
tp14743
sS'a,may,further'
p14744
(F1
F0.00076452599388379206
I0
I1
I-1
tp14745
sS'cimetidine,cimetidine,a'
p14746
(F1
F0.00076452599388379206
I1
I0
I1
tp14747
sS'other,drugs,has'
p14748
(F1
F0.0015290519877675841
I0
I2
I-2
tp14749
sS'in,patients,dosage'
p14750
(F1
F0.00076452599388379206
I0
I1
I-1
tp14751
sS'oral,dose,of'
p14752
(F1
F0.00076452599388379206
I0
I1
I-1
tp14753
sS'in,addition,dznep'
p14754
(F1
F0.00076452599388379206
I1
I0
I1
tp14755
sS'by,cyp,a4'
p14756
(F1
F0.00076452599388379206
I1
I0
I1
tp14757
sS'anticipated,and,infusion'
p14758
(F1
F0.00076452599388379206
I1
I0
I1
tp14759
sS'studies,of,tobi'
p14760
(F1
F0.00076452599388379206
I1
I0
I1
tp14761
sS'coadministration,of,an'
p14762
(F1
F0.00076452599388379206
I1
I0
I1
tp14763
sS'or,other,potent'
p14764
(F1
F0.0015290519877675841
I2
I0
I2
tp14765
sS'and,premixed,formulations'
p14766
(F1
F0.00076452599388379206
I1
I0
I1
tp14767
sS'thrombotic,cardiovascular,events'
p14768
(F1
F0.00076452599388379206
I1
I0
I1
tp14769
sS'and,its,combination'
p14770
(F1
F0.0015290519877675841
I0
I2
I-2
tp14771
sS'indicated,are,recommended'
p14772
(F1
F0.00076452599388379206
I1
I0
I1
tp14773
sS'levels,and,or'
p14774
(F1
F0.00076452599388379206
I1
I0
I1
tp14775
sS'possible,that,and'
p14776
(F1
F0.00076452599388379206
I1
I0
I1
tp14777
sS'at,the,same'
p14778
(F1
F0.0015290519877675841
I2
I0
I2
tp14779
sS'because,is,metabolized'
p14780
(F1
F0.00076452599388379206
I0
I1
I-1
tp14781
sS'that,alter,gastrointestinal'
p14782
(F1
F0.0015290519877675841
I2
I0
I2
tp14783
sS'activity,of,and'
p14784
(F1
F0.0015290519877675841
I0
I2
I-2
tp14785
sS'with,oral,mg'
p14786
(F1
F0.00076452599388379206
I0
I1
I-1
tp14787
sS'in,plasma,concentrations'
p14788
(F1
F0.00076452599388379206
I1
I0
I1
tp14789
sS'the,frequency,and'
p14790
(F1
F0.0015290519877675841
I2
I0
I2
tp14791
sS'acid,should,be'
p14792
(F1
F0.00076452599388379206
I0
I1
I-1
tp14793
sS'response,for,this'
p14794
(F1
F0.00076452599388379206
I0
I1
I-1
tp14795
sS'but,only,female'
p14796
(F1
F0.00076452599388379206
I0
I1
I-1
tp14797
sS'in,an,increase'
p14798
(F1
F0.00076452599388379206
I1
I0
I1
tp14799
sS'metabolic,pathways,involving'
p14800
(F1
F0.00076452599388379206
I0
I1
I-1
tp14801
sS'half-life,of,and'
p14802
(F1
F0.00076452599388379206
I1
I0
I1
tp14803
sS'both,drugs,remarkably'
p14804
(F1
F0.00076452599388379206
I1
I0
I1
tp14805
sS'indications,for,therapy'
p14806
(F1
F0.00076452599388379206
I0
I1
I-1
tp14807
sS'not,result,in'
p14808
(F1
F0.0015290519877675841
I0
I2
I-2
tp14809
sS'pressure,has,stabilized'
p14810
(F1
F0.00076452599388379206
I1
I0
I1
tp14811
sS'the,variability,in'
p14812
(F1
F0.00076452599388379206
I0
I1
I-1
tp14813
sS'striatal,intensity,measurements'
p14814
(F1
F0.00076452599388379206
I1
I0
I1
tp14815
sS'salicylate,drugs,will'
p14816
(F1
F0.00076452599388379206
I1
I0
I1
tp14817
sS'and,mobic,patients'
p14818
(F1
F0.00076452599388379206
I1
I0
I1
tp14819
sS'patients,showed,that'
p14820
(F1
F0.00076452599388379206
I0
I1
I-1
tp14821
sS'coumarin-type,interactions,with'
p14822
(F1
F0.00076452599388379206
I1
I0
I1
tp14823
sS'a,much,weaker'
p14824
(F1
F0.00076452599388379206
I1
I0
I1
tp14825
sS'e,acetate,supplement'
p14826
(F1
F0.00076452599388379206
I1
I0
I1
tp14827
sS'of,supplemental,vitamin'
p14828
(F1
F0.00076452599388379206
I0
I1
I-1
tp14829
sS'minor,bleeding,vs'
p14830
(F1
F0.00076452599388379206
I1
I0
I1
tp14831
sS'administrations,of,both'
p14832
(F1
F0.00076452599388379206
I1
I0
I1
tp14833
sS'the,basis,of'
p14834
(F1
F0.0015290519877675841
I2
I0
I2
tp14835
sS'information,on,drug'
p14836
(F1
F0.00076452599388379206
I0
I1
I-1
tp14837
sS'is,sequence,dependent'
p14838
(F1
F0.00076452599388379206
I1
I0
I1
tp14839
sS'for,a,change'
p14840
(F1
F0.0015290519877675841
I2
I0
I2
tp14841
sS'combination,with,or'
p14842
(F1
F0.00076452599388379206
I0
I1
I-1
tp14843
sS'been,demonstrated,with'
p14844
(F1
F0.00076452599388379206
I1
I0
I1
tp14845
sS'with,other,chelation'
p14846
(F1
F0.00076452599388379206
I1
I0
I1
tp14847
sS'of,achievement,of'
p14848
(F1
F0.00076452599388379206
I0
I1
I-1
tp14849
sS'of,bcl-2,and'
p14850
(F1
F0.0022935779816513763
I3
I0
I3
tp14851
sS'from,a,xenical'
p14852
(F1
F0.00076452599388379206
I1
I0
I1
tp14853
sS'selective,and,potent'
p14854
(F1
F0.0015290519877675841
I2
I0
I2
tp14855
sS'of,is,also'
p14856
(F1
F0.00076452599388379206
I1
I0
I1
tp14857
sS'pro-oxidant,in,the'
p14858
(F1
F0.00076452599388379206
I0
I1
I-1
tp14859
sS'with,most,other'
p14860
(F1
F0.00076452599388379206
I0
I1
I-1
tp14861
sS'activity,chronically,administered'
p14862
(F1
F0.00076452599388379206
I1
I0
I1
tp14863
sS'of,cyp2c8,such'
p14864
(F1
F0.00076452599388379206
I1
I0
I1
tp14865
sS'b,if,they'
p14866
(F1
F0.00076452599388379206
I0
I1
I-1
tp14867
sS'monitored,if,is'
p14868
(F1
F0.00076452599388379206
I1
I0
I1
tp14869
sS'three,times,a'
p14870
(F1
F0.0053516819571865441
I0
I7
I-7
tp14871
sS'kept,in,mind'
p14872
(F0
F0
I1
I1
I0
tp14873
sS'interaction,and,associated'
p14874
(F1
F0.00076452599388379206
I0
I1
I-1
tp14875
sS'orally,active,histone'
p14876
(F1
F0.00076452599388379206
I0
I1
I-1
tp14877
sS'adequate,drug-drug,interaction'
p14878
(F1
F0.00076452599388379206
I0
I1
I-1
tp14879
sS'effects,on,gastric'
p14880
(F1
F0.00076452599388379206
I1
I0
I1
tp14881
sS'combination,with,hmg-coa'
p14882
(F1
F0.00076452599388379206
I0
I1
I-1
tp14883
sS'of,the,interaction'
p14884
(F1
F0.00076452599388379206
I1
I0
I1
tp14885
sS'all,the,tests'
p14886
(F1
F0.00076452599388379206
I0
I1
I-1
tp14887
sS'agents,including,ergot'
p14888
(F1
F0.00076452599388379206
I0
I1
I-1
tp14889
sS'discontinuation,of,these'
p14890
(F1
F0.00076452599388379206
I1
I0
I1
tp14891
sS'between,these,two'
p14892
(F1
F0.00076452599388379206
I0
I1
I-1
tp14893
sS'catecholamines,in,patients'
p14894
(F1
F0.00076452599388379206
I1
I0
I1
tp14895
sS'of,declining,renal'
p14896
(F1
F0.00076452599388379206
I1
I0
I1
tp14897
sS'for,growth,inhibition'
p14898
(F1
F0.00076452599388379206
I0
I1
I-1
tp14899
sS'inhibit,cyp450,metabolism'
p14900
(F1
F0.00076452599388379206
I0
I1
I-1
tp14901
sS'ace,inhibition,curve'
p14902
(F1
F0.00076452599388379206
I0
I1
I-1
tp14903
sS'non-steroidal,anti-inflammatory,drugs'
p14904
(F1
F0.00076452599388379206
I1
I0
I1
tp14905
sS'that,rat,liver'
p14906
(F1
F0.00076452599388379206
I0
I1
I-1
tp14907
sS'of,each,other'
p14908
(F1
F0.00076452599388379206
I1
I0
I1
tp14909
sS'patient,should,be'
p14910
(F1
F0.00076452599388379206
I1
I0
I1
tp14911
sS'odds,ratio,of'
p14912
(F1
F0.00076452599388379206
I1
I0
I1
tp14913
sS'sirna,vs,difference'
p14914
(F1
F0.00076452599388379206
I0
I1
I-1
tp14915
sS'an,ssri,is'
p14916
(F1
F0.00076452599388379206
I1
I0
I1
tp14917
sS'taking,a,tricyclic'
p14918
(F1
F0.00076452599388379206
I0
I1
I-1
tp14919
sS'disposition,of,the'
p14920
(F1
F0.00076452599388379206
I0
I1
I-1
tp14921
sS'when,not,otherwise'
p14922
(F1
F0.00076452599388379206
I0
I1
I-1
tp14923
sS'administration,of,in'
p14924
(F1
F0.00076452599388379206
I1
I0
I1
tp14925
sS'hydroxide,when,used'
p14926
(F1
F0.00076452599388379206
I1
I0
I1
tp14927
sS'relationship,has,not'
p14928
(F1
F0.00076452599388379206
I1
I0
I1
tp14929
sS'administration,of,it'
p14930
(F1
F0.00076452599388379206
I1
I0
I1
tp14931
sS'however,increased,prothrombin'
p14932
(F1
F0.00076452599388379206
I1
I0
I1
tp14933
sS'which,were,all'
p14934
(F1
F0.00076452599388379206
I1
I0
I1
tp14935
sS'phase,i,trial'
p14936
(F1
F0.00076452599388379206
I0
I1
I-1
tp14937
sS'which,are,metabolised'
p14938
(F1
F0.00076452599388379206
I1
I0
I1
tp14939
sS'inhibitors,or,since'
p14940
(F1
F0.00076452599388379206
I1
I0
I1
tp14941
sS'zemuron,before,or'
p14942
(F1
F0.00076452599388379206
I0
I1
I-1
tp14943
sS'monitored,when,initiating'
p14944
(F1
F0.00076452599388379206
I1
I0
I1
tp14945
sS'study,examined,drug-drug'
p14946
(F1
F0.00076452599388379206
I0
I1
I-1
tp14947
sS'proamatine,cardiac,glycosides'
p14948
(F1
F0.00076452599388379206
I1
I0
I1
tp14949
sS'of,given,as'
p14950
(F1
F0.00076452599388379206
I1
I0
I1
tp14951
sS'may,be,potentiated'
p14952
(F0.33333333333333331
F0.00076452599388379206
I2
I1
I1
tp14953
sS'basis,of,this'
p14954
(F1
F0.0015290519877675841
I2
I0
I2
tp14955
sS'metabolism,of,ethinyl'
p14956
(F1
F0.00076452599388379206
I1
I0
I1
tp14957
sS'phenyl-1,tetrahydropyridine,mptp'
p14958
(F1
F0.00076452599388379206
I0
I1
I-1
tp14959
sS'coumarin-type,anticoagulants,phenytoin'
p14960
(F1
F0.00076452599388379206
I1
I0
I1
tp14961
sS'or,or,both'
p14962
(F1
F0.00076452599388379206
I0
I1
I-1
tp14963
sS'taking,infacol,drops'
p14964
(F1
F0.00076452599388379206
I0
I1
I-1
tp14965
sS'of,mecamylamine,may'
p14966
(F1
F0.00076452599388379206
I1
I0
I1
tp14967
sS'in,experiment,the'
p14968
(F1
F0.00076452599388379206
I1
I0
I1
tp14969
sS'drug-drug,interactions,effect'
p14970
(F1
F0.00076452599388379206
I0
I1
I-1
tp14971
sS'of,skelid,by'
p14972
(F1
F0.00076452599388379206
I1
I0
I1
tp14973
sS'in,auc,and'
p14974
(F1
F0.00076452599388379206
I1
I0
I1
tp14975
sS'compared,to,the'
p14976
(F1
F0.00076452599388379206
I1
I0
I1
tp14977
sS'observed,data,from'
p14978
(F1
F0.00076452599388379206
I1
I0
I1
tp14979
sS'with,other,anticholinergic'
p14980
(F1
F0.0015290519877675841
I2
I0
I2
tp14981
sS'or,leave,unchanged'
p14982
(F1
F0.00076452599388379206
I1
I0
I1
tp14983
sS'administered,alone,or'
p14984
(F1
F0.00076452599388379206
I0
I1
I-1
tp14985
sS'day,yielded,a'
p14986
(F1
F0.00076452599388379206
I1
I0
I1
tp14987
sS'for,days,resulted'
p14988
(F1
F0.00076452599388379206
I0
I1
I-1
tp14989
sS'or,are,receiving'
p14990
(F1
F0.00076452599388379206
I1
I0
I1
tp14991
sS'potentiate,the,myeloproliferative'
p14992
(F1
F0.00076452599388379206
I1
I0
I1
tp14993
sS'shown,to,increase'
p14994
(F1
F0.00076452599388379206
I1
I0
I1
tp14995
sS'by,approximately,half'
p14996
(F1
F0.00076452599388379206
I1
I0
I1
tp14997
sS'did,not,have'
p14998
(F1
F0.0015290519877675841
I0
I2
I-2
tp14999
sS'hours,and,auc'
p15000
(F1
F0.00076452599388379206
I1
I0
I1
tp15001
sS'hospitalization,for,gastrointestinal'
p15002
(F1
F0.00076452599388379206
I0
I1
I-1
tp15003
sS'some,patients,receiving'
p15004
(F1
F0.00076452599388379206
I1
I0
I1
tp15005
sS'for,lenalidomide-cci,interaction'
p15006
(F1
F0.00076452599388379206
I0
I1
I-1
tp15007
sS'effects,in,vitro'
p15008
(F1
F0.0015290519877675841
I2
I0
I2
tp15009
sS'of,vitamin,k'
p15010
(F1
F0.00076452599388379206
I0
I1
I-1
tp15011
sS'when,concomitant,administration'
p15012
(F1
F0.00076452599388379206
I0
I1
I-1
tp15013
sS'has,some,anti-proliferative'
p15014
(F1
F0.00076452599388379206
I1
I0
I1
tp15015
sS'concurrent,or,sequential'
p15016
(F1
F0.00076452599388379206
I0
I1
I-1
tp15017
sS'abraded,skin,of'
p15018
(F1
F0.00076452599388379206
I1
I0
I1
tp15019
sS'metaproterenol,sulfate,usp'
p15020
(F1
F0.00076452599388379206
I1
I0
I1
tp15021
sS'patients,on,coumarin-type'
p15022
(F1
F0.00076452599388379206
I1
I0
I1
tp15023
sS'may,interact,with'
p15024
(F1
F0.0038226299694189602
I5
I0
I5
tp15025
sS'alter,pharmacokinetics,and'
p15026
(F1
F0.00076452599388379206
I0
I1
I-1
tp15027
sS'antidepressants,and,other'
p15028
(F1
F0.0015290519877675841
I2
I0
I2
tp15029
sS'following,precautions,should'
p15030
(F1
F0.00076452599388379206
I1
I0
I1
tp15031
sS'metabolism,and,may'
p15032
(F1
F0.00076452599388379206
I1
I0
I1
tp15033
sS'rats,times,the'
p15034
(F1
F0.00076452599388379206
I0
I1
I-1
tp15035
sS'in,one,controlled'
p15036
(F1
F0.00076452599388379206
I1
I0
I1
tp15037
sS'at,least,days'
p15038
(F1
F0.00076452599388379206
I1
I0
I1
tp15039
sS'exhibited,dose-dependent,growth'
p15040
(F1
F0.00076452599388379206
I0
I1
I-1
tp15041
sS'were,assessed,using'
p15042
(F1
F0.00076452599388379206
I0
I1
I-1
tp15043
sS'listed,in,the'
p15044
(F1
F0.00076452599388379206
I0
I1
I-1
tp15045
sS'that,reduce,plasma'
p15046
(F1
F0.00076452599388379206
I1
I0
I1
tp15047
sS'or,other,agents'
p15048
(F1
F0.00076452599388379206
I1
I0
I1
tp15049
sS'can,be,administered'
p15050
(F1
F0.00076452599388379206
I1
I0
I1
tp15051
sS'were,not,affected'
p15052
(F1
F0.00076452599388379206
I0
I1
I-1
tp15053
sS'the,locus,coeruleus'
p15054
(F1
F0.00076452599388379206
I1
I0
I1
tp15055
sS'the,starting,dose'
p15056
(F1
F0.00076452599388379206
I0
I1
I-1
tp15057
sS'of,demser,with'
p15058
(F1
F0.00076452599388379206
I1
I0
I1
tp15059
sS'of,crm197,plus'
p15060
(F1
F0.00076452599388379206
I1
I0
I1
tp15061
sS'compared,with,quinpirole-free'
p15062
(F0
F0
I1
I1
I0
tp15063
sS'study,showed,a'
p15064
(F1
F0.00076452599388379206
I1
I0
I1
tp15065
sS'is,administered,with'
p15066
(F1
F0.0015290519877675841
I0
I2
I-2
tp15067
sS'schedules,and,between'
p15068
(F1
F0.00076452599388379206
I1
I0
I1
tp15069
sS'tested,therapeutically,relevant'
p15070
(F1
F0.00076452599388379206
I1
I0
I1
tp15071
sS'and,thus,the'
p15072
(F1
F0.00076452599388379206
I1
I0
I1
tp15073
sS'increases,the,risk'
p15074
(F1
F0.00076452599388379206
I0
I1
I-1
tp15075
sS'healthy,volunteers,to'
p15076
(F1
F0.00076452599388379206
I0
I1
I-1
tp15077
sS'increase,levels,in'
p15078
(F1
F0.00076452599388379206
I1
I0
I1
tp15079
sS'in,some,patients'
p15080
(F0.33333333333333331
F0.00076452599388379206
I2
I1
I1
tp15081
sS'zemuron,mg,kg'
p15082
(F1
F0.00076452599388379206
I0
I1
I-1
tp15083
sS'therefore,as,vitamin'
p15084
(F1
F0.00076452599388379206
I1
I0
I1
tp15085
sS'and,cotreatment,with'
p15086
(F1
F0.00076452599388379206
I1
I0
I1
tp15087
sS'of,multiple,metastatic'
p15088
(F1
F0.00076452599388379206
I1
I0
I1
tp15089
sS'gastrointestinal,bleeding,upon'
p15090
(F1
F0.00076452599388379206
I1
I0
I1
tp15091
sS'signs,of,declining'
p15092
(F1
F0.00076452599388379206
I1
I0
I1
tp15093
sS'were,routinely,treated'
p15094
(F1
F0.00076452599388379206
I0
I1
I-1
tp15095
sS'at,high,levels'
p15096
(F1
F0.00076452599388379206
I0
I1
I-1
tp15097
sS'with,and,vitamin'
p15098
(F1
F0.00076452599388379206
I1
I0
I1
tp15099
sS'other,similar,drugs'
p15100
(F1
F0.00076452599388379206
I1
I0
I1
tp15101
sS'of,the,proton'
p15102
(F1
F0.00076452599388379206
I0
I1
I-1
tp15103
sS'other,cns,depression-producing'
p15104
(F1
F0.00076452599388379206
I1
I0
I1
tp15105
sS'human,non-small,lung'
p15106
(F1
F0.00076452599388379206
I1
I0
I1
tp15107
sS'medications,can,cause'
p15108
(F1
F0.00076452599388379206
I1
I0
I1
tp15109
sS'no,clinical,data'
p15110
(F1
F0.00076452599388379206
I0
I1
I-1
tp15111
sS'osteocalcin,a,marker'
p15112
(F1
F0.00076452599388379206
I0
I1
I-1
tp15113
sS'the,dosage,and'
p15114
(F1
F0.00076452599388379206
I1
I0
I1
tp15115
sS'low-dose,in,conjunction'
p15116
(F1
F0.00076452599388379206
I0
I1
I-1
tp15117
sS'cross-resistance,with,other'
p15118
(F1
F0.00076452599388379206
I0
I1
I-1
tp15119
sS'predominantly,by,the'
p15120
(F1
F0.00076452599388379206
I1
I0
I1
tp15121
sS'with,herceptin,improved'
p15122
(F1
F0.00076452599388379206
I1
I0
I1
tp15123
sS'her2-positive,breast,cancer'
p15124
(F0.33333333333333331
F0.00076452599388379206
I1
I2
I-1
tp15125
sS'capsules,should,be'
p15126
(F1
F0.00076452599388379206
I1
I0
I1
tp15127
sS'doses,of,demonstrate'
p15128
(F1
F0.00076452599388379206
I1
I0
I1
tp15129
sS'study,investigates,the'
p15130
(F1
F0.00076452599388379206
I0
I1
I-1
tp15131
sS'although,mg,qid'
p15132
(F1
F0.00076452599388379206
I1
I0
I1
tp15133
sS'studies,demonstrated,that'
p15134
(F1
F0.00076452599388379206
I0
I1
I-1
tp15135
sS'and,or,drug'
p15136
(F1
F0.00076452599388379206
I0
I1
I-1
tp15137
sS'the,pro-oxidant,in'
p15138
(F1
F0.00076452599388379206
I0
I1
I-1
tp15139
sS'mean,pre-dose,concentration'
p15140
(F1
F0.00076452599388379206
I1
I0
I1
tp15141
sS'inhibited,absorption,of'
p15142
(F1
F0.00076452599388379206
I1
I0
I1
tp15143
sS'careful,monitoring,of'
p15144
(F1
F0.0038226299694189602
I5
I0
I5
tp15145
sS'patients,on,may'
p15146
(F1
F0.00076452599388379206
I1
I0
I1
tp15147
sS'and,others,can'
p15148
(F1
F0.00076452599388379206
I0
I1
I-1
tp15149
sS'mivacron,a,mixture'
p15150
(F1
F0.00076452599388379206
I0
I1
I-1
tp15151
sS'the,apparent,total'
p15152
(F1
F0.00076452599388379206
I1
I0
I1
tp15153
sS'revealed,that,the'
p15154
(F1
F0.00076452599388379206
I0
I1
I-1
tp15155
sS'of,aggrastat,in'
p15156
(F1
F0.00076452599388379206
I1
I0
I1
tp15157
sS'synergistic,action,of'
p15158
(F1
F0.00076452599388379206
I0
I1
I-1
tp15159
sS'with,herceptin,in'
p15160
(F1
F0.00076452599388379206
I0
I1
I-1
tp15161
sS'the,other,proton'
p15162
(F1
F0.00076452599388379206
I0
I1
I-1
tp15163
sS'evaluate,whether,the'
p15164
(F1
F0.00076452599388379206
I0
I1
I-1
tp15165
sS'found,that,concomitant'
p15166
(F1
F0.00076452599388379206
I1
I0
I1
tp15167
sS'significant,adverse,interactions'
p15168
(F1
F0.0015290519877675841
I0
I2
I-2
tp15169
sS'than,milligrams,in'
p15170
(F1
F0.00076452599388379206
I0
I1
I-1
tp15171
sS'before,hot,plate'
p15172
(F1
F0.00076452599388379206
I0
I1
I-1
tp15173
sS'layer,and,increased'
p15174
(F1
F0.00076452599388379206
I0
I1
I-1
tp15175
sS'fatality,has,been'
p15176
(F1
F0.00076452599388379206
I1
I0
I1
tp15177
sS'all,studies,and'
p15178
(F1
F0.00076452599388379206
I0
I1
I-1
tp15179
sS'concomitant,administration,of'
p15180
(F0.77777777777777779
F0.010703363914373088
I16
I2
I14
tp15181
sS'observed,at,mg'
p15182
(F1
F0.00076452599388379206
I0
I1
I-1
tp15183
sS'the,mechanism,is'
p15184
(F1
F0.00076452599388379206
I1
I0
I1
tp15185
sS'first,few,days'
p15186
(F1
F0.00076452599388379206
I1
I0
I1
tp15187
sS'prolongation,in,a'
p15188
(F1
F0.00076452599388379206
I0
I1
I-1
tp15189
sS'of,but,to'
p15190
(F1
F0.00076452599388379206
I1
I0
I1
tp15191
sS'cause,shortness,of'
p15192
(F1
F0.00076452599388379206
I1
I0
I1
tp15193
sS'and,until,blood'
p15194
(F1
F0.00076452599388379206
I1
I0
I1
tp15195
sS'resulting,in,vasospasm'
p15196
(F1
F0.00076452599388379206
I0
I1
I-1
tp15197
sS'which,include,some'
p15198
(F1
F0.00076452599388379206
I1
I0
I1
tp15199
sS'the,reported,in'
p15200
(F1
F0.00076452599388379206
I0
I1
I-1
tp15201
sS'sedative,effects,of'
p15202
(F1
F0.00076452599388379206
I1
I0
I1
tp15203
sS'receiving,azole,antifungals'
p15204
(F1
F0.00076452599388379206
I1
I0
I1
tp15205
sS'reports,of,serious'
p15206
(F1
F0.00076452599388379206
I0
I1
I-1
tp15207
sS'than,those,in'
p15208
(F1
F0.00076452599388379206
I0
I1
I-1
tp15209
sS'increased,total,concentrations'
p15210
(F0
F0
I1
I1
I0
tp15211
sS'hcl,hcl,and'
p15212
(F1
F0.00076452599388379206
I1
I0
I1
tp15213
sS'healthy,volunteers,ingested'
p15214
(F1
F0.00076452599388379206
I0
I1
I-1
tp15215
sS'the,kinetics,of'
p15216
(F1
F0.0022935779816513763
I0
I3
I-3
tp15217
sS'was,noticeably,effective'
p15218
(F1
F0.00076452599388379206
I0
I1
I-1
tp15219
sS'analgesic,agents,and'
p15220
(F1
F0.00076452599388379206
I0
I1
I-1
tp15221
sS'or,enhances,sensitivity'
p15222
(F1
F0.00076452599388379206
I1
I0
I1
tp15223
sS'not,be,an'
p15224
(F1
F0.00076452599388379206
I0
I1
I-1
tp15225
sS'up-regulation,of,cell'
p15226
(F1
F0.00076452599388379206
I1
I0
I1
tp15227
sS'has,a,much'
p15228
(F1
F0.00076452599388379206
I1
I0
I1
tp15229
sS's-ketamine,should,be'
p15230
(F1
F0.00076452599388379206
I1
I0
I1
tp15231
sS'terfenadine,cisapride,astemizole'
p15232
(F1
F0.00076452599388379206
I1
I0
I1
tp15233
sS'also,which,is'
p15234
(F1
F0.00076452599388379206
I1
I0
I1
tp15235
sS'hcl,was,administered'
p15236
(F1
F0.00076452599388379206
I1
I0
I1
tp15237
sS'had,a,limited'
p15238
(F1
F0.00076452599388379206
I0
I1
I-1
tp15239
sS'in,a,formal'
p15240
(F0
F0
I1
I1
I0
tp15241
sS'medicines,for,pain'
p15242
(F1
F0.00076452599388379206
I0
I1
I-1
tp15243
sS'tolectin,and,other'
p15244
(F1
F0.00076452599388379206
I1
I0
I1
tp15245
sS'were,carried,out'
p15246
(F1
F0.00076452599388379206
I0
I1
I-1
tp15247
sS'receiving,cylert,concomitantly'
p15248
(F1
F0.00076452599388379206
I1
I0
I1
tp15249
sS'receiving,treatment,although'
p15250
(F1
F0.00076452599388379206
I0
I1
I-1
tp15251
sS'kg,of,bw'
p15252
(F1
F0.00076452599388379206
I0
I1
I-1
tp15253
sS'the,influence,of'
p15254
(F1
F0.00076452599388379206
I0
I1
I-1
tp15255
sS'within,hours,after'
p15256
(F1
F0.00076452599388379206
I1
I0
I1
tp15257
sS'may,interfere,with'
p15258
(F1
F0.0045871559633027525
I6
I0
I6
tp15259
sS'in,overall,exposure'
p15260
(F1
F0.00076452599388379206
I1
I0
I1
tp15261
sS'fixed,combination,as'
p15262
(F1
F0.00076452599388379206
I1
I0
I1
tp15263
sS'prolong,the,elimination'
p15264
(F1
F0.00076452599388379206
I1
I0
I1
tp15265
sS'warrant,dosage,adjustment'
p15266
(F1
F0.00076452599388379206
I0
I1
I-1
tp15267
sS'known,inhibitor,of'
p15268
(F0
F0
I1
I1
I0
tp15269
sS'be,a,promising'
p15270
(F1
F0.00076452599388379206
I0
I1
I-1
tp15271
sS'can,be,a'
p15272
(F1
F0.00076452599388379206
I0
I1
I-1
tp15273
sS'prolonged,sedation,and'
p15274
(F1
F0.00076452599388379206
I1
I0
I1
tp15275
sS'inhibitors,reduce,clearance'
p15276
(F1
F0.00076452599388379206
I1
I0
I1
tp15277
sS'dose,of,meq'
p15278
(F1
F0.00076452599388379206
I1
I0
I1
tp15279
sS'c,patients,concomitantly'
p15280
(F1
F0.00076452599388379206
I1
I0
I1
tp15281
sS'of,a,specific'
p15282
(F1
F0.00076452599388379206
I0
I1
I-1
tp15283
sS'to,the,potential'
p15284
(F1
F0.00076452599388379206
I1
I0
I1
tp15285
sS'possible,the,starting'
p15286
(F1
F0.00076452599388379206
I0
I1
I-1
tp15287
sS'determinant,of,effectiveness'
p15288
(F1
F0.00076452599388379206
I1
I0
I1
tp15289
sS'of,and,hydrochloride'
p15290
(F1
F0.00076452599388379206
I1
I0
I1
tp15291
sS'phase,whereas,arrested'
p15292
(F1
F0.00076452599388379206
I0
I1
I-1
tp15293
sS'a,large,compassionate'
p15294
(F1
F0.00076452599388379206
I0
I1
I-1
tp15295
sS'signs,of,atropinization'
p15296
(F1
F0.00076452599388379206
I1
I0
I1
tp15297
sS'is,not,listed'
p15298
(F1
F0.00076452599388379206
I0
I1
I-1
tp15299
sS'decreased,dasatinib-,and'
p15300
(F1
F0.00076452599388379206
I0
I1
I-1
tp15301
sS'of,was,not'
p15302
(F1
F0.00076452599388379206
I0
I1
I-1
tp15303
sS'convert,herceptin-refractory,to'
p15304
(F1
F0.00076452599388379206
I0
I1
I-1
tp15305
sS'alpha,lipoic,acid'
p15306
(F1
F0.00076452599388379206
I0
I1
I-1
tp15307
sS'the,mexitil,dose'
p15308
(F1
F0.00076452599388379206
I1
I0
I1
tp15309
sS'and,may,decrease'
p15310
(F1
F0.00076452599388379206
I1
I0
I1
tp15311
sS'after,topical,application'
p15312
(F1
F0.00076452599388379206
I1
I0
I1
tp15313
sS'sequential,administration,of'
p15314
(F0
F0
I1
I1
I0
tp15315
sS'and,performance,were'
p15316
(F1
F0.00076452599388379206
I0
I1
I-1
tp15317
sS'pain,medicines,to'
p15318
(F1
F0.00076452599388379206
I0
I1
I-1
tp15319
sS'inhalational,agents,analgesic'
p15320
(F1
F0.00076452599388379206
I0
I1
I-1
tp15321
sS'lines,and,evaluated'
p15322
(F1
F0.00076452599388379206
I0
I1
I-1
tp15323
sS'the,bactericidal,action'
p15324
(F1
F0.00076452599388379206
I1
I0
I1
tp15325
sS'pediatric,oncology,patients'
p15326
(F1
F0.00076452599388379206
I0
I1
I-1
tp15327
sS'nonsteroidal,anti-inflammatory,drugs'
p15328
(F0
F0
I1
I1
I0
tp15329
sS'only,enhanced,but'
p15330
(F1
F0.00076452599388379206
I1
I0
I1
tp15331
sS'calcium,was,administered'
p15332
(F1
F0.00076452599388379206
I0
I1
I-1
tp15333
sS'extracellular,matrix,degrading'
p15334
(F1
F0.00076452599388379206
I0
I1
I-1
tp15335
sS'studied,in,stable'
p15336
(F1
F0.00076452599388379206
I0
I1
I-1
tp15337
sS'no,clinically,important'
p15338
(F1
F0.00076452599388379206
I0
I1
I-1
tp15339
sS'the,absence,and'
p15340
(F1
F0.00076452599388379206
I0
I1
I-1
tp15341
sS'pills,medicines,for'
p15342
(F1
F0.00076452599388379206
I0
I1
I-1
tp15343
sS'of,dose,was'
p15344
(F1
F0.00076452599388379206
I0
I1
I-1
tp15345
sS'steroids,or,acth'
p15346
(F1
F0.00076452599388379206
I0
I1
I-1
tp15347
sS'zavesca,appeared,to'
p15348
(F1
F0.00076452599388379206
I1
I0
I1
tp15349
sS'was,the,second'
p15350
(F1
F0.00076452599388379206
I1
I0
I1
tp15351
sS'drugs,may,be'
p15352
(F0
F0
I1
I1
I0
tp15353
sS'secretion,population,pharmacokinetic'
p15354
(F1
F0.00076452599388379206
I1
I0
I1
tp15355
sS'warfarin,the,coadministration'
p15356
(F1
F0.00076452599388379206
I0
I1
I-1
tp15357
sS'pointe,as,a'
p15358
(F1
F0.00076452599388379206
I1
I0
I1
tp15359
sS'returned,to,pre-mexitil'
p15360
(F1
F0.00076452599388379206
I1
I0
I1
tp15361
sS'administration,of,trental'
p15362
(F1
F0.00076452599388379206
I1
I0
I1
tp15363
sS'imaging,data,and'
p15364
(F1
F0.00076452599388379206
I1
I0
I1
tp15365
sS'bioavailability,of,was'
p15366
(F1
F0.00076452599388379206
I0
I1
I-1
tp15367
sS'in,found,that'
p15368
(F1
F0.00076452599388379206
I1
I0
I1
tp15369
sS'components,because,it'
p15370
(F1
F0.00076452599388379206
I1
I0
I1
tp15371
sS'on,prothrombin,time'
p15372
(F1
F0.00076452599388379206
I0
I1
I-1
tp15373
sS'with,drugs,may'
p15374
(F1
F0.00076452599388379206
I1
I0
I1
tp15375
sS'may,counteract,the'
p15376
(F1
F0.00076452599388379206
I1
I0
I1
tp15377
sS'may,develop,delirium'
p15378
(F1
F0.00076452599388379206
I1
I0
I1
tp15379
sS'mg,kg,s-ketamine'
p15380
(F1
F0.00076452599388379206
I0
I1
I-1
tp15381
sS'is,contraindicated,selective'
p15382
(F1
F0.00076452599388379206
I1
I0
I1
tp15383
sS'but,significant,increase'
p15384
(F1
F0.00076452599388379206
I1
I0
I1
tp15385
sS'two,classes,of'
p15386
(F1
F0.00076452599388379206
I0
I1
I-1
tp15387
sS'drug-drug,interaction,study'
p15388
(F0.33333333333333331
F0.00076452599388379206
I2
I1
I1
tp15389
sS'n,did,not'
p15390
(F1
F0.00076452599388379206
I0
I1
I-1
tp15391
sS'does,not,inhibit'
p15392
(F1
F0.0015290519877675841
I0
I2
I-2
tp15393
sS'prescribing,isoenzyme,cyp'
p15394
(F1
F0.00076452599388379206
I1
I0
I1
tp15395
sS'for,the,purpose'
p15396
(F1
F0.00076452599388379206
I0
I1
I-1
tp15397
sS'between,purinethol,and'
p15398
(F1
F0.00076452599388379206
I1
I0
I1
tp15399
sS'fluoroquinolone,used,in'
p15400
(F1
F0.00076452599388379206
I0
I1
I-1
tp15401
sS'in,connection,with'
p15402
(F1
F0.00076452599388379206
I0
I1
I-1
tp15403
sS'since,patients,on'
p15404
(F1
F0.00076452599388379206
I1
I0
I1
tp15405
sS'patients,with,congenital'
p15406
(F1
F0.00076452599388379206
I0
I1
I-1
tp15407
sS'the,same,subjects'
p15408
(F1
F0.00076452599388379206
I1
I0
I1
tp15409
sS'with,against,isolates'
p15410
(F1
F0.00076452599388379206
I0
I1
I-1
tp15411
sS'when,given,with'
p15412
(F1
F0.0015290519877675841
I2
I0
I2
tp15413
sS'effects,of,other'
p15414
(F1
F0.00076452599388379206
I1
I0
I1
tp15415
sS'patients,studied,in'
p15416
(F1
F0.00076452599388379206
I0
I1
I-1
tp15417
sS'of,or,other'
p15418
(F1
F0.00076452599388379206
I1
I0
I1
tp15419
sS'present,a,case'
p15420
(F1
F0.00076452599388379206
I1
I0
I1
tp15421
sS'cell,lines,that'
p15422
(F1
F0.00076452599388379206
I0
I1
I-1
tp15423
sS'bicarbonate,to,parenteral'
p15424
(F1
F0.00076452599388379206
I0
I1
I-1
tp15425
sS'as,an,approach'
p15426
(F1
F0.00076452599388379206
I1
I0
I1
tp15427
sS'that,produced,an'
p15428
(F1
F0.00076452599388379206
I0
I1
I-1
tp15429
sS'can,increase,their'
p15430
(F1
F0.00076452599388379206
I1
I0
I1
tp15431
sS'been,studied,and'
p15432
(F1
F0.00076452599388379206
I1
I0
I1
tp15433
sS'the,following,precautions'
p15434
(F1
F0.00076452599388379206
I1
I0
I1
tp15435
sS'dosage,adjustment,for'
p15436
(F1
F0.00076452599388379206
I1
I0
I1
tp15437
sS'is,evidence,that'
p15438
(F1
F0.0015290519877675841
I2
I0
I2
tp15439
sS'that,the,high'
p15440
(F1
F0.00076452599388379206
I1
I0
I1
tp15441
sS'concentrations,of,bismuth'
p15442
(F1
F0.00076452599388379206
I1
I0
I1
tp15443
sS'synergistic,effect,may'
p15444
(F1
F0.00076452599388379206
I1
I0
I1
tp15445
sS'theophylline,clearance,may'
p15446
(F1
F0.00076452599388379206
I0
I1
I-1
tp15447
sS'than,might,be'
p15448
(F1
F0.00076452599388379206
I1
I0
I1
tp15449
sS'with,and,leading'
p15450
(F1
F0.00076452599388379206
I1
I0
I1
tp15451
sS'prior,administration,of'
p15452
(F1
F0.00076452599388379206
I1
I0
I1
tp15453
sS'it,will,compete'
p15454
(F1
F0.00076452599388379206
I0
I1
I-1
tp15455
sS'of,atropinization,flushing'
p15456
(F1
F0.00076452599388379206
I1
I0
I1
tp15457
sS'or,following,administration'
p15458
(F1
F0.00076452599388379206
I0
I1
I-1
tp15459
sS'due,to,both'
p15460
(F1
F0.00076452599388379206
I0
I1
I-1
tp15461
sS'and,nutritionally-derived,vitamin'
p15462
(F1
F0.00076452599388379206
I0
I1
I-1
tp15463
sS'when,taken,hours'
p15464
(F1
F0.00076452599388379206
I1
I0
I1
tp15465
sS'richens,at,the'
p15466
(F1
F0.00076452599388379206
I1
I0
I1
tp15467
sS'safety,of,gsls'
p15468
(F1
F0.00076452599388379206
I0
I1
I-1
tp15469
sS'prolonged,prothrombin,time'
p15470
(F1
F0.00076452599388379206
I1
I0
I1
tp15471
sS'cyp2c8,such,as'
p15472
(F1
F0.00076452599388379206
I1
I0
I1
tp15473
sS'kg,g,kg'
p15474
(F1
F0.00076452599388379206
I0
I1
I-1
tp15475
sS'or,the,combination'
p15476
(F1
F0.00076452599388379206
I0
I1
I-1
tp15477
sS'fu,has,been'
p15478
(F1
F0.00076452599388379206
I0
I1
I-1
tp15479
sS'administered,with,can'
p15480
(F1
F0.00076452599388379206
I1
I0
I1
tp15481
sS'metabolite,an,oral'
p15482
(F1
F0.00076452599388379206
I0
I1
I-1
tp15483
sS'slow,the,intestinal'
p15484
(F1
F0.00076452599388379206
I1
I0
I1
tp15485
sS'in,a,woman'
p15486
(F1
F0.00076452599388379206
I0
I1
I-1
tp15487
sS'cyp450,enzyme,inducer'
p15488
(F1
F0.00076452599388379206
I1
I0
I1
tp15489
sS'pharmacological,effects,may'
p15490
(F1
F0.00076452599388379206
I1
I0
I1
tp15491
sS'and,apparent,oral'
p15492
(F1
F0.00076452599388379206
I1
I0
I1
tp15493
sS'total,dose,of'
p15494
(F1
F0.00076452599388379206
I0
I1
I-1
tp15495
sS'anticoagulation,and,antiplatelets'
p15496
(F1
F0.00076452599388379206
I0
I1
I-1
tp15497
sS'taking,the,recommended'
p15498
(F1
F0.00076452599388379206
I1
I0
I1
tp15499
sS'nitrogen,substituted,imidazole'
p15500
(F1
F0.00076452599388379206
I1
I0
I1
tp15501
sS'anti-inflammatory,drugs,have'
p15502
(F1
F0.00076452599388379206
I1
I0
I1
tp15503
sS'tomography,dopamine,transporter'
p15504
(F1
F0.00076452599388379206
I1
I0
I1
tp15505
sS'dose,from,mg'
p15506
(F1
F0.00076452599388379206
I0
I1
I-1
tp15507
sS'p27,kip1,mediated'
p15508
(F1
F0.00076452599388379206
I1
I0
I1
tp15509
sS'metabolism,of,is'
p15510
(F1
F0.00076452599388379206
I0
I1
I-1
tp15511
sS'agents,h2,blockers'
p15512
(F1
F0.00076452599388379206
I0
I1
I-1
tp15513
sS'observed,in,patients'
p15514
(F0
F0
I1
I1
I0
tp15515
sS'and,additional,birth'
p15516
(F1
F0.00076452599388379206
I1
I0
I1
tp15517
sS'therapy,may,require'
p15518
(F1
F0.00076452599388379206
I1
I0
I1
tp15519
sS'the,recommended,doses'
p15520
(F1
F0.00076452599388379206
I1
I0
I1
tp15521
sS'which,a,second'
p15522
(F1
F0.00076452599388379206
I1
I0
I1
tp15523
sS'period,of,days'
p15524
(F1
F0.00076452599388379206
I1
I0
I1
tp15525
sS'days,with,infusion'
p15526
(F1
F0.00076452599388379206
I1
I0
I1
tp15527
sS'of,low-dose,with'
p15528
(F1
F0.00076452599388379206
I1
I0
I1
tp15529
sS'herceptin,improved,the'
p15530
(F1
F0.00076452599388379206
I1
I0
I1
tp15531
sS'effective,in,reducing'
p15532
(F1
F0.00076452599388379206
I0
I1
I-1
tp15533
sS'use,on,the'
p15534
(F1
F0.00076452599388379206
I0
I1
I-1
tp15535
sS'the,vascular,system'
p15536
(F1
F0.00076452599388379206
I1
I0
I1
tp15537
sS'interactions,drugs,that'
p15538
(F1
F0.00076452599388379206
I0
I1
I-1
tp15539
sS'of,folic,acid'
p15540
(F1
F0.00076452599388379206
I1
I0
I1
tp15541
sS'live,virus,vaccines'
p15542
(F1
F0.00076452599388379206
I1
I0
I1
tp15543
sS'anticholinergic,drugs,in'
p15544
(F1
F0.00076452599388379206
I1
I0
I1
tp15545
sS'to,avoid,prescribing'
p15546
(F1
F0.00076452599388379206
I1
I0
I1
tp15547
sS'used,cautiously,if'
p15548
(F1
F0.00076452599388379206
I1
I0
I1
tp15549
sS'hypothyroidism,on,who'
p15550
(F1
F0.00076452599388379206
I1
I0
I1
tp15551
sS'as,to,assure'
p15552
(F1
F0.00076452599388379206
I1
I0
I1
tp15553
sS'used,cautiously,in'
p15554
(F1
F0.0022935779816513763
I3
I0
I3
tp15555
sS'other,drugs,to'
p15556
(F1
F0.00076452599388379206
I0
I1
I-1
tp15557
sS'was,to,ascertain'
p15558
(F1
F0.00076452599388379206
I0
I1
I-1
tp15559
sS'increased,intraocular,pressure'
p15560
(F1
F0.00076452599388379206
I1
I0
I1
tp15561
sS'and,local,anesthetic'
p15562
(F1
F0.00076452599388379206
I0
I1
I-1
tp15563
sS'taking,beta,adrenergic'
p15564
(F1
F0.00076452599388379206
I1
I0
I1
tp15565
sS'and,protease,inhibitors'
p15566
(F1
F0.00076452599388379206
I0
I1
I-1
tp15567
sS'have,a,significant'
p15568
(F1
F0.00076452599388379206
I0
I1
I-1
tp15569
sS'cyp1a2,enzymes,inhibition'
p15570
(F1
F0.00076452599388379206
I0
I1
I-1
tp15571
sS'may,be,decreased'
p15572
(F1
F0.0015290519877675841
I2
I0
I2
tp15573
sS'in,supplement,absorption'
p15574
(F1
F0.00076452599388379206
I1
I0
I1
tp15575
sS'therefore,when,coadministered'
p15576
(F1
F0.00076452599388379206
I0
I1
I-1
tp15577
sS'increase,serum,levels'
p15578
(F1
F0.00076452599388379206
I1
I0
I1
tp15579
sS'have,not,demonstrated'
p15580
(F1
F0.00076452599388379206
I0
I1
I-1
tp15581
sS'increase,in,ethinyl'
p15582
(F1
F0.00076452599388379206
I1
I0
I1
tp15583
sS'enhance,the,effects'
p15584
(F1
F0.00076452599388379206
I1
I0
I1
tp15585
sS'increased,odds,ratio'
p15586
(F1
F0.00076452599388379206
I1
I0
I1
tp15587
sS'in,the,liver'
p15588
(F1
F0.00076452599388379206
I1
I0
I1
tp15589
sS'mainly,comes,from'
p15590
(F1
F0.00076452599388379206
I1
I0
I1
tp15591
sS'during,anesthesia,and'
p15592
(F1
F0.0015290519877675841
I2
I0
I2
tp15593
sS'with,and,has'
p15594
(F1
F0.00076452599388379206
I1
I0
I1
tp15595
sS'patients,in,two'
p15596
(F1
F0.00076452599388379206
I0
I1
I-1
tp15597
sS'overall,mean,increase'
p15598
(F1
F0.00076452599388379206
I1
I0
I1
tp15599
sS'been,studied,on'
p15600
(F0
F0
I1
I1
I0
tp15601
sS'concurrently,with,prothrombin'
p15602
(F1
F0.00076452599388379206
I1
I0
I1
tp15603
sS'agents,may,increase'
p15604
(F1
F0.00076452599388379206
I1
I0
I1
tp15605
sS'concurrently,with,drugs'
p15606
(F1
F0.00076452599388379206
I0
I1
I-1
tp15607
sS'topical,administration,because'
p15608
(F1
F0.00076452599388379206
I0
I1
I-1
tp15609
sS'administration,of,xenical'
p15610
(F1
F0.00076452599388379206
I0
I1
I-1
tp15611
sS'auc,values,with'
p15612
(F1
F0.00076452599388379206
I0
I1
I-1
tp15613
sS'pharmacokinetic,properties,of'
p15614
(F1
F0.00076452599388379206
I0
I1
I-1
tp15615
sS'conditioned,with,high-dose'
p15616
(F1
F0.00076452599388379206
I1
I0
I1
tp15617
sS'reported,to,lower'
p15618
(F1
F0.00076452599388379206
I1
I0
I1
tp15619
sS'serum,levels,of'
p15620
(F1
F0.0022935779816513763
I3
I0
I3
tp15621
sS'half-lives,all,patients'
p15622
(F1
F0.00076452599388379206
I1
I0
I1
tp15623
sS'diazepam,concomitant,administration'
p15624
(F1
F0.00076452599388379206
I1
I0
I1
tp15625
sS'in,another,formal'
p15626
(F1
F0.00076452599388379206
I0
I1
I-1
tp15627
sS'as,sulfate,and'
p15628
(F1
F0.00076452599388379206
I1
I0
I1
tp15629
sS'with,cns,depressant'
p15630
(F1
F0.00076452599388379206
I1
I0
I1
tp15631
sS'drug,interaction,studies'
p15632
(F0
F0
I1
I1
I0
tp15633
sS'of,with,or'
p15634
(F1
F0.0015290519877675841
I2
I0
I2
tp15635
sS'serum,levels,or'
p15636
(F1
F0.0015290519877675841
I2
I0
I2
tp15637
sS'adjustment,for,is'
p15638
(F1
F0.00076452599388379206
I1
I0
I1
tp15639
sS'rate,of,diprivan'
p15640
(F1
F0.00076452599388379206
I1
I0
I1
tp15641
sS'evaluated,how,interacts'
p15642
(F1
F0.00076452599388379206
I0
I1
I-1
tp15643
sS'of,symlin,were'
p15644
(F1
F0.00076452599388379206
I1
I0
I1
tp15645
sS'carbamazepine,and,rifampicin'
p15646
(F1
F0.00076452599388379206
I1
I0
I1
tp15647
sS'their,combination,normalized'
p15648
(F1
F0.00076452599388379206
I1
I0
I1
tp15649
sS'as,and,may'
p15650
(F0.7142857142857143
F0.0038226299694189602
I6
I1
I5
tp15651
sS'these,enzymes,in'
p15652
(F1
F0.00076452599388379206
I0
I1
I-1
tp15653
sS'a,cytochrome,p450'
p15654
(F0
F0
I1
I1
I0
tp15655
sS'on,the,basis'
p15656
(F1
F0.0015290519877675841
I2
I0
I2
tp15657
sS'for,combination,of'
p15658
(F1
F0.00076452599388379206
I0
I1
I-1
tp15659
sS'this,experience,we'
p15660
(F1
F0.00076452599388379206
I1
I0
I1
tp15661
sS'pr,qrs,and'
p15662
(F1
F0.00076452599388379206
I0
I1
I-1
tp15663
sS'seizures,such,as'
p15664
(F1
F0.00076452599388379206
I0
I1
I-1
tp15665
sS'may,change,the'
p15666
(F1
F0.00076452599388379206
I0
I1
I-1
tp15667
sS'compared,with,traditional'
p15668
(F1
F0.00076452599388379206
I1
I0
I1
tp15669
sS'studies,indicate,that'
p15670
(F1
F0.0015290519877675841
I2
I0
I2
tp15671
sS'by,steady,state'
p15672
(F1
F0.00076452599388379206
I0
I1
I-1
tp15673
sS'to,depress,plasma'
p15674
(F1
F0.00076452599388379206
I1
I0
I1
tp15675
sS'patients,already,receiving'
p15676
(F1
F0.00076452599388379206
I1
I0
I1
tp15677
sS'occur,when,is'
p15678
(F1
F0.00076452599388379206
I1
I0
I1
tp15679
sS'with,is,initiated'
p15680
(F1
F0.00076452599388379206
I0
I1
I-1
tp15681
sS'interactions,with,coumarin-type'
p15682
(F1
F0.00076452599388379206
I1
I0
I1
tp15683
sS'of,will,influence'
p15684
(F1
F0.00076452599388379206
I1
I0
I1
tp15685
sS'with,prevention,of'
p15686
(F1
F0.00076452599388379206
I1
I0
I1
tp15687
sS'may,compete,for'
p15688
(F1
F0.00076452599388379206
I0
I1
I-1
tp15689
sS'great,caution,or'
p15690
(F1
F0.0015290519877675841
I2
I0
I2
tp15691
sS'clinical,drug-drug,interaction'
p15692
(F1
F0.00076452599388379206
I0
I1
I-1
tp15693
sS'steady,state,did'
p15694
(F1
F0.0015290519877675841
I0
I2
I-2
tp15695
sS'interactions,the,pharmacokinetic'
p15696
(F1
F0.00076452599388379206
I0
I1
I-1
tp15697
sS'cyp2a6,cyp2c9,and'
p15698
(F1
F0.00076452599388379206
I0
I1
I-1
tp15699
sS'diffusion,tests,when'
p15700
(F1
F0.00076452599388379206
I1
I0
I1
tp15701
sS'decreased,by,when'
p15702
(F1
F0.0015290519877675841
I2
I0
I2
tp15703
sS'use,of,hydrochloride'
p15704
(F1
F0.0030581039755351682
I4
I0
I4
tp15705
sS'of,toxicity,have'
p15706
(F0
F0
I1
I1
I0
tp15707
sS'of,did,not'
p15708
(F1
F0.0015290519877675841
I0
I2
I-2
tp15709
sS'whereas,treatment,did'
p15710
(F1
F0.00076452599388379206
I1
I0
I1
tp15711
sS'system,depressants,the'
p15712
(F1
F0.00076452599388379206
I1
I0
I1
tp15713
sS'myfortic,with,caution'
p15714
(F1
F0.00076452599388379206
I1
I0
I1
tp15715
sS'the,ratio,of'
p15716
(F1
F0.00076452599388379206
I0
I1
I-1
tp15717
sS'in,a,non-human'
p15718
(F1
F0.00076452599388379206
I1
I0
I1
tp15719
sS'intramuscularly,injected,with'
p15720
(F1
F0.00076452599388379206
I0
I1
I-1
tp15721
sS'a,cyp450,enzyme'
p15722
(F1
F0.00076452599388379206
I1
I0
I1
tp15723
sS'not,studied,the'
p15724
(F1
F0.00076452599388379206
I1
I0
I1
tp15725
sS'alkaloid,drugs,and'
p15726
(F1
F0.00076452599388379206
I0
I1
I-1
tp15727
sS'clinical,isolates,of'
p15728
(F1
F0.00076452599388379206
I0
I1
I-1
tp15729
sS'female,rats,neonatally'
p15730
(F1
F0.00076452599388379206
I0
I1
I-1
tp15731
sS'on,the,qt'
p15732
(F1
F0.00076452599388379206
I0
I1
I-1
tp15733
sS'with,other,highly'
p15734
(F1
F0.00076452599388379206
I1
I0
I1
tp15735
sS'salicylic,acid,to'
p15736
(F1
F0.00076452599388379206
I1
I0
I1
tp15737
sS'qtc,interval,in'
p15738
(F1
F0.00076452599388379206
I1
I0
I1
tp15739
sS'system,are,concomitantly'
p15740
(F1
F0.00076452599388379206
I1
I0
I1
tp15741
sS'inhibitors,reports,suggest'
p15742
(F1
F0.00076452599388379206
I1
I0
I1
tp15743
sS'group,mg,kg'
p15744
(F1
F0.00076452599388379206
I0
I1
I-1
tp15745
sS'its,metabolism,increasing'
p15746
(F1
F0.00076452599388379206
I1
I0
I1
tp15747
sS'in,exposure,following'
p15748
(F1
F0.00076452599388379206
I0
I1
I-1
tp15749
sS'in,mice,co-administration'
p15750
(F1
F0.00076452599388379206
I1
I0
I1
tp15751
sS'including,a,range'
p15752
(F1
F0.00076452599388379206
I0
I1
I-1
tp15753
sS'of,bacteriostatic,may'
p15754
(F1
F0.00076452599388379206
I1
I0
I1
tp15755
sS'of,their,mechanism'
p15756
(F1
F0.00076452599388379206
I1
I0
I1
tp15757
sS'depression,and,possible'
p15758
(F1
F0.00076452599388379206
I0
I1
I-1
tp15759
sS'or,both,sj'
p15760
(F1
F0.00076452599388379206
I0
I1
I-1
tp15761
sS'the,coadministration,of'
p15762
(F0.20000000000000001
F0.00076452599388379206
I3
I2
I1
tp15763
sS'basis,of,available'
p15764
(F1
F0.00076452599388379206
I1
I0
I1
tp15765
sS'for,other,drugs'
p15766
(F1
F0.00076452599388379206
I0
I1
I-1
tp15767
sS'cmax,and,for'
p15768
(F1
F0.00076452599388379206
I1
I0
I1
tp15769
sS'be,diminished,by'
p15770
(F1
F0.00076452599388379206
I1
I0
I1
tp15771
sS'medications,certain,heart'
p15772
(F1
F0.00076452599388379206
I1
I0
I1
tp15773
sS'hypokalemia,may,develop'
p15774
(F1
F0.00076452599388379206
I0
I1
I-1
tp15775
sS'when,hyperthyroid,patients'
p15776
(F1
F0.0015290519877675841
I0
I2
I-2
tp15777
sS'sedative,non-steroidal,anti-inflammatory'
p15778
(F1
F0.00076452599388379206
I0
I1
I-1
tp15779
sS'safety,and,effectiveness'
p15780
(F1
F0.00076452599388379206
I0
I1
I-1
tp15781
sS'effects,of,neonatal'
p15782
(F1
F0.00076452599388379206
I0
I1
I-1
tp15783
sS'on,serotonin,and'
p15784
(F1
F0.00076452599388379206
I0
I1
I-1
tp15785
sS'binding,sites,will'
p15786
(F1
F0.00076452599388379206
I0
I1
I-1
tp15787
sS'be,contributing,to'
p15788
(F1
F0.00076452599388379206
I0
I1
I-1
tp15789
sS'or,cardiac,arrythmias'
p15790
(F1
F0.00076452599388379206
I1
I0
I1
tp15791
sS'patient,controlled,administration'
p15792
(F1
F0.00076452599388379206
I1
I0
I1
tp15793
sS'parameters,of,or'
p15794
(F1
F0.00076452599388379206
I0
I1
I-1
tp15795
sS'or,oral,activated'
p15796
(F1
F0.00076452599388379206
I1
I0
I1
tp15797
sS'therapy,is,initiated'
p15798
(F1
F0.00076452599388379206
I1
I0
I1
tp15799
sS'hydrochloride,may,result'
p15800
(F1
F0.00076452599388379206
I1
I0
I1
tp15801
sS'emerge,if,is'
p15802
(F1
F0.00076452599388379206
I1
I0
I1
tp15803
sS'indication,that,is'
p15804
(F1
F0.00076452599388379206
I0
I1
I-1
tp15805
sS'dexmedetomidine-induced,antinociception,and'
p15806
(F1
F0.00076452599388379206
I0
I1
I-1
tp15807
sS'used,the,risk'
p15808
(F1
F0.00076452599388379206
I1
I0
I1
tp15809
sS'drugs,used,during'
p15810
(F1
F0.00076452599388379206
I0
I1
I-1
tp15811
sS'inhibition,of,drug-metab'
p15812
(F1
F0.00076452599388379206
I0
I1
I-1
tp15813
sS'overexpression,of,bcl-2'
p15814
(F1
F0.00076452599388379206
I1
I0
I1
tp15815
sS'cyclosporine,diflucan,may'
p15816
(F1
F0.00076452599388379206
I1
I0
I1
tp15817
sS'was,also,noted'
p15818
(F1
F0.00076452599388379206
I1
I0
I1
tp15819
sS'whether,initiation,of'
p15820
(F1
F0.00076452599388379206
I0
I1
I-1
tp15821
sS'reductions,of,these'
p15822
(F1
F0.00076452599388379206
I1
I0
I1
tp15823
sS'there,was,and'
p15824
(F1
F0.00076452599388379206
I1
I0
I1
tp15825
sS'state,did,not'
p15826
(F1
F0.0015290519877675841
I0
I2
I-2
tp15827
sS'conjunction,with,enzymes'
p15828
(F1
F0.00076452599388379206
I0
I1
I-1
tp15829
sS'potassium-sparing,diuretics,univasc'
p15830
(F1
F0.00076452599388379206
I0
I1
I-1
tp15831
sS'following,drugs,oral'
p15832
(F1
F0.00076452599388379206
I0
I1
I-1
tp15833
sS'its,carboxylated,metabolite'
p15834
(F1
F0.00076452599388379206
I0
I1
I-1
tp15835
sS'wort,with,hormonal'
p15836
(F1
F0.00076452599388379206
I1
I0
I1
tp15837
sS'suggests,that,inhibits'
p15838
(F1
F0.00076452599388379206
I1
I0
I1
tp15839
sS'tetracycline,a,bacteriostatic'
p15840
(F1
F0.00076452599388379206
I1
I0
I1
tp15841
sS'and,to,sharply'
p15842
(F1
F0.00076452599388379206
I1
I0
I1
tp15843
sS'with,in,basic'
p15844
(F1
F0.00076452599388379206
I1
I0
I1
tp15845
sS'inducers,or,inhibitors'
p15846
(F1
F0.00076452599388379206
I0
I1
I-1
tp15847
sS'levothyroxine,sodium,medroxyprogesterone'
p15848
(F1
F0.00076452599388379206
I0
I1
I-1
tp15849
sS'this,single,dose'
p15850
(F1
F0.00076452599388379206
I1
I0
I1
tp15851
sS'leaf,saponins,gsls'
p15852
(F1
F0.00076452599388379206
I0
I1
I-1
tp15853
sS'with,common,premedications'
p15854
(F1
F0.00076452599388379206
I0
I1
I-1
tp15855
sS'with,a,number'
p15856
(F1
F0.00076452599388379206
I1
I0
I1
tp15857
sS'pharmacokinetic,and,pharmacodynamic'
p15858
(F1
F0.00076452599388379206
I0
I1
I-1
tp15859
sS'clinical,studies,patients'
p15860
(F1
F0.00076452599388379206
I1
I0
I1
tp15861
sS'altered,by,the'
p15862
(F1
F0.00076452599388379206
I0
I1
I-1
tp15863
sS'sedative-hypnotics,including,barbiturates'
p15864
(F1
F0.00076452599388379206
I1
I0
I1
tp15865
sS'of,vesicare,when'
p15866
(F1
F0.00076452599388379206
I1
I0
I1
tp15867
sS'with,edema,concomitant'
p15868
(F1
F0.00076452599388379206
I0
I1
I-1
tp15869
sS'of,healthy,subjects'
p15870
(F1
F0.00076452599388379206
I0
I1
I-1
tp15871
sS'several,studies,demonstrate'
p15872
(F1
F0.00076452599388379206
I1
I0
I1
tp15873
sS'clinical,pharmacokinetics,of'
p15874
(F1
F0.00076452599388379206
I0
I1
I-1
tp15875
sS'of,when,it'
p15876
(F1
F0.00076452599388379206
I1
I0
I1
tp15877
sS'of,metabolites,possibly'
p15878
(F1
F0.00076452599388379206
I1
I0
I1
tp15879
sS'seizure,threshold,has'
p15880
(F1
F0.00076452599388379206
I1
I0
I1
tp15881
sS'prothrombin,time,of'
p15882
(F1
F0.00076452599388379206
I0
I1
I-1
tp15883
sS'are,no,significant'
p15884
(F1
F0.00076452599388379206
I0
I1
I-1
tp15885
sS'increased,risk,of'
p15886
(F1
F0.0022935779816513763
I3
I0
I3
tp15887
sS'by,oral,administration'
p15888
(F1
F0.00076452599388379206
I0
I1
I-1
tp15889
sS'prothrombin,time,or'
p15890
(F0
F0
I1
I1
I0
tp15891
sS'absorption,of,mg'
p15892
(F0
F0
I2
I2
I0
tp15893
sS'nondepolarizing,neuromuscular,blocking'
p15894
(F1
F0.00076452599388379206
I1
I0
I1
tp15895
sS'concurrent,use,with'
p15896
(F1
F0.00076452599388379206
I0
I1
I-1
tp15897
sS'study,concomitant,administration'
p15898
(F0
F0
I1
I1
I0
tp15899
sS'p,o,as'
p15900
(F1
F0.00076452599388379206
I0
I1
I-1
tp15901
sS'specific,inhibitor,of'
p15902
(F1
F0.00076452599388379206
I0
I1
I-1
tp15903
sS'vitro,studies,have'
p15904
(F1
F0.0015290519877675841
I0
I2
I-2
tp15905
sS'pump,inhibitors,on'
p15906
(F1
F0.00076452599388379206
I0
I1
I-1
tp15907
sS'require,reduced,doses'
p15908
(F1
F0.00076452599388379206
I1
I0
I1
tp15909
sS'inr,or,prothrombin'
p15910
(F1
F0.00076452599388379206
I1
I0
I1
tp15911
sS'studies,have,shown'
p15912
(F0
F0
I1
I1
I0
tp15913
sS'incidence,of,reinfarction'
p15914
(F1
F0.00076452599388379206
I0
I1
I-1
tp15915
sS'tended,to,increase'
p15916
(F1
F0.00076452599388379206
I1
I0
I1
tp15917
sS'other,nsaids,concomitant'
p15918
(F1
F0.00076452599388379206
I1
I0
I1
tp15919
sS'although,this,has'
p15920
(F1
F0.00076452599388379206
I1
I0
I1
tp15921
sS'the,intensity,and'
p15922
(F1
F0.00076452599388379206
I1
I0
I1
tp15923
sS'concentration,of,sanctura'
p15924
(F1
F0.00076452599388379206
I0
I1
I-1
tp15925
sS'concurrently,taking,or'
p15926
(F1
F0.00076452599388379206
I1
I0
I1
tp15927
sS'i,increased,exposure'
p15928
(F1
F0.00076452599388379206
I1
I0
I1
tp15929
sS'half-life,of,but'
p15930
(F1
F0.00076452599388379206
I1
I0
I1
tp15931
sS'theophylline-containing,drugs,leads'
p15932
(F1
F0.00076452599388379206
I1
I0
I1
tp15933
sS'used,in,combination'
p15934
(F1
F0.00076452599388379206
I1
I0
I1
tp15935
sS'anticholinergic,pharmacological,effects'
p15936
(F1
F0.00076452599388379206
I1
I0
I1
tp15937
sS'drugs,periodic,serum'
p15938
(F1
F0.00076452599388379206
I1
I0
I1
tp15939
sS'prolongation,or,enhancement'
p15940
(F1
F0.00076452599388379206
I1
I0
I1
tp15941
sS'a,controlled,study'
p15942
(F1
F0.00076452599388379206
I1
I0
I1
tp15943
sS'to,the,study'
p15944
(F1
F0.00076452599388379206
I1
I0
I1
tp15945
sS'by,the,mechanism'
p15946
(F1
F0.00076452599388379206
I1
I0
I1
tp15947
sS'mg,kg,group'
p15948
(F1
F0.00076452599388379206
I0
I1
I-1
tp15949
sS'been,administered,safely'
p15950
(F1
F0.00076452599388379206
I0
I1
I-1
tp15951
sS'concurrent,use,of'
p15952
(F1
F0.010703363914373088
I14
I0
I14
tp15953
sS'also,evaluated,the'
p15954
(F1
F0.00076452599388379206
I0
I1
I-1
tp15955
sS'medical,supervision,should'
p15956
(F1
F0.00076452599388379206
I1
I0
I1
tp15957
sS'induce,hepatic,enzymes'
p15958
(F1
F0.0015290519877675841
I2
I0
I2
tp15959
sS'a4,inhibitors,macrolide'
p15960
(F1
F0.00076452599388379206
I0
I1
I-1
tp15961
sS'does,not,displace'
p15962
(F1
F0.00076452599388379206
I0
I1
I-1
tp15963
sS'recommended,until,use'
p15964
(F1
F0.00076452599388379206
I1
I0
I1
tp15965
sS'properties,may,be'
p15966
(F1
F0.00076452599388379206
I0
I1
I-1
tp15967
sS'of,drugs,oral'
p15968
(F1
F0.00076452599388379206
I0
I1
I-1
tp15969
sS'evidence,for,a'
p15970
(F1
F0.00076452599388379206
I1
I0
I1
tp15971
sS'thalidomide,has,been'
p15972
(F1
F0.00076452599388379206
I1
I0
I1
tp15973
sS'somnolence,drowsiness,and'
p15974
(F1
F0.00076452599388379206
I1
I0
I1
tp15975
sS'beneficial,effects,in'
p15976
(F1
F0.00076452599388379206
I1
I0
I1
tp15977
sS'mutagenesis,impairment,of'
p15978
(F1
F0.00076452599388379206
I0
I1
I-1
tp15979
sS'the,adverse,event'
p15980
(F1
F0.00076452599388379206
I0
I1
I-1
tp15981
sS'acetylcholine,chloride,miochol'
p15982
(F1
F0.00076452599388379206
I1
I0
I1
tp15983
sS'enterohepatic,recirculation,or'
p15984
(F1
F0.00076452599388379206
I1
I0
I1
tp15985
sS'increased,in,patients'
p15986
(F1
F0.00076452599388379206
I1
I0
I1
tp15987
sS'impaired,by,containing'
p15988
(F1
F0.00076452599388379206
I1
I0
I1
tp15989
sS'treated,with,resulted'
p15990
(F1
F0.00076452599388379206
I1
I0
I1
tp15991
sS'mtor,inhibitor,cci-779'
p15992
(F1
F0.00076452599388379206
I1
I0
I1
tp15993
sS'following,concomitant,drugs'
p15994
(F1
F0.00076452599388379206
I0
I1
I-1
tp15995
sS'given,at,a'
p15996
(F1
F0.00076452599388379206
I1
I0
I1
tp15997
sS'known,to,interact'
p15998
(F1
F0.00076452599388379206
I0
I1
I-1
tp15999
sS'bone,marrow,depressants'
p16000
(F1
F0.00076452599388379206
I1
I0
I1
tp16001
sS'already,receiving,can'
p16002
(F1
F0.00076452599388379206
I1
I0
I1
tp16003
sS'mg,in,healthy'
p16004
(F1
F0.00076452599388379206
I1
I0
I1
tp16005
sS'was,necessary,to'
p16006
(F1
F0.00076452599388379206
I0
I1
I-1
tp16007
sS'not,itself,cause'
p16008
(F1
F0.00076452599388379206
I1
I0
I1
tp16009
sS'phenytoin,carbamazepine,and'
p16010
(F1
F0.00076452599388379206
I1
I0
I1
tp16011
sS'tetrahydropyridine,methyl-1,thiazol-4'
p16012
(F0.5
F0.0015290519877675841
I3
I1
I2
tp16013
sS'of,the,dosage'
p16014
(F0.33333333333333331
F0.00076452599388379206
I2
I1
I1
tp16015
sS'did,not,prolong'
p16016
(F1
F0.00076452599388379206
I0
I1
I-1
tp16017
sS'tubular,secretion,may'
p16018
(F1
F0.00076452599388379206
I0
I1
I-1
tp16019
sS'and,extent,of'
p16020
(F1
F0.00076452599388379206
I0
I1
I-1
tp16021
sS'of,angiotensin-converting,enzyme'
p16022
(F1
F0.00076452599388379206
I1
I0
I1
tp16023
sS'therefore,the,use'
p16024
(F1
F0.00076452599388379206
I1
I0
I1
tp16025
sS'patients,receiving,proton'
p16026
(F1
F0.00076452599388379206
I1
I0
I1
tp16027
sS'of,five,different'
p16028
(F1
F0.00076452599388379206
I0
I1
I-1
tp16029
sS'anionic,transport,system'
p16030
(F1
F0.00076452599388379206
I1
I0
I1
tp16031
sS'mobic,is,introduced'
p16032
(F1
F0.00076452599388379206
I1
I0
I1
tp16033
sS'from,different,origins'
p16034
(F1
F0.00076452599388379206
I0
I1
I-1
tp16035
sS'kg,intraperitoneally,min'
p16036
(F1
F0.00076452599388379206
I0
I1
I-1
tp16037
sS'egfr,t790m,and'
p16038
(F1
F0.00076452599388379206
I1
I0
I1
tp16039
sS'for,these,cytochrome'
p16040
(F1
F0.00076452599388379206
I0
I1
I-1
tp16041
sS'this,is,typical'
p16042
(F1
F0.00076452599388379206
I1
I0
I1
tp16043
sS'the,following,categories'
p16044
(F1
F0.00076452599388379206
I1
I0
I1
tp16045
sS'for,increased,cns'
p16046
(F1
F0.00076452599388379206
I1
I0
I1
tp16047
sS'enhanced,paclitaxel-induced,apoptosis'
p16048
(F1
F0.00076452599388379206
I1
I0
I1
tp16049
sS'female,rats,neonatal'
p16050
(F1
F0.00076452599388379206
I1
I0
I1
tp16051
sS'versed,syrup,is'
p16052
(F1
F0.00076452599388379206
I1
I0
I1
tp16053
sS'apparent,oral,clearance'
p16054
(F1
F0.00076452599388379206
I1
I0
I1
tp16055
sS'when,used,to'
p16056
(F1
F0.00076452599388379206
I1
I0
I1
tp16057
sS'in,adolescent,rats'
p16058
(F1
F0.00076452599388379206
I0
I1
I-1
tp16059
sS'min,caution,should'
p16060
(F1
F0.00076452599388379206
I1
I0
I1
tp16061
sS'exercised,when,administering'
p16062
(F1
F0.0015290519877675841
I2
I0
I2
tp16063
sS'test,tst,in'
p16064
(F1
F0.00076452599388379206
I0
I1
I-1
tp16065
sS'on,cmax,in'
p16066
(F1
F0.00076452599388379206
I1
I0
I1
tp16067
sS'in,the,ovulation-suppressing'
p16068
(F1
F0.00076452599388379206
I0
I1
I-1
tp16069
sS'interactions,may,be'
p16070
(F1
F0.00076452599388379206
I1
I0
I1
tp16071
sS'different,drugs,were'
p16072
(F1
F0.00076452599388379206
I1
I0
I1
tp16073
sS'rimmer,and,richens'
p16074
(F1
F0.00076452599388379206
I1
I0
I1
tp16075
sS'with,for,breast'
p16076
(F1
F0.00076452599388379206
I1
I0
I1
tp16077
sS'when,diflucan,is'
p16078
(F1
F0.00076452599388379206
I1
I0
I1
tp16079
sS'be,counteracted,when'
p16080
(F1
F0.00076452599388379206
I1
I0
I1
tp16081
sS'in,this,crossover'
p16082
(F1
F0.00076452599388379206
I0
I1
I-1
tp16083
sS'the,breast,cancer'
p16084
(F1
F0.00076452599388379206
I1
I0
I1
tp16085
sS'more,pronounced,following'
p16086
(F1
F0.00076452599388379206
I1
I0
I1
tp16087
sS'interaction,with,other'
p16088
(F1
F0.00076452599388379206
I1
I0
I1
tp16089
sS'does,not,itself'
p16090
(F1
F0.00076452599388379206
I1
I0
I1
tp16091
sS'assess,drug-drug,interactions'
p16092
(F1
F0.00076452599388379206
I1
I0
I1
tp16093
sS'pt,should,be'
p16094
(F1
F0.00076452599388379206
I1
I0
I1
tp16095
sS'that,the,strains'
p16096
(F1
F0.00076452599388379206
I0
I1
I-1
tp16097
sS'affect,the,hypoprothrombinemic'
p16098
(F1
F0.00076452599388379206
I1
I0
I1
tp16099
sS'may,be,advisable'
p16100
(F1
F0.00076452599388379206
I1
I0
I1
tp16101
sS'steady,state,study'
p16102
(F1
F0.00076452599388379206
I0
I1
I-1
tp16103
sS'a,xenical,and'
p16104
(F1
F0.00076452599388379206
I1
I0
I1
tp16105
sS'usage,with,alcohol'
p16106
(F1
F0.00076452599388379206
I1
I0
I1
tp16107
sS'failure,in,an'
p16108
(F1
F0.00076452599388379206
I1
I0
I1
tp16109
sS'mice,with,plus'
p16110
(F1
F0.00076452599388379206
I1
I0
I1
tp16111
sS'the,co,administration'
p16112
(F1
F0.00076452599388379206
I1
I0
I1
tp16113
sS'radiotherapy,or,has'
p16114
(F1
F0.00076452599388379206
I0
I1
I-1
tp16115
sS'result,in,alteration'
p16116
(F1
F0.00076452599388379206
I0
I1
I-1
tp16117
sS'and,confusional,states'
p16118
(F1
F0.00076452599388379206
I1
I0
I1
tp16119
sS'or,cholinergic,agonists'
p16120
(F1
F0.00076452599388379206
I1
I0
I1
tp16121
sS'initiation,of,cimetidine'
p16122
(F1
F0.00076452599388379206
I1
I0
I1
tp16123
sS'surface,of,her2-positive'
p16124
(F1
F0.00076452599388379206
I1
I0
I1
tp16125
sS'reduce,the,rate'
p16126
(F1
F0.00076452599388379206
I1
I0
I1
tp16127
sS'efficacy,studies,acetylsalicylic'
p16128
(F1
F0.00076452599388379206
I0
I1
I-1
tp16129
sS'used,to,treat'
p16130
(F1
F0.00076452599388379206
I1
I0
I1
tp16131
sS'of,normal-weight,mildly'
p16132
(F1
F0.00076452599388379206
I0
I1
I-1
tp16133
sS'whether,the,psychostimulant'
p16134
(F1
F0.00076452599388379206
I0
I1
I-1
tp16135
sS'base,is,due'
p16136
(F1
F0.00076452599388379206
I1
I0
I1
tp16137
sS'concurrently,treated,with'
p16138
(F1
F0.00076452599388379206
I1
I0
I1
tp16139
sS'retinal,ganglion,cell'
p16140
(F1
F0.00076452599388379206
I0
I1
I-1
tp16141
sS'adjusted,according,to'
p16142
(F1
F0.00076452599388379206
I1
I0
I1
tp16143
sS'may,reduce,the'
p16144
(F1
F0.0022935779816513763
I3
I0
I3
tp16145
sS'glass,jar,and'
p16146
(F1
F0.00076452599388379206
I0
I1
I-1
tp16147
sS'dysrhythmias,secondary,to'
p16148
(F1
F0.00076452599388379206
I1
I0
I1
tp16149
sS'and,anticholinesterase,agents'
p16150
(F1
F0.00076452599388379206
I1
I0
I1
tp16151
sS'of,the,cyp3a4'
p16152
(F1
F0.0015290519877675841
I2
I0
I2
tp16153
sS'or,prothrombin,time'
p16154
(F1
F0.00076452599388379206
I1
I0
I1
tp16155
sS'test,fst,in'
p16156
(F1
F0.00076452599388379206
I0
I1
I-1
tp16157
sS'by,a,cyp450'
p16158
(F1
F0.00076452599388379206
I1
I0
I1
tp16159
sS'broad,range,of'
p16160
(F1
F0.00076452599388379206
I0
I1
I-1
tp16161
sS'of,mg,were'
p16162
(F1
F0.00076452599388379206
I0
I1
I-1
tp16163
sS'cyp,a4,inhibitors'
p16164
(F1
F0.0015290519877675841
I0
I2
I-2
tp16165
sS'in,healthy,women'
p16166
(F1
F0.0015290519877675841
I0
I2
I-2
tp16167
sS'conjugated,estrogens,hydroxychloroquine'
p16168
(F1
F0.00076452599388379206
I0
I1
I-1
tp16169
sS'monitored,if,a'
p16170
(F1
F0.00076452599388379206
I1
I0
I1
tp16171
sS'myfortic,was,decreased'
p16172
(F1
F0.00076452599388379206
I1
I0
I1
tp16173
sS'normal,healthy,adults'
p16174
(F1
F0.00076452599388379206
I1
I0
I1
tp16175
sS'neuromuscular,blocking,agents'
p16176
(F0.5
F0.0015290519877675841
I3
I1
I2
tp16177
sS'with,qt,interval'
p16178
(F1
F0.00076452599388379206
I1
I0
I1
tp16179
sS'extrapolated,to,infinity'
p16180
(F1
F0.00076452599388379206
I1
I0
I1
tp16181
sS'of,effectiveness,such'
p16182
(F1
F0.00076452599388379206
I1
I0
I1
tp16183
sS'be,administered,concomitantly'
p16184
(F1
F0.0015290519877675841
I2
I0
I2
tp16185
sS'de,pointe,as'
p16186
(F1
F0.00076452599388379206
I1
I0
I1
tp16187
sS'used,with,care'
p16188
(F1
F0.00076452599388379206
I1
I0
I1
tp16189
sS'did,not,produce'
p16190
(F1
F0.00076452599388379206
I1
I0
I1
tp16191
sS'secretion,of,such'
p16192
(F1
F0.00076452599388379206
I1
I0
I1
tp16193
sS'is,a,net'
p16194
(F1
F0.00076452599388379206
I1
I0
I1
tp16195
sS'increased,serum,levels'
p16196
(F1
F0.00076452599388379206
I1
I0
I1
tp16197
sS'by,those,methods'
p16198
(F1
F0.00076452599388379206
I0
I1
I-1
tp16199
sS'when,is,used'
p16200
(F1
F0.00076452599388379206
I1
I0
I1
tp16201
sS'metabolism,it,is'
p16202
(F1
F0.00076452599388379206
I1
I0
I1
tp16203
sS'influence,the,pharmacokinetics'
p16204
(F1
F0.00076452599388379206
I0
I1
I-1
tp16205
sS'concurrent,ingestion,of'
p16206
(F1
F0.00076452599388379206
I0
I1
I-1
tp16207
sS'such,as,antimycotic'
p16208
(F1
F0.00076452599388379206
I1
I0
I1
tp16209
sS'consideration,should,be'
p16210
(F1
F0.0015290519877675841
I2
I0
I2
tp16211
sS'patients,concomitantly,treated'
p16212
(F1
F0.00076452599388379206
I0
I1
I-1
tp16213
sS'renal,transplant,patient'
p16214
(F1
F0.00076452599388379206
I1
I0
I1
tp16215
sS'result,in,any'
p16216
(F1
F0.00076452599388379206
I0
I1
I-1
tp16217
sS'fixed,combination,compared'
p16218
(F1
F0.00076452599388379206
I1
I0
I1
tp16219
sS'was,and,fold'
p16220
(F1
F0.00076452599388379206
I1
I0
I1
tp16221
sS'estradiol-,and,levonorgestrel-containing'
p16222
(F1
F0.00076452599388379206
I1
I0
I1
tp16223
sS'for,the,metabolic'
p16224
(F1
F0.00076452599388379206
I0
I1
I-1
tp16225
sS'writhing,and,formalin'
p16226
(F1
F0.00076452599388379206
I1
I0
I1
tp16227
sS'patients,receiving,mao-a'
p16228
(F1
F0.00076452599388379206
I1
I0
I1
tp16229
sS'or,greater,significantly'
p16230
(F1
F0.00076452599388379206
I1
I0
I1
tp16231
sS'with,sanctura,have'
p16232
(F1
F0.00076452599388379206
I1
I0
I1
tp16233
sS'include,some,steroid'
p16234
(F1
F0.00076452599388379206
I1
I0
I1
tp16235
sS'those,agents,were'
p16236
(F1
F0.00076452599388379206
I1
I0
I1
tp16237
sS'of,steady-state,mycamine'
p16238
(F1
F0.0015290519877675841
I2
I0
I2
tp16239
sS'of,neurons,in'
p16240
(F1
F0.00076452599388379206
I1
I0
I1
tp16241
sS'an,interesting,case'
p16242
(F1
F0.00076452599388379206
I1
I0
I1
tp16243
sS'concentration,was,also'
p16244
(F1
F0.00076452599388379206
I1
I0
I1
tp16245
sS'failed,to,identify'
p16246
(F1
F0.00076452599388379206
I0
I1
I-1
tp16247
sS'not,be,used'
p16248
(F1
F0.0022935779816513763
I3
I0
I3
tp16249
sS'may,produce,additive'
p16250
(F1
F0.00076452599388379206
I0
I1
I-1
tp16251
sS'trimethoprim,given,at'
p16252
(F1
F0.00076452599388379206
I1
I0
I1
tp16253
sS'and,bronchospasm,killed'
p16254
(F1
F0.00076452599388379206
I1
I0
I1
tp16255
sS'of,oxycodone,hydrochloride'
p16256
(F1
F0.00076452599388379206
I1
I0
I1
tp16257
sS'by,whereas,the'
p16258
(F1
F0.00076452599388379206
I1
I0
I1
tp16259
sS'to,decrease,the'
p16260
(F1
F0.00076452599388379206
I1
I0
I1
tp16261
sS'in,all,studies'
p16262
(F1
F0.00076452599388379206
I0
I1
I-1
tp16263
sS'metabolized,by,cyp1a2'
p16264
(F1
F0.00076452599388379206
I0
I1
I-1
tp16265
sS'whereas,the,extent'
p16266
(F1
F0.00076452599388379206
I1
I0
I1
tp16267
sS'sharply,increase,platelet'
p16268
(F1
F0.00076452599388379206
I1
I0
I1
tp16269
sS'did,not,isolate'
p16270
(F1
F0.00076452599388379206
I1
I0
I1
tp16271
sS'a,single,agent'
p16272
(F1
F0.00076452599388379206
I1
I0
I1
tp16273
sS'dose,of,did'
p16274
(F1
F0.00076452599388379206
I0
I1
I-1
tp16275
sS'following,classes,of'
p16276
(F1
F0.00076452599388379206
I0
I1
I-1
tp16277
sS'significant,inhibitory,effect'
p16278
(F1
F0.00076452599388379206
I0
I1
I-1
tp16279
sS'mitotane,has,been'
p16280
(F1
F0.00076452599388379206
I1
I0
I1
tp16281
sS'total,of,clinical'
p16282
(F1
F0.00076452599388379206
I0
I1
I-1
tp16283
sS'in,certain,cases'
p16284
(F1
F0.00076452599388379206
I1
I0
I1
tp16285
sS'expected,to,alter'
p16286
(F1
F0.0015290519877675841
I0
I2
I-2
tp16287
sS'that,the,combination'
p16288
(F1
F0.00076452599388379206
I1
I0
I1
tp16289
sS'confusional,states,may'
p16290
(F1
F0.00076452599388379206
I1
I0
I1
tp16291
sS'itself,cause,orthostatic'
p16292
(F1
F0.00076452599388379206
I1
I0
I1
tp16293
sS'effect,of,dtic'
p16294
(F1
F0.00076452599388379206
I0
I1
I-1
tp16295
sS'recommended,dose,oral'
p16296
(F1
F0.00076452599388379206
I1
I0
I1
tp16297
sS'areas,under,the'
p16298
(F1
F0.00076452599388379206
I0
I1
I-1
tp16299
sS'of,and,thiazide'
p16300
(F1
F0.00076452599388379206
I1
I0
I1
tp16301
sS'in,an,adverse'
p16302
(F1
F0.00076452599388379206
I1
I0
I1
tp16303
sS'which,produce,dry'
p16304
(F1
F0.00076452599388379206
I1
I0
I1
tp16305
sS'pump,inhibitors,when'
p16306
(F1
F0.00076452599388379206
I0
I1
I-1
tp16307
sS'since,is,a'
p16308
(F1
F0.00076452599388379206
I1
I0
I1
tp16309
sS'to,herceptin-sensitive,tumors'
p16310
(F1
F0.00076452599388379206
I0
I1
I-1
tp16311
sS'result,in,additive'
p16312
(F1
F0.0015290519877675841
I2
I0
I2
tp16313
sS'co-administration,of,with'
p16314
(F1
F0.00076452599388379206
I0
I1
I-1
tp16315
sS'of,lbh589,an'
p16316
(F1
F0.00076452599388379206
I0
I1
I-1
tp16317
sS'capsules,may,be'
p16318
(F1
F0.00076452599388379206
I1
I0
I1
tp16319
sS'of,than,with'
p16320
(F1
F0.00076452599388379206
I1
I0
I1
tp16321
sS'phenothiazines,are,capable'
p16322
(F1
F0.00076452599388379206
I1
I0
I1
tp16323
sS'days,following,administration'
p16324
(F1
F0.00076452599388379206
I1
I0
I1
tp16325
sS'of,treatment,with'
p16326
(F1
F0.00076452599388379206
I0
I1
I-1
tp16327
sS'oral,no,drug'
p16328
(F1
F0.00076452599388379206
I0
I1
I-1
tp16329
sS'of,it,is'
p16330
(F1
F0.00076452599388379206
I1
I0
I1
tp16331
sS'cheese,and,bananas'
p16332
(F1
F0.00076452599388379206
I1
I0
I1
tp16333
sS'effects,of,anti-parkinsonian'
p16334
(F1
F0.00076452599388379206
I0
I1
I-1
tp16335
sS'caffeine,and,or'
p16336
(F1
F0.00076452599388379206
I1
I0
I1
tp16337
sS'its,effects,on'
p16338
(F1
F0.00076452599388379206
I1
I0
I1
tp16339
sS'of,increase,in'
p16340
(F1
F0.00076452599388379206
I1
I0
I1
tp16341
sS'sirna,vs,p27'
p16342
(F1
F0.00076452599388379206
I0
I1
I-1
tp16343
sS'with,can,be'
p16344
(F1
F0.00076452599388379206
I1
I0
I1
tp16345
sS'in,patients,with'
p16346
(F0.090909090909090912
F0.00076452599388379206
I6
I5
I1
tp16347
sS'or,the,coadministered'
p16348
(F1
F0.00076452599388379206
I0
I1
I-1
tp16349
sS'the,clearance,of'
p16350
(F1
F0.0068807339449541288
I9
I0
I9
tp16351
sS'shimadzu,hplc,system'
p16352
(F1
F0.00076452599388379206
I0
I1
I-1
tp16353
sS'single,dose,pharmacokinetic'
p16354
(F1
F0.00076452599388379206
I0
I1
I-1
tp16355
sS'between,and,in'
p16356
(F1
F0.00076452599388379206
I1
I0
I1
tp16357
sS'salt,intake,before'
p16358
(F1
F0.00076452599388379206
I0
I1
I-1
tp16359
sS'that,may,affect'
p16360
(F1
F0.00076452599388379206
I1
I0
I1
tp16361
sS'serum,levels,in'
p16362
(F1
F0.00076452599388379206
I1
I0
I1
tp16363
sS'symlin,and,should'
p16364
(F1
F0.00076452599388379206
I0
I1
I-1
tp16365
sS'does,not,affect'
p16366
(F1
F0.00076452599388379206
I0
I1
I-1
tp16367
sS'monitored,particularly,in'
p16368
(F1
F0.00076452599388379206
I1
I0
I1
tp16369
sS'others,can,increase'
p16370
(F1
F0.00076452599388379206
I0
I1
I-1
tp16371
sS'be,additive,use'
p16372
(F1
F0.00076452599388379206
I1
I0
I1
tp16373
sS'increase,the,side'
p16374
(F1
F0.00076452599388379206
I1
I0
I1
tp16375
sS'adverse,effect,was'
p16376
(F1
F0.00076452599388379206
I0
I1
I-1
tp16377
sS'n,n,channel'
p16378
(F1
F0.00076452599388379206
I0
I1
I-1
tp16379
sS'the,total,dose'
p16380
(F1
F0.00076452599388379206
I0
I1
I-1
tp16381
sS'abt-737,a,bcl-2'
p16382
(F1
F0.00076452599388379206
I1
I0
I1
tp16383
sS'administration,of,mg'
p16384
(F0.33333333333333331
F0.00076452599388379206
I2
I1
I1
tp16385
sS'deb,induced,toxicity'
p16386
(F1
F0.00076452599388379206
I1
I0
I1
tp16387
sS'inhibits,the,glucuronidation'
p16388
(F1
F0.00076452599388379206
I1
I0
I1
tp16389
sS'doses,for,mice'
p16390
(F1
F0.00076452599388379206
I0
I1
I-1
tp16391
sS'mg,heme,as'
p16392
(F1
F0.00076452599388379206
I0
I1
I-1
tp16393
sS'increased,and,blood'
p16394
(F1
F0.00076452599388379206
I1
I0
I1
tp16395
sS'of,the,qtc'
p16396
(F1
F0.00076452599388379206
I1
I0
I1
tp16397
sS'with,absorption,of'
p16398
(F1
F0.00076452599388379206
I1
I0
I1
tp16399
sS'mouth,constipation,and'
p16400
(F1
F0.00076452599388379206
I1
I0
I1
tp16401
sS'multiple,metastatic,tumors'
p16402
(F1
F0.00076452599388379206
I1
I0
I1
tp16403
sS'a,total,of'
p16404
(F1
F0.00076452599388379206
I0
I1
I-1
tp16405
sS'action,of,nondepolarizing'
p16406
(F1
F0.0015290519877675841
I2
I0
I2
tp16407
sS'an,in,vitro'
p16408
(F1
F0.0015290519877675841
I2
I0
I2
tp16409
sS'known,to,inhibit'
p16410
(F1
F0.00076452599388379206
I1
I0
I1
tp16411
sS'in,the,drug'
p16412
(F1
F0.00076452599388379206
I1
I0
I1
tp16413
sS'vitro,data,indicate'
p16414
(F1
F0.00076452599388379206
I1
I0
I1
tp16415
sS'measured,bp,quicker'
p16416
(F1
F0.00076452599388379206
I1
I0
I1
tp16417
sS'employed,antianginal,and'
p16418
(F1
F0.00076452599388379206
I0
I1
I-1
tp16419
sS'with,treatment,are'
p16420
(F1
F0.00076452599388379206
I0
I1
I-1
tp16421
sS'heme,and,the'
p16422
(F1
F0.00076452599388379206
I0
I1
I-1
tp16423
sS'be,monitored,if'
p16424
(F1
F0.00076452599388379206
I1
I0
I1
tp16425
sS'which,may,be'
p16426
(F1
F0.00076452599388379206
I1
I0
I1
tp16427
sS'and,phases,the'
p16428
(F1
F0.00076452599388379206
I0
I1
I-1
tp16429
sS'may,alter,the'
p16430
(F1
F0.00076452599388379206
I1
I0
I1
tp16431
sS'conjunction,with,for'
p16432
(F1
F0.00076452599388379206
I0
I1
I-1
tp16433
sS'the,following,agents'
p16434
(F1
F0.00076452599388379206
I1
I0
I1
tp16435
sS'if,a,is'
p16436
(F1
F0.00076452599388379206
I1
I0
I1
tp16437
sS'better,to,avoid'
p16438
(F1
F0.00076452599388379206
I1
I0
I1
tp16439
sS'and,during,maintenance'
p16440
(F1
F0.00076452599388379206
I0
I1
I-1
tp16441
sS'reports,of,cardiac'
p16442
(F1
F0.00076452599388379206
I1
I0
I1
tp16443
sS'greater,potentiation,of'
p16444
(F1
F0.00076452599388379206
I0
I1
I-1
tp16445
sS'clinical,trials,of'
p16446
(F0
F0
I1
I1
I0
tp16447
sS'increase,in,their'
p16448
(F1
F0.00076452599388379206
I1
I0
I1
tp16449
sS'of,to,streptokinase'
p16450
(F1
F0.00076452599388379206
I1
I0
I1
tp16451
sS'a,clinically,significant'
p16452
(F1
F0.0015290519877675841
I0
I2
I-2
tp16453
sS'an,important,determinant'
p16454
(F1
F0.00076452599388379206
I1
I0
I1
tp16455
sS'alterations,in,pharmacokinetic'
p16456
(F1
F0.00076452599388379206
I0
I1
I-1
tp16457
sS'trials,of,tnkase'
p16458
(F1
F0.00076452599388379206
I0
I1
I-1
tp16459
sS'and,auc,from'
p16460
(F1
F0.00076452599388379206
I1
I0
I1
tp16461
sS'plate,or,holed'
p16462
(F1
F0.00076452599388379206
I0
I1
I-1
tp16463
sS'dose,pharmacodynamics,and'
p16464
(F1
F0.00076452599388379206
I0
I1
I-1
tp16465
sS'in,an,animal'
p16466
(F1
F0.00076452599388379206
I1
I0
I1
tp16467
sS'in,experiment,oral'
p16468
(F1
F0.00076452599388379206
I0
I1
I-1
tp16469
sS'injections,mg,kg'
p16470
(F1
F0.00076452599388379206
I0
I1
I-1
tp16471
sS'breast,but,not'
p16472
(F1
F0.00076452599388379206
I1
I0
I1
tp16473
sS'treatment,of,pain'
p16474
(F1
F0.00076452599388379206
I1
I0
I1
tp16475
sS'before,taking,this'
p16476
(F1
F0.00076452599388379206
I0
I1
I-1
tp16477
sS'because,of,profound'
p16478
(F1
F0.00076452599388379206
I1
I0
I1
tp16479
sS'other,medications,with'
p16480
(F1
F0.00076452599388379206
I1
I0
I1
tp16481
sS'and,combinations,of'
p16482
(F1
F0.00076452599388379206
I0
I1
I-1
tp16483
sS'associated,with,reduction'
p16484
(F1
F0.00076452599388379206
I0
I1
I-1
tp16485
sS'may,be,reduced'
p16486
(F1
F0.0022935779816513763
I3
I0
I3
tp16487
sS'anticholinergic,drugs,or'
p16488
(F1
F0.00076452599388379206
I1
I0
I1
tp16489
sS'pressor,effect,of'
p16490
(F1
F0.0015290519877675841
I2
I0
I2
tp16491
sS'of,hypertensive,crisis'
p16492
(F1
F0.00076452599388379206
I1
I0
I1
tp16493
sS'dopamine,agonist,it'
p16494
(F1
F0.00076452599388379206
I1
I0
I1
tp16495
sS'drug,interactions,inhibitors'
p16496
(F1
F0.00076452599388379206
I1
I0
I1
tp16497
sS'in,intracellular,levels'
p16498
(F1
F0.00076452599388379206
I1
I0
I1
tp16499
sS'hypoglycemic,agents,and'
p16500
(F1
F0.00076452599388379206
I0
I1
I-1
tp16501
sS'caution,in,patients'
p16502
(F1
F0.0015290519877675841
I2
I0
I2
tp16503
sS'tubal,pregnancies,on'
p16504
(F1
F0.00076452599388379206
I1
I0
I1
tp16505
sS'whether,hb-egf,is'
p16506
(F1
F0.00076452599388379206
I0
I1
I-1
tp16507
sS'transporter,and,tyrosine'
p16508
(F1
F0.00076452599388379206
I1
I0
I1
tp16509
sS'thiazides,may,decrease'
p16510
(F1
F0.00076452599388379206
I1
I0
I1
tp16511
sS'administration,to,patients'
p16512
(F1
F0.00076452599388379206
I1
I0
I1
tp16513
sS'of,milligrams,of'
p16514
(F1
F0.00076452599388379206
I0
I1
I-1
tp16515
sS'single,or,concurrent'
p16516
(F1
F0.00076452599388379206
I1
I0
I1
tp16517
sS'the,british,national'
p16518
(F1
F0.00076452599388379206
I0
I1
I-1
tp16519
sS'single,intravenous,dose'
p16520
(F1
F0.00076452599388379206
I0
I1
I-1
tp16521
sS'foods,with,known'
p16522
(F1
F0.00076452599388379206
I1
I0
I1
tp16523
sS'anti-inflammatory,drugs,n'
p16524
(F1
F0.00076452599388379206
I0
I1
I-1
tp16525
sS'expected,when,cholinesterase'
p16526
(F1
F0.00076452599388379206
I1
I0
I1
tp16527
sS'administration,of,methyl-1'
p16528
(F1
F0.00076452599388379206
I0
I1
I-1
tp16529
sS'agent,exhibits,anti-proliferative'
p16530
(F1
F0.00076452599388379206
I1
I0
I1
tp16531
sS'true,if,the'
p16532
(F1
F0.00076452599388379206
I0
I1
I-1
tp16533
sS'and,effient,for'
p16534
(F1
F0.00076452599388379206
I0
I1
I-1
tp16535
sS'effect,of,angiotensin-converting'
p16536
(F1
F0.00076452599388379206
I1
I0
I1
tp16537
sS'adohcy,hydrolase,inhibitors'
p16538
(F1
F0.00076452599388379206
I0
I1
I-1
tp16539
sS'patients,for,a'
p16540
(F1
F0.0015290519877675841
I2
I0
I2
tp16541
sS'progression-free,survival,rate'
p16542
(F1
F0.00076452599388379206
I1
I0
I1
tp16543
sS'action,of,beta'
p16544
(F1
F0.00076452599388379206
I1
I0
I1
tp16545
sS'conclusive,because,of'
p16546
(F1
F0.00076452599388379206
I1
I0
I1
tp16547
sS'not,verified,for'
p16548
(F1
F0.00076452599388379206
I0
I1
I-1
tp16549
sS'vivo,in,human'
p16550
(F0
F0
I1
I1
I0
tp16551
sS'the,absorption,of'
p16552
(F0
F0
I2
I2
I0
tp16553
sS'vascular,system,may'
p16554
(F1
F0.00076452599388379206
I1
I0
I1
tp16555
sS'mutations,but,the'
p16556
(F1
F0.00076452599388379206
I1
I0
I1
tp16557
sS'influenced,by,commonly'
p16558
(F1
F0.00076452599388379206
I0
I1
I-1
tp16559
sS'total,level,increased'
p16560
(F1
F0.00076452599388379206
I1
I0
I1
tp16561
sS'patients,receiving,monoamine'
p16562
(F1
F0.0022935779816513763
I3
I0
I3
tp16563
sS'to,improve,immunization'
p16564
(F1
F0.00076452599388379206
I0
I1
I-1
tp16565
sS'and,toxicity,in'
p16566
(F1
F0.00076452599388379206
I1
I0
I1
tp16567
sS'caution,to,patients'
p16568
(F1
F0.0022935779816513763
I3
I0
I3
tp16569
sS'decreased,when,administered'
p16570
(F1
F0.00076452599388379206
I1
I0
I1
tp16571
sS'enzyme,they,should'
p16572
(F1
F0.00076452599388379206
I1
I0
I1
tp16573
sS'be,more,pronounced'
p16574
(F1
F0.00076452599388379206
I1
I0
I1
tp16575
sS'the,following,and'
p16576
(F1
F0.00076452599388379206
I0
I1
I-1
tp16577
sS'diffusion,rate,of'
p16578
(F1
F0.00076452599388379206
I1
I0
I1
tp16579
sS'and,the,administration'
p16580
(F1
F0.00076452599388379206
I0
I1
I-1
tp16581
sS'provera,may,significantly'
p16582
(F1
F0.00076452599388379206
I1
I0
I1
tp16583
sS'potential,for,other'
p16584
(F1
F0.00076452599388379206
I0
I1
I-1
tp16585
sS'is,reasonable,to'
p16586
(F1
F0.0015290519877675841
I2
I0
I2
tp16587
sS'in,clinical,studies'
p16588
(F1
F0.0015290519877675841
I2
I0
I2
tp16589
sS'and,s-enantiomers,or'
p16590
(F1
F0.00076452599388379206
I0
I1
I-1
tp16591
sS'increased,cns,depressants'
p16592
(F1
F0.00076452599388379206
I1
I0
I1
tp16593
sS'and,or,ischemia'
p16594
(F1
F0.00076452599388379206
I0
I1
I-1
tp16595
sS'causes,bone,marrow'
p16596
(F1
F0.00076452599388379206
I0
I1
I-1
tp16597
sS'the,tests,were'
p16598
(F1
F0.00076452599388379206
I0
I1
I-1
tp16599
sS'and,are,used'
p16600
(F1
F0.00076452599388379206
I1
I0
I1
tp16601
sS'stereological,counts,of'
p16602
(F1
F0.00076452599388379206
I1
I0
I1
tp16603
sS'other,beta,adrenergic'
p16604
(F1
F0.00076452599388379206
I1
I0
I1
tp16605
sS'to,potentiate,the'
p16606
(F1
F0.00076452599388379206
I1
I0
I1
tp16607
sS'when,or,other'
p16608
(F1
F0.00076452599388379206
I1
I0
I1
tp16609
sS'an,excessive,reduction'
p16610
(F1
F0.00076452599388379206
I1
I0
I1
tp16611
sS'for,several,days'
p16612
(F1
F0.00076452599388379206
I0
I1
I-1
tp16613
sS'auc,from,to'
p16614
(F1
F0.00076452599388379206
I1
I0
I1
tp16615
sS'may,reverse,the'
p16616
(F1
F0.00076452599388379206
I1
I0
I1
tp16617
sS'either,phenotype,by'
p16618
(F1
F0.00076452599388379206
I0
I1
I-1
tp16619
sS'carbidopa,levodopa,does'
p16620
(F1
F0.00076452599388379206
I0
I1
I-1
tp16621
sS'no,conclusive,evidence'
p16622
(F1
F0.00076452599388379206
I0
I1
I-1
tp16623
sS'to,may,be'
p16624
(F1
F0.0015290519877675841
I2
I0
I2
tp16625
sS'to,determine,whether'
p16626
(F1
F0.00076452599388379206
I0
I1
I-1
tp16627
sS'discontinued,well,before'
p16628
(F1
F0.00076452599388379206
I1
I0
I1
tp16629
sS'glasses,of,wine'
p16630
(F1
F0.00076452599388379206
I0
I1
I-1
tp16631
sS'great,a,decrease'
p16632
(F1
F0.00076452599388379206
I1
I0
I1
tp16633
sS'such,as,given'
p16634
(F1
F0.00076452599388379206
I1
I0
I1
tp16635
sS'in,seven,children'
p16636
(F1
F0.00076452599388379206
I0
I1
I-1
tp16637
sS'coadministered,drug,due'
p16638
(F1
F0.00076452599388379206
I0
I1
I-1
tp16639
sS'refer,to,the'
p16640
(F1
F0.0015290519877675841
I0
I2
I-2
tp16641
sS'potent,non-competitive,inhibitors'
p16642
(F1
F0.00076452599388379206
I1
I0
I1
tp16643
sS'of,zemuron,before'
p16644
(F1
F0.00076452599388379206
I0
I1
I-1
tp16645
sS'hyaluronidase,hyaluronidase,may'
p16646
(F1
F0.00076452599388379206
I1
I0
I1
tp16647
sS'increased,inr,and'
p16648
(F1
F0.00076452599388379206
I1
I0
I1
tp16649
sS'in,any,change'
p16650
(F1
F0.00076452599388379206
I0
I1
I-1
tp16651
sS'increased,in,dose'
p16652
(F1
F0.00076452599388379206
I1
I0
I1
tp16653
sS'commonly,used,premedications'
p16654
(F1
F0.00076452599388379206
I0
I1
I-1
tp16655
sS'represents,a,novel'
p16656
(F1
F0.00076452599388379206
I1
I0
I1
tp16657
sS'agonists,should,be'
p16658
(F1
F0.00076452599388379206
I1
I0
I1
tp16659
sS'potential,for,pharmacokinetic'
p16660
(F1
F0.00076452599388379206
I1
I0
I1
tp16661
sS'simultaneously,with,has'
p16662
(F1
F0.00076452599388379206
I0
I1
I-1
tp16663
sS'in,normal,weight'
p16664
(F1
F0.00076452599388379206
I0
I1
I-1
tp16665
sS'of,chronic,or'
p16666
(F1
F0.00076452599388379206
I1
I0
I1
tp16667
sS'patients,in,association'
p16668
(F1
F0.00076452599388379206
I0
I1
I-1
tp16669
sS'degrading,enzymes,improves'
p16670
(F1
F0.00076452599388379206
I0
I1
I-1
tp16671
sS'contradictory,results,regarding'
p16672
(F1
F0.00076452599388379206
I0
I1
I-1
tp16673
sS'mouse,leukemia,model'
p16674
(F1
F0.00076452599388379206
I1
I0
I1
tp16675
sS'dznep,one,of'
p16676
(F1
F0.00076452599388379206
I0
I1
I-1
tp16677
sS'between,mg,m2'
p16678
(F1
F0.00076452599388379206
I0
I1
I-1
tp16679
sS'and,monoamine,oxidase'
p16680
(F1
F0.00076452599388379206
I0
I1
I-1
tp16681
sS'are,concurrently,receiving'
p16682
(F1
F0.00076452599388379206
I1
I0
I1
tp16683
sS'such,as,the'
p16684
(F1
F0.0030581039755351682
I4
I0
I4
tp16685
sS'urine,screening,tests'
p16686
(F1
F0.00076452599388379206
I0
I1
I-1
tp16687
sS'of,has,been'
p16688
(F1
F0.0015290519877675841
I0
I2
I-2
tp16689
sS'in,the,human'
p16690
(F1
F0.00076452599388379206
I0
I1
I-1
tp16691
sS'because,of,their'
p16692
(F1
F0.00076452599388379206
I1
I0
I1
tp16693
sS'when,and,are'
p16694
(F1
F0.0015290519877675841
I2
I0
I2
tp16695
sS'adamantyl,hexamethylenimine,mg'
p16696
(F1
F0.00076452599388379206
I0
I1
I-1
tp16697
sS'with,herceptin,resulted'
p16698
(F1
F0.00076452599388379206
I1
I0
I1
tp16699
sS'parathyroid,hormone,control'
p16700
(F1
F0.00076452599388379206
I0
I1
I-1
tp16701
sS'induction,leading,to'
p16702
(F1
F0.00076452599388379206
I1
I0
I1
tp16703
sS'general,anesthetics,phenothiazines'
p16704
(F1
F0.00076452599388379206
I1
I0
I1
tp16705
sS'that,markedly,inhibits'
p16706
(F1
F0.00076452599388379206
I1
I0
I1
tp16707
sS'gh,treatment,increases'
p16708
(F1
F0.00076452599388379206
I1
I0
I1
tp16709
sS'feldene,to,patients'
p16710
(F1
F0.00076452599388379206
I1
I0
I1
tp16711
sS'inhibitory,activity,sympathomimetic'
p16712
(F1
F0.00076452599388379206
I1
I0
I1
tp16713
sS'females,times,the'
p16714
(F1
F0.00076452599388379206
I0
I1
I-1
tp16715
sS'attenuating,some,of'
p16716
(F1
F0.00076452599388379206
I0
I1
I-1
tp16717
sS'been,performed,the'
p16718
(F1
F0.00076452599388379206
I0
I1
I-1
tp16719
sS'not,been,demonstrated'
p16720
(F1
F0.00076452599388379206
I1
I0
I1
tp16721
sS'concentration,in,patients'
p16722
(F1
F0.00076452599388379206
I1
I0
I1
tp16723
sS'therapy,should,not'
p16724
(F1
F0.00076452599388379206
I1
I0
I1
tp16725
sS'improved,by,co-injection'
p16726
(F1
F0.00076452599388379206
I1
I0
I1
tp16727
sS'also,affect,the'
p16728
(F1
F0.00076452599388379206
I1
I0
I1
tp16729
sS'the,precocene,i'
p16730
(F1
F0.00076452599388379206
I0
I1
I-1
tp16731
sS'treatment,with,low'
p16732
(F1
F0.00076452599388379206
I0
I1
I-1
tp16733
sS'no,formal,drug'
p16734
(F1
F0.00076452599388379206
I0
I1
I-1
tp16735
sS'antagonist,opioid,analgesics'
p16736
(F1
F0.00076452599388379206
I1
I0
I1
tp16737
sS'with,diabetes,mellitus'
p16738
(F1
F0.00076452599388379206
I1
I0
I1
tp16739
sS'or,agents,structurally'
p16740
(F1
F0.00076452599388379206
I1
I0
I1
tp16741
sS'and,sympathomimetic,agents'
p16742
(F1
F0.00076452599388379206
I1
I0
I1
tp16743
sS'be,given,until'
p16744
(F1
F0.00076452599388379206
I1
I0
I1
tp16745
sS'the,concurrent,administration'
p16746
(F1
F0.00076452599388379206
I0
I1
I-1
tp16747
sS'psychotic,episodes,when'
p16748
(F1
F0.00076452599388379206
I1
I0
I1
tp16749
sS'with,overexpression,of'
p16750
(F1
F0.00076452599388379206
I1
I0
I1
tp16751
sS'reactivity,as,a'
p16752
(F1
F0.00076452599388379206
I1
I0
I1
tp16753
sS'studies,conducted,in'
p16754
(F1
F0.00076452599388379206
I0
I1
I-1
tp16755
sS'drugs,antidepressant,drugs'
p16756
(F1
F0.00076452599388379206
I1
I0
I1
tp16757
sS'fixed,combination,n'
p16758
(F1
F0.00076452599388379206
I0
I1
I-1
tp16759
sS'folinic,acid,should'
p16760
(F1
F0.00076452599388379206
I0
I1
I-1
tp16761
sS'sedation,and,respiratory'
p16762
(F1
F0.00076452599388379206
I1
I0
I1
tp16763
sS'with,the,coadministration'
p16764
(F1
F0.00076452599388379206
I0
I1
I-1
tp16765
sS'between,and,is'
p16766
(F1
F0.00076452599388379206
I1
I0
I1
tp16767
sS'a,dznep,one'
p16768
(F1
F0.00076452599388379206
I0
I1
I-1
tp16769
sS'significant,changes,in'
p16770
(F1
F0.00076452599388379206
I0
I1
I-1
tp16771
sS'of,either,component'
p16772
(F1
F0.00076452599388379206
I0
I1
I-1
tp16773
sS'fertility,a,week'
p16774
(F1
F0.00076452599388379206
I0
I1
I-1
tp16775
sS'after,weeks,of'
p16776
(F1
F0.00076452599388379206
I1
I0
I1
tp16777
sS'carefully,monitored,for'
p16778
(F1
F0.00076452599388379206
I1
I0
I1
tp16779
sS'of,abt-737,and'
p16780
(F1
F0.00076452599388379206
I1
I0
I1
tp16781
sS'diuretics,aceon,tablets'
p16782
(F1
F0.00076452599388379206
I0
I1
I-1
tp16783
sS'normal-weight,subjects,receiving'
p16784
(F1
F0.0030581039755351682
I0
I4
I-4
tp16785
sS'marrow,depression,neurotoxic'
p16786
(F1
F0.00076452599388379206
I1
I0
I1
tp16787
sS'safety,of,using'
p16788
(F1
F0.00076452599388379206
I0
I1
I-1
tp16789
sS'one,case,of'
p16790
(F1
F0.00076452599388379206
I1
I0
I1
tp16791
sS'therapy,with,and'
p16792
(F1
F0.00076452599388379206
I1
I0
I1
tp16793
sS'as,may,increase'
p16794
(F1
F0.00076452599388379206
I1
I0
I1
tp16795
sS'should,be,taken'
p16796
(F1
F0.00076452599388379206
I1
I0
I1
tp16797
sS'others,supplements,or'
p16798
(F1
F0.00076452599388379206
I0
I1
I-1
tp16799
sS'time,with,the'
p16800
(F1
F0.00076452599388379206
I1
I0
I1
tp16801
sS'rifampin,theophylline,terfenadine'
p16802
(F1
F0.00076452599388379206
I1
I0
I1
tp16803
sS'supplemental,vitamin,d'
p16804
(F1
F0.00076452599388379206
I0
I1
I-1
tp16805
sS'treatment,of,anticholinesterase'
p16806
(F1
F0.00076452599388379206
I1
I0
I1
tp16807
sS'adverse,interactions,with'
p16808
(F1
F0.0015290519877675841
I0
I2
I-2
tp16809
sS'of,trental,and'
p16810
(F1
F0.00076452599388379206
I1
I0
I1
tp16811
sS'the,bactericidal,effects'
p16812
(F1
F0.00076452599388379206
I1
I0
I1
tp16813
sS'should,be,exercised'
p16814
(F0.59999999999999998
F0.0022935779816513763
I4
I1
I3
tp16815
sS'of,on,the'
p16816
(F0.59999999999999998
F0.0022935779816513763
I1
I4
I-3
tp16817
sS'the,concurrent,use'
p16818
(F1
F0.0015290519877675841
I2
I0
I2
tp16819
sS'patients,in,either'
p16820
(F1
F0.00076452599388379206
I0
I1
I-1
tp16821
sS'inr,were,observed'
p16822
(F1
F0.00076452599388379206
I1
I0
I1
tp16823
sS'frequency,and,or'
p16824
(F1
F0.0015290519877675841
I2
I0
I2
tp16825
sS'clinical,dosage,increased'
p16826
(F1
F0.00076452599388379206
I1
I0
I1
tp16827
sS'and,rabbits,during'
p16828
(F1
F0.00076452599388379206
I0
I1
I-1
tp16829
sS'in,the,poor'
p16830
(F1
F0.00076452599388379206
I0
I1
I-1
tp16831
sS'these,or,other'
p16832
(F1
F0.00076452599388379206
I1
I0
I1
tp16833
sS'healthy,subjects,concurrently'
p16834
(F1
F0.00076452599388379206
I1
I0
I1
tp16835
sS'other,cns,depressants'
p16836
(F0.5
F0.0015290519877675841
I3
I1
I2
tp16837
sS'use,of,since'
p16838
(F1
F0.00076452599388379206
I1
I0
I1
tp16839
sS'that,may,be'
p16840
(F0
F0
I1
I1
I0
tp16841
sS'treated,with,plus'
p16842
(F1
F0.00076452599388379206
I1
I0
I1
tp16843
sS'of,the,isoform-specific'
p16844
(F1
F0.00076452599388379206
I0
I1
I-1
tp16845
sS'increase,blood,levels'
p16846
(F1
F0.00076452599388379206
I0
I1
I-1
tp16847
sS'there,are,no'
p16848
(F0.5
F0.0015290519877675841
I1
I3
I-2
tp16849
sS'of,coumarin,and'
p16850
(F1
F0.00076452599388379206
I1
I0
I1
tp16851
sS'bw,for,d'
p16852
(F1
F0.00076452599388379206
I0
I1
I-1
tp16853
sS'calcium,is,the'
p16854
(F1
F0.00076452599388379206
I1
I0
I1
tp16855
sS'a,pharmacokinetic,interaction'
p16856
(F1
F0.00076452599388379206
I1
I0
I1
tp16857
sS'although,it,was'
p16858
(F1
F0.00076452599388379206
I1
I0
I1
tp16859
sS'is,not,affected'
p16860
(F1
F0.00076452599388379206
I0
I1
I-1
tp16861
sS'thrombocytopenia,and,gastrointestinal'
p16862
(F1
F0.00076452599388379206
I1
I0
I1
tp16863
sS'prothrombin,time,should'
p16864
(F1
F0.00076452599388379206
I1
I0
I1
tp16865
sS'xenograft-bearing,mice,with'
p16866
(F1
F0.00076452599388379206
I1
I0
I1
tp16867
sS'who,initiated,or'
p16868
(F1
F0.00076452599388379206
I1
I0
I1
tp16869
sS'study,found,that'
p16870
(F1
F0.00076452599388379206
I1
I0
I1
tp16871
sS'shown,a,significant'
p16872
(F1
F0.00076452599388379206
I1
I0
I1
tp16873
sS'potassium,chloride,supplements'
p16874
(F1
F0.00076452599388379206
I1
I0
I1
tp16875
sS'appeared,to,augment'
p16876
(F1
F0.00076452599388379206
I1
I0
I1
tp16877
sS'and,decreased,by'
p16878
(F1
F0.00076452599388379206
I1
I0
I1
tp16879
sS'recently,may,occasionally'
p16880
(F1
F0.00076452599388379206
I1
I0
I1
tp16881
sS'single,dose,of'
p16882
(F1
F0.00076452599388379206
I1
I0
I1
tp16883
sS'experience,changes,in'
p16884
(F1
F0.00076452599388379206
I1
I0
I1
tp16885
sS'hela,hct116,hepg2'
p16886
(F1
F0.00076452599388379206
I0
I1
I-1
tp16887
sS'stimulate,alpha-adrenergic,receptors'
p16888
(F1
F0.00076452599388379206
I1
I0
I1
tp16889
sS'or,pt,has'
p16890
(F1
F0.00076452599388379206
I1
I0
I1
tp16891
sS'selective,serotonin,reuptake'
p16892
(F0.33333333333333331
F0.00076452599388379206
I2
I1
I1
tp16893
sS'clinical,trials,concomitantly'
p16894
(F1
F0.00076452599388379206
I0
I1
I-1
tp16895
sS'with,or,is'
p16896
(F1
F0.0015290519877675841
I2
I0
I2
tp16897
sS'single,dose,or'
p16898
(F1
F0.00076452599388379206
I0
I1
I-1
tp16899
sS'predominantly,a,cytochrome'
p16900
(F1
F0.00076452599388379206
I0
I1
I-1
tp16901
sS'multiple,dose,studies'
p16902
(F1
F0.00076452599388379206
I0
I1
I-1
tp16903
sS'hormonal,contraceptives,concomitant'
p16904
(F1
F0.00076452599388379206
I0
I1
I-1
tp16905
sS'be,required,and'
p16906
(F1
F0.00076452599388379206
I1
I0
I1
tp16907
sS'effects,with,univasc'
p16908
(F1
F0.00076452599388379206
I0
I1
I-1
tp16909
sS'of,three,stereoisomers'
p16910
(F1
F0.00076452599388379206
I0
I1
I-1
tp16911
sS'may,predispose,to'
p16912
(F1
F0.00076452599388379206
I1
I0
I1
tp16913
sS'for,d,on'
p16914
(F1
F0.00076452599388379206
I0
I1
I-1
tp16915
sS'depending,on,clinical'
p16916
(F1
F0.00076452599388379206
I1
I0
I1
tp16917
sS'with,other,drugs'
p16918
(F0.25
F0.0015290519877675841
I3
I5
I-2
tp16919
sS'since,the,toxic'
p16920
(F1
F0.00076452599388379206
I1
I0
I1
tp16921
sS'and,are,to'
p16922
(F1
F0.00076452599388379206
I1
I0
I1
tp16923
sS'system,depressants,including'
p16924
(F1
F0.00076452599388379206
I1
I0
I1
tp16925
sS'approximately,following,a'
p16926
(F1
F0.0015290519877675841
I0
I2
I-2
tp16927
sS'other,anticholinergic,drugs'
p16928
(F1
F0.0015290519877675841
I2
I0
I2
tp16929
sS'also,interact,with'
p16930
(F1
F0.0015290519877675841
I0
I2
I-2
tp16931
sS'of,available,data'
p16932
(F1
F0.00076452599388379206
I1
I0
I1
tp16933
sS'evaluated,the,effect'
p16934
(F1
F0.0015290519877675841
I0
I2
I-2
tp16935
sS'episodes,when,coadministered'
p16936
(F1
F0.00076452599388379206
I1
I0
I1
tp16937
sS'hypotensive,agents,or'
p16938
(F1
F0.00076452599388379206
I0
I1
I-1
tp16939
sS'clinically,significant,hypoglycemia'
p16940
(F1
F0.00076452599388379206
I1
I0
I1
tp16941
sS'given,until,recovery'
p16942
(F1
F0.00076452599388379206
I1
I0
I1
tp16943
sS'and,smoking,may'
p16944
(F1
F0.00076452599388379206
I0
I1
I-1
tp16945
sS'small,bowel,may'
p16946
(F1
F0.00076452599388379206
I1
I0
I1
tp16947
sS'cell,cycle,apoptosis'
p16948
(F1
F0.00076452599388379206
I0
I1
I-1
tp16949
sS'high,content,such'
p16950
(F1
F0.00076452599388379206
I1
I0
I1
tp16951
sS'phenyl-1,tetrahydropyridine,injections'
p16952
(F1
F0.00076452599388379206
I0
I1
I-1
tp16953
sS'when,zetia,is'
p16954
(F1
F0.00076452599388379206
I0
I1
I-1
tp16955
sS'presence,of,other'
p16956
(F1
F0.00076452599388379206
I1
I0
I1
tp16957
sS'skelid,is,decreased'
p16958
(F1
F0.00076452599388379206
I1
I0
I1
tp16959
sS'versus,methyl-4,phenyl-1'
p16960
(F1
F0.00076452599388379206
I0
I1
I-1
tp16961
sS'enhancement,of,the'
p16962
(F1
F0.00076452599388379206
I1
I0
I1
tp16963
sS'to,treat,gastrointestinal'
p16964
(F1
F0.00076452599388379206
I1
I0
I1
tp16965
sS'the,following,seven'
p16966
(F1
F0.00076452599388379206
I0
I1
I-1
tp16967
sS'myfortic,with,or'
p16968
(F1
F0.00076452599388379206
I1
I0
I1
tp16969
sS'potentiated,by,anesthesia'
p16970
(F1
F0.00076452599388379206
I1
I0
I1
tp16971
sS'increase,certain,actions'
p16972
(F1
F0.00076452599388379206
I1
I0
I1
tp16973
sS'is,used,with'
p16974
(F1
F0.00076452599388379206
I1
I0
I1
tp16975
sS'of,nonmatched,tacrolimus-treated'
p16976
(F1
F0.00076452599388379206
I0
I1
I-1
tp16977
sS'necessary,eg,may'
p16978
(F1
F0.00076452599388379206
I1
I0
I1
tp16979
sS'marked,shrinkage,of'
p16980
(F1
F0.00076452599388379206
I1
I0
I1
tp16981
sS'coadministration,with,a'
p16982
(F1
F0.00076452599388379206
I1
I0
I1
tp16983
sS'of,these,isozymes'
p16984
(F1
F0.00076452599388379206
I0
I1
I-1
tp16985
sS'these,therapeutic,agents'
p16986
(F1
F0.00076452599388379206
I1
I0
I1
tp16987
sS'patients,receiving,other'
p16988
(F1
F0.00076452599388379206
I1
I0
I1
tp16989
sS'rifabutin,tacrolimus,short-acting'
p16990
(F1
F0.00076452599388379206
I1
I0
I1
tp16991
sS'effectiveness,of,administered'
p16992
(F1
F0.00076452599388379206
I0
I1
I-1
tp16993
sS'with,spent,more'
p16994
(F1
F0.00076452599388379206
I0
I1
I-1
tp16995
sS'diminish,the,bactericidal'
p16996
(F1
F0.00076452599388379206
I1
I0
I1
tp16997
sS'of,adrenergic,agents'
p16998
(F1
F0.0015290519877675841
I2
I0
I2
tp16999
sS'users,had,an'
p17000
(F1
F0.00076452599388379206
I1
I0
I1
tp17001
sS'to,increase,steady'
p17002
(F1
F0.00076452599388379206
I1
I0
I1
tp17003
sS'seen,when,was'
p17004
(F1
F0.00076452599388379206
I0
I1
I-1
tp17005
sS'to,interaction,with'
p17006
(F1
F0.00076452599388379206
I1
I0
I1
tp17007
sS'cyp2d6,coadministration,of'
p17008
(F1
F0.00076452599388379206
I0
I1
I-1
tp17009
sS'high,levels,only'
p17010
(F1
F0.00076452599388379206
I0
I1
I-1
tp17011
sS'and,infusion,rate'
p17012
(F1
F0.00076452599388379206
I1
I0
I1
tp17013
sS'approximately,in,the'
p17014
(F1
F0.00076452599388379206
I1
I0
I1
tp17015
sS'single,dose,was'
p17016
(F1
F0.00076452599388379206
I0
I1
I-1
tp17017
sS'days,before,the'
p17018
(F1
F0.0015290519877675841
I2
I0
I2
tp17019
sS'or,enhancement,of'
p17020
(F1
F0.00076452599388379206
I1
I0
I1
tp17021
sS'with,enterohepatic,recirculation'
p17022
(F1
F0.00076452599388379206
I1
I0
I1
tp17023
sS'activity,should,be'
p17024
(F1
F0.00076452599388379206
I1
I0
I1
tp17025
sS'that,and,can'
p17026
(F1
F0.00076452599388379206
I1
I0
I1
tp17027
sS'pharmacokinetic,study,has'
p17028
(F1
F0.00076452599388379206
I1
I0
I1
tp17029
sS'tobi,should,not'
p17030
(F1
F0.00076452599388379206
I1
I0
I1
tp17031
sS'the,humoral,immune'
p17032
(F1
F0.00076452599388379206
I0
I1
I-1
tp17033
sS'with,no,effect'
p17034
(F1
F0.00076452599388379206
I1
I0
I1
tp17035
sS'concluded,that,can'
p17036
(F1
F0.00076452599388379206
I1
I0
I1
tp17037
sS'a,g,dose'
p17038
(F1
F0.00076452599388379206
I1
I0
I1
tp17039
sS'to,human,plasma'
p17040
(F1
F0.00076452599388379206
I0
I1
I-1
tp17041
sS'occurred,in,in'
p17042
(F1
F0.00076452599388379206
I1
I0
I1
tp17043
sS'enhance,the,sedative'
p17044
(F1
F0.0015290519877675841
I2
I0
I2
tp17045
sS'and,therefore,should'
p17046
(F1
F0.0015290519877675841
I2
I0
I2
tp17047
sS'coadministration,of,sanctura'
p17048
(F1
F0.00076452599388379206
I0
I1
I-1
tp17049
sS'administration,of,or'
p17050
(F1
F0.00076452599388379206
I1
I0
I1
tp17051
sS'of,sodium,and'
p17052
(F1
F0.00076452599388379206
I1
I0
I1
tp17053
sS'oxide,to,achieve'
p17054
(F1
F0.00076452599388379206
I0
I1
I-1
tp17055
sS'second,herceptin,treatment'
p17056
(F1
F0.00076452599388379206
I1
I0
I1
tp17057
sS'indicate,that,gh'
p17058
(F1
F0.00076452599388379206
I1
I0
I1
tp17059
sS'with,guanethidine,although'
p17060
(F1
F0.00076452599388379206
I1
I0
I1
tp17061
sS'pharmacokinetics,and,the'
p17062
(F1
F0.00076452599388379206
I0
I1
I-1
tp17063
sS'also,conducted,in'
p17064
(F1
F0.00076452599388379206
I0
I1
I-1
tp17065
sS'of,src,and'
p17066
(F1
F0.00076452599388379206
I0
I1
I-1
tp17067
sS'potassium-sparing,diuretics,aceon'
p17068
(F1
F0.00076452599388379206
I0
I1
I-1
tp17069
sS'those,in,two'
p17070
(F1
F0.00076452599388379206
I0
I1
I-1
tp17071
sS'to,accelerate,the'
p17072
(F1
F0.00076452599388379206
I1
I0
I1
tp17073
sS'yl,ethynyl,pyridine-treated'
p17074
(F1
F0.0015290519877675841
I2
I0
I2
tp17075
sS'was,found,throughout'
p17076
(F1
F0.00076452599388379206
I0
I1
I-1
tp17077
sS'shown,to,reduce'
p17078
(F1
F0.00076452599388379206
I0
I1
I-1
tp17079
sS'reduction,in,supplement'
p17080
(F1
F0.00076452599388379206
I1
I0
I1
tp17081
sS'blocking,agents,or'
p17082
(F1
F0.00076452599388379206
I1
I0
I1
tp17083
sS'be,expected,when'
p17084
(F1
F0.0015290519877675841
I2
I0
I2
tp17085
sS'difference,in,responsiveness'
p17086
(F1
F0.00076452599388379206
I0
I1
I-1
tp17087
sS'by,drugs,that'
p17088
(F1
F0.00076452599388379206
I1
I0
I1
tp17089
sS'control,sirna,sub-g1'
p17090
(F1
F0.00076452599388379206
I0
I1
I-1
tp17091
sS'the,dose,response'
p17092
(F1
F0.00076452599388379206
I0
I1
I-1
tp17093
sS'anticholinergic,agents,may'
p17094
(F1
F0.00076452599388379206
I1
I0
I1
tp17095
sS'the,they,should'
p17096
(F1
F0.00076452599388379206
I1
I0
I1
tp17097
sS'increase,the,risk'
p17098
(F0.33333333333333331
F0.0022935779816513763
I6
I3
I3
tp17099
sS'weakness,hyperreflexia,and'
p17100
(F1
F0.00076452599388379206
I1
I0
I1
tp17101
sS'usp,modified,pharmacokinetics'
p17102
(F1
F0.00076452599388379206
I0
I1
I-1
tp17103
sS'serum,concentration,of'
p17104
(F1
F0.00076452599388379206
I0
I1
I-1
tp17105
sS'to,ng,hr'
p17106
(F1
F0.00076452599388379206
I1
I0
I1
tp17107
sS'effect,in,the'
p17108
(F1
F0.00076452599388379206
I0
I1
I-1
tp17109
sS'increase,plasma,levels'
p17110
(F1
F0.00076452599388379206
I1
I0
I1
tp17111
sS'the,or,increasing'
p17112
(F1
F0.00076452599388379206
I1
I0
I1
tp17113
sS'bid,with,mg'
p17114
(F1
F0.00076452599388379206
I1
I0
I1
tp17115
sS'levels,reports,of'
p17116
(F1
F0.00076452599388379206
I1
I0
I1
tp17117
sS'been,associated,with'
p17118
(F1
F0.0022935779816513763
I3
I0
I3
tp17119
sS'analogues,a,pharmacokinetic'
p17120
(F1
F0.00076452599388379206
I1
I0
I1
tp17121
sS'disease,hospitalized,in'
p17122
(F1
F0.00076452599388379206
I0
I1
I-1
tp17123
sS'especially,ssri,such'
p17124
(F1
F0.00076452599388379206
I1
I0
I1
tp17125
sS'or,other,cns'
p17126
(F1
F0.00076452599388379206
I1
I0
I1
tp17127
sS'are,described,in'
p17128
(F1
F0.00076452599388379206
I1
I0
I1
tp17129
sS'and,agents,that'
p17130
(F1
F0.00076452599388379206
I1
I0
I1
tp17131
sS'p,lt,and'
p17132
(F1
F0.00076452599388379206
I0
I1
I-1
tp17133
sS'and,narcotics,the'
p17134
(F1
F0.00076452599388379206
I0
I1
I-1
tp17135
sS'for,total,intravenous'
p17136
(F1
F0.00076452599388379206
I0
I1
I-1
tp17137
sS'increase,in,s-warfarin'
p17138
(F1
F0.00076452599388379206
I1
I0
I1
tp17139
sS'of,cytochrome,p4501a2'
p17140
(F1
F0.00076452599388379206
I1
I0
I1
tp17141
sS'amines,may,cause'
p17142
(F1
F0.00076452599388379206
I1
I0
I1
tp17143
sS'parent,compound,and'
p17144
(F1
F0.00076452599388379206
I1
I0
I1
tp17145
sS'respectively,than,when'
p17146
(F1
F0.00076452599388379206
I1
I0
I1
tp17147
sS'been,reported,in'
p17148
(F0.63636363636363635
F0.0053516819571865441
I9
I2
I7
tp17149
sS'agents,which,produce'
p17150
(F1
F0.00076452599388379206
I1
I0
I1
tp17151
sS'a,mean,increase'
p17152
(F1
F0.0015290519877675841
I2
I0
I2
tp17153
sS'the,only,known'
p17154
(F1
F0.00076452599388379206
I1
I0
I1
tp17155
sS'higher,when,ditropan'
p17156
(F1
F0.00076452599388379206
I1
I0
I1
tp17157
sS'studies,with,failed'
p17158
(F1
F0.00076452599388379206
I0
I1
I-1
tp17159
sS'with,calcium-channel,blocking'
p17160
(F1
F0.00076452599388379206
I0
I1
I-1
tp17161
sS'chloride,on,absorption'
p17162
(F1
F0.00076452599388379206
I1
I0
I1
tp17163
sS'agents,may,also'
p17164
(F1
F0.0015290519877675841
I2
I0
I2
tp17165
sS'evaluate,the,potential'
p17166
(F1
F0.00076452599388379206
I0
I1
I-1
tp17167
sS'mg,bid,for'
p17168
(F1
F0.0015290519877675841
I2
I0
I2
tp17169
sS'present,study,mg'
p17170
(F1
F0.00076452599388379206
I1
I0
I1
tp17171
sS'melatonin,may,interact'
p17172
(F1
F0.00076452599388379206
I1
I0
I1
tp17173
sS'crossover,steady,state'
p17174
(F1
F0.00076452599388379206
I0
I1
I-1
tp17175
sS'not,significantly,affected'
p17176
(F1
F0.00076452599388379206
I0
I1
I-1
tp17177
sS'risk,of,respiratory'
p17178
(F1
F0.00076452599388379206
I1
I0
I1
tp17179
sS'also,responsible,for'
p17180
(F1
F0.00076452599388379206
I1
I0
I1
tp17181
sS'patients,with,or'
p17182
(F1
F0.00076452599388379206
I1
I0
I1
tp17183
sS'patients,n,and'
p17184
(F1
F0.00076452599388379206
I0
I1
I-1
tp17185
sS'other,hdac,inhibitors'
p17186
(F1
F0.00076452599388379206
I1
I0
I1
tp17187
sS'acid,to,subtherapeutic'
p17188
(F1
F0.00076452599388379206
I1
I0
I1
tp17189
sS'with,since,patients'
p17190
(F1
F0.00076452599388379206
I1
I0
I1
tp17191
sS'infusional,fu,has'
p17192
(F1
F0.00076452599388379206
I0
I1
I-1
tp17193
sS'vivo,drug-drug,interaction'
p17194
(F1
F0.0015290519877675841
I0
I2
I-2
tp17195
sS'ventricular,arrhythmia,including'
p17196
(F1
F0.00076452599388379206
I0
I1
I-1
tp17197
sS'herbal,supplements,such'
p17198
(F1
F0.00076452599388379206
I0
I1
I-1
tp17199
sS'been,reported,previously'
p17200
(F1
F0.00076452599388379206
I0
I1
I-1
tp17201
sS'administration,with,adrenal'
p17202
(F1
F0.00076452599388379206
I0
I1
I-1
tp17203
sS'drugs,potentiation,of'
p17204
(F1
F0.00076452599388379206
I1
I0
I1
tp17205
sS'taken,concurrently,with'
p17206
(F1
F0.0015290519877675841
I2
I0
I2
tp17207
sS'calcium,does,not'
p17208
(F1
F0.00076452599388379206
I0
I1
I-1
tp17209
sS'often,needed,higher'
p17210
(F1
F0.00076452599388379206
I1
I0
I1
tp17211
sS'neurologic,toxicity,phenytoin'
p17212
(F1
F0.00076452599388379206
I1
I0
I1
tp17213
sS'usually,complete,cross-resistance'
p17214
(F1
F0.00076452599388379206
I1
I0
I1
tp17215
sS'oral,s-ketamine,with'
p17216
(F1
F0.00076452599388379206
I0
I1
I-1
tp17217
sS'and,rare,serious'
p17218
(F1
F0.00076452599388379206
I1
I0
I1
tp17219
sS'were,seen,when'
p17220
(F1
F0.00076452599388379206
I0
I1
I-1
tp17221
sS'when,administering,tolectin'
p17222
(F1
F0.00076452599388379206
I1
I0
I1
tp17223
sS'drugs,which,include'
p17224
(F1
F0.00076452599388379206
I1
I0
I1
tp17225
sS'the,addition,of'
p17226
(F0.20000000000000001
F0.00076452599388379206
I2
I3
I-1
tp17227
sS'blood,glucose,concentrations'
p17228
(F1
F0.00076452599388379206
I1
I0
I1
tp17229
sS'therapy,having,tubal'
p17230
(F1
F0.00076452599388379206
I1
I0
I1
tp17231
sS'possibly,enhancing,the'
p17232
(F1
F0.00076452599388379206
I1
I0
I1
tp17233
sS'relative,to,the'
p17234
(F1
F0.00076452599388379206
I0
I1
I-1
tp17235
sS'high,dose,of'
p17236
(F1
F0.00076452599388379206
I1
I0
I1
tp17237
sS'increase,in,bleeding'
p17238
(F1
F0.00076452599388379206
I1
I0
I1
tp17239
sS'be,necessary,during'
p17240
(F1
F0.00076452599388379206
I1
I0
I1
tp17241
sS'intake,prior,to'
p17242
(F1
F0.00076452599388379206
I1
I0
I1
tp17243
sS'frequent,monitoring,of'
p17244
(F1
F0.00076452599388379206
I1
I0
I1
tp17245
sS'with,other,central'
p17246
(F1
F0.0015290519877675841
I2
I0
I2
tp17247
sS'not,increase,the'
p17248
(F1
F0.00076452599388379206
I1
I0
I1
tp17249
sS'cyp3a4,isozymes,caution'
p17250
(F1
F0.00076452599388379206
I1
I0
I1
tp17251
sS'on,the,abraded'
p17252
(F1
F0.00076452599388379206
I1
I0
I1
tp17253
sS'of,therapy,with'
p17254
(F1
F0.00076452599388379206
I1
I0
I1
tp17255
sS'primary,cns,effects'
p17256
(F1
F0.00076452599388379206
I1
I0
I1
tp17257
sS'potentiation,hypotensive,agents'
p17258
(F1
F0.00076452599388379206
I0
I1
I-1
tp17259
sS'be,to,g'
p17260
(F1
F0.00076452599388379206
I1
I0
I1
tp17261
sS'd,on,the'
p17262
(F1
F0.00076452599388379206
I0
I1
I-1
tp17263
sS'thrombocytopenia,increased,nephrotoxicity'
p17264
(F1
F0.0015290519877675841
I0
I2
I-2
tp17265
sS'the,dose-dependent,antinociceptive'
p17266
(F1
F0.00076452599388379206
I1
I0
I1
tp17267
sS'and,were,unaffected'
p17268
(F1
F0.00076452599388379206
I0
I1
I-1
tp17269
sS'is,that,the'
p17270
(F1
F0.00076452599388379206
I1
I0
I1
tp17271
sS'synergistically,inhibited,growth'
p17272
(F1
F0.00076452599388379206
I1
I0
I1
tp17273
sS'treat,gastrointestinal,symptoms'
p17274
(F1
F0.00076452599388379206
I1
I0
I1
tp17275
sS'a,mixture,of'
p17276
(F1
F0.00076452599388379206
I0
I1
I-1
tp17277
sS'mild,to,moderate'
p17278
(F1
F0.0015290519877675841
I2
I0
I2
tp17279
sS'administration,for,days'
p17280
(F1
F0.00076452599388379206
I0
I1
I-1
tp17281
sS'derivatives,is,anticipated'
p17282
(F1
F0.00076452599388379206
I1
I0
I1
tp17283
sS'the,cns-depressant,effect'
p17284
(F1
F0.00076452599388379206
I1
I0
I1
tp17285
sS'on,studies,evaluating'
p17286
(F1
F0.00076452599388379206
I0
I1
I-1
tp17287
sS'has,the,potential'
p17288
(F1
F0.00076452599388379206
I1
I0
I1
tp17289
sS'did,not,noticeably'
p17290
(F1
F0.00076452599388379206
I0
I1
I-1
tp17291
sS'system,ie,some'
p17292
(F1
F0.00076452599388379206
I1
I0
I1
tp17293
sS'in,healthy,volunteers'
p17294
(F1
F0.0015290519877675841
I0
I2
I-2
tp17295
sS'children,due,to'
p17296
(F1
F0.00076452599388379206
I1
I0
I1
tp17297
sS'and,other,similar'
p17298
(F1
F0.00076452599388379206
I1
I0
I1
tp17299
sS'bleeding,risk,in'
p17300
(F1
F0.00076452599388379206
I0
I1
I-1
tp17301
sS'concurrently,administered,zolinza'
p17302
(F1
F0.00076452599388379206
I1
I0
I1
tp17303
sS'metabolism,the,metabolism'
p17304
(F1
F0.00076452599388379206
I0
I1
I-1
tp17305
sS'interaction,between,mycamine'
p17306
(F1
F0.00076452599388379206
I0
I1
I-1
tp17307
sS'effects,of,are'
p17308
(F1
F0.00076452599388379206
I1
I0
I1
tp17309
sS'with,the,efficacy'
p17310
(F1
F0.00076452599388379206
I1
I0
I1
tp17311
sS'dosage,and,the'
p17312
(F1
F0.00076452599388379206
I1
I0
I1
tp17313
sS'conjunction,with,interaction'
p17314
(F1
F0.00076452599388379206
I1
I0
I1
tp17315
sS'of,hcl,was'
p17316
(F1
F0.00076452599388379206
I1
I0
I1
tp17317
sS'but,the,sequential'
p17318
(F1
F0.00076452599388379206
I1
I0
I1
tp17319
sS'by,the,presence'
p17320
(F1
F0.00076452599388379206
I1
I0
I1
tp17321
sS'found,to,decrease'
p17322
(F1
F0.00076452599388379206
I1
I0
I1
tp17323
sS'with,tiva,but'
p17324
(F1
F0.00076452599388379206
I0
I1
I-1
tp17325
sS'be,an,antiproliferative'
p17326
(F1
F0.00076452599388379206
I1
I0
I1
tp17327
sS'pharmacokinetics,of,lbh589'
p17328
(F1
F0.00076452599388379206
I0
I1
I-1
tp17329
sS'monoamine,oxidase,inhibitor'
p17330
(F1
F0.00076452599388379206
I1
I0
I1
tp17331
sS'of,were,reduced'
p17332
(F1
F0.00076452599388379206
I1
I0
I1
tp17333
sS'the,hot,plate'
p17334
(F1
F0.00076452599388379206
I1
I0
I1
tp17335
sS'is,a,substrate'
p17336
(F1
F0.00076452599388379206
I0
I1
I-1
tp17337
sS'results,for,and'
p17338
(F1
F0.00076452599388379206
I0
I1
I-1
tp17339
sS'tofranil,anafranil,vivactil'
p17340
(F1
F0.00076452599388379206
I0
I1
I-1
tp17341
sS'mg,kg,plus'
p17342
(F1
F0.00076452599388379206
I0
I1
I-1
tp17343
sS'or,timing,of'
p17344
(F1
F0.00076452599388379206
I1
I0
I1
tp17345
sS'administered,agent,is'
p17346
(F1
F0.00076452599388379206
I1
I0
I1
tp17347
sS'change,the,pharmacokinetic'
p17348
(F1
F0.00076452599388379206
I0
I1
I-1
tp17349
sS'this,interaction,should'
p17350
(F1
F0.00076452599388379206
I1
I0
I1
tp17351
sS'administering,nexavar,with'
p17352
(F1
F0.00076452599388379206
I1
I0
I1
tp17353
sS'given,concurrently,with'
p17354
(F1
F0.0015290519877675841
I2
I0
I2
tp17355
sS'induce,or,inhibit'
p17356
(F1
F0.0015290519877675841
I0
I2
I-2
tp17357
sS'inhibitor,and,the'
p17358
(F1
F0.00076452599388379206
I0
I1
I-1
tp17359
sS'mivacron,are,unknown'
p17360
(F1
F0.00076452599388379206
I1
I0
I1
tp17361
sS'agents,that,may'
p17362
(F1
F0.00076452599388379206
I1
I0
I1
tp17363
sS'decreased,c,max'
p17364
(F1
F0.00076452599388379206
I1
I0
I1
tp17365
sS'the,most,serious'
p17366
(F1
F0.00076452599388379206
I1
I0
I1
tp17367
sS'negative,control,sirna'
p17368
(F1
F0.00076452599388379206
I0
I1
I-1
tp17369
sS'not,bear,directly'
p17370
(F1
F0.00076452599388379206
I1
I0
I1
tp17371
sS'induction,dose,requirements'
p17372
(F1
F0.00076452599388379206
I1
I0
I1
tp17373
sS'breast,cancer,cells'
p17374
(F1
F0.00076452599388379206
I1
I0
I1
tp17375
sS'and,potent,cyp'
p17376
(F1
F0.00076452599388379206
I0
I1
I-1
tp17377
sS'of,and,mexitil'
p17378
(F1
F0.00076452599388379206
I1
I0
I1
tp17379
sS'mean,auc,and'
p17380
(F1
F0.00076452599388379206
I1
I0
I1
tp17381
sS'vitro,and,represents'
p17382
(F1
F0.00076452599388379206
I1
I0
I1
tp17383
sS'patients,the,clearance'
p17384
(F1
F0.00076452599388379206
I1
I0
I1
tp17385
sS'other,tranquilizers,sedative-hypnotics'
p17386
(F1
F0.00076452599388379206
I1
I0
I1
tp17387
sS'periods,at,intervals'
p17388
(F1
F0.00076452599388379206
I0
I1
I-1
tp17389
sS'n,nonsteroidal,anti-inflammatory'
p17390
(F1
F0.00076452599388379206
I0
I1
I-1
tp17391
sS'plasma,proteins,is'
p17392
(F1
F0.00076452599388379206
I0
I1
I-1
tp17393
sS'thiazol-4,yl,ethynyl'
p17394
(F0.42857142857142855
F0.0022935779816513763
I5
I2
I3
tp17395
sS'affect,the,binding'
p17396
(F1
F0.00076452599388379206
I0
I1
I-1
tp17397
sS'competitive,inhibition,such'
p17398
(F1
F0.00076452599388379206
I0
I1
I-1
tp17399
sS'to,that,of'
p17400
(F0
F0
I1
I1
I0
tp17401
sS'the,objective,was'
p17402
(F1
F0.00076452599388379206
I0
I1
I-1
tp17403
sS'absorption,that,is'
p17404
(F1
F0.00076452599388379206
I0
I1
I-1
tp17405
sS'therapeutic,range,considered'
p17406
(F1
F0.00076452599388379206
I1
I0
I1
tp17407
sS'warfarin,a,multidose'
p17408
(F1
F0.00076452599388379206
I1
I0
I1
tp17409
sS'time,or,other'
p17410
(F1
F0.00076452599388379206
I1
I0
I1
tp17411
sS'is,prescribed,for'
p17412
(F1
F0.00076452599388379206
I0
I1
I-1
tp17413
sS'to,inactivated,nd'
p17414
(F1
F0.00076452599388379206
I0
I1
I-1
tp17415
sS'effects,of,mivacron'
p17416
(F1
F0.00076452599388379206
I0
I1
I-1
tp17417
sS'of,organic,acids'
p17418
(F1
F0.00076452599388379206
I0
I1
I-1
tp17419
sS'there,have,been'
p17420
(F0.5
F0.0030581039755351682
I6
I2
I4
tp17421
sS'particularly,eg,and'
p17422
(F1
F0.00076452599388379206
I1
I0
I1
tp17423
sS'increased,serum,concentrations'
p17424
(F1
F0.00076452599388379206
I1
I0
I1
tp17425
sS'the,depth,of'
p17426
(F1
F0.00076452599388379206
I0
I1
I-1
tp17427
sS'net,inducer,of'
p17428
(F1
F0.00076452599388379206
I1
I0
I1
tp17429
sS'hydrochloride,may,be'
p17430
(F1
F0.00076452599388379206
I1
I0
I1
tp17431
sS'may,antagonize,the'
p17432
(F1
F0.0022935779816513763
I3
I0
I3
tp17433
sS'observed,increase,in'
p17434
(F1
F0.00076452599388379206
I0
I1
I-1
tp17435
sS'assessed,using,a'
p17436
(F1
F0.00076452599388379206
I0
I1
I-1
tp17437
sS'm2,eloxatin,and'
p17438
(F1
F0.00076452599388379206
I0
I1
I-1
tp17439
sS'between,and,flomax'
p17440
(F1
F0.00076452599388379206
I0
I1
I-1
tp17441
sS'use,of,at'
p17442
(F1
F0.00076452599388379206
I1
I0
I1
tp17443
sS'mg,than,with'
p17444
(F1
F0.00076452599388379206
I0
I1
I-1
tp17445
sS'expected,to,affect'
p17446
(F1
F0.00076452599388379206
I0
I1
I-1
tp17447
sS'patients,receiving,diflucan'
p17448
(F1
F0.0022935779816513763
I3
I0
I3
tp17449
sS'agents,and,may'
p17450
(F1
F0.00076452599388379206
I1
I0
I1
tp17451
sS'healthy,adults,was'
p17452
(F1
F0.00076452599388379206
I1
I0
I1
tp17453
sS'levels,only,and'
p17454
(F1
F0.00076452599388379206
I0
I1
I-1
tp17455
sS'phosphorylation,of,is'
p17456
(F1
F0.00076452599388379206
I1
I0
I1
tp17457
sS'different,conditions,and'
p17458
(F1
F0.00076452599388379206
I0
I1
I-1
tp17459
sS'least,hour,prior'
p17460
(F1
F0.00076452599388379206
I1
I0
I1
tp17461
sS'the,therapeutic,actions'
p17462
(F1
F0.00076452599388379206
I1
I0
I1
tp17463
sS'hepatic,enzyme,inducers'
p17464
(F1
F0.00076452599388379206
I1
I0
I1
tp17465
sS'did,not,cause'
p17466
(F1
F0.0015290519877675841
I0
I2
I-2
tp17467
sS'only,with,great'
p17468
(F1
F0.0015290519877675841
I2
I0
I2
tp17469
sS'interact,with,concurrently'
p17470
(F1
F0.00076452599388379206
I1
I0
I1
tp17471
sS'motor,skills,produced'
p17472
(F1
F0.0015290519877675841
I2
I0
I2
tp17473
sS'either,agent,alone'
p17474
(F1
F0.00076452599388379206
I1
I0
I1
tp17475
sS'and,auc,of'
p17476
(F1
F0.0022935779816513763
I3
I0
I3
tp17477
sS'a,tricyclic,antidepressant'
p17478
(F1
F0.00076452599388379206
I0
I1
I-1
tp17479
sS'losses,of,fluid'
p17480
(F1
F0.00076452599388379206
I1
I0
I1
tp17481
sS'clearance,ml,min'
p17482
(F1
F0.00076452599388379206
I1
I0
I1
tp17483
sS'to,affect,the'
p17484
(F1
F0.00076452599388379206
I0
I1
I-1
tp17485
sS'and,or,prolonged'
p17486
(F1
F0.00076452599388379206
I1
I0
I1
tp17487
sS'in,the,marked'
p17488
(F1
F0.00076452599388379206
I1
I0
I1
tp17489
sS'capable,of,causing'
p17490
(F1
F0.00076452599388379206
I1
I0
I1
tp17491
sS'treatment,of,xenical'
p17492
(F1
F0.00076452599388379206
I0
I1
I-1
tp17493
sS'initiating,adjusting,and'
p17494
(F1
F0.00076452599388379206
I1
I0
I1
tp17495
sS'inhibitor,activity,in'
p17496
(F1
F0.00076452599388379206
I0
I1
I-1
tp17497
sS'theophylline,plasma,levels'
p17498
(F1
F0.00076452599388379206
I1
I0
I1
tp17499
sS'proamatine,is,administered'
p17500
(F1
F0.00076452599388379206
I1
I0
I1
tp17501
sS'mixed,and,must'
p17502
(F1
F0.00076452599388379206
I0
I1
I-1
tp17503
sS'of,chemotherapy,tumor'
p17504
(F1
F0.00076452599388379206
I1
I0
I1
tp17505
sS'in,the,diet'
p17506
(F1
F0.00076452599388379206
I1
I0
I1
tp17507
sS'respectively,lower,in'
p17508
(F1
F0.00076452599388379206
I1
I0
I1
tp17509
sS'that,inhibits,metabolism'
p17510
(F1
F0.00076452599388379206
I1
I0
I1
tp17511
sS'elicit,important,drug-drug'
p17512
(F1
F0.00076452599388379206
I0
I1
I-1
tp17513
sS'in,normal-weight,female'
p17514
(F1
F0.00076452599388379206
I0
I1
I-1
tp17515
sS'absorption,by,an'
p17516
(F1
F0.00076452599388379206
I1
I0
I1
tp17517
sS'except,where,compatibility'
p17518
(F1
F0.00076452599388379206
I0
I1
I-1
tp17519
sS'pharmacokinetic,interactions,were'
p17520
(F1
F0.00076452599388379206
I0
I1
I-1
tp17521
sS'compassionate,use,program'
p17522
(F1
F0.00076452599388379206
I0
I1
I-1
tp17523
sS'on,mptp-evoked,behavior'
p17524
(F1
F0.00076452599388379206
I0
I1
I-1
tp17525
sS'the,coadministered,drug'
p17526
(F1
F0.00076452599388379206
I0
I1
I-1
tp17527
sS'may,require,downward'
p17528
(F1
F0.00076452599388379206
I1
I0
I1
tp17529
sS'pt,and,adjustment'
p17530
(F1
F0.00076452599388379206
I1
I0
I1
tp17531
sS'that,combined,with'
p17532
(F1
F0.00076452599388379206
I1
I0
I1
tp17533
sS'male,or,female'
p17534
(F1
F0.00076452599388379206
I0
I1
I-1
tp17535
sS'with,maxair,autohaler'
p17536
(F1
F0.00076452599388379206
I1
I0
I1
tp17537
sS'kinetics,of,oral'
p17538
(F1
F0.00076452599388379206
I0
I1
I-1
tp17539
sS'in,oral,gavage'
p17540
(F1
F0.00076452599388379206
I0
I1
I-1
tp17541
sS'study,n,extensive'
p17542
(F1
F0.00076452599388379206
I0
I1
I-1
tp17543
sS'that,releases,catecholamines'
p17544
(F1
F0.00076452599388379206
I1
I0
I1
tp17545
sS'increase,the,cns'
p17546
(F1
F0.00076452599388379206
I1
I0
I1
tp17547
sS'elevated,temperature,has'
p17548
(F1
F0.00076452599388379206
I1
I0
I1
tp17549
sS'and,or,stimulantes'
p17550
(F1
F0.00076452599388379206
I1
I0
I1
tp17551
sS'inhibitors,of,the'
p17552
(F1
F0.0022935779816513763
I3
I0
I3
tp17553
sS'myfortic,not,be'
p17554
(F1
F0.00076452599388379206
I1
I0
I1
tp17555
sS'it,can,be'
p17556
(F1
F0.00076452599388379206
I1
I0
I1
tp17557
sS'of,exelon,tartrate'
p17558
(F1
F0.00076452599388379206
I0
I1
I-1
tp17559
sS'sub-g1,fraction,control'
p17560
(F1
F0.00076452599388379206
I0
I1
I-1
tp17561
sS'considering,the,safety'
p17562
(F1
F0.00076452599388379206
I0
I1
I-1
tp17563
sS'p450,system,may'
p17564
(F1
F0.00076452599388379206
I1
I0
I1
tp17565
sS'with,in,patients'
p17566
(F1
F0.0015290519877675841
I2
I0
I2
tp17567
sS'anticholinergic,agents,such'
p17568
(F1
F0.00076452599388379206
I1
I0
I1
tp17569
sS'was,administered,concomitantly'
p17570
(F1
F0.00076452599388379206
I0
I1
I-1
tp17571
sS'rats,there,was'
p17572
(F1
F0.00076452599388379206
I0
I1
I-1
tp17573
sS'with,anticholinergics,because'
p17574
(F1
F0.00076452599388379206
I1
I0
I1
tp17575
sS'have,been,the'
p17576
(F1
F0.00076452599388379206
I0
I1
I-1
tp17577
sS'chloride,concurrent,use'
p17578
(F1
F0.00076452599388379206
I1
I0
I1
tp17579
sS'drops,or,medications'
p17580
(F1
F0.00076452599388379206
I1
I0
I1
tp17581
sS'in,cyclosporine-treated,patients'
p17582
(F1
F0.00076452599388379206
I1
I0
I1
tp17583
sS'of,neuronal,loss'
p17584
(F1
F0.00076452599388379206
I1
I0
I1
tp17585
sS'chelation,therapy,such'
p17586
(F1
F0.00076452599388379206
I1
I0
I1
tp17587
sS'normal-weight,subjects,administration'
p17588
(F1
F0.00076452599388379206
I0
I1
I-1
tp17589
sS'blockers,may,decrease'
p17590
(F1
F0.00076452599388379206
I1
I0
I1
tp17591
sS'patients,taking,drugs'
p17592
(F1
F0.00076452599388379206
I1
I0
I1
tp17593
sS'depression,due,to'
p17594
(F1
F0.00076452599388379206
I1
I0
I1
tp17595
sS'the,ability,of'
p17596
(F1
F0.00076452599388379206
I0
I1
I-1
tp17597
sS'oral,contraceptives,given'
p17598
(F1
F0.00076452599388379206
I0
I1
I-1
tp17599
sS'drugs,with,oral'
p17600
(F1
F0.00076452599388379206
I1
I0
I1
tp17601
sS'increased,nephrotoxicity,agents'
p17602
(F1
F0.0015290519877675841
I0
I2
I-2
tp17603
sS'the,curve,auc'
p17604
(F1
F0.00076452599388379206
I1
I0
I1
tp17605
sS'impairment,of,cognitive'
p17606
(F1
F0.00076452599388379206
I1
I0
I1
tp17607
sS'interactions,were,seen'
p17608
(F1
F0.00076452599388379206
I0
I1
I-1
tp17609
sS'if,at,all'
p17610
(F1
F0.0015290519877675841
I2
I0
I2
tp17611
sS'with,may,have'
p17612
(F1
F0.00076452599388379206
I1
I0
I1
tp17613
sS'alkeran,vaccinations,with'
p17614
(F1
F0.00076452599388379206
I1
I0
I1
tp17615
sS'can,potentiate,the'
p17616
(F1
F0.00076452599388379206
I1
I0
I1
tp17617
sS'the,administration,of'
p17618
(F1
F0.00076452599388379206
I0
I1
I-1
tp17619
sS'bleeding,have,been'
p17620
(F1
F0.0015290519877675841
I2
I0
I2
tp17621
sS'of,and,that'
p17622
(F1
F0.00076452599388379206
I0
I1
I-1
tp17623
sS'to,affect,elimination'
p17624
(F1
F0.00076452599388379206
I0
I1
I-1
tp17625
sS'to,convert,herceptin-refractory'
p17626
(F1
F0.00076452599388379206
I0
I1
I-1
tp17627
sS'drug,interaction,study'
p17628
(F1
F0.00076452599388379206
I1
I0
I1
tp17629
sS'association,with,combined'
p17630
(F1
F0.00076452599388379206
I1
I0
I1
tp17631
sS'inducer,of,ethinyl'
p17632
(F1
F0.00076452599388379206
I1
I0
I1
tp17633
sS'therefore,physicians,should'
p17634
(F1
F0.0015290519877675841
I2
I0
I2
tp17635
sS'spent,in,the'
p17636
(F1
F0.00076452599388379206
I0
I1
I-1
tp17637
sS'interaction,study,demonstrated'
p17638
(F1
F0.00076452599388379206
I1
I0
I1
tp17639
sS'are,likely,the'
p17640
(F1
F0.00076452599388379206
I0
I1
I-1
tp17641
sS'narcotics,the,hypotensive'
p17642
(F1
F0.00076452599388379206
I0
I1
I-1
tp17643
sS'to,identify,any'
p17644
(F1
F0.00076452599388379206
I0
I1
I-1
tp17645
sS'mydriasis,tachycardia,dryness'
p17646
(F1
F0.00076452599388379206
I1
I0
I1
tp17647
sS'drugs,that,bind'
p17648
(F1
F0.00076452599388379206
I0
I1
I-1
tp17649
sS'the,combination,of'
p17650
(F1
F0.0045871559633027525
I6
I0
I6
tp17651
sS'avoid,taking,nsaids'
p17652
(F1
F0.00076452599388379206
I1
I0
I1
tp17653
sS'can,be,concluded'
p17654
(F1
F0.00076452599388379206
I1
I0
I1
tp17655
sS'p450,a4,enzyme'
p17656
(F1
F0.0015290519877675841
I2
I0
I2
tp17657
sS'are,antagonized,by'
p17658
(F1
F0.00076452599388379206
I1
I0
I1
tp17659
sS'previously,and,is'
p17660
(F1
F0.00076452599388379206
I0
I1
I-1
tp17661
sS'with,bcl-2,and'
p17662
(F1
F0.00076452599388379206
I0
I1
I-1
tp17663
sS'coadministration,beta,blockers'
p17664
(F1
F0.00076452599388379206
I1
I0
I1
tp17665
sS'pharmacokinetic,study,of'
p17666
(F1
F0.00076452599388379206
I1
I0
I1
tp17667
sS'for,this,effect'
p17668
(F1
F0.00076452599388379206
I0
I1
I-1
tp17669
sS'shorter,durations,of'
p17670
(F1
F0.00076452599388379206
I1
I0
I1
tp17671
sS'average,anticoagulant,effect'
p17672
(F1
F0.00076452599388379206
I0
I1
I-1
tp17673
sS'added,sometimes,with'
p17674
(F1
F0.00076452599388379206
I0
I1
I-1
tp17675
sS'systemic,toxicity,since'
p17676
(F1
F0.00076452599388379206
I1
I0
I1
tp17677
sS'of,exelon,drugs'
p17678
(F1
F0.00076452599388379206
I0
I1
I-1
tp17679
sS'individuals,nalidixic,acid'
p17680
(F1
F0.00076452599388379206
I1
I0
I1
tp17681
sS'multiple,dose,drug-drug'
p17682
(F1
F0.00076452599388379206
I1
I0
I1
tp17683
sS'administration,of,and'
p17684
(F0.7142857142857143
F0.0038226299694189602
I6
I1
I5
tp17685
sS'local,or,agents'
p17686
(F1
F0.00076452599388379206
I1
I0
I1
tp17687
sS'rate,of,concealed'
p17688
(F1
F0.00076452599388379206
I1
I0
I1
tp17689
sS'vs,difference,ci'
p17690
(F1
F0.00076452599388379206
I0
I1
I-1
tp17691
sS'in,responsiveness,before'
p17692
(F1
F0.00076452599388379206
I0
I1
I-1
tp17693
sS'drugs,may,result'
p17694
(F1
F0.00076452599388379206
I1
I0
I1
tp17695
sS'effects,of,in'
p17696
(F1
F0.00076452599388379206
I0
I1
I-1
tp17697
sS'of,wales,reported'
p17698
(F1
F0.00076452599388379206
I1
I0
I1
tp17699
sS'that,of,but'
p17700
(F1
F0.00076452599388379206
I1
I0
I1
tp17701
sS'affect,other,drugs'
p17702
(F1
F0.00076452599388379206
I0
I1
I-1
tp17703
sS'drug,interactions,with'
p17704
(F1
F0.00076452599388379206
I1
I0
I1
tp17705
sS'have,no,proven'
p17706
(F1
F0.00076452599388379206
I0
I1
I-1
tp17707
sS'positron,emission,tomography'
p17708
(F1
F0.00076452599388379206
I1
I0
I1
tp17709
sS'vs,ml,min'
p17710
(F1
F0.00076452599388379206
I1
I0
I1
tp17711
sS'when,concomitant,use'
p17712
(F1
F0.00076452599388379206
I1
I0
I1
tp17713
sS'ethinyl,following,administration'
p17714
(F1
F0.00076452599388379206
I0
I1
I-1
tp17715
sS'inducers,of,cyp3a4'
p17716
(F1
F0.0015290519877675841
I2
I0
I2
tp17717
sS'abl,kinases,with'
p17718
(F1
F0.00076452599388379206
I1
I0
I1
tp17719
sS'chickens,to,inactivated'
p17720
(F1
F0.00076452599388379206
I0
I1
I-1
tp17721
sS'were,altered,when'
p17722
(F1
F0.00076452599388379206
I1
I0
I1
tp17723
sS'pharmacokinetic,interactions,with'
p17724
(F0
F0
I1
I1
I0
tp17725
sS'incidence,of,extra'
p17726
(F1
F0.00076452599388379206
I0
I1
I-1
tp17727
sS'with,proamatine,cardiac'
p17728
(F1
F0.00076452599388379206
I1
I0
I1
tp17729
sS'gastric,emptying,symlin'
p17730
(F1
F0.00076452599388379206
I1
I0
I1
tp17731
sS'in,mice,in'
p17732
(F1
F0.00076452599388379206
I0
I1
I-1
tp17733
sS'pressure,may,occur'
p17734
(F1
F0.00076452599388379206
I0
I1
I-1
tp17735
sS'that,are,secreted'
p17736
(F1
F0.00076452599388379206
I1
I0
I1
tp17737
sS'analysis,with,a'
p17738
(F1
F0.00076452599388379206
I0
I1
I-1
tp17739
sS'containing,ml,the'
p17740
(F1
F0.00076452599388379206
I1
I0
I1
tp17741
sS'emptying,symlin,therapy'
p17742
(F1
F0.00076452599388379206
I1
I0
I1
tp17743
sS'beta,adrenergic,antagonists'
p17744
(F1
F0.00076452599388379206
I1
I0
I1
tp17745
sS'was,no,change'
p17746
(F1
F0.00076452599388379206
I0
I1
I-1
tp17747
sS'diflucan,when,it'
p17748
(F1
F0.00076452599388379206
I1
I0
I1
tp17749
sS'other,local,or'
p17750
(F1
F0.00076452599388379206
I1
I0
I1
tp17751
sS'your,doctor,if'
p17752
(F1
F0.00076452599388379206
I0
I1
I-1
tp17753
sS'hypertensive,disease,hospitalized'
p17754
(F1
F0.00076452599388379206
I0
I1
I-1
tp17755
sS'clearance,of,by'
p17756
(F1
F0.00076452599388379206
I1
I0
I1
tp17757
sS'also,taking,magnesium-aluminum'
p17758
(F1
F0.00076452599388379206
I1
I0
I1
tp17759
sS'are,depressed,to'
p17760
(F1
F0.00076452599388379206
I1
I0
I1
tp17761
sS'if,zemuron,is'
p17762
(F1
F0.00076452599388379206
I1
I0
I1
tp17763
sS'been,performed,to'
p17764
(F1
F0.00076452599388379206
I0
I1
I-1
tp17765
sS'vitamin,d,vitamin'
p17766
(F1
F0.00076452599388379206
I0
I1
I-1
tp17767
sS'is,recommended,in'
p17768
(F1
F0.00076452599388379206
I1
I0
I1
tp17769
sS'with,is,effective'
p17770
(F1
F0.00076452599388379206
I0
I1
I-1
tp17771
sS'drug-interaction,studies,the'
p17772
(F1
F0.00076452599388379206
I0
I1
I-1
tp17773
sS'agents,were,administered'
p17774
(F1
F0.00076452599388379206
I1
I0
I1
tp17775
sS'cci-779,has,displayed'
p17776
(F1
F0.00076452599388379206
I1
I0
I1
tp17777
sS'by,these,enzymes'
p17778
(F1
F0.0015290519877675841
I0
I2
I-2
tp17779
sS'interaction,of,cylert'
p17780
(F1
F0.00076452599388379206
I0
I1
I-1
tp17781
sS'diminish,the,effectiveness'
p17782
(F1
F0.00076452599388379206
I1
I0
I1
tp17783
sS'with,such,drugs'
p17784
(F1
F0.00076452599388379206
I0
I1
I-1
tp17785
sS'of,and,concurrent'
p17786
(F1
F0.00076452599388379206
I1
I0
I1
tp17787
sS'to,did,not'
p17788
(F1
F0.00076452599388379206
I0
I1
I-1
tp17789
sS'responsiveness,before,and'
p17790
(F1
F0.00076452599388379206
I0
I1
I-1
tp17791
sS'be,additive,to'
p17792
(F1
F0.00076452599388379206
I1
I0
I1
tp17793
sS'diuretics,univasc,can'
p17794
(F1
F0.00076452599388379206
I0
I1
I-1
tp17795
sS'in,conjunction,with'
p17796
(F0.42857142857142855
F0.0022935779816513763
I5
I2
I3
tp17797
sS'to,date,there'
p17798
(F1
F0.00076452599388379206
I0
I1
I-1
tp17799
sS'isozyme,including,some'
p17800
(F1
F0.00076452599388379206
I1
I0
I1
tp17801
sS'from,the,stomach'
p17802
(F1
F0.00076452599388379206
I1
I0
I1
tp17803
sS'induced,antinociception,and'
p17804
(F1
F0.00076452599388379206
I0
I1
I-1
tp17805
sS'indicate,that,is'
p17806
(F1
F0.00076452599388379206
I0
I1
I-1
tp17807
sS'to,be,to'
p17808
(F1
F0.00076452599388379206
I1
I0
I1
tp17809
sS'tiva,but,did'
p17810
(F1
F0.00076452599388379206
I0
I1
I-1
tp17811
sS'zemplar,capsules,may'
p17812
(F1
F0.00076452599388379206
I1
I0
I1
tp17813
sS'of,the,possibility'
p17814
(F1
F0.00076452599388379206
I1
I0
I1
tp17815
sS'where,compatibility,has'
p17816
(F1
F0.00076452599388379206
I0
I1
I-1
tp17817
sS'those,methods,which'
p17818
(F1
F0.00076452599388379206
I0
I1
I-1
tp17819
sS'subject,of,much'
p17820
(F1
F0.00076452599388379206
I0
I1
I-1
tp17821
sS'transplant,patients,usp'
p17822
(F1
F0.00076452599388379206
I0
I1
I-1
tp17823
sS'drugs,that,impair'
p17824
(F1
F0.00076452599388379206
I1
I0
I1
tp17825
sS'via,competitive,inhibition'
p17826
(F1
F0.00076452599388379206
I0
I1
I-1
tp17827
sS'were,shown,not'
p17828
(F1
F0.00076452599388379206
I0
I1
I-1
tp17829
sS'exelon,drugs,that'
p17830
(F1
F0.00076452599388379206
I0
I1
I-1
tp17831
sS'orally,disintegrating,tablets'
p17832
(F1
F0.00076452599388379206
I0
I1
I-1
tp17833
sS'with,the,inr'
p17834
(F1
F0.00076452599388379206
I1
I0
I1
tp17835
sS'found,that,bcl-2'
p17836
(F1
F0.00076452599388379206
I1
I0
I1
tp17837
sS'the,mouth,and'
p17838
(F1
F0.00076452599388379206
I1
I0
I1
tp17839
sS'its,addition,to'
p17840
(F1
F0.00076452599388379206
I0
I1
I-1
tp17841
sS'recommended,clinical,dose'
p17842
(F1
F0.00076452599388379206
I0
I1
I-1
tp17843
sS'ethynyl,pyridine,treatment'
p17844
(F1
F0.00076452599388379206
I1
I0
I1
tp17845
sS'are,metabolised,by'
p17846
(F1
F0.00076452599388379206
I1
I0
I1
tp17847
sS'acromegalic,patients,with'
p17848
(F1
F0.00076452599388379206
I1
I0
I1
tp17849
sS'carried,out,with'
p17850
(F1
F0.00076452599388379206
I0
I1
I-1
tp17851
sS'calcium-channel,blocking,agents'
p17852
(F1
F0.00076452599388379206
I0
I1
I-1
tp17853
sS'increased,by,in'
p17854
(F1
F0.00076452599388379206
I1
I0
I1
tp17855
sS'and,other,highly'
p17856
(F1
F0.00076452599388379206
I1
I0
I1
tp17857
sS'potential,to,reduce'
p17858
(F1
F0.00076452599388379206
I1
I0
I1
tp17859
sS'adequate,sedation,may'
p17860
(F1
F0.00076452599388379206
I0
I1
I-1
tp17861
sS'the,rapid,onset'
p17862
(F1
F0.00076452599388379206
I1
I0
I1
tp17863
sS'inhibitors,no,clinically'
p17864
(F1
F0.00076452599388379206
I0
I1
I-1
tp17865
sS'the,pharmacokinetic,profiles'
p17866
(F1
F0.00076452599388379206
I0
I1
I-1
tp17867
sS'weeks,of,methyl-4'
p17868
(F1
F0.00076452599388379206
I1
I0
I1
tp17869
sS'hour,prior,to'
p17870
(F1
F0.00076452599388379206
I1
I0
I1
tp17871
sS'use,with,other'
p17872
(F1
F0.00076452599388379206
I1
I0
I1
tp17873
sS'for,at,least'
p17874
(F1
F0.0015290519877675841
I2
I0
I2
tp17875
sS'initiated,or,had'
p17876
(F1
F0.00076452599388379206
I1
I0
I1
tp17877
sS'antifungal,agents,including'
p17878
(F1
F0.00076452599388379206
I1
I0
I1
tp17879
sS'mechanism,which,may'
p17880
(F1
F0.00076452599388379206
I1
I0
I1
tp17881
sS'are,prescribed,xenical'
p17882
(F1
F0.00076452599388379206
I1
I0
I1
tp17883
sS'the,half-life,by'
p17884
(F1
F0.00076452599388379206
I1
I0
I1
tp17885
sS'to,mexitil,has'
p17886
(F1
F0.00076452599388379206
I1
I0
I1
tp17887
sS'decrease,the,hypotensive'
p17888
(F1
F0.00076452599388379206
I1
I0
I1
tp17889
sS'paroxetine,and,reduce'
p17890
(F1
F0.00076452599388379206
I1
I0
I1
tp17891
sS'no,pharmacokinetic,interaction'
p17892
(F1
F0.0015290519877675841
I0
I2
I-2
tp17893
sS'demonstrated,appropriateness,of'
p17894
(F1
F0.00076452599388379206
I1
I0
I1
tp17895
sS'intramuscular,methyl-4,phenyl-1'
p17896
(F1
F0.00076452599388379206
I0
I1
I-1
tp17897
sS'by,both,acetic'
p17898
(F1
F0.00076452599388379206
I1
I0
I1
tp17899
sS'cells,treated,with'
p17900
(F1
F0.00076452599388379206
I1
I0
I1
tp17901
sS'cyclosporine-treated,patients,n'
p17902
(F1
F0.00076452599388379206
I1
I0
I1
tp17903
sS'such,as,acetylcholine'
p17904
(F1
F0.00076452599388379206
I1
I0
I1
tp17905
sS'not,expected,to'
p17906
(F1
F0.0015290519877675841
I0
I2
I-2
tp17907
sS'multiple,dose,pharmacodynamics'
p17908
(F1
F0.00076452599388379206
I0
I1
I-1
tp17909
sS'unaffected,by,and'
p17910
(F1
F0.00076452599388379206
I0
I1
I-1
tp17911
sS'with,cerezyme,and'
p17912
(F1
F0.00076452599388379206
I1
I0
I1
tp17913
sS'plasma,concentrations,when'
p17914
(F1
F0.00076452599388379206
I1
I0
I1
tp17915
sS'dose,studies,of'
p17916
(F1
F0.00076452599388379206
I0
I1
I-1
tp17917
sS'we,evaluated,the'
p17918
(F1
F0.00076452599388379206
I0
I1
I-1
tp17919
sS'trental,and,theophylline-containing'
p17920
(F1
F0.00076452599388379206
I1
I0
I1
tp17921
sS'establish,potential,effects'
p17922
(F1
F0.00076452599388379206
I0
I1
I-1
tp17923
sS'agents,has,been'
p17924
(F1
F0.0015290519877675841
I2
I0
I2
tp17925
sS'has,any,effect'
p17926
(F1
F0.00076452599388379206
I0
I1
I-1
tp17927
sS'before,the,day'
p17928
(F1
F0.0015290519877675841
I2
I0
I2
tp17929
sS'of,symlin,on'
p17930
(F1
F0.00076452599388379206
I0
I1
I-1
tp17931
sS'demonstrated,a,reduction'
p17932
(F1
F0.00076452599388379206
I0
I1
I-1
tp17933
sS'approximately,of,their'
p17934
(F1
F0.00076452599388379206
I1
I0
I1
tp17935
sS'of,prothrombin,time'
p17936
(F0.33333333333333331
F0.00076452599388379206
I2
I1
I1
tp17937
sS'marketing,therefore,physicians'
p17938
(F1
F0.00076452599388379206
I1
I0
I1
tp17939
sS's-warfarin,half-life,from'
p17940
(F1
F0.00076452599388379206
I1
I0
I1
tp17941
sS'study,aimed,to'
p17942
(F1
F0.00076452599388379206
I0
I1
I-1
tp17943
sS'decreased,due,to'
p17944
(F1
F0.00076452599388379206
I1
I0
I1
tp17945
sS'cyp3a,inhibitors,is'
p17946
(F1
F0.00076452599388379206
I0
I1
I-1
tp17947
sS'accelerate,the,metabolism'
p17948
(F1
F0.00076452599388379206
I1
I0
I1
tp17949
sS'decreases,the,clearance'
p17950
(F1
F0.00076452599388379206
I1
I0
I1
tp17951
sS'increase,the,sensitivity'
p17952
(F1
F0.00076452599388379206
I1
I0
I1
tp17953
sS'estrogens,hydroxychloroquine,sulfate'
p17954
(F1
F0.00076452599388379206
I0
I1
I-1
tp17955
sS'followed,by,is'
p17956
(F1
F0.00076452599388379206
I1
I0
I1
tp17957
sS'departments,of,general'
p17958
(F1
F0.00076452599388379206
I0
I1
I-1
tp17959
sS'drug,or,food'
p17960
(F1
F0.00076452599388379206
I1
I0
I1
tp17961
sS'to,monitor,blood'
p17962
(F1
F0.00076452599388379206
I1
I0
I1
tp17963
sS'and,dznep,could'
p17964
(F1
F0.00076452599388379206
I1
I0
I1
tp17965
sS'tumor,growth,more'
p17966
(F1
F0.00076452599388379206
I1
I0
I1
tp17967
sS'to,evaluate,potential'
p17968
(F1
F0.00076452599388379206
I0
I1
I-1
tp17969
sS'antibody-dependent,cellular,cytotoxicity'
p17970
(F1
F0.00076452599388379206
I1
I0
I1
tp17971
sS'in,a,mean'
p17972
(F1
F0.00076452599388379206
I1
I0
I1
tp17973
sS'change,the,plasma'
p17974
(F1
F0.00076452599388379206
I0
I1
I-1
tp17975
sS'altered,the,relative'
p17976
(F1
F0.00076452599388379206
I1
I0
I1
tp17977
sS'of,to,did'
p17978
(F1
F0.00076452599388379206
I0
I1
I-1
tp17979
sS'for,days,a'
p17980
(F1
F0.00076452599388379206
I1
I0
I1
tp17981
sS'rimantadine,hcl,mg'
p17982
(F1
F0.0015290519877675841
I0
I2
I-2
tp17983
sS'in,healthy,subjects'
p17984
(F1
F0.0015290519877675841
I2
I0
I2
tp17985
sS'antagonist,is,the'
p17986
(F1
F0.00076452599388379206
I0
I1
I-1
tp17987
sS'month,after,discontinuation'
p17988
(F1
F0.00076452599388379206
I1
I0
I1
tp17989
sS'miochol,and,carboptic'
p17990
(F1
F0.00076452599388379206
I1
I0
I1
tp17991
sS'whereas,the,rate'
p17992
(F1
F0.00076452599388379206
I1
I0
I1
tp17993
sS'require,downward,adjustment'
p17994
(F1
F0.00076452599388379206
I1
I0
I1
tp17995
sS'kg,and,mg'
p17996
(F1
F0.00076452599388379206
I0
I1
I-1
tp17997
sS'states,may,emerge'
p17998
(F1
F0.00076452599388379206
I1
I0
I1
tp17999
sS'agencies,state,that'
p18000
(F1
F0.00076452599388379206
I1
I0
I1
tp18001
sS'cause,neurologic,toxicity'
p18002
(F1
F0.00076452599388379206
I1
I0
I1
tp18003
sS'may,be,affected'
p18004
(F1
F0.00076452599388379206
I0
I1
I-1
tp18005
sS'with,results,in'
p18006
(F0
F0
I1
I1
I0
tp18007
sS'lower,than,mg'
p18008
(F1
F0.00076452599388379206
I1
I0
I1
tp18009
sS'co-administration,of,zavesca'
p18010
(F1
F0.00076452599388379206
I1
I0
I1
tp18011
sS'attenuate,some,of'
p18012
(F1
F0.00076452599388379206
I0
I1
I-1
tp18013
sS'to,enhance,the'
p18014
(F1
F0.00076452599388379206
I1
I0
I1
tp18015
sS'a,terminal,deoxynucleotidyl'
p18016
(F1
F0.00076452599388379206
I0
I1
I-1
tp18017
sS'that,are,eliminated'
p18018
(F0
F0
I1
I1
I0
tp18019
sS'the,vaccination,and'
p18020
(F1
F0.00076452599388379206
I1
I0
I1
tp18021
sS'no,cross-resistance,with'
p18022
(F1
F0.00076452599388379206
I0
I1
I-1
tp18023
sS'be,increased,when'
p18024
(F1
F0.00076452599388379206
I0
I1
I-1
tp18025
sS'by,with,no'
p18026
(F1
F0.00076452599388379206
I1
I0
I1
tp18027
sS'myeloma,evidence,for'
p18028
(F1
F0.00076452599388379206
I0
I1
I-1
tp18029
sS'prior,to,or'
p18030
(F1
F0.0015290519877675841
I2
I0
I2
tp18031
sS'bile,acids,these'
p18032
(F1
F0.00076452599388379206
I0
I1
I-1
tp18033
sS'treatment,did,not'
p18034
(F1
F0.00076452599388379206
I1
I0
I1
tp18035
sS'the,primary,objective'
p18036
(F1
F0.00076452599388379206
I0
I1
I-1
tp18037
sS'the,metabotropic,glutamate'
p18038
(F1
F0.00076452599388379206
I1
I0
I1
tp18039
sS'that,stimulate,alpha-adrenergic'
p18040
(F1
F0.00076452599388379206
I1
I0
I1
tp18041
sS'were,not,altered'
p18042
(F1
F0.00076452599388379206
I0
I1
I-1
tp18043
sS'potentiated,by,anti-vitamin'
p18044
(F1
F0.00076452599388379206
I1
I0
I1
tp18045
sS'or,may,enhance'
p18046
(F1
F0.00076452599388379206
I1
I0
I1
tp18047
sS'reports,of,uveitis'
p18048
(F1
F0.00076452599388379206
I1
I0
I1
tp18049
sS'platelet,reactivity,during'
p18050
(F1
F0.00076452599388379206
I1
I0
I1
tp18051
sS'prothrombin,time,in'
p18052
(F1
F0.0038226299694189602
I5
I0
I5
tp18053
sS'to,be,additive'
p18054
(F1
F0.0015290519877675841
I2
I0
I2
tp18055
sS'quinpirole-free,controls,conditioned'
p18056
(F1
F0.00076452599388379206
I0
I1
I-1
tp18057
sS'depress,plasma,prothrombin'
p18058
(F1
F0.00076452599388379206
I1
I0
I1
tp18059
sS'was,decreased,when'
p18060
(F1
F0.00076452599388379206
I1
I0
I1
tp18061
sS'parameters,for,cmax'
p18062
(F1
F0.00076452599388379206
I1
I0
I1
tp18063
sS'of,cyclooxygenase-2,inhibitors'
p18064
(F1
F0.00076452599388379206
I0
I1
I-1
tp18065
sS'not,cause,clinically'
p18066
(F1
F0.00076452599388379206
I0
I1
I-1
tp18067
sS'dose,containing,mg'
p18068
(F1
F0.00076452599388379206
I0
I1
I-1
tp18069
sS'drugs,being,given'
p18070
(F1
F0.00076452599388379206
I0
I1
I-1
tp18071
sS'the,mitomycin-c,may'
p18072
(F1
F0.00076452599388379206
I1
I0
I1
tp18073
sS'full,examination,of'
p18074
(F1
F0.00076452599388379206
I1
I0
I1
tp18075
sS'a,pharmacokinetic,study'
p18076
(F0.5
F0.0015290519877675841
I3
I1
I2
tp18077
sS'supervision,should,be'
p18078
(F1
F0.00076452599388379206
I1
I0
I1
tp18079
sS'with,known,high'
p18080
(F1
F0.00076452599388379206
I1
I0
I1
tp18081
sS'therapy,resulting,in'
p18082
(F1
F0.00076452599388379206
I1
I0
I1
tp18083
sS'and,furthermore,the'
p18084
(F1
F0.00076452599388379206
I1
I0
I1
tp18085
sS'of,increased,inr'
p18086
(F1
F0.00076452599388379206
I1
I0
I1
tp18087
sS'of,oral,s-ketamine'
p18088
(F1
F0.00076452599388379206
I0
I1
I-1
tp18089
sS'use,of,hiv-protease'
p18090
(F1
F0.00076452599388379206
I0
I1
I-1
tp18091
sS'recommended,doses,of'
p18092
(F1
F0.0015290519877675841
I2
I0
I2
tp18093
sS'be,kept,in'
p18094
(F0
F0
I1
I1
I0
tp18095
sS'co-administration,of,g'
p18096
(F1
F0.00076452599388379206
I1
I0
I1
tp18097
sS'alter,mean,pharmacokinetic'
p18098
(F1
F0.00076452599388379206
I1
I0
I1
tp18099
sS'glutamate,receptor,antagonist'
p18100
(F0
F0
I1
I1
I0
tp18101
sS'with,ganglionic,or'
p18102
(F1
F0.00076452599388379206
I0
I1
I-1
tp18103
sS'less,potent,inhibitors'
p18104
(F1
F0.00076452599388379206
I0
I1
I-1
tp18105
sS'as,striatal,intensity'
p18106
(F1
F0.00076452599388379206
I1
I0
I1
tp18107
sS'coadministered,with,ethinyl'
p18108
(F1
F0.00076452599388379206
I1
I0
I1
tp18109
sS'is,purported,to'
p18110
(F1
F0.00076452599388379206
I1
I0
I1
tp18111
sS'known,component,in'
p18112
(F1
F0.00076452599388379206
I1
I0
I1
tp18113
sS'arrythmias,typically,torsades'
p18114
(F1
F0.00076452599388379206
I1
I0
I1
tp18115
sS'human,a375,melanoma'
p18116
(F1
F0.00076452599388379206
I0
I1
I-1
tp18117
sS'resistances,at,comparatively'
p18118
(F1
F0.00076452599388379206
I0
I1
I-1
tp18119
sS'patients,had,indications'
p18120
(F1
F0.00076452599388379206
I0
I1
I-1
tp18121
sS'with,mild,to'
p18122
(F1
F0.0015290519877675841
I2
I0
I2
tp18123
sS'p4501a2,such,as'
p18124
(F1
F0.00076452599388379206
I1
I0
I1
tp18125
sS'known,drug,drug'
p18126
(F1
F0.00076452599388379206
I1
I0
I1
tp18127
sS'no,effect,on'
p18128
(F0.5
F0.0015290519877675841
I3
I1
I2
tp18129
sS'of,a,base'
p18130
(F1
F0.00076452599388379206
I1
I0
I1
tp18131
sS'inoculated,with,inactivated'
p18132
(F1
F0.00076452599388379206
I1
I0
I1
tp18133
sS'loss,was,lower'
p18134
(F1
F0.00076452599388379206
I1
I0
I1
tp18135
sS'and,tail,suspension'
p18136
(F1
F0.00076452599388379206
I0
I1
I-1
tp18137
sS'levels,or,increase'
p18138
(F1
F0.0015290519877675841
I2
I0
I2
tp18139
sS'believed,to,interact'
p18140
(F1
F0.00076452599388379206
I1
I0
I1
tp18141
sS'lines,and,arrested'
p18142
(F1
F0.00076452599388379206
I0
I1
I-1
tp18143
sS'absorption,of,milligrams'
p18144
(F1
F0.00076452599388379206
I0
I1
I-1
tp18145
sS'mean,cmax,and'
p18146
(F1
F0.00076452599388379206
I1
I0
I1
tp18147
sS'cyp2d6,cyp1a2,inducers'
p18148
(F1
F0.00076452599388379206
I0
I1
I-1
tp18149
sS'also,been,reported'
p18150
(F1
F0.00076452599388379206
I1
I0
I1
tp18151
sS'and,who,subsequently'
p18152
(F1
F0.00076452599388379206
I1
I0
I1
tp18153
sS'female,rats,and'
p18154
(F1
F0.00076452599388379206
I0
I1
I-1
tp18155
sS'acid,artificial,tears'
p18156
(F1
F0.00076452599388379206
I0
I1
I-1
tp18157
sS'no,significant,alterations'
p18158
(F1
F0.00076452599388379206
I0
I1
I-1
tp18159
sS'has,been,used'
p18160
(F1
F0.0038226299694189602
I0
I5
I-5
tp18161
sS'and,within,hours'
p18162
(F1
F0.00076452599388379206
I1
I0
I1
tp18163
sS'an,acute,and'
p18164
(F1
F0.00076452599388379206
I0
I1
I-1
tp18165
sS'of,the,vaccination'
p18166
(F1
F0.00076452599388379206
I1
I0
I1
tp18167
sS'drugs,and,foods'
p18168
(F1
F0.00076452599388379206
I1
I0
I1
tp18169
sS'resulted,in,no'
p18170
(F1
F0.00076452599388379206
I0
I1
I-1
tp18171
sS'reported,previously,and'
p18172
(F1
F0.00076452599388379206
I0
I1
I-1
tp18173
sS'qt,prolonging,effect'
p18174
(F1
F0.00076452599388379206
I0
I1
I-1
tp18175
sS'occasionally,experience,an'
p18176
(F1
F0.00076452599388379206
I1
I0
I1
tp18177
sS'on,often,needed'
p18178
(F1
F0.00076452599388379206
I1
I0
I1
tp18179
sS'medications,with,anticholinergic'
p18180
(F1
F0.00076452599388379206
I1
I0
I1
tp18181
sS'hydrochloride,resulting,in'
p18182
(F1
F0.00076452599388379206
I1
I0
I1
tp18183
sS'significantly,increase,levels'
p18184
(F1
F0.00076452599388379206
I1
I0
I1
tp18185
sS'pharmacokinetics,of,the'
p18186
(F1
F0.00076452599388379206
I0
I1
I-1
tp18187
sS'are,birth,control'
p18188
(F1
F0.00076452599388379206
I0
I1
I-1
tp18189
sS'cell,lines,leading'
p18190
(F1
F0.00076452599388379206
I1
I0
I1
tp18191
sS'locomotor,sensitization,compared'
p18192
(F1
F0.00076452599388379206
I1
I0
I1
tp18193
sS'with,strong,inhibitors'
p18194
(F1
F0.00076452599388379206
I1
I0
I1
tp18195
sS'day,the,apparent'
p18196
(F1
F0.00076452599388379206
I1
I0
I1
tp18197
sS'compared,with,their'
p18198
(F1
F0.00076452599388379206
I1
I0
I1
tp18199
sS'as,and,should'
p18200
(F1
F0.00076452599388379206
I1
I0
I1
tp18201
sS'carcinogenesis,mutagenesis,impairment'
p18202
(F1
F0.00076452599388379206
I0
I1
I-1
tp18203
sS'control,of,a'
p18204
(F1
F0.00076452599388379206
I0
I1
I-1
tp18205
sS'of,central,nervous'
p18206
(F1
F0.00076452599388379206
I1
I0
I1
tp18207
sS'src,family,and'
p18208
(F1
F0.00076452599388379206
I1
I0
I1
tp18209
sS'particularly,may,cause'
p18210
(F1
F0.0015290519877675841
I2
I0
I2
tp18211
sS'however,a,causal'
p18212
(F1
F0.00076452599388379206
I1
I0
I1
tp18213
sS'of,mometasone,furoate'
p18214
(F1
F0.00076452599388379206
I1
I0
I1
tp18215
sS'and,histamine-like,flushing'
p18216
(F1
F0.00076452599388379206
I1
I0
I1
tp18217
sS'between,and,mg'
p18218
(F1
F0.0015290519877675841
I0
I2
I-2
tp18219
sS'because,amplifies,the'
p18220
(F1
F0.00076452599388379206
I1
I0
I1
tp18221
sS'the,c,max'
p18222
(F1
F0.00076452599388379206
I1
I0
I1
tp18223
sS'can,be,minimized'
p18224
(F0
F0
I1
I1
I0
tp18225
sS'alone,for,patients'
p18226
(F1
F0.00076452599388379206
I1
I0
I1
tp18227
sS'a,mg,daily'
p18228
(F1
F0.00076452599388379206
I1
I0
I1
tp18229
sS'its,administration,to'
p18230
(F1
F0.00076452599388379206
I1
I0
I1
tp18231
sS'not,be,expected'
p18232
(F1
F0.00076452599388379206
I0
I1
I-1
tp18233
sS'suggest,that,low-dose'
p18234
(F1
F0.00076452599388379206
I1
I0
I1
tp18235
sS'tetrahydropyridine,injections,mg'
p18236
(F1
F0.00076452599388379206
I0
I1
I-1
tp18237
sS'containing,or,and'
p18238
(F1
F0.00076452599388379206
I1
I0
I1
tp18239
sS'higher,in,methyl-4'
p18240
(F1
F0.00076452599388379206
I1
I0
I1
tp18241
sS'experience,we,suggest'
p18242
(F1
F0.00076452599388379206
I1
I0
I1
tp18243
sS'while,taking,remeron'
p18244
(F1
F0.00076452599388379206
I1
I0
I1
tp18245
sS'concomitant,administration,increased'
p18246
(F0
F0
I1
I1
I0
tp18247
sS'lower,rate,of'
p18248
(F1
F0.00076452599388379206
I1
I0
I1
tp18249
sS'diuretics,furosemide,and'
p18250
(F1
F0.00076452599388379206
I1
I0
I1
tp18251
sS'on,oral,have'
p18252
(F1
F0.00076452599388379206
I1
I0
I1
tp18253
sS'in,clopidogrel-treated,patients'
p18254
(F1
F0.00076452599388379206
I0
I1
I-1
tp18255
sS'healthy,women,the'
p18256
(F1
F0.0015290519877675841
I0
I2
I-2
tp18257
sS'absorption,when,concomitantly'
p18258
(F1
F0.00076452599388379206
I1
I0
I1
tp18259
sS'ldl-c,reduction,due'
p18260
(F1
F0.00076452599388379206
I1
I0
I1
tp18261
sS'a,possible,drug'
p18262
(F1
F0.00076452599388379206
I1
I0
I1
tp18263
sS'tyrosine,hydroxylase-positive,neurons'
p18264
(F1
F0.00076452599388379206
I1
I0
I1
tp18265
sS'the,mean,dose'
p18266
(F1
F0.00076452599388379206
I0
I1
I-1
tp18267
sS'concomitantly,with,or'
p18268
(F1
F0.00076452599388379206
I1
I0
I1
tp18269
sS'given,twice,daily'
p18270
(F1
F0.0015290519877675841
I0
I2
I-2
tp18271
sS'no,proven,preventive'
p18272
(F1
F0.00076452599388379206
I0
I1
I-1
tp18273
sS'is,not,appreciably'
p18274
(F1
F0.00076452599388379206
I0
I1
I-1
tp18275
sS'associated,with,lower'
p18276
(F1
F0.00076452599388379206
I1
I0
I1
tp18277
sS'some,drug,interactions'
p18278
(F1
F0.00076452599388379206
I0
I1
I-1
tp18279
sS'pindolol,has,been'
p18280
(F0
F0
I1
I1
I0
tp18281
sS'if,short-acting,benzodiazepines'
p18282
(F1
F0.00076452599388379206
I1
I0
I1
tp18283
sS'and,the,fact'
p18284
(F1
F0.00076452599388379206
I0
I1
I-1
tp18285
sS'multiple,doses,of'
p18286
(F1
F0.0015290519877675841
I0
I2
I-2
tp18287
sS'shown,not,to'
p18288
(F1
F0.00076452599388379206
I0
I1
I-1
tp18289
sS'doubled,auc0-,since'
p18290
(F1
F0.00076452599388379206
I1
I0
I1
tp18291
sS'of,this,study'
p18292
(F1
F0.0015290519877675841
I0
I2
I-2
tp18293
sS'should,be,used'
p18294
(F0.80952380952380953
F0.012996941896024464
I19
I2
I17
tp18295
sS'acth,in,patients'
p18296
(F1
F0.00076452599388379206
I0
I1
I-1
tp18297
sS'are,not,expected'
p18298
(F1
F0.00076452599388379206
I0
I1
I-1
tp18299
sS'also,increased,when'
p18300
(F1
F0.00076452599388379206
I1
I0
I1
tp18301
sS'greater,detail,below'
p18302
(F1
F0.00076452599388379206
I1
I0
I1
tp18303
sS'plasma,levels,and'
p18304
(F1
F0.0015290519877675841
I2
I0
I2
tp18305
sS'these,medications,included'
p18306
(F1
F0.00076452599388379206
I0
I1
I-1
tp18307
sS'recommended,when,administering'
p18308
(F1
F0.0015290519877675841
I2
I0
I2
tp18309
sS'was,significantly,decreased'
p18310
(F1
F0.00076452599388379206
I0
I1
I-1
tp18311
sS'the,purpose,of'
p18312
(F1
F0.0015290519877675841
I0
I2
I-2
tp18313
sS'or,medications,such'
p18314
(F1
F0.00076452599388379206
I1
I0
I1
tp18315
sS'and,has,some'
p18316
(F1
F0.00076452599388379206
I1
I0
I1
tp18317
sS'also,inhibited,at'
p18318
(F1
F0.00076452599388379206
I1
I0
I1
tp18319
sS'use,of,live'
p18320
(F1
F0.00076452599388379206
I1
I0
I1
tp18321
sS'be,of,clinical'
p18322
(F1
F0.00076452599388379206
I0
I1
I-1
tp18323
sS'generally,should,not'
p18324
(F1
F0.00076452599388379206
I1
I0
I1
tp18325
sS'risk,of,urinary'
p18326
(F1
F0.00076452599388379206
I1
I0
I1
tp18327
sS'enzyme,induction,leading'
p18328
(F1
F0.00076452599388379206
I1
I0
I1
tp18329
sS'to,the,mitomycin-c'
p18330
(F1
F0.00076452599388379206
I1
I0
I1
tp18331
sS'rats,treated,with'
p18332
(F1
F0.00076452599388379206
I0
I1
I-1
tp18333
sS'volume,contraction,that'
p18334
(F1
F0.00076452599388379206
I0
I1
I-1
tp18335
sS'mtt,radiolabeled,drug'
p18336
(F1
F0.00076452599388379206
I0
I1
I-1
tp18337
sS'was,not,considered'
p18338
(F1
F0.00076452599388379206
I0
I1
I-1
tp18339
sS'significant,pharmacokinetic,interactions'
p18340
(F1
F0.00076452599388379206
I0
I1
I-1
tp18341
sS'pharmacokinetics,were,unaffected'
p18342
(F1
F0.00076452599388379206
I0
I1
I-1
tp18343
sS'day,in,male'
p18344
(F1
F0.00076452599388379206
I0
I1
I-1
tp18345
sS'agonist,antagonist,analgesics'
p18346
(F1
F0.00076452599388379206
I1
I0
I1
tp18347
sS'daily,or,placebo'
p18348
(F1
F0.00076452599388379206
I0
I1
I-1
tp18349
sS'other,suitable,anticoagulation'
p18350
(F1
F0.00076452599388379206
I1
I0
I1
tp18351
sS'certain,interact,with'
p18352
(F1
F0.00076452599388379206
I1
I0
I1
tp18353
sS'growth,more,than'
p18354
(F1
F0.00076452599388379206
I1
I0
I1
tp18355
sS'drug,interactions,associated'
p18356
(F1
F0.00076452599388379206
I0
I1
I-1
tp18357
sS'by,following,the'
p18358
(F1
F0.00076452599388379206
I1
I0
I1
tp18359
sS'elderly,patients,concurrently'
p18360
(F1
F0.00076452599388379206
I0
I1
I-1
tp18361
sS'arrhythmias,during,anesthesia'
p18362
(F1
F0.0015290519877675841
I2
I0
I2
tp18363
sS'or,induction,of'
p18364
(F1
F0.00076452599388379206
I0
I1
I-1
tp18365
sS'the,deazaneplanocin,a'
p18366
(F1
F0.00076452599388379206
I0
I1
I-1
tp18367
sS'coumarin-type,have,been'
p18368
(F1
F0.00076452599388379206
I1
I0
I1
tp18369
sS'hypokalemia,can,increase'
p18370
(F1
F0.00076452599388379206
I1
I0
I1
tp18371
sS'the,in,vitro'
p18372
(F1
F0.0015290519877675841
I0
I2
I-2
tp18373
sS'case,of,hypertensive'
p18374
(F1
F0.00076452599388379206
I1
I0
I1
tp18375
sS'i,and,therefore'
p18376
(F1
F0.00076452599388379206
I0
I1
I-1
tp18377
sS'ssri,is,clinically'
p18378
(F1
F0.00076452599388379206
I1
I0
I1
tp18379
sS'of,ziagen,twice'
p18380
(F1
F0.00076452599388379206
I1
I0
I1
tp18381
sS'predominantly,metabolized,by'
p18382
(F1
F0.00076452599388379206
I0
I1
I-1
tp18383
sS'with,alimta,in'
p18384
(F1
F0.00076452599388379206
I1
I0
I1
tp18385
sS'plavix,and,effient'
p18386
(F1
F0.00076452599388379206
I0
I1
I-1
tp18387
sS'either,pharmacokinetics,both'
p18388
(F1
F0.00076452599388379206
I0
I1
I-1
tp18389
sS'leading,to,an'
p18390
(F1
F0.00076452599388379206
I1
I0
I1
tp18391
sS'psychostimulant,drug,has'
p18392
(F1
F0.00076452599388379206
I0
I1
I-1
tp18393
sS'drug,due,to'
p18394
(F1
F0.00076452599388379206
I0
I1
I-1
tp18395
sS'in,combination,to'
p18396
(F1
F0.00076452599388379206
I0
I1
I-1
tp18397
sS'interpreted,according,to'
p18398
(F1
F0.00076452599388379206
I0
I1
I-1
tp18399
sS'to,achieve,the'
p18400
(F1
F0.0015290519877675841
I2
I0
I2
tp18401
sS'appears,to,reduce'
p18402
(F1
F0.00076452599388379206
I1
I0
I1
tp18403
sS'however,in,some'
p18404
(F1
F0.00076452599388379206
I0
I1
I-1
tp18405
sS'study,indicate,a'
p18406
(F1
F0.00076452599388379206
I1
I0
I1
tp18407
sS'are,capable,of'
p18408
(F1
F0.0015290519877675841
I2
I0
I2
tp18409
sS'different,incubation,schedules'
p18410
(F1
F0.00076452599388379206
I0
I1
I-1
tp18411
sS'like,or,and'
p18412
(F1
F0.00076452599388379206
I1
I0
I1
tp18413
sS'drug,therapies,may'
p18414
(F1
F0.00076452599388379206
I1
I0
I1
tp18415
sS'receiving,doses,ranging'
p18416
(F1
F0.00076452599388379206
I1
I0
I1
tp18417
sS'results,revealed,that'
p18418
(F1
F0.00076452599388379206
I0
I1
I-1
tp18419
sS'of,the,patient'
p18420
(F1
F0.00076452599388379206
I1
I0
I1
tp18421
sS'with,cyp3a,inhibitors'
p18422
(F1
F0.0015290519877675841
I0
I2
I-2
tp18423
sS'increased,plasma,bismuth'
p18424
(F1
F0.00076452599388379206
I1
I0
I1
tp18425
sS'disc,diffusion,tests'
p18426
(F1
F0.00076452599388379206
I1
I0
I1
tp18427
sS'if,confirmed,in-vivo'
p18428
(F1
F0.00076452599388379206
I0
I1
I-1
tp18429
sS'and,a7,noradrenaline'
p18430
(F1
F0.00076452599388379206
I1
I0
I1
tp18431
sS'xenical,mg,three'
p18432
(F1
F0.0045871559633027525
I0
I6
I-6
tp18433
sS'of,a,higher'
p18434
(F1
F0.00076452599388379206
I1
I0
I1
tp18435
sS'drugs,in,the'
p18436
(F1
F0.0022935779816513763
I3
I0
I3
tp18437
sS'significantly,increase,the'
p18438
(F1
F0.00076452599388379206
I1
I0
I1
tp18439
sS'used,in,clinical'
p18440
(F1
F0.0015290519877675841
I0
I2
I-2
tp18441
sS'on,concomitant,tolectin'
p18442
(F1
F0.00076452599388379206
I1
I0
I1
tp18443
sS'rocuronium,bromide,injection'
p18444
(F1
F0.00076452599388379206
I0
I1
I-1
tp18445
sS'nph,and,premixed'
p18446
(F1
F0.00076452599388379206
I1
I0
I1
tp18447
sS'different,origins,to'
p18448
(F1
F0.00076452599388379206
I0
I1
I-1
tp18449
sS'activities,are,significantly'
p18450
(F1
F0.00076452599388379206
I0
I1
I-1
tp18451
sS'a,history,of'
p18452
(F1
F0.00076452599388379206
I1
I0
I1
tp18453
sS'therapeutic,agents,after'
p18454
(F1
F0.00076452599388379206
I1
I0
I1
tp18455
sS'however,interactions,may'
p18456
(F1
F0.00076452599388379206
I1
I0
I1
tp18457
sS'if,this,is'
p18458
(F1
F0.00076452599388379206
I0
I1
I-1
tp18459
sS'drug,has,any'
p18460
(F1
F0.00076452599388379206
I0
I1
I-1
tp18461
sS'by,anticholinergic,drugs'
p18462
(F1
F0.00076452599388379206
I1
I0
I1
tp18463
sS'weight,subjects,coadministration'
p18464
(F1
F0.00076452599388379206
I0
I1
I-1
tp18465
sS'gastrointestinal,symptoms,due'
p18466
(F1
F0.00076452599388379206
I1
I0
I1
tp18467
sS'total,users,contributed'
p18468
(F1
F0.00076452599388379206
I0
I1
I-1
tp18469
sS'mg,and,mg'
p18470
(F1
F0.0015290519877675841
I2
I0
I2
tp18471
sS'is,also,inhibited'
p18472
(F1
F0.00076452599388379206
I1
I0
I1
tp18473
sS'coeruleus,and,adjoining'
p18474
(F1
F0.00076452599388379206
I1
I0
I1
tp18475
sS'treatment,on,effects'
p18476
(F1
F0.00076452599388379206
I0
I1
I-1
tp18477
sS'is,not,expected'
p18478
(F1
F0.00076452599388379206
I0
I1
I-1
tp18479
sS'reduced,by,increasing'
p18480
(F1
F0.00076452599388379206
I1
I0
I1
tp18481
sS'are,resistant,to'
p18482
(F1
F0.00076452599388379206
I0
I1
I-1
tp18483
sS'the,chemical,similarity'
p18484
(F1
F0.00076452599388379206
I1
I0
I1
tp18485
sS'hydroxide,hydroxide,and'
p18486
(F1
F0.00076452599388379206
I0
I1
I-1
tp18487
sS'of,pharmacokinetics,pharmacodynamics'
p18488
(F1
F0.00076452599388379206
I0
I1
I-1
tp18489
sS'cyp3a,and,le'
p18490
(F1
F0.00076452599388379206
I1
I0
I1
tp18491
sS'premedications,or,drugs'
p18492
(F1
F0.00076452599388379206
I0
I1
I-1
tp18493
sS'on,therapy,having'
p18494
(F1
F0.00076452599388379206
I1
I0
I1
tp18495
sS'steroid,therapy,i'
p18496
(F1
F0.00076452599388379206
I0
I1
I-1
tp18497
sS'metabolism,are,not'
p18498
(F1
F0.00076452599388379206
I0
I1
I-1
tp18499
sS'was,decreased,by'
p18500
(F1
F0.0015290519877675841
I2
I0
I2
tp18501
sS'does,not,significantly'
p18502
(F1
F0.00076452599388379206
I0
I1
I-1
tp18503
sS'in,the,and'
p18504
(F1
F0.00076452599388379206
I0
I1
I-1
tp18505
sS'to,achieve,target'
p18506
(F1
F0.00076452599388379206
I1
I0
I1
tp18507
sS'receiving,daily,doses'
p18508
(F1
F0.00076452599388379206
I0
I1
I-1
tp18509
sS'and,the,cyp2c19'
p18510
(F1
F0.00076452599388379206
I1
I0
I1
tp18511
sS'reducing,plasma,parathyroid'
p18512
(F1
F0.00076452599388379206
I0
I1
I-1
tp18513
sS'nsaids,may,lower'
p18514
(F1
F0.00076452599388379206
I1
I0
I1
tp18515
sS'the,analgesic,activity'
p18516
(F1
F0.00076452599388379206
I1
I0
I1
tp18517
sS'evidence,of,spontaneous'
p18518
(F1
F0.00076452599388379206
I1
I0
I1
tp18519
sS'and,leading,to'
p18520
(F1
F0.00076452599388379206
I1
I0
I1
tp18521
sS'administration,of,valproic'
p18522
(F1
F0.00076452599388379206
I1
I0
I1
tp18523
sS'appropriate,observation,of'
p18524
(F1
F0.00076452599388379206
I1
I0
I1
tp18525
sS'twice,daily,twice'
p18526
(F1
F0.00076452599388379206
I1
I0
I1
tp18527
sS'fda,has,approved'
p18528
(F1
F0.00076452599388379206
I1
I0
I1
tp18529
sS'decreased,the,auc'
p18530
(F1
F0.0015290519877675841
I0
I2
I-2
tp18531
sS'however,the,evidence'
p18532
(F1
F0.00076452599388379206
I1
I0
I1
tp18533
sS'or,in,combination'
p18534
(F0
F0
I2
I2
I0
tp18535
sS'to,evaluate,whether'
p18536
(F1
F0.0015290519877675841
I0
I2
I-2
tp18537
sS'incubation,schedules,and'
p18538
(F1
F0.00076452599388379206
I1
I0
I1
tp18539
sS'acute,model,three'
p18540
(F1
F0.00076452599388379206
I0
I1
I-1
tp18541
sS'significantly,affected,by'
p18542
(F1
F0.00076452599388379206
I0
I1
I-1
tp18543
sS'plasma,parathyroid,hormone'
p18544
(F1
F0.00076452599388379206
I0
I1
I-1
tp18545
sS'of,hepatic,microsomal'
p18546
(F1
F0.00076452599388379206
I1
I0
I1
tp18547
sS'have,identified,and'
p18548
(F1
F0.00076452599388379206
I0
I1
I-1
tp18549
sS'agents,may,require'
p18550
(F1
F0.00076452599388379206
I1
I0
I1
tp18551
sS'pump,inhibitors,and'
p18552
(F0
F0
I1
I1
I0
tp18553
sS'were,administered,alone'
p18554
(F1
F0.00076452599388379206
I0
I1
I-1
tp18555
sS'potassium-sparing,and,others'
p18556
(F1
F0.00076452599388379206
I0
I1
I-1
tp18557
sS'metabolism,of,are'
p18558
(F1
F0.00076452599388379206
I0
I1
I-1
tp18559
sS'these,enzymes,an'
p18560
(F1
F0.00076452599388379206
I0
I1
I-1
tp18561
sS'intraperitoneally,not,only'
p18562
(F1
F0.00076452599388379206
I1
I0
I1
tp18563
sS'phenytoin,diflucan,increases'
p18564
(F1
F0.00076452599388379206
I1
I0
I1
tp18565
sS'the,induction,dose'
p18566
(F1
F0.00076452599388379206
I1
I0
I1
tp18567
sS'were,consistent,with'
p18568
(F1
F0.00076452599388379206
I1
I0
I1
tp18569
sS'of,hydrochloride,and'
p18570
(F1
F0.0030581039755351682
I4
I0
I4
tp18571
sS'agents,increased,response'
p18572
(F1
F0.0015290519877675841
I0
I2
I-2
tp18573
sS'vasospasm,leading,to'
p18574
(F1
F0.00076452599388379206
I0
I1
I-1
tp18575
sS'yl,ethynyl,pyridine'
p18576
(F0
F0
I2
I2
I0
tp18577
sS'have,taken,a'
p18578
(F1
F0.00076452599388379206
I1
I0
I1
tp18579
sS'of,evaluated,by'
p18580
(F1
F0.00076452599388379206
I1
I0
I1
tp18581
sS'demonstrated,an,isolated'
p18582
(F1
F0.00076452599388379206
I1
I0
I1
tp18583
sS'of,nonheme,and'
p18584
(F1
F0.00076452599388379206
I0
I1
I-1
tp18585
sS'the,metabolic,clearance'
p18586
(F1
F0.00076452599388379206
I1
I0
I1
tp18587
sS'antipsychotic,agents,mao'
p18588
(F1
F0.00076452599388379206
I1
I0
I1
tp18589
sS'acids,these,drugs'
p18590
(F1
F0.00076452599388379206
I0
I1
I-1
tp18591
sS'of,and,days'
p18592
(F1
F0.0015290519877675841
I2
I0
I2
tp18593
sS'which,was,the'
p18594
(F1
F0.00076452599388379206
I1
I0
I1
tp18595
sS'an,estrogen,antagonist'
p18596
(F1
F0.00076452599388379206
I0
I1
I-1
tp18597
sS'which,could,proceed'
p18598
(F1
F0.00076452599388379206
I1
I0
I1
tp18599
sS'cancer,especially,ssri'
p18600
(F1
F0.00076452599388379206
I1
I0
I1
tp18601
sS'onset,intensity,or'
p18602
(F1
F0.00076452599388379206
I0
I1
I-1
tp18603
sS'necessary,until,a'
p18604
(F1
F0.00076452599388379206
I1
I0
I1
tp18605
sS'but,is,not'
p18606
(F1
F0.00076452599388379206
I1
I0
I1
tp18607
sS'be,used,concomitantly'
p18608
(F1
F0.0015290519877675841
I2
I0
I2
tp18609
sS'levels,but,its'
p18610
(F1
F0.00076452599388379206
I0
I1
I-1
tp18611
sS'corresponding,decrease,in'
p18612
(F1
F0.00076452599388379206
I1
I0
I1
tp18613
sS'should,have,more'
p18614
(F1
F0.00076452599388379206
I1
I0
I1
tp18615
sS'days,with,significantly'
p18616
(F1
F0.00076452599388379206
I1
I0
I1
tp18617
sS'hot,plate,test'
p18618
(F1
F0.00076452599388379206
I1
I0
I1
tp18619
sS'another,formal,study'
p18620
(F1
F0.00076452599388379206
I0
I1
I-1
tp18621
sS'if,they,have'
p18622
(F1
F0.00076452599388379206
I0
I1
I-1
tp18623
sS'been,assessed,under'
p18624
(F1
F0.00076452599388379206
I0
I1
I-1
tp18625
sS'aids,patients,for'
p18626
(F1
F0.00076452599388379206
I1
I0
I1
tp18627
sS'healthy,volunteers,n'
p18628
(F1
F0.00076452599388379206
I0
I1
I-1
tp18629
sS'cyp3a,inhibitors,close'
p18630
(F1
F0.00076452599388379206
I0
I1
I-1
tp18631
sS'contraceptives,given,the'
p18632
(F1
F0.00076452599388379206
I0
I1
I-1
tp18633
sS'and,evaluated,the'
p18634
(F1
F0.00076452599388379206
I0
I1
I-1
tp18635
sS'drug,classes,of'
p18636
(F1
F0.00076452599388379206
I1
I0
I1
tp18637
sS'combination,of,with'
p18638
(F0
F0
I1
I1
I0
tp18639
sS'to,oral,s-ketamine'
p18640
(F1
F0.00076452599388379206
I1
I0
I1
tp18641
sS'compete,with,plavix'
p18642
(F1
F0.00076452599388379206
I0
I1
I-1
tp18643
sS'risk,is,not'
p18644
(F1
F0.00076452599388379206
I0
I1
I-1
tp18645
sS'with,normal,renal'
p18646
(F1
F0.00076452599388379206
I1
I0
I1
tp18647
sS'greatly,enhanced,transduction'
p18648
(F1
F0.00076452599388379206
I0
I1
I-1
tp18649
sS'absorption,may,be'
p18650
(F1
F0.00076452599388379206
I1
I0
I1
tp18651
sS'effect,of,and'
p18652
(F1
F0.0030581039755351682
I4
I0
I4
tp18653
sS'pregnancy,category,and'
p18654
(F1
F0.00076452599388379206
I0
I1
I-1
tp18655
sS'auc,was,decreased'
p18656
(F1
F0.00076452599388379206
I1
I0
I1
tp18657
sS'catecholamines,levels,in'
p18658
(F1
F0.00076452599388379206
I0
I1
I-1
tp18659
sS'reduce,clearance,significantly'
p18660
(F1
F0.00076452599388379206
I1
I0
I1
tp18661
sS'cholestyramine,and,drugs'
p18662
(F1
F0.00076452599388379206
I0
I1
I-1
tp18663
sS'same,time,and'
p18664
(F1
F0.00076452599388379206
I1
I0
I1
tp18665
sS'demonstrated,with,concomitant'
p18666
(F1
F0.00076452599388379206
I1
I0
I1
tp18667
sS'thiazide,may,accentuate'
p18668
(F1
F0.00076452599388379206
I1
I0
I1
tp18669
sS'anticholinergic,activity,when'
p18670
(F1
F0.00076452599388379206
I1
I0
I1
tp18671
sS'the,objective,of'
p18672
(F1
F0.00076452599388379206
I0
I1
I-1
tp18673
sS'breath,and,bronchospasm'
p18674
(F1
F0.00076452599388379206
I1
I0
I1
tp18675
sS'or,to,warrant'
p18676
(F1
F0.00076452599388379206
I0
I1
I-1
tp18677
sS'sympathomimetic,amines,may'
p18678
(F1
F0.00076452599388379206
I1
I0
I1
tp18679
sS'may,be,precipitated'
p18680
(F1
F0.00076452599388379206
I1
I0
I1
tp18681
sS'of,adverse,effects'
p18682
(F1
F0.00076452599388379206
I1
I0
I1
tp18683
sS'clearance,were,vs'
p18684
(F1
F0.00076452599388379206
I1
I0
I1
tp18685
sS'increase,the,plasma'
p18686
(F1
F0.00076452599388379206
I1
I0
I1
tp18687
sS'but,does,not'
p18688
(F1
F0.00076452599388379206
I1
I0
I1
tp18689
sS'with,other,alpha-adrenergic'
p18690
(F1
F0.00076452599388379206
I1
I0
I1
tp18691
sS'coadministered,to,rheumatoid'
p18692
(F1
F0.00076452599388379206
I0
I1
I-1
tp18693
sS'order,of,cyp'
p18694
(F1
F0.00076452599388379206
I0
I1
I-1
tp18695
sS'combination,with,zerit'
p18696
(F1
F0.00076452599388379206
I1
I0
I1
tp18697
sS'agents,radiotherapy,or'
p18698
(F1
F0.00076452599388379206
I0
I1
I-1
tp18699
sS'at,a,mg'
p18700
(F1
F0.00076452599388379206
I1
I0
I1
tp18701
sS'of,either,of'
p18702
(F1
F0.0015290519877675841
I0
I2
I-2
tp18703
sS'from,plasma,protein'
p18704
(F1
F0.00076452599388379206
I0
I1
I-1
tp18705
sS'reported,to,potentiate'
p18706
(F1
F0.00076452599388379206
I1
I0
I1
tp18707
sS'in,shorter,time'
p18708
(F1
F0.00076452599388379206
I1
I0
I1
tp18709
sS'taking,drugs,that'
p18710
(F1
F0.00076452599388379206
I1
I0
I1
tp18711
sS'hematuria,and,melena'
p18712
(F1
F0.00076452599388379206
I1
I0
I1
tp18713
sS'mobic,with,since'
p18714
(F1
F0.00076452599388379206
I1
I0
I1
tp18715
sS'noradrenaline,cell,groups'
p18716
(F1
F0.00076452599388379206
I1
I0
I1
tp18717
sS'medicines,for,angina'
p18718
(F1
F0.00076452599388379206
I0
I1
I-1
tp18719
sS'on,the,humoral'
p18720
(F1
F0.00076452599388379206
I0
I1
I-1
tp18721
sS'taken,in,doses'
p18722
(F1
F0.00076452599388379206
I1
I0
I1
tp18723
sS'increase,or,decrease'
p18724
(F1
F0.00076452599388379206
I1
I0
I1
tp18725
sS'the,pharmacokinetic,interaction'
p18726
(F1
F0.00076452599388379206
I0
I1
I-1
tp18727
sS'drowsiness,and,performance'
p18728
(F1
F0.00076452599388379206
I0
I1
I-1
tp18729
sS'increased,the,risk'
p18730
(F1
F0.00076452599388379206
I1
I0
I1
tp18731
sS'and,gastrointestinal,bleeding'
p18732
(F1
F0.00076452599388379206
I1
I0
I1
tp18733
sS'antidiabetic,drugs,of'
p18734
(F1
F0.00076452599388379206
I1
I0
I1
tp18735
sS'ultram,is,associated'
p18736
(F1
F0.00076452599388379206
I0
I1
I-1
tp18737
sS'counteracted,when,are'
p18738
(F1
F0.00076452599388379206
I1
I0
I1
tp18739
sS'these,results,suggest'
p18740
(F1
F0.00076452599388379206
I0
I1
I-1
tp18741
sS'transport,system,and'
p18742
(F1
F0.00076452599388379206
I1
I0
I1
tp18743
sS'retinal,transduction,is'
p18744
(F1
F0.00076452599388379206
I1
I0
I1
tp18745
sS'cholinomimetics,and,other'
p18746
(F1
F0.00076452599388379206
I1
I0
I1
tp18747
sS'significantly,increases,plasma'
p18748
(F1
F0.00076452599388379206
I1
I0
I1
tp18749
sS'shown,antitumor,activities'
p18750
(F1
F0.00076452599388379206
I0
I1
I-1
tp18751
sS'lines,that,are'
p18752
(F1
F0.00076452599388379206
I0
I1
I-1
tp18753
sS'feldene,since,marketing'
p18754
(F1
F0.00076452599388379206
I1
I0
I1
tp18755
sS'lower,than,of'
p18756
(F1
F0.00076452599388379206
I1
I0
I1
tp18757
sS'of,when,t'
p18758
(F1
F0.00076452599388379206
I0
I1
I-1
tp18759
sS'administered,with,have'
p18760
(F1
F0.00076452599388379206
I0
I1
I-1
tp18761
sS'recommended,that,oral'
p18762
(F1
F0.00076452599388379206
I1
I0
I1
tp18763
sS'can,also,displace'
p18764
(F1
F0.00076452599388379206
I1
I0
I1
tp18765
sS'and,the,average'
p18766
(F1
F0.00076452599388379206
I0
I1
I-1
tp18767
sS'on,absorption,of'
p18768
(F0.5
F0.0015290519877675841
I1
I3
I-2
tp18769
sS'such,as,elavil'
p18770
(F1
F0.00076452599388379206
I0
I1
I-1
tp18771
sS'administered,with,alimta'
p18772
(F1
F0.00076452599388379206
I1
I0
I1
tp18773
sS'with,can,cause'
p18774
(F1
F0.00076452599388379206
I1
I0
I1
tp18775
sS'mexitil,is,a'
p18776
(F1
F0.00076452599388379206
I0
I1
I-1
tp18777
sS'protein-bound,in,fresh'
p18778
(F1
F0.00076452599388379206
I1
I0
I1
tp18779
sS'in,dasatinib-enhanced,cytotoxicity'
p18780
(F1
F0.00076452599388379206
I1
I0
I1
tp18781
sS'has,not,been'
p18782
(F0.45454545454545453
F0.0038226299694189602
I3
I8
I-5
tp18783
sS'alkaloids,and,smoking'
p18784
(F1
F0.00076452599388379206
I0
I1
I-1
tp18785
sS'this,crossover,steady'
p18786
(F1
F0.00076452599388379206
I0
I1
I-1
tp18787
sS'volunteers,tended,to'
p18788
(F1
F0.00076452599388379206
I1
I0
I1
tp18789
sS'and,respiratory,depression'
p18790
(F1
F0.00076452599388379206
I1
I0
I1
tp18791
sS'monitored,closely,for'
p18792
(F1
F0.00076452599388379206
I1
I0
I1
tp18793
sS'enzymes,has,not'
p18794
(F1
F0.00076452599388379206
I0
I1
I-1
tp18795
sS'bid,for,days'
p18796
(F1
F0.0015290519877675841
I2
I0
I2
tp18797
sS'and,the,dose'
p18798
(F0.33333333333333331
F0.00076452599388379206
I2
I1
I1
tp18799
sS'has,been,the'
p18800
(F1
F0.00076452599388379206
I0
I1
I-1
tp18801
sS'and,other,non-steroidal'
p18802
(F1
F0.00076452599388379206
I1
I0
I1
tp18803
sS'initiation,of,treatment'
p18804
(F1
F0.00076452599388379206
I0
I1
I-1
tp18805
sS'erythema,and,histamine-like'
p18806
(F1
F0.00076452599388379206
I1
I0
I1
tp18807
sS'labeling,tunel,assay'
p18808
(F1
F0.00076452599388379206
I0
I1
I-1
tp18809
sS'suppression,of,bcl-2'
p18810
(F1
F0.00076452599388379206
I1
I0
I1
tp18811
sS'plasma,levels,when'
p18812
(F1
F0.00076452599388379206
I1
I0
I1
tp18813
sS'elevation,of,plasma'
p18814
(F1
F0.00076452599388379206
I1
I0
I1
tp18815
sS'effects,can,be'
p18816
(F1
F0.00076452599388379206
I1
I0
I1
tp18817
sS'with,alupent,metaproterenol'
p18818
(F1
F0.00076452599388379206
I1
I0
I1
tp18819
sS'patients,with,acute'
p18820
(F1
F0.00076452599388379206
I1
I0
I1
tp18821
sS'prescribed,xenical,should'
p18822
(F1
F0.00076452599388379206
I1
I0
I1
tp18823
sS'mao-is,type,b'
p18824
(F1
F0.00076452599388379206
I0
I1
I-1
tp18825
sS'renal,impairment,their'
p18826
(F1
F0.00076452599388379206
I0
I1
I-1
tp18827
sS'statistically,significant,increase'
p18828
(F1
F0.00076452599388379206
I1
I0
I1
tp18829
sS'concomitant,therapy,with'
p18830
(F1
F0.00076452599388379206
I1
I0
I1
tp18831
sS'as,blockers,selective'
p18832
(F1
F0.00076452599388379206
I0
I1
I-1
tp18833
sS'out,with,and'
p18834
(F1
F0.00076452599388379206
I0
I1
I-1
tp18835
sS'and,an,ssri'
p18836
(F1
F0.00076452599388379206
I1
I0
I1
tp18837
sS'of,spiriva,with'
p18838
(F1
F0.00076452599388379206
I1
I0
I1
tp18839
sS'at,doses,up'
p18840
(F1
F0.0022935779816513763
I0
I3
I-3
tp18841
sS'zemuron,rocuronium,bromide'
p18842
(F1
F0.00076452599388379206
I0
I1
I-1
tp18843
sS'with,inactivated,nd'
p18844
(F1
F0.00076452599388379206
I0
I1
I-1
tp18845
sS'levonorgestrel-containing,oral,produced'
p18846
(F1
F0.00076452599388379206
I1
I0
I1
tp18847
sS'inhibitors,can,increase'
p18848
(F1
F0.00076452599388379206
I1
I0
I1
tp18849
sS'receiving,low-dose,and'
p18850
(F1
F0.00076452599388379206
I0
I1
I-1
tp18851
sS'lyase,had,a'
p18852
(F1
F0.00076452599388379206
I0
I1
I-1
tp18853
sS'range,of,solid'
p18854
(F1
F0.00076452599388379206
I0
I1
I-1
tp18855
sS'a,bcl-2,family'
p18856
(F1
F0.00076452599388379206
I1
I0
I1
tp18857
sS'rapid,onset,of'
p18858
(F1
F0.00076452599388379206
I1
I0
I1
tp18859
sS'mesylate,is,coadministered'
p18860
(F1
F0.00076452599388379206
I0
I1
I-1
tp18861
sS'mg,diminished,nonheme'
p18862
(F1
F0.00076452599388379206
I1
I0
I1
tp18863
sS'ergot,alkaloids,and'
p18864
(F1
F0.00076452599388379206
I0
I1
I-1
tp18865
sS'not,improve,their'
p18866
(F1
F0.00076452599388379206
I0
I1
I-1
tp18867
sS'nonheme,or,heme'
p18868
(F1
F0.00076452599388379206
I0
I1
I-1
tp18869
sS'to,and,concomitant'
p18870
(F1
F0.00076452599388379206
I1
I0
I1
tp18871
sS'interaction,with,mixed'
p18872
(F1
F0.00076452599388379206
I1
I0
I1
tp18873
sS'mice,at,doses'
p18874
(F1
F0.00076452599388379206
I0
I1
I-1
tp18875
sS'they,do,not'
p18876
(F1
F0.00076452599388379206
I1
I0
I1
tp18877
sS'methyl-1,thiazol-4,yl'
p18878
(F0.42857142857142855
F0.0022935779816513763
I5
I2
I3
tp18879
sS'produced,by,remeron'
p18880
(F1
F0.0015290519877675841
I2
I0
I2
tp18881
sS'that,of,other'
p18882
(F1
F0.0022935779816513763
I3
I0
I3
tp18883
sS'additive,sedative,effects'
p18884
(F1
F0.0015290519877675841
I2
I0
I2
tp18885
sS'to,the,therapeutic'
p18886
(F1
F0.00076452599388379206
I0
I1
I-1
tp18887
sS'for,days,with'
p18888
(F1
F0.00076452599388379206
I1
I0
I1
tp18889
sS'result,in,increased'
p18890
(F1
F0.0015290519877675841
I2
I0
I2
tp18891
sS'may,be,taken'
p18892
(F1
F0.00076452599388379206
I0
I1
I-1
tp18893
sS'animals,displayed,parkinsonian'
p18894
(F1
F0.00076452599388379206
I1
I0
I1
tp18895
sS'clinical,pharmacology,variability'
p18896
(F1
F0.00076452599388379206
I1
I0
I1
tp18897
sS'a,prolongation,of'
p18898
(F1
F0.00076452599388379206
I1
I0
I1
tp18899
sS'to,minimize,cns'
p18900
(F1
F0.00076452599388379206
I0
I1
I-1
tp18901
sS'ritalin,may,decrease'
p18902
(F1
F0.00076452599388379206
I1
I0
I1
tp18903
sS'be,used,only'
p18904
(F1
F0.0015290519877675841
I2
I0
I2
tp18905
sS'test,should,be'
p18906
(F1
F0.00076452599388379206
I1
I0
I1
tp18907
sS'isopto,carbachol,may'
p18908
(F1
F0.00076452599388379206
I1
I0
I1
tp18909
sS'concentrations,were,approximately'
p18910
(F1
F0.00076452599388379206
I1
I0
I1
tp18911
sS'they,may,have'
p18912
(F1
F0.0015290519877675841
I2
I0
I2
tp18913
sS'not,significantly,modified'
p18914
(F1
F0.00076452599388379206
I0
I1
I-1
tp18915
sS'is,especially,true'
p18916
(F1
F0.00076452599388379206
I0
I1
I-1
tp18917
sS'not,influenced,by'
p18918
(F1
F0.00076452599388379206
I0
I1
I-1
tp18919
sS'of,fixed,combination'
p18920
(F0
F0
I2
I2
I0
tp18921
sS'that,aminosalicylate,derivatives'
p18922
(F1
F0.00076452599388379206
I1
I0
I1
tp18923
sS'cytotoxicity,by,up-regulation'
p18924
(F1
F0.00076452599388379206
I1
I0
I1
tp18925
sS'produce,dry,mouth'
p18926
(F1
F0.0015290519877675841
I2
I0
I2
tp18927
sS'either,of,the'
p18928
(F1
F0.00076452599388379206
I0
I1
I-1
tp18929
sS'alcohol,concomitant,administration'
p18930
(F1
F0.00076452599388379206
I1
I0
I1
tp18931
sS'unaffected,by,but'
p18932
(F1
F0.00076452599388379206
I1
I0
I1
tp18933
sS'when,feldene,is'
p18934
(F1
F0.00076452599388379206
I1
I0
I1
tp18935
sS'at,a,g'
p18936
(F1
F0.00076452599388379206
I1
I0
I1
tp18937
sS'min,p,respectively'
p18938
(F1
F0.00076452599388379206
I1
I0
I1
tp18939
sS'thus,symlin,and'
p18940
(F1
F0.00076452599388379206
I0
I1
I-1
tp18941
sS'pharmacokinetic,steady,state'
p18942
(F1
F0.0015290519877675841
I0
I2
I-2
tp18943
sS'important,determinant,of'
p18944
(F1
F0.00076452599388379206
I1
I0
I1
tp18945
sS'drugs,from,the'
p18946
(F1
F0.00076452599388379206
I1
I0
I1
tp18947
sS'produced,an,inr'
p18948
(F1
F0.00076452599388379206
I0
I1
I-1
tp18949
sS'such,a,risk'
p18950
(F1
F0.00076452599388379206
I0
I1
I-1
tp18951
sS'increases,in,inr'
p18952
(F1
F0.00076452599388379206
I1
I0
I1
tp18953
sS'similar,increases,in'
p18954
(F1
F0.00076452599388379206
I1
I0
I1
tp18955
sS'interfere,with,enterohepatic'
p18956
(F1
F0.00076452599388379206
I1
I0
I1
tp18957
sS'regarding,the,effect'
p18958
(F1
F0.00076452599388379206
I0
I1
I-1
tp18959
sS'after,discontinuation,of'
p18960
(F1
F0.00076452599388379206
I1
I0
I1
tp18961
sS'interaction,study,the'
p18962
(F1
F0.00076452599388379206
I0
I1
I-1
tp18963
sS'megestrol,acetate,is'
p18964
(F1
F0.00076452599388379206
I0
I1
I-1
tp18965
sS'and,cysteine,with'
p18966
(F1
F0.00076452599388379206
I0
I1
I-1
tp18967
sS'interval,prolongation,with'
p18968
(F1
F0.00076452599388379206
I0
I1
I-1
tp18969
sS'study,at,a'
p18970
(F1
F0.00076452599388379206
I1
I0
I1
tp18971
sS'or,sedation,including'
p18972
(F1
F0.00076452599388379206
I0
I1
I-1
tp18973
sS'use,of,demser'
p18974
(F1
F0.00076452599388379206
I1
I0
I1
tp18975
sS'cellular,thiol,content'
p18976
(F1
F0.00076452599388379206
I0
I1
I-1
tp18977
sS'blocking,agents,have'
p18978
(F1
F0.00076452599388379206
I0
I1
I-1
tp18979
sS'conducted,sanctura,has'
p18980
(F1
F0.00076452599388379206
I1
I0
I1
tp18981
sS'of,the,more'
p18982
(F1
F0.00076452599388379206
I0
I1
I-1
tp18983
sS'used,premedications,or'
p18984
(F1
F0.00076452599388379206
I0
I1
I-1
tp18985
sS'showed,that,does'
p18986
(F1
F0.0015290519877675841
I0
I2
I-2
tp18987
sS'with,topical,administration'
p18988
(F1
F0.00076452599388379206
I0
I1
I-1
tp18989
sS'in,combination,with'
p18990
(F0.38461538461538464
F0.0038226299694189602
I9
I4
I5
tp18991
sS'drugs,has,not'
p18992
(F0.33333333333333331
F0.00076452599388379206
I1
I2
I-1
tp18993
sS'by,and,were'
p18994
(F1
F0.00076452599388379206
I0
I1
I-1
tp18995
sS'to,be,a'
p18996
(F1
F0.00076452599388379206
I1
I0
I1
tp18997
sS'potentiation,of,antihypertensive'
p18998
(F1
F0.00076452599388379206
I1
I0
I1
tp18999
sS'high-dose,intravenous,has'
p19000
(F1
F0.00076452599388379206
I1
I0
I1
tp19001
sS'mcf7,and,u251'
p19002
(F1
F0.00076452599388379206
I0
I1
I-1
tp19003
sS'development,of,parkinsonian'
p19004
(F1
F0.00076452599388379206
I0
I1
I-1
tp19005
sS'the,initiation,of'
p19006
(F1
F0.0015290519877675841
I2
I0
I2
tp19007
sS'u251,to,fu'
p19008
(F1
F0.00076452599388379206
I0
I1
I-1
tp19009
sS'monitor,patients,for'
p19010
(F1
F0.0015290519877675841
I2
I0
I2
tp19011
sS'vitamin,b2,riboflavin'
p19012
(F1
F0.00076452599388379206
I1
I0
I1
tp19013
sS'including,torsades,de'
p19014
(F1
F0.00076452599388379206
I0
I1
I-1
tp19015
sS'exposure,observed,following'
p19016
(F1
F0.00076452599388379206
I0
I1
I-1
tp19017
sS'by,containing,or'
p19018
(F1
F0.00076452599388379206
I1
I0
I1
tp19019
sS'same,time,the'
p19020
(F1
F0.00076452599388379206
I1
I0
I1
tp19021
sS'found,that,causes'
p19022
(F1
F0.00076452599388379206
I1
I0
I1
tp19023
sS'and,the,clearance'
p19024
(F1
F0.00076452599388379206
I1
I0
I1
tp19025
sS'the,secretion,of'
p19026
(F1
F0.00076452599388379206
I1
I0
I1
tp19027
sS'autohaler,because,they'
p19028
(F1
F0.00076452599388379206
I1
I0
I1
tp19029
sS'target,bp,and'
p19030
(F1
F0.00076452599388379206
I1
I0
I1
tp19031
sS'to,the,enhancement'
p19032
(F1
F0.00076452599388379206
I1
I0
I1
tp19033
sS'may,require,dose'
p19034
(F1
F0.00076452599388379206
I1
I0
I1
tp19035
sS'the,prothrombin,time'
p19036
(F0
F0
I1
I1
I0
tp19037
sS'tablets,are,used'
p19038
(F1
F0.00076452599388379206
I1
I0
I1
tp19039
sS'with,food,does'
p19040
(F1
F0.00076452599388379206
I0
I1
I-1
tp19041
sS'alter,the,oral'
p19042
(F1
F0.00076452599388379206
I0
I1
I-1
tp19043
sS'cdk1,expression,vectors'
p19044
(F1
F0.00076452599388379206
I0
I1
I-1
tp19045
sS'subjects,receiving,daily'
p19046
(F1
F0.00076452599388379206
I0
I1
I-1
tp19047
sS'administered,concomitantly,with'
p19048
(F1
F0.0045871559633027525
I6
I0
I6
tp19049
sS'kg,administered,after'
p19050
(F1
F0.00076452599388379206
I0
I1
I-1
tp19051
sS'of,these,two'
p19052
(F1
F0.00076452599388379206
I0
I1
I-1
tp19053
sS'a,day,the'
p19054
(F1
F0.00076452599388379206
I1
I0
I1
tp19055
sS'with,relapsed,multiple'
p19056
(F1
F0.00076452599388379206
I0
I1
I-1
tp19057
sS'acids,via,the'
p19058
(F1
F0.00076452599388379206
I0
I1
I-1
tp19059
sS'this,was,muted'
p19060
(F1
F0.00076452599388379206
I0
I1
I-1
tp19061
sS'was,observed,in'
p19062
(F1
F0.00076452599388379206
I1
I0
I1
tp19063
sS'such,occurrences,have'
p19064
(F1
F0.00076452599388379206
I0
I1
I-1
tp19065
sS'of,fst,with'
p19066
(F1
F0.00076452599388379206
I0
I1
I-1
tp19067
sS'administration,vitamin,k'
p19068
(F1
F0.00076452599388379206
I0
I1
I-1
tp19069
sS'twice,the,currently'
p19070
(F1
F0.00076452599388379206
I1
I0
I1
tp19071
sS'or,mg,bid'
p19072
(F1
F0.00076452599388379206
I1
I0
I1
tp19073
sS'to,increased,levels'
p19074
(F1
F0.00076452599388379206
I1
I0
I1
tp19075
sS'transplant,patient,receiving'
p19076
(F1
F0.00076452599388379206
I1
I0
I1
tp19077
sS'of,these,therapeutic'
p19078
(F1
F0.00076452599388379206
I1
I0
I1
tp19079
sS'single,dose,in'
p19080
(F1
F0.00076452599388379206
I1
I0
I1
tp19081
sS'should,be,advised'
p19082
(F1
F0.0022935779816513763
I3
I0
I3
tp19083
sS'an,inducer,of'
p19084
(F1
F0.00076452599388379206
I1
I0
I1
tp19085
sS'drugs,metabolized,by'
p19086
(F0
F0
I1
I1
I0
tp19087
sS'in,prolongation,or'
p19088
(F1
F0.00076452599388379206
I1
I0
I1
tp19089
sS'cyp450,metabolism,are'
p19090
(F1
F0.00076452599388379206
I0
I1
I-1
tp19091
sS'moderate,renal,insufficiency'
p19092
(F1
F0.0015290519877675841
I2
I0
I2
tp19093
sS'significant,alterations,in'
p19094
(F1
F0.00076452599388379206
I0
I1
I-1
tp19095
sS'hexamethylenimine,mg,kg'
p19096
(F1
F0.00076452599388379206
I0
I1
I-1
tp19097
sS'been,reported,from'
p19098
(F1
F0.00076452599388379206
I1
I0
I1
tp19099
sS'once,daily,or'
p19100
(F1
F0.00076452599388379206
I0
I1
I-1
tp19101
sS'or,other,suitable'
p19102
(F1
F0.00076452599388379206
I1
I0
I1
tp19103
sS'average,tumor,volume'
p19104
(F1
F0.00076452599388379206
I1
I0
I1
tp19105
sS'with,increased,thrombocytopenia'
p19106
(F1
F0.0015290519877675841
I0
I2
I-2
tp19107
sS'inhibition,of,metabolism'
p19108
(F1
F0.00076452599388379206
I1
I0
I1
tp19109
sS'the,absorption,and'
p19110
(F1
F0.00076452599388379206
I1
I0
I1
tp19111
sS'for,protein,binding'
p19112
(F1
F0.00076452599388379206
I1
I0
I1
tp19113
sS'potentially,result,in'
p19114
(F1
F0.00076452599388379206
I1
I0
I1
tp19115
sS'as,and,were'
p19116
(F1
F0.00076452599388379206
I1
I0
I1
tp19117
sS'may,increase,the'
p19118
(F0.80000000000000004
F0.012232415902140673
I18
I2
I16
tp19119
sS'by,and,to'
p19120
(F1
F0.00076452599388379206
I1
I0
I1
tp19121
sS'patients,also,taking'
p19122
(F1
F0.00076452599388379206
I1
I0
I1
tp19123
sS'the,aruonic,transporter'
p19124
(F1
F0.00076452599388379206
I0
I1
I-1
tp19125
sS'can,increase,the'
p19126
(F0.33333333333333331
F0.00076452599388379206
I2
I1
I1
tp19127
sS'to,mg,kg'
p19128
(F1
F0.0022935779816513763
I0
I3
I-3
tp19129
sS'may,be,similar'
p19130
(F1
F0.00076452599388379206
I1
I0
I1
tp19131
sS'and,bleeding,have'
p19132
(F1
F0.00076452599388379206
I1
I0
I1
tp19133
sS'on,metabolism,by'
p19134
(F1
F0.00076452599388379206
I1
I0
I1
tp19135
sS'also,prolonged,the'
p19136
(F1
F0.00076452599388379206
I1
I0
I1
tp19137
sS'in,all,patients'
p19138
(F1
F0.00076452599388379206
I0
I1
I-1
tp19139
sS'the,progression-free,survival'
p19140
(F1
F0.00076452599388379206
I1
I0
I1
tp19141
sS'the,dose,of'
p19142
(F0.5
F0.0015290519877675841
I3
I1
I2
tp19143
sS'receiving,proton,pump'
p19144
(F1
F0.00076452599388379206
I1
I0
I1
tp19145
sS'bleeding,events,bruising'
p19146
(F1
F0.00076452599388379206
I1
I0
I1
tp19147
sS'of,oral,certain'
p19148
(F1
F0.00076452599388379206
I1
I0
I1
tp19149
sS'prolongation,of,prothrombin'
p19150
(F1
F0.00076452599388379206
I1
I0
I1
tp19151
sS'increase,in,patient'
p19152
(F1
F0.00076452599388379206
I1
I0
I1
tp19153
sS'to,patients,already'
p19154
(F1
F0.00076452599388379206
I1
I0
I1
tp19155
sS'phenyl-1,tetrahydropyridine,methyl-1'
p19156
(F0.5
F0.0015290519877675841
I3
I1
I2
tp19157
sS'with,combined,diflucan'
p19158
(F1
F0.00076452599388379206
I1
I0
I1
tp19159
sS'sensitization,and,conditioned'
p19160
(F1
F0.0015290519877675841
I0
I2
I-2
tp19161
sS'it,is,recommended'
p19162
(F1
F0.0030581039755351682
I4
I0
I4
tp19163
sS'did,not,change'
p19164
(F1
F0.0015290519877675841
I0
I2
I-2
tp19165
sS'not,alter,the'
p19166
(F1
F0.0068807339449541288
I0
I9
I-9
tp19167
sS'of,isolated,rat'
p19168
(F1
F0.00076452599388379206
I1
I0
I1
tp19169
sS'tramadol,although,no'
p19170
(F1
F0.00076452599388379206
I1
I0
I1
tp19171
sS'of,such,compounds'
p19172
(F1
F0.00076452599388379206
I1
I0
I1
tp19173
sS'abc,lyase,than'
p19174
(F1
F0.00076452599388379206
I0
I1
I-1
tp19175
sS'other,drugs,metabolized'
p19176
(F0
F0
I1
I1
I0
tp19177
sS'as,well,as'
p19178
(F0.5
F0.0030581039755351682
I6
I2
I4
tp19179
sS'mg,kg,intraperitoneally'
p19180
(F1
F0.00076452599388379206
I1
I0
I1
tp19181
sS'following,coadministration,of'
p19182
(F1
F0.00076452599388379206
I1
I0
I1
tp19183
sS'cytochrome,p450,a'
p19184
(F1
F0.00076452599388379206
I1
I0
I1
tp19185
sS'and,this,was'
p19186
(F1
F0.00076452599388379206
I0
I1
I-1
tp19187
sS'nonheme,absorption,by'
p19188
(F1
F0.00076452599388379206
I1
I0
I1
tp19189
sS'bound,to,plasma'
p19190
(F1
F0.00076452599388379206
I0
I1
I-1
tp19191
sS'with,monoamine,oxidase'
p19192
(F1
F0.00076452599388379206
I1
I0
I1
tp19193
sS'cerezyme,by,these'
p19194
(F1
F0.00076452599388379206
I1
I0
I1
tp19195
sS'on,the,immune'
p19196
(F1
F0.00076452599388379206
I0
I1
I-1
tp19197
sS'synergism,is,that'
p19198
(F1
F0.00076452599388379206
I1
I0
I1
tp19199
sS'with,an,hmg-coa'
p19200
(F1
F0.00076452599388379206
I0
I1
I-1
tp19201
sS'if,tolectin,is'
p19202
(F1
F0.00076452599388379206
I1
I0
I1
tp19203
sS'interaction,between,the'
p19204
(F1
F0.00076452599388379206
I0
I1
I-1
tp19205
sS'class,drugs,in'
p19206
(F1
F0.00076452599388379206
I1
I0
I1
tp19207
sS'of,these,drugs'
p19208
(F0.66666666666666663
F0.0030581039755351682
I5
I1
I4
tp19209
sS'i,and,the'
p19210
(F1
F0.00076452599388379206
I1
I0
I1
tp19211
sS'with,coadministration,beta'
p19212
(F1
F0.00076452599388379206
I1
I0
I1
tp19213
sS'no,evidence,of'
p19214
(F1
F0.00076452599388379206
I0
I1
I-1
tp19215
sS'effect,of,is'
p19216
(F1
F0.00076452599388379206
I1
I0
I1
tp19217
sS'to,the,neuromuscular'
p19218
(F1
F0.00076452599388379206
I1
I0
I1
tp19219
sS'lomefloxacin,reacts,faster'
p19220
(F1
F0.00076452599388379206
I1
I0
I1
tp19221
sS'two-fold,decrease,in'
p19222
(F1
F0.00076452599388379206
I1
I0
I1
tp19223
sS'of,neuromuscular,block'
p19224
(F1
F0.00076452599388379206
I1
I0
I1
tp19225
sS'action,of,mecamylamine'
p19226
(F1
F0.00076452599388379206
I1
I0
I1
tp19227
sS'regulating,bcl-2,and'
p19228
(F1
F0.00076452599388379206
I1
I0
I1
tp19229
sS'symlin,therapy,should'
p19230
(F1
F0.00076452599388379206
I1
I0
I1
tp19231
sS'isozymes,caution,is'
p19232
(F1
F0.00076452599388379206
I1
I0
I1
tp19233
sS'in,increased,systemic'
p19234
(F1
F0.00076452599388379206
I1
I0
I1
tp19235
sS'aramine,should,be'
p19236
(F1
F0.00076452599388379206
I1
I0
I1
tp19237
sS'platelet,reactivity,as'
p19238
(F1
F0.00076452599388379206
I1
I0
I1
tp19239
sS'orally,doses,for'
p19240
(F1
F0.00076452599388379206
I0
I1
I-1
tp19241
sS'binding,drug,interaction'
p19242
(F1
F0.00076452599388379206
I0
I1
I-1
tp19243
sS'apoptosis,induced,by'
p19244
(F1
F0.00076452599388379206
I0
I1
I-1
tp19245
sS'with,these,or'
p19246
(F1
F0.00076452599388379206
I1
I0
I1
tp19247
sS'ordinarily,should,not'
p19248
(F1
F0.00076452599388379206
I1
I0
I1
tp19249
sS'approximately,reduction,of'
p19250
(F1
F0.00076452599388379206
I0
I1
I-1
tp19251
sS'because,the,extrapyramidal'
p19252
(F1
F0.00076452599388379206
I1
I0
I1
tp19253
sS'do,not,affect'
p19254
(F1
F0.00076452599388379206
I0
I1
I-1
tp19255
sS'the,expression,of'
p19256
(F1
F0.00076452599388379206
I0
I1
I-1
tp19257
sS'disalcid,and,may'
p19258
(F1
F0.00076452599388379206
I1
I0
I1
tp19259
sS'a,strong,inhibitor'
p19260
(F1
F0.00076452599388379206
I1
I0
I1
tp19261
sS'in,the,absence'
p19262
(F0.33333333333333331
F0.00076452599388379206
I1
I2
I-1
tp19263
sS'interaction,should,be'
p19264
(F1
F0.00076452599388379206
I1
I0
I1
tp19265
sS'the,cytochrome,p450'
p19266
(F0.59999999999999998
F0.0022935779816513763
I4
I1
I3
tp19267
sS'monoamine,oxidase,inhibitors'
p19268
(F0.5
F0.0015290519877675841
I3
I1
I2
tp19269
sS'acetate,with,or'
p19270
(F1
F0.00076452599388379206
I0
I1
I-1
tp19271
sS'to,cause,weakness'
p19272
(F1
F0.00076452599388379206
I1
I0
I1
tp19273
sS'to,plasma,proteins'
p19274
(F1
F0.00076452599388379206
I0
I1
I-1
tp19275
sS'some,may,interact'
p19276
(F1
F0.00076452599388379206
I1
I0
I1
tp19277
sS'cmax,were,increased'
p19278
(F1
F0.00076452599388379206
I1
I0
I1
tp19279
sS'hypotension,and,profound'
p19280
(F1
F0.00076452599388379206
I1
I0
I1
tp19281
sS'charcoal,because,of'
p19282
(F1
F0.00076452599388379206
I1
I0
I1
tp19283
sS'maoi,such,as'
p19284
(F1
F0.00076452599388379206
I1
I0
I1
tp19285
sS'combination,with,and'
p19286
(F0.33333333333333331
F0.00076452599388379206
I1
I2
I-1
tp19287
sS'concentrations,of,either'
p19288
(F1
F0.00076452599388379206
I0
I1
I-1
tp19289
sS'and,auc,were'
p19290
(F1
F0.0015290519877675841
I2
I0
I2
tp19291
sS'have,the,potential'
p19292
(F0
F0
I1
I1
I0
tp19293
sS'the,central,nervous'
p19294
(F1
F0.00076452599388379206
I1
I0
I1
tp19295
sS'cyp1a2,inducers,or'
p19296
(F1
F0.00076452599388379206
I0
I1
I-1
tp19297
sS'ethynyl,pyridine,or'
p19298
(F1
F0.00076452599388379206
I0
I1
I-1
tp19299
sS'and,can,exert'
p19300
(F1
F0.00076452599388379206
I1
I0
I1
tp19301
sS'breast,cancer,the'
p19302
(F1
F0.00076452599388379206
I1
I0
I1
tp19303
sS'all,cell,lines'
p19304
(F1
F0.00076452599388379206
I1
I0
I1
tp19305
sS'not,listed,in'
p19306
(F1
F0.00076452599388379206
I0
I1
I-1
tp19307
sS'returned,to,of'
p19308
(F1
F0.00076452599388379206
I0
I1
I-1
tp19309
sS'with,elevations,in'
p19310
(F1
F0.00076452599388379206
I1
I0
I1
tp19311
sS'by,when,and'
p19312
(F1
F0.00076452599388379206
I1
I0
I1
tp19313
sS'vitro,assay,induced'
p19314
(F1
F0.00076452599388379206
I1
I0
I1
tp19315
sS'effects,of,has'
p19316
(F1
F0.0015290519877675841
I0
I2
I-2
tp19317
sS'skelid,are,administered'
p19318
(F1
F0.00076452599388379206
I1
I0
I1
tp19319
sS'and,that,altered'
p19320
(F1
F0.00076452599388379206
I1
I0
I1
tp19321
sS'of,zavesca,appeared'
p19322
(F1
F0.00076452599388379206
I1
I0
I1
tp19323
sS'certain,and,sodium'
p19324
(F1
F0.00076452599388379206
I1
I0
I1
tp19325
sS'and,by,disc'
p19326
(F1
F0.00076452599388379206
I1
I0
I1
tp19327
sS'of,anticoagulants,and'
p19328
(F1
F0.00076452599388379206
I1
I0
I1
tp19329
sS'bactericidal,effect,of'
p19330
(F1
F0.00076452599388379206
I1
I0
I1
tp19331
sS'in,the,british'
p19332
(F1
F0.00076452599388379206
I0
I1
I-1
tp19333
sS'clinically,significant,effect'
p19334
(F1
F0.00076452599388379206
I1
I0
I1
tp19335
sS'to,avoid,giving'
p19336
(F1
F0.00076452599388379206
I1
I0
I1
tp19337
sS'difference,cm3,confidence'
p19338
(F1
F0.00076452599388379206
I1
I0
I1
tp19339
sS'is,in,vitro'
p19340
(F1
F0.00076452599388379206
I1
I0
I1
tp19341
sS'on,the,oral'
p19342
(F1
F0.00076452599388379206
I1
I0
I1
tp19343
sS'is,no,supporting'
p19344
(F1
F0.00076452599388379206
I1
I0
I1
tp19345
sS'pills,anti-infective,medicines'
p19346
(F1
F0.00076452599388379206
I1
I0
I1
tp19347
sS'result,in,a'
p19348
(F1
F0.00076452599388379206
I1
I0
I1
tp19349
sS'of,with,oral'
p19350
(F1
F0.00076452599388379206
I1
I0
I1
tp19351
sS'iiia,inhibitors,may'
p19352
(F1
F0.00076452599388379206
I1
I0
I1
tp19353
sS'day,but,concomitant'
p19354
(F1
F0.00076452599388379206
I1
I0
I1
tp19355
sS'regarding,potential,interaction'
p19356
(F1
F0.00076452599388379206
I1
I0
I1
tp19357
sS'initiation,of,therapy'
p19358
(F1
F0.00076452599388379206
I1
I0
I1
tp19359
sS'demonstrated,adverse,experience'
p19360
(F1
F0.00076452599388379206
I1
I0
I1
tp19361
sS'a,second,herceptin'
p19362
(F1
F0.00076452599388379206
I1
I0
I1
tp19363
sS'severe,thrombocytopenia,and'
p19364
(F1
F0.00076452599388379206
I1
I0
I1
tp19365
sS'drugs,which,may'
p19366
(F1
F0.0015290519877675841
I2
I0
I2
tp19367
sS'other,drugs,such'
p19368
(F1
F0.0015290519877675841
I2
I0
I2
tp19369
sS'well,as,to'
p19370
(F1
F0.00076452599388379206
I1
I0
I1
tp19371
sS'on,the,serum'
p19372
(F1
F0.00076452599388379206
I0
I1
I-1
tp19373
sS'to,the,chemical'
p19374
(F1
F0.00076452599388379206
I1
I0
I1
tp19375
sS'in,normal,healthy'
p19376
(F1
F0.00076452599388379206
I1
I0
I1
tp19377
sS'and,mean,peak'
p19378
(F1
F0.00076452599388379206
I1
I0
I1
tp19379
sS'drugs,will,be'
p19380
(F1
F0.00076452599388379206
I1
I0
I1
tp19381
sS'the,areas,under'
p19382
(F1
F0.00076452599388379206
I0
I1
I-1
tp19383
sS'dose,was,necessary'
p19384
(F1
F0.00076452599388379206
I0
I1
I-1
tp19385
sS'not,noticeably,influence'
p19386
(F1
F0.00076452599388379206
I0
I1
I-1
tp19387
sS'p450,a4,may'
p19388
(F1
F0.00076452599388379206
I1
I0
I1
tp19389
sS'john,s,wort'
p19390
(F1
F0.0015290519877675841
I2
I0
I2
tp19391
sS'of,their,normal'
p19392
(F1
F0.00076452599388379206
I1
I0
I1
tp19393
sS'approximately,have,been'
p19394
(F1
F0.00076452599388379206
I1
I0
I1
tp19395
sS'incidence,of,thrombopenia'
p19396
(F1
F0.00076452599388379206
I0
I1
I-1
tp19397
sS'can,antagonize,the'
p19398
(F1
F0.00076452599388379206
I1
I0
I1
tp19399
sS'data,have,suggested'
p19400
(F1
F0.00076452599388379206
I1
I0
I1
tp19401
sS'risk,of,hospitalization'
p19402
(F0
F0
I1
I1
I0
tp19403
sS'finding,that,releases'
p19404
(F1
F0.00076452599388379206
I1
I0
I1
tp19405
sS'of,subjects,studied'
p19406
(F1
F0.00076452599388379206
I1
I0
I1
tp19407
sS'with,that,of'
p19408
(F1
F0.0015290519877675841
I2
I0
I2
tp19409
sS'congenital,hypothyroidism,on'
p19410
(F1
F0.00076452599388379206
I1
I0
I1
tp19411
sS'studies,of,conducted'
p19412
(F1
F0.00076452599388379206
I0
I1
I-1
tp19413
sS'state,study,the'
p19414
(F1
F0.00076452599388379206
I0
I1
I-1
tp19415
sS'plus,formed,fewer'
p19416
(F1
F0.00076452599388379206
I1
I0
I1
tp19417
sS'significant,increase,in'
p19418
(F1
F0.0030581039755351682
I4
I0
I4
tp19419
sS'per,day,or'
p19420
(F1
F0.00076452599388379206
I1
I0
I1
tp19421
sS'addition,of,heparinase'
p19422
(F1
F0.00076452599388379206
I0
I1
I-1
tp19423
sS'long,lasting,inhibition'
p19424
(F1
F0.00076452599388379206
I1
I0
I1
tp19425
sS'mcf7,following,all'
p19426
(F1
F0.00076452599388379206
I1
I0
I1
tp19427
sS'oxandrolone,may,inhibit'
p19428
(F1
F0.00076452599388379206
I1
I0
I1
tp19429
sS'infusion,rate,requirements'
p19430
(F1
F0.00076452599388379206
I1
I0
I1
tp19431
sS'i,metabolite,profile'
p19432
(F1
F0.00076452599388379206
I0
I1
I-1
tp19433
sS'after,interaction,with'
p19434
(F1
F0.00076452599388379206
I0
I1
I-1
tp19435
sS'tablets,may,be'
p19436
(F1
F0.00076452599388379206
I0
I1
I-1
tp19437
sS'use,with,vasoconstrictor'
p19438
(F1
F0.00076452599388379206
I0
I1
I-1
tp19439
sS'metabolizers,see,clinical'
p19440
(F1
F0.00076452599388379206
I1
I0
I1
tp19441
sS'increase,in,c'
p19442
(F1
F0.00076452599388379206
I1
I0
I1
tp19443
sS'clinically-relevant,interaction,between'
p19444
(F1
F0.00076452599388379206
I0
I1
I-1
tp19445
sS'not,isolate,the'
p19446
(F1
F0.00076452599388379206
I1
I0
I1
tp19447
sS'day,males,and'
p19448
(F1
F0.00076452599388379206
I0
I1
I-1
tp19449
sS'preliminary,data,from'
p19450
(F1
F0.00076452599388379206
I1
I0
I1
tp19451
sS'if,is,given'
p19452
(F1
F0.00076452599388379206
I1
I0
I1
tp19453
sS'determine,whether,the'
p19454
(F1
F0.00076452599388379206
I0
I1
I-1
tp19455
sS'or,precipitate,bradycardia'
p19456
(F1
F0.00076452599388379206
I1
I0
I1
tp19457
sS'the,treatment,of'
p19458
(F0.20000000000000001
F0.00076452599388379206
I2
I3
I-1
tp19459
sS'may,affect,gastrointestinal'
p19460
(F1
F0.00076452599388379206
I1
I0
I1
tp19461
sS'are,given,concurrently'
p19462
(F1
F0.00076452599388379206
I1
I0
I1
tp19463
sS'of,potential,interactions'
p19464
(F1
F0.00076452599388379206
I1
I0
I1
tp19465
sS'mg,kg,of'
p19466
(F1
F0.00076452599388379206
I0
I1
I-1
tp19467
sS'a,case,report'
p19468
(F1
F0.00076452599388379206
I1
I0
I1
tp19469
sS'other,antihypertensive,drugs'
p19470
(F1
F0.0015290519877675841
I2
I0
I2
tp19471
sS'are,not,recommended'
p19472
(F1
F0.00076452599388379206
I1
I0
I1
tp19473
sS'in,vivo,hepatic'
p19474
(F1
F0.00076452599388379206
I0
I1
I-1
tp19475
sS'evaluate,the,in'
p19476
(F1
F0.00076452599388379206
I0
I1
I-1
tp19477
sS'reported,in,one'
p19478
(F1
F0.00076452599388379206
I1
I0
I1
tp19479
sS'an,enhanced,serum'
p19480
(F1
F0.00076452599388379206
I1
I0
I1
tp19481
sS'mao-a,inhibitors,is'
p19482
(F1
F0.00076452599388379206
I1
I0
I1
tp19483
sS'been,the,result'
p19484
(F1
F0.00076452599388379206
I0
I1
I-1
tp19485
sS'when,and,were'
p19486
(F1
F0.00076452599388379206
I1
I0
I1
tp19487
sS'interference,of,mpag'
p19488
(F1
F0.00076452599388379206
I0
I1
I-1
tp19489
sS'groups,n,in'
p19490
(F1
F0.00076452599388379206
I0
I1
I-1
tp19491
sS'particularly,in,the'
p19492
(F1
F0.00076452599388379206
I1
I0
I1
tp19493
sS'added,to,may'
p19494
(F1
F0.00076452599388379206
I1
I0
I1
tp19495
sS'caused,a,increase'
p19496
(F1
F0.00076452599388379206
I1
I0
I1
tp19497
sS'mg,kg,was'
p19498
(F1
F0.00076452599388379206
I0
I1
I-1
tp19499
sS'changes,in,and'
p19500
(F1
F0.00076452599388379206
I1
I0
I1
tp19501
sS'dryness,of,the'
p19502
(F1
F0.00076452599388379206
I1
I0
I1
tp19503
sS'use,of,ergotamine-containing'
p19504
(F1
F0.00076452599388379206
I1
I0
I1
tp19505
sS'dose,of,adjusted'
p19506
(F1
F0.00076452599388379206
I1
I0
I1
tp19507
sS'drugs,were,potent'
p19508
(F1
F0.00076452599388379206
I1
I0
I1
tp19509
sS'increase,the,auc'
p19510
(F1
F0.0015290519877675841
I2
I0
I2
tp19511
sS'before,test,of'
p19512
(F1
F0.00076452599388379206
I0
I1
I-1
tp19513
sS'or,and,within'
p19514
(F1
F0.00076452599388379206
I1
I0
I1
tp19515
sS'and,and,potent'
p19516
(F1
F0.00076452599388379206
I0
I1
I-1
tp19517
sS'rats,neonatal,treatment'
p19518
(F1
F0.00076452599388379206
I1
I0
I1
tp19519
sS'n,males,the'
p19520
(F1
F0.00076452599388379206
I1
I0
I1
tp19521
sS'be,observed,closely'
p19522
(F1
F0.00076452599388379206
I1
I0
I1
tp19523
sS'was,found,in'
p19524
(F1
F0.00076452599388379206
I1
I0
I1
tp19525
sS'qt,were,not'
p19526
(F1
F0.00076452599388379206
I0
I1
I-1
tp19527
sS'by,this,enzyme'
p19528
(F1
F0.00076452599388379206
I0
I1
I-1
tp19529
sS'consistent,with,in'
p19530
(F1
F0.00076452599388379206
I1
I0
I1
tp19531
sS'auc,and,a'
p19532
(F1
F0.00076452599388379206
I1
I0
I1
tp19533
sS'the,four,drugs'
p19534
(F1
F0.00076452599388379206
I1
I0
I1
tp19535
sS'with,for,induction'
p19536
(F1
F0.00076452599388379206
I1
I0
I1
tp19537
sS'in,normal-weight,subjects'
p19538
(F1
F0.0038226299694189602
I0
I5
I-5
tp19539
sS'include,sympathomimetic,bronchodilators'
p19540
(F1
F0.00076452599388379206
I0
I1
I-1
tp19541
sS'evaluated,by,both'
p19542
(F1
F0.00076452599388379206
I1
I0
I1
tp19543
sS'mptp-evoked,behavior,violations'
p19544
(F1
F0.00076452599388379206
I0
I1
I-1
tp19545
sS'possibility,of,hypotensive'
p19546
(F0
F0
I1
I1
I0
tp19547
sS'durations,of,neuromuscular'
p19548
(F1
F0.00076452599388379206
I1
I0
I1
tp19549
sS'any,effect,on'
p19550
(F1
F0.00076452599388379206
I0
I1
I-1
tp19551
sS'loss,of,neurons'
p19552
(F1
F0.00076452599388379206
I1
I0
I1
tp19553
sS'reacts,faster,with'
p19554
(F1
F0.00076452599388379206
I1
I0
I1
tp19555
sS'clinically,significant,change'
p19556
(F1
F0.0015290519877675841
I0
I2
I-2
tp19557
sS'on,appears,to'
p19558
(F1
F0.00076452599388379206
I1
I0
I1
tp19559
sS'has,been,reported'
p19560
(F1
F0.012232415902140673
I16
I0
I16
tp19561
sS'and,abl,kinases'
p19562
(F0
F0
I1
I1
I0
tp19563
sS'when,administered,with'
p19564
(F1
F0.0015290519877675841
I2
I0
I2
tp19565
sS'clinical,studies,of'
p19566
(F1
F0.00076452599388379206
I1
I0
I1
tp19567
sS'cns,depression,and'
p19568
(F1
F0.00076452599388379206
I0
I1
I-1
tp19569
sS'involving,cyp2d6,and'
p19570
(F1
F0.00076452599388379206
I0
I1
I-1
tp19571
sS'of,bleeding,complications'
p19572
(F1
F0.00076452599388379206
I1
I0
I1
tp19573
sS'neuronal,loss,in'
p19574
(F1
F0.00076452599388379206
I0
I1
I-1
tp19575
sS'levels,and,symptoms'
p19576
(F1
F0.00076452599388379206
I1
I0
I1
tp19577
sS'g,dose,produced'
p19578
(F1
F0.00076452599388379206
I1
I0
I1
tp19579
sS'of,the,non-specific'
p19580
(F1
F0.00076452599388379206
I0
I1
I-1
tp19581
sS'kg,body,weight'
p19582
(F1
F0.00076452599388379206
I0
I1
I-1
tp19583
sS'allowing,to,achieve'
p19584
(F1
F0.00076452599388379206
I1
I0
I1
tp19585
sS'in,vivo,the'
p19586
(F1
F0.00076452599388379206
I1
I0
I1
tp19587
sS'in,immunocompromised,individuals'
p19588
(F1
F0.00076452599388379206
I1
I0
I1
tp19589
sS'is,feasible,as'
p19590
(F1
F0.00076452599388379206
I0
I1
I-1
tp19591
sS'administration,of,has'
p19592
(F0
F0
I1
I1
I0
tp19593
sS'bacteriostatic,may,diminish'
p19594
(F1
F0.00076452599388379206
I1
I0
I1
tp19595
sS'and,decreases,the'
p19596
(F1
F0.00076452599388379206
I1
I0
I1
tp19597
sS'protein-binding,sites,thus'
p19598
(F1
F0.00076452599388379206
I1
I0
I1
tp19599
sS'relating,to,the'
p19600
(F1
F0.00076452599388379206
I1
I0
I1
tp19601
sS'the,methyl-4,phenyl-1'
p19602
(F1
F0.0015290519877675841
I2
I0
I2
tp19603
sS'bactericidal,action,of'
p19604
(F1
F0.00076452599388379206
I1
I0
I1
tp19605
sS'active,metabolite,an'
p19606
(F1
F0.00076452599388379206
I0
I1
I-1
tp19607
sS'use,of,or'
p19608
(F1
F0.00076452599388379206
I0
I1
I-1
tp19609
sS'of,potassium-sparing,and'
p19610
(F1
F0.00076452599388379206
I0
I1
I-1
tp19611
sS'min,p,and'
p19612
(F1
F0.00076452599388379206
I1
I0
I1
tp19613
sS'bp,in,shorter'
p19614
(F1
F0.00076452599388379206
I1
I0
I1
tp19615
sS'beta,blockers,may'
p19616
(F1
F0.00076452599388379206
I1
I0
I1
tp19617
sS'as,and,agents'
p19618
(F1
F0.00076452599388379206
I1
I0
I1
tp19619
sS'on,a,background'
p19620
(F1
F0.00076452599388379206
I0
I1
I-1
tp19621
sS'may,be,increased'
p19622
(F0.33333333333333331
F0.00076452599388379206
I2
I1
I1
tp19623
sS'univasc,if,this'
p19624
(F1
F0.00076452599388379206
I0
I1
I-1
tp19625
sS'to,inhibit,the'
p19626
(F1
F0.00076452599388379206
I1
I0
I1
tp19627
sS'use,of,remeron'
p19628
(F1
F0.00076452599388379206
I0
I1
I-1
tp19629
sS'cyp3a4,family,st'
p19630
(F1
F0.00076452599388379206
I1
I0
I1
tp19631
sS'the,response,of'
p19632
(F1
F0.00076452599388379206
I0
I1
I-1
tp19633
sS'variability,in,metabolism'
p19634
(F1
F0.00076452599388379206
I1
I0
I1
tp19635
sS'pressure,after,initiation'
p19636
(F1
F0.00076452599388379206
I1
I0
I1
tp19637
sS'to,therapy,which'
p19638
(F1
F0.00076452599388379206
I0
I1
I-1
tp19639
sS'bleeding,associated,with'
p19640
(F1
F0.00076452599388379206
I1
I0
I1
tp19641
sS'no,evidence,that'
p19642
(F1
F0.00076452599388379206
I1
I0
I1
tp19643
sS'response,increased,effect'
p19644
(F1
F0.0015290519877675841
I0
I2
I-2
tp19645
sS'or,macrolide,and'
p19646
(F1
F0.00076452599388379206
I1
I0
I1
tp19647
sS'however,the,extent'
p19648
(F1
F0.00076452599388379206
I0
I1
I-1
tp19649
sS'of,cognitive,and'
p19650
(F1
F0.00076452599388379206
I1
I0
I1
tp19651
sS'the,exposure,auc'
p19652
(F1
F0.00076452599388379206
I1
I0
I1
tp19653
sS'study,was,aimed'
p19654
(F1
F0.00076452599388379206
I0
I1
I-1
tp19655
sS'were,not,influenced'
p19656
(F1
F0.00076452599388379206
I0
I1
I-1
tp19657
sS'that,and,grapefruit'
p19658
(F1
F0.00076452599388379206
I1
I0
I1
tp19659
sS'and,in,reduced'
p19660
(F1
F0.00076452599388379206
I1
I0
I1
tp19661
sS'conditions,and,temperature'
p19662
(F1
F0.00076452599388379206
I0
I1
I-1
tp19663
sS'sufficient,to,preclude'
p19664
(F1
F0.00076452599388379206
I1
I0
I1
tp19665
sS'humoral,immune,responses'
p19666
(F1
F0.0015290519877675841
I0
I2
I-2
tp19667
sS'controlled,administration,of'
p19668
(F1
F0.00076452599388379206
I1
I0
I1
tp19669
sS'suggest,that,rat'
p19670
(F1
F0.00076452599388379206
I0
I1
I-1
tp19671
sS'patients,with,diabetes'
p19672
(F1
F0.00076452599388379206
I1
I0
I1
tp19673
sS'specific,drug,or'
p19674
(F1
F0.00076452599388379206
I1
I0
I1
tp19675
sS'or,acth,in'
p19676
(F1
F0.00076452599388379206
I0
I1
I-1
tp19677
sS'respiratory,depression,which'
p19678
(F1
F0.00076452599388379206
I1
I0
I1
tp19679
sS'treatment,enhanced,locomotor'
p19680
(F1
F0.00076452599388379206
I1
I0
I1
tp19681
sS'is,known,to'
p19682
(F1
F0.00076452599388379206
I1
I0
I1
tp19683
sS'depressant,medications,may'
p19684
(F1
F0.00076452599388379206
I1
I0
I1
tp19685
sS'occur,with,topical'
p19686
(F1
F0.00076452599388379206
I0
I1
I-1
tp19687
sS'with,mexitil,lowered'
p19688
(F1
F0.00076452599388379206
I1
I0
I1
tp19689
sS'drug-drug,interaction,studies'
p19690
(F1
F0.0030581039755351682
I0
I4
I-4
tp19691
sS'to,interact,with'
p19692
(F0
F0
I1
I1
I0
tp19693
sS'and,please,note'
p19694
(F1
F0.00076452599388379206
I1
I0
I1
tp19695
sS'interaction,studies,with'
p19696
(F1
F0.0015290519877675841
I0
I2
I-2
tp19697
sS'by,intravitreal,injection'
p19698
(F1
F0.00076452599388379206
I0
I1
I-1
tp19699
sS'levels,bioavailability,of'
p19700
(F1
F0.00076452599388379206
I1
I0
I1
tp19701
sS'a,bacteriostatic,may'
p19702
(F1
F0.00076452599388379206
I1
I0
I1
tp19703
sS'the,antinociceptive,effect'
p19704
(F1
F0.00076452599388379206
I1
I0
I1
tp19705
sS'inhibitor,maoi,such'
p19706
(F1
F0.00076452599388379206
I1
I0
I1
tp19707
sS'a,known,inhibitor'
p19708
(F0
F0
I1
I1
I0
tp19709
sS'found,no,protein'
p19710
(F1
F0.00076452599388379206
I0
I1
I-1
tp19711
sS'did,cells,treated'
p19712
(F1
F0.00076452599388379206
I1
I0
I1
tp19713
sS'an,antiproliferative,effect'
p19714
(F1
F0.00076452599388379206
I1
I0
I1
tp19715
sS'with,an,increase'
p19716
(F1
F0.0015290519877675841
I2
I0
I2
tp19717
sS'days,respectively,lesser'
p19718
(F1
F0.00076452599388379206
I1
I0
I1
tp19719
sS'effect,of,acetyl-l'
p19720
(F1
F0.00076452599388379206
I0
I1
I-1
tp19721
sS'agents,may,reduce'
p19722
(F1
F0.00076452599388379206
I1
I0
I1
tp19723
sS'with,for,total'
p19724
(F1
F0.00076452599388379206
I0
I1
I-1
tp19725
sS'of,with,can'
p19726
(F1
F0.00076452599388379206
I1
I0
I1
tp19727
sS'with,resulted,in'
p19728
(F1
F0.0015290519877675841
I2
I0
I2
tp19729
sS'ethinyl,estradiol,and'
p19730
(F0
F0
I1
I1
I0
tp19731
sS'had,an,increased'
p19732
(F1
F0.0015290519877675841
I2
I0
I2
tp19733
sS'studies,with,agents'
p19734
(F1
F0.00076452599388379206
I0
I1
I-1
tp19735
sS'treated,with,an'
p19736
(F1
F0.00076452599388379206
I0
I1
I-1
tp19737
sS'in,renal,transplant'
p19738
(F1
F0.00076452599388379206
I1
I0
I1
tp19739
sS'based,on,auc0-24hr'
p19740
(F1
F0.0030581039755351682
I0
I4
I-4
tp19741
sS'r-,and,s-enantiomers'
p19742
(F1
F0.00076452599388379206
I0
I1
I-1
tp19743
sS'actions,or,side'
p19744
(F1
F0.00076452599388379206
I1
I0
I1
tp19745
sS'block,may,be'
p19746
(F1
F0.00076452599388379206
I1
I0
I1
tp19747
sS'coumarin-type,anticoagulants,prothrombin'
p19748
(F1
F0.00076452599388379206
I1
I0
I1
tp19749
sS'alter,the,bioavailability'
p19750
(F1
F0.00076452599388379206
I0
I1
I-1
tp19751
sS'their,serum,level'
p19752
(F1
F0.00076452599388379206
I1
I0
I1
tp19753
sS'with,other,antihypertensive'
p19754
(F1
F0.0015290519877675841
I2
I0
I2
tp19755
sS'following,categories,blood'
p19756
(F1
F0.00076452599388379206
I1
I0
I1
tp19757
sS'or,inhibit,the'
p19758
(F1
F0.00076452599388379206
I1
I0
I1
tp19759
sS'animal,data,have'
p19760
(F1
F0.00076452599388379206
I1
I0
I1
tp19761
sS'pharmacokinetic,parameters,of'
p19762
(F0.33333333333333331
F0.00076452599388379206
I1
I2
I-1
tp19763
sS'changes,to,or'
p19764
(F1
F0.00076452599388379206
I0
I1
I-1
tp19765
sS'x,mg,kg'
p19766
(F1
F0.00076452599388379206
I0
I1
I-1
tp19767
sS'aminosalicylate,derivatives,or'
p19768
(F1
F0.00076452599388379206
I1
I0
I1
tp19769
sS'of,proamatine,therefore'
p19770
(F1
F0.00076452599388379206
I1
I0
I1
tp19771
sS'with,enzymes,including'
p19772
(F1
F0.00076452599388379206
I0
I1
I-1
tp19773
sS'protein,binding,drug'
p19774
(F1
F0.00076452599388379206
I0
I1
I-1
tp19775
sS'much,study,in'
p19776
(F1
F0.00076452599388379206
I0
I1
I-1
tp19777
sS'for,use,with'
p19778
(F1
F0.00076452599388379206
I1
I0
I1
tp19779
sS'once,daily,and'
p19780
(F1
F0.00076452599388379206
I1
I0
I1
tp19781
sS'for,thc,in'
p19782
(F1
F0.00076452599388379206
I0
I1
I-1
tp19783
sS'of,plasma,levels'
p19784
(F1
F0.00076452599388379206
I1
I0
I1
tp19785
sS'or,drug,mg'
p19786
(F1
F0.00076452599388379206
I0
I1
I-1
tp19787
sS'corticosteroids,may,increase'
p19788
(F1
F0.00076452599388379206
I1
I0
I1
tp19789
sS'hydrochloride,and,anticholinesterase'
p19790
(F1
F0.00076452599388379206
I1
I0
I1
tp19791
sS'high-dose,and,concomitantly'
p19792
(F1
F0.00076452599388379206
I1
I0
I1
tp19793
sS'the,non-specific,cyp'
p19794
(F1
F0.00076452599388379206
I0
I1
I-1
tp19795
sS'warranted,appropriate,observation'
p19796
(F1
F0.00076452599388379206
I1
I0
I1
tp19797
sS'pharmacokinetic,interaction,study'
p19798
(F1
F0.00076452599388379206
I1
I0
I1
tp19799
sS'was,found,to'
p19800
(F1
F0.00076452599388379206
I1
I0
I1
tp19801
sS'other,non-steroidal,anti-inflammatory'
p19802
(F1
F0.00076452599388379206
I1
I0
I1
tp19803
sS'acyclovir,ganciclovir,may'
p19804
(F1
F0.00076452599388379206
I0
I1
I-1
tp19805
sS'mometasone,furoate,during'
p19806
(F1
F0.00076452599388379206
I1
I0
I1
tp19807
sS'needed,with,concomitant'
p19808
(F1
F0.00076452599388379206
I0
I1
I-1
tp19809
sS'cytotoxicity,in,human'
p19810
(F1
F0.00076452599388379206
I1
I0
I1
tp19811
sS'is,administered,concomitantly'
p19812
(F1
F0.0015290519877675841
I2
I0
I2
tp19813
sS'may,extend,the'
p19814
(F1
F0.00076452599388379206
I1
I0
I1
tp19815
sS'controlled,pharmacokinetic,study'
p19816
(F1
F0.00076452599388379206
I1
I0
I1
tp19817
sS'and,phases,p'
p19818
(F1
F0.00076452599388379206
I0
I1
I-1
tp19819
sS'enhance,the,effect'
p19820
(F1
F0.00076452599388379206
I1
I0
I1
tp19821
sS'when,and,skelid'
p19822
(F1
F0.00076452599388379206
I1
I0
I1
tp19823
sS'a,concomitant,orally'
p19824
(F1
F0.00076452599388379206
I1
I0
I1
tp19825
sS'of,since,are'
p19826
(F1
F0.00076452599388379206
I1
I0
I1
tp19827
sS'decreased,renal,excretion'
p19828
(F1
F0.0015290519877675841
I0
I2
I-2
tp19829
sS'to,inactivated,newcastle'
p19830
(F1
F0.00076452599388379206
I0
I1
I-1
tp19831
sS'with,adjustment,of'
p19832
(F1
F0.00076452599388379206
I0
I1
I-1
tp19833
sS'enzyme,system,ie'
p19834
(F1
F0.00076452599388379206
I1
I0
I1
tp19835
sS'study,mg,kg'
p19836
(F1
F0.00076452599388379206
I1
I0
I1
tp19837
sS'carefully,monitor,pt'
p19838
(F1
F0.00076452599388379206
I1
I0
I1
tp19839
sS'administered,with,myfortic'
p19840
(F1
F0.00076452599388379206
I1
I0
I1
tp19841
sS'protein,gfp,under'
p19842
(F1
F0.00076452599388379206
I0
I1
I-1
tp19843
sS'various,drugs,such'
p19844
(F1
F0.00076452599388379206
I1
I0
I1
tp19845
sS'enterohepatic,recirculation,and'
p19846
(F1
F0.00076452599388379206
I0
I1
I-1
tp19847
sS'inhibitors,in,rats'
p19848
(F1
F0.00076452599388379206
I0
I1
I-1
tp19849
sS'while,appeared,to'
p19850
(F1
F0.00076452599388379206
I1
I0
I1
tp19851
sS'when,administered,hour'
p19852
(F1
F0.00076452599388379206
I1
I0
I1
tp19853
sS'and,associated,gastrointestinal'
p19854
(F1
F0.00076452599388379206
I0
I1
I-1
tp19855
sS'and,the,combination'
p19856
(F1
F0.00076452599388379206
I1
I0
I1
tp19857
sS'cp450,mediated,clearance'
p19858
(F1
F0.00076452599388379206
I1
I0
I1
tp19859
sS'in,plasma,levels'
p19860
(F1
F0.0015290519877675841
I2
I0
I2
tp19861
sS'inhibition,mtt,radiolabeled'
p19862
(F1
F0.00076452599388379206
I0
I1
I-1
tp19863
sS'mivacron,and,has'
p19864
(F1
F0.00076452599388379206
I0
I1
I-1
tp19865
sS'paliperidone,is,not'
p19866
(F1
F0.0015290519877675841
I0
I2
I-2
tp19867
sS'reports,of,psychotic'
p19868
(F1
F0.00076452599388379206
I1
I0
I1
tp19869
sS'heparinase,iii,or'
p19870
(F0.33333333333333331
F0.00076452599388379206
I1
I2
I-1
tp19871
sS'be,attributed,to'
p19872
(F1
F0.00076452599388379206
I1
I0
I1
tp19873
sS'and,cyp1a2,enzymes'
p19874
(F1
F0.00076452599388379206
I0
I1
I-1
tp19875
sS'or,parenteral,demonstrated'
p19876
(F1
F0.00076452599388379206
I1
I0
I1
tp19877
sS'mouse,vs,vs'
p19878
(F1
F0.00076452599388379206
I1
I0
I1
tp19879
sS'birth,control,methods'
p19880
(F1
F0.00076452599388379206
I1
I0
I1
tp19881
sS'reports,of,increased'
p19882
(F1
F0.00076452599388379206
I1
I0
I1
tp19883
sS'effects,of,or'
p19884
(F0
F0
I1
I1
I0
tp19885
sS'the,dose,is'
p19886
(F1
F0.00076452599388379206
I1
I0
I1
tp19887
sS'effects,of,on'
p19888
(F0
F0
I1
I1
I0
tp19889
sS'and,other,drugs'
p19890
(F1
F0.0015290519877675841
I2
I0
I2
tp19891
sS'these,drugs,tramadol'
p19892
(F1
F0.00076452599388379206
I1
I0
I1
tp19893
sS'tested,for,an'
p19894
(F1
F0.00076452599388379206
I0
I1
I-1
tp19895
sS'were,conditioned,with'
p19896
(F1
F0.00076452599388379206
I1
I0
I1
tp19897
sS'increase,the,exposure'
p19898
(F1
F0.00076452599388379206
I1
I0
I1
tp19899
sS'combination,in,hospitalized'
p19900
(F1
F0.00076452599388379206
I0
I1
I-1
tp19901
sS'cytochrome,p450,system'
p19902
(F1
F0.0015290519877675841
I2
I0
I2
tp19903
sS'effect,of,was'
p19904
(F0
F0
I1
I1
I0
tp19905
sS'patients,concomitantly,taking'
p19906
(F1
F0.00076452599388379206
I1
I0
I1
tp19907
sS'of,and,can'
p19908
(F1
F0.00076452599388379206
I1
I0
I1
tp19909
sS'imexon,and,show'
p19910
(F1
F0.00076452599388379206
I1
I0
I1
tp19911
sS'diuretics,oral,contraceptives'
p19912
(F1
F0.00076452599388379206
I1
I0
I1
tp19913
sS'inhibition,in,nsclc'
p19914
(F1
F0.00076452599388379206
I0
I1
I-1
tp19915
sS'a,dose,of'
p19916
(F0.33333333333333331
F0.00076452599388379206
I1
I2
I-1
tp19917
sS'increased,plasma,concentrations'
p19918
(F1
F0.0015290519877675841
I2
I0
I2
tp19919
sS'observed,between,and'
p19920
(F0
F0
I1
I1
I0
tp19921
sS'clearances,similar,to'
p19922
(F1
F0.00076452599388379206
I0
I1
I-1
tp19923
sS'the,combined,use'
p19924
(F1
F0.0015290519877675841
I2
I0
I2
tp19925
sS'g,had,a'
p19926
(F1
F0.00076452599388379206
I1
I0
I1
tp19927
sS'categories,blood,dyscrasia'
p19928
(F1
F0.00076452599388379206
I1
I0
I1
tp19929
sS'a,substrate,for'
p19930
(F1
F0.00076452599388379206
I0
I1
I-1
tp19931
sS'although,this,was'
p19932
(F1
F0.00076452599388379206
I0
I1
I-1
tp19933
sS'presently,available,indicate'
p19934
(F1
F0.00076452599388379206
I0
I1
I-1
tp19935
sS'grens,efficacy,studies'
p19936
(F1
F0.00076452599388379206
I0
I1
I-1
tp19937
sS'response,in,chickens'
p19938
(F1
F0.00076452599388379206
I0
I1
I-1
tp19939
sS'can,exert,an'
p19940
(F1
F0.00076452599388379206
I1
I0
I1
tp19941
sS'of,qrs,qtc'
p19942
(F1
F0.00076452599388379206
I0
I1
I-1
tp19943
sS'clearance,significantly,increasing'
p19944
(F1
F0.00076452599388379206
I1
I0
I1
tp19945
sS'curve,extrapolated,to'
p19946
(F1
F0.00076452599388379206
I1
I0
I1
tp19947
sS'study,n,males'
p19948
(F1
F0.00076452599388379206
I1
I0
I1
tp19949
sS'since,celontin,may'
p19950
(F1
F0.00076452599388379206
I1
I0
I1
tp19951
sS'of,the,sulfonylurea'
p19952
(F1
F0.00076452599388379206
I1
I0
I1
tp19953
sS'other,eye,drops'
p19954
(F1
F0.00076452599388379206
I1
I0
I1
tp19955
sS'discontinuing,mexitil,if'
p19956
(F1
F0.00076452599388379206
I1
I0
I1
tp19957
sS'treated,with,neonatal'
p19958
(F1
F0.00076452599388379206
I0
I1
I-1
tp19959
sS'with,cyp3a4,inhibitors'
p19960
(F1
F0.00076452599388379206
I0
I1
I-1
tp19961
sS'analgesics,and,sympathomimetic'
p19962
(F1
F0.00076452599388379206
I1
I0
I1
tp19963
sS'aspirin,and,other'
p19964
(F1
F0.00076452599388379206
I1
I0
I1
tp19965
sS'diminished,by,whereas'
p19966
(F1
F0.00076452599388379206
I1
I0
I1
tp19967
sS'salt-retaining,steroid,therapy'
p19968
(F1
F0.00076452599388379206
I0
I1
I-1
tp19969
sS'pharmacokinetic,analysis,suggests'
p19970
(F0
F0
I1
I1
I0
tp19971
sS'well,as,striatal'
p19972
(F1
F0.00076452599388379206
I1
I0
I1
tp19973
sS'auc,and,cmax'
p19974
(F1
F0.0015290519877675841
I2
I0
I2
tp19975
sS'that,caused,a'
p19976
(F1
F0.00076452599388379206
I1
I0
I1
tp19977
sS'in,either,phenotype'
p19978
(F1
F0.00076452599388379206
I0
I1
I-1
tp19979
sS'is,the,only'
p19980
(F1
F0.00076452599388379206
I1
I0
I1
tp19981
sS'effect,of,oral'
p19982
(F0
F0
I1
I1
I0
tp19983
sS'enhances,sensitivity,of'
p19984
(F1
F0.00076452599388379206
I1
I0
I1
tp19985
sS'serious,cardiac,dysrhythmias'
p19986
(F1
F0.00076452599388379206
I1
I0
I1
tp19987
sS'increasing,salt,intake'
p19988
(F1
F0.00076452599388379206
I0
I1
I-1
tp19989
sS'be,used,cautiously'
p19990
(F1
F0.0030581039755351682
I4
I0
I4
tp19991
sS'additive,use,of'
p19992
(F1
F0.00076452599388379206
I1
I0
I1
tp19993
sS'trials,of,and'
p19994
(F1
F0.00076452599388379206
I1
I0
I1
tp19995
sS'known,high,content'
p19996
(F1
F0.00076452599388379206
I1
I0
I1
tp19997
sS'approximately,glasses,of'
p19998
(F1
F0.00076452599388379206
I0
I1
I-1
tp19999
sS'with,dornase,alfa'
p20000
(F1
F0.00076452599388379206
I1
I0
I1
tp20001
sS'via,the,aruonic'
p20002
(F1
F0.00076452599388379206
I0
I1
I-1
tp20003
sS'fold,whereas,treatment'
p20004
(F1
F0.00076452599388379206
I1
I0
I1
tp20005
sS'the,natriuretic,effect'
p20006
(F1
F0.00076452599388379206
I1
I0
I1
tp20007
sS'monitor,pt,and'
p20008
(F1
F0.00076452599388379206
I1
I0
I1
tp20009
sS'platelet,function,such'
p20010
(F1
F0.0015290519877675841
I2
I0
I2
tp20011
sS'chronic,hepatitis,c'
p20012
(F1
F0.00076452599388379206
I1
I0
I1
tp20013
sS'at,the,university'
p20014
(F1
F0.00076452599388379206
I1
I0
I1
tp20015
sS'of,that,produced'
p20016
(F1
F0.00076452599388379206
I0
I1
I-1
tp20017
sS'of,toxicity,when'
p20018
(F1
F0.0015290519877675841
I2
I0
I2
tp20019
sS'barbiturates,and,narcotics'
p20020
(F1
F0.00076452599388379206
I0
I1
I-1
tp20021
sS'metabolism,occurs,with'
p20022
(F1
F0.00076452599388379206
I1
I0
I1
tp20023
sS'altering,concentrations,in'
p20024
(F1
F0.00076452599388379206
I1
I0
I1
tp20025
sS'sites,of,metabolism'
p20026
(F1
F0.00076452599388379206
I1
I0
I1
tp20027
sS'the,intestines,and'
p20028
(F1
F0.00076452599388379206
I1
I0
I1
tp20029
sS'substrate,of,cytochrome'
p20030
(F1
F0.00076452599388379206
I0
I1
I-1
tp20031
sS'evaluating,possible,interactions'
p20032
(F1
F0.00076452599388379206
I0
I1
I-1
tp20033
sS'reported,that,administering'
p20034
(F1
F0.00076452599388379206
I1
I0
I1
tp20035
sS'should,be,slowly'
p20036
(F1
F0.00076452599388379206
I0
I1
I-1
tp20037
sS'and,certain,may'
p20038
(F1
F0.00076452599388379206
I1
I0
I1
tp20039
sS'not,appear,to'
p20040
(F1
F0.00076452599388379206
I1
I0
I1
tp20041
sS'when,the,rapid'
p20042
(F1
F0.00076452599388379206
I1
I0
I1
tp20043
sS'of,with,are'
p20044
(F1
F0.00076452599388379206
I0
I1
I-1
tp20045
sS's-ketamine,after,pretreatments'
p20046
(F1
F0.00076452599388379206
I0
I1
I-1
tp20047
sS'neurotoxic,medications,can'
p20048
(F1
F0.00076452599388379206
I1
I0
I1
tp20049
sS'myocardial,infarction,the'
p20050
(F1
F0.00076452599388379206
I0
I1
I-1
tp20051
sS'or,certain,given'
p20052
(F1
F0.00076452599388379206
I0
I1
I-1
tp20053
sS'family,and,abl'
p20054
(F1
F0.00076452599388379206
I1
I0
I1
tp20055
sS'enzyme,inhibition,and'
p20056
(F1
F0.00076452599388379206
I0
I1
I-1
tp20057
sS'about,while,those'
p20058
(F1
F0.00076452599388379206
I1
I0
I1
tp20059
sS'patient,s,response'
p20060
(F1
F0.00076452599388379206
I1
I0
I1
tp20061
sS'p450,enzymes,the'
p20062
(F1
F0.00076452599388379206
I0
I1
I-1
tp20063
sS'and,prolonged,sedation'
p20064
(F1
F0.00076452599388379206
I1
I0
I1
tp20065
sS'might,be,expected'
p20066
(F1
F0.00076452599388379206
I1
I0
I1
tp20067
sS'combination,with,antiplatelet'
p20068
(F1
F0.00076452599388379206
I1
I0
I1
tp20069
sS'drugs,is,antagonistic'
p20070
(F1
F0.00076452599388379206
I1
I0
I1
tp20071
sS'the,pressor,effect'
p20072
(F1
F0.0015290519877675841
I2
I0
I2
tp20073
sS'mean,auc,was'
p20074
(F1
F0.00076452599388379206
I1
I0
I1
tp20075
sS'and,grapefruit,juice'
p20076
(F1
F0.00076452599388379206
I1
I0
I1
tp20077
sS'of,metopirone,is'
p20078
(F1
F0.00076452599388379206
I1
I0
I1
tp20079
sS'seven,children,receiving'
p20080
(F1
F0.00076452599388379206
I0
I1
I-1
tp20081
sS'when,administering,zadaxin'
p20082
(F1
F0.00076452599388379206
I1
I0
I1
tp20083
sS'used,concurrently,blood'
p20084
(F1
F0.00076452599388379206
I1
I0
I1
tp20085
sS'patients,on,and'
p20086
(F1
F0.00076452599388379206
I1
I0
I1
tp20087
sS'interactions,effect,of'
p20088
(F1
F0.00076452599388379206
I0
I1
I-1
tp20089
sS'this,study,investigates'
p20090
(F1
F0.00076452599388379206
I0
I1
I-1
tp20091
sS'or,other,oral'
p20092
(F1
F0.00076452599388379206
I1
I0
I1
tp20093
sS'myfortic,was,administered'
p20094
(F1
F0.00076452599388379206
I1
I0
I1
tp20095
sS'saline,mg,kg'
p20096
(F1
F0.00076452599388379206
I0
I1
I-1
tp20097
sS'drugs,and,diminishing'
p20098
(F1
F0.00076452599388379206
I1
I0
I1
tp20099
sS'been,reported,that'
p20100
(F1
F0.0015290519877675841
I2
I0
I2
tp20101
sS'smoking,may,result'
p20102
(F1
F0.00076452599388379206
I0
I1
I-1
tp20103
sS'as,or,were'
p20104
(F1
F0.00076452599388379206
I0
I1
I-1
tp20105
sS'coadministration,of,did'
p20106
(F1
F0.00076452599388379206
I0
I1
I-1
tp20107
sS'invega,should,be'
p20108
(F1
F0.00076452599388379206
I1
I0
I1
tp20109
sS'of,like,activity'
p20110
(F1
F0.00076452599388379206
I0
I1
I-1
tp20111
sS'of,cerezyme,by'
p20112
(F1
F0.00076452599388379206
I1
I0
I1
tp20113
sS'to,the,most'
p20114
(F1
F0.00076452599388379206
I0
I1
I-1
tp20115
sS'of,decreased,hepatic'
p20116
(F1
F0.0015290519877675841
I0
I2
I-2
tp20117
sS'we,have,demonstrated'
p20118
(F1
F0.00076452599388379206
I1
I0
I1
tp20119
sS'agents,or,should'
p20120
(F1
F0.00076452599388379206
I0
I1
I-1
tp20121
sS'comparable,with,that'
p20122
(F1
F0.00076452599388379206
I0
I1
I-1
tp20123
sS'receiving,mao-a,inhibitors'
p20124
(F1
F0.00076452599388379206
I1
I0
I1
tp20125
sS'with,permax,a'
p20126
(F1
F0.00076452599388379206
I1
I0
I1
tp20127
sS'concomitant,use,of'
p20128
(F0.20000000000000001
F0.0022935779816513763
I9
I6
I3
tp20129
sS'reduction,of,dose'
p20130
(F1
F0.00076452599388379206
I0
I1
I-1
tp20131
sS'reduced,in,the'
p20132
(F1
F0.00076452599388379206
I1
I0
I1
tp20133
sS'of,when,coadministered'
p20134
(F1
F0.00076452599388379206
I1
I0
I1
tp20135
sS'herceptin-sensitive,tumors,in'
p20136
(F1
F0.00076452599388379206
I0
I1
I-1
tp20137
sS'inhalational,agents,eg'
p20138
(F1
F0.00076452599388379206
I0
I1
I-1
tp20139
sS's-ketamine,is,unaffected'
p20140
(F1
F0.00076452599388379206
I1
I0
I1
tp20141
sS'not,been,established'
p20142
(F1
F0.00076452599388379206
I1
I0
I1
tp20143
sS'resulting,in,two'
p20144
(F1
F0.00076452599388379206
I1
I0
I1
tp20145
sS'mg,were,administered'
p20146
(F1
F0.00076452599388379206
I0
I1
I-1
tp20147
sS'gh,administration,may'
p20148
(F1
F0.00076452599388379206
I1
I0
I1
tp20149
sS'salt,intake,prior'
p20150
(F1
F0.00076452599388379206
I1
I0
I1
tp20151
sS'for,a,effect'
p20152
(F1
F0.00076452599388379206
I1
I0
I1
tp20153
sS'synergistic,antinociception,activity'
p20154
(F1
F0.00076452599388379206
I1
I0
I1
tp20155
sS'gsls,because,no'
p20156
(F1
F0.00076452599388379206
I0
I1
I-1
tp20157
sS'locus,coeruleus,and'
p20158
(F1
F0.00076452599388379206
I1
I0
I1
tp20159
sS'half-life,from,to'
p20160
(F1
F0.00076452599388379206
I1
I0
I1
tp20161
sS'lines,leading,to'
p20162
(F1
F0.00076452599388379206
I1
I0
I1
tp20163
sS'necessary,it,may'
p20164
(F1
F0.00076452599388379206
I1
I0
I1
tp20165
sS'potent,cyp3a,inhibitor'
p20166
(F1
F0.00076452599388379206
I0
I1
I-1
tp20167
sS'on,the,plasma'
p20168
(F1
F0.00076452599388379206
I1
I0
I1
tp20169
sS'in,patients,treated'
p20170
(F0.33333333333333331
F0.00076452599388379206
I2
I1
I1
tp20171
sS'causal,relationship,has'
p20172
(F1
F0.00076452599388379206
I1
I0
I1
tp20173
sS'of,reproductive,toxicity'
p20174
(F1
F0.00076452599388379206
I0
I1
I-1
tp20175
sS'of,the,methyl-4'
p20176
(F1
F0.00076452599388379206
I1
I0
I1
tp20177
sS'they,are,less'
p20178
(F1
F0.00076452599388379206
I0
I1
I-1
tp20179
sS'hb-egf,is,a'
p20180
(F1
F0.00076452599388379206
I0
I1
I-1
tp20181
sS'not,known,to'
p20182
(F1
F0.00076452599388379206
I0
I1
I-1
tp20183
sS'effect,relating,to'
p20184
(F1
F0.00076452599388379206
I1
I0
I1
tp20185
sS'acetate,is,administered'
p20186
(F1
F0.00076452599388379206
I0
I1
I-1
tp20187
sS'target,for,t-all'
p20188
(F1
F0.00076452599388379206
I0
I1
I-1
tp20189
sS'is,not,a'
p20190
(F1
F0.0030581039755351682
I0
I4
I-4
tp20191
sS'diflucan,may,significantly'
p20192
(F1
F0.00076452599388379206
I1
I0
I1
tp20193
sS'administered,as,chloride'
p20194
(F1
F0.00076452599388379206
I0
I1
I-1
tp20195
sS'reductions,in,blood'
p20196
(F1
F0.00076452599388379206
I0
I1
I-1
tp20197
sS'of,on,oral'
p20198
(F0
F0
I1
I1
I0
tp20199
sS'be,given,consideration'
p20200
(F1
F0.00076452599388379206
I1
I0
I1
tp20201
sS'drug-drug,interactions,that'
p20202
(F1
F0.00076452599388379206
I0
I1
I-1
tp20203
sS'inhibitor,aminobenzotriazole,abt'
p20204
(F1
F0.00076452599388379206
I0
I1
I-1
tp20205
sS'induced,toxicity,which'
p20206
(F1
F0.00076452599388379206
I1
I0
I1
tp20207
sS'single-dose,interaction,study'
p20208
(F1
F0.00076452599388379206
I1
I0
I1
tp20209
sS'with,the,drugs'
p20210
(F1
F0.00076452599388379206
I1
I0
I1
tp20211
sS'where,gastric,ph'
p20212
(F1
F0.00076452599388379206
I1
I0
I1
tp20213
sS'and,sodium,colistimethate'
p20214
(F1
F0.00076452599388379206
I1
I0
I1
tp20215
sS'daily,fro,days'
p20216
(F1
F0.00076452599388379206
I0
I1
I-1
tp20217
sS'the,acute,toxicity'
p20218
(F1
F0.00076452599388379206
I0
I1
I-1
tp20219
sS'of,with,the'
p20220
(F1
F0.0015290519877675841
I2
I0
I2
tp20221
sS'mg,kg,dose'
p20222
(F1
F0.00076452599388379206
I0
I1
I-1
tp20223
sS'the,development,of'
p20224
(F1
F0.00076452599388379206
I0
I1
I-1
tp20225
sS'potential,to,interfere'
p20226
(F1
F0.00076452599388379206
I1
I0
I1
tp20227
sS'influenza,vaccines,by'
p20228
(F1
F0.00076452599388379206
I0
I1
I-1
tp20229
sS'potentiated,by,the'
p20230
(F0.33333333333333331
F0.00076452599388379206
I2
I1
I1
tp20231
sS'effects,of,curariform'
p20232
(F1
F0.00076452599388379206
I1
I0
I1
tp20233
sS'and,or,other'
p20234
(F1
F0.00076452599388379206
I1
I0
I1
tp20235
sS'neuromuscular,blocking,effect'
p20236
(F1
F0.00076452599388379206
I1
I0
I1
tp20237
sS'and,may,result'
p20238
(F1
F0.0015290519877675841
I2
I0
I2
tp20239
sS'of,was,studied'
p20240
(F1
F0.00076452599388379206
I0
I1
I-1
tp20241
sS'precocene,i,and'
p20242
(F1
F0.00076452599388379206
I0
I1
I-1
tp20243
sS'concomitant,administrations,not'
p20244
(F1
F0.00076452599388379206
I1
I0
I1
tp20245
sS'mao-a,inhibitors,reduce'
p20246
(F1
F0.00076452599388379206
I1
I0
I1
tp20247
sS'carboptic,isopto,carbachol'
p20248
(F1
F0.00076452599388379206
I1
I0
I1
tp20249
sS'concomitantly,treated,with'
p20250
(F1
F0.00076452599388379206
I0
I1
I-1
tp20251
sS'high,blood,pressure'
p20252
(F1
F0.00076452599388379206
I0
I1
I-1
tp20253
sS'recommended,dose,of'
p20254
(F1
F0.00076452599388379206
I1
I0
I1
tp20255
sS'use,of,anticoagulants'
p20256
(F1
F0.00076452599388379206
I1
I0
I1
tp20257
sS'studied,in,a'
p20258
(F1
F0.00076452599388379206
I0
I1
I-1
tp20259
sS'to,stable,renal'
p20260
(F1
F0.00076452599388379206
I1
I0
I1
tp20261
sS'extent,of,absorption'
p20262
(F0.33333333333333331
F0.00076452599388379206
I1
I2
I-1
tp20263
sS'using,locomotor,sensitization'
p20264
(F1
F0.00076452599388379206
I0
I1
I-1
tp20265
sS'potent,cytochrome,p450'
p20266
(F1
F0.0022935779816513763
I3
I0
I3
tp20267
sS'these,effects,should'
p20268
(F1
F0.00076452599388379206
I0
I1
I-1
tp20269
sS'these,results,are'
p20270
(F1
F0.00076452599388379206
I1
I0
I1
tp20271
sS'for,angina,or'
p20272
(F1
F0.00076452599388379206
I0
I1
I-1
tp20273
sS'other,inhibitors,of'
p20274
(F1
F0.00076452599388379206
I1
I0
I1
tp20275
sS'these,changes,has'
p20276
(F1
F0.00076452599388379206
I1
I0
I1
tp20277
sS'pyridine,significantly,reduces'
p20278
(F1
F0.00076452599388379206
I1
I0
I1
tp20279
sS'dtic,and,the'
p20280
(F1
F0.00076452599388379206
I0
I1
I-1
tp20281
sS'monitored,for,or'
p20282
(F1
F0.00076452599388379206
I1
I0
I1
tp20283
sS'before,or,after'
p20284
(F1
F0.00076452599388379206
I0
I1
I-1
tp20285
sS'which,different,drugs'
p20286
(F1
F0.00076452599388379206
I1
I0
I1
tp20287
sS'how,interacts,with'
p20288
(F1
F0.00076452599388379206
I0
I1
I-1
tp20289
sS'stable,target,inr'
p20290
(F1
F0.00076452599388379206
I1
I0
I1
tp20291
sS'a,particular,focus'
p20292
(F1
F0.00076452599388379206
I0
I1
I-1
tp20293
sS'natriuretic,effect,of'
p20294
(F1
F0.00076452599388379206
I1
I0
I1
tp20295
sS'than,treatment,with'
p20296
(F1
F0.00076452599388379206
I1
I0
I1
tp20297
sS'with,significant,inhibitors'
p20298
(F1
F0.00076452599388379206
I1
I0
I1
tp20299
sS'patients,on,these'
p20300
(F1
F0.00076452599388379206
I1
I0
I1
tp20301
sS'fu,plasma,concentrations'
p20302
(F1
F0.00076452599388379206
I1
I0
I1
tp20303
sS'alter,the,pharmacokinetics'
p20304
(F1
F0.0022935779816513763
I0
I3
I-3
tp20305
sS'and,may,be'
p20306
(F1
F0.0015290519877675841
I2
I0
I2
tp20307
sS'profile,only,was'
p20308
(F1
F0.00076452599388379206
I0
I1
I-1
tp20309
sS'dietary,components,because'
p20310
(F1
F0.00076452599388379206
I1
I0
I1
tp20311
sS'clinical,studies,as'
p20312
(F1
F0.00076452599388379206
I1
I0
I1
tp20313
sS'dose,drug-drug,interaction'
p20314
(F1
F0.00076452599388379206
I1
I0
I1
tp20315
sS'drugs,that,are'
p20316
(F0.25
F0.0015290519877675841
I5
I3
I2
tp20317
sS'of,nephrotoxicity,in'
p20318
(F1
F0.00076452599388379206
I1
I0
I1
tp20319
sS'antinociception,activity,of'
p20320
(F1
F0.00076452599388379206
I1
I0
I1
tp20321
sS'time,the,locomotor'
p20322
(F1
F0.00076452599388379206
I1
I0
I1
tp20323
sS'increase,in,herceptin'
p20324
(F1
F0.00076452599388379206
I1
I0
I1
tp20325
sS'concentrations,of,when'
p20326
(F1
F0.00076452599388379206
I1
I0
I1
tp20327
sS'have,been,spontaneous'
p20328
(F1
F0.00076452599388379206
I1
I0
I1
tp20329
sS'in,nsclc,cell'
p20330
(F0.33333333333333331
F0.00076452599388379206
I1
I2
I-1
tp20331
sS'synergy,in,vitro'
p20332
(F1
F0.00076452599388379206
I1
I0
I1
tp20333
sS'sensitivity,of,ovarian'
p20334
(F1
F0.00076452599388379206
I1
I0
I1
tp20335
sS'patients,who,take'
p20336
(F1
F0.00076452599388379206
I1
I0
I1
tp20337
sS'of,and,should'
p20338
(F1
F0.00076452599388379206
I1
I0
I1
tp20339
sS'aminobenzotriazole,abt,and'
p20340
(F1
F0.00076452599388379206
I0
I1
I-1
tp20341
sS'of,p27,kip1'
p20342
(F0
F0
I2
I2
I0
tp20343
sS'requirements,for,may'
p20344
(F1
F0.00076452599388379206
I1
I0
I1
tp20345
sS'use,of,as'
p20346
(F1
F0.00076452599388379206
I1
I0
I1
tp20347
sS'use,of,in'
p20348
(F1
F0.0022935779816513763
I3
I0
I3
tp20349
sS'an,animal,model'
p20350
(F1
F0.00076452599388379206
I1
I0
I1
tp20351
sS'herceptin-refractory,to,herceptin-sensitive'
p20352
(F1
F0.00076452599388379206
I0
I1
I-1
tp20353
sS'suggests,that,is'
p20354
(F1
F0.00076452599388379206
I0
I1
I-1
tp20355
sS'mycophenolate,mofetil,given'
p20356
(F1
F0.00076452599388379206
I1
I0
I1
tp20357
sS'effects,of,anticholinergic'
p20358
(F1
F0.00076452599388379206
I1
I0
I1
tp20359
sS'given,in,combination'
p20360
(F1
F0.00076452599388379206
I0
I1
I-1
tp20361
sS'suggests,that,it'
p20362
(F1
F0.00076452599388379206
I1
I0
I1
tp20363
sS'arthritis,patients,in'
p20364
(F1
F0.0015290519877675841
I0
I2
I-2
tp20365
sS'antiplatelet,drug,for'
p20366
(F1
F0.00076452599388379206
I1
I0
I1
tp20367
sS'almost,loss,of'
p20368
(F1
F0.00076452599388379206
I1
I0
I1
tp20369
sS'and,weekly,doses'
p20370
(F1
F0.0015290519877675841
I0
I2
I-2
tp20371
sS'for,breast,cancer'
p20372
(F0
F0
I1
I1
I0
tp20373
sS'by,however,and'
p20374
(F1
F0.00076452599388379206
I0
I1
I-1
tp20375
sS'streptokinase,alone,or'
p20376
(F1
F0.00076452599388379206
I1
I0
I1
tp20377
sS'of,with,cyp3a'
p20378
(F1
F0.00076452599388379206
I0
I1
I-1
tp20379
sS'no,clinically,significant'
p20380
(F0.33333333333333331
F0.00076452599388379206
I1
I2
I-1
tp20381
sS'in,locus,coeruleus'
p20382
(F1
F0.00076452599388379206
I1
I0
I1
tp20383
sS'these,cells,alone'
p20384
(F1
F0.00076452599388379206
I0
I1
I-1
tp20385
sS'may,inhibit,the'
p20386
(F1
F0.0045871559633027525
I6
I0
I6
tp20387
sS'overexpressed,in,dznep'
p20388
(F1
F0.00076452599388379206
I1
I0
I1
tp20389
sS'of,the,occurrence'
p20390
(F1
F0.00076452599388379206
I1
I0
I1
tp20391
sS'is,a,critical'
p20392
(F1
F0.00076452599388379206
I1
I0
I1
tp20393
sS'excessive,reduction,of'
p20394
(F1
F0.00076452599388379206
I1
I0
I1
tp20395
sS'levels,of,mg'
p20396
(F1
F0.0015290519877675841
I2
I0
I2
tp20397
sS'barbiturates,may,decrease'
p20398
(F1
F0.00076452599388379206
I1
I0
I1
tp20399
sS'not,significantly,lower'
p20400
(F1
F0.00076452599388379206
I0
I1
I-1
tp20401
sS'an,oral,antiplatelet'
p20402
(F1
F0.00076452599388379206
I1
I0
I1
tp20403
sS'of,potassium-sparing,or'
p20404
(F1
F0.00076452599388379206
I1
I0
I1
tp20405
sS'metabolism,by,cyp'
p20406
(F1
F0.00076452599388379206
I1
I0
I1
tp20407
sS'woman,of,childbearing'
p20408
(F1
F0.00076452599388379206
I0
I1
I-1
tp20409
sS'with,neonatal,enhanced'
p20410
(F1
F0.00076452599388379206
I0
I1
I-1
tp20411
sS'their,normal,values'
p20412
(F1
F0.00076452599388379206
I1
I0
I1
tp20413
sS'incompatible,with,sodium'
p20414
(F1
F0.00076452599388379206
I1
I0
I1
tp20415
sS'use,of,the'
p20416
(F1
F0.00076452599388379206
I0
I1
I-1
tp20417
sS'the,first,dose'
p20418
(F1
F0.00076452599388379206
I1
I0
I1
tp20419
sS'mg,were,coadministered'
p20420
(F1
F0.00076452599388379206
I0
I1
I-1
tp20421
sS'a,statistically,significant'
p20422
(F1
F0.00076452599388379206
I1
I0
I1
tp20423
sS'in,all,cell'
p20424
(F1
F0.00076452599388379206
I1
I0
I1
tp20425
sS'highly,protein-bound,drugs'
p20426
(F1
F0.00076452599388379206
I1
I0
I1
tp20427
sS'catecholamine-depleting,drugs,may'
p20428
(F1
F0.0015290519877675841
I2
I0
I2
tp20429
sS'hypotensive,effects,with'
p20430
(F1
F0.00076452599388379206
I0
I1
I-1
tp20431
sS'effects,of,either'
p20432
(F1
F0.00076452599388379206
I0
I1
I-1
tp20433
sS'in,dose,to'
p20434
(F1
F0.0015290519877675841
I2
I0
I2
tp20435
sS'circumstances,consideration,should'
p20436
(F1
F0.00076452599388379206
I1
I0
I1
tp20437
sS'mice,group,vehicle'
p20438
(F1
F0.00076452599388379206
I0
I1
I-1
tp20439
sS'and,are,given'
p20440
(F1
F0.00076452599388379206
I1
I0
I1
tp20441
sS'other,containing,drugs'
p20442
(F1
F0.00076452599388379206
I1
I0
I1
tp20443
sS'from,to,ng'
p20444
(F1
F0.00076452599388379206
I1
I0
I1
tp20445
sS'when,used,concurrently'
p20446
(F1
F0.00076452599388379206
I1
I0
I1
tp20447
sS'be,used,when'
p20448
(F1
F0.0030581039755351682
I4
I0
I4
tp20449
sS'suitable,anticoagulation,test'
p20450
(F1
F0.00076452599388379206
I1
I0
I1
tp20451
sS'that,altered,the'
p20452
(F1
F0.00076452599388379206
I1
I0
I1
tp20453
sS'of,fu,plasma'
p20454
(F1
F0.00076452599388379206
I1
I0
I1
tp20455
sS'of,the,other'
p20456
(F1
F0.00076452599388379206
I0
I1
I-1
tp20457
sS'tobi,concomitantly,with'
p20458
(F1
F0.00076452599388379206
I1
I0
I1
tp20459
sS'examined,drug-drug,interactions'
p20460
(F1
F0.00076452599388379206
I0
I1
I-1
tp20461
sS'of,an,infant'
p20462
(F1
F0.00076452599388379206
I1
I0
I1
tp20463
sS'in,bone,marrow'
p20464
(F1
F0.00076452599388379206
I1
I0
I1
tp20465
sS'tubular,secretion,of'
p20466
(F0.33333333333333331
F0.00076452599388379206
I2
I1
I1
tp20467
sS'a,reaction,has'
p20468
(F1
F0.00076452599388379206
I1
I0
I1
tp20469
sS'hyaluronan,lyase,heparinase'
p20470
(F1
F0.00076452599388379206
I0
I1
I-1
tp20471
sS'furosemide,single,and'
p20472
(F1
F0.00076452599388379206
I0
I1
I-1
tp20473
sS'when,administering,feldene'
p20474
(F1
F0.00076452599388379206
I1
I0
I1
tp20475
sS'is,increased,fold'
p20476
(F1
F0.00076452599388379206
I1
I0
I1
tp20477
sS'cause,a,predictable'
p20478
(F1
F0.00076452599388379206
I1
I0
I1
tp20479
sS'immune,responses,of'
p20480
(F1
F0.00076452599388379206
I0
I1
I-1
tp20481
sS'may,emerge,if'
p20482
(F1
F0.00076452599388379206
I1
I0
I1
tp20483
sS'marrow,fibrosis,leading'
p20484
(F1
F0.00076452599388379206
I0
I1
I-1
tp20485
sS'should,be,reduced'
p20486
(F1
F0.0022935779816513763
I3
I0
I3
tp20487
sS'used,when,administering'
p20488
(F1
F0.0015290519877675841
I2
I0
I2
tp20489
sS'proamatine,has,been'
p20490
(F1
F0.00076452599388379206
I0
I1
I-1
tp20491
sS'oral,or,certain'
p20492
(F1
F0.00076452599388379206
I1
I0
I1
tp20493
sS'leads,to,increased'
p20494
(F1
F0.00076452599388379206
I1
I0
I1
tp20495
sS'addition,of,to'
p20496
(F0
F0
I1
I1
I0
tp20497
sS'who,take,both'
p20498
(F1
F0.00076452599388379206
I1
I0
I1
tp20499
sS'as,a,result'
p20500
(F1
F0.0015290519877675841
I2
I0
I2
tp20501
sS'prevention,of,ea'
p20502
(F1
F0.00076452599388379206
I1
I0
I1
tp20503
sS'was,aimed,to'
p20504
(F1
F0.00076452599388379206
I0
I1
I-1
tp20505
sS'secretion,may,increase'
p20506
(F1
F0.00076452599388379206
I0
I1
I-1
tp20507
sS'this,effect,on'
p20508
(F1
F0.00076452599388379206
I1
I0
I1
tp20509
sS'of,the,potential'
p20510
(F1
F0.0015290519877675841
I2
I0
I2
tp20511
sS'times,the,human'
p20512
(F1
F0.0030581039755351682
I0
I4
I-4
tp20513
sS'both,sj,grens'
p20514
(F1
F0.00076452599388379206
I0
I1
I-1
tp20515
sS'result,in,profound'
p20516
(F1
F0.00076452599388379206
I1
I0
I1
tp20517
sS'decreased,the,metabolic'
p20518
(F1
F0.00076452599388379206
I1
I0
I1
tp20519
sS'were,shown,to'
p20520
(F1
F0.0015290519877675841
I2
I0
I2
tp20521
sS'not,be,mixed'
p20522
(F1
F0.00076452599388379206
I0
I1
I-1
tp20523
sS'no,significant,adverse'
p20524
(F1
F0.0015290519877675841
I0
I2
I-2
tp20525
sS'of,sutent,with'
p20526
(F1
F0.0015290519877675841
I2
I0
I2
tp20527
sS'other,sedating,drugs'
p20528
(F1
F0.00076452599388379206
I1
I0
I1
tp20529
sS'cyp3a4,mg,bid'
p20530
(F1
F0.00076452599388379206
I1
I0
I1
tp20531
sS'be,a,useful'
p20532
(F1
F0.00076452599388379206
I0
I1
I-1
tp20533
sS'and,show,additive'
p20534
(F1
F0.00076452599388379206
I1
I0
I1
tp20535
sS'interesting,case,of'
p20536
(F1
F0.00076452599388379206
I1
I0
I1
tp20537
sS'may,experience,changes'
p20538
(F1
F0.00076452599388379206
I1
I0
I1
tp20539
sS'glutathione,and,cysteine'
p20540
(F1
F0.00076452599388379206
I0
I1
I-1
tp20541
sS'improved,control,of'
p20542
(F1
F0.00076452599388379206
I0
I1
I-1
tp20543
sS'significant,effect,on'
p20544
(F0.33333333333333331
F0.00076452599388379206
I2
I1
I1
tp20545
sS'with,quinpirole-free,controls'
p20546
(F0
F0
I1
I1
I0
tp20547
sS'on,these,drugs'
p20548
(F1
F0.00076452599388379206
I1
I0
I1
tp20549
sS'of,renal,tubular'
p20550
(F0
F0
I1
I1
I0
tp20551
sS'identified,and,as'
p20552
(F1
F0.00076452599388379206
I0
I1
I-1
tp20553
sS'ii,acetyl-l,carnitine'
p20554
(F1
F0.00076452599388379206
I1
I0
I1
tp20555
sS'by,competing,for'
p20556
(F1
F0.00076452599388379206
I1
I0
I1
tp20557
sS'inducer,of,cyp2c8'
p20558
(F1
F0.00076452599388379206
I1
I0
I1
tp20559
sS'hyaluronan,lyase,had'
p20560
(F1
F0.00076452599388379206
I0
I1
I-1
tp20561
sS'digoxin,a,controlled'
p20562
(F1
F0.00076452599388379206
I1
I0
I1
tp20563
sS'pyridine,treatment,also'
p20564
(F1
F0.00076452599388379206
I1
I0
I1
tp20565
sS'to,those,in'
p20566
(F1
F0.00076452599388379206
I0
I1
I-1
tp20567
sS'is,better,to'
p20568
(F1
F0.00076452599388379206
I1
I0
I1
tp20569
sS'mean,increase,in'
p20570
(F1
F0.0015290519877675841
I2
I0
I2
tp20571
sS'elimination,are,not'
p20572
(F1
F0.00076452599388379206
I0
I1
I-1
tp20573
sS'and,anesthetic,agents'
p20574
(F1
F0.00076452599388379206
I1
I0
I1
tp20575
sS'the,diet,that'
p20576
(F1
F0.00076452599388379206
I1
I0
I1
tp20577
sS'as,a,single'
p20578
(F1
F0.00076452599388379206
I1
I0
I1
tp20579
sS'diflucan,is,used'
p20580
(F1
F0.00076452599388379206
I1
I0
I1
tp20581
sS'and,xanthine,derivatives'
p20582
(F1
F0.00076452599388379206
I1
I0
I1
tp20583
sS'the,sensitivity,of'
p20584
(F1
F0.00076452599388379206
I1
I0
I1
tp20585
sS'dosage,or,timing'
p20586
(F1
F0.00076452599388379206
I1
I0
I1
tp20587
sS'additionally,in,one'
p20588
(F1
F0.00076452599388379206
I1
I0
I1
tp20589
sS'the,bactericidal,effect'
p20590
(F1
F0.00076452599388379206
I1
I0
I1
tp20591
sS'risk,of,hypokalemia'
p20592
(F1
F0.00076452599388379206
I0
I1
I-1
tp20593
sS'kinases,with,either'
p20594
(F1
F0.00076452599388379206
I1
I0
I1
tp20595
sS'bruising,epistaxis,gastrointestinal'
p20596
(F1
F0.00076452599388379206
I1
I0
I1
tp20597
sS'treatment,should,be'
p20598
(F1
F0.00076452599388379206
I1
I0
I1
tp20599
sS'observations,were,consistent'
p20600
(F1
F0.00076452599388379206
I1
I0
I1
tp20601
sS'time,and,bleeding'
p20602
(F1
F0.00076452599388379206
I1
I0
I1
tp20603
sS'effect,on,metabolism'
p20604
(F1
F0.00076452599388379206
I1
I0
I1
tp20605
sS'does,not,influence'
p20606
(F1
F0.00076452599388379206
I0
I1
I-1
tp20607
sS'we,also,found'
p20608
(F1
F0.00076452599388379206
I1
I0
I1
tp20609
sS'pharmacokinetic,interactions,occurred'
p20610
(F1
F0.00076452599388379206
I0
I1
I-1
tp20611
sS'with,other,or'
p20612
(F1
F0.00076452599388379206
I1
I0
I1
tp20613
sS'subjects,receiving,doses'
p20614
(F1
F0.00076452599388379206
I1
I0
I1
tp20615
sS'application,of,altabax'
p20616
(F1
F0.00076452599388379206
I0
I1
I-1
tp20617
sS'bp,quicker,achievement'
p20618
(F1
F0.00076452599388379206
I1
I0
I1
tp20619
sS'p450,enzyme,inducers'
p20620
(F1
F0.0015290519877675841
I2
I0
I2
tp20621
sS'maxair,autohaler,because'
p20622
(F1
F0.00076452599388379206
I1
I0
I1
tp20623
sS'important,pharmacokinetic,interactions'
p20624
(F1
F0.0015290519877675841
I0
I2
I-2
tp20625
sS'effects,and,confusional'
p20626
(F1
F0.00076452599388379206
I1
I0
I1
tp20627
sS'hypercholesterolemic,patients,receiving'
p20628
(F1
F0.00076452599388379206
I0
I1
I-1
tp20629
sS'use,of,sanctura'
p20630
(F1
F0.00076452599388379206
I1
I0
I1
tp20631
sS'infacol,drops,before'
p20632
(F1
F0.00076452599388379206
I0
I1
I-1
tp20633
sS'potentiate,the,neuromuscular'
p20634
(F1
F0.00076452599388379206
I1
I0
I1
tp20635
sS'influence,of,and'
p20636
(F1
F0.00076452599388379206
I0
I1
I-1
tp20637
sS'premedication,particularly,with'
p20638
(F1
F0.00076452599388379206
I1
I0
I1
tp20639
sS'her2,expression,at'
p20640
(F1
F0.00076452599388379206
I1
I0
I1
tp20641
sS'with,ultram,is'
p20642
(F1
F0.00076452599388379206
I0
I1
I-1
tp20643
sS'of,was,reduced'
p20644
(F0
F0
I1
I1
I0
tp20645
sS'ascorbic,acid,may'
p20646
(F1
F0.00076452599388379206
I1
I0
I1
tp20647
sS'platelet,reactivity,and'
p20648
(F1
F0.00076452599388379206
I0
I1
I-1
tp20649
sS'suggest,that,nsaids'
p20650
(F1
F0.00076452599388379206
I1
I0
I1
tp20651
sS'extend,the,plasma'
p20652
(F1
F0.00076452599388379206
I1
I0
I1
tp20653
sS'a,slight,but'
p20654
(F1
F0.00076452599388379206
I1
I0
I1
tp20655
sS'metabolism,of,exelon'
p20656
(F1
F0.00076452599388379206
I0
I1
I-1
tp20657
sS'two,larger,cohorts'
p20658
(F1
F0.00076452599388379206
I0
I1
I-1
tp20659
sS'at,all,in'
p20660
(F1
F0.00076452599388379206
I1
I0
I1
tp20661
sS'of,recombinant,human'
p20662
(F1
F0.00076452599388379206
I1
I0
I1
tp20663
sS'containing,drugs,has'
p20664
(F1
F0.00076452599388379206
I1
I0
I1
tp20665
sS'mg,of,acetate'
p20666
(F1
F0.00076452599388379206
I0
I1
I-1
tp20667
sS'chronically,administered,oral'
p20668
(F1
F0.00076452599388379206
I1
I0
I1
tp20669
sS'used,when,proamatine'
p20670
(F1
F0.00076452599388379206
I1
I0
I1
tp20671
sS'shown,that,nsaids'
p20672
(F1
F0.00076452599388379206
I1
I0
I1
tp20673
sS'enhanced,transduction,of'
p20674
(F1
F0.00076452599388379206
I0
I1
I-1
tp20675
sS'because,the,action'
p20676
(F1
F0.00076452599388379206
I1
I0
I1
tp20677
sS'eye,drops,or'
p20678
(F1
F0.00076452599388379206
I1
I0
I1
tp20679
sS'ph,is,an'
p20680
(F1
F0.00076452599388379206
I1
I0
I1
tp20681
sS'with,higher,concentrations'
p20682
(F1
F0.0015290519877675841
I0
I2
I-2
tp20683
sS'patient,already,receiving'
p20684
(F1
F0.00076452599388379206
I1
I0
I1
tp20685
sS'clinically,important,effects'
p20686
(F1
F0.00076452599388379206
I0
I1
I-1
tp20687
sS'combination,with,mycamine'
p20688
(F1
F0.00076452599388379206
I1
I0
I1
tp20689
sS'prolong,the,prothrombin'
p20690
(F1
F0.00076452599388379206
I1
I0
I1
tp20691
sS'have,been,reported'
p20692
(F0.5
F0.0061162079510703364
I12
I4
I8
tp20693
sS'the,activity,of'
p20694
(F1
F0.0015290519877675841
I2
I0
I2
tp20695
sS'however,on,the'
p20696
(F1
F0.00076452599388379206
I1
I0
I1
tp20697
sS'first,test,point'
p20698
(F1
F0.00076452599388379206
I1
I0
I1
tp20699
sS'area,under,the'
p20700
(F1
F0.0015290519877675841
I2
I0
I2
tp20701
sS'drugs,interrupt,enterohepatic'
p20702
(F1
F0.00076452599388379206
I0
I1
I-1
tp20703
sS'and,multiple,dose'
p20704
(F1
F0.00076452599388379206
I0
I1
I-1
tp20705
sS'when,both,drugs'
p20706
(F1
F0.00076452599388379206
I1
I0
I1
tp20707
sS'advised,to,avoid'
p20708
(F1
F0.0015290519877675841
I2
I0
I2
tp20709
sS'or,ergot-type,medications'
p20710
(F1
F0.00076452599388379206
I1
I0
I1
tp20711
sS'adjustment,of,or'
p20712
(F1
F0.00076452599388379206
I0
I1
I-1
tp20713
sS'labeling,for,the'
p20714
(F1
F0.00076452599388379206
I0
I1
I-1
tp20715
sS'treated,with,and'
p20716
(F1
F0.00076452599388379206
I1
I0
I1
tp20717
sS'kg,day,females'
p20718
(F1
F0.00076452599388379206
I0
I1
I-1
tp20719
sS'connection,with,the'
p20720
(F1
F0.00076452599388379206
I0
I1
I-1
tp20721
sS'of,absorption,that'
p20722
(F1
F0.00076452599388379206
I0
I1
I-1
tp20723
sS'concentrations,in,patients'
p20724
(F1
F0.0015290519877675841
I2
I0
I2
tp20725
sS'interval,in,patients'
p20726
(F1
F0.00076452599388379206
I1
I0
I1
tp20727
sS'be,potentiated,by'
p20728
(F0.5
F0.0015290519877675841
I3
I1
I2
tp20729
sS'result,of,increase'
p20730
(F1
F0.00076452599388379206
I1
I0
I1
tp20731
sS'agents,mao,inhibitors'
p20732
(F1
F0.00076452599388379206
I1
I0
I1
tp20733
sS'decrease,in,herceptin'
p20734
(F1
F0.00076452599388379206
I1
I0
I1
tp20735
sS'plasma,kinetics,of'
p20736
(F1
F0.00076452599388379206
I0
I1
I-1
tp20737
sS'injection,to,adult'
p20738
(F1
F0.00076452599388379206
I0
I1
I-1
tp20739
sS'reduced,by,however'
p20740
(F1
F0.00076452599388379206
I0
I1
I-1
tp20741
sS'other,drugs,capable'
p20742
(F1
F0.00076452599388379206
I0
I1
I-1
tp20743
sS'synergism,was,observed'
p20744
(F1
F0.00076452599388379206
I1
I0
I1
tp20745
sS'mice,in,conjunction'
p20746
(F1
F0.00076452599388379206
I0
I1
I-1
tp20747
sS'alter,the,prothrombin'
p20748
(F1
F0.00076452599388379206
I0
I1
I-1
tp20749
sS'been,used,in'
p20750
(F1
F0.0015290519877675841
I0
I2
I-2
tp20751
sS'herceptin-refractory,her2-positive,metastatic'
p20752
(F1
F0.00076452599388379206
I1
I0
I1
tp20753
sS'of,chronic,hepatitis'
p20754
(F1
F0.00076452599388379206
I1
I0
I1
tp20755
sS'hydrochloride,may,extend'
p20756
(F1
F0.00076452599388379206
I1
I0
I1
tp20757
sS'variability,in,exposure'
p20758
(F1
F0.00076452599388379206
I0
I1
I-1
tp20759
sS's,disease,prior'
p20760
(F1
F0.00076452599388379206
I1
I0
I1
tp20761
sS'of,mg,qid'
p20762
(F1
F0.00076452599388379206
I0
I1
I-1
tp20763
sS'enzymes,such,as'
p20764
(F1
F0.0015290519877675841
I2
I0
I2
tp20765
sS'suppressed,by,the'
p20766
(F1
F0.00076452599388379206
I1
I0
I1
tp20767
sS'abt-737,and,dznep'
p20768
(F1
F0.00076452599388379206
I1
I0
I1
tp20769
sS'le,is,known'
p20770
(F1
F0.00076452599388379206
I1
I0
I1
tp20771
sS'performance,were,significantly'
p20772
(F1
F0.00076452599388379206
I0
I1
I-1
tp20773
sS'on,the,metabolism'
p20774
(F1
F0.0030581039755351682
I0
I4
I-4
tp20775
sS'the,co-administration,of'
p20776
(F1
F0.00076452599388379206
I1
I0
I1
tp20777
sS'other,centrally,acting'
p20778
(F0
F0
I1
I1
I0
tp20779
sS'with,the,activity'
p20780
(F1
F0.00076452599388379206
I1
I0
I1
tp20781
sS'to,patients,who'
p20782
(F1
F0.00076452599388379206
I1
I0
I1
tp20783
sS'from,should,be'
p20784
(F1
F0.00076452599388379206
I1
I0
I1
tp20785
sS'other,complications,compared'
p20786
(F1
F0.00076452599388379206
I1
I0
I1
tp20787
sS'with,mg,three'
p20788
(F1
F0.00076452599388379206
I0
I1
I-1
tp20789
sS'reported,to,accelerate'
p20790
(F1
F0.00076452599388379206
I1
I0
I1
tp20791
sS'elevation,of,prothrombin'
p20792
(F1
F0.00076452599388379206
I0
I1
I-1
tp20793
sS'enzymes,in,vivo'
p20794
(F1
F0.00076452599388379206
I0
I1
I-1
tp20795
sS'isozymes,cytochrome,p450'
p20796
(F1
F0.00076452599388379206
I1
I0
I1
tp20797
sS'in,mice,at'
p20798
(F1
F0.00076452599388379206
I0
I1
I-1
tp20799
sS'potentially,neurotoxic,and'
p20800
(F1
F0.00076452599388379206
I0
I1
I-1
tp20801
sS'of,demonstrate,qt'
p20802
(F1
F0.00076452599388379206
I1
I0
I1
tp20803
sS'or,influence,the'
p20804
(F1
F0.00076452599388379206
I0
I1
I-1
tp20805
sS'of,cyps,a6'
p20806
(F1
F0.00076452599388379206
I0
I1
I-1
tp20807
sS'adrenergic,agents,may'
p20808
(F1
F0.0015290519877675841
I2
I0
I2
tp20809
sS'other,drugs,known'
p20810
(F1
F0.00076452599388379206
I0
I1
I-1
tp20811
sS'inhibitors,resulting,in'
p20812
(F1
F0.00076452599388379206
I0
I1
I-1
tp20813
sS'of,were,not'
p20814
(F1
F0.0015290519877675841
I0
I2
I-2
tp20815
sS'database,of,patients'
p20816
(F1
F0.00076452599388379206
I0
I1
I-1
tp20817
sS'used,with,caution'
p20818
(F1
F0.0038226299694189602
I5
I0
I5
tp20819
sS'cell,lines,with'
p20820
(F0
F0
I1
I1
I0
tp20821
sS'anticholinesterase,agents,may'
p20822
(F1
F0.00076452599388379206
I1
I0
I1
tp20823
sS'of,certain,ergot'
p20824
(F1
F0.00076452599388379206
I0
I1
I-1
tp20825
sS'of,containing,hydroxide'
p20826
(F1
F0.00076452599388379206
I0
I1
I-1
tp20827
sS'controlled,study,in'
p20828
(F1
F0.00076452599388379206
I1
I0
I1
tp20829
sS'slight,decrease,in'
p20830
(F1
F0.00076452599388379206
I0
I1
I-1
tp20831
sS'induced,her2,expression'
p20832
(F1
F0.00076452599388379206
I1
I0
I1
tp20833
sS'bleeding,complications,when'
p20834
(F1
F0.00076452599388379206
I1
I0
I1
tp20835
sS'k,is,not'
p20836
(F1
F0.00076452599388379206
I0
I1
I-1
tp20837
sS'have,been,taken'
p20838
(F1
F0.00076452599388379206
I1
I0
I1
tp20839
sS'showed,resistances,at'
p20840
(F1
F0.00076452599388379206
I0
I1
I-1
tp20841
sS'formal,single-dose,interaction'
p20842
(F1
F0.00076452599388379206
I1
I0
I1
tp20843
sS'observed,in,all'
p20844
(F1
F0.00076452599388379206
I0
I1
I-1
tp20845
sS'tst,in,mice'
p20846
(F1
F0.00076452599388379206
I0
I1
I-1
tp20847
sS'anticoagulants,interaction,studies'
p20848
(F1
F0.00076452599388379206
I0
I1
I-1
tp20849
sS'the,currently,recommended'
p20850
(F1
F0.00076452599388379206
I1
I0
I1
tp20851
sS'fewer,drugs,and'
p20852
(F1
F0.00076452599388379206
I1
I0
I1
tp20853
sS'particularly,with,eg'
p20854
(F1
F0.00076452599388379206
I1
I0
I1
tp20855
sS'may,lower,levels'
p20856
(F1
F0.00076452599388379206
I1
I0
I1
tp20857
sS'gentamicin,animal,data'
p20858
(F1
F0.00076452599388379206
I1
I0
I1
tp20859
sS'absorption,of,folic'
p20860
(F1
F0.00076452599388379206
I1
I0
I1
tp20861
sS'treatment,following,resulted'
p20862
(F1
F0.00076452599388379206
I1
I0
I1
tp20863
sS'may,be,used'
p20864
(F1
F0.00076452599388379206
I0
I1
I-1
tp20865
sS'therapy,in,patients'
p20866
(F1
F0.00076452599388379206
I1
I0
I1
tp20867
sS'concomitantly,with,these'
p20868
(F1
F0.00076452599388379206
I1
I0
I1
tp20869
sS'conjunction,with,in'
p20870
(F1
F0.0015290519877675841
I2
I0
I2
tp20871
sS'decrease,the,effects'
p20872
(F1
F0.00076452599388379206
I1
I0
I1
tp20873
sS'g1,phase,whereas'
p20874
(F1
F0.00076452599388379206
I0
I1
I-1
tp20875
sS'geometric,mean,auc'
p20876
(F1
F0.00076452599388379206
I1
I0
I1
tp20877
sS'with,increases,in'
p20878
(F1
F0.00076452599388379206
I1
I0
I1
tp20879
sS'of,mg,did'
p20880
(F1
F0.00076452599388379206
I0
I1
I-1
tp20881
sS'received,to,prevent'
p20882
(F1
F0.00076452599388379206
I1
I0
I1
tp20883
sS'lower,respectively,than'
p20884
(F1
F0.00076452599388379206
I1
I0
I1
tp20885
sS'below,oral,coumarin-type'
p20886
(F1
F0.00076452599388379206
I1
I0
I1
tp20887
sS'and,other,cns'
p20888
(F1
F0.0015290519877675841
I2
I0
I2
tp20889
sS'the,rate,or'
p20890
(F1
F0.00076452599388379206
I0
I1
I-1
tp20891
sS'a,multidose,study'
p20892
(F1
F0.00076452599388379206
I1
I0
I1
tp20893
sS'conducted,in,healthy'
p20894
(F0
F0
I1
I1
I0
tp20895
sS'cyp3a4,inhibition,on'
p20896
(F1
F0.00076452599388379206
I0
I1
I-1
tp20897
sS'pharmacokinetics,both,r-'
p20898
(F1
F0.00076452599388379206
I0
I1
I-1
tp20899
sS'the,elderly,may'
p20900
(F1
F0.00076452599388379206
I1
I0
I1
tp20901
sS'nsaids,concomitantly,with'
p20902
(F1
F0.00076452599388379206
I1
I0
I1
tp20903
sS'the,rate,of'
p20904
(F0.59999999999999998
F0.0022935779816513763
I4
I1
I3
tp20905
sS'be,decreased,due'
p20906
(F1
F0.00076452599388379206
I1
I0
I1
tp20907
sS'and,pharmacokinetics,are'
p20908
(F1
F0.00076452599388379206
I0
I1
I-1
tp20909
sS'thus,strong,inhibitors'
p20910
(F1
F0.00076452599388379206
I1
I0
I1
tp20911
sS'have,been,performed'
p20912
(F1
F0.0015290519877675841
I0
I2
I-2
tp20913
sS'only,female,controls'
p20914
(F1
F0.00076452599388379206
I0
I1
I-1
tp20915
sS'the,dosage,should'
p20916
(F1
F0.00076452599388379206
I1
I0
I1
tp20917
sS'fixed,combination,was'
p20918
(F1
F0.0015290519877675841
I0
I2
I-2
tp20919
sS'kinetics,of,a'
p20920
(F1
F0.00076452599388379206
I0
I1
I-1
tp20921
sS'these,enzymes,would'
p20922
(F1
F0.00076452599388379206
I0
I1
I-1
tp20923
sS'days,or,cautiously'
p20924
(F1
F0.00076452599388379206
I0
I1
I-1
tp20925
sS'in,t-all,cell'
p20926
(F1
F0.00076452599388379206
I0
I1
I-1
tp20927
sS'cci-779,in,patients'
p20928
(F1
F0.00076452599388379206
I0
I1
I-1
tp20929
sS'respiratory,depression,hypotension'
p20930
(F1
F0.00076452599388379206
I1
I0
I1
tp20931
sS'an,appropriate,model'
p20932
(F1
F0.00076452599388379206
I0
I1
I-1
tp20933
sS'lead,to,severe'
p20934
(F1
F0.00076452599388379206
I1
I0
I1
tp20935
sS'achievement,of,target'
p20936
(F0
F0
I1
I1
I0
tp20937
sS'and,tyrosine,hydroxylase'
p20938
(F1
F0.00076452599388379206
I1
I0
I1
tp20939
sS'tetrahydropyridine,treatment,all'
p20940
(F1
F0.00076452599388379206
I1
I0
I1
tp20941
sS'been,spontaneous,reports'
p20942
(F1
F0.00076452599388379206
I1
I0
I1
tp20943
sS'proteins,is,unaffected'
p20944
(F1
F0.00076452599388379206
I0
I1
I-1
tp20945
sS'values,within,hours'
p20946
(F1
F0.00076452599388379206
I1
I0
I1
tp20947
sS'and,possible,potentiation'
p20948
(F1
F0.00076452599388379206
I0
I1
I-1
tp20949
sS'inhibitors,or,by'
p20950
(F1
F0.00076452599388379206
I1
I0
I1
tp20951
sS'lowered,the,serum'
p20952
(F1
F0.00076452599388379206
I1
I0
I1
tp20953
sS'to,low,systemic'
p20954
(F1
F0.00076452599388379206
I0
I1
I-1
tp20955
sS'agents,may,affect'
p20956
(F1
F0.00076452599388379206
I1
I0
I1
tp20957
sS'and,have,been'
p20958
(F1
F0.0015290519877675841
I2
I0
I2
tp20959
sS'tests,for,thc'
p20960
(F1
F0.00076452599388379206
I0
I1
I-1
tp20961
sS'patients,receiving,azole'
p20962
(F1
F0.00076452599388379206
I1
I0
I1
tp20963
sS'inhibitor,of,src'
p20964
(F1
F0.00076452599388379206
I0
I1
I-1
tp20965
sS'supplements,and,potassium-sparing'
p20966
(F1
F0.0015290519877675841
I0
I2
I-2
tp20967
sS'single,agent,exhibits'
p20968
(F1
F0.00076452599388379206
I1
I0
I1
tp20969
sS'associated,gastrointestinal,bleeding'
p20970
(F1
F0.00076452599388379206
I0
I1
I-1
tp20971
sS'can,be,expected'
p20972
(F1
F0.00076452599388379206
I1
I0
I1
tp20973
sS'if,you,are'
p20974
(F1
F0.00076452599388379206
I0
I1
I-1
tp20975
sS'metabolite,by,and'
p20976
(F1
F0.00076452599388379206
I1
I0
I1
tp20977
sS'vaccines,and,an'
p20978
(F1
F0.00076452599388379206
I1
I0
I1
tp20979
sS'secretion,although,studies'
p20980
(F1
F0.00076452599388379206
I1
I0
I1
tp20981
sS'in,administering,vumon'
p20982
(F1
F0.00076452599388379206
I0
I1
I-1
tp20983
sS'in,the,present'
p20984
(F0.33333333333333331
F0.00076452599388379206
I1
I2
I-1
tp20985
sS'sulfonamides,concurrent,use'
p20986
(F1
F0.00076452599388379206
I1
I0
I1
tp20987
sS'substances,that,are'
p20988
(F1
F0.00076452599388379206
I1
I0
I1
tp20989
sS'did,not,lead'
p20990
(F1
F0.00076452599388379206
I0
I1
I-1
tp20991
sS'oral,anticoagulants,interaction'
p20992
(F1
F0.00076452599388379206
I0
I1
I-1
tp20993
sS'by,some,aluminum-'
p20994
(F1
F0.00076452599388379206
I1
I0
I1
tp20995
sS'had,a,minimal'
p20996
(F1
F0.0015290519877675841
I2
I0
I2
tp20997
sS'adjustment,of,zemplar'
p20998
(F1
F0.00076452599388379206
I1
I0
I1
tp20999
sS'kinetics,of,when'
p21000
(F1
F0.00076452599388379206
I0
I1
I-1
tp21001
sS'folic,acid,and'
p21002
(F1
F0.00076452599388379206
I1
I0
I1
tp21003
sS'coadministration,of,with'
p21004
(F1
F0.0030581039755351682
I4
I0
I4
tp21005
sS'hdac,inhibitors,severe'
p21006
(F1
F0.00076452599388379206
I1
I0
I1
tp21007
sS'patients,receiving,or'
p21008
(F1
F0.0030581039755351682
I4
I0
I4
tp21009
sS'of,and,after'
p21010
(F1
F0.00076452599388379206
I0
I1
I-1
tp21011
sS'the,use,of'
p21012
(F0.33333333333333331
F0.0038226299694189602
I10
I5
I5
tp21013
sS'food,to,the'
p21014
(F1
F0.00076452599388379206
I1
I0
I1
tp21015
sS'sensitivity,was,measured'
p21016
(F1
F0.00076452599388379206
I0
I1
I-1
tp21017
sS'hyperthyroid,patients,on'
p21018
(F1
F0.0015290519877675841
I0
I2
I-2
tp21019
sS'in,drs,rimmer'
p21020
(F1
F0.00076452599388379206
I1
I0
I1
tp21021
sS'the,due,to'
p21022
(F1
F0.00076452599388379206
I0
I1
I-1
tp21023
sS'the,potential,for'
p21024
(F0.5
F0.0015290519877675841
I3
I1
I2
tp21025
sS'nondepolarizing,agents,such'
p21026
(F1
F0.00076452599388379206
I1
I0
I1
tp21027
sS'n,poor,metabolizers'
p21028
(F1
F0.00076452599388379206
I0
I1
I-1
tp21029
sS'dose,should,be'
p21030
(F1
F0.00076452599388379206
I0
I1
I-1
tp21031
sS'and,increased,the'
p21032
(F1
F0.00076452599388379206
I0
I1
I-1
tp21033
sS'medications,may,result'
p21034
(F1
F0.00076452599388379206
I1
I0
I1
tp21035
sS'the,pressor,response'
p21036
(F1
F0.0015290519877675841
I2
I0
I2
tp21037
sS'pronounced,following,oral'
p21038
(F1
F0.00076452599388379206
I1
I0
I1
tp21039
sS'the,observed,increase'
p21040
(F1
F0.00076452599388379206
I0
I1
I-1
tp21041
sS'may,decrease,patient'
p21042
(F1
F0.00076452599388379206
I1
I0
I1
tp21043
sS'on,chronic,stable'
p21044
(F1
F0.00076452599388379206
I1
I0
I1
tp21045
sS'in,patient,controlled'
p21046
(F1
F0.00076452599388379206
I1
I0
I1
tp21047
sS'precocene,i,increased'
p21048
(F1
F0.00076452599388379206
I1
I0
I1
tp21049
sS'when,used,simultaneously'
p21050
(F1
F0.00076452599388379206
I0
I1
I-1
tp21051
sS'of,in,the'
p21052
(F1
F0.00076452599388379206
I0
I1
I-1
tp21053
sS'may,cause,marrow'
p21054
(F1
F0.00076452599388379206
I1
I0
I1
tp21055
s.